<SEC-DOCUMENT>0001679363-21-000067.txt : 20211104
<SEC-HEADER>0001679363-21-000067.hdr.sgml : 20211104
<ACCEPTANCE-DATETIME>20211104164116
ACCESSION NUMBER:		0001679363-21-000067
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		64
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211104
DATE AS OF CHANGE:		20211104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Morphic Holding, Inc.
		CENTRAL INDEX KEY:			0001679363
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				473878772
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38940
		FILM NUMBER:		211380520

	BUSINESS ADDRESS:	
		STREET 1:		35 GATEHOUSE DRIVE A2
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		9787296480

	MAIL ADDRESS:	
		STREET 1:		35 GATEHOUSE DRIVE A2
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Morphic Holding, LLC
		DATE OF NAME CHANGE:	20160712
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>morf-20210930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:a0fdcec5-f1a8-410f-b814-f85a654bede4,g:4b0f2f4e-5307-47a8-ad80-54240ea99d78,d:78343c0ada4c4eb7afb5039f4dd8197f--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:morf="http://morphictx.com/20210930" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>morf-20210930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80L2ZyYWc6ZjhhOGQzNzUzYTQ3NDI5MDkwMDA4ZGNjOWM1MjkwMGEvdGFibGU6NDkxMmU0M2FiMmY4NDhjNzlkZjgxNGIyY2U4YjY0MGMvdGFibGVyYW5nZTo0OTEyZTQzYWIyZjg0OGM3OWRmODE0YjJjZThiNjQwY18yLTEtMS0xLTIxMzY_ba55f4c5-edf1-403b-8a7c-9496144ea607">0001679363</ix:nonNumeric><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" format="ixt:date-month-day" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80L2ZyYWc6ZjhhOGQzNzUzYTQ3NDI5MDkwMDA4ZGNjOWM1MjkwMGEvdGFibGU6NDkxMmU0M2FiMmY4NDhjNzlkZjgxNGIyY2U4YjY0MGMvdGFibGVyYW5nZTo0OTEyZTQzYWIyZjg0OGM3OWRmODE0YjJjZThiNjQwY18zLTEtMS0xLTIxMzY_ef24286f-bad5-4e6e-9195-a7c6eac70cd8">12-31</ix:nonNumeric><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80L2ZyYWc6ZjhhOGQzNzUzYTQ3NDI5MDkwMDA4ZGNjOWM1MjkwMGEvdGFibGU6NDkxMmU0M2FiMmY4NDhjNzlkZjgxNGIyY2U4YjY0MGMvdGFibGVyYW5nZTo0OTEyZTQzYWIyZjg0OGM3OWRmODE0YjJjZThiNjQwY180LTEtMS0xLTIxMzY_be288f6d-ec81-4e46-91d8-3c79a76ba994">2021</ix:nonNumeric><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80L2ZyYWc6ZjhhOGQzNzUzYTQ3NDI5MDkwMDA4ZGNjOWM1MjkwMGEvdGFibGU6NDkxMmU0M2FiMmY4NDhjNzlkZjgxNGIyY2U4YjY0MGMvdGFibGVyYW5nZTo0OTEyZTQzYWIyZjg0OGM3OWRmODE0YjJjZThiNjQwY181LTEtMS0xLTIxMzY_a6f4cf1c-c9d8-4678-8fd7-7db29e0fd4b7">Q3</ix:nonNumeric><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80L2ZyYWc6ZjhhOGQzNzUzYTQ3NDI5MDkwMDA4ZGNjOWM1MjkwMGEvdGFibGU6NDkxMmU0M2FiMmY4NDhjNzlkZjgxNGIyY2U4YjY0MGMvdGFibGVyYW5nZTo0OTEyZTQzYWIyZjg0OGM3OWRmODE0YjJjZThiNjQwY182LTEtMS0xLTIxMzY_874bc3f9-9325-4e20-bf10-47831ffc32d0">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="morf-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i418fd438d137415fa9b558a67ab1fce8_I20211101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d6197cbb2f545b7ab683c1901d4ea29_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i243f3682abd5424ba05ed1db40ccb97c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27ecd01750ae41fab6b59da5854ce971_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic197e04f10c7408ba4ef7db9f441c28a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66ab197779d14e8b9af5bcb81478b4c6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i901f8ecd744645b8a45d1b64a74c0f58_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9be65219686545cf83e7c3cd5542dd20_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d3e2328ff2041f58dcaeaaebb4233bc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia01ec15ac72b4497a0496ccada0d94dc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4efb9d0eda5b4f64829d51d0b07ac1b0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06ca94fcd1b246778b2f5c3579ac9473_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:SecondaryOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58aa03ecfdd643a5894ce9870d82dbf6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:SecondaryOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e6d9c7159174b0789e9ced5c520204e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:SecondaryOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5690066625a42e3b87d0384affb2d01_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib800117992e243cf8a7585686b33a363_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i515d2c5350ad4f2d83c7a0bdffb1c873_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc97a27759e34d4cb8df378b38cdacaf_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1553aca7f70042e7abd871d77d833356_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58cda165edf34fb0b54d026018e62af0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f81b65df28e4c0eb8e87eb238682f6f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbabfe222fdf4273a3a4864d3c46bb31_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6b9e0cfb6c842a3a3373453c72b93c0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6533246bc7740bfb131bb0f31d5ebce_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4bbeefbdf784a4a86d7368751611e4d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3a28dfdb1574133a31c2bbdc51e68b2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id787d30e67454f57ad1994ca3038b201_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib159d5476c2447b29c76c974f6a73e16_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie78e1f680612471088c63f49b5dd8a18_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6938de3cb6cf4fa7806a42ee8d41f58e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i045fb029fd9f4fd3ba7809ee012e5352_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c8425c2e88641d2abdbb94c5d478327_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib378bf3c290247ed8a0dcf860e280f0f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie46f079ac4224779be66b7117f7c7607_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a9a17e2241e4a3f9bf48a8a07ea581f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93e1933f2bc44d94bea2dcf014ef6034_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if47513e8e86f49968b6af3544f6b81c9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02e02a526a804154b6839aa55df1b6cb_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i525829a7d9e441d0ba3b4b60e68895fc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67cb7e787c6f404fba5246e0f6e89ee6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5674ed6b01654ebeaed47a14ff3407ec_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a0cdc60fdbc4ada914dbb870ef3b65e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0289611dea94928a98cb550c8c5397a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b404164f5bb4d7ca737270c6e265def_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6bb096c70634192838a382eb5887887_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ided2a95523e74652809cc83e76cc2c1c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2e37d454f86483da5d113ba5bb9c6ae_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28b354f9bb8d47e8a80d9ddf5b84ae8c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i678eec9b2b244447b18fc4ba9a55fb5d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id44003b9b0fc4840a4b1164b5acc2433_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0b42c7d7a4a4d258150923a53914e00_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47ae904392494a1691f66d44af867fd5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib198e32eebb44ca09f321ba259b29ce2_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id62a5c373f8043a49ac6d4b6edcb5f03_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcc27241cea443418ead40c7a7f13130_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f787d6a671940b0a2ba97e900ceeba5_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i831afc5715a74d2ebfcc35bdfd047f7f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd4b367ccae649d798f837bc4bae25cf_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b9b5c829b794265abbba640d8790b61_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie820eb1d183044f29008086e76bb8abb_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaa73485876b4e858b467fc72c87dc11_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2b9993359cb456984780b6ee2dcb181_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44de926c8806430b8699f3779b9c08b1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c86edc9380f4e658d4c9376a669e0d9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie08a82cfc7f24fbbad0fe77f2bfe3618_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22f2eddba4d5410b914c1f3b00fc8918_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61f47238d1b44b2a9637c0aa85dc0ee4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49f954fe973a4718a7bb027c7e112f91_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i763837ff1bfa4e4395a5c9985fb3ea1d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb907e28eb904c5abe8778dff7854225_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c337f23b5d94bce847216e32970fc13_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ce691e108d44f41854e25c5b8aa249f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58e35bd616704d81933f455f82a367b9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e417c1626c0447da3ff198c9dbd9029_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifecee13ba23d4d56894bc6a643e63e62_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5762a65d06864432a626e61cf3346d84_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdf49025fcce47b8a9f8b80534c93448_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d5c7026852d4a94bec2b79ab34bc87d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64b5dd8c546640129471ee97d4f9028f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f1bf035ce6148889916ac0580538d5b_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">morf:OpenMarketSaleAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i3a3fb30525ad4997ad257edca9bb1309_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">morf:OpenMarketSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c1c09e4655f462d8172c3fed16c5d41_D20210811-20210811"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">morf:OpenMarketSaleAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-11</xbrli:startDate><xbrli:endDate>2021-08-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8539e76f9660442e9d169db576c8aedd_D20210811-20210811"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">morf:OpenMarketSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-11</xbrli:startDate><xbrli:endDate>2021-08-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16001d4e30b441e1808c258ac136a45a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a6c3241ca9141c9bbb04c6d0c0c55fa_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77369a4a13ef44fa8daace2f7956ce2a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie84d1725167c4a75be6380089ca4347a_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cf597d615c64759b8f60cb2d5d4e180_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i196c1e6bf66247b98fa293ce7ce21c10_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">morf:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i385155a063a54593b7698266553fa968_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic691b1bab6064f3d9b9e1c90394f4e2d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id40e4cfd2a8045e1a1e666498fe4e815_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i037043297a254ed9b5cf0826c9db9fa9_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb831f5a17f54f7584aa402e76bb36fe_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i486fa776a3f04f34ac576895fc27dad7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fb8ba20056d490189b4417c8db4fc8b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8565d342aa34348b2d8b3de28ae62d2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64b03ce48904405aa038b9b8f79e221c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79dd709730de462484976109499248c0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3093e8eb0fbf40cfaf61a51b86743dfc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0460516fcd64ec5939869a8cc9083fc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7a2b23055c14610b9b9f0122e0bc83c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57619922f2b04e87b375de9b0c6abf2f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f4e846feef646b38404ae6f8ed330dc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd960eb27fba42f3a7c083248ce24430_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i488d3d9e7497417dae3338d286bf285c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1efba4c0bfa64c24912b8e57773d8914_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a595f6291d745078296fee41e88b0b5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if06a28dfa4674c8da99858f333e14322_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddb9c72e419f4eadbe5c615a694858f7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i078df3d57b71434481ab87bd4712a953_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f25b4bb5f1f4854b5ecb14766c3ca49_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12b799caa9b242aabc2dbefff0e5f757_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib207c5a6d64c4722b33aa55f1f923141_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8109e4aa5a0416e9392220462770a8c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie493a72a05bd4a50bb01b9136293db44_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0f1e91996364358920d91dc6eedb07f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f5553a6ec7c411da7d58ef985358ba5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i103b3b3fd13b4d969b9f99f276f756be_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie233b4a2750a4b268a177be345cf1c52_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fa385b09a9947cbaaa1c35bef4b2881_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d81d7faa05e4d72ba315f45f8ca2b93_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b8872a576284d399ea67d6b51d01d5b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccd54f681834442eb165955240d9e74a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcf0ba2ceaab4483a2bfe533ce701a43_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia79f1a27faad4ee0b5c7c77ea717ed13_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic423ff5ccdca4effbe4d4211fa5e77f6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf513a6144654bceada542de288df958_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f9166bb425c44ada5c593577d00e22a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2eee8a4601534a4a917d268a6e6ed3c0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad4849d4849a4887af432c78ad0245a8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24c99804fc6044a5a6faa8fb23d4c212_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa63b4b83d8c4eaca119ea3ed2510c96_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f2f1b5251e94bbe8ef420f9ff484d6e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65aaf5db173b49e9ab4c31517132d9ec_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i039b981d5def4df5ac1cd4a91d5e0229_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9b7b224fe294b00affdcc71cba4f7d6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28dbbd4689134d678129e0ec4c7edb79_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4d1f97a11f54bcb896bca14bdcd10f2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1efef8ae596461dbbceea676d6cf299_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf03edf7a50641cfb11f3e5cc6746127_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i673a34526db04381a03c0b2e761aca2a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9e3e64d44494241956eb0fdacb21e56_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21ee8d1c8ad34b4e80c662e251e209ae_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71df2423ac2c4debbc999ef809fd11c1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bcc85b10d794d0c98147f0f99a5a07a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5998a9c8f16249a5a5aed5bd18c1e529_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55558d3807264cfebb3cf65d4a4463df_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3b3a9e7b9604013adda880bf9c86908_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic35b086f16144f27b108d50ef91c71d5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3306469c42b0426c851e95ee8d3af6bf_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19b2674b6d5149d0b8ee34f673c706f2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafc120c8b5bb4f488b7898393d9badba_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id827d0b4de4c40aebffdd742a897d8e7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i336ef268b2b54d5a8d41335f5521475d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1bba300f18d4aa9a80235013244a2ca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41bca88497e24b96b89b016e9cea4fe6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i500b2548238d418785e416f8b2eb9f96_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idecb2791d4e644adac2b17f62a0ffc4d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f2623aae9e042109d449218c4a952e2_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4fd934abc1c47eeb0364ac66d1ad27d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i933ed6a72813427384dce0d77c868663_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cb15e50535f4e87b974bc0af2a7bb9c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd339294a59643f7b3b5f6dd55384718_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaacbf9b146694148984076cec6a6afd1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i291b9147c1ae41379197349d37bd173b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i230a2ca85b2a4dccb1eb0099d20ad182_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae18ebb70c3c4104ab905dae334545e6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccbf9f78a6bf4f6d936be01c6bdf3bde_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf1288ac2081418ea5506b9b964c318e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3686e9bb301546d3b3f298fb3add79a3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if51ea1a4ae7b4814bdd7be74ca589c83_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf36089b555c48e58d97c007d1218b7e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04814fa766f14a87b1a4f5090088feac_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b5652f4187946c99d351a84522e3224_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id854b4ee36ae41358df7d8160430d227_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:ReimbursementRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia72ac23116b546868709c55972ad7552_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:ReimbursementRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd2abd0024994ee09ba37323fe37f011_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:ReimbursementRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id12aad613d2c4493984ca5f33bb35df9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:ReimbursementRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01c98160846146719189240b8058862e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9354f5fe43946dc8a9f666176548cf0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f177f36d3854a15b812deee9a7d9bdb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1757a9161a324b048e54e4ae0d303a19_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7428ecf2c9c2487f9fb6cb0173822e37_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95e6d1a476764b22afd007e50518a6b3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib185e590ec714546bf7f6029f9dbac37_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38ff992e2599451b9c12dca8f4da6c0e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfcdd8be7e094adb844410ae8c290692_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6809bfeafd44664a693a85e7e121e7a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bf19a2caf8b4d509a379811f8a3c1ea_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">morf:RestrictedCommonStockAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12795b2676c0493781d9a5bdadfbf6cc_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">morf:RestrictedCommonStockAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a64c5a4066049d08858e72736c24a45_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">morf:RestrictedCommonStockAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20a672c9e2164a1480e1ae0fd1133627_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">morf:RestrictedCommonStockAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1117ebd626644baebf8cd85f62f25c00_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ec79f5f2c2143ed87b1024777fbb963_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id77ac29ae1c946708d972f4329a5fd16_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb5f82106070482cae1bfd5c69ed3333_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ea8f4ed8fbc4550aa703adec2e38d33_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icccb7da2fdfc4873a395a07afd73be7c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea0a178c00d24c538b17f43b4a9992b0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79f148df7d7a454d8deed12b42736ccb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a342db77baf4dcc9e4c05d95f989378_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33b959e99b544061a1ad9375c42039bd_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica73f41d57df4863906446bbbec208e0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc431739b79043079a7eb95d72fdb304_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4299c25bbef841838f8943aab9d90e62_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">morf:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_1"></div><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:120%"></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGV4dHJlZ2lvbjowZjUxMGQ0MTQyOGU0ZWI3OWJlMjQ3ODkyODllYzMxZF8yMDMx_2921aeaa-3241-4df8-8797-f297d725b4c5">10-Q</ix:nonNumeric></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Mark One)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" format="ixt:fixed-true" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGFibGU6MjE0MjM5NzEwNWU4NDA5YTgwMGQwYjhhODRiNzViMjkvdGFibGVyYW5nZToyMTQyMzk3MTA1ZTg0MDlhODAwZDBiOGE4NGI3NWIyOV8xLTAtMS0xLTIxMzY_5f922287-f87f-4553-bc65-67d367eebaae">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13, OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGV4dHJlZ2lvbjowZjUxMGQ0MTQyOGU0ZWI3OWJlMjQ3ODkyODllYzMxZF82NTk3MDY5NzY4NzE1_d4a949a5-8ae6-49ff-b622-9d274d5faf47">September 30, 2021</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" format="ixt:fixed-false" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGFibGU6NGYxYjgzNjg5YmI1NGFlOWFiZDkxMGY1OGFhNzJiNmUvdGFibGVyYW5nZTo0ZjFiODM2ODliYjU0YWU5YWJkOTEwZjU4YWE3MmI2ZV8wLTAtMS0xLTIxMzY_95e3b9c9-9435-48bd-9ddc-a55fac32c4e4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</span></div><div style="text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGV4dHJlZ2lvbjowZjUxMGQ0MTQyOGU0ZWI3OWJlMjQ3ODkyODllYzMxZF8yMDI2_a4acd4c5-6467-47f2-a515-431e960e85ca">001-38940</ix:nonNumeric></span></div><div style="text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGV4dHJlZ2lvbjowZjUxMGQ0MTQyOGU0ZWI3OWJlMjQ3ODkyODllYzMxZF8yMDI3_43f44aa8-f689-4c69-a5d9-7def64e8c354">MORPHIC HOLDING,&#160;INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGFibGU6ZjQ4OTcwMGVlNTY2NDY5N2EzYWE3ZjRlMTg5NjU1ZDAvdGFibGVyYW5nZTpmNDg5NzAwZWU1NjY0Njk3YTNhYTdmNGUxODk2NTVkMF8wLTAtMS0xLTIxMzYvdGV4dHJlZ2lvbjpkYzI3NTE2ZDE3MjI0ZGY5OTExOWMyZDUwZTA2YWIwOV81_2e360f39-35d8-415c-8790-db32162a8618">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporation or Organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGFibGU6ZjQ4OTcwMGVlNTY2NDY5N2EzYWE3ZjRlMTg5NjU1ZDAvdGFibGVyYW5nZTpmNDg5NzAwZWU1NjY0Njk3YTNhYTdmNGUxODk2NTVkMF8wLTEtMS0xLTIxMzYvdGV4dHJlZ2lvbjoyZjc1ZjMzNDljNGM0ODg1YmQ4ZTgyOGZmM2I2YTkyNF81_7090f37d-c55b-4135-9281-02ff67edd567">47-3878772</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification No.)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGFibGU6ZjQ4OTcwMGVlNTY2NDY5N2EzYWE3ZjRlMTg5NjU1ZDAvdGFibGVyYW5nZTpmNDg5NzAwZWU1NjY0Njk3YTNhYTdmNGUxODk2NTVkMF8xLTAtMS0xLTIxMzYvdGV4dHJlZ2lvbjoxMDcxMGQ5MjQ4ZjM0ZTIyODI2NjBjNDI3ZDkzNmQ2MV83_34e05301-376b-4c52-8e60-3cf295ff2395">35 Gatehouse Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGFibGU6ZjQ4OTcwMGVlNTY2NDY5N2EzYWE3ZjRlMTg5NjU1ZDAvdGFibGVyYW5nZTpmNDg5NzAwZWU1NjY0Njk3YTNhYTdmNGUxODk2NTVkMF8xLTAtMS0xLTIxMzYvdGV4dHJlZ2lvbjoxMDcxMGQ5MjQ4ZjM0ZTIyODI2NjBjNDI3ZDkzNmQ2MV8xMQ_0866ba64-6b98-462f-95b4-5253c824d824">A2</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGFibGU6ZjQ4OTcwMGVlNTY2NDY5N2EzYWE3ZjRlMTg5NjU1ZDAvdGFibGVyYW5nZTpmNDg5NzAwZWU1NjY0Njk3YTNhYTdmNGUxODk2NTVkMF8xLTAtMS0xLTIxMzYvdGV4dHJlZ2lvbjoxMDcxMGQ5MjQ4ZjM0ZTIyODI2NjBjNDI3ZDkzNmQ2MV8xNA_b9578f5e-377b-4618-859f-4662ddb8c645">Waltham</ix:nonNumeric>, <ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGFibGU6ZjQ4OTcwMGVlNTY2NDY5N2EzYWE3ZjRlMTg5NjU1ZDAvdGFibGVyYW5nZTpmNDg5NzAwZWU1NjY0Njk3YTNhYTdmNGUxODk2NTVkMF8xLTAtMS0xLTIxMzYvdGV4dHJlZ2lvbjoxMDcxMGQ5MjQ4ZjM0ZTIyODI2NjBjNDI3ZDkzNmQ2MV8xOA_b9d0588b-4fda-48a2-94c5-586e3b6964e5">MA</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGFibGU6ZjQ4OTcwMGVlNTY2NDY5N2EzYWE3ZjRlMTg5NjU1ZDAvdGFibGVyYW5nZTpmNDg5NzAwZWU1NjY0Njk3YTNhYTdmNGUxODk2NTVkMF8xLTEtMS0xLTIxMzYvdGV4dHJlZ2lvbjpkNThhNWU0YTU1NWI0YzQ4YTljNzZjZWM5ZjkyZGZmY183_c59bf62d-e4e6-46c5-acfb-c012eda16f55">02451</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGV4dHJlZ2lvbjowZjUxMGQ0MTQyOGU0ZWI3OWJlMjQ3ODkyODllYzMxZF8yMDI4_759909dc-d755-4185-9f1f-fb15335b90e1">781</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGV4dHJlZ2lvbjowZjUxMGQ0MTQyOGU0ZWI3OWJlMjQ3ODkyODllYzMxZF8yMDMy_dd3ae3db-bc66-4a21-877a-1d5fb0a2747b">996-0955</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Exchange Act:</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGFibGU6MzYwN2YyMmJiMmNkNDFhNDk3YmUzOTIwNmY1MWM4MjkvdGFibGVyYW5nZTozNjA3ZjIyYmIyY2Q0MWE0OTdiZTM5MjA2ZjUxYzgyOV8xLTAtMS0xLTIxMzY_d26e27f9-3c67-444c-9ad6-e19056d5b9f8">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGFibGU6MzYwN2YyMmJiMmNkNDFhNDk3YmUzOTIwNmY1MWM4MjkvdGFibGVyYW5nZTozNjA3ZjIyYmIyY2Q0MWE0OTdiZTM5MjA2ZjUxYzgyOV8xLTEtMS0xLTIxMzY_44503a68-c6c1-4fa1-b020-2935c3ae8690">MORF</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGFibGU6MzYwN2YyMmJiMmNkNDFhNDk3YmUzOTIwNmY1MWM4MjkvdGFibGVyYW5nZTozNjA3ZjIyYmIyY2Q0MWE0OTdiZTM5MjA2ZjUxYzgyOV8xLTItMS0xLTIxMzY_462e9603-2b25-4057-b679-16a5e1dfc077">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;<ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGV4dHJlZ2lvbjowZjUxMGQ0MTQyOGU0ZWI3OWJlMjQ3ODkyODllYzMxZF8yMDI5_cf25db3d-048f-488a-8398-987bdea010fe">Yes</ix:nonNumeric>&#160;&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No&#160;&#9744;</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (Section&#160;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;<ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGV4dHJlZ2lvbjowZjUxMGQ0MTQyOGU0ZWI3OWJlMjQ3ODkyODllYzMxZF8yMDMz_084295da-446d-4903-88f9-15ab1b2cc6b9">Yes</ix:nonNumeric>&#160;&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No&#160;&#9744;</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer &#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer &#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGFibGU6MGM4NzFhZjFiYzlhNDQzMmE3YzVjNWMyYzYxOGVlNTkvdGFibGVyYW5nZTowYzg3MWFmMWJjOWE0NDMyYTdjNWM1YzJjNjE4ZWU1OV8xLTAtMS0xLTIxMzYvdGV4dHJlZ2lvbjoyOGQ2MDFjM2JlMjE0MDAzYmFhYjBmMzdkNzE1MDdmY180_e953fe14-6d7f-4138-8d34-1f429a8ef447">Non-accelerated filer</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> &#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company <ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" format="ixt:fixed-true" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGFibGU6MGM4NzFhZjFiYzlhNDQzMmE3YzVjNWMyYzYxOGVlNTkvdGFibGVyYW5nZTowYzg3MWFmMWJjOWE0NDMyYTdjNWM1YzJjNjE4ZWU1OV8xLTEtMS0xLTIxMzYvdGV4dHJlZ2lvbjo5ZGJlODdlNDZiN2Y0NDFkYWFjNzUyOTI3ZTViOTAzMl8zMA_e59e941d-7195-4fe9-a2f0-1ffbc4f43c9f">&#9746;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company <ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" format="ixt:fixed-true" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGFibGU6MGM4NzFhZjFiYzlhNDQzMmE3YzVjNWMyYzYxOGVlNTkvdGFibGVyYW5nZTowYzg3MWFmMWJjOWE0NDMyYTdjNWM1YzJjNjE4ZWU1OV8yLTEtMS0xLTIxMzYvdGV4dHJlZ2lvbjo2MWExMzNkYTlmNDQ0ZDlmYjkxZjk0MGRjYjMwYTQyNl8yOA_b379d844-7a8f-4cd0-8a84-492d3f76ff90">&#9746;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" format="ixt:fixed-false" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGV4dHJlZ2lvbjowZjUxMGQ0MTQyOGU0ZWI3OWJlMjQ3ODkyODllYzMxZF8yMDM0_320c535a-b033-4d96-81a7-b4904c03f71f">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule&#160;12b-2).&#160;Yes&#160;<ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" format="ixt:fixed-false" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGV4dHJlZ2lvbjowZjUxMGQ0MTQyOGU0ZWI3OWJlMjQ3ODkyODllYzMxZF8yMDMw_c9f44b82-16d1-4725-9821-ad933ea73ee4">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No&#160;&#9746;</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares outstanding of the registrant&#8217;s Common Stock as of November&#160;1, 2021 was <ix:nonFraction unitRef="shares" contextRef="i418fd438d137415fa9b558a67ab1fce8_I20211101" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGV4dHJlZ2lvbjowZjUxMGQ0MTQyOGU0ZWI3OWJlMjQ3ODkyODllYzMxZF8xNjQ5MjY3NDQzNzUw_f449de5e-1908-4e6e-b0b2-b7199312f474">36,961,618</ix:nonFraction>.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:91.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.672%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_10">Part&#160;I&#8212;Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_10">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_13">Item&#160;1&#8212;Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_13">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_16">Condensed Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_16">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_16"> 30, 2021 and December 31, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_16">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_19">Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_22">Condensed Consolidated Statements of Stockholders&#8217; Equity for the three and nine months ended September 30, 2021 and 2020</a> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_25">Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_25">nine </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_25">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_25">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_25"> 30, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_25">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_28">Notes to Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_28">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_94">Item&#160;2&#8212;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_94">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_103">Item&#160;3&#8212;Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_103">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_106">Item&#160;4&#8212;Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_106">30</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_109">Part&#160;II&#8212;Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_109">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_112">Item&#160;1&#8212;Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_112">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_115">Item&#160;1A&#8212;Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_115">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_118">Item&#160;2&#8212;Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_118">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_121">Item 3&#8212;Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_121">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_124">Item 4&#8212;Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_124">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_127">Item 5&#8212;Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_127">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_130">Item&#160;6&#8212;Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_130">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_133">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_133">84</a></span></div></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div style="text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:120%"></span></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_13"></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">. Condensed Consolidated Financial Statements (unaudited)</span></div></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></span></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_16"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share data)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfNC0xLTEtMS0yMTM2_55baceaf-cfa0-48a1-97dd-591c33405fc4">184,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfNC0zLTEtMS0yMTM2_2039d01e-220e-4382-9378-873dcb926218">102,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfNS0xLTEtMS0yMTM2_a7c2ae64-b720-4da1-9b26-e95151524b5c">243,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfNS0zLTEtMS0yMTM2_7b673c2c-d0f8-4770-92a8-a5d3ab9d759e">126,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfNi0xLTEtMS0yMTM2_3bf3de25-f3e5-4e5e-a9b5-4a3231df563f">2,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfNi0zLTEtMS0yMTM2_2de0a58d-1671-4e68-ad18-fafbb86dce00">7,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfNy0xLTEtMS0yMTM2_a5016b74-ae79-4f4c-8e63-a59eee1e22b2">5,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfNy0zLTEtMS0yMTM2_30ad188d-8d6d-4060-8582-7b8a21a8bcc3">3,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfOC0xLTEtMS0yMTM2_079f7d26-05c7-4efb-82d0-0735db0f3fcb">435,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfOC0zLTEtMS0yMTM2_086adf4c-8068-420a-96ac-481ded64f101">239,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTAtMS0xLTEtMjEzNg_ad5ff557-abb8-464f-ba86-9f369dcc3816">2,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTAtMy0xLTEtMjEzNg_f507da0b-71cc-409c-991e-533f23558f68">2,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTEtMS0xLTEtMjEzNg_bbac4bb2-4de8-424d-8465-aa72ffcc0db7">560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTEtMy0xLTEtMjEzNg_1d11643f-05ad-41aa-a5c6-f39c82520850">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTItMS0xLTEtMjEzNg_efab2516-d2bb-4596-877b-a81736523aeb">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTItMy0xLTEtMjEzNg_f170ce0f-0922-4f78-8b9e-3ca937d7d5bd">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTMtMS0xLTEtMjEzNg_8af1b418-f6e3-40e1-94e7-21183ed58e28">438,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTMtMy0xLTEtMjEzNg_a4bfd9dd-caa5-48c8-8da3-9c0b9b99458a">242,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTYtMS0xLTEtMjEzNg_65d20e6a-8a08-4aa8-a8b5-0148f6fdd0df">3,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTYtMy0xLTEtMjEzNg_67a76c98-b69b-4837-863c-0b69cc6b67ed">3,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTctMS0xLTEtMjEzNg_df96444e-8856-4920-bc58-ea1d6b24da34">8,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTctMy0xLTEtMjEzNg_828e0c9a-378a-4774-a7a3-a4183d9e9f3f">10,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTgtMS0xLTEtMjEzNg_891018ea-6606-4f1a-9252-c57a90b26b31">30,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTgtMy0xLTEtMjEzNg_901e4ce4-abdb-4865-b70d-20fb2b1fc85a">25,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred rent, current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" name="us-gaap:AccruedRentCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTktMS0xLTEtMjEzNg_ce1c189c-2d3b-4c1c-850a-2407b53a5e33">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" name="us-gaap:AccruedRentCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTktMy0xLTEtMjEzNg_ed6950da-46a5-4c8c-b2b4-7c9b35a831c6">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjAtMS0xLTEtMjEzNg_9c4b9b9b-6b37-4fe8-95e3-33003dd505ee">41,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjAtMy0xLTEtMjEzNg_b68229ae-db0e-4c73-ad32-b208e0836a9d">39,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjMtMS0xLTEtMjEzNg_9f5976ea-e76b-4856-b9cb-6c86e73f1a85">46,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjMtMy0xLTEtMjEzNg_f6c3bec7-afe3-4074-bad4-b75b03356064">57,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred rent, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" name="us-gaap:AccruedRentNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjQtMS0xLTEtMjEzNg_2af37f65-2677-4ec5-a039-3694c62794dc">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" name="us-gaap:AccruedRentNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjQtMy0xLTEtMjEzNg_2fe54e83-e60b-4222-a1d6-a744d857be62">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjUtMS0xLTEtMjEzNg_e8b91b35-a72c-47fd-bb1a-7311d141703b">88,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjUtMy0xLTEtMjEzNg_531d767f-af16-4d4b-8476-48c3f0b4d101">97,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred shares, $<ix:nonFraction unitRef="usdPerShare" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjgtMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjE2YWI2OTlmZDZlOTQ4N2ZiNTZjZDMxODUzYTgzOWM5XzIy_67afc8ef-84cb-416f-a833-d7ad3a057327"><ix:nonFraction unitRef="usdPerShare" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjgtMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjE2YWI2OTlmZDZlOTQ4N2ZiNTZjZDMxODUzYTgzOWM5XzIy_79989d10-ba84-4f3d-a6a1-d45223b82ef7">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjgtMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjE2YWI2OTlmZDZlOTQ4N2ZiNTZjZDMxODUzYTgzOWM5XzM2_9d1a745b-4295-4a7e-ba28-23dc4ed9fac0"><ix:nonFraction unitRef="shares" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjgtMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjE2YWI2OTlmZDZlOTQ4N2ZiNTZjZDMxODUzYTgzOWM5XzM2_b63c0acd-7d8b-48ee-aec8-d77b4824998e">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjgtMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjE2YWI2OTlmZDZlOTQ4N2ZiNTZjZDMxODUzYTgzOWM5XzU4_00ebd298-6be6-487b-a4f4-04333e30b95c"><ix:nonFraction unitRef="shares" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjgtMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjE2YWI2OTlmZDZlOTQ4N2ZiNTZjZDMxODUzYTgzOWM5XzU4_d9e560f9-c330-49c7-9469-aa844b466a4c"><ix:nonFraction unitRef="shares" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjgtMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjE2YWI2OTlmZDZlOTQ4N2ZiNTZjZDMxODUzYTgzOWM5XzU4_dc436d9e-72d7-4aca-bb4a-c48ca95be2f0"><ix:nonFraction unitRef="shares" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjgtMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjE2YWI2OTlmZDZlOTQ4N2ZiNTZjZDMxODUzYTgzOWM5XzU4_de90c241-d92b-42a2-b1b2-52fa62153acd">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September&#160;30, 2021 and December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjgtMS0xLTEtMjEzNg_1fd8c36c-ece4-40f5-824f-e7bee70af4d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjgtMy0xLTEtMjEzNg_535e26fe-2f36-454c-8642-7513d5451d1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares, $<ix:nonFraction unitRef="usdPerShare" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjktMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjVjNjY4NWFlMWEwMjQxOTc4OGU1ZDc5YmU5YTdiNTkyXzE5_30d283d0-c022-4db5-bfdd-9f98bf088b89"><ix:nonFraction unitRef="usdPerShare" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjktMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjVjNjY4NWFlMWEwMjQxOTc4OGU1ZDc5YmU5YTdiNTkyXzE5_8794d62c-a340-465f-acce-6ee0e2827585">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjktMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjVjNjY4NWFlMWEwMjQxOTc4OGU1ZDc5YmU5YTdiNTkyXzMz_ccdc694a-88e5-4927-ab27-f4274fa6e0c9"><ix:nonFraction unitRef="shares" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjktMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjVjNjY4NWFlMWEwMjQxOTc4OGU1ZDc5YmU5YTdiNTkyXzMz_d5faebca-7736-45cc-aae6-04fc226a6228">400,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjktMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjVjNjY4NWFlMWEwMjQxOTc4OGU1ZDc5YmU5YTdiNTkyXzU1_fa3d4711-34b2-4c81-86a9-7e1ad65f2341"><ix:nonFraction unitRef="shares" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjktMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjVjNjY4NWFlMWEwMjQxOTc4OGU1ZDc5YmU5YTdiNTkyXzU1_ff253210-0bc7-480d-9998-25a51b5cde14">36,892,411</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September&#160;30, 2021 and <ix:nonFraction unitRef="shares" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjktMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjVjNjY4NWFlMWEwMjQxOTc4OGU1ZDc5YmU5YTdiNTkyXzExMg_88c3e55e-03d0-4785-a17e-163a91d3a674"><ix:nonFraction unitRef="shares" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjktMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjVjNjY4NWFlMWEwMjQxOTc4OGU1ZDc5YmU5YTdiNTkyXzExMg_dea8e94a-7055-4199-8a81-bb12da741c77">32,037,686</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjktMS0xLTEtMjEzNg_40bfab6b-bbc4-4a84-86a4-2415b1fc0049">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjktMy0xLTEtMjEzNg_e297d95d-53f9-460b-a40b-e310c386c0e1">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid&#8209;in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMzAtMS0xLTEtMjEzNg_ce598f43-2e39-4e36-9dec-b1aae36892a5">566,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMzAtMy0xLTEtMjEzNg_06129725-30b2-45d1-9d0a-aead5eb34aa2">287,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMzEtMS0xLTEtMjEzNg_7bbe30df-2eb0-4632-b1cb-d81b2e19485f">216,652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMzEtMy0xLTEtMjEzNg_dea98e0d-93a8-436c-8e6f-0c9184a261e8">142,512</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMzItMS0xLTEtMjEzNg_341ee3c7-67d8-415f-ac4d-2d7d29a24fe7">93</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMzItMy0xLTEtMjEzNg_8331cd71-7372-4cee-95c4-df0567106818">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMzMtMS0xLTEtMjEzNg_8eb42156-3275-4202-9fe2-9f35d8b72abd">350,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMzMtMy0xLTEtMjEzNg_a6e9d18c-811e-4b6a-a555-ef763aebb8cb">145,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMzQtMS0xLTEtMjEzNg_4cc02510-2c28-4439-ac0a-2a9fc7585044">438,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMzQtMy0xLTEtMjEzNg_ab4e263e-1bd6-460e-ad1d-1d391f3e7303">242,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MORPHIC HOLDING, INC.<br/>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited)<br/>(In thousands, except share and per share data)</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMy0xLTEtMS0yMTM2_63f762d8-191e-4a85-9dee-3d3ca9822a91">3,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMy0zLTEtMS0yMTM2_5152ff84-e2fb-4cd5-9ea2-114dea4ec602">25,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMy01LTEtMS0yMTM2_4a321af0-18c3-43a3-bcc8-eb806255c6a2">10,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMy03LTEtMS0yMTM2_81a95ea7-fd35-4dd3-9acd-f4bd881b23aa">39,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfNS0xLTEtMS0yMTM2_ee0aca43-dda3-437e-935c-7cc5acdf73ae">20,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfNS0zLTEtMS0yMTM2_9bc06629-7e87-4340-8385-71ff0fe271d4">15,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfNS01LTEtMS0yMTM2_b41ce81c-362a-4c5e-8198-d3d8248903a9">64,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfNS03LTEtMS0yMTM2_d7e0b0c9-9fc3-4aa1-91ab-d586692dbb15">54,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfNi0xLTEtMS0yMTM2_bffeaba1-f139-4efe-8e9f-efd1edde00e6">7,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfNi0zLTEtMS0yMTM2_92244266-585f-4f3d-849d-30af894260cc">4,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfNi01LTEtMS0yMTM2_3da80be0-0579-416c-afa4-78d4aa74b04f">20,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfNi03LTEtMS0yMTM2_b0118d9a-77aa-483f-810d-e29397e81475">13,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfNy0xLTEtMS0yMTM2_4944b808-1f59-42b0-862b-d5bc8cb5c69b">28,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfNy0zLTEtMS0yMTM2_63822278-5bbc-4379-86ec-c28c781aed33">20,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfNy01LTEtMS0yMTM2_16e3c4ad-1089-49e5-94c9-a9245570cfe5">84,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfNy03LTEtMS0yMTM2_6c11339d-ab0a-4b26-864b-ff041d4dcdc6">68,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) Income from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfOC0xLTEtMS0yMTM2_0b33c897-0ce6-46aa-88e3-cb56f192697b">25,118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfOC0zLTEtMS0yMTM2_5ed6c4ed-3607-45fd-8c11-7f49f856704c">5,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfOC01LTEtMS0yMTM2_f4461b44-78ac-4cf7-98d5-314ac465a152">74,260</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfOC03LTEtMS0yMTM2_96fa0e4c-7c38-4776-814f-92d5165474a9">29,201</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTAtMS0xLTEtMjEzNg_0a41c4b4-d2ce-48c2-910b-770e895cce8a">77</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTAtMy0xLTEtMjEzNg_250caf89-1a80-48e5-83c0-ab5017ae765c">237</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTAtNS0xLTEtMjEzNg_65442dca-89f6-4f0a-b902-99ba4c8b36c9">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTAtNy0xLTEtMjEzNg_109654b4-7230-4401-ad04-9f2f56b74dfd">1,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTEtMS0xLTEtMjEzNg_78fc9dfb-074f-4c6f-abff-b92ccd1ecbbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTEtMy0xLTEtMjEzNg_7c38c159-435e-4963-8f79-795085968105">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTEtNS0xLTEtMjEzNg_85ea44a1-4935-4d09-b6a3-162ea42185c8">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTEtNy0xLTEtMjEzNg_fd933df3-5e6f-4a4e-8a69-68b547dc89b6">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTItMS0xLTEtMjEzNg_3da67055-4260-4b7e-9d6d-be3d115ba538">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTItMy0xLTEtMjEzNg_11aeb642-5d4a-4330-bf52-08cdc72dcf0b">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTItNS0xLTEtMjEzNg_16c30221-68d9-45c6-b3b9-4b8dc79d2c4c">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTItNy0xLTEtMjEzNg_19c61240-9c14-4715-92db-ddedd29a2c0e">1,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) Income before benefit from income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTMtMS0xLTEtMjEzNg_6330bab7-e623-4f16-9b7b-2c21d7bf322f">25,041</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTMtMy0xLTEtMjEzNg_2dab9a37-70fb-4e50-b751-02b0b62637c3">5,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTMtNS0xLTEtMjEzNg_c2ef99bf-b9e2-4ca3-b11c-442de8bb711e">74,140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTMtNy0xLTEtMjEzNg_47658af0-af19-44b0-ad09-30c78fd54086">27,677</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTQtMS0xLTEtMjEzNg_c7f30281-30b7-4109-9a3e-b27780f1e711">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTQtMy0xLTEtMjEzNg_86b1b654-1780-455e-88e6-3b4218cbec0c">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTQtNS0xLTEtMjEzNg_6a14587b-eeec-4c2a-996e-8585364d6ad0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTQtNy0xLTEtMjEzNg_fa80066e-19b8-44fa-b6fc-2824e1a7ccba">427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTUtMS0xLTEtMjEzNg_172f3ede-705c-40e5-9068-b1501d12816e">25,041</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTUtMy0xLTEtMjEzNg_9e1ccf23-fc2d-4bb0-8a75-820d5156b1c7">5,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTUtNS0xLTEtMjEzNg_23b29a7f-d182-47cd-8ca8-040601c2cc74">74,140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTUtNy0xLTEtMjEzNg_7d8eeb7a-2df7-4356-a390-235b7513d136">27,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share, basic </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTYtMS0xLTEtMjEzNg_f2eab23e-37c7-41d2-b99a-c10b9cad2e42">0.69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTYtMy0xLTEtMjEzNg_b1f014c5-1d96-44ff-92f1-af428e2439e2">0.18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTYtNS0xLTEtMjEzNg_7086749f-f604-4cbb-a151-cd0dddbde57d">2.09</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTYtNy0xLTEtMjEzNg_92d4f044-2677-4ce2-bba4-9724ed66a46a">0.90</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share, diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTctMS0xLTEtMzIzMw_79806467-afcf-4b8c-be86-3d2ad5dca9e3"><ix:nonFraction unitRef="usdPerShare" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTctMS0xLTEtMzIzMw_804d6c04-826f-4040-8267-7f8f30485929">0.69</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTctMy0xLTEtMzIzMw_b831b3c0-dd7e-4681-8b13-4c29ea9d0613">0.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTctNS0xLTEtMzIzMw_54816111-70ae-48ef-b789-f7061e8dff0c">2.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTctNy0xLTEtMzIzMw_547eb4aa-908b-4ab6-afc9-062c05893440">0.90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTgtMS0xLTEtMjEzNg_16b61173-78ef-471f-bf7d-89aebd053823">36,547,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTgtMy0xLTEtMjEzNg_1e3618e5-2c38-4d59-97a6-f03baac82b93">30,533,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTgtNS0xLTEtMjEzNg_60a728ed-2999-4329-9ef7-9c5af11c7f1b">35,392,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTgtNy0xLTEtMjEzNg_83ea6809-8076-4794-861f-f1c055f8acc8">30,368,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjAtMS0xLTEtMzI0NQ_433664a5-964d-421d-a6d9-3b9c8a5c36a0">36,547,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjAtMy0xLTEtMzI0NQ_13de2d2e-096f-4544-821d-21af080aeaad">32,366,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjAtNS0xLTEtMzI0NQ_518b28e4-710d-4034-bcac-cfe20c9b80fe">35,392,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjAtNy0xLTEtMzI0NQ_5a01372b-5e08-410f-9aea-6bc74b16ff4d">30,368,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive (loss) income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjEtMS0xLTEtMjEzNg_535ed7dd-dba4-408b-953e-7236683dfe81">25,041</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjEtMy0xLTEtMjEzNg_28c9ee6a-5a18-4be1-8811-2c81ee59867a">5,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjEtNS0xLTEtMjEzNg_d93c3c83-8743-40ce-b4db-82b6e32cb1ec">74,140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjEtNy0xLTEtMjEzNg_adbf4fc0-2659-4e02-aa2f-8c1cd330a6c1">27,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized holding losses on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjMtMS0xLTEtMjEzNg_6c815e8b-c655-43a0-af03-f76134abe9d1">73</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjMtMy0xLTEtMjEzNg_30867330-5aef-40f3-bd56-af643405044d">190</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjMtNS0xLTEtMjEzNg_1b723a48-b3ad-48ac-8594-55845c2fdb8d">72</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjMtNy0xLTEtMjEzNg_400be2da-c306-49a3-9ed1-fecca4ffa89d">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjQtMS0xLTEtMjEzNg_8d182329-3e11-4895-8451-50a8202fc1c5">73</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjQtMy0xLTEtMjEzNg_51442c91-5d6b-407a-85de-d38397de5375">190</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjQtNS0xLTEtMjEzNg_b6a0ca9a-87c1-44c4-8cf9-f844c7736f79">72</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjQtNy0xLTEtMjEzNg_d044492f-d5c4-46b7-8e3f-1d731855cf0a">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive (loss) income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjUtMS0xLTEtMjEzNg_32488dd4-1d8c-4054-8a76-4a78c87fa647">25,114</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjUtMy0xLTEtMjEzNg_007f5ece-d7fe-49cf-9ed1-0883c82b2ee6">5,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjUtNS0xLTEtMjEzNg_3e1d5d21-aeb3-491f-bfe5-97d53c56f5e7">74,212</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjUtNy0xLTEtMjEzNg_a121666b-e786-403e-9835-f8dfc02ad1b9">27,260</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MORPHIC HOLDING, INC.<br/>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (Unaudited)<br/>(In thousands, except share data)</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.320%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid&#8209;in<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income (Loss)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d6197cbb2f545b7ab683c1901d4ea29_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMi0xLTEtMS00NjM4_7afc5e57-5669-4298-922a-afd3735c3604">32,037,686</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d6197cbb2f545b7ab683c1901d4ea29_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMi0zLTEtMS00NjM4_7a795159-d5e1-4628-9bae-a9f2b5567c44">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i243f3682abd5424ba05ed1db40ccb97c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMi01LTEtMS00NjM4_58062c7f-b912-416f-b806-641dc5c4584b">287,727</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27ecd01750ae41fab6b59da5854ce971_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMi03LTEtMS00NjM4_6d4e867e-4de9-425d-8f0e-05fb144b843f">142,512</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic197e04f10c7408ba4ef7db9f441c28a_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMi05LTEtMS00NjM4_0afc3498-95fe-418c-812a-c6840b74a4fa">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMi0xMS0xLTEtNDYzOA_0c347755-9915-4dac-92ac-251d26a79e6a">145,197</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity&#8209;based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66ab197779d14e8b9af5bcb81478b4c6_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMy01LTEtMS00NjM4_299b9e05-824b-4cf7-b799-a9a838858986">4,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i901f8ecd744645b8a45d1b64a74c0f58_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMy0xMS0xLTEtNDYzOA_2702d7be-849d-4f90-b16a-3889ec93b5dd">4,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of restricted shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9be65219686545cf83e7c3cd5542dd20_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfNC0xLTEtMS00NjM4_2414c3be-b99c-4807-b443-a7c33813088b">46,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common shares upon stock option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9be65219686545cf83e7c3cd5542dd20_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfNS0xLTEtMS00NjM4_5258e136-fc96-4569-a436-08aeba5e9eab">279,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66ab197779d14e8b9af5bcb81478b4c6_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfNS01LTEtMS00NjM4_33063866-68dc-4c32-b45d-eab89980686b">2,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i901f8ecd744645b8a45d1b64a74c0f58_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfNS0xMS0xLTEtNDYzOA_5a47f397-8f3d-45b1-9127-160194f341df">2,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common shares under the Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9be65219686545cf83e7c3cd5542dd20_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfNi0xLTEtMS00NjM4_80e46cd5-d00c-4f33-a47c-ed3ace038c1f">26,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66ab197779d14e8b9af5bcb81478b4c6_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfNi01LTEtMS00NjM4_34055cc2-577b-4348-9b01-f6ee2d2e7f67">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i901f8ecd744645b8a45d1b64a74c0f58_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfNi0xMS0xLTEtNDYzOA_5dd77d55-0d53-42cd-a322-d33ea2547c5c">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common shares through at-the-market offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i1d3e2328ff2041f58dcaeaaebb4233bc_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfNy0wLTEtMS00NjE3L3RleHRyZWdpb246ZmI2NTQ1MGRiMzQ3NDU4OTk5Mzk1MDJjNmU5ZGE3NWFfMTA5OTUxMTYyNzg4OQ_b947f005-f868-4e70-a4ad-5a8433d5f377">0.2</ix:nonFraction> million</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia01ec15ac72b4497a0496ccada0d94dc_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfNy0xLTEtMS00NjM4_224b5060-36b8-4d59-9eeb-557750a6e343">240,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4efb9d0eda5b4f64829d51d0b07ac1b0_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfNy01LTEtMS00NjM4_61212a5a-4966-4a75-b8ff-bc8f7cd56f98">7,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d3e2328ff2041f58dcaeaaebb4233bc_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfNy0xMS0xLTEtNDYzOA_aae3a9de-3ce5-4283-9e85-e67270e311dd">7,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common shares in secondary offering, net of offering costs of $<ix:nonFraction unitRef="usd" contextRef="i06ca94fcd1b246778b2f5c3579ac9473_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfOC0wLTEtMS00NjE3L3RleHRyZWdpb246MTQxM2UyYTM1YTBhNDg1MGI3YjRiY2ExMDI5NmQ5YzNfMTA5OTUxMTYyNzg4MA_721e518c-8966-4480-bf1f-a964096575a8">15.0</ix:nonFraction> million</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i58aa03ecfdd643a5894ce9870d82dbf6_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfOC0xLTEtMS00NjM4_04a71261-c059-4778-b932-0a5dd6183c34">3,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58aa03ecfdd643a5894ce9870d82dbf6_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfOC0zLTEtMS00NjM4_227f67e3-68e2-4fea-8c98-a98cb09b9bdc">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e6d9c7159174b0789e9ced5c520204e_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfOC01LTEtMS00NjM4_0fa24971-c290-4bbe-8f5b-037ef269a59e">230,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ca94fcd1b246778b2f5c3579ac9473_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfOC0xMS0xLTEtNDYzOA_5af7b58a-88c6-41a4-9a59-e6d75ed457f6">230,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized holding gains on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5690066625a42e3b87d0384affb2d01_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfOS05LTEtMS00NjM4_a926911c-1638-4535-85f1-93a2d7910613">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i901f8ecd744645b8a45d1b64a74c0f58_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfOS0xMS0xLTEtNDYzOA_4cebe9d1-2ff7-4d5d-8e04-00f34311aa3a">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib800117992e243cf8a7585686b33a363_D20210101-20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTAtNy0xLTEtNDYzOA_6df3906f-23bb-4a81-957a-478b5c696ac0">21,284</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i901f8ecd744645b8a45d1b64a74c0f58_D20210101-20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTAtMTEtMS0xLTQ2Mzg_c0f9a14f-6a20-4cef-9737-c00ca27bfff8">21,284</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i515d2c5350ad4f2d83c7a0bdffb1c873_I20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTEtMS0xLTEtNDYzOA_49b75cca-c304-4993-81b5-9e49b0ba15ef">36,131,275</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i515d2c5350ad4f2d83c7a0bdffb1c873_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTEtMy0xLTEtNDYzOA_3797cea2-1f12-429d-905e-792264c66a71">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc97a27759e34d4cb8df378b38cdacaf_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTEtNS0xLTEtNDYzOA_369da7f5-5f06-49d2-b9d4-736d9ab14456">532,700</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1553aca7f70042e7abd871d77d833356_I20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTEtNy0xLTEtNDYzOA_ea220ec0-383f-4336-be24-7bb2a41a7a61">163,796</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58cda165edf34fb0b54d026018e62af0_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTEtOS0xLTEtNDYzOA_068ae29b-1510-4f5b-84ae-62be8bcb01b8">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f81b65df28e4c0eb8e87eb238682f6f_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTEtMTEtMS0xLTQ2Mzg_872074ef-fa45-48f7-adca-0993df2479a6">368,892</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity&#8209;based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbabfe222fdf4273a3a4864d3c46bb31_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTItNS0xLTEtNDYzOA_0b861568-0919-4471-8d76-ce416f464ae8">5,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6b9e0cfb6c842a3a3373453c72b93c0_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTItMTEtMS0xLTQ2Mzg_a234f25f-9334-449c-977c-6fd138af9efe">5,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of restricted shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib6533246bc7740bfb131bb0f31d5ebce_D20210401-20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTMtMS0xLTEtNDYzOA_85202987-aece-49f4-bd9d-5dfd2dd3b0fd">24,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common shares upon stock option exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib6533246bc7740bfb131bb0f31d5ebce_D20210401-20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTQtMS0xLTEtNDYzOA_230d7fd8-6f87-450d-b2d9-06d66fd60694">122,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbabfe222fdf4273a3a4864d3c46bb31_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTQtNS0xLTEtNDYzOA_6ac8e6ca-0f5f-4591-869b-738dd49d69d6">1,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6b9e0cfb6c842a3a3373453c72b93c0_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTQtMTEtMS0xLTQ2Mzg_09cad903-fe2e-43d4-8d11-baedcd1e8d97">1,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized holding losses on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4bbeefbdf784a4a86d7368751611e4d_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTUtOS0xLTEtNDYzOA_3c52e657-15fb-407a-b8d5-f13802fa701a">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6b9e0cfb6c842a3a3373453c72b93c0_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTUtMTEtMS0xLTQ2Mzg_e166d4d1-6974-49fa-a2a1-b55985195ce4">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Offering costs incurred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbabfe222fdf4273a3a4864d3c46bb31_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTYtNS0xLTEtNDYzOA_8ac38698-3b10-4245-9e9c-515a8e3f6e9a">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6b9e0cfb6c842a3a3373453c72b93c0_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTYtMTEtMS0xLTQ2Mzg_3b119725-1eab-4ea7-a5fa-6c8809e51ff4">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3a28dfdb1574133a31c2bbdc51e68b2_D20210401-20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTctNy0xLTEtNDYzOA_12318f83-0ced-4118-87ee-9ee526d2d805">27,815</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6b9e0cfb6c842a3a3373453c72b93c0_D20210401-20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTctMTEtMS0xLTQ2Mzg_35c2c8ab-855e-4c70-b0b5-0f6050b60320">27,815</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2021 </span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id787d30e67454f57ad1994ca3038b201_I20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTgtMS0xLTEtNDYzOA_73a11cf7-2e64-4172-80fb-76ec652e1c0e">36,277,511</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id787d30e67454f57ad1994ca3038b201_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTgtMy0xLTEtNDYzOA_45e60c1d-9a16-4e63-af0e-d028d6ad8fec">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib159d5476c2447b29c76c974f6a73e16_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTgtNS0xLTEtNDYzOA_b7014998-d0a6-4c1e-adab-fc00530eb4c8">539,536</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie78e1f680612471088c63f49b5dd8a18_I20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTgtNy0xLTEtNDYzOA_5b057c47-2f27-45dc-9a20-1b047f0ca7fd">191,611</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6938de3cb6cf4fa7806a42ee8d41f58e_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTgtOS0xLTEtNDYzOA_02ea91bc-6293-49a7-abb7-892c2efd3563">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i045fb029fd9f4fd3ba7809ee012e5352_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTgtMTEtMS0xLTQ2Mzg_1ed94494-3b82-46b6-b9b7-c198ae14111b">347,909</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity&#8209;based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c8425c2e88641d2abdbb94c5d478327_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTktNS0xLTEtNDYzOA_1c522ff3-5661-49c2-ad61-4ff01bba9337">5,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTktMTEtMS0xLTQ2Mzg_ebd0b159-267f-4e99-a3bc-305a8f30fc34">5,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of restricted shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib378bf3c290247ed8a0dcf860e280f0f_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjAtMS0xLTEtNDYzOA_645f7f6c-6cd7-4a17-8cda-86216368f7ac">34,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common shares upon stock option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib378bf3c290247ed8a0dcf860e280f0f_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjEtMS0xLTEtNDYzOA_cd53783f-65b3-4b4d-909a-20d39d6425bc">273,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c8425c2e88641d2abdbb94c5d478327_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjEtNS0xLTEtNDYzOA_4b37f146-e58d-440d-a9c6-08e1d822453d">3,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjEtMTEtMS0xLTQ2Mzg_738f806f-6ce6-4d30-9172-9cfe50802b8a">3,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under the Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib378bf3c290247ed8a0dcf860e280f0f_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjItMS0xLTEtNDYzOA_09b518eb-7802-409c-b7cd-1ef88301937a">9,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c8425c2e88641d2abdbb94c5d478327_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjItNS0xLTEtNDYzOA_001f6979-f0de-499b-8f36-f68b52aac4a3">482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjItMTEtMS0xLTQ2Mzg_b530c3e0-97d2-4254-8be6-1e8d5c2014ea">482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common shares through at-the-market offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ie46f079ac4224779be66b7117f7c7607_D20210701-20210930" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjMtMC0xLTEtMjI2MDYvdGV4dHJlZ2lvbjozZmFlMDA5NGQ3ZTc0ZThhYjc2MTFlNWUxZGNlN2U5NF8xMDk5NTExNjI3ODg5_ded46afb-d10b-4953-bb3f-f1ba371ee60f">0.9</ix:nonFraction> million</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a9a17e2241e4a3f9bf48a8a07ea581f_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjMtMS0xLTEtMjExMDU_7e1b45c2-d2b3-4098-a235-9aa46229b6a1">298,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93e1933f2bc44d94bea2dcf014ef6034_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjMtNS0xLTEtMjExMDU_81815a19-cbb7-4430-9d9c-446d8fe959f0">17,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46f079ac4224779be66b7117f7c7607_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjMtMTEtMS0xLTIxMTA1_3e914668-af4a-42d5-81c0-9aa583e8e4af">17,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized holding losses on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if47513e8e86f49968b6af3544f6b81c9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjMtOS0xLTEtNDYzOA_ecfd7268-fbb2-4b58-8e29-4458156fff5e">73</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjMtMTEtMS0xLTQ2Mzg_fa29055c-49b9-4d70-8172-fc18c025fef1">73</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02e02a526a804154b6839aa55df1b6cb_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjQtNy0xLTEtNDYzOA_b0c504db-e4d4-4e92-a2dd-727ee956e8be">25,041</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjQtMTEtMS0xLTQ2Mzg_0cca5336-764c-4ad7-9a42-b35683ece295">25,041</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i525829a7d9e441d0ba3b4b60e68895fc_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjUtMS0xLTEtNDYzOA_8d6f9da6-7a6a-420b-a602-45179ff09b1e">36,892,411</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i525829a7d9e441d0ba3b4b60e68895fc_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjUtMy0xLTEtNDYzOA_685985e7-7016-43a7-935d-5e5f8f37e93c">4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67cb7e787c6f404fba5246e0f6e89ee6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjUtNS0xLTEtNDYzOA_5612fa77-1cb8-4382-af1f-e9167223c2dc">566,906</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5674ed6b01654ebeaed47a14ff3407ec_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjUtNy0xLTEtNDYzOA_2b75b3ef-792e-48dc-b088-998eb3a242c5">216,652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a0cdc60fdbc4ada914dbb870ef3b65e_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjUtOS0xLTEtNDYzOA_1b11f4ae-8205-40e6-938a-a71e07589113">93</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjUtMTEtMS0xLTQ2Mzg_0dba3706-f3ed-4ca3-89e1-d9be687bc921">350,165</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MORPHIC HOLDING, INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) (Continued)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share data)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.403%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid&#8209;in<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0289611dea94928a98cb550c8c5397a_I20191231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMi0yLTEtMS0yMTM2_af997c29-3b49-4626-be8c-cd9600e6f551">30,110,251</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0289611dea94928a98cb550c8c5397a_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMi00LTEtMS0yMTM2_161f9603-e9ce-47bc-915d-c8522db4e67f">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b404164f5bb4d7ca737270c6e265def_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMi02LTEtMS0yMTM2_0ee9bfdf-7bd7-4a0d-b725-cec67d88f480">238,384</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6bb096c70634192838a382eb5887887_I20191231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMi04LTEtMS0yMTM2_99185c6d-3b39-45f0-93c2-48271c3e9698">97,513</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2a95523e74652809cc83e76cc2c1c_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMi0xMC0xLTEtMjEzNg_06f946f1-8d01-4c34-8e6d-85b7da4cc88d">44</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2e37d454f86483da5d113ba5bb9c6ae_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMi0xMi0xLTEtMjEzNg_711794d8-b5fc-401b-89c8-7199c7e5a5fe">140,918</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b354f9bb8d47e8a80d9ddf5b84ae8c_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMy02LTEtMS0yNDY0_19b1c719-0b28-4ccb-832e-b7c8de9ae33c">2,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i678eec9b2b244447b18fc4ba9a55fb5d_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMy0xMi0xLTEtMjQ2NA_24a778d8-646c-4f9f-a778-69a5b0f5c39d">2,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of restricted shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id44003b9b0fc4840a4b1164b5acc2433_D20200101-20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfNC0yLTEtMS0yNDY0_2f29d0f3-5cb8-4087-a058-a14bb491e980">84,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common shares upon stock option exercises</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id44003b9b0fc4840a4b1164b5acc2433_D20200101-20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfNS0yLTEtMS0yNDY0_b615109d-7ca1-4ac1-b302-6a2ebe30f8a9">35,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b354f9bb8d47e8a80d9ddf5b84ae8c_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfNS02LTEtMS0yNDY0_de82c479-76e8-4b98-8f45-a2954e79bb62">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i678eec9b2b244447b18fc4ba9a55fb5d_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfNS0xMi0xLTEtMjQ2NA_dc3d2782-f2ad-48d0-a2dc-d2f291553e86">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under the Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id44003b9b0fc4840a4b1164b5acc2433_D20200101-20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfNi0yLTEtMS0yNDY0_378b6e21-54b8-437a-aad2-b3d4cffd024c">53,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b354f9bb8d47e8a80d9ddf5b84ae8c_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfNi02LTEtMS0yNDY0_9530b313-27cd-47cf-8cc9-dc2d6b87828c">681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i678eec9b2b244447b18fc4ba9a55fb5d_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfNi0xMi0xLTEtMjQ2NA_9ffb2ce7-ab18-408d-964c-caf4ce68622c">681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized holding gains on marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0b42c7d7a4a4d258150923a53914e00_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfNy0xMC0xLTEtMjQ2NA_5e7c07cd-10ad-4089-af18-05cb5d64834e">571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i678eec9b2b244447b18fc4ba9a55fb5d_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfNy0xMi0xLTEtMjQ2NA_86b5126d-4bfe-44fd-8202-595dbe187b5a">571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47ae904392494a1691f66d44af867fd5_D20200101-20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfOC04LTEtMS0yNDY0_737469ca-1989-47e1-b687-7c5f9c942db1">16,746</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i678eec9b2b244447b18fc4ba9a55fb5d_D20200101-20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfOC0xMi0xLTEtMjQ2NA_30ed7b30-fa95-455b-88fb-71f6b4dfed99">16,746</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib198e32eebb44ca09f321ba259b29ce2_I20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfOS0yLTEtMS0yMTM2_d4c39390-163c-4220-8145-1db90e3ee7e5">30,283,725</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib198e32eebb44ca09f321ba259b29ce2_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfOS00LTEtMS0yMTM2_509dcc1b-d162-49cb-a89f-eab8de6e559a">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id62a5c373f8043a49ac6d4b6edcb5f03_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfOS02LTEtMS0yMTM2_9e11a98f-95d6-48da-b45e-4219f94def15">241,776</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcc27241cea443418ead40c7a7f13130_I20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfOS04LTEtMS0yMTM2_4d6fea99-1924-47c0-aac1-6e8b64511557">114,259</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f787d6a671940b0a2ba97e900ceeba5_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfOS0xMC0xLTEtMjEzNg_d2180c88-9a0c-42d2-b86b-91427946e264">615</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i831afc5715a74d2ebfcc35bdfd047f7f_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfOS0xMi0xLTEtMjEzNg_1e31a1ab-2688-4dca-a840-b97035997165">128,135</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd4b367ccae649d798f837bc4bae25cf_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTAtNi0xLTEtMjEzNg_e46cbaab-dc95-45fb-9558-34ceebea770f">2,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b9b5c829b794265abbba640d8790b61_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTAtMTItMS0xLTIxMzY_46a428d8-f946-4159-a96b-f369fda3a436">2,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of restricted shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie820eb1d183044f29008086e76bb8abb_D20200401-20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTEtMi0xLTEtMjEzNg_83a037da-2ea6-4de1-b608-a0657bd24b75">57,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common shares upon stock option exercises</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie820eb1d183044f29008086e76bb8abb_D20200401-20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTItMi0xLTEtMjEzNg_224b7372-59de-4ec5-ac82-7ccf73b27a0a">80,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd4b367ccae649d798f837bc4bae25cf_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTItNi0xLTEtMjEzNg_549c71b8-8ec5-4455-bb48-e906df1d8b22">542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b9b5c829b794265abbba640d8790b61_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTItMTItMS0xLTIxMzY_f9f107cd-1184-458c-a130-a8bb3dd3a168">542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized holding gains on marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaa73485876b4e858b467fc72c87dc11_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTMtMTAtMS0xLTIxMzY_a0693995-eb23-497e-8ae2-fa20c98fcd79">391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b9b5c829b794265abbba640d8790b61_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTMtMTItMS0xLTIxMzY_823f72ea-2f76-497f-8d2e-8c83e9959cab">391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2b9993359cb456984780b6ee2dcb181_D20200401-20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTQtOC0xLTEtMjEzNg_4d5711ff-9bd8-4d98-9dca-2485868eb12c">15,858</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b9b5c829b794265abbba640d8790b61_D20200401-20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTQtMTItMS0xLTIxMzY_667469ad-d80b-4ed7-a590-7836724b9be7">15,858</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44de926c8806430b8699f3779b9c08b1_I20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTUtMi0xLTEtMjEzNg_23726da2-8075-4fbb-a38c-8028281c929a">30,421,775</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44de926c8806430b8699f3779b9c08b1_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTUtNC0xLTEtMjEzNg_7cabbed0-47dc-41d1-a48e-fda4ec87cc75">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c86edc9380f4e658d4c9376a669e0d9_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTUtNi0xLTEtMjEzNg_2e276488-ddde-4df0-ba62-b7112688d5aa">244,807</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie08a82cfc7f24fbbad0fe77f2bfe3618_I20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTUtOC0xLTEtMjEzNg_1d3c10e6-ee98-45b1-90f1-c5f0a175ce5e">130,117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22f2eddba4d5410b914c1f3b00fc8918_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTUtMTAtMS0xLTIxMzY_509d2182-ffa4-4de7-b680-ec77f8cca439">224</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61f47238d1b44b2a9637c0aa85dc0ee4_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTUtMTItMS0xLTIxMzY_212a314b-0aa1-43cb-9e79-2094a4182876">114,917</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49f954fe973a4718a7bb027c7e112f91_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTYtNi0xLTEtMjQyMg_dde0b266-f5d4-486c-9322-89a5c7325094">2,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTYtMTItMS0xLTI0MjI_dfece723-c33b-41e6-bcdc-04e58723288e">2,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of restricted shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i763837ff1bfa4e4395a5c9985fb3ea1d_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTctMi0xLTEtMjQyMg_f20c7ca7-7e8a-4ca0-9332-97a6c52cd6fc">56,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common shares through at-the-market offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ibb907e28eb904c5abe8778dff7854225_D20200701-20200930" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTgtMC0xLTEtMjQyMi90ZXh0cmVnaW9uOjk4MzU1NzUwNmU3YTQzNjc5NWViNWJiNTAzMGQ0ZmY1XzEwOTk1MTE2Mjc4ODc_cd6019be-2bab-4d82-bb9c-19b394df3469">0.6</ix:nonFraction> million</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7c337f23b5d94bce847216e32970fc13_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTgtMi0xLTEtMjQyMg_46118cb2-b7fa-4572-bc5d-f39b16b1e1ad">256,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ce691e108d44f41854e25c5b8aa249f_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTgtNi0xLTEtMjQyMg_52446dd5-2744-44f2-b4f2-7052f57049d6">6,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb907e28eb904c5abe8778dff7854225_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTgtMTItMS0xLTI0MjI_2330bc43-a807-4193-aec2-0bff44fadb2a">6,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common shares upon stock option exercises</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i763837ff1bfa4e4395a5c9985fb3ea1d_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTktMi0xLTEtMjQyMg_662cc422-d6ee-4ae1-98ea-07f392a0a7d5">60,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49f954fe973a4718a7bb027c7e112f91_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTktNi0xLTEtMjQyMg_8cef2b48-3af5-44ba-ba3c-393aedcbefbe">477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTktMTItMS0xLTI0MjI_2087a929-6cae-435c-ac4d-bd78ece93ac6">477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common shares under the Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i763837ff1bfa4e4395a5c9985fb3ea1d_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMjAtMi0xLTEtMjQyMg_4d72a67f-e893-40f1-9c4d-7d709782ca52">31,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49f954fe973a4718a7bb027c7e112f91_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMjAtNi0xLTEtMjQyMg_30b131be-fb79-4d5c-931a-d1496ed868d0">431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMjAtMTItMS0xLTI0MjI_2f8713a1-8699-48e6-a2fd-ea9ccefc58ad">431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized holding losses on marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58e35bd616704d81933f455f82a367b9_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMjEtMTAtMS0xLTI0MjI_29bd91a6-5644-496c-bc0c-e4c0260301ab">190</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMjEtMTItMS0xLTI0MjI_ea3ea892-d956-4bf5-8e69-ebec4ae33818">190</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e417c1626c0447da3ff198c9dbd9029_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMjItOC0xLTEtMjQyMg_ebdc12a5-26a3-465b-a50f-2a30f10ec04b">5,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMjItMTItMS0xLTI0MjI_34290133-a832-46de-bfac-0a22d531864d">5,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifecee13ba23d4d56894bc6a643e63e62_I20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMjMtMi0xLTEtMjQyMg_8126afb7-da62-4bdc-9e70-ce8790ffa5d1">30,827,653</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifecee13ba23d4d56894bc6a643e63e62_I20200930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMjMtNC0xLTEtMjQyMg_562c743a-63f4-403f-8853-28dc1855119e">3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5762a65d06864432a626e61cf3346d84_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMjMtNi0xLTEtMjQyMg_a4ca7f87-6fd7-455e-8695-82cc8a5fb7b9">255,030</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifdf49025fcce47b8a9f8b80534c93448_I20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMjMtOC0xLTEtMjQyMg_7b20c463-7d70-43c8-a1a4-830faaefddc7">124,763</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5c7026852d4a94bec2b79ab34bc87d_I20200930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMjMtMTAtMS0xLTI0MjI_0ab077dd-29d2-43d1-95ad-db5cdada28ae">34</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64b5dd8c546640129471ee97d4f9028f_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMjMtMTItMS0xLTI0MjI_2dc56f72-fe01-45ba-9d1b-5a235e9e2a58">130,304</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MORPHIC HOLDING, INC.<br/>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)<br/>(In thousands)</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMy0xLTEtMS0yMTM2_af48b730-0286-41c6-92a3-0d0c0d7c04e0">74,140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMy0zLTEtMS0yMTM2_26ca0ea9-476b-4489-a78a-42e7f524b595">27,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfNS0xLTEtMS0yMTM2_161e4172-05b0-4d56-be34-99a08a13c8c9">754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfNS0zLTEtMS0yMTM2_a4fedf39-0cdb-458b-803d-6be1ff252992">852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium amortization and discount accretion on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfNi0xLTEtMS0yMTM2_43e38b5a-ca4f-4ec7-99c1-4563e9eb0b09">531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfNi0zLTEtMS0yMTM2_08eb3691-902e-4692-bced-a6f28bc8934b">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity&#8209;based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfNy0xLTEtMS0yMTM2_b103b699-feef-4bef-833c-3b0e03db7622">15,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfNy0zLTEtMS0yMTM2_eb28147a-4ab0-4758-801f-66916f00651a">8,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on disposal of equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfOC0xLTEtMS0yMTM2_87255541-c661-459e-8ad8-c988c02b0c43">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfOC0zLTEtMS0yMTM2_d3c6e15f-895a-49a3-a9b6-820094acab03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTAtMS0xLTEtMjEzNg_54396d2c-c11b-4a1d-a1d4-bff038292197">4,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTAtMy0xLTEtMjEzNg_19dd40fa-6e04-4e60-b681-79306ced5da2">1,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTEtMS0xLTEtMjEzNg_71fba497-8741-499d-a788-839f73074376">1,353</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTEtMy0xLTEtMjEzNg_a0dcaf8c-39dd-4a90-be11-3c88a92fc614">530</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTItMS0xLTEtMjEzNg_6f901ab4-5236-4ed3-9e41-9e02cadedaf4">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTItMy0xLTEtMjEzNg_93e3c5b8-af53-4efc-91a3-f9e87e7da4c0">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTMtMS0xLTEtMjEzNg_9a577dcc-ec90-4410-ab11-5e4c274428fe">842</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTMtMy0xLTEtMjEzNg_6492b82d-f882-4ba6-9b20-d7f0b41b51d5">1,893</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTQtMS0xLTEtMjEzNg_0978443c-1377-49dd-9349-6a5754148b3e">1,743</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTQtMy0xLTEtMjEzNg_9d88f8ba-4818-4c4d-aa56-a40a56a610ba">818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTUtMS0xLTEtMjEzNg_15fe41ca-693d-4538-9d67-fc695a4c6205">6,295</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTUtMy0xLTEtMjEzNg_4927448c-4ae8-4a61-8375-eb20082bf1c5">13,878</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred rent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" sign="-" name="morf:IncreaseDecreaseInDeferredRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTYtMS0xLTEtMjEzNg_811f1099-14d4-4f5b-8ae3-3e0db32dcf77">80</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" sign="-" name="morf:IncreaseDecreaseInDeferredRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTYtMy0xLTEtMjEzNg_72200d81-89d9-49d1-9093-614ebb821735">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTgtMS0xLTEtMjEzNg_1a9e3bc8-aac6-4709-a0a5-585d3ce9183c">62,876</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTgtMy0xLTEtMjEzNg_6f26bfcc-af4f-40e2-b7d1-3d07979f943f">31,572</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjAtMS0xLTEtMjEzNg_715d052d-8222-4102-ba0a-49b0899139e5">223,803</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjAtMy0xLTEtMjEzNg_f80f0387-79f2-4866-bf6a-6cb4e01d9bb4">95,049</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from maturities of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjEtMS0xLTEtMjEzNg_5ca3c9ad-1136-435a-b9fb-aedbf7029480">106,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjEtMy0xLTEtMjEzNg_1264482a-2513-4102-83e3-cd9bfb3ffe21">115,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjItMS0xLTEtMjEzNg_caae0bec-57fb-4b71-8024-afb5cd7cbfb8">563</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjItMy0xLTEtMjEzNg_1c0f6aa7-8563-44ce-9c64-e1028de05406">475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjMtMS0xLTEtMjEzNg_5f1821a3-32bb-4dfd-b5d7-5b8d40c54535">118,366</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjMtMy0xLTEtMjEzNg_c450de47-64c3-4a15-b5ff-2c6d86b4740f">19,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from issuance of common shares under Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjYtMS0xLTEtMjEzNg_6fd786e8-30cd-421c-9240-334c6f890d0b">1,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjYtMy0xLTEtMjEzNg_1746a628-e370-452e-9236-800fdc0042e5">1,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from at-the-market offering, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjctMS0xLTEtMjEzNg_9a2f5813-27cd-48ab-8f5b-aa8222a33a98">24,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjctMy0xLTEtMjEzNg_ef3775f1-5380-485a-8a17-59d7051e85ab">6,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from secondary offering, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjgtMS0xLTEtMjEzNg_c4edbae5-f553-4a4f-8c1d-b5bc960285e2">229,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjgtMy0xLTEtMjEzNg_ca810c78-b910-4f44-8985-fc5491828652">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from issuance of common shares upon stock option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjktMS0xLTEtMjEzNg_e7f127b3-c4d4-4f0b-883b-f36c607fd6e6">7,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjktMy0xLTEtMjEzNg_c78c088b-e8b4-4760-a890-64fb6bf15f07">1,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMzAtMS0xLTEtMjEzNg_8e01a05b-98b2-4307-9ed4-e278acaa480e">263,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMzAtMy0xLTEtMjEzNg_42e41ed4-cdf8-47fd-af6d-41e3e9ee8a7d">8,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMzEtMS0xLTEtMjEzNg_f39d381f-d348-4d15-8715-83d4b4ab64ef">82,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMzEtMy0xLTEtMjEzNg_f7e5580c-7c22-4e78-afe5-d21851c231a9">3,479</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMzItMS0xLTEtMjEzNg_c63cf0da-5393-460d-99e5-9b09870bd6a7">102,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2e37d454f86483da5d113ba5bb9c6ae_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMzItMy0xLTEtMjEzNg_b9e84d4a-40c0-4502-8532-330bad465e4c">101,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMzMtMS0xLTEtMjEzNg_221370d5-e9dc-4f94-ab3c-b2cd01a58979">184,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64b5dd8c546640129471ee97d4f9028f_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMzMtMy0xLTEtMjEzNg_447a9ee8-7b1c-4c4a-8011-83e789ee5671">98,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of property and equipment included in accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMzYtMS0xLTEtMjEzNg_4189e854-395d-4d1f-a9af-b40f7f566549">173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMzYtMy0xLTEtMjEzNg_57fc9c4b-34f8-4d82-bf17-ef23efafe325">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfNDEtMS0xLTEtMjEzNg_1223b470-cfe7-4bd5-bcf5-64e0d5c789d5">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfNDEtMy0xLTEtMjEzNg_8c526979-02fe-405d-bdf4-0d34cecce9e1">480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)</span></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_31"></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zMS9mcmFnOmU3OGNjZWI4NzVlYjQ0MGU4ZGIxNmJlMGQ3MDkwZDYzL3RleHRyZWdpb246ZTc4Y2NlYjg3NWViNDQwZThkYjE2YmUwZDcwOTBkNjNfNDE1OA_c82455e4-c016-48bf-9f6e-44cf33d12c34" continuedAt="i4873f30ae776402089db52d995bf4cbb" escape="true">Nature of the Business and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="i4873f30ae776402089db52d995bf4cbb"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization and Liquidity</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Morphic Holding, Inc. (the &#8220;Company&#8221;) was formed under the laws of the State of Delaware in August 2014. The Company is a biopharmaceutical company applying proprietary insights into integrin medicine to discover and develop first-in-class oral small molecule integrin therapeutics. Integrins are a validated target class with multiple approved drugs for the treatment of serious chronic diseases. Despite significant biopharmaceutical industry investment, no oral integrin therapies have been approved. The Company has created the Morphic integrin technology platform, or MInT Platform, by leveraging its unique understanding of integrin structure and biology, to develop a pipeline of novel product candidates designed to achieve potency, high selectivity, and the pharmaceutical properties required for oral administration.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.&#160;The Company expects to continue to incur losses from operations for the foreseeable future. The Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements through at least the next 12 months from the date these financial statements were issued.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2020, the Company entered into an Open Market Sale Agreement (&#8220;the Original Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;) with respect to an at-the-market (&#8220;ATM&#8221;) offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of our common stock, having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i5f1bf035ce6148889916ac0580538d5b_D20200701-20200731" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zMS9mcmFnOmU3OGNjZWI4NzVlYjQ0MGU4ZGIxNmJlMGQ3MDkwZDYzL3RleHRyZWdpb246ZTc4Y2NlYjg3NWViNDQwZThkYjE2YmUwZDcwOTBkNjNfNDk0NzgwMjMzNDE0OQ_a6240f26-a8cc-4881-bb03-ddcf919635ce">75,000,000</ix:nonFraction>, referred to as Placement Shares, through Jefferies as its sales agent. The Company paid Jefferies a commission equal to <ix:nonFraction unitRef="number" contextRef="i3a3fb30525ad4997ad257edca9bb1309_D20200701-20200731" decimals="INF" name="morf:PercentageOfCommissionOnGrossSaleProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zMS9mcmFnOmU3OGNjZWI4NzVlYjQ0MGU4ZGIxNmJlMGQ3MDkwZDYzL3RleHRyZWdpb246ZTc4Y2NlYjg3NWViNDQwZThkYjE2YmUwZDcwOTBkNjNfNDk0NzgwMjMzNDE2Mg_335dc75e-9ab7-4698-a641-71cc54e0f943">3.0</ix:nonFraction>% of the gross sales proceeds of any Placement Shares sold through Jefferies under the Original Agreement, and also has provided Jefferies with customary indemnification and contribution rights. On August 11, 2021, the Company entered into an Amendment No. 1 to the Open Market Sale Agreement with Jefferies, establishing a new at-the-market offering (&#8220;New ATM&#8221;) with an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i2c1c09e4655f462d8172c3fed16c5d41_D20210811-20210811" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zMS9mcmFnOmU3OGNjZWI4NzVlYjQ0MGU4ZGIxNmJlMGQ3MDkwZDYzL3RleHRyZWdpb246ZTc4Y2NlYjg3NWViNDQwZThkYjE2YmUwZDcwOTBkNjNfMTA5OTUxMTY0MDczNA_d964b5b2-3655-470e-b780-dc0fd5956edf">150,000,000</ix:nonFraction>, also subject to a commission equal to <ix:nonFraction unitRef="number" contextRef="i8539e76f9660442e9d169db576c8aedd_D20210811-20210811" decimals="INF" name="morf:PercentageOfCommissionOnGrossSaleProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zMS9mcmFnOmU3OGNjZWI4NzVlYjQ0MGU4ZGIxNmJlMGQ3MDkwZDYzL3RleHRyZWdpb246ZTc4Y2NlYjg3NWViNDQwZThkYjE2YmUwZDcwOTBkNjNfNDk0NzgwMjMzNzk1OQ_23592277-6c27-4957-9346-adc19f1b279e">3.0</ix:nonFraction>% of gross sales proceeds from Placement Shares sold through Jefferies.  Under the New ATM, the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, referred to as Placement Shares, through Jefferies as its sales agent.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended September&#160;30, 2021, <ix:nonFraction unitRef="shares" contextRef="i16001d4e30b441e1808c258ac136a45a_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zMS9mcmFnOmU3OGNjZWI4NzVlYjQ0MGU4ZGIxNmJlMGQ3MDkwZDYzL3RleHRyZWdpb246ZTc4Y2NlYjg3NWViNDQwZThkYjE2YmUwZDcwOTBkNjNfMTA5OTUxMTYzMjAzNg_94c25b78-c44b-44fb-b32a-872d9fbfafdc">298,070</ix:nonFraction> shares under the ATM were sold for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i16001d4e30b441e1808c258ac136a45a_D20210701-20210930" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zMS9mcmFnOmU3OGNjZWI4NzVlYjQ0MGU4ZGIxNmJlMGQ3MDkwZDYzL3RleHRyZWdpb246ZTc4Y2NlYjg3NWViNDQwZThkYjE2YmUwZDcwOTBkNjNfMTA5OTUxMTYzMjA2MQ_0066da11-ae98-4f6d-b6ed-00eabbe8e57d">17.4</ix:nonFraction> million after deducting offering commissions and offering expenses paid by the Company. During the nine months ended September&#160;30, 2021, the Company issued and sold <ix:nonFraction unitRef="shares" contextRef="i6a6c3241ca9141c9bbb04c6d0c0c55fa_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zMS9mcmFnOmU3OGNjZWI4NzVlYjQ0MGU4ZGIxNmJlMGQ3MDkwZDYzL3RleHRyZWdpb246ZTc4Y2NlYjg3NWViNDQwZThkYjE2YmUwZDcwOTBkNjNfMTA5OTUxMTYzMjMyOA_a90b2c43-7019-40b2-a2f9-618afad2a39f">538,774</ix:nonFraction> shares for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i6a6c3241ca9141c9bbb04c6d0c0c55fa_D20210101-20210930" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zMS9mcmFnOmU3OGNjZWI4NzVlYjQ0MGU4ZGIxNmJlMGQ3MDkwZDYzL3RleHRyZWdpb246ZTc4Y2NlYjg3NWViNDQwZThkYjE2YmUwZDcwOTBkNjNfMTA5OTUxMTYzMjMzMg_a67faba0-bf52-4250-a068-2469168898e5">24.6</ix:nonFraction> million after deducting offering commissions and offering expenses paid by the Company. As of September&#160;30, 2021, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="i77369a4a13ef44fa8daace2f7956ce2a_I20210930" decimals="-5" name="morf:CommonStockAvailableForIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zMS9mcmFnOmU3OGNjZWI4NzVlYjQ0MGU4ZGIxNmJlMGQ3MDkwZDYzL3RleHRyZWdpb246ZTc4Y2NlYjg3NWViNDQwZThkYjE2YmUwZDcwOTBkNjNfMTA5OTUxMTYzMjM0MA_c9cf1e75-1888-43a3-a9c2-1bbea0953916">138.9</ix:nonFraction> million of common stock remaining available for sale under the ATM.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company completed an underwritten follow-on public offering of <ix:nonFraction unitRef="shares" contextRef="ie84d1725167c4a75be6380089ca4347a_D20210301-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zMS9mcmFnOmU3OGNjZWI4NzVlYjQ0MGU4ZGIxNmJlMGQ3MDkwZDYzL3RleHRyZWdpb246ZTc4Y2NlYjg3NWViNDQwZThkYjE2YmUwZDcwOTBkNjNfMzg1Mg_a4d7e1a9-c699-41e9-b3e5-04e2022ae2bb">3,500,000</ix:nonFraction> shares of its common stock at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="i8cf597d615c64759b8f60cb2d5d4e180_I20210331" decimals="INF" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zMS9mcmFnOmU3OGNjZWI4NzVlYjQ0MGU4ZGIxNmJlMGQ3MDkwZDYzL3RleHRyZWdpb246ZTc4Y2NlYjg3NWViNDQwZThkYjE2YmUwZDcwOTBkNjNfMzkxMA_131bfb69-6433-4d87-8385-aec14bd62f8d">70.00</ix:nonFraction> per share. Gross proceeds from the secondary offering were approximately $<ix:nonFraction unitRef="usd" contextRef="ie84d1725167c4a75be6380089ca4347a_D20210301-20210331" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zMS9mcmFnOmU3OGNjZWI4NzVlYjQ0MGU4ZGIxNmJlMGQ3MDkwZDYzL3RleHRyZWdpb246ZTc4Y2NlYjg3NWViNDQwZThkYjE2YmUwZDcwOTBkNjNfMzk4Ng_50747fde-2af2-4f9b-b62a-2c95c5c679cb">245.0</ix:nonFraction>&#160;million, before deducting underwriting discounts, commissions and other offering expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="ie84d1725167c4a75be6380089ca4347a_D20210301-20210331" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zMS9mcmFnOmU3OGNjZWI4NzVlYjQ0MGU4ZGIxNmJlMGQ3MDkwZDYzL3RleHRyZWdpb246ZTc4Y2NlYjg3NWViNDQwZThkYjE2YmUwZDcwOTBkNjNfNDA4OA_7ee159e7-c938-4121-846a-2656e5a23755">15.0</ix:nonFraction>&#160;million, paid by the Company, resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="ie84d1725167c4a75be6380089ca4347a_D20210301-20210331" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zMS9mcmFnOmU3OGNjZWI4NzVlYjQ0MGU4ZGIxNmJlMGQ3MDkwZDYzL3RleHRyZWdpb246ZTc4Y2NlYjg3NWViNDQwZThkYjE2YmUwZDcwOTBkNjNfNDE1Ng_c92276fa-5038-4d52-9a03-352356e34e54">230.0</ix:nonFraction>&#160;million.</span></div></ix:continuation><div id="i78343c0ada4c4eb7afb5039f4dd8197f_34"></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNC9mcmFnOjMyZGVhNWI1NDQzMzQ0MjhiODBiZmIwYzkyYjBlY2ZlL3RleHRyZWdpb246MzJkZWE1YjU0NDMzNDQyOGI4MGJmYjBjOTJiMGVjZmVfNzkwNQ_98acac90-e37f-421a-9d19-616ea63a0af9" continuedAt="ibcbec8fd67784a3d80316bcd432f0d5f" escape="true">Basis of Presentation and Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ibcbec8fd67784a3d80316bcd432f0d5f" continuedAt="ib80088669ab1485d96545ba0ddeb9803"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements include the accounts of Morphic Holding, Inc. and its wholly owned subsidiaries, Morphic Therapeutic, Inc. and a Massachusetts Security Corporation, organized in December 2019 to take advantage of the favorable tax treatment of income earned on securities held within such entity. All intercompany balances have been eliminated in consolidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). Certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements have been </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="ib80088669ab1485d96545ba0ddeb9803" continuedAt="ic57250cf4e6b44c091cc609848878112"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condensed or omitted. These unaudited interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company&#8217;s financial position and results of operations for the interim periods ended September&#160;30, 2021 and 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December&#160;31, 2020, and the notes thereto, which are included in the Company&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 1, 2021.</span></div><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNC9mcmFnOjMyZGVhNWI1NDQzMzQ0MjhiODBiZmIwYzkyYjBlY2ZlL3RleHRyZWdpb246MzJkZWE1YjU0NDMzNDQyOGI4MGJmYjBjOTJiMGVjZmVfNzkwNg_846128c6-6b84-46fe-908a-b8582535750d" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates and Summary of Significant Accounting Policies</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP requires management to make estimates and judgments that may affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the related reporting of revenues and expenses during the reporting period. Significant estimates of accounting reflected in these consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued research and development expenses, the valuation of equity-based compensation, and income taxes. Actual results could differ from those estimates.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant accounting policies</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant accounting policies used in preparation of these condensed consolidated financial statements as of and for the three and nine months ended September&#160;30, 2021 are consistent with those discussed in Note 2 to the consolidated financial statements in the Company&#8217;s 2020 Annual Report on Form 10-K, except as described below.</span></div><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="morf:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNC9mcmFnOjMyZGVhNWI1NDQzMzQ0MjhiODBiZmIwYzkyYjBlY2ZlL3RleHRyZWdpb246MzJkZWE1YjU0NDMzNDQyOGI4MGJmYjBjOTJiMGVjZmVfNzkwNw_fd0079d0-bca3-464f-9623-2d7dd71c6c8a" continuedAt="if151023af4664aae906355f1fb6b67ca" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements not yet Adopted</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At IPO, as an &#8220;emerging growth company,&#8221; or EGC, under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, the Company has made an election under Section 107 of the JOBS Act to take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards and has been following requirements applicable to the private companies for adopting new and updated accounting standards. Based on the value of the Company's common stock held by non-affiliates on June 30, 2021, the Company will become a large accelerated filer for the year ending December 31, 2021 and will follow adoption guidance mandated for non-EGC entities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, Financial Instruments Credit Losses (Topic 326) (&#8220;ASU 2016-13&#8221;), which requires consideration of a broader range of reasonable and supportable information in developing credit loss estimates. In April 2019, the FASB issued ASU 2019-04, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments (&#8220;ASU 2019-04&#8221;). Certain provisions of ASU 2019-04 amend the guidance of ASU 2016-13, are applicable to the Company&#8217;s investments portfolio, and allow the Company to make certain accounting policy elections regarding establishing allowance for credit losses for the accrued interest receivable and the corresponding disclosures. In November 2019, the FASB issued ASU No. 2019-11, Codification Improvements to Topic 326, Financial Instruments &#8211; Credit Losses (&#8220;ASU 2019-11&#8221;), which clarifies certain areas of the guidance to ensure all companies and organizations can make a smoother transition to the standard. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company will become a large accelerated filer and as a result, the guidance under ASU 2019-04, ASU 2016-13 and ASU 2019-11 is effective for the Company's Annual Report on Form 10-K to be filed for the year ended December 31, 2021. The Company will record a cumulative effect adjustment to retained earnings retroactive to January 1, 2021, the date of adoption. The Company is currently evaluating the impact of ASU 2019-11 and the related ASU 2019-04 and ASU 2016-13 on its consolidated financial statements, including the impact of the available accounting policy elections. The Company does not expect this guidance to have a material impact on its consolidated financial statements. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), with guidance regarding the accounting for and disclosure of leases. In general, for lease arrangements exceeding a twelve-month term, these arrangements must now be recognized as assets and liabilities on the balance sheet of the lessee. Under ASU 2016-02, a right-of-use asset and lease obligation will be recorded for all leases, whether operating or financing, while the income statement will reflect lease expense for operating leases and amortization/interest expense for financing leases. The balance sheet amount recorded for existing leases at the date of adoption of ASU 2016-02 must be calculated using the applicable incremental borrowing rate at the date of adoption. This update also requires lessees and lessors to disclose key information about their leasing transactions. In July 2018, the FASB issued ASU 2018-11, Leases - Targeted Improvements, intended to ease the implementation of the new lease </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="ic57250cf4e6b44c091cc609848878112" continuedAt="i4939f2623bf54ab2aa32e2d6c1e19b2c"><ix:continuation id="if151023af4664aae906355f1fb6b67ca" continuedAt="i875228d9e1ff43329463c0de672823b9"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">standard for financial statement preparers by, among other things, allowing for an additional transition method. In lieu of presenting transition requirements to comparative periods, as previously required, an entity may now elect to show a cumulative effect adjustment on the date of adoption without the requirement to recast prior period financial statements or disclosures presented in accordance with ASU 2016-02.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently expects to elect the available package of practical expedients which allows the Company to not reassess previous accounting conclusions around whether arrangements are or contain leases, the classification of leases, and the treatment of initial direct costs. The Company also expects it will make an accounting policy election to keep leases with an initial term of 12 months or less off of the balance sheet. </span></div></ix:continuation></ix:continuation><div style="margin-bottom:18pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i4939f2623bf54ab2aa32e2d6c1e19b2c"><ix:continuation id="i875228d9e1ff43329463c0de672823b9">In August 2021, the Company exercised its one-time extension right for its existing lease for <ix:nonFraction unitRef="sqft" contextRef="i196c1e6bf66247b98fa293ce7ce21c10_I20210831" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AreaOfLand" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNC9mcmFnOjMyZGVhNWI1NDQzMzQ0MjhiODBiZmIwYzkyYjBlY2ZlL3RleHRyZWdpb246MzJkZWE1YjU0NDMzNDQyOGI4MGJmYjBjOTJiMGVjZmVfNDk0NzgwMjMzMzI1Mg_8f5ee994-3cc8-4d10-9a38-c69b13d1b85b">35,000</ix:nonFraction> square feet of office and laboratory space through May 2025, as provided for under the terms of the lease. The Company is currently evaluating the effect of adopting the requirements of ASU 2016-02 as it relates to its facility lease, as amended in August 2021, and discussed in Note 10 to the consolidated financial statements appearing in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2020. The Company is also performing an evaluation of other material contracts to determine if any contain embedded leases, and has not identified any to date. As of December 31, 2021, the Company will become a large accelerated filer and as a result, the guidance under ASU 2016-02 is effective for the Company's Annual Report on Form 10-K to be filed for the year ended December 31, 2021, with an effective date of adoption of January 1, 2021.</ix:continuation></ix:continuation> </span></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_37"></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RleHRyZWdpb246YjZmM2VmNzM3MDhmNGI4N2FhZTYyNDYzYjMxZmQxN2ZfMjQ0Ng_00c86c13-304a-4f46-afed-67243d296bc0" continuedAt="iaec66091d1384eeba6bf105d80d32b1a" escape="true">Fair Value of Financial Assets and Liabilities</ix:nonNumeric></span></div><ix:continuation id="iaec66091d1384eeba6bf105d80d32b1a" continuedAt="if7c1a09d0fef40fca612beed65919db9"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has certain financial assets and liabilities that are recorded at fair value which have been classified as Level&#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8212; Quoted market prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8212; Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8212; Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At September&#160;30, 2021, investments also include corporate debt securities which are valued either based on recent trades of securities in inactive markets or based on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RleHRyZWdpb246YjZmM2VmNzM3MDhmNGI4N2FhZTYyNDYzYjMxZmQxN2ZfMjQ0Nw_20e1e410-492e-49a7-bc3c-c1572f9f0a73" continuedAt="i804625f5c7bd43eba5afe7ae38cd1c82" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about the Company&#8217;s financial assets that are measured at fair value on a recurring basis as of September&#160;30, 2021 and December&#160;31, 2020 (in thousands) and indicate the level within the fair value hierarchy where each measurement is classified.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i385155a063a54593b7698266553fa968_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfNC0xLTEtMS0yMTM2_4df7d99c-570c-4c12-a22a-1e1ac1f855ee">143,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic691b1bab6064f3d9b9e1c90394f4e2d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfNC0zLTEtMS0yMTM2_5a7579ff-e22d-4ba0-b83f-1406284fe19a">143,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40e4cfd2a8045e1a1e666498fe4e815_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfNC01LTEtMS0yMTM2_86354921-b4e9-409a-804e-81b4f802c08d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i037043297a254ed9b5cf0826c9db9fa9_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfNC03LTEtMS0yMTM2_b6b6d7c7-a76e-4bbb-8360-d8998ef7e929">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb831f5a17f54f7584aa402e76bb36fe_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfNS0xLTEtMS0yMTM2_373a7a83-db9f-423b-98e1-70ddfe9b1588">32,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486fa776a3f04f34ac576895fc27dad7_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfNS0zLTEtMS0yMTM2_8d7eec36-0ff2-41ec-96ad-2a9b39fef5a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fb8ba20056d490189b4417c8db4fc8b_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfNS01LTEtMS0yMTM2_3d6af515-fffd-499d-ab9d-cb627a3306f3">32,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8565d342aa34348b2d8b3de28ae62d2_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfNS03LTEtMS0yMTM2_1bba3481-4620-4f9f-89ed-64f495c5306a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64b03ce48904405aa038b9b8f79e221c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfOC0xLTEtMS0yMDI2OA_8e26636e-ed9f-4795-8213-397d4cdf2461">211,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79dd709730de462484976109499248c0_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfOC0zLTEtMS0yMDI2OA_178befd4-fe3b-4606-ae1a-b5221125d741">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3093e8eb0fbf40cfaf61a51b86743dfc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfOC01LTEtMS0yMDI2OA_cb16671a-0991-4814-a4e9-cbd795694a19">211,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0460516fcd64ec5939869a8cc9083fc_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfOC03LTEtMS0yMDI2OA_c619f01b-b89f-4636-8c7e-b16cd144574f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a2b23055c14610b9b9f0122e0bc83c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfNi0xLTEtMS0yMTM2_272c9d88-6504-4f16-b6ba-45b0ca611c43">387,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57619922f2b04e87b375de9b0c6abf2f_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfNi0zLTEtMS0yMTM2_8028e8cb-2468-4c5e-9fda-c6f98270805d">143,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4e846feef646b38404ae6f8ed330dc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfNi01LTEtMS0yMTM2_16483793-242c-4dc4-a27f-36e0a25f4fe6">243,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd960eb27fba42f3a7c083248ce24430_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfNi03LTEtMS0yMTM2_d483d9e7-b624-4eba-8bcd-e92fadcfb7f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if7c1a09d0fef40fca612beed65919db9"><div><ix:continuation id="i804625f5c7bd43eba5afe7ae38cd1c82"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i488d3d9e7497417dae3338d286bf285c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjgxMDdmNGM3M2JhYjQ3ZGI4YmUyOGQyNjZkMTJiMzFlL3RhYmxlcmFuZ2U6ODEwN2Y0YzczYmFiNDdkYjhiZTI4ZDI2NmQxMmIzMWVfNC0xLTEtMS0yMTM2_f412186d-9931-40b7-834a-e070cb57313f">101,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1efba4c0bfa64c24912b8e57773d8914_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjgxMDdmNGM3M2JhYjQ3ZGI4YmUyOGQyNjZkMTJiMzFlL3RhYmxlcmFuZ2U6ODEwN2Y0YzczYmFiNDdkYjhiZTI4ZDI2NmQxMmIzMWVfNC0zLTEtMS0yMTM2_80f1b08f-7131-4c77-8c4d-7d9bfc763aae">101,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a595f6291d745078296fee41e88b0b5_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjgxMDdmNGM3M2JhYjQ3ZGI4YmUyOGQyNjZkMTJiMzFlL3RhYmxlcmFuZ2U6ODEwN2Y0YzczYmFiNDdkYjhiZTI4ZDI2NmQxMmIzMWVfNC01LTEtMS0yMTM2_27fb7d78-630a-4392-a194-986395899522">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06a28dfa4674c8da99858f333e14322_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjgxMDdmNGM3M2JhYjQ3ZGI4YmUyOGQyNjZkMTJiMzFlL3RhYmxlcmFuZ2U6ODEwN2Y0YzczYmFiNDdkYjhiZTI4ZDI2NmQxMmIzMWVfNC03LTEtMS0yMTM2_674e7d30-116e-4413-b815-bbc45eeaa25c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddb9c72e419f4eadbe5c615a694858f7_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjgxMDdmNGM3M2JhYjQ3ZGI4YmUyOGQyNjZkMTJiMzFlL3RhYmxlcmFuZ2U6ODEwN2Y0YzczYmFiNDdkYjhiZTI4ZDI2NmQxMmIzMWVfNi0xLTEtMS0yMTM2_14486803-c3b3-4236-86c2-518ffd93ed12">126,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i078df3d57b71434481ab87bd4712a953_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjgxMDdmNGM3M2JhYjQ3ZGI4YmUyOGQyNjZkMTJiMzFlL3RhYmxlcmFuZ2U6ODEwN2Y0YzczYmFiNDdkYjhiZTI4ZDI2NmQxMmIzMWVfNi0zLTEtMS0yMTM2_5501f123-2c78-40d8-bfd3-3eeaa27e09c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f25b4bb5f1f4854b5ecb14766c3ca49_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjgxMDdmNGM3M2JhYjQ3ZGI4YmUyOGQyNjZkMTJiMzFlL3RhYmxlcmFuZ2U6ODEwN2Y0YzczYmFiNDdkYjhiZTI4ZDI2NmQxMmIzMWVfNi01LTEtMS0yMTM2_91ea2ada-f545-4b17-a0d7-f6bcab2d8a0f">126,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12b799caa9b242aabc2dbefff0e5f757_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjgxMDdmNGM3M2JhYjQ3ZGI4YmUyOGQyNjZkMTJiMzFlL3RhYmxlcmFuZ2U6ODEwN2Y0YzczYmFiNDdkYjhiZTI4ZDI2NmQxMmIzMWVfNi03LTEtMS0yMTM2_240ebd08-9ee8-4083-8130-dd71aa7dfa4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib207c5a6d64c4722b33aa55f1f923141_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjgxMDdmNGM3M2JhYjQ3ZGI4YmUyOGQyNjZkMTJiMzFlL3RhYmxlcmFuZ2U6ODEwN2Y0YzczYmFiNDdkYjhiZTI4ZDI2NmQxMmIzMWVfNy0xLTEtMS0yMTM2_831257e0-3f4b-4759-a046-ff63aab8afb7">227,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8109e4aa5a0416e9392220462770a8c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjgxMDdmNGM3M2JhYjQ3ZGI4YmUyOGQyNjZkMTJiMzFlL3RhYmxlcmFuZ2U6ODEwN2Y0YzczYmFiNDdkYjhiZTI4ZDI2NmQxMmIzMWVfNy0zLTEtMS0yMTM2_81f79176-81c6-4f67-99fe-c07d7838b179">101,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie493a72a05bd4a50bb01b9136293db44_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjgxMDdmNGM3M2JhYjQ3ZGI4YmUyOGQyNjZkMTJiMzFlL3RhYmxlcmFuZ2U6ODEwN2Y0YzczYmFiNDdkYjhiZTI4ZDI2NmQxMmIzMWVfNy01LTEtMS0yMTM2_6445ccc3-1440-452f-ad35-94d638c7c639">126,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f1e91996364358920d91dc6eedb07f_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjgxMDdmNGM3M2JhYjQ3ZGI4YmUyOGQyNjZkMTJiMzFlL3RhYmxlcmFuZ2U6ODEwN2Y0YzczYmFiNDdkYjhiZTI4ZDI2NmQxMmIzMWVfNy03LTEtMS0yMTM2_9f8594b5-e12d-4d72-80e2-29be10891467">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The money market funds included in the tables above invest in U.S. government securities that are valued using quoted market prices. Accordingly, money market funds are categorized as Level 1 as of September&#160;30, 2021 and December&#160;31, 2020. Marketable securities included in the tables above consist of U.S. Treasury securities and corporate debt securities, and these securities are categorized as Level 2 as of September&#160;30, 2021 and December&#160;31, 2020. During the nine months ended September&#160;30, 2021, no assets were transferred between the fair value hierarchy categories. The Company had no liabilities measured at fair value on a recurring basis at September&#160;30, 2021 or December&#160;31, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that the carrying amounts of the Company&#8217;s condensed consolidated financial instruments, including prepaid expenses and other current assets, accounts receivable, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments.</span></div></ix:continuation><div id="i78343c0ada4c4eb7afb5039f4dd8197f_40"></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RleHRyZWdpb246OTAyNzM3YTgwZDAyNDY2NTk3YzY0OWM5MzJhMjdjNTRfMTA5OTUxMTYyNzk0MDk_559ace01-8e07-45cc-892d-953a7e6aae92" continuedAt="ibc90aff26f9d4eb6a7b23b7369d91d2c" escape="true">Marketable securities</ix:nonNumeric></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><ix:continuation id="ibc90aff26f9d4eb6a7b23b7369d91d2c"><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RleHRyZWdpb246OTAyNzM3YTgwZDAyNDY2NTk3YzY0OWM5MzJhMjdjNTRfMTY2_36079d3b-a18c-4ce8-a2fa-72f3cf15452b" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s investments in marketable securities classified as available for sale (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.642%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less than 1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f5553a6ec7c411da7d58ef985358ba5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOjJmNGQ5N2E1NjQ2NTQxZjRhMTViZWE2NWVmMzZjYTMwL3RhYmxlcmFuZ2U6MmY0ZDk3YTU2NDY1NDFmNGExNWJlYTY1ZWYzNmNhMzBfMi0zLTEtMS0yMTM2_9fed219f-dd67-4ae0-9ed1-992842bdab4f">32,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f5553a6ec7c411da7d58ef985358ba5_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOjJmNGQ5N2E1NjQ2NTQxZjRhMTViZWE2NWVmMzZjYTMwL3RhYmxlcmFuZ2U6MmY0ZDk3YTU2NDY1NDFmNGExNWJlYTY1ZWYzNmNhMzBfMi01LTEtMS0yMTM2_565d7be6-a24f-42c6-bc46-0280624c8fc3">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f5553a6ec7c411da7d58ef985358ba5_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOjJmNGQ5N2E1NjQ2NTQxZjRhMTViZWE2NWVmMzZjYTMwL3RhYmxlcmFuZ2U6MmY0ZDk3YTU2NDY1NDFmNGExNWJlYTY1ZWYzNmNhMzBfMi03LTEtMS0yMTM2_5f90ec35-cc23-428f-b8d5-23c11c3a83f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f5553a6ec7c411da7d58ef985358ba5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOjJmNGQ5N2E1NjQ2NTQxZjRhMTViZWE2NWVmMzZjYTMwL3RhYmxlcmFuZ2U6MmY0ZDk3YTU2NDY1NDFmNGExNWJlYTY1ZWYzNmNhMzBfMi05LTEtMS0yMTM2_ddb9c492-63e3-403a-baf2-bce9c2dc60df">32,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">within 2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i103b3b3fd13b4d969b9f99f276f756be_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOjJmNGQ5N2E1NjQ2NTQxZjRhMTViZWE2NWVmMzZjYTMwL3RhYmxlcmFuZ2U6MmY0ZDk3YTU2NDY1NDFmNGExNWJlYTY1ZWYzNmNhMzBfNS0zLTEtMS0yMDM5MQ_3cb1c6ea-f40b-4ba3-935f-e5ddb37141b7">211,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i103b3b3fd13b4d969b9f99f276f756be_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOjJmNGQ5N2E1NjQ2NTQxZjRhMTViZWE2NWVmMzZjYTMwL3RhYmxlcmFuZ2U6MmY0ZDk3YTU2NDY1NDFmNGExNWJlYTY1ZWYzNmNhMzBfNS01LTEtMS0yMDM5MQ_6313bac9-dedf-49a0-86b2-edf50e01252d">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i103b3b3fd13b4d969b9f99f276f756be_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOjJmNGQ5N2E1NjQ2NTQxZjRhMTViZWE2NWVmMzZjYTMwL3RhYmxlcmFuZ2U6MmY0ZDk3YTU2NDY1NDFmNGExNWJlYTY1ZWYzNmNhMzBfNS03LTEtMS0yMDM5MQ_2d75cdb2-ad1e-408c-b710-96da5c200954">83</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i103b3b3fd13b4d969b9f99f276f756be_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOjJmNGQ5N2E1NjQ2NTQxZjRhMTViZWE2NWVmMzZjYTMwL3RhYmxlcmFuZ2U6MmY0ZDk3YTU2NDY1NDFmNGExNWJlYTY1ZWYzNmNhMzBfNS05LTEtMS0yMDM5MQ_d043ac46-e06c-48c8-a714-e4612c269da4">211,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOjJmNGQ5N2E1NjQ2NTQxZjRhMTViZWE2NWVmMzZjYTMwL3RhYmxlcmFuZ2U6MmY0ZDk3YTU2NDY1NDFmNGExNWJlYTY1ZWYzNmNhMzBfOC0zLTEtMS0yMDM5MQ_e09ada1c-140c-4a56-a0b3-ee9d02403c71">243,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOjJmNGQ5N2E1NjQ2NTQxZjRhMTViZWE2NWVmMzZjYTMwL3RhYmxlcmFuZ2U6MmY0ZDk3YTU2NDY1NDFmNGExNWJlYTY1ZWYzNmNhMzBfOC01LTEtMS0yMDM5MQ_2ec72347-0a23-4313-ac1e-fcc1c83d7088">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOjJmNGQ5N2E1NjQ2NTQxZjRhMTViZWE2NWVmMzZjYTMwL3RhYmxlcmFuZ2U6MmY0ZDk3YTU2NDY1NDFmNGExNWJlYTY1ZWYzNmNhMzBfOC03LTEtMS0yMDM5MQ_cdbb96f5-bd3a-4cc7-9197-5b2cd8ce3655">83</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOjJmNGQ5N2E1NjQ2NTQxZjRhMTViZWE2NWVmMzZjYTMwL3RhYmxlcmFuZ2U6MmY0ZDk3YTU2NDY1NDFmNGExNWJlYTY1ZWYzNmNhMzBfOC05LTEtMS0yMDM5MQ_7d9eb4f3-8289-4e1d-9e3e-78f8a9f1e3a1">243,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.642%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less than 1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie233b4a2750a4b268a177be345cf1c52_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOmUzYWFjNGJkYjFmODQ3ODQ5NTQzYTY2NTJmNzU5ZGY3L3RhYmxlcmFuZ2U6ZTNhYWM0YmRiMWY4NDc4NDk1NDNhNjY1MmY3NTlkZjdfMi0zLTEtMS0yMTM2_181b4cf0-1bbe-44d4-ab9a-c374c4ef7bea">126,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie233b4a2750a4b268a177be345cf1c52_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOmUzYWFjNGJkYjFmODQ3ODQ5NTQzYTY2NTJmNzU5ZGY3L3RhYmxlcmFuZ2U6ZTNhYWM0YmRiMWY4NDc4NDk1NDNhNjY1MmY3NTlkZjdfMi01LTEtMS0yMTM2_efb2faec-1e21-4a10-9ea3-50a7ed207aa0">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie233b4a2750a4b268a177be345cf1c52_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOmUzYWFjNGJkYjFmODQ3ODQ5NTQzYTY2NTJmNzU5ZGY3L3RhYmxlcmFuZ2U6ZTNhYWM0YmRiMWY4NDc4NDk1NDNhNjY1MmY3NTlkZjdfMi03LTEtMS0yMTM2_96acfb7d-9f5b-4705-b94e-fe1ddb96ddc0">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie233b4a2750a4b268a177be345cf1c52_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOmUzYWFjNGJkYjFmODQ3ODQ5NTQzYTY2NTJmNzU5ZGY3L3RhYmxlcmFuZ2U6ZTNhYWM0YmRiMWY4NDc4NDk1NDNhNjY1MmY3NTlkZjdfMi05LTEtMS0yMTM2_3d496245-7c67-4edc-bc52-45d38e3fb0a9">126,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOmUzYWFjNGJkYjFmODQ3ODQ5NTQzYTY2NTJmNzU5ZGY3L3RhYmxlcmFuZ2U6ZTNhYWM0YmRiMWY4NDc4NDk1NDNhNjY1MmY3NTlkZjdfNC0zLTEtMS0yMDQxNA_44598178-49fd-46e6-9e66-193a7f3b1dd0">126,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOmUzYWFjNGJkYjFmODQ3ODQ5NTQzYTY2NTJmNzU5ZGY3L3RhYmxlcmFuZ2U6ZTNhYWM0YmRiMWY4NDc4NDk1NDNhNjY1MmY3NTlkZjdfNC01LTEtMS0yMDQxNA_f55aeb7a-45eb-4f5a-8034-ce9ece3dedd4">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOmUzYWFjNGJkYjFmODQ3ODQ5NTQzYTY2NTJmNzU5ZGY3L3RhYmxlcmFuZ2U6ZTNhYWM0YmRiMWY4NDc4NDk1NDNhNjY1MmY3NTlkZjdfNC03LTEtMS0yMDQxNA_5d8fdf15-e267-4660-a6ac-601b12269e23">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOmUzYWFjNGJkYjFmODQ3ODQ5NTQzYTY2NTJmNzU5ZGY3L3RhYmxlcmFuZ2U6ZTNhYWM0YmRiMWY4NDc4NDk1NDNhNjY1MmY3NTlkZjdfNC05LTEtMS0yMDQxNA_bd4a5663-12eb-4428-8e35-eb4931c43fe7">126,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s investments are classified as available-for-sale and are carried at fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income (loss). The Company considers all available-for-sale securities, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs and therefore classifies all securities with maturity dates beyond 90 days at the date of purchase as current assets.</span></div></ix:continuation><div id="i78343c0ada4c4eb7afb5039f4dd8197f_43"></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RleHRyZWdpb246YjdlZTdjOWE4MDhhNDM5ZGJiZjFkNDA0NmYyNTYxMmVfMzc0_f5dd6fc1-15cb-48c4-b31e-39934078eaa6" continuedAt="i8e8b885583ae45eeb07db6837c6f6816" escape="true">Cash, Cash Equivalents and Restricted Cash</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8e8b885583ae45eeb07db6837c6f6816" continuedAt="i49c08611230e4ea49bc5ebd030839d27">Restricted cash consists of a letter of credit in the amount of $<ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RleHRyZWdpb246YjdlZTdjOWE4MDhhNDM5ZGJiZjFkNDA0NmYyNTYxMmVfMTEz_aa45083a-f6e1-45e4-8024-f1b59c4fb229">560,000</ix:nonFraction> issued to the landlord of the Company&#8217;s facility lease as of September 30, 2021. The letter of credit increased from $<ix:nonFraction unitRef="usd" contextRef="i9fa385b09a9947cbaaa1c35bef4b2881_I20210831" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RleHRyZWdpb246YjdlZTdjOWE4MDhhNDM5ZGJiZjFkNDA0NmYyNTYxMmVfNDk0NzgwMjMyNTYxMA_4ae2dc2f-3133-4f25-bd79-7fb1f3d3934e">275,000</ix:nonFraction> in August 2021 due to the operating lease extension discussed further in Note 2. The terms of the letter of credit extend beyond <ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RleHRyZWdpb246YjdlZTdjOWE4MDhhNDM5ZGJiZjFkNDA0NmYyNTYxMmVfMjIw_d1a9e565-0794-44a8-8f15-45fbb1c6b079">one year</ix:nonNumeric>. <ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RleHRyZWdpb246YjdlZTdjOWE4MDhhNDM5ZGJiZjFkNDA0NmYyNTYxMmVfMzc1_5e543b18-1292-4bcc-93cb-ab4f76bce87b" continuedAt="i2b9d41cc581b4f3589e65bbdb184bbd9" escape="true">The following table reconciles cash, cash equivalents and restricted cash per the balance sheet to the statements of cash flows (in thousands):</ix:nonNumeric></ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><ix:continuation id="i49c08611230e4ea49bc5ebd030839d27"><ix:continuation id="i2b9d41cc581b4f3589e65bbdb184bbd9"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RhYmxlOjkxMjY3MjAxM2FmNjRlNjI4YmNhZTFlNmRjODk2NjcyL3RhYmxlcmFuZ2U6OTEyNjcyMDEzYWY2NGU2MjhiY2FlMWU2ZGM4OTY2NzJfMy0xLTEtMS0yMTM2_dc082eef-8366-4b4b-a9ee-35e8617bcbdb">184,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RhYmxlOjkxMjY3MjAxM2FmNjRlNjI4YmNhZTFlNmRjODk2NjcyL3RhYmxlcmFuZ2U6OTEyNjcyMDEzYWY2NGU2MjhiY2FlMWU2ZGM4OTY2NzJfMy0zLTEtMS0yMTM2_0d480679-5d63-4a76-ac7e-aaa750988aad">102,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64b5dd8c546640129471ee97d4f9028f_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RhYmxlOjkxMjY3MjAxM2FmNjRlNjI4YmNhZTFlNmRjODk2NjcyL3RhYmxlcmFuZ2U6OTEyNjcyMDEzYWY2NGU2MjhiY2FlMWU2ZGM4OTY2NzJfMy01LTEtMS0yMTM2_e8130edb-f347-49a3-a519-0595c9b75a34">98,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2e37d454f86483da5d113ba5bb9c6ae_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RhYmxlOjkxMjY3MjAxM2FmNjRlNjI4YmNhZTFlNmRjODk2NjcyL3RhYmxlcmFuZ2U6OTEyNjcyMDEzYWY2NGU2MjhiY2FlMWU2ZGM4OTY2NzJfMy03LTEtMS0yMTM2_c05044e8-7d0b-4e1c-8cce-870ceee4204a">101,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RhYmxlOjkxMjY3MjAxM2FmNjRlNjI4YmNhZTFlNmRjODk2NjcyL3RhYmxlcmFuZ2U6OTEyNjcyMDEzYWY2NGU2MjhiY2FlMWU2ZGM4OTY2NzJfNC0xLTEtMS0yMTM2_f6dcd046-848a-44f1-8634-0a1210e3dd90">560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RhYmxlOjkxMjY3MjAxM2FmNjRlNjI4YmNhZTFlNmRjODk2NjcyL3RhYmxlcmFuZ2U6OTEyNjcyMDEzYWY2NGU2MjhiY2FlMWU2ZGM4OTY2NzJfNC0zLTEtMS0yMTM2_201df9b6-a364-4ddd-b578-474662c1689d">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64b5dd8c546640129471ee97d4f9028f_I20200930" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RhYmxlOjkxMjY3MjAxM2FmNjRlNjI4YmNhZTFlNmRjODk2NjcyL3RhYmxlcmFuZ2U6OTEyNjcyMDEzYWY2NGU2MjhiY2FlMWU2ZGM4OTY2NzJfNC01LTEtMS0yMTM2_eb4f1c9a-159e-41a5-ac1a-9d98b1e35d6f">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2e37d454f86483da5d113ba5bb9c6ae_I20191231" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RhYmxlOjkxMjY3MjAxM2FmNjRlNjI4YmNhZTFlNmRjODk2NjcyL3RhYmxlcmFuZ2U6OTEyNjcyMDEzYWY2NGU2MjhiY2FlMWU2ZGM4OTY2NzJfNC03LTEtMS0yMTM2_d7b29593-b59b-4acf-a1a4-f94d8f53a5fa">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RhYmxlOjkxMjY3MjAxM2FmNjRlNjI4YmNhZTFlNmRjODk2NjcyL3RhYmxlcmFuZ2U6OTEyNjcyMDEzYWY2NGU2MjhiY2FlMWU2ZGM4OTY2NzJfNS0xLTEtMS0yMTM2_592f20b7-2abd-4448-b781-0b4861f18fcb">184,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RhYmxlOjkxMjY3MjAxM2FmNjRlNjI4YmNhZTFlNmRjODk2NjcyL3RhYmxlcmFuZ2U6OTEyNjcyMDEzYWY2NGU2MjhiY2FlMWU2ZGM4OTY2NzJfNS0zLTEtMS0yMTM2_c893b16a-dd26-42c4-9e59-a598ed01457d">102,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64b5dd8c546640129471ee97d4f9028f_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RhYmxlOjkxMjY3MjAxM2FmNjRlNjI4YmNhZTFlNmRjODk2NjcyL3RhYmxlcmFuZ2U6OTEyNjcyMDEzYWY2NGU2MjhiY2FlMWU2ZGM4OTY2NzJfNS01LTEtMS0yMTM2_e1d65f70-b879-4db7-a4c6-9a6fded745ca">98,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2e37d454f86483da5d113ba5bb9c6ae_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RhYmxlOjkxMjY3MjAxM2FmNjRlNjI4YmNhZTFlNmRjODk2NjcyL3RhYmxlcmFuZ2U6OTEyNjcyMDEzYWY2NGU2MjhiY2FlMWU2ZGM4OTY2NzJfNS03LTEtMS0yMTM2_0acf0c33-bc6e-466f-8e75-5f6f93a12af7">101,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_46"></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80Ni9mcmFnOjU2YjRhZjlmYzc1MjRjMmQ4OWQ3YTZkYTY5YmRlYTYwL3RleHRyZWdpb246NTZiNGFmOWZjNzUyNGMyZDg5ZDdhNmRhNjliZGVhNjBfOTU_23cbae94-3f00-46b2-8dcf-f27a2357ab18" continuedAt="i314e2c08cca64c05ae9c468553796b02" escape="true">Accrued Expenses</ix:nonNumeric></span></div><ix:continuation id="i314e2c08cca64c05ae9c468553796b02"><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80Ni9mcmFnOjU2YjRhZjlmYzc1MjRjMmQ4OWQ3YTZkYTY5YmRlYTYwL3RleHRyZWdpb246NTZiNGFmOWZjNzUyNGMyZDg5ZDdhNmRhNjliZGVhNjBfOTY_4c111b3f-2616-497f-a891-994d6996df89" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2021 and December&#160;31, 2020 accrued expenses consist of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related expenses</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80Ni9mcmFnOjU2YjRhZjlmYzc1MjRjMmQ4OWQ3YTZkYTY5YmRlYTYwL3RhYmxlOjI0NjM4Y2I3OTc0MTQ0OGQ4NzBiZjc2ZGMzZDZlNWNkL3RhYmxlcmFuZ2U6MjQ2MzhjYjc5NzQxNDQ4ZDg3MGJmNzZkYzNkNmU1Y2RfMy0xLTEtMS0yMTM2_f0e1b785-de51-47db-8e51-2dcb3b52ad11">4,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80Ni9mcmFnOjU2YjRhZjlmYzc1MjRjMmQ4OWQ3YTZkYTY5YmRlYTYwL3RhYmxlOjI0NjM4Y2I3OTc0MTQ0OGQ4NzBiZjc2ZGMzZDZlNWNkL3RhYmxlcmFuZ2U6MjQ2MzhjYjc5NzQxNDQ4ZDg3MGJmNzZkYzNkNmU1Y2RfMy0zLTEtMS0yMTM2_10d9d109-00bb-4fad-a39b-36627ee65e3b">5,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="morf:AccruedResearchAndDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80Ni9mcmFnOjU2YjRhZjlmYzc1MjRjMmQ4OWQ3YTZkYTY5YmRlYTYwL3RhYmxlOjI0NjM4Y2I3OTc0MTQ0OGQ4NzBiZjc2ZGMzZDZlNWNkL3RhYmxlcmFuZ2U6MjQ2MzhjYjc5NzQxNDQ4ZDg3MGJmNzZkYzNkNmU1Y2RfNC0xLTEtMS0yMTM2_0a172fc6-bd33-4d06-b86e-bc1fcfdd8cd9">3,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="morf:AccruedResearchAndDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80Ni9mcmFnOjU2YjRhZjlmYzc1MjRjMmQ4OWQ3YTZkYTY5YmRlYTYwL3RhYmxlOjI0NjM4Y2I3OTc0MTQ0OGQ4NzBiZjc2ZGMzZDZlNWNkL3RhYmxlcmFuZ2U6MjQ2MzhjYjc5NzQxNDQ4ZDg3MGJmNzZkYzNkNmU1Y2RfNC0zLTEtMS0yMTM2_ad4c6cbf-682b-45db-85c9-0b38b51e8518">4,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80Ni9mcmFnOjU2YjRhZjlmYzc1MjRjMmQ4OWQ3YTZkYTY5YmRlYTYwL3RhYmxlOjI0NjM4Y2I3OTc0MTQ0OGQ4NzBiZjc2ZGMzZDZlNWNkL3RhYmxlcmFuZ2U6MjQ2MzhjYjc5NzQxNDQ4ZDg3MGJmNzZkYzNkNmU1Y2RfNS0xLTEtMS0yMTM2_06ec2ca3-923b-4ff5-996f-2b85a3a9787c">1,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80Ni9mcmFnOjU2YjRhZjlmYzc1MjRjMmQ4OWQ3YTZkYTY5YmRlYTYwL3RhYmxlOjI0NjM4Y2I3OTc0MTQ0OGQ4NzBiZjc2ZGMzZDZlNWNkL3RhYmxlcmFuZ2U6MjQ2MzhjYjc5NzQxNDQ4ZDg3MGJmNzZkYzNkNmU1Y2RfNS0zLTEtMS0yMTM2_c218bef9-56fa-4c57-86ac-4ddcced984af">677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80Ni9mcmFnOjU2YjRhZjlmYzc1MjRjMmQ4OWQ3YTZkYTY5YmRlYTYwL3RhYmxlOjI0NjM4Y2I3OTc0MTQ0OGQ4NzBiZjc2ZGMzZDZlNWNkL3RhYmxlcmFuZ2U6MjQ2MzhjYjc5NzQxNDQ4ZDg3MGJmNzZkYzNkNmU1Y2RfNi0xLTEtMS0yMTM2_fbd77782-e825-4d68-81d2-264d7bce8be6">8,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80Ni9mcmFnOjU2YjRhZjlmYzc1MjRjMmQ4OWQ3YTZkYTY5YmRlYTYwL3RhYmxlOjI0NjM4Y2I3OTc0MTQ0OGQ4NzBiZjc2ZGMzZDZlNWNkL3RhYmxlcmFuZ2U6MjQ2MzhjYjc5NzQxNDQ4ZDg3MGJmNzZkYzNkNmU1Y2RfNi0zLTEtMS0yMTM2_79a30603-47c4-47a4-9070-0d0df0762e8d">10,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric></ix:continuation><div id="i78343c0ada4c4eb7afb5039f4dd8197f_49"></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfMzA4OQ_902a82b1-0f3d-4d1a-9d49-5b487792904d" continuedAt="ib2a669c935e9407d9ad7d0fee2f4472b" escape="true">Equity Based Compensation</ix:nonNumeric></span></div><ix:continuation id="ib2a669c935e9407d9ad7d0fee2f4472b" continuedAt="icedddc0701b24914aec44235d17dae87"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company&#8217;s initial public offering in July 2019, the Company adopted the 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;) in June 2019, which replaced the 2018 Stock Incentive Plan. The 2019 Plan provides for the grant of stock options, restricted stock awards, stock bonus awards, cash awards, stock appreciation right, RSUs, and performance awards to directors, officers and employees of the Company, as well as consultants and advisors of the Company.  As a result of the automatic increase provision of the 2019 Plan, the number of shares of common stock available for issuance under the 2019 Plan increased by <ix:nonFraction unitRef="shares" contextRef="i1d81d7faa05e4d72ba315f45f8ca2b93_I20210101" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfNjY0_84c03127-8054-4be8-b981-79e580b8fd39">1.3</ix:nonFraction>&#160;million shares on January 2021. As of&#160;September&#160;30, 2021, there were a total of&#160;<ix:nonFraction unitRef="shares" contextRef="i9b8872a576284d399ea67d6b51d01d5b_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfNzIz_2735c360-edac-4511-9ec5-df9b39b02458">1.3</ix:nonFraction>&#160;million shares available for future award grants under the 2019 Plan.</span></div><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfMzA5MA_9f06a47e-2d0c-48b0-90a2-c453b906ef86" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized equity-based compensation expense in the condensed consolidated statements of operations and comprehensive loss, by award type, as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccd54f681834442eb165955240d9e74a_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfMi0xLTEtMS0yMTM2_cb83b2ad-a2d3-474b-9543-0c94da15dcc8">5,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcf0ba2ceaab4483a2bfe533ce701a43_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfMi0zLTEtMS0yMTM2_842802ee-598d-47a0-9157-451c51623572">2,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia79f1a27faad4ee0b5c7c77ea717ed13_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfMi01LTEtMS0yMTM2_f6ca46e7-86fd-48c8-b699-e318bffa71ae">14,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic423ff5ccdca4effbe4d4211fa5e77f6_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfMi03LTEtMS0yMTM2_daa3aa2a-ab87-405e-a7b7-27b5ea43c3db">6,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf513a6144654bceada542de288df958_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfMy0xLTEtMS0yMTM2_ff6eec6d-7def-4370-9ca8-e890d5e3b261">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f9166bb425c44ada5c593577d00e22a_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfMy0zLTEtMS0yMTM2_f0dd558a-f3c3-4dd0-aea2-c2c7373d77a1">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eee8a4601534a4a917d268a6e6ed3c0_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfMy01LTEtMS0yMTM2_01f152df-d951-4a5f-a9e5-8ef5ffe2762a">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad4849d4849a4887af432c78ad0245a8_D20200101-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfMy03LTEtMS0yMTM2_b287a99f-dfdf-45c5-b614-4b6cb0ac4311">832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24c99804fc6044a5a6faa8fb23d4c212_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfNC0xLTEtMS0yMTM2_3d966332-ca55-4a3f-b147-708f526bcb5e">163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa63b4b83d8c4eaca119ea3ed2510c96_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfNC0zLTEtMS0yMTM2_4a1c9326-18c5-47bf-a8d1-2e5f5654d42b">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f2f1b5251e94bbe8ef420f9ff484d6e_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfNC01LTEtMS0yMTM2_c6a7a476-6646-4bde-a2c4-87434895cfb7">385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65aaf5db173b49e9ab4c31517132d9ec_D20200101-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfNC03LTEtMS0yMTM2_83cbb4d9-ac70-4b6b-96dd-804f7d667363">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i039b981d5def4df5ac1cd4a91d5e0229_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfNS0xLTEtMS0yMTM2_ed888c89-6643-4b3c-83c9-92cb6d9cfac3">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9b7b224fe294b00affdcc71cba4f7d6_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfNS0zLTEtMS0yMTM2_b4f742ca-2632-4be8-a768-dcf2e0867f12">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dbbd4689134d678129e0ec4c7edb79_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfNS01LTEtMS0yMTM2_25bca380-007f-4807-9fe9-36cb82f985cf">484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4d1f97a11f54bcb896bca14bdcd10f2_D20200101-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfNS03LTEtMS0yMTM2_2555c467-0d32-452c-a34c-2b795d1b069b">339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfNi0xLTEtMS0yMTM2_364026d8-eb43-4228-a9b3-ae64964033e7">5,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfNi0zLTEtMS0yMTM2_f8dc7294-20a3-4a6d-8d1e-c566a5af4b08">2,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfNi01LTEtMS0yMTM2_a65a26d0-8618-4ee6-916e-1387951ea11a">15,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfNi03LTEtMS0yMTM2_8dc3ef1d-4ba0-484b-8840-3a8dba8332a0">8,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the allocation of equity-based compensation expense in the condensed consolidated statements of operations and comprehensive loss, by expense category (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1efef8ae596461dbbceea676d6cf299_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjg0MjUxNGRiYjViNDQ5NGFhZmY3NDBmZTY5NTZjYzhiL3RhYmxlcmFuZ2U6ODQyNTE0ZGJiNWI0NDk0YWFmZjc0MGZlNjk1NmNjOGJfMi0xLTEtMS0yMTM2_485d1837-8cfc-4bb0-90fa-962ed3c81766">2,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf03edf7a50641cfb11f3e5cc6746127_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjg0MjUxNGRiYjViNDQ5NGFhZmY3NDBmZTY5NTZjYzhiL3RhYmxlcmFuZ2U6ODQyNTE0ZGJiNWI0NDk0YWFmZjc0MGZlNjk1NmNjOGJfMi0zLTEtMS0yMTM2_a40f548c-7fc9-4bf4-95cc-7bccc9d66e95">1,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i673a34526db04381a03c0b2e761aca2a_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjg0MjUxNGRiYjViNDQ5NGFhZmY3NDBmZTY5NTZjYzhiL3RhYmxlcmFuZ2U6ODQyNTE0ZGJiNWI0NDk0YWFmZjc0MGZlNjk1NmNjOGJfMi01LTEtMS0yMTM2_b5e1a6d1-42a0-47e0-804f-8036c5dcfdf3">7,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9e3e64d44494241956eb0fdacb21e56_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjg0MjUxNGRiYjViNDQ5NGFhZmY3NDBmZTY5NTZjYzhiL3RhYmxlcmFuZ2U6ODQyNTE0ZGJiNWI0NDk0YWFmZjc0MGZlNjk1NmNjOGJfMi03LTEtMS0yMTM2_9f6602d4-d519-498e-97dc-fb444954caaa">4,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ee8d1c8ad34b4e80c662e251e209ae_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjg0MjUxNGRiYjViNDQ5NGFhZmY3NDBmZTY5NTZjYzhiL3RhYmxlcmFuZ2U6ODQyNTE0ZGJiNWI0NDk0YWFmZjc0MGZlNjk1NmNjOGJfMy0xLTEtMS0yMTM2_f79e7d80-ffb8-4b8b-8264-fa9d5f960e80">3,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71df2423ac2c4debbc999ef809fd11c1_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjg0MjUxNGRiYjViNDQ5NGFhZmY3NDBmZTY5NTZjYzhiL3RhYmxlcmFuZ2U6ODQyNTE0ZGJiNWI0NDk0YWFmZjc0MGZlNjk1NmNjOGJfMy0zLTEtMS0yMTM2_164c8422-2360-463c-9fff-e85efec9ed18">1,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bcc85b10d794d0c98147f0f99a5a07a_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjg0MjUxNGRiYjViNDQ5NGFhZmY3NDBmZTY5NTZjYzhiL3RhYmxlcmFuZ2U6ODQyNTE0ZGJiNWI0NDk0YWFmZjc0MGZlNjk1NmNjOGJfMy01LTEtMS0yMTM2_ff23ace3-79a0-411e-a9a1-d585397419e7">8,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5998a9c8f16249a5a5aed5bd18c1e529_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjg0MjUxNGRiYjViNDQ5NGFhZmY3NDBmZTY5NTZjYzhiL3RhYmxlcmFuZ2U6ODQyNTE0ZGJiNWI0NDk0YWFmZjc0MGZlNjk1NmNjOGJfMy03LTEtMS0yMTM2_1ff71ccd-6d7e-45ad-824e-ef3a2d6e356a">3,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjg0MjUxNGRiYjViNDQ5NGFhZmY3NDBmZTY5NTZjYzhiL3RhYmxlcmFuZ2U6ODQyNTE0ZGJiNWI0NDk0YWFmZjc0MGZlNjk1NmNjOGJfNC0xLTEtMS0yMTM2_2f044201-ca11-490e-a67f-faf19c03229d">5,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjg0MjUxNGRiYjViNDQ5NGFhZmY3NDBmZTY5NTZjYzhiL3RhYmxlcmFuZ2U6ODQyNTE0ZGJiNWI0NDk0YWFmZjc0MGZlNjk1NmNjOGJfNC0zLTEtMS0yMTM2_eea67926-8bce-48e7-aec9-4637622459a3">2,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjg0MjUxNGRiYjViNDQ5NGFhZmY3NDBmZTY5NTZjYzhiL3RhYmxlcmFuZ2U6ODQyNTE0ZGJiNWI0NDk0YWFmZjc0MGZlNjk1NmNjOGJfNC01LTEtMS0yMTM2_dd211850-cb6e-4b57-b428-c0904014b0b7">15,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjg0MjUxNGRiYjViNDQ5NGFhZmY3NDBmZTY5NTZjYzhiL3RhYmxlcmFuZ2U6ODQyNTE0ZGJiNWI0NDk0YWFmZjc0MGZlNjk1NmNjOGJfNC03LTEtMS0yMTM2_0f90033c-bba8-44ff-ab1a-96541da56144">8,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="icedddc0701b24914aec44235d17dae87" continuedAt="ic447ddb576b54aeb93797ee5332ee290"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Restricted Common Stock</span></div><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfMzA5MQ_6b67c9ac-4953-4610-9da2-4d370928f437" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the restricted stock awards activity during the nine months ended September&#160;30, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of&#160;Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average Fair<br/>Value per Share<br/>at Issuance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted common stock as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i55558d3807264cfebb3cf65d4a4463df_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjI0NTU2NTRhMGQ4NzQ2ODFhZDRhM2U0MzU4MmY5ZjMwL3RhYmxlcmFuZ2U6MjQ1NTY1NGEwZDg3NDY4MWFkNGEzZTQzNTgyZjlmMzBfMS0xLTEtMS0yMTM2_dc10cc38-5478-4c72-9c82-b8016927a3b5">100,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i55558d3807264cfebb3cf65d4a4463df_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjI0NTU2NTRhMGQ4NzQ2ODFhZDRhM2U0MzU4MmY5ZjMwL3RhYmxlcmFuZ2U6MjQ1NTY1NGEwZDg3NDY4MWFkNGEzZTQzNTgyZjlmMzBfMS0zLTEtMS0yMTM2_d99f67ae-fdc8-40cf-8885-75e1b2981418">4.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie3b3a9e7b9604013adda880bf9c86908_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjI0NTU2NTRhMGQ4NzQ2ODFhZDRhM2U0MzU4MmY5ZjMwL3RhYmxlcmFuZ2U6MjQ1NTY1NGEwZDg3NDY4MWFkNGEzZTQzNTgyZjlmMzBfMi0xLTEtMS0yMTM2_08694e21-fcf4-47c6-ba0f-dc31b8f29820">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie3b3a9e7b9604013adda880bf9c86908_D20210101-20210930" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjI0NTU2NTRhMGQ4NzQ2ODFhZDRhM2U0MzU4MmY5ZjMwL3RhYmxlcmFuZ2U6MjQ1NTY1NGEwZDg3NDY4MWFkNGEzZTQzNTgyZjlmMzBfMi0zLTEtMS0yMTM2_34b5a0ba-54a8-4025-938a-d17ba2908ccd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie3b3a9e7b9604013adda880bf9c86908_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjI0NTU2NTRhMGQ4NzQ2ODFhZDRhM2U0MzU4MmY5ZjMwL3RhYmxlcmFuZ2U6MjQ1NTY1NGEwZDg3NDY4MWFkNGEzZTQzNTgyZjlmMzBfMy0xLTEtMS0yMTM2_3a3962cc-047b-42db-ae4c-8b30edf8b2ba">73,056</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie3b3a9e7b9604013adda880bf9c86908_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjI0NTU2NTRhMGQ4NzQ2ODFhZDRhM2U0MzU4MmY5ZjMwL3RhYmxlcmFuZ2U6MjQ1NTY1NGEwZDg3NDY4MWFkNGEzZTQzNTgyZjlmMzBfMy0zLTEtMS0yMTM2_3ecf0786-bc93-4414-b20d-d6acaeda6db0">4.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie3b3a9e7b9604013adda880bf9c86908_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjI0NTU2NTRhMGQ4NzQ2ODFhZDRhM2U0MzU4MmY5ZjMwL3RhYmxlcmFuZ2U6MjQ1NTY1NGEwZDg3NDY4MWFkNGEzZTQzNTgyZjlmMzBfNC0xLTEtMS0yMTM2_b7617c8b-b990-4c9a-b0bd-ec445a19616a">3,540</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie3b3a9e7b9604013adda880bf9c86908_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjI0NTU2NTRhMGQ4NzQ2ODFhZDRhM2U0MzU4MmY5ZjMwL3RhYmxlcmFuZ2U6MjQ1NTY1NGEwZDg3NDY4MWFkNGEzZTQzNTgyZjlmMzBfNC0zLTEtMS0yMTM2_159c0f54-fc50-42a4-acb5-cabb339e956e">4.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted common stock as of September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic35b086f16144f27b108d50ef91c71d5_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjI0NTU2NTRhMGQ4NzQ2ODFhZDRhM2U0MzU4MmY5ZjMwL3RhYmxlcmFuZ2U6MjQ1NTY1NGEwZDg3NDY4MWFkNGEzZTQzNTgyZjlmMzBfNS0xLTEtMS0yMTM2_245e86d0-4aaf-4c22-9c7f-e10637b09d74">24,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic35b086f16144f27b108d50ef91c71d5_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjI0NTU2NTRhMGQ4NzQ2ODFhZDRhM2U0MzU4MmY5ZjMwL3RhYmxlcmFuZ2U6MjQ1NTY1NGEwZDg3NDY4MWFkNGEzZTQzNTgyZjlmMzBfNS0zLTEtMS0yMTM2_eccbc7b5-4b99-4a51-ab64-4c9707b4f354">4.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the Company had unrecognized equity-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i3306469c42b0426c851e95ee8d3af6bf_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfMTM3Ng_3d4c3427-46d0-49c8-857c-44c676c7b606">0.1</ix:nonFraction>&#160;million related to the restricted stock awards, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i2eee8a4601534a4a917d268a6e6ed3c0_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfMTQ4OA_514071eb-b290-4570-8f06-0d32e6acae4e">0.3</ix:nonNumeric> years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Restricted Stock Units</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfMzA5Mg_1fc40d89-fe7f-4676-8f75-ff1729a4bbff" continuedAt="i1af098a073ea4da5b46f25c330429edc" escape="true">The following table summarizes the restricted stock units activity during the nine months ended September&#160;30, 2021:</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i1af098a073ea4da5b46f25c330429edc"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:72.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of&#160;Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average Fair<br/>Value per Share<br/>at Issuance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units as of  December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i19b2674b6d5149d0b8ee34f673c706f2_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmY5OGVmZDMyZWQxNzQyYThhMGJiMGYyYWMyZDllMzE5L3RhYmxlcmFuZ2U6Zjk4ZWZkMzJlZDE3NDJhOGEwYmIwZjJhYzJkOWUzMTlfMS0xLTEtMS0yMTM2_7d7d1811-98d9-4b99-be72-26eab711f736">66,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i19b2674b6d5149d0b8ee34f673c706f2_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmY5OGVmZDMyZWQxNzQyYThhMGJiMGYyYWMyZDllMzE5L3RhYmxlcmFuZ2U6Zjk4ZWZkMzJlZDE3NDJhOGEwYmIwZjJhYzJkOWUzMTlfMS0zLTEtMS0yMTM2_ae3e061d-4580-43ce-bf5a-fab0d11cfa58">10.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iafc120c8b5bb4f488b7898393d9badba_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmY5OGVmZDMyZWQxNzQyYThhMGJiMGYyYWMyZDllMzE5L3RhYmxlcmFuZ2U6Zjk4ZWZkMzJlZDE3NDJhOGEwYmIwZjJhYzJkOWUzMTlfMi0xLTEtMS0yMTM2_db455384-6b41-4296-acfa-3898e04d0a38">7,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iafc120c8b5bb4f488b7898393d9badba_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmY5OGVmZDMyZWQxNzQyYThhMGJiMGYyYWMyZDllMzE5L3RhYmxlcmFuZ2U6Zjk4ZWZkMzJlZDE3NDJhOGEwYmIwZjJhYzJkOWUzMTlfMi0zLTEtMS0yMTM2_6464165f-dc87-4958-9dd9-db76ea0bcd8b">57.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iafc120c8b5bb4f488b7898393d9badba_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmY5OGVmZDMyZWQxNzQyYThhMGJiMGYyYWMyZDllMzE5L3RhYmxlcmFuZ2U6Zjk4ZWZkMzJlZDE3NDJhOGEwYmIwZjJhYzJkOWUzMTlfMy0xLTEtMS0yMTM2_f40d24e3-a87b-4276-a92e-0b3cab6e4f09">32,121</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iafc120c8b5bb4f488b7898393d9badba_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmY5OGVmZDMyZWQxNzQyYThhMGJiMGYyYWMyZDllMzE5L3RhYmxlcmFuZ2U6Zjk4ZWZkMzJlZDE3NDJhOGEwYmIwZjJhYzJkOWUzMTlfMy0zLTEtMS0yMTM2_4f6e5797-adc2-4757-a69b-aea8a4b776ae">10.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iafc120c8b5bb4f488b7898393d9badba_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmY5OGVmZDMyZWQxNzQyYThhMGJiMGYyYWMyZDllMzE5L3RhYmxlcmFuZ2U6Zjk4ZWZkMzJlZDE3NDJhOGEwYmIwZjJhYzJkOWUzMTlfNC0xLTEtMS0yMTM2_4e603e0f-f43c-499c-94a3-f7964bf7f1f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iafc120c8b5bb4f488b7898393d9badba_D20210101-20210930" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmY5OGVmZDMyZWQxNzQyYThhMGJiMGYyYWMyZDllMzE5L3RhYmxlcmFuZ2U6Zjk4ZWZkMzJlZDE3NDJhOGEwYmIwZjJhYzJkOWUzMTlfNC0zLTEtMS0yMTM2_e046e5dc-d71c-4c22-855c-a97edf842511">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units as of September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id827d0b4de4c40aebffdd742a897d8e7_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmY5OGVmZDMyZWQxNzQyYThhMGJiMGYyYWMyZDllMzE5L3RhYmxlcmFuZ2U6Zjk4ZWZkMzJlZDE3NDJhOGEwYmIwZjJhYzJkOWUzMTlfNS0xLTEtMS0yMTM2_98b69057-22c7-42cf-b305-8fecb2e3d5e6">41,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id827d0b4de4c40aebffdd742a897d8e7_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmY5OGVmZDMyZWQxNzQyYThhMGJiMGYyYWMyZDllMzE5L3RhYmxlcmFuZ2U6Zjk4ZWZkMzJlZDE3NDJhOGEwYmIwZjJhYzJkOWUzMTlfNS0zLTEtMS0yMTM2_9b5b3ae5-8713-42f3-b31c-8ab30704659a">18.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the Company had unrecognized equity-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i336ef268b2b54d5a8d41335f5521475d_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfMTY5Mg_808fc3dc-e284-47bf-ba29-59be72257ea0">0.5</ix:nonFraction>&#160;million related to the restricted stock units, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i0f2f1b5251e94bbe8ef420f9ff484d6e_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfMTgwMw_dcefc73c-e88e-4d51-be8f-479d42802dd2">2.2</ix:nonNumeric> years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Stock Options</span></div><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfMzA5Mw_ebed68e6-0101-45ad-a626-18ef11fcd4c0" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity during the nine months ended September&#160;30, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:45.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie1bba300f18d4aa9a80235013244a2ca_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfMi0xLTEtMS0yMTM2_350492d3-88ac-495b-b8fc-43fe1bbeb7b0">4,352,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie1bba300f18d4aa9a80235013244a2ca_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfMi0zLTEtMS0yMTM2_10fb899d-0726-4dcd-8d8f-f76040d13a97">12.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i41bca88497e24b96b89b016e9cea4fe6_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfMi01LTEtMS0yMTM2_dd1fe5b8-83b4-4183-a57d-085c7f51bc1a">8.68</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ie1bba300f18d4aa9a80235013244a2ca_I20201231" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfMi03LTEtMS0yMTM2_fe226740-6ccd-4c87-9a81-1470c737d80f"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia79f1a27faad4ee0b5c7c77ea717ed13_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfMy0xLTEtMS0yMTM2_0f14578b-cc39-41dd-9c79-61e3f3b348e1">1,550,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia79f1a27faad4ee0b5c7c77ea717ed13_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfMy0zLTEtMS0yMTM2_df4524d0-ea3d-46cb-8339-09daf1a85675">35.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia79f1a27faad4ee0b5c7c77ea717ed13_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfNC0xLTEtMS0yMTM2_3584355d-8f60-4b15-b9ed-fb33d8193517">675,211</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia79f1a27faad4ee0b5c7c77ea717ed13_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfNC0zLTEtMS0yMTM2_7497101d-15cd-4f92-9894-1f4979760cc4">11.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia79f1a27faad4ee0b5c7c77ea717ed13_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfNS0xLTEtMS0yMTM2_bf546d4a-94cf-456d-a1d5-0c2140ce7d84">140,722</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia79f1a27faad4ee0b5c7c77ea717ed13_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfNS0zLTEtMS0yMTM2_1111b202-abdf-4607-a938-bf98db36a0f1">17.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i500b2548238d418785e416f8b2eb9f96_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfNi0xLTEtMS0yMTM2_adbb93de-571e-41d4-b3c7-873f67710a30">5,086,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i500b2548238d418785e416f8b2eb9f96_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfNi0zLTEtMS0yMTM2_07bac347-8e71-452a-af7e-ed4a5df0278c">19.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia79f1a27faad4ee0b5c7c77ea717ed13_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfNi01LTEtMS0yMTM2_50c52e1b-db18-483e-98fa-9395b5dbea91">8.38</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i500b2548238d418785e416f8b2eb9f96_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfNi03LTEtMS0yMTM2_55b7b803-a37d-4fa1-bce9-aec7a35e9d14">191,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i500b2548238d418785e416f8b2eb9f96_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfNy0xLTEtMS0yMTM2_c0f2dd0a-372a-410e-9014-d2b83e6659c1">1,729,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i500b2548238d418785e416f8b2eb9f96_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfNy0zLTEtMS0yMTM2_fe4b6311-860d-4a8c-a152-85417d78d519">12.98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia79f1a27faad4ee0b5c7c77ea717ed13_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfNy01LTEtMS0yMTM2_e318ff44-440a-444a-8873-5faaa7c469d2">7.97</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i500b2548238d418785e416f8b2eb9f96_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfNy03LTEtMS0yMTM2_835eef8a-5b61-4d3c-8c6c-edc8b42b6f54">75,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the Company had unrecognized equity-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfMTk5OQ_ee1a6eb7-e7b6-4d1c-a5b6-a00aa8f6d413">50.3</ix:nonFraction>&#160;million related to stock options issued to employees and non-employees, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfMjEzNQ_e819192e-3fee-468c-8d55-35101aff5df1">2.4</ix:nonNumeric> years.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">ESPP</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company adopted the 2019 Employee Stock Purchase Plan (&#8220;ESPP&#8221;), which became effective on June 26, 2019. The Company initially reserved <ix:nonFraction unitRef="shares" contextRef="idecb2791d4e644adac2b17f62a0ffc4d_I20191231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfMjI5Mw_0ef47d46-7dd4-46a6-8dc0-9dd5957c29be">300,000</ix:nonFraction> shares of common stock for sale under the ESPP. As a result of the automatic increase provision of the ESPP, the number of shares of common stock available for issuance under the ESPP increased by <ix:nonFraction unitRef="shares" contextRef="i9f2623aae9e042109d449218c4a952e2_I20210101" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfMjQ5Mw_8cd8fb53-ef7e-4f12-a01c-e2e9ebb423f1">0.3</ix:nonFraction>&#160;million </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="ic447ddb576b54aeb93797ee5332ee290"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares on January 1, 2021. The ESPP is a qualified, compensatory plan under Section 423 of the Internal Revenue Code and offers substantially all employees opportunity to purchase up to $<ix:nonFraction unitRef="usd" contextRef="if4fd934abc1c47eeb0364ac66d1ad27d_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="morf:EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfMjY4Mg_76551ab3-d3de-46c6-8f59-7cfdae248b19">25,000</ix:nonFraction> of common stock per year at <ix:nonFraction unitRef="number" contextRef="i933ed6a72813427384dce0d77c868663_D20210101-20210930" decimals="INF" name="morf:ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfMjcxMw_6c96dd82-53e1-4d63-baea-337316fe4056">15</ix:nonFraction>% discount to the lower of the beginning of the offering period price or the end of the offering period price.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense for discounted purchases under the ESPP is measured using the Black-Scholes model to compute the fair value of the lookback provision plus the purchase discount and is recognized as compensation expense over the course of the offering period.</span></div></ix:continuation><div id="i78343c0ada4c4eb7afb5039f4dd8197f_55"></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.    <ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl81NS9mcmFnOjNmMWIwZDhiN2FlZDQ2YTFhNDAwMzAxN2UwNTFiMDBkL3RleHRyZWdpb246M2YxYjBkOGI3YWVkNDZhMWE0MDAzMDE3ZTA1MWIwMGRfMjAzOQ_bae97fa0-fe5d-474e-a6e2-37d632db4f6c" continuedAt="ia612cb46dd7e4daab0a1674a4f0a2f5c" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="ia612cb46dd7e4daab0a1674a4f0a2f5c" continuedAt="ibbefd17170c347d184b093debaa8b129"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to use its operating loss carryforwards and tax credits to offset future taxable income is subject to restrictions under Sections&#160;382 and 383 of the United States Internal Revenue Code, or the Internal Revenue Code. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50 percent, as defined under Sections 382 and 383 of the Internal Revenue Code. Such changes would limit the Company&#8217;s use of its operating loss carryforwards and tax credits. In such a situation, the Company may be required to pay income taxes, even though significant operating loss carryforwards and tax credits exist.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the Coronavirus Aid Relief and Economic Security (&#8220;CARES&#8221;) Act was signed into law.&#160;The CARES Act included several income tax changes, included allowing for the carryback of net operating losses, expanding interest deductibility, and allowing for accelerated expensing of certain capital improvements.&#160;</span></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibbefd17170c347d184b093debaa8b129">The Company records a provision or benefit for income taxes on ordinary pre-tax income or loss based on its estimated effective tax rate for the year. As of September&#160;30, 2021, the Company forecasts an ordinary pre-tax loss for the year ended December 31, 2021 and, since it maintains a full valuation allowance on its deferred tax assets, the Company did not record an income tax benefit in 2021. Based on the carryback allowance under the CARES Act, the Company recorded an income tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="morf:IncomeTaxExpenseBenefitCARESAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl81NS9mcmFnOjNmMWIwZDhiN2FlZDQ2YTFhNDAwMzAxN2UwNTFiMDBkL3RleHRyZWdpb246M2YxYjBkOGI3YWVkNDZhMWE0MDAzMDE3ZTA1MWIwMGRfODc5NjA5MzAyNDMxNw_c487a4ee-7a81-409e-b31b-df4cb0ed41d6">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="morf:IncomeTaxExpenseBenefitCARESAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl81NS9mcmFnOjNmMWIwZDhiN2FlZDQ2YTFhNDAwMzAxN2UwNTFiMDBkL3RleHRyZWdpb246M2YxYjBkOGI3YWVkNDZhMWE0MDAzMDE3ZTA1MWIwMGRfODc5NjA5MzAyNDMwMg_aa8ec002-8212-4a29-91c0-0742f4f1feb7">0.4</ix:nonFraction>&#160;million for the three and nine months ended September&#160;30, 2020, respectively.</ix:continuation> </span></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_58"></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl81OC9mcmFnOmQ3NjVjYmNmZDlkODQ5NTI5Y2ZkOTI1OWVkZmRkZGYzL3RleHRyZWdpb246ZDc2NWNiY2ZkOWQ4NDk1MjljZmQ5MjU5ZWRmZGRkZjNfMjA5MA_3563f5ab-8cd4-4b41-ae77-0df19a8b41aa" continuedAt="ib19aaa176975406b9f7c248a313a4d35" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="ib19aaa176975406b9f7c248a313a4d35" continuedAt="i9da5d9d3e0224bd986f928fa0ecc9bcd"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guarantees and Indemnifications</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered, and intends to continue to enter, into separate indemnification agreements with directors, officers, and certain of key employees, in addition to the indemnification provided for in the restated certificate of incorporation and restated bylaws. These agreements, among other things, require the Company to indemnify directors, officers, and key employees for certain expenses, including attorneys' fees, judgments, penalties, fines, and settlement amounts actually incurred by these individuals in any action or proceeding arising out of their service to the Company or any of its subsidiaries or any other company or enterprise to which these individuals provide services at the Company&#8217;s request. Subject to certain limitations, the indemnification agreements also require the Company to advance expenses incurred by directors, officers, and key employees for the defense of any action for which indemnification is required or permitted.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has standard indemnification arrangements in its leases for laboratory and office space that require it to indemnify the landlord against any liability for injury, loss, accident, or damage from any claims, actions, proceedings, or costs resulting from certain acts, breaches, violations, or non-performance under the Company&#8217;s lease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through September&#160;30, 2021, the Company had not experienced any losses related to these indemnification obligations, and no material claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2021, the Company exercised its one-time extension right for its existing lease for <ix:nonFraction unitRef="sqft" contextRef="i196c1e6bf66247b98fa293ce7ce21c10_I20210831" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AreaOfLand" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl81OC9mcmFnOmQ3NjVjYmNmZDlkODQ5NTI5Y2ZkOTI1OWVkZmRkZGYzL3RleHRyZWdpb246ZDc2NWNiY2ZkOWQ4NDk1MjljZmQ5MjU5ZWRmZGRkZjNfNDk0NzgwMjMyNzQ5MA_73ee5a7c-27d3-4eb7-b1c2-cdfba2cd75e6">35,000</ix:nonFraction> square feet of office and laboratory space through May 2025, as provided for under the terms of the lease. During the three and nine months ended September&#160;30, 2021, there were no other material changes to our contractual obligations and commitments previously disclosed in Note 10 to the consolidated financial statements appearing in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="i9da5d9d3e0224bd986f928fa0ecc9bcd"><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl81OC9mcmFnOmQ3NjVjYmNmZDlkODQ5NTI5Y2ZkOTI1OWVkZmRkZGYzL3RleHRyZWdpb246ZDc2NWNiY2ZkOWQ4NDk1MjljZmQ5MjU5ZWRmZGRkZjNfMTA5OTUxMTYyODA2NTA_848a2e5e-2274-4b65-afd8-c7e752c91b83" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Minimum annual rent payments after the exercise of the lease extension right, excluding operating expenses and taxes, which are not fixed for future periods, are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Minimum Lease Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl81OC9mcmFnOmQ3NjVjYmNmZDlkODQ5NTI5Y2ZkOTI1OWVkZmRkZGYzL3RhYmxlOjAwNGM5NjdmOGQ3MzRmMjM4YTMyNzBmZDI4YjM4YjliL3RhYmxlcmFuZ2U6MDA0Yzk2N2Y4ZDczNGYyMzhhMzI3MGZkMjhiMzhiOWJfMS0yLTEtMS0yMjczNg_5c4956e4-2270-4155-a17f-923ae65ba059">316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl81OC9mcmFnOmQ3NjVjYmNmZDlkODQ5NTI5Y2ZkOTI1OWVkZmRkZGYzL3RhYmxlOjAwNGM5NjdmOGQ3MzRmMjM4YTMyNzBmZDI4YjM4YjliL3RhYmxlcmFuZ2U6MDA0Yzk2N2Y4ZDczNGYyMzhhMzI3MGZkMjhiMzhiOWJfMi0yLTEtMS0yMjczNg_7563604f-c6cb-44c7-8c58-ab841b728caf">1,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl81OC9mcmFnOmQ3NjVjYmNmZDlkODQ5NTI5Y2ZkOTI1OWVkZmRkZGYzL3RhYmxlOjAwNGM5NjdmOGQ3MzRmMjM4YTMyNzBmZDI4YjM4YjliL3RhYmxlcmFuZ2U6MDA0Yzk2N2Y4ZDczNGYyMzhhMzI3MGZkMjhiMzhiOWJfMy0yLTEtMS0yMjczNg_56885635-0c7e-4857-9897-ffcc793931e1">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl81OC9mcmFnOmQ3NjVjYmNmZDlkODQ5NTI5Y2ZkOTI1OWVkZmRkZGYzL3RhYmxlOjAwNGM5NjdmOGQ3MzRmMjM4YTMyNzBmZDI4YjM4YjliL3RhYmxlcmFuZ2U6MDA0Yzk2N2Y4ZDczNGYyMzhhMzI3MGZkMjhiMzhiOWJfNC0yLTEtMS0yMjczNg_a93ac5fd-7477-4cea-aa4c-753cb79181d3">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl81OC9mcmFnOmQ3NjVjYmNmZDlkODQ5NTI5Y2ZkOTI1OWVkZmRkZGYzL3RhYmxlOjAwNGM5NjdmOGQ3MzRmMjM4YTMyNzBmZDI4YjM4YjliL3RhYmxlcmFuZ2U6MDA0Yzk2N2Y4ZDczNGYyMzhhMzI3MGZkMjhiMzhiOWJfNS0yLTEtMS0yMjczNg_46e3e4c8-1cd5-49d8-bf54-7254dfe16661">727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl81OC9mcmFnOmQ3NjVjYmNmZDlkODQ5NTI5Y2ZkOTI1OWVkZmRkZGYzL3RhYmxlOjAwNGM5NjdmOGQ3MzRmMjM4YTMyNzBmZDI4YjM4YjliL3RhYmxlcmFuZ2U6MDA0Yzk2N2Y4ZDczNGYyMzhhMzI3MGZkMjhiMzhiOWJfNi0yLTEtMS0yMjczNg_2a0ba46f-e01b-4881-9698-3ed6d8216822">5,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not currently a party to any material legal proceedings.</span></div></ix:continuation><div id="i78343c0ada4c4eb7afb5039f4dd8197f_61"></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RleHRyZWdpb246MjgxZjNiZTQzYzhmNGJiMWI3ZWZhY2YyZjBkZTBhYWJfNDUzMw_ed328f9f-3a43-4903-899f-7a653cb5bc4e" continuedAt="i6b330a702b524364b3da0dd966087d74" escape="true">Option and License Agreements</ix:nonNumeric></span></div><ix:continuation id="i6b330a702b524364b3da0dd966087d74" continuedAt="idfc5a740092a4f8c944ace6b39ad3072"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Detailed description of contractual terms and the Company&#8217;s accounting for agreements described below were included in the Company&#8217;s audited financial statements and notes in the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2021, the Company continued to perform under its agreement with AbbVie, (the &#8220;AbbVie Agreement&#8221;) pursuant to which the Company recognizes revenues in proportion to the costs incurred. As a result, the Company recognizes as revenue the $<ix:nonFraction unitRef="usd" contextRef="i2cb15e50535f4e87b974bc0af2a7bb9c_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RleHRyZWdpb246MjgxZjNiZTQzYzhmNGJiMWI3ZWZhY2YyZjBkZTBhYWJfNTcz_2e51d973-6a93-4fdc-bc64-1a924078165e"><ix:nonFraction unitRef="usd" contextRef="ifd339294a59643f7b3b5f6dd55384718_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RleHRyZWdpb246MjgxZjNiZTQzYzhmNGJiMWI3ZWZhY2YyZjBkZTBhYWJfNTcz_82c51b0f-0ffd-4dce-89ee-7d5d0eb00a04">100.0</ix:nonFraction></ix:nonFraction> million up-front payment as research and development services are performed, which is expected to be completed through 2024. <ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RleHRyZWdpb246MjgxZjNiZTQzYzhmNGJiMWI3ZWZhY2YyZjBkZTBhYWJfNDUzMQ_6bc5c83b-7ace-4dc3-9a3a-095caceee51e" continuedAt="i64f416faeb1b4968a835a5c1a37f2bee" escape="true">The following table summarizes research and development costs incurred and revenue recognized in connection with Company's performance under the AbbVie Agreement during the three and nine months ended September 30, 2021 and 2020 (in thousands):</ix:nonNumeric></span></div><div style="margin-top:12pt"><ix:continuation id="i64f416faeb1b4968a835a5c1a37f2bee" continuedAt="i04c5a040058445919bf35ccb5380ee4b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacbf9b146694148984076cec6a6afd1_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOjVhNmViMzFhZGE5YzQzZTA5MGVhNmQ1NDRhMTdlYWU2L3RhYmxlcmFuZ2U6NWE2ZWIzMWFkYTljNDNlMDkwZWE2ZDU0NGExN2VhZTZfMi0xLTEtMS0yMTM2_9c29801f-8cdf-49a2-ad22-128e61f24989">1,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i291b9147c1ae41379197349d37bd173b_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOjVhNmViMzFhZGE5YzQzZTA5MGVhNmQ1NDRhMTdlYWU2L3RhYmxlcmFuZ2U6NWE2ZWIzMWFkYTljNDNlMDkwZWE2ZDU0NGExN2VhZTZfMi0zLTEtMS0yMTM2_d2a98ec1-4ce3-46f2-9e0e-c47cacf6dcf9">23,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i230a2ca85b2a4dccb1eb0099d20ad182_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOjVhNmViMzFhZGE5YzQzZTA5MGVhNmQ1NDRhMTdlYWU2L3RhYmxlcmFuZ2U6NWE2ZWIzMWFkYTljNDNlMDkwZWE2ZDU0NGExN2VhZTZfMi01LTEtMS0yMTM2_7206334f-a0a6-4421-97ad-03bf26b03011">5,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae18ebb70c3c4104ab905dae334545e6_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOjVhNmViMzFhZGE5YzQzZTA5MGVhNmQ1NDRhMTdlYWU2L3RhYmxlcmFuZ2U6NWE2ZWIzMWFkYTljNDNlMDkwZWE2ZDU0NGExN2VhZTZfMi03LTEtMS0yMTM2_f1bc2b27-86a5-4e97-b2b8-c5aaf656a340">32,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs incurred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacbf9b146694148984076cec6a6afd1_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOjVhNmViMzFhZGE5YzQzZTA5MGVhNmQ1NDRhMTdlYWU2L3RhYmxlcmFuZ2U6NWE2ZWIzMWFkYTljNDNlMDkwZWE2ZDU0NGExN2VhZTZfMy0xLTEtMS0yMTM2_39fc118b-45ff-411d-917d-559a3be3bf2d">1,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i291b9147c1ae41379197349d37bd173b_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOjVhNmViMzFhZGE5YzQzZTA5MGVhNmQ1NDRhMTdlYWU2L3RhYmxlcmFuZ2U6NWE2ZWIzMWFkYTljNDNlMDkwZWE2ZDU0NGExN2VhZTZfMy0zLTEtMS0yMTM2_b3c9d2db-552e-40fd-9707-8dfdb65f1a61">2,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i230a2ca85b2a4dccb1eb0099d20ad182_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOjVhNmViMzFhZGE5YzQzZTA5MGVhNmQ1NDRhMTdlYWU2L3RhYmxlcmFuZ2U6NWE2ZWIzMWFkYTljNDNlMDkwZWE2ZDU0NGExN2VhZTZfMy01LTEtMS0yMTM2_25330732-94a9-4a22-8f6a-d6e04f3b32e1">4,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae18ebb70c3c4104ab905dae334545e6_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOjVhNmViMzFhZGE5YzQzZTA5MGVhNmQ1NDRhMTdlYWU2L3RhYmxlcmFuZ2U6NWE2ZWIzMWFkYTljNDNlMDkwZWE2ZDU0NGExN2VhZTZfMy03LTEtMS0yMTM2_ef515178-a57d-420e-9798-8043baaa63e8">10,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 25, 2020, AbbVie exercised its option to license and control further development and commercialization of Morphic&#8217;s &#945;v&#946;6&#8211;specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications. In connection with the exercise of the option, AbbVie paid the Company $<ix:nonFraction unitRef="usd" contextRef="iccbf9f78a6bf4f6d936be01c6bdf3bde_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RleHRyZWdpb246MjgxZjNiZTQzYzhmNGJiMWI3ZWZhY2YyZjBkZTBhYWJfMTI0Mg_455fb57d-896c-47f5-95ac-864a2fb76d2d"><ix:nonFraction unitRef="usd" contextRef="idf1288ac2081418ea5506b9b964c318e_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RleHRyZWdpb246MjgxZjNiZTQzYzhmNGJiMWI3ZWZhY2YyZjBkZTBhYWJfMTI0Mg_acfd753b-05e0-48a2-a1b3-38a51cc500b2">20.0</ix:nonFraction></ix:nonFraction> million, which was recognized as revenue during the three and nine months ended September 30, 2021. The Company is eligible to receive potential milestones and royalties on future development and commercialization of Morphic&#8217;s &#945;v&#946;6&#8211;specific integrin inhibitors, as further described in the Company&#8217;s audited financial statements and notes in the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2021, all of which have been fully constrained as of September&#160;30, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="i3686e9bb301546d3b3f298fb3add79a3_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RleHRyZWdpb246MjgxZjNiZTQzYzhmNGJiMWI3ZWZhY2YyZjBkZTBhYWJfMTczNw_67289270-6174-484d-8b50-70a9fb8a3b09">66.7</ix:nonFraction> million of deferred revenue, which is classified as either current or long-term deferred revenue in the accompanying condensed consolidated balance sheets based on the period over which the revenue is expected to be recognized. This deferred revenue balance represents the aggregate amount of the transaction price allocated to the performance obligations that are partially unsatisfied as of September&#160;30, 2021.</span><span style="color:#1d1c1d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company had $<ix:nonFraction unitRef="usd" contextRef="i3686e9bb301546d3b3f298fb3add79a3_I20210930" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RleHRyZWdpb246MjgxZjNiZTQzYzhmNGJiMWI3ZWZhY2YyZjBkZTBhYWJfMTA5OTUxMTYzMjMxMw_00903fc3-503e-494b-951b-9db32320e356">29</ix:nonFraction> thousand and  $<ix:nonFraction unitRef="usd" contextRef="if51ea1a4ae7b4814bdd7be74ca589c83_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RleHRyZWdpb246MjgxZjNiZTQzYzhmNGJiMWI3ZWZhY2YyZjBkZTBhYWJfMjE0Ng_8f03b7a6-9d5b-4528-a4b5-95842a8e78c1">0.9</ix:nonFraction>&#160;million recorded as accounts receivable from AbbVie </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheet </span><span style="color:#1d1c1d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2021 and </span><span style="color:#1d1c1d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31. 2020, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As the Company progresses towards satisfaction of performance obligations under the AbbVie Agreement, the estimated costs associated with the remaining effort required to complete the performance obligations may change, which may materially impact revenue recognition. The Company regularly evaluates and, when necessary, updates the costs associated with the remaining effort pursuant to each performance obligation under the AbbVie Agreement. Accordingly, revenue may fluctuate from period to period due to revisions to estimated costs, resulting in a change in the measure of progress for a performance </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="idfc5a740092a4f8c944ace6b39ad3072"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">obligation. Such changes can also impact the allocation of deferred revenue between current and long term based on changes in expected timing of the satisfaction of performance obligations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2021, the Company continued to perform under its agreement with Janssen (the "Janssen Agreement"), pursuant to which the Company recognizes revenue in proportion to the costs incurred to date. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Janssen paid the Company an upfront fee of $<ix:nonFraction unitRef="usd" contextRef="icf36089b555c48e58d97c007d1218b7e_D20190101-20191231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RleHRyZWdpb246MjgxZjNiZTQzYzhmNGJiMWI3ZWZhY2YyZjBkZTBhYWJfMzQ0MQ_3a76551b-d41c-4167-833b-726ace7ff014"><ix:nonFraction unitRef="usd" contextRef="i04814fa766f14a87b1a4f5090088feac_D20201201-20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RleHRyZWdpb246MjgxZjNiZTQzYzhmNGJiMWI3ZWZhY2YyZjBkZTBhYWJfMzQ0MQ_59885763-d4ab-42b7-921b-cd970336b2f9">10.0</ix:nonFraction></ix:nonFraction>&#160;million for the first two research programs in 2019 and in December 2020 the Company reached an agreement with Janssen to commence work on the third research program, and Janssen paid to the Company $<ix:nonFraction unitRef="usd" contextRef="i8b5652f4187946c99d351a84522e3224_D20210201-20210228" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RleHRyZWdpb246MjgxZjNiZTQzYzhmNGJiMWI3ZWZhY2YyZjBkZTBhYWJfMzYzNQ_005bb37f-1973-4632-8971-eec2ab35f39c">5.0</ix:nonFraction>&#160;million for the third research program commencement fee in February 2021. The Company expects to provide research services and recognize revenue through 2024. </span></div><ix:continuation id="i04c5a040058445919bf35ccb5380ee4b"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes research and development costs incurred and revenue recognized in connection with Company's performance under the Janssen Agreement during three and nine months ended September 30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement revenue</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id854b4ee36ae41358df7d8160430d227_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfMi0xLTEtMS0yMTM2_004cbe6b-74c5-4a58-9d51-58a0fcf09d06">1,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72ac23116b546868709c55972ad7552_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfMi0zLTEtMS0yMTM2_9da1b157-5840-4aca-a6dd-17c894b51f5e">1,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd2abd0024994ee09ba37323fe37f011_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfMi01LTEtMS0yMTM2_70fb1bbd-de21-4faa-a770-198edf364ea2">3,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id12aad613d2c4493984ca5f33bb35df9_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfMi03LTEtMS0yMTM2_554767b1-1d0e-4acf-809b-ec988ccb54a0">5,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront payment revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01c98160846146719189240b8058862e_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfMy0xLTEtMS0yMTM2_9ed4cf34-d990-4741-acba-d3474b111c31">372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9354f5fe43946dc8a9f666176548cf0_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfMy0zLTEtMS0yMTM2_165a7d68-cffa-4ca8-9965-39a8af23afe4">476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f177f36d3854a15b812deee9a7d9bdb_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfMy01LTEtMS0yMTM2_5c682e7e-25e4-4aa9-9279-c0acf37426e1">1,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1757a9161a324b048e54e4ae0d303a19_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfMy03LTEtMS0yMTM2_77228490-1e76-499b-854f-3b2a4bb030e8">1,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue recognized</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7428ecf2c9c2487f9fb6cb0173822e37_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfNC0xLTEtMS0yMTM2_f8960ebd-dba3-45c3-9a79-4a8a4970e2b7">1,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95e6d1a476764b22afd007e50518a6b3_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfNC0zLTEtMS0yMTM2_a731defd-78c2-41db-addb-e4dad80a4442">2,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib185e590ec714546bf7f6029f9dbac37_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfNC01LTEtMS0yMTM2_3576ba43-ed91-429f-83ba-a2917abd6e0c">5,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ff992e2599451b9c12dca8f4da6c0e_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfNC03LTEtMS0yMTM2_1013b282-4937-45ce-8cca-2a2d646a6b36">6,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs incurred</span></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7428ecf2c9c2487f9fb6cb0173822e37_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfNS0xLTEtMS0yMTM2_faa6c9ed-9135-496e-a771-59697d64cfcd">1,118</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95e6d1a476764b22afd007e50518a6b3_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfNS0zLTEtMS0yMTM2_352b3d63-c270-4ae5-94a6-d97ae06804fa">1,439</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib185e590ec714546bf7f6029f9dbac37_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfNS01LTEtMS0yMTM2_bb7c0da1-1ff7-4277-85cf-5a3ab05b6351">3,388</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ff992e2599451b9c12dca8f4da6c0e_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfNS03LTEtMS0yMTM2_3c01e473-0be5-4350-b6f7-a75cfd6dee08">4,540</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had $<ix:nonFraction unitRef="usd" contextRef="idfcdd8be7e094adb844410ae8c290692_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RleHRyZWdpb246MjgxZjNiZTQzYzhmNGJiMWI3ZWZhY2YyZjBkZTBhYWJfNDAwNA_1c790e34-9e7f-4f1a-a762-edead266dd6e">2.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id6809bfeafd44664a693a85e7e121e7a_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RleHRyZWdpb246MjgxZjNiZTQzYzhmNGJiMWI3ZWZhY2YyZjBkZTBhYWJfNDAxMQ_fbbae9ea-3b99-466b-838e-19e29538bd4e">6.4</ix:nonFraction>&#160;million due from Janssen included in accounts receivable on the condensed consolidated balance sheets as of September&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, $<ix:nonFraction unitRef="usd" contextRef="idfcdd8be7e094adb844410ae8c290692_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RleHRyZWdpb246MjgxZjNiZTQzYzhmNGJiMWI3ZWZhY2YyZjBkZTBhYWJfNDE1MA_6bcccc95-009a-4bbc-9937-5163eb30320c">10.0</ix:nonFraction> million of deferred revenue is classified as either current or long-term deferred revenue in the accompanying condensed consolidated balance sheet based on the period over which the revenue is expected to be recognized. This deferred revenue balance represents the portion of the upfront payment received allocated to the performance obligations that are partially unsatisfied as of September&#160;30, 2021.</span></div></ix:continuation><div id="i78343c0ada4c4eb7afb5039f4dd8197f_67"></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RleHRyZWdpb246NWZlZjg0Y2JhMTM0NGZlMmFiMDIyMTc5NTM5OTE0NWZfMTYyMw_3ede08d0-bb84-4555-88e7-9650f20e1b00" continuedAt="i0bdb9c1b887a4cc0823baa0c7e9b0a8d" escape="true">Net (Loss) Income per Share</ix:nonNumeric></span></div><ix:continuation id="i0bdb9c1b887a4cc0823baa0c7e9b0a8d" continuedAt="ia70af8361dd34a31a22ceda315f40b20"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share is calculated by dividing net income (loss) allocable to common stockholders by the weighted-average common shares outstanding during the period, without consideration of common stock equivalents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods with net income, diluted net income per share is calculated by adjusting the weighted-average shares outstanding for the dilutive effect of common stock equivalents, including stock options and restricted common stock and stock units outstanding for the period as determined using the treasury stock method.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation if their effect would be anti-dilutive. As such, basic and diluted net loss per share applicable to common stockholders are the same for periods with a net loss.</span></div><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RleHRyZWdpb246NWZlZjg0Y2JhMTM0NGZlMmFiMDIyMTc5NTM5OTE0NWZfMTYyMQ_343a888c-f609-4468-a457-64c0b33fe8e3" continuedAt="ief6a58bae3334c9c8584ffa1bdd7d414" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables illustrate the determination of basic and diluted loss per share for each period presented (in thousands, except share data):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:45.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.775%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjdiMDUzZTQwY2FjMzRiYjJhZmJjMmNlMzg5MjFjZTc0L3RhYmxlcmFuZ2U6N2IwNTNlNDBjYWMzNGJiMmFmYmMyY2UzODkyMWNlNzRfMi0xLTEtMS0yMTM2_0fde3029-a8e6-4d25-989b-79f320d1b6d4">25,041</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjdiMDUzZTQwY2FjMzRiYjJhZmJjMmNlMzg5MjFjZTc0L3RhYmxlcmFuZ2U6N2IwNTNlNDBjYWMzNGJiMmFmYmMyY2UzODkyMWNlNzRfMi0zLTEtMS0yMTM2_c0d412a2-5502-4a42-9c65-1882a0f4af61">5,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjdiMDUzZTQwY2FjMzRiYjJhZmJjMmNlMzg5MjFjZTc0L3RhYmxlcmFuZ2U6N2IwNTNlNDBjYWMzNGJiMmFmYmMyY2UzODkyMWNlNzRfMi01LTEtMS0yMTM2_d4a75067-aea3-4a39-b6f4-e03ff35c3df3">74,140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjdiMDUzZTQwY2FjMzRiYjJhZmJjMmNlMzg5MjFjZTc0L3RhYmxlcmFuZ2U6N2IwNTNlNDBjYWMzNGJiMmFmYmMyY2UzODkyMWNlNzRfMi03LTEtMS0yMTM2_dbb7e303-9ef3-4ea3-b0a5-e505f0d5d756">27,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjdiMDUzZTQwY2FjMzRiYjJhZmJjMmNlMzg5MjFjZTc0L3RhYmxlcmFuZ2U6N2IwNTNlNDBjYWMzNGJiMmFmYmMyY2UzODkyMWNlNzRfMy0xLTEtMS0yMTM2_a66f0772-14f7-4b77-8d85-2064549ba1cd">36,547,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjdiMDUzZTQwY2FjMzRiYjJhZmJjMmNlMzg5MjFjZTc0L3RhYmxlcmFuZ2U6N2IwNTNlNDBjYWMzNGJiMmFmYmMyY2UzODkyMWNlNzRfMy0zLTEtMS0yMTM2_f4e3d2c8-70c1-4b0a-aac0-7d041bef324c">30,533,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjdiMDUzZTQwY2FjMzRiYjJhZmJjMmNlMzg5MjFjZTc0L3RhYmxlcmFuZ2U6N2IwNTNlNDBjYWMzNGJiMmFmYmMyY2UzODkyMWNlNzRfMy01LTEtMS0yMTM2_b66dccaa-ed39-4a8e-b7b4-56e6506c5878">35,392,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjdiMDUzZTQwY2FjMzRiYjJhZmJjMmNlMzg5MjFjZTc0L3RhYmxlcmFuZ2U6N2IwNTNlNDBjYWMzNGJiMmFmYmMyY2UzODkyMWNlNzRfMy03LTEtMS0yMTM2_04a9e057-dfe9-41c2-a7aa-d23833f11ca6">30,368,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share, basic</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjdiMDUzZTQwY2FjMzRiYjJhZmJjMmNlMzg5MjFjZTc0L3RhYmxlcmFuZ2U6N2IwNTNlNDBjYWMzNGJiMmFmYmMyY2UzODkyMWNlNzRfNC0xLTEtMS0yMTM2_0e2bf4d6-6e5d-4002-8be9-12da550ac230">0.69</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjdiMDUzZTQwY2FjMzRiYjJhZmJjMmNlMzg5MjFjZTc0L3RhYmxlcmFuZ2U6N2IwNTNlNDBjYWMzNGJiMmFmYmMyY2UzODkyMWNlNzRfNC0zLTEtMS0yMTM2_c4869766-9cd3-4425-a6ce-d5b824f3d774">0.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjdiMDUzZTQwY2FjMzRiYjJhZmJjMmNlMzg5MjFjZTc0L3RhYmxlcmFuZ2U6N2IwNTNlNDBjYWMzNGJiMmFmYmMyY2UzODkyMWNlNzRfNC01LTEtMS0yMTM2_73b54b2f-73b7-4354-8c04-413f90271fca">2.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjdiMDUzZTQwY2FjMzRiYjJhZmJjMmNlMzg5MjFjZTc0L3RhYmxlcmFuZ2U6N2IwNTNlNDBjYWMzNGJiMmFmYmMyY2UzODkyMWNlNzRfNC03LTEtMS0yMTM2_a0573c3c-41b9-457c-bcf9-ad28be92dd8d">0.90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="ia70af8361dd34a31a22ceda315f40b20"><div><ix:continuation id="ief6a58bae3334c9c8584ffa1bdd7d414"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfMi0xLTEtMS00MjEy_186af6e8-3234-4e70-9c58-31b97920ca1f">25,041</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfMi0zLTEtMS00MjEy_870ed8bc-42f9-4a1b-a945-e133aa0d72ff">5,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfMi01LTEtMS00MjEy_1973f8ab-38c4-4138-89f2-458afacf4feb">74,140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfMi03LTEtMS00MjEy_a1ab0a3f-349b-430b-b9f0-d84b88210394">27,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfMy0xLTEtMS00MjEy_fbdd521c-fe58-4697-afc6-1d794424a61e">36,547,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfMy0zLTEtMS00MjEy_4877f692-f1c6-4d0d-ac36-929dab21f84c">30,533,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfMy01LTEtMS00MjEy_93071084-2da0-400b-a51e-5687eef30a1a">35,392,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfMy03LTEtMS00MjEy_8d98d37c-b8d9-4e19-8e03-2aadae72d471">30,368,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive impact from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iccd54f681834442eb165955240d9e74a_D20210701-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfNi0xLTEtMS00MjEy_71006b49-ebe4-4a75-8e97-463acd57a787">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idcf0ba2ceaab4483a2bfe533ce701a43_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfNi0zLTEtMS00MjEy_4f001b1d-c39d-4eb8-be24-85f68a862c73">1,605,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia79f1a27faad4ee0b5c7c77ea717ed13_D20210101-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfNi01LTEtMS00MjEy_31d005fe-640f-49df-aa77-697f5852d50d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic423ff5ccdca4effbe4d4211fa5e77f6_D20200101-20200930" decimals="0" format="ixt:fixed-zero" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfNi03LTEtMS00MjEy_e505c02a-59aa-4868-bc5b-4ffb26666e3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted common stock and stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8bf19a2caf8b4d509a379811f8a3c1ea_D20210701-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfNy0xLTEtMS00MjEy_911cf9c8-c083-4428-a8d1-b6979c936fe8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12795b2676c0493781d9a5bdadfbf6cc_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfNy0zLTEtMS00MjEy_303b2ab1-7876-40a5-9da5-c902e8eaa683">226,631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a64c5a4066049d08858e72736c24a45_D20210101-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfNy01LTEtMS00MjEy_0b11bdf2-3781-4992-bc6a-d7fe003bd8ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20a672c9e2164a1480e1ae0fd1133627_D20200101-20200930" decimals="0" format="ixt:fixed-zero" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfNy03LTEtMS00MjEy_40a9bc1e-9023-4fab-84e8-b3959ee7dee4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfOC0xLTEtMS00MjEy_5e115bd8-0882-4140-aaf6-e6696a361c1b">36,547,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfOC0zLTEtMS00MjEy_2a1dc011-47d1-4f6b-a731-8e6a01d83c45">32,366,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfOC01LTEtMS00MjEy_0f9e522f-81c0-47f3-ad06-07884ca1a2ed">35,392,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfOC03LTEtMS00MjEy_69fcb58e-4210-42c0-ba4f-e9f629e83348">30,368,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share, diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfMTAtMS0xLTEtNDIxMg_393f65a9-1e97-4f69-b0c2-b93a24a15c87">0.69</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfMTAtMy0xLTEtNDIxMg_62c8280f-c481-45be-b779-ad87619de494">0.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfMTAtNS0xLTEtNDIxMg_cf78680c-2a9e-45ce-8a9f-09f0b26ae7b2">2.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfMTAtNy0xLTEtNDIxMg_1d120151-d4b1-4f84-8a4e-1ac69607a726">0.90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RleHRyZWdpb246NWZlZjg0Y2JhMTM0NGZlMmFiMDIyMTc5NTM5OTE0NWZfMTYyMg_ca12cacc-df40-4a8d-90e5-f8e4bce6a9b8" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding common stock equivalents, presented based on amounts outstanding at each period end, that have been excluded from the calculation of diluted net loss per share for the periods indicated because their inclusion would have been anti-dilutive (in common stock equivalent shares, as applicable):</span></div><div style="margin-top:12pt;text-align:center;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1117ebd626644baebf8cd85f62f25c00_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfMi0xLTEtMS0yMTM2_044fe011-956f-43ea-8180-7dedacfe56f4">24,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ec79f5f2c2143ed87b1024777fbb963_D20200701-20200930" decimals="0" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfMi0zLTEtMS0yMTM2_a038fca5-ab8b-4c3f-9db9-2dbcc8df17b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id77ac29ae1c946708d972f4329a5fd16_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfMi01LTEtMS0yMDY0Nw_85f33374-421d-42ad-a4e5-2b7e73f50a44">24,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb5f82106070482cae1bfd5c69ed3333_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfMi03LTEtMS0yMDY0Nw_992d4759-6436-450e-bb25-9544b5f80113">167,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4ea8f4ed8fbc4550aa703adec2e38d33_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfMy0xLTEtMS0yMTM2_32903f5d-f9aa-4cd2-aa5f-0ba6599edd41">41,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icccb7da2fdfc4873a395a07afd73be7c_D20200701-20200930" decimals="0" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfMy0zLTEtMS0yMTM2_5ccec520-1afa-4bc9-ba45-6cc08a843412">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea0a178c00d24c538b17f43b4a9992b0_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfMy01LTEtMS0yMDY0Nw_60803e6a-eb28-4e76-b7c8-a8bc9ae46f73">41,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i79f148df7d7a454d8deed12b42736ccb_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfMy03LTEtMS0yMDY0Nw_019493fd-2d3d-4d0f-863d-6f0ef66a2bf1">66,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a342db77baf4dcc9e4c05d95f989378_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfNC0xLTEtMS0yMTM2_e2f16d03-29eb-4c4c-9ac8-44499b41971e">5,086,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33b959e99b544061a1ad9375c42039bd_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfNC0zLTEtMS0yMTM2_5622343a-ab3b-4be5-aa62-fcf7c24268d7">553,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica73f41d57df4863906446bbbec208e0_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfNC01LTEtMS0yMDY0Nw_829c11d9-ab78-4a2f-969a-3bbdc1308267">5,086,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibc431739b79043079a7eb95d72fdb304_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfNC03LTEtMS0yMDY0Nw_dbd33bda-2ac9-43b8-b356-509a6b7ad764">4,685,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfNS0xLTEtMS0yMTM2_e76b5149-9aad-4805-81d5-914e432b1b12">5,151,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfNS0zLTEtMS0yMTM2_052c194f-1ced-46f2-a48b-c260b61e05f1">553,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfNS01LTEtMS0yMDY0Nw_05a14e17-a58a-4497-8acb-b4c5d80aa9fa">5,151,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfNS03LTEtMS0yMDY0Nw_8e6494f7-08d4-45d2-87b2-1db6ee1234b8">4,918,732</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the securities listed in the table above, as of September&#160;30, 2021 the Company had reserved <ix:nonFraction unitRef="shares" contextRef="i4299c25bbef841838f8943aab9d90e62_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RleHRyZWdpb246NWZlZjg0Y2JhMTM0NGZlMmFiMDIyMTc5NTM5OTE0NWZfMTQ0NA_6f97e100-4008-44ae-bd00-4a265971d0e7">801,622</ix:nonFraction> shares of common stock for sale under the ESPP, which, if issued, would be anti-dilutive if included in calculation of diluted net loss per share for the nine months ended September&#160;30, 2021.</span><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion of our financial condition and results of operations in conjunction with our condensed financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q. In addition to historical financial information, this discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties, such as statements of our plans, objectives, expectations, intentions and belief. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the section titled &#8220;Risk Factors&#8221; under Part II, Item 1A below.&#160;&#160;These forward-looking statements may include, but are not limited to, statements regarding our future results of operations and financial position, the impact of the COVID-19 pandemic, business strategy, market size, potential growth opportunities, preclinical and clinical development activities, efficacy and safety profile of our product candidates, use of net proceeds from our offerings, our ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical studies and clinical trials, commercial collaborations with third parties and the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;potentially,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;predict,&#8221; &#8220;target,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;project,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company applying our proprietary insights into integrins to discover and develop a pipeline of potentially first-in-class oral small molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. To date, no oral small molecule integrin therapies have been approved by the U.S. Food and Drug Administration, or FDA. Despite significant unsuccessful efforts by others, we believe tremendous untapped potential remains for us to develop oral integrin therapies. The Morphic integrin technology platform, or MInT Platform, was created leveraging our unique understanding of integrin structure and function to develop novel product candidates designed to achieve the potency, high selectivity, and pharmaceutical properties required for oral administration. We are advancing our pipeline, including our lead product candidate, MORF-057, an &#945;4&#946;7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease, or IBD. We submitted an investigational new drug application, or IND, for MORF-057 in July 2020, and the FDA permitted the study submitted under the IND to proceed in August 2020. In September 2020, we initiated a Phase 1 clinical trial of MORF-057 in healthy volunteers comprised of single-ascending dose, or SAD, food effect, and multiple-ascending dose, or MAD, cohorts to establish our clinical program and select doses for our Phase 2 program in IBD with an initial focus on ulcerative colitis, or UC.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2021, we announced interim results from the SAD portion of the Phase 1 trial and MORF-057 was found to be generally well tolerated in all five dose cohorts receiving MORF-057 in single doses ranging from 25 mg to 400 mg; no serious or severe adverse events were noted across all subjects in these cohorts. The pharmacokinetic profile exhibited generally dose-proportional and predictable pharmacokinetics, or PK, that continue to support BID (twice-daily) dosing. The key pharmacodynamic, or PD, measurement in the trial was mean &#945;4&#946;7 receptor occupancy (RO), which indicated the percentage of &#945;4&#946;7 receptors bound by MORF-057 to be greater than 95% at 12 hours after a single dose across the three highest dose cohorts.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2021, we announced complete Phase 1 results that included SAD, MAD and food effect (FE) cohorts evaluating MORF-057 for safety, pharmacokinetic and pharmacodynamic measures.  A total of 67 eligible healthy subject were enrolled and 66 subjects completed the study. MORF-057 was well tolerated in all cohorts and no safety signals were identified. MORF-057 also demonstrated a predictable and dose-dependent PK profile. Results from the food effect cohort showed that high fat meal intake did not impact trough levels of MORF-057 and indicated that MORF-057 can be administered without regard to food in planned studies in patients.  In the key PD measurement of &#945;4&#946;7 RO, MORF-057 demonstrated dose and time-dependent receptor occupancy of &#945;4&#946;7 with complete receptor saturation in all subjects in the 100mg BID cohort. Changes in additional investigational PD biomarkers including &#945;4&#946;7 specific lymphocyte subsets and CCR9 transcripts were consistent with published literature for other intravenous biologic &#945;4&#946;7 inhibitors, providing additional mechanistic validation. These results taken as whole provide a basis upon which to select candidate doses for our upcoming Phase 2 ulcerative colitis program.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, AbbVie exercised the option and now controls and is responsible for the development and commercialization of our &#945;v&#946;6-specific integrin inhibitor program. In connection with the option exercise, AbbVie made a one-time $20.0 million payment to us. We are entitled to additional payments upon the achievement of certain milestones and royalties in accordance with the AbbVie Agreement. In February 2019, we entered into an agreement with Janssen Pharmaceuticals, Inc., or Janssen, to develop novel integrin therapeutics, or the Janssen Agreement. In February 2021 Janssen paid us $5.0 million to commence work on a third research program. We are entitled to additional payments upon the achievement of certain milestones and royalties in accordance with the Janssen Agreement. We continue to advance additional discovery programs with AbbVie and Janssen as a part of these collaborations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beyond these targets, we are using our MInT Platform to advance a broad pipeline of preclinical programs across a variety of additional therapeutic areas, all of which aim to harness the potential of inhibition or activation of an integrin receptor. Additional wholly-owned programs have advanced near to or into lead optimization phase of discovery. We p</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">resented positive preclinical data from our </span><span style="background-color:#ffffff;color:#00101f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#945;v&#946;8 program at the American Association for Cancer Research Annual Meeting demonstrating anti-tumor activity in checkpoint refractory cancer models and continue our focus on advancing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> our avb8 program in oncology.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we announced an upsized underwritten public offering of 3,500,000 shares of our common stock at a price to the public of $70.00 per share, resulting in net proceeds of approximately $230.0 million, after deducting underwriting discounts, commissions and other offering expenses paid by us. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2020, we entered into an Open Market Sale Agreement, or the Original Agreement, with Jefferies LLC, or Jefferies, with respect to an at-the-market offering program, or the Previous ATM, under which we may offer and sell, from time to time at our sole discretion, shares of our common stock, having an aggregate offering price of up to $75,000,000, referred to as Placement Shares, through Jefferies as its sales agent. In August 2021, we entered into Amended No. 1 to the Original Agreement with Jefferies with respect to an at-the-market offering program, or the New ATM, increasing the amount of Placement Shares, under the Original Agreement, which we may offer and sell, from time to time at its sole discretion, through Jefferies as is sales agent, up to an aggregate offering price of up to $150,000,000. We refer to the Previous ATM and the New ATM, collectively, as the ATM. During the three months ended September&#160;30, 2021, 298,070 shares under the ATM were sold for net proceeds of $17.4 million after deducting offering commissions and expenses. During the nine months ended September&#160;30, 2021, we issued and sold 538,774 shares for net proceeds of $24.6 million after deducting offering commissions and expenses. As of September 30, 2021, we had approximately $138.9 million of common stock remaining available for sale under the ATM. </span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> may not sell any Placement Shares under the Previous ATM.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, our operations have focused on organizing and staffing our company, business planning, raising capital, establishing our intellectual property portfolio, and performing research to discover and develop oral small-molecule integrin therapeutics. Revenue generation activities to date have been limited to payments received from our collaboration agreements with AbbVie and Janssen, discussed further in Note 10 of the accompanying condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q. We do not have any products approved for sale and have not generated any revenue from product sales. From inception through September&#160;30, 2021, we raised an aggregate of approximately $696.2 million of gross proceeds primarily through the issuance of equity, including our convertible preferred equity securities, our IPO, our underwritten public offering in March 2021, and sales of shares of our common stock pursuant to the ATM, along with payments received under our collaboration agreements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred significant operating losses. As of September&#160;30, 2021, we had an accumulated deficit of $216.7 million. We expect to continue to incur significant and increasing expenses and operating losses for the foreseeable future, as we advance our current and future product candidates through preclinical and clinical development, seek regulatory approval for them, maintain and expand our intellectual property portfolio, hire additional research and development and business personnel, and operate as a public company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for our product candidates. In addition, if we obtain regulatory approval for our product candidates and do not enter into a third-party commercialization partnership, we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing, manufacturing, and distribution activities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity offerings and debt financings or other sources, such as additional collaboration agreements. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on acceptable terms, or at all. Our failure to raise capital or enter into such agreements as, and when, needed, could have a material adverse effect on our business, results of operations, and financial condition.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, we had cash, cash equivalents, and marketable securities of $427.6 million. We believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements until the end of 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of the COVID-19 Pandemic</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The current COVID-19 pandemic continues to present a substantial public health and economic challenge around the world and is affecting our employees, patients, communities and business operations, as well as the U.S. economy and financial markets. The extent of the ongoing impact of the novel strain of coronavirus, SARS-CoV-2, or COVID-19, on our operational and financial performance will depend on certain developments, including the duration and spread of the outbreak, including the rise of variants that may be less responsive to existing vaccines, impact on our clinical and preclinical studies, employee or industry events, and effect on our suppliers and manufacturers, all of which are uncertain and cannot be predicted. Although we currently have not experienced much of an impact on our business, excluding minor changes to our development timelines, if there are closures or other restrictions in places we or our vendors work or transport supply that may result in constrained supply of our product candidates or delays in our clinical and preclinical studies or planned clinical trials, our business, results of operations and overall financial performance in future periods could be materially adversely impacted. In addition, we have experienced impacts from changes in how we and companies worldwide conduct business due to the COVID-19 pandemic, including but not limited to restrictions on travel and in-person meetings, delays in future site activations and future enrollment of clinical trials, prioritization of hospital resources toward the COVID-19 pandemic effort, and delays in review by the FDA and comparable foreign regulatory agencies. As of the filing date of this Form 10-Q, the extent to which COVID-19 may impact our financial condition, results of operations or guidance is uncertain. The effects of the COVID-19 pandemic will not be fully reflected in our results of operations and overall financial performance until future periods. See &#8220;Risk Factors&#8221; included elsewhere in this Quarterly Report on Form 10-Q for further discussion of the possible impact of the COVID-19 pandemic on our business.</span></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_79"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any products approved for sale, and as a result, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, all of our collaboration revenue has been derived from our agreements with AbbVie and Janssen. We expect that our revenue, until we have a marketed product, will be derived primarily from payments under our collaboration and option agreements with AbbVie and Janssen or other collaboration and license agreements that we may enter into in the future, if any.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue&#160;&#8212; AbbVie</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we entered into a collaboration with AbbVie, an investor that held approximately 5% of our common stock at the time of the agreement, designed to advance a number of our oral integrin therapeutics for fibrosis-related indications. Under the terms of the AbbVie Agreement, AbbVie paid us an upfront payment of $100.0 million for research and development activities, and we provided to AbbVie exclusive license options on product candidates directed at multiple targets. In August 2020, AbbVie exercised its option to license the selective &#945;v&#946;6-specific integrin inhibitors program and paid us a one-time payment of $20.0 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each lead compound against a target under the AbbVie Agreement, we conduct research and development activities through the completion of IND-enabling studies, at which point AbbVie may pay a license fee of $20.0 million, on a target-by-target basis, to exercise its exclusive license option and assume responsibility for global development and commercialization. We are also eligible for clinical and commercial milestone payments and tiered royalties from high single digit to low teens on worldwide net sales for each licensed product. In addition, for certain compounds for which we have completed IND-enabling studies and which meet certain advancement criteria for a liver indication, we have the option to commit to share development costs in exchange for an increased fixed royalty rate. We may exercise this option following completion of the first Phase 2b clinical trial for the relevant product.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue&#160;&#8212;&#160;Janssen</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we entered into the Janssen Agreement to discover and develop novel integrin therapeutics for patients with conditions not adequately addressed by current therapies. The Janssen Agreement focuses on three integrin targets, each target the subject of a research program, with the ability to substitute up to two integrin targets not explored by us. Upon completing IND-enabling studies, on a research program-by-research program basis, Janssen may exercise an exclusive option to obtain an </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exclusive license with respect to the target that is the subject of the research program, including all licensed compounds that are the subject of the applicable research program, and then Janssen will be responsible for global clinical development and commercialization. In consideration of the rights granted, during 2019, Janssen paid us an upfront fee of $10.0 million for each of the first two research programs, and in December 2020 we agreed with Janssen to commence work on the third research program, and in February 2021 Janssen paid us $5.0 million for the third research program commencement fee. Janssen also funds research activities at agreed upon rates. Pursuant to the terms of the agreement, we are also eligible to receive additional milestone and royalty payments.</span></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_82"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for our research and development activities, including our product candidate discovery efforts and preclinical studies under our research programs, which include:</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">employee-related expenses, including salaries, benefits, and equity-based compensation expense for our research and development personnel;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">costs of funding research performed by third parties that conduct research and development and preclinical activities on our behalf;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">costs of manufacturing clinical supply related to any of our current or future product candidates;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">expenses incurred under agreements with contract research organizations and investigative sites that conduct our clinical trials;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">costs of conducting preclinical studies of any of our current or future product candidates;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">consulting and professional fees related to research and development activities, including equity-based compensation to non-employees;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">costs of purchasing laboratory supplies and non-capital equipment used in our preclinical studies;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">costs related to compliance with clinical regulatory requirements;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">facility costs and other allocated expenses, which include expenses for rent and maintenance of facilities, insurance, depreciation and other supplies; and</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">fees for maintaining licenses and other amounts due under our third-party licensing agreements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Costs for certain activities are recognized based on an evaluation of the progress to completion of specific tasks using data such as information provided to us by our vendors and analyzing the progress of our preclinical studies or other services performed. Significant judgment and estimates are made in determining the accrued expense balances at the end of any reporting period. Non-refundable advance payments for research and development goods or services to be received in the future from third parties are capitalized and expensed as the related goods are delivered or the services are performed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development of our product candidates is highly uncertain. As such, at this time, we cannot reasonably estimate or know the nature, timing, and costs of the efforts that will be necessary to complete our future product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from the sale of our product candidates, if approved. This is due to the numerous risks and uncertainties associated with developing product candidates, including the uncertainty of:</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the scope, rate of progress, and expenses of our ongoing research activities as well as any additional preclinical studies and clinical trials and other research and development activities;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">establishing an appropriate safety profile;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">successful enrollment in and completion of clinical trials;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">whether our product candidates show safety and efficacy in our clinical trials;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">receipt of marketing approvals from applicable regulatory authorities, if any;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">commercializing the product candidates, if and when approved, whether alone or in collaboration with others; and</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">continued acceptable safety profile of the products following any regulatory approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development of our current and future product candidates would significantly change the costs and timing associated with the development of those product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect research and development costs to increase significantly for the foreseeable future as we continue the development of our product candidates. However, we do not believe that it is possible at this time to accurately project total program-specific expenses through commercialization. There are numerous factors associated with the successful commercialization of any of our product candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development. Additionally, future commercial and regulatory factors beyond our control will impact our clinical development programs and plans.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of employee-related expenses, including salaries, benefits, and equity-based compensation expenses for personnel in executive, finance, accounting, business development, legal, and human resources functions. Other significant general and administrative expenses include facility costs not otherwise included in research and development expenses, legal fees relating to patent and corporate matters, and fees for accounting and consulting services.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses will increase in the future as our business expands to support expected growth in research and development activities, including our future clinical programs. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside consultants, among other expenses. We also incur expenses associated with being a public company, including costs for audit, legal, regulatory, and tax-related services related to compliance with the rules and regulations of the Securities and Exchange Commission, (&#8220;SEC&#8221;), and listing standards applicable to companies listed on Nasdaq, director and officer compensation and insurance premiums, and investor relations costs. In addition, if we obtain regulatory approval for any of our product candidates and do not enter into a third-party commercialization collaboration, we expect to incur significant general and administrative expenses related to supporting product sales, marketing and distribution activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income, Net</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net consists primarily of interest income earned on our cash, cash equivalents and marketable securities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Benefit from Income Tax Expense for Interim Periods</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefit from or provision for income tax expense recorded in any interim period is based on the estimated effective tax rate for the fiscal&#160;year for those tax jurisdictions that can be reliably estimated. Our calculation of the estimated effective tax rate requires us to estimate pre-tax income by tax jurisdiction as well as total tax expense for the fiscal&#160;year.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the Coronavirus Aid Relief and Economic Security, or the CARES Act, was signed into law. The CARES Act included several income tax changes, included allowing for the carryback of net operating losses, expanding interest deductibility, and allowing for accelerated expensing of certain capital improvements. We evaluated the changes and anticipate a full recovery of all federal income tax paid for the December 31, 2019 tax period due to the carryback allowance of the net operating loss generated during fiscal year 2020. Based on the anticipated recovery of the federal income tax paid for the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2019 tax period, we recorded a $0.1 million and $0.4 million benefit from income taxes during the three and nine months ended September&#160;30, 2020.</span></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the three months ended September 30, 2021 and September&#160;30, 2020</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended September 30, 2021 and September&#160;30, 2020:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,633)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,242&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,749&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,493&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) Income from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,118)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,008&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,126)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(602)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) Income before benefit from income taxes</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,041)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,239&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,280)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(578)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,041)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,354&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,395)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(568)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Percentage not meaningful</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in collaboration revenue of $22.6 million is primarily attributable to a decrease in activity under the AbbVie Agreement.  In the prior year period, AbbVie exercised its option for the selective &#945;v&#946;6 -specific integrin inhibitors program resulting in the payment of a $20.0 million option exercise payment from AbbVie, which was recognized during the three months ended September 30, 2020. Further, upon the AbbVie option exercise, we revised our estimates to complete the remaining performance obligations under the &#945;v&#946;6 -specific integrin inhibitors program, which resulted in an increase in revenue during the prior year period. The revenue for our collaborations fluctuates based on the timing and magnitude of costs incurred under the collaboration programs, as well as changes to our estimates to complete the remaining performance obligations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense increased by $5.0 million, or 31% from $16.0 million for the three months ended September 30, 2020 to $21.0 million for the three months ended September 30, 2021. A significant portion of our research and development costs have been external clinical and preclinical contract research organization (&#8220;CRO&#8221;) costs, which we track on a program-by-program basis related to a clinical product candidate, once the candidate has been identified. Our internal research and development costs are primarily personnel-related costs, depreciation, and other indirect costs. The following table summarizes our research and development expense for three months ended September 30, 2021 and 2020:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External costs by program:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MORF-057</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#945;v&#946;6 Program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(493)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other AbbVie Agreement programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(376)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen Agreement programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#945;v&#946;1 Program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#945;v&#946;8 Program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other early development candidates and unallocated costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total external costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,890&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,016&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,874&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total internal costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,076&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,982&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,094&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,966&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,998&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,968&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Percentage not meaningful</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in research and development expense were primarily attributable to the following:</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The $2.9 million increase in external costs from the three months ended September 30, 2020 to the period ended September&#160;30, 2021 primarily related to manufacturing costs and other development activities to support Phase 2 clinical studies for MORF-057, as well as other external research costs to support our early development candidates, including &#945;v&#946;8. These increases were partially offset by a decrease in expenditures associated with the &#945;v&#946;6 program as a result of the option exercise by AbbVie in August 2020 and decreases in activity regarding other programs with AbbVie and Janssen.</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The $2.1 million increase in internal costs from the three months ended September 30, 2020 to the period ended September&#160;30, 2021 was primarily driven by an increase in headcount to support the ongoing clinical activity for MORF-057 as well as our early stage pipeline candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense increased by $2.5 million, or 53%, from $4.8 million for the three months ended September 30, 2020 to $7.3 million for the three months ended September 30, 2021. The increase in general and administrative expense was primarily attributable to a $1.7 million increase in non-cash stock-based compensation expense, a $0.3 million increase in personnel costs, and a $0.4 million increase in professional and consulting fees.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Income, Net</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income decreased by $0.2 million due to a decrease in marketable securities held during the current period as well as a decrease in yields earned on marketable securities during the three months ended September 30, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Benefit from Income Tax</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the CARES Act was signed into law. The CARES Act included several income tax changes, included allowing for the carryback of net operating losses, expanding interest deductibility, and allowing for accelerated expensing of certain capital improvements. Based on the anticipated recovery of the federal income tax paid for the December 31, 2019 tax period, we recognized an income tax benefit of $0.1 million for the three months ended September 30, 2020. </span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Nine Months Ended September 30, 2021 and 2020</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the nine months ended September&#160;30, 2021 and 2020:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,806)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,498&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,245&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,253&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,260)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,201)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,059)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,396)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,524&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,404)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before benefit from income taxes</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,140)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,677)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,463)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(427)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,140)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,250)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,890)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      *Percentage not meaningful</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in collaboration revenue of $28.8 million is primarily attributable to a decrease in activity under the AbbVie Agreement. In the prior year period, we successfully completed preclinical studies for the &#945;v&#946;6 program and AbbVie exercised its option for the selective &#945;v&#946;6 -specific integrin inhibitors program resulting in the payment of a $20.0 million option exercise fee, which was recognized during the nine months ended September&#160;30, 2020. Further, upon the AbbVie option exercise, we revised our estimates to complete the remaining performance obligations under the &#945;v&#946;6 -specific integrin inhibitors program, which resulted in an increase in revenue during the prior year period. The revenue for our collaborations fluctuates based on the timing and magnitude of costs incurred under the collaboration programs, as well as changes to our estimates to complete the remaining performance obligations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense increased by $9.3 million. A significant portion of our research and development costs have been external clinical and preclinical contract research organization (&#8220;CRO&#8221;) costs, which we track on a program-by-program basis related to a clinical product candidate, once the candidate has been identified. Our internal research and development costs are primarily personnel-related costs, depreciation, and other indirect costs. The following table summarizes our research and development expense for nine months ended September&#160;30, 2021 and 2020:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External costs by program:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MORF-057</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#945;v&#946;6 Program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,944)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other AbbVie Agreement programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(569)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen Agreement programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(757)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#945;v&#946;1 Program</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(874)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#945;v&#946;8 Program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other early development candidates and unallocated costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total external costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,309&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,140&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,169&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total internal costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,822&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,737&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,085&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,131&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,877&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,254&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Percentage  not meaningful </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in research and development expense were primarily attributable to the following:</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The $4.2 million increase in external costs from the nine months ended September&#160;30, 2020 to the period ended September&#160;30, 2021 primarily related further development activities in MORF-057 to support its clinical activity, as well as an increase in preclinical research for the &#945;v&#946;8 program and other early programs, partially offset by a decrease in expenditures due to the cessation of work on &#945;v&#946;6 program following the exercise of the option by AbbVie in August 2020.</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The $5.1 million increase in internal costs from the nine months ended September&#160;30, 2020 to the period ended September&#160;30, 2021 was primarily driven by an increase in headcount to support the ongoing clinical activity for MORF-057 as well as our early stage pipeline candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense increased by $7.0 million, or 52%, from $13.4 million for the nine months ended September&#160;30, 2020 to $20.4 million for the nine months ended September&#160;30, 2021. The increase in general and administrative expense was primarily attributable to a $4.7 million increase in non-cash stock-based compensation expense, a $1.0 million increase in personnel costs, and a $1.2 million increase in consulting and professional fees. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Income, Net</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income decreased by $1.4 million due to a decrease in marketable securities held during the current period as well as a decrease in yields earned on marketable securities during the nine months ended September&#160;30, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Benefit from Income Tax</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the CARES Act was signed into law. The CARES Act included several income tax changes, included allowing for the carryback of net operating losses, expanding interest deductibility, and allowing for accelerated expensing of certain capital improvements. Based on the anticipated recovery of the federal income tax paid for the December 31, 2019 tax period, we recognized an income tax benefit of $0.4 for the nine months ended September&#160;30, 2020.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span><br/></span></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_91"></div><div style="margin-top:12pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through September&#160;30, 2021, we raised an aggregate of approximately $696.2 million of gross proceeds primarily through the issuance of equity, including our convertible preferred equity securities, our IPO and follow-on equity offering, and sales of shares of our common stock under the ATM, along with payments received under our collaboration agreements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our total cash, cash equivalents, and marketable securities, each of which are stated at their respective fair values as of September&#160;30, 2021 and December&#160;31, 2020:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds (included in cash equivalents)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,576&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,264&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our cash flows for the nine months ended September&#160;30, 2021 and 2020:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,876)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,572)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,366)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,397&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,479)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Cash Used in Operating Activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of cash in all periods resulted primarily from our net losses adjusted for non-cash charges and changes in components of working capital. Net cash used in operating activities was $62.9 million for the nine months ended September&#160;30, 2021 compared to $31.6 million in cash used in operating activities for the nine months ended September&#160;30, 2020. The increase in cash used in operating activities was primarily driven primarily by a $46.9 million increase in net loss, partially offset by  changes in operating assets and liabilities, and a $7.5 million increase equity-based compensation. The increase in net loss was primarily attributable to the $20.0 million option exercise payment from AbbVie in the prior year as well as a $16.3 million increase in operating expenses in the current year.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Cash (Used In) Provided by Investing Activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $118.4 million for the nine months ended September&#160;30, 2021 compared to $19.5 million provided by investing activities for the nine months ended September&#160;30, 2020. The increase in cash used in investing activities in the current year is due to an increase in investments in marketable securities with proceeds from the underwritten public offering completed in March 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Cash Provided by Financing Activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities of $263.6 million for the nine months ended September&#160;30, 2021 primarily resulted from the $230.0 million in net proceeds received from the underwritten public offering completed in March 2021, $24.6 million in net proceeds received from sales of shares of common stock under the ATM, and $9.0 million in proceeds received from issuance of common shares under ESPP and stock option exercises. During the nine months ended September&#160;30, 2020, the Company received $9.0 million from the issuance of common shares under ESPP and stock option exercises.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our expenses to increase in connection with our ongoing activities, particularly as we continue research and development, conduct clinical trials, and seek marketing approval for our current and any of our future product candidates. In addition, if we obtain marketing approval for any of our current or our future product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution, which costs we might offset through entry into collaboration agreements with third parties. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on acceptable terms, including, but not limited to, as a result of COVID-19, we would be forced to delay, reduce, or eliminate our research and development programs or future commercialization efforts. We expect our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements until the end of 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based this estimate on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the costs of conducting additional clinical and preclinical studies and future clinical trials;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the costs of future manufacturing;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the scope, progress, results and costs of discovery, preclinical development, laboratory testing, and clinical trials for other potential product candidates we may develop, if any;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the costs, timing, and outcome of regulatory review of our product candidates;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our ability to establish and maintain collaborations on favorable terms, if at all;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the achievement of milestones or occurrence of other developments that trigger payments under any collaboration agreements we might have at such time;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the costs and timing of future commercialization activities, including product sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining and enforcing our intellectual property rights, and defending intellectual property-related claims;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">our headcount growth and associated costs as we expand our business operations and research and development activities;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the potential delays in our preclinical studies, our development programs and our current and planned clinical trials due to the effects of the COVID-19 pandemic; and</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the cost of operating as a public company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements.</span></div><div style="margin-top:12pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our critical accounting policies are those policies which require the most significant judgments and estimates in the preparation of our condensed consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended September&#160;30, 2021, there were no material changes to our critical accounting policies as detailed&#160;in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020, which was filed with the SEC on March 1, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For detailed information regarding&#160;recently issued accounting pronouncements&#160;and the actual and expected impact on our condensed consolidated financial statements, see Note 2 in the accompanying condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form&#160;10-Q.</span></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have, during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable SEC rules.</span></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_100"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2021, the Company exercised its one-time extension right for its existing lease for <ix:nonFraction unitRef="sqft" contextRef="i196c1e6bf66247b98fa293ce7ce21c10_I20210831" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AreaOfLand" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xMDAvZnJhZzo3MTc2MTdiZmY2NDA0MDhhOTdlMGM4MDI4ZTNjNzYxZi90ZXh0cmVnaW9uOjcxNzYxN2JmZjY0MDQwOGE5N2UwYzgwMjhlM2M3NjFmXzIxOTkwMjMyNTg3NTg_73ee5a7c-27d3-4eb7-b1c2-cdfba2cd75e6">35,000</ix:nonFraction> square feet of office and laboratory space through May 2025, as provided for under the terms of the lease, and with future rent payments of $6.0 million as reflected in Note 9, "Commitments and Contingencies." As of&#160;September&#160;30, 2021, our contractual obligations remain consistent with those disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2020 other than the office and laboratory space lease extension.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Emerging Growth Company and Smaller Reporting Status</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to be an &#8220;emerging growth company,&#8221; or EGC, under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act until December 31, 2021. Section 107 of the JOBS Act provides that an EGC can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards. Thus, an EGC can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of delayed adoption of new or revised accounting standards and, therefore, we will be subject to the same requirements to adopt new or revised accounting standards as private entities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an EGC, we may take advantage of certain exemptions and reduced reporting requirements under the JOBS Act. Subject to certain conditions, as an EGC:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we will avail ourselves of the exemption from providing an auditor&#8217;s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we will avail ourselves of the exemption from complying with any requirement that may be adopted by the Public Company Accounting Oversight Board, or PCAOB, regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements, known as the auditor report on Critical Audit Matters;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we will provide reduced disclosure about our executive compensation arrangements; and</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we will not require nonbinding advisory votes on executive compensation or stockholder approval of any golden parachute payments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also a &#8220;smaller reporting company,&#8221; meaning that the market value of our stock held by non-affiliates is less than $700.0 million and our annual revenue is less than $100.0 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250.0 million or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700.0 million as of the last day of the second quarter of the most recently completed fiscal year.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div><span><br/></span></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_103"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.</span></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_106"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Evaluation of our Disclosure Controls and Procedures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our management, including our Chief Financial Officer and our Chief Executive Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under Exchange Act as of September 30,&#160;2021. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Based on our management&#8217;s evaluation (with the participation of our Chief Executive Officer and our Chief Financial Officer), as of the end of the period covered by this report, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the quarter ended September 30,&#160;2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II&#8212;OTHER INFORMATION</span></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_112"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity and reputational harm, and other factors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_115"></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk Factors</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. Before making your decision to invest in shares of our common stock, you should carefully consider the risks described below, together with the other information contained in this quarterly report, including our financial statements and the related notes&#160;and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us.&#160;We cannot assure you that any of the events discussed below will not occur. These events could have a material and adverse impact on our business, financial condition, results of operations and prospects. If that were to happen, the trading price of our common stock could decline, and you could lose all or part of your investment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The below summary risks provide an overview of many of the risks we are exposed to in the normal course of our business activities. As a result, the below summary risks do not contain all of the information that may be important to you, and you should read the summary risks together with the more detailed discussion of risks set forth following this section under the heading &#8220;Risk Factors,&#8221; as well as elsewhere in this Annual Report on Form 10-K under the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; Additional risks, beyond those summarized below or discussed in &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; may apply to our activities or operations as currently conducted or as we may conduct them in the future or in the markets in which we operate or may in the future operate. Consistent with the foregoing, we are exposed to a variety of risks, including risks associated with: </span></div><div style="margin-top:6pt;text-align:justify;text-indent:23pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are a clinical stage biopharmaceutical company with a limited operating history, no product candidates approved for commercial sale, and a history of significant losses. We expect to continue to incur significant losses for the foreseeable future and we may never achieve profitability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will require substantial additional funding to pursue our business objectives. If we are unable to raise capital when needed or on terms acceptable to us, we could be forced to delay, reduce or eliminate our research or drug development programs or any future commercialization efforts or other operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Raising additional equity capital may cause dilution to our stockholders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Obtaining debt financing may restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidates are in early stages of development. We and our partners may not obtain regulatory approvals for or successfully commercialize our product candidates, including our lead product candidate MORF-057 and our candidates in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">selective &#945;v&#946;6-specific integrin inhibitors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">program</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> licensed to AbbVie.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ongoing and future clinical trials may reveal significant adverse events not seen in our preclinical studies, and there is no guarantee that successful results in preclinical studies will lead to successful results in clinical trials. In addition, significant adverse events or other side effects may lead to difficulty in recruiting patients to our clinical trials, and we may be required to abandon our development efforts of our product candidates, which will adversely affect our business and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently have collaborations with AbbVie and Janssen, from which we have derived substantially all of our revenue. Continued revenue from these collaborations will require successful development of our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidates are subject to extensive governmental regulations, and we and/or our collaborators may be unable to obtain, or may be delayed in obtaining, U.S. or foreign regulatory approval. If we do not receive regulatory approval, we may be unable to commercialize our product candidates. We do not have prior experience in managing the clinical trials necessary to obtain such regulatory approvals.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are not able to obtain, maintain and enforce patent protection for our technologies or our product candidates, the development and commercialization of our product candidates may be adversely affected. </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success largely depends on the continued service of our key management, advisors and other specialized technical personnel involved with the crystallization of integrins.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A sale of a substantial number of shares of our common stock, including under our &#8220;at-the-market&#8221; offering with Jefferies or other equity or debt offering of our securities, may cause the price of our common stock to decline.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our executive officers, directors and certain of our stockholders and their affiliates beneficially own approximately 54% of our outstanding voting stock. As a result, these stockholders have substantial control over our company and their interests may not be aligned with the interests of our other stockholders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The COVID-19 pandemic could adversely impact our business, including our clinical trials and clinical trial operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Delaware law and provisions in our restated certificate of incorporation and amended and restated bylaws could make a merger, tender offer, or proxy contest difficult, thereby depressing the market price of our common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The exclusive forum provision in our organizational documents may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to our Business and Operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The outbreak of COVID-19, or a similar pandemic, epidemic or outbreak of an infectious disease in the United States or elsewhere, could have a material adverse impact on our business, financial condition and results of operations, including the execution of our preclinical studies and clinical trials and the use and sufficiency of our existing cash.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outbreak of COVID-19 has evolved into a global pandemic. The extent to which COVID-19 impacts our business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19, the availability of an effective vaccine, and the actions to contain the virus or treat its impact, among others. Many countries around the world have imposed quarantines and restrictions on travel and mass gatherings to slow the spread of the virus. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spread of an infectious disease, including COVID-19, may also result in the inability of our suppliers to deliver supplies to us on a timely basis. We currently utilize third parties to, among other things, manufacture components of our product candidates and, in the future, intend to utilize third parties to conduct our preclinical studies and clinical trials. If either we or any third-party parties in the supply chain for materials used in the production of our product candidates are adversely impacted by restrictions resulting from the COVID-19 pandemic, our supply chain may be disrupted, limiting our ability to manufacture our product candidates for our preclinical studies and clinical trials. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic could also potentially affect the business of the FDA, EMA or other health authorities, which could result in delays in meetings related to current and planned clinical trials and ultimately of reviews and approvals of our product candidates. Infections and deaths related to COVID-19 are disrupting certain healthcare and healthcare regulatory systems worldwide. The effects of COVID-19 may also slow potential enrollment of current and planned clinical trials, reduce the number of eligible patients for our current and planned clinical trials, create difficulties in recruiting clinical site investigators and staff, divert healthcare resources away from the conduct of clinical trials, delay receiving approval from local authorities to initiate our current and planned clinical trials, delay necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees, interrupt key clinical trial activities (like site monitoring) due to travel limitations imposed by authorities, and create difficulties in data collection and analysis, among other things. It is unknown how long these disruptions could continue, were they to occur. Any elongation or de-prioritization of our preclinical or clinical studies or delay in regulatory review resulting </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from such disruptions could materially affect the development and study of our product candidates. Any delays to our current and planned timelines could also impact the use and sufficiency of our existing cash reserves, and we may be required to raise additional capital earlier than we had previously planned. We may be unable to raise additional capital if and when needed, which may result in further delays or suspension of our development plans. If we are able to raise additional capital, challenging and uncertain economic conditions can make capital raising costly and dilutive.   </span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, we limited our office to only those employees completing laboratory-based tasks essential to the development efforts, and are starting to allow other employees to work outside of our office with certain precautions in place that we believe will ensure our employees&#8217; safety and wellbeing. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Essential&#8221; employees that are unable to telework continue to work at our facilities, and we have implemented appropriate safety measures, including social distancing, face covering, and increased sanitation standards. We have also suspended any requirement for an employee to obtain a doctor&#8217;s note to be absent from or return to the workplace, and are following guidance from the Center for Disease Control and the Occupational Safety and Health Administration regarding suspension of nonessential travel, self-isolation recommendations for employees returning from certain geographic areas, confirmed reports of any COVID-19 diagnosis among our employees, and the return of such employees to our workplace. Pursuant to updated guidance from the Equal Employment Opportunity Commission, we are engaging in limited and appropriate inquiries of employees regarding potential COVID-19 exposure, based on the direct threat that such exposure may present to our workforce. We continue to address other unique situations that arise among our workforce due to the COVID-19 pandemic on a case-by-case basis. While we believe that we have taken appropriate measures to ensure the health and well-being of our &#8220;essential&#8221; employees, there can be no assurances that our measures will be sufficient to protect our employees in our workplace or that they may otherwise be exposed to COVID-19 outside of our workplace. If a number of our essential employees become ill, incapacitated or are otherwise unable to continue working during the current or any future epidemic, our operations may be adversely impacted. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a shelter-in-place order or other mandated local travel restrictions or quarantines, particularly if there are additional reclosures where we do business, including with our collaborators, partners and contractors in the United States, Europe and China, our collaborators, partners and contractors conducting preclinical, clinical, research or manufacturing activities may not be able to access laboratory or manufacturing space, and our core activities may be significantly limited or curtailed, possibly for an extended period of time. Furthermore, to the extent the pandemic is ongoing and there are outbreaks in the laboratory space or office space, we may be subject to risk of&#160;liability&#160;should any employee allege we failed to adequately mitigate the risk of exposure to&#160;COVID-19. The spread of COVID-19, which has caused a broad impact globally, including restrictions on travel and quarantine policies put into place by businesses and governments, may have a material economic effect on our business. While the potential economic impact brought by and the duration of the pandemic may be difficult to assess or predict, it has already caused, and is likely to result in further, significant disruption of global financial markets and the trading prices for our common stock and other biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic, which may reduce our ability to access capital either at all or on favorable terms. In addition, a recession, depression or other sustained adverse market event resulting from the global effort to control COVID-19 infections could materially and adversely affect our business and the value of our common stock. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic and mitigation measures also have had, and may continue to have, an adverse impact on global economic conditions which could have an adverse effect on our business and financial condition, including impairing our ability to raise capital when needed. The extent to which the COVID-19 pandemic impacts our business and operations will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of the virus and the actions to contain its impact.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such events may result in a period of business disruption, and in reduced operations, any of which could materially affect our business, financial condition and results of operations. We do not yet know the full extent of potential delays or impacts on our business, our preclinical studies and clinical trials, healthcare systems or the global economy as a whole. However, these effects could have a material impact on our operations, and we will continue to monitor the situation closely. Although, as of the date of this Annual Report on Form 10-K, we do not expect any material impact on our long-term activity. The extent to which COVID-19 impacts our business will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to grow our organization, and we may experience difficulties in managing our growth and expanding our operations, which could adversely affect our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30,&#160;2021, we had approximately 101 full time employees. As a newly public company, and as our development and commercialization plans and strategies develop, we expect to expand our employee base for managerial, operational, financial and other resources. In addition, we have limited experience in product development. As our product candidates enter and advance through preclinical studies and clinical trials, we will need to expand our development and regulatory capabilities and contract with other organizations to provide manufacturing and other capabilities for us. In the future, we expect to have to manage additional relationships with collaborators or partners, suppliers and other organizations. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls. Our inability to successfully manage our growth and expand our operations could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success largely depends on the continued service of Praveen P. Tipirneni, M.D., our chief executive officer, as well as other members of our management team, other key employees and advisors. We currently do not maintain key person insurance on these individuals. The loss of one or more members of our management team or other key employees or advisors, including due to illness resulting from COVID-19, could delay our research and development programs and have a material and adverse effect on our business, financial condition, results of operations and prospects. The relationships that our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are dependent on the continued service of our technical personnel, in particular, personnel involved with crystallization of integrins, because of the highly technical nature of our product candidates and technologies related to our MInT Platform, and the specialized nature of the regulatory approval process. Because our management team and key employees are not obligated to provide us with continued service, they could terminate their employment with us at any time without penalty.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct our operations at our facility in Waltham, Massachusetts. This region is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. We also face competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations. Our future success will depend in large part on our continued ability to attract and retain other highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical testing, manufacturing, governmental regulation and commercialization. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover and develop product candidates will be limited which could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future growth may depend, in part, on our ability to develop and commercialize our product candidates in foreign markets for which we may rely on collaboration with third parties. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the applicable regulatory authority in that foreign market, and may never receive such regulatory approval for any of our product candidates. To obtain separate regulatory approval in many other countries, we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our product candidates, and we cannot predict success in these jurisdictions. If we fail to comply with the regulatory requirements in international markets and receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business will be adversely affected. We may not obtain foreign regulatory approvals on a timely basis, if at all. Our failure to obtain approval of any of our product candidates by regulatory authorities in another country may significantly diminish the commercial prospects of that product candidate and our business, financial condition, results of operations and prospects could be materially and adversely affected. Moreover, even if we obtain approval of our product candidates and ultimately commercialize </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our product candidates in foreign markets, we would be subject to the risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and reduced protection of intellectual property rights in some foreign countries.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business entails a significant risk of product liability and our ability to obtain sufficient insurance coverage could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we conduct clinical trials of our product candidates, we may be exposed to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products, such claims could result in an FDA investigation of the safety and effectiveness of our products, our manufacturing processes and facilities or our marketing programs and potentially a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, termination of clinical trial sites or entire trial programs, withdrawal of clinical trial participants, injury to our reputation and significant negative media attention, significant costs to defend the related litigation, a diversion of management&#8217;s time and our resources from our business operations, substantial monetary awards to trial participants or patients, loss of revenue, the inability to commercialize and products that we may develop, and a decline in our stock price. We currently maintain general liability insurance with coverage up to $10.0&#160;million. We may, however, need to obtain higher levels of product liability insurance for later stages of clinical development or marketing any of our product candidates. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other illegal activity by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to comply with FDA regulations, provide true, complete and accurate information to the FDA and other similar foreign regulatory bodies, comply with manufacturing standards we may establish, comply with healthcare fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under these laws will increase significantly, and our costs associated with compliance with these laws are likely to increase. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material and adverse effect on our business, financial condition, results of operations and prospects, including the imposition of significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, the curtailment or restructuring of our operations, loss of eligibility to obtain approvals from the FDA, exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, integrity oversight and reporting obligations, or reputational harm.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on our information technology systems, and any failure of these systems, or those of our CROs or other contractors or consultants we may utilize, could harm our business. Security breaches, cyber-attacks, loss of data, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations, financial condition and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We collect and maintain information in digital form that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal data. It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We have established physical, electronic and organizational measures to safeguard and secure our systems to prevent a data compromise, and rely on commercially available systems, software, tools, and monitoring to provide security for our information technology systems and the processing, transmission and storage of digital information. We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may or could have access to our confidential information. Our internal information technology systems and infrastructure, and those of our current and any future collaborators, contractors and consultants and other third parties on which we rely, are vulnerable to damage from cyber incidents such as third parties getting access to employee accounts using stolen or inferred credentials, computer viruses, phishing attacks, spamming, malware, cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization, and attempts to gain unauthorized access to computer systems and networks. Our internal information technology systems and infrastructure is also vulnerable to damage from natural disasters, terrorism, war, telecommunication and electrical failures. System failures or outages, including any potential disruptions due to significantly increased global demand on certain cloud-based systems during the COVID-19 situation, could compromise our ability to perform these functions in a timely manner, which could harm our ability to conduct business or delay our financial reporting. Such failures could materially adversely affect our operating results and financial condition.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk of a security breach or disruption or data loss, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. In addition, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information or other intellectual property. The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service and other harm to our business and our competitive position. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Moreover, if a computer security breach affects our systems or results in the unauthorized release of personally identifiable information, our reputation could be materially damaged. In addition, such a breach may require notification to governmental agencies, the media or individuals pursuant to various federal and state privacy and security laws, if applicable, including the Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and its implementing rules&#160;and regulations, as well as regulations promulgated by the Federal Trade Commission and state breach notification laws. In addition, such cyber-attacks, data breaches or destruction or loss of data could result in violation of applicable international privacy, data protection and other laws, resulting in exposure to material civil and/or criminal liability. Further, our general liability insurance and corporate risk program may not cover all potential claims to which we are exposed and may not be adequate to indemnify us for all liability that may be imposed; and could materially adversely affect our business, results of operations, financial condition and prospects. In addition, we may suffer reputational harm or face litigation or adverse regulatory action as a result of cyber-attacks or other data security breaches and may incur significant additional expense to implement further data protection measures.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be affected adversely.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development activities include the use of hazardous chemicals and materials, including radioactive materials. We maintain quantities of various flammable and toxic chemicals in our facilities in Waltham, Massachusetts that are required for our research and development activities. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous chemicals and materials. We believe our procedures for storing, handling and disposing these materials in our facilities comply with the relevant guidelines of Middlesex County, Massachusetts. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by applicable regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of animals and biohazardous materials. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current operations are concentrated in one location, and we or the third parties upon whom we depend may be adversely affected by a heavy snowstorm or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our current operations are located in our facilities in Waltham, Massachusetts. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemic, including the COVID-19 pandemic, power shortage, telecommunication failure or other natural or manmade accidents or incidents that result in us being unable to fully utilize our facilities, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. For example, our operations are concentrated primarily on the east coast of the United States, and any adverse weather event or natural disaster, such as a hurricane or heavy snowstorm, could have a material adverse effect on a substantial portion of our operations. Loss of access to these facilities may result in increased costs, delays in the development of our product candidates or interruption of our business operations. Extreme weather conditions or other natural disasters could further disrupt our operations, and have a material and adverse effect on our business, financial condition, results of operations and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our research facilities or the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. In addition, the long-term effects of climate change on general economic conditions and the pharmaceutical industry in particular are unclear and may heighten or intensify existing risk of natural disasters.  As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, or the manufacturing facilities of our third-party contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to complex tax rules&#160;relating to our business, and any audits, investigations or tax proceedings could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income and non-income taxes in the United States. Income tax accounting often involves complex issues, and judgment is required in determining our provision for income taxes and other tax liabilities. We may operate in other non-United States jurisdictions in the future. We could become subject to income and non-income taxes in non-United States jurisdictions as well. In addition, many jurisdictions have detailed transfer pricing rules, which require that all transactions with non-resident related parties be priced using arm&#8217;s length pricing principles within the meaning of such rules. The application of withholding tax, goods and services tax, sales taxes and other non-income taxes is not always clear and we may be subject to tax audits relating to such withholding or non-income taxes. We believe that our tax positions are reasonable. We are currently not subject to any tax audits. </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, the Internal Revenue Service or other taxing authorities may disagree with our positions. If the Internal Revenue Service or any other tax authorities were successful in challenging our positions, we may be liable for additional tax and penalties and interest related thereto or other taxes, as applicable, in excess of any reserves established therefor, which may have a significant impact on our results and operations and future cash flow.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we had net operating loss carryforwards for federal and state income tax purposes of $45.6 million and $56.4 million, respectively, which begin to expire in 2037. As of December 31, 2020, we also had available tax credit carryforwards for federal and state income tax purposes of $5.4 million and $1.1 million, respectively, which begin to expire in 2032. To the extent that our taxable income exceeds any current year operating losses, we plan to use our carryforwards to offset income that would otherwise be taxable. However, utilization of carryforwards generated in tax years beginning after December 31, 2018 is limited to a maximum of 80% of the taxable income for such year determined without regard to such carryforwards. In addition, under Section 382 of the Code, changes in our ownership may limit the amount of our net operating loss carryforwards and tax credit carryforwards that could be utilized annually to offset our future taxable income, if any. This limitation would generally apply in the event of a cumulative change in ownership of our company of more than 50% within a three-year period. We have not performed an analysis to determine whether there has been an ownership change pursuant to Section 382. Any such limitation may significantly reduce our ability to utilize our net operating loss carryforwards and tax credit carryforwards before they expire. Private placements, our IPO and other transactions that have occurred since our inception may trigger such an ownership change pursuant to Section 382. Any such limitation, whether as the result of our IPO, prior private placements, sales of our common stock by our existing stockholders or additional sales of our common stock by us, could have a material adverse effect on our results of operations in future years. There is also a risk that due to regulatory changes, such as suspensions on the use of net operating losses (&#8220;NOLs&#8221;), or other unforeseen reasons, our existing NOLs could expire or otherwise be unavailable to offset future income tax liabilities. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security (&#8220;CARES Act&#8221;), was signed into law. The CARES Act changes certain provisions of the Tax Cuts and Jobs Act of 2017 (&#8220;Tax Act&#8221;).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Tax Act, as modified by the CARES Act, NOLs from tax years that began after December 31, 2017 may offset no more than 80% of current taxable income annually for taxable years beginning after December 31, 2020. Accordingly, if we generate NOLs after the tax year ended December 31, 2017, we might have to pay more federal income taxes in a subsequent year as a result of the 80% taxable income limitation than we would have had to pay under the law in effect before the Tax Act as modified by the CARES Act.</span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Capital</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a clinical stage biopharmaceutical company with a limited operating history and no products approved for commercial sale. We have a history of significant losses and expect to continue to incur significant losses for the foreseeable future.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage biopharmaceutical company with a limited operating history. Biopharmaceutical product development is a highly speculative undertaking because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval or become commercially viable.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, MORF-057, has completed a Phase 1 clinical trial in healthy volunteers and we plan to conduct a Phase 2 program initially in ulcerative colitis. We have no products approved for commercial sale and have not generated any revenue from commercial product sales, and we will continue to incur significant research and development and other expenses related to our clinical development and ongoing operations. For the quarter ended September&#160;30, 2021, we reported a net loss of $25.0 million. As of September&#160;30, 2021, we had an accumulated deficit of approximately $216.7 million. Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect to incur significant losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of our product candidates.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our expenses will increase substantially if, and as, we:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct clinical trials for our current and any future product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discover and develop new product candidates, and conduct research and development activities, preclinical studies and clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacture, or have manufactured, preclinical, clinical and commercial supplies of our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory approvals for our product candidates or any future product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercialize our current product candidates or any future product candidates, if approved;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attempt to transition from a company with a research focus to a company capable of supporting commercial activities, including establishing sales, marketing and distribution infrastructure;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional clinical, scientific and management personnel;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add operational, financial and management information systems and personnel;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identify additional compounds or product candidates and acquire rights from third parties to those compounds or product candidates through licenses; and </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">experience any delays in our preclinical or clinical studies and regulatory approval for our product candidates due to the impacts of COVID-19.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we succeed in commercializing one or more product candidates, we may continue to incur substantial research and development and other expenditures to develop and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never generated revenue from product sales and may never be profitable.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to become and remain profitable depends on our ability to generate revenue. We do not expect to generate significant revenue, unless and until we, either alone or with a collaborator, are able to obtain regulatory approval for, and successfully commercialize, our lead product candidate for our &#945;4&#946;7 program, or any other product candidates we may develop. Successful commercialization will require achievement of many key milestones, including demonstrating safety and efficacy in clinical trials, obtaining regulatory, including marketing, approval for these product candidates, manufacturing, marketing and selling those products for which we, or any of our current or future collaborators, may obtain regulatory approval, satisfying any post-marketing requirements and obtaining reimbursement for our products from private insurance or government payors. Because of the uncertainties and risks associated with these activities, we are unable to accurately and precisely predict the timing and amount of revenues, the extent of any further losses or if or when we might achieve profitability. We and any current or future collaborators may never succeed in these activities and, even if we do, or any collaborators do, we may never generate revenues that are large enough for us to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to become and remain profitable may depress the market price of our common stock and could impair our ability to raise capital, expand our business or continue our operations. If we continue to suffer losses as we have in the past, investors may not receive any return on their investment and may lose their entire investment.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional funds to advance development of our product candidates, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development programs, commercialization efforts or other operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of biopharmaceutical product candidates is capital-intensive. If our product candidates enter and advance through preclinical studies and clinical trials, we will need substantial additional funds to expand or create our development, regulatory, manufacturing, marketing and sales capabilities. We have used substantial funds to develop our technology and product candidates and will require significant funds to conduct further research and development and preclinical testing and clinical trials of our product candidates, to seek regulatory approvals for our product candidates and to manufacture and market products, if any, which are approved for commercial sale. In addition, we expect to incur increased costs associated with operating as a public company. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have invested a significant portion of our efforts and financial resources in research and development activities. As of September&#160;30, 2021, we had $427.6 million in cash, cash equivalents and marketable securities. Based on our current operating plan, we believe that our available cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements until the end of 2024. However, our future capital requirements and the period for which we expect our existing resources to support our operations, fund expansion, develop new or enhanced products, or otherwise respond to competitive pressures, may vary significantly from what we expect and we may need to seek additional funds sooner than planned. Because the length of time and activities associated with successful research and development of our product candidates is highly uncertain, we are unable to estimate the actual funds we will require for development and any marketing and commercialization activities for approved products. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, cost and progress of preclinical and clinical development activities;</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and scope of preclinical and clinical programs we decide to pursue;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress of the development efforts of parties with whom we have entered or may in the future enter into collaborations and/or research and development agreements;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and amount of milestone and other payments we may receive or make under our collaboration agreements;</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain our current licenses and research and development programs and to establish new collaboration arrangements;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in prosecuting and enforcing patent and other intellectual property claims;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of manufacturing our product candidates by third parties;</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of regulatory submissions and timing of regulatory approvals;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of commercialization activities if our product candidates or any future product candidates are approved for sale, including marketing, sales and distribution costs;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our efforts to enhance operational systems and hire additional personnel, including personnel to support development of our product candidates; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need to implement additional internal systems and infrastructure, including financial and reporting systems to satisfy our obligations as a public company.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain funding on a timely basis or on acceptable terms, we may have to delay, reduce or terminate our research and development programs and preclinical studies or clinical trials, limit strategic opportunities or undergo reductions in our workforce or other corporate restructuring activities. To date, we have primarily financed our operations through payments received under our collaboration agreements, the sale of equity securities and debt financing.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be required to seek additional funding in the future and currently intend to do so through public or private equity offerings or debt financings, additional collaborations and/or licensing agreements, credit or loan facilities, or a combination of one or more of these funding sources. If we raise additional funds by issuing equity securities, including pursuant to our currently effective registration statement on Form S-3, our stockholders will suffer dilution and the terms of any financing may adversely affect the rights of our stockholders. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Our future debt financings, if any, are likely to involve restrictive covenants limiting our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of our equity securities received any distribution of our corporate assets. If we raise additional funds through licensing or collaboration arrangements with third parties, we may have to relinquish valuable rights to our product candidates, or grant licenses on terms that are not favorable to us. We also could be required to seek collaborators for product candidates at an earlier stage than otherwise would be desirable or relinquish our rights to product candidates or technologies that we otherwise would seek to develop or commercialize ourselves. Failure to obtain capital when needed on acceptable terms may force us to delay, limit or terminate our product development and commercialization of our current or future product candidates, which could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Discovery, Development and Commercialization</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is heavily dependent on the success of our current and future product candidates, including our lead product candidate for our &#945;4&#946;7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">program. Existing and future preclinical studies and clinical trials of these product candidates may not be successful, and if we are unable to commercialize these product candidates or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have invested a significant portion of our efforts and financial resources in the development of our &#945;4&#946;7- and &#945;v&#946;6-specific integrin inhibitors programs. Our ability to generate commercial product revenues, which we do not expect will occur for many&#160;years, if ever, will depend heavily on the successful development and eventual commercialization of our lead product candidate for our &#945;4&#946;7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">program. We have not previously submitted a new drug application, or NDA, to the FDA, or similar regulatory approval filings to comparable foreign authorities, for any product candidate, and we cannot be certain that our product candidates will be successful in clinical trials or receive regulatory approval. Further, our product candidates may not receive regulatory approval even if they are successful in clinical trials. In addition, regulatory authorities may not complete their review processes in a timely manner, or additional delays may result if an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory authority policy during the period of product development, clinical trials and the review process. Regulatory authorities also may approve a product candidate for more limited indications than requested or with labeling that includes warnings, contraindications or precautions with respect to conditions of use. Regulatory authorities may also require Risk Evaluation and Mitigation Strategies, or REMS, or the performance of costly post-marketing clinical trials. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory approvals to market our product candidates, our revenues will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights. If the markets for patient subsets that we are targeting are not as significant as we estimate, we may not generate significant revenues from sales of such products, if approved.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to seek regulatory approval to commercialize our product candidates both in the United States and in selected foreign countries. In order to obtain separate regulatory approvals in other countries, we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy. Other countries also have their own regulations governing, among other things, clinical trials and commercial sales, as well as pricing and distribution of our product candidates, and we may be required to expend significant resources to obtain regulatory approval, which may not be successful, and to comply with ongoing regulations in these jurisdictions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our current and future product candidates will depend on many factors, including the following actions to be taken by us or our collaborators, as applicable:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful completion of necessary preclinical studies to enable the initiation of clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful enrollment of patients in, and the completion of, our clinical trials with favorable results;</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receiving required regulatory authorizations for the development and approvals for the commercialization of our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing and maintaining arrangements with third-party manufacturers;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining patent and trade secret protection and non-patent exclusivity for our product candidates and their components;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enforcing and defending our intellectual property rights and claims;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">achieving desirable therapeutic properties for our product candidates&#8217; intended indications;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with third parties;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of our product candidates, if and when approved, by patients, the medical community and third-party payors;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectively competing with other therapies; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining an acceptable safety profile of our product candidates through clinical trials and following regulatory approval.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates are in early stages of development and may fail in development or suffer delays that materially adversely affect their commercial viability. If we or our collaborators are unable to complete development of, or commercialize, our product candidates or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products on the market and all of our product candidates are in early stages of development. Additionally, we have a portfolio of targets and programs that are in earlier stages of discovery and preclinical development and may never advance to clinical-stage development. Our ability to achieve and sustain profitability depends on obtaining regulatory approvals for, and successfully commercializing our product candidates, either alone or with third parties, and we cannot guarantee you that we will ever obtain regulatory approval for any of our product candidates. We have limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA. Before obtaining regulatory approval for the commercial distribution of our product candidates, we or an existing or future collaborator must conduct extensive preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of our product candidates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not have the financial resources to continue development of, or to modify existing or enter into new collaborations for, a product candidate if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, product candidates, including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preclinical study results may show the product candidate to be less effective than desired or to have harmful or problematic side effects;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preclinical studies conducted outside of the United States may be affected by tariffs or import/export restrictions imposed by the United States or other governments;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative or inconclusive results from our clinical trials or the clinical trials of others for product candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product-related side effects experienced by patients in our clinical trials or by individuals using drugs or therapeutic biologics similar to our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our third-party manufacturers&#8217; inability to successfully manufacture our products;</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability of any third-party contract manufacturer to scale up manufacturing of our product candidates and those of our collaborators to supply the needs of clinical trials or commercial sales;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in submitting INDs or comparable foreign applications or delays or failures in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conditions imposed by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in enrolling patients in our clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">high drop-out rates of our clinical trial patients;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inadequate supply or quality of product candidate components or materials or other supplies necessary for the conduct of our clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to obtain alternative sources of supply for which we have a single source for product candidate components or materials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">harmful side effects or inability of our product candidates to meet efficacy endpoints during clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to demonstrate a benefit-risk profile acceptable to the FDA or other regulatory agencies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unfavorable FDA or other regulatory agency inspection and review of one or more clinical trial sites or manufacturing facilities used in the testing and manufacture of any of our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular or as a result of the impacts of COVID-19; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">varying interpretations of our data by the FDA and similar foreign regulatory agencies.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We or our collaborators&#8217; inability to complete development of, or commercialize our product candidates, or significant delays in doing so due to one or more of these factors, could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our products may be delayed and, as a result, our stock price may decline.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we estimate the timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of scientific studies and clinical trials and the submission of regulatory filings. From time to time, we may publicly announce the expected timing of some of these milestones. All of these milestones are and will be based on numerous assumptions. The actual timing of these milestones can vary dramatically compared to our estimates, in some cases for reasons beyond our control. If we do not meet these milestones as publicly announced, or at all, the commercialization of our products may be delayed or never achieved and, as a result, our stock price may decline.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our approach to the discovery and development of our therapeutic treatments is based on novel technologies that are unproven and may not result in marketable products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing a pipeline of product candidates using our MInT Platform. Historically, dozens of integrin-targeted oral small molecule candidates of other companies that entered late-stage clinical trials have failed to result in FDA or EMA approved medicines. Development efforts and clinical results of other companies exploring oral approaches to integrins may be unsuccessful, resulting in a negative perception of oral integrins and negatively impacting the regulatory approval process of our product candidates, which would have a material and adverse </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effect on our business. We believe that product candidates identified with our MInT Platform may offer an optimized therapeutic approach by taking advantage of conformational targeting next-generation physics-based technologies augmented with machine learning and artificial intelligence, which allow us to design, iterate and optimize leads in our discovery process. However, the scientific research that forms the basis of our efforts to develop product candidates using our MInT Platform is ongoing and may not result in viable product candidates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may ultimately discover that our MInT Platform and any product candidates resulting therefrom do not possess certain properties required for therapeutic effectiveness, including the ability to lock specific integrin conformations. Our product candidates may also be unable to remain stable in the human body for the period of time required for the drug to reach the target tissue or they may trigger immune responses that inhibit the ability of the product candidate to reach the target tissue or that cause adverse side effects in humans. In addition, product candidates based on our MInT Platform may demonstrate different chemical and pharmacological properties in patients than they do in laboratory studies. Our MInT Platform and any product candidates resulting therefrom may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better known or extensively studied product candidates. To our knowledge, no regulatory authority has granted approval for an oral small-molecule integrin inhibitor. We believe the FDA has limited experience with integrin-based therapeutics, which may increase the complexity, uncertainty and length of the regulatory approval process for our product candidates. We and our existing or future collaborators may never receive approval to market and commercialize any product candidate. Even if we or an existing or future collaborator obtains regulatory approval, the approval may be for targets, disease indications or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We or an existing or future collaborator may be required to perform additional or unanticipated clinical trials to obtain approval or be subject to post-marketing testing requirements to maintain regulatory approval. If the products resulting from our MInT Platform and research programs prove to be ineffective, unsafe or commercially unviable, our MInT Platform and pipeline would have little, if any, value, which would have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and clinical development involve a lengthy and expensive process, with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our current product candidates or any future product candidates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our product candidates are in preclinical or clinical development, and the risk of failure is high for all programs. It is impossible to predict accurately when or if any of our product candidates will receive regulatory approval. To obtain the requisite regulatory approvals to commercialize any product candidates, we must demonstrate through extensive preclinical studies and lengthy, complex and expensive clinical trials that our product candidates are safe and effective in humans. Clinical testing can take many&#160;years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. We may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful, and a clinical trial can fail at any stage of testing. Differences in trial design between early-stage clinical trials and later-stage clinical trials make it difficult to extrapolate the results of earlier clinical trials to later clinical trials. Moreover, clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in clinical trials have nonetheless failed to obtain marketing approval of their products. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or to unfavorable safety profiles, notwithstanding promising results in earlier trials. There is typically a high rate of failure of product candidates proceeding through clinical trials. Most product candidates that commence clinical trials are never approved as products and there can be no assurance that any of our future clinical trials will ultimately be successful or support clinical development of our current or any of our future product candidates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencement of clinical trials is subject to finalizing the trial design and submitting an IND or similar submission to the FDA or similar foreign regulatory authority. Even after we submit our IND or comparable submissions in other jurisdictions, the FDA or other regulatory authorities could disagree that we have satisfied their requirements to commence our clinical trials or disagree with our study design, which may require us to complete additional preclinical studies or amend our protocols or impose stricter conditions on the commencement of clinical trials.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our collaborators may experience delays in initiating or completing clinical trials. We or our collaborators also may experience numerous unforeseen events during, or as a result of, current or future clinical trials that we could conduct that could delay or prevent our ability to receive marketing approval or commercialize our integrin inhibitor programs or any future product candidates, including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators or institutional review boards, or IRBs, the FDA or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trial sites may deviate from a trial&#8217;s protocol or drop out of a trial;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trials of any product candidates may fail to show safety or efficacy, produce negative or inconclusive results and we may decide, or regulators may require us, to conduct additional preclinical studies or clinical trials or we may decide to abandon product development programs;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of subjects required for clinical trials of any product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or subjects may drop out of these clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may elect to, or regulators, IRBs, or ethics committees may require that we or our investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants in our trials are being exposed to unacceptable health risks;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of clinical trials of any of our product candidates may be greater than we anticipate;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be inadequate to initiate or complete a given clinical trial;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to manufacture sufficient quantities of our product candidates for use in clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reports from clinical testing of other therapies may raise safety or efficacy concerns about our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may fail to establish an appropriate safety profile for a product candidate based on clinical or preclinical data for such product candidate as well as data emerging from other molecules in the same class as our product candidate; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA, EMA or other regulatory authorities may require us to submit additional data such as long-term toxicology studies or impose other requirements before permitting us to initiate a clinical trial.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the number and location of clinical sites we enroll, the proximity of patients to clinical sites, the eligibility and exclusion criteria for the trial, the design of the clinical trial, the inability to obtain and maintain patient consents, the risk that enrolled participants will drop out before completion, competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs or therapeutic biologics that may be approved for the indications being investigated by us. Furthermore, we expect to rely on our collaborators, CROs and clinical trial sites to ensure the proper and timely conduct of our current or future clinical trials, including the patient enrollment process, and we have limited influence over their performance. Additionally, we could encounter delays if treating physicians encounter unresolved ethical issues associated with enrolling patients in current or future clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also encounter delays if a clinical trial is suspended or terminated by us, the IRBs of the institutions in which such trials are being conducted, or the FDA, EMA or other regulatory authorities, or if a clinical trial is recommended for suspension or termination by the Data Safety Monitoring Board, or the DSMB, for such trial. A suspension or termination may be imposed due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product or treatment, failure to establish or achieve clinically meaningful trial endpoints, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Clinical studies may also be delayed or terminated as a result of ambiguous or negative interim results. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Further, the FDA, EMA or other regulatory authorities may disagree with our clinical trial design and our interpretation of data from clinical trials or may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product development costs will increase if we experience delays in clinical testing or marketing approvals. We do not know whether any of our clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates and may allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates and harming our business and results of operations. Any delays in our clinical development programs may harm our business, financial condition and results of operations significantly.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of preclinical studies and early clinical trials may not be predictive of results of later clinical trials.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and interim results of clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in earlier development, and we could face similar setbacks. The design of a clinical trial can determine whether its results will support approval of a product, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. In addition, preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for the product candidates. Even if we, or future collaborators, believe that the results of clinical trials for our product candidates warrant marketing approval, the FDA or comparable foreign regulatory authorities may disagree and may not grant marketing approval of our product candidates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial patients. If we fail to receive positive results in clinical trials of our product candidates, the development timeline and regulatory approval and commercialization prospects for our product candidates, and, correspondingly, our business and financial prospects would be negatively impacted.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim and preliminary or topline data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publish interim topline or preliminary data from our anticipated clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary or topline data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between interim or preliminary or topline data and final data could significantly harm our reputation and business prospects.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current and future clinical trials or those of our current and future collaborators may reveal significant adverse events not seen in our preclinical studies and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If significant adverse events or other side effects are observed in any of our clinical trials, we may have difficulty recruiting patients to our clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of one or more product candidates altogether. For example, progressive multifocal leukoencephalopathy, or PML, has been observed by others as an adverse effect during late-stage clinical development of infusible antibody inhibitor of &#945;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#946;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> integrin, natalizumab. This adverse effect was not observed in the preclinical studies or during early clinical development of natalizumab. We, the FDA, EMA or other applicable regulatory authorities, or an IRB may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects or patients in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies. Any of these developments could materially harm our business, financial condition and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to use our MInT Platform to expand our pipeline of product candidates and develop marketable products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business depends in part upon our ability to discover, develop and commercialize products based on our MInT Platform. Our lead program for &#945;4&#946;7 and our research programs, or those of our collaborators, may fail to identify other potential product candidates for clinical development for a number of reasons. Our research methodology may be unsuccessful in identifying potential product candidates or our potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval. If any of these events occur, we may be forced to abandon our development efforts for a program or for multiple programs, which would materially harm our business and could potentially cause us to cease operations. Research programs to identify new product candidates require substantial technical, financial and human resources.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus our research and development efforts on certain selected product candidates. For example, we are initially focused on our lead product candidate, MORF-057, in our &#945;4&#946;7-specific integrin inhibitor program. As a result, we may forgo or delay pursuit of opportunities with other product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face competition from entities that have developed or may develop product candidates for autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer, including companies developing novel treatments and technology platforms. If these companies develop technologies or product candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize product candidates may be adversely affected.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of drugs is highly competitive. Our product candidates, if approved, will face significant competition and our failure to effectively compete may prevent us from achieving significant market penetration. Most of our competitors have significantly greater resources than we do, and we may not be able to successfully compete. We compete with a variety of multinational biopharmaceutical companies, specialized biotechnology companies and emerging biotechnology companies, as well as with technologies and product candidates being developed at universities and other research institutions. Our competitors have developed, are developing or will develop product candidates and processes competitive with our product candidates and processes. Competitive therapeutic treatments include those that have already been approved and accepted by the medical </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">community and any new treatments, including those based on novel technology platforms that enter the market. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we are trying, or may try, to develop product candidates. There is intense and rapidly evolving competition in the biotechnology, biopharmaceutical and integrin and immunoregulatory therapeutics fields. Competition from many sources exists or may arise in the future. Our competitors include larger and better funded biopharmaceutical, biotechnological and therapeutics companies, including companies focused on therapeutics for autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer, as well as numerous small companies. Moreover, we also compete with current and future therapeutics developed at universities and other research institutions. Some of these companies are well-capitalized and, in contrast to us, have significant clinical experience, and may include our existing or future collaborators. In addition, these companies compete with us in recruiting scientific and managerial talent.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend partially on our ability to develop and commercialize therapeutics that are safer and more effective than competing products. Our commercial opportunity and success will be reduced or eliminated if competing products are safer, more effective, or less expensive than the therapeutics we develop.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our &#945;4&#946;7 clinical program, initially under development for treatment of IBD, if approved would face competition from approved IBD treatments marketed by AbbVie, Johnson&#160;&amp; Johnson, UCB, Biogen Inc., Pfizer Inc., and Bristol-Myers Squibb Company, in addition to other major pharmaceutical companies, against which our product candidate may compete, if approved. Further, Takeda Pharmaceutical Company&#160;Ltd. currently markets Entyvio, which is an &#945;4&#946;7 monoclonal antibody to treat&#160;ulcerative colitis and Crohn&#8217;s disease. In addition, we are aware of IBD treatments in clinical development by AbbVie, Johnson &amp; Johnson, Pfizer Inc., Gilead Sciences, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Boehringer Ingelheim, Theravance Inc., Protagonist Therapeutics, Inc., Roche Holding AG, and Arena Pharmaceuticals, Inc., in addition to other pharmaceutical companies. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our &#945;v&#946;6-specific</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">integrin inhibitor program is under development for the treatment of idiopathic pulmonary fibrosis, or IPF, by our collaboration partner AbbVie, and if any of our compounds licensed to AbbVie is approved for IPF, it would face competition from approved IPF treatments marketed by Roche Holding AG and Boehringer Ingelheim&#160;GmbH. In addition, we are aware of IPF treatments in development by Galapagos&#160;NV, FibroGen, Inc., Galecto, Inc., Roche Holding AG, Bristol-Myers Squibb Company, Kadmon Holdings, Inc. and Liminal BioSciences, Inc., in addition to other pharmaceutical companies. Further, we are aware of programs targeting &#945;v&#946;6 that are currently being investigated in clinical trials by companies including Pliant Therapeutics,&#160;Inc. In September 2019, Biogen Inc. announced the termination of a Phase 2 study of its monoclonal antibody targeting &#945;v&#946;6, citing safety concerns. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of these competitors have significantly greater financial, technical, manufacturing, marketing, sales, and supply resources or experience than we have. If we successfully obtain approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, less expensive or marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current product candidates or any future product candidates may not achieve adequate market acceptance among physicians, patients, healthcare third-party payors and others in the medical community necessary for commercial success, if approved, and we may not generate any future revenue from the sale or licensing of product candidates.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if regulatory approval is obtained for a product candidate, we may not generate or sustain revenue from sales of the product due to factors such as whether the product can be sold at a competitive cost and whether it will otherwise be accepted in the market. Historically, several injectable integrin inhibitors have been approved by the FDA for treatment of inflammatory bowel disease, multiple sclerosis, psoriasis, acute coronary syndrome and dry eye disease. However, our product candidates are based on a novel approach to oral integrin therapies, and while integrins are a well-understood receptor family, to date, no oral small molecule integrin therapies have been approved by the FDA. Market participants with significant influence over acceptance of new treatments, such as physicians and third-party payors, may not adopt an orally bioavailable product based on our novel technologies, </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and we may not be able to convince the medical community and thirdparty payors to accept and use, or to provide favorable reimbursement for, any product candidates developed by us or our existing or future collaborators. Market acceptance of our product candidates will depend on, among other factors:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of our receipt of any marketing and commercialization approvals;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms of any approvals and the countries in which approvals are obtained;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the safety and efficacy of our product candidates as demonstrated in clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any adverse side effects associated with our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations or warnings contained in any labeling approved by the FDA or other regulatory authority;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relative convenience and ease of administration of our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of patients to accept any new methods of administration;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unfavorable publicity relating to our current product candidates or any future product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our physician education programs;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of sales and marketing efforts;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of coverage and adequate reimbursement from government and third-party payors;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing of our products, particularly as compared to alternative treatments; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of alternative effective treatments for the disease indications our product candidates are intended to treat and the relative risks, benefits and costs of those treatments.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of medical products also depend on the willingness of physicians to prescribe the treatment, which is likely to be based on a determination by these physicians that the products are safe, therapeutically effective and cost effective. In addition, the inclusion or exclusion of products from treatment guidelines established by various physician groups and the viewpoints of influential physicians can affect the willingness of other physicians to prescribe the treatment. We cannot predict whether physicians, physicians&#8217; organizations, hospitals, other healthcare providers, government agencies or private insurers will determine that our product is safe, therapeutically effective and cost effective as compared with competing treatments. If any product candidate is approved but does not achieve an adequate level of acceptance by such parties, we may not generate or derive sufficient revenue from that product candidate and may not become or remain profitable.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our product candidates are based on new technology, we expect that they will require extensive research and development and have substantial manufacturing and processing costs. In addition, our estimates regarding potential market size for any indication may be materially different from what we discover to exist at the time we commence commercialization, if any, for a product, which could result in significant changes in our business plan and have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if any product candidate we commercialize fails to achieve market acceptance, it could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If in the future we are unable to establish U.S. or global sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates if they are approved and we may not be able to generate any revenue.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not have a marketing or sales team for the marketing, sales and distribution of any of our product candidates that are able to obtain regulatory approval. To commercialize any product candidates after approval, we must build on a territory-by-territory basis marketing, sales, distribution, managerial and other non-technical capabilities or arrange with third parties to perform these services, and we may not be successful in doing so. If our product candidates receive regulatory approval, we may decide to establish an internal sales or marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates, which will be </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expensive and time consuming and will require significant attention of our executive officers to manage. For example, some state and local jurisdictions have licensing and continuing education requirements for pharmaceutical sales representatives, which requires time and financial resources. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of any of our product candidates that we obtain approval to market.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the commercialization of all or certain of our product candidates, we may choose to collaborate, either globally or on a territory-by-territory basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements when needed on acceptable terms, or at all, we may not be able to successfully commercialize any of our product candidates that receive regulatory approval, or any such commercialization may experience delays or limitations. If we are not successful in commercializing our product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer, and we may incur significant additional losses.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any of our product candidates receives marketing approval and we or others later identify undesirable side effects caused by the product candidate, our ability to market and derive revenue from the product candidates could be compromised.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable side effects caused by our product candidates could cause regulatory authorities to interrupt, delay or halt clinical trials and could result in more restrictive labeling or the delay or denial of regulatory approval by the FDA or other regulatory authorities. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects. In such an event, our future clinical trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. Such side effects could also affect patient recruitment or the ability of enrolled patients to initiate or complete the clinical trial or result in potential product liability claims. Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the product candidate.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates receive regulatory approval and we or others identify undesirable side effects caused by such product, any of the following adverse events could occur:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw their approval of the product or seize the product;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to recall the product or change the way the product is administered to patients;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to fines, injunctions or the imposition of civil or criminal penalties;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, such as a boxed warning or a contraindication;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to create a Medication Guide outlining the risks of such side effects for distribution to patients;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product may become less competitive; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these occurrences could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We anticipate that some of our product candidates may be studied in combination with third-party drugs, some of which may still be in development, and we have limited or no control over the supply, regulatory status, or regulatory approval of such drugs.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our product candidates may be studied in combination with third-party drugs. The development of product candidates for use in combination with another product or product candidate may present challenges that are not faced for single agent product candidates. The FDA or other regulatory authorities may require us to use more complex clinical trial designs in order to evaluate the contribution of each product and product candidate to any observed effects. It is possible that the results of these trials could show that any positive previous trial results are attributable to the combination therapy and not our product candidates. Moreover, following product approval, the FDA or other regulatory authorities may require that products used in conjunction with each other be cross labeled for combined use. To the extent that we do not have rights to the other product, this may require us to work with a third party to satisfy such a requirement. Moreover, developments related to the other product may impact our clinical trials for the combination as well as our commercial prospects should we receive marketing approval. Such developments may include changes to the other product&#8217;s safety or efficacy profile, changes to the availability of the approved product, and changes to the standard of care.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we pursue such combination therapies, we cannot be certain that a steady supply of such drugs will be commercially available. Any failure to enter into such commercial relationships, or the expense of purchasing therapies in the market, may delay our development timelines, increase our costs and jeopardize our ability to develop our product candidates as commercially viable combination therapies. The occurrence of any of these could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that any future collaborator or supplier cannot continue to supply their products on commercially reasonable terms, we would need to identify alternatives for accessing such products. Additionally, should the supply of products of any collaborator or supplier be interrupted, delayed or otherwise be unavailable to us, our clinical trials may be delayed. In the event we are unable to source a supply of any alternative therapy, or are unable to do so on commercially reasonable terms, our business, results of operations and financial condition may be adversely affected.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have entered into collaborations with AbbVie and Janssen and may, in the future, seek to enter into collaborations with other third parties for the discovery, development and commercialization of our product candidates. If our collaborators cease development efforts under our collaboration agreements, or if any of those agreements are terminated, these collaborations may fail to lead to commercial products and we may never receive milestone payments or future royalties under these agreements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into collaborations with AbbVie and Janssen to discover or develop certain integrin-based therapeutics, and such collaborations could represent a significant portion of our product pipeline. In both collaborations, we agreed to conduct research and development activities through the completion of IND-enabling studies, upon which AbbVie and Janssen can exercise their options to develop and commercialize a successful product candidate. On January 5, 2021, we also announced the expansion of our collaboration agreement with Janssen relating to a third integrin target, for which we received a milestone payment. We have derived substantially all of our revenue to date from these collaboration agreements, and we may derive a significant portion of our future revenue from these agreements or other similar agreements into which we may enter in the future. Revenue from research and development collaborations depends upon continuation of the collaborations, payments for research and development services and resulting options to acquire any licenses of successful product candidates, and the achievement of milestones, contingent payments and royalties, if any, derived from future products developed from our research. If we are unable to successfully advance the development of our product candidates or achieve milestones, revenue and cash resources from milestone payments under our collaboration agreements will be substantially less than expected.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may in the future seek third-party collaborators for research, development and commercialization of other therapeutic technologies or product candidates. Biopharmaceutical companies are our prior and likely future collaborators for any marketing, distribution, development, licensing or broader collaboration arrangements. If we fail to enter into future collaborations on commercially reasonable terms, or at all, or such collaborations are not successful, we may not be able to execute our strategy to develop certain targets, product candidates or disease areas </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that we believe could benefit from the resources of either larger biopharmaceutical companies or those specialized in a particular area of relevance.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our existing collaboration agreements, and what we expect will be the case with any future collaboration agreements, we have and expect to continue to have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Moreover, our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations involving our product candidates currently pose, and will continue to pose, the following risks to us:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on preclinical studies or clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the foregoing, our current and any future collaboration agreements may not lead to development or commercialization of our product candidates in the most efficient manner or at all. If a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated. Any failure to successfully develop or commercialize our product candidates pursuant to our current or any future collaboration agreements could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, to the extent that any of our existing or future collaborators were to terminate a collaboration agreement, we may be forced to independently develop these product candidates, including funding preclinical studies or clinical trials, assuming marketing and distribution costs and defending intellectual property rights, or, in certain instances, abandon product candidates altogether, any of which could result in a change to our business plan and have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our existing discovery collaboration with Schr&#246;dinger is important to our business. If we are unable to maintain this collaboration, or if this collaboration is not successful, our business could be adversely affected.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June&#160;2015, we entered into a Collaboration Agreement with Schr&#246;dinger, which was subsequently amended in March&#160;2018 and in May&#160;2019, or the Schr&#246;dinger Agreement. Under the collaboration, Schr&#246;dinger will use its technology platform to perform virtual screens of members of the target class of human integrins, and we and Schr&#246;dinger will collaborate to facilitate prioritization of targets, perform target validation and analysis, identify leads and perform lead optimization. Schr&#246;dinger has granted us an exclusive license for all intellectual property for our product candidates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we currently rely on Schr&#246;dinger for a substantial portion of our discovery capabilities, if Schr&#246;dinger delays or fails to perform its obligations under the Schr&#246;dinger Agreement, disagrees with our interpretation of the terms of the collaboration or our discovery plan or terminates the Schr&#246;dinger Agreement, our pipeline of product candidates would be adversely affected. Schr&#246;dinger may also fail to properly maintain or defend the intellectual property we have licensed from them, or even infringe upon, our intellectual property rights, leading to the potential invalidation of our intellectual property or subjecting us to litigation or arbitration, any of which would be time-consuming and expensive. Additionally, either party has the right to terminate the collaboration pursuant to the terms of the Schr&#246;dinger Agreement. If our collaboration with Schr&#246;dinger is terminated, especially during our discovery phase, the development of our product candidates would be materially delayed or harmed.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may have conflicts with our collaborators that could delay or prevent the development or commercialization of our product candidates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may have conflicts with our collaborators, such as conflicts concerning the interpretation of preclinical or clinical data, the achievement of milestones, the interpretation of contractual obligations, payments for services, development obligations or the ownership of intellectual property developed during our collaboration. If any conflicts arise with any of our collaborators, such collaborator may act in a manner that is averse to our best interests. Any such disagreement could result in one or more of the following, each of which could delay or prevent the development or commercialization of our product candidates, and in turn prevent us from generating revenues: unwillingness on the part of a collaborator to pay us milestone payments or royalties we believe are due to us under a collaboration, which could require us to raise additional capital; uncertainty regarding ownership of intellectual property rights arising from our collaborative activities, which could prevent us from entering into additional collaborations; unwillingness by the collaborator to cooperate in the development or manufacture of the product, including providing us with product data or materials; unwillingness on the part of a collaborator to keep us informed regarding the progress of its development and commercialization activities or to permit public disclosure of the results of those activities; initiating of litigation or alternative dispute resolution options by either party to resolve the dispute; or attempts by either party to terminate the agreement.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may engage in strategic transactions, including any additional collaborations we seek, that could adversely affect our ability to develop and commercialize product candidates, impact our cash position, increase our expenses and present significant distractions to our management.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may consider strategic transactions, such as additional collaborations, acquisitions of companies, asset purchases and out or in licensing of product candidates or technologies that we believe will complement or augment our existing business. In particular, we will evaluate and, if strategically attractive, seek to enter into additional collaborations, including with major biotechnology or biopharmaceutical companies. The competition for collaborators is intense, and the negotiation process is time-consuming and complex. Any new collaboration may be on terms that are not optimal for us, and we may not be able to maintain any new collaboration if, for example, development or approval of a product candidate is delayed, sales of an approved product candidate do not meet expectations or the collaborator terminates the collaboration. In addition, a significant number of recent business combinations among large pharmaceutical companies has resulted in a reduced number of potential future strategic partners. Our collaborators may consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the strategic partner&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed strategic partner&#8217;s evaluation of a number of factors. These factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. Moreover, if we acquire assets with promising markets or technologies, we may not be able to realize the benefit of acquiring such assets if we are not able to successfully integrate them with our existing technologies. We may encounter numerous difficulties in developing, testing, manufacturing and marketing any new products resulting from a strategic acquisition that delay or prevent us from realizing their expected benefits or enhancing our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that following any such collaboration, or other strategic transaction, we will achieve the expected synergies to justify the transaction. For example, such transactions may require us to incur non-recurring or other charges, increase our near and long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business. These transactions would entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management&#8217;s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and would have a material and adverse effect on our business, financial condition, results of operations and prospects. Conversely, any failure to enter any additional collaboration or other strategic transaction that would be beneficial to us could delay the development and potential commercialization of our product candidates and have a negative impact on the competitiveness of any product candidate that reaches market.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely and expect to continue to rely on third parties to conduct certain of our preclinical studies or clinical trials. If those third parties do not perform as contractually required, fail to satisfy legal or regulatory requirements, miss expected deadlines or terminate the relationship, our development program could be delayed with potentially material and adverse effects on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely and intend to rely in the future on third-party clinical investigators, CROs, clinical data management organizations and consultants to assist or provide the design, conduct, supervision and monitoring of preclinical studies and clinical trials of our product candidates. Because we rely on these third parties and will not have the ability to conduct all preclinical studies or clinical trials independently, we will have less control over the timing, quality and other aspects of preclinical studies and clinical trials than we would have had we conducted them on our own. These investigators, CROs and consultants will not be our employees and we will have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs. The third parties with which we may contract might not be diligent, careful or timely in conducting our preclinical studies or clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all events, we will be responsible for ensuring that each of our preclinical studies and clinical trials are conducted in accordance with the general investigational plan and protocols for the trial as well as applicable legal and regulatory requirements. The FDA generally requires preclinical studies to be conducted in accordance with good laboratory practices and clinical trials to be conducted in accordance with good clinical practices, including for designing, conducting, recording and reporting the results of preclinical studies and clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. Our reliance on third parties that we do not control will not relieve us of these responsibilities and requirements. Any adverse development or delay in our preclinical studies or clinical trials as a result of our reliance on third parties could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our relationships with these third-party CROs or others terminate, we may not be able to enter into arrangements with alternative CROs or other third parties or to do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO begins work. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third-party manufacturers and suppliers to supply components of our product candidates. The loss of our third-party manufacturers or suppliers, or our or their failure to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate facilities for drug manufacturing, storage, distribution or quality testing. We currently rely, and may continue to rely, on third-party contract manufacturers, including in the U.K. and China, to manufacture bulk drug substances, drug products, raw materials, samples, components, or other materials and reports. Reliance on third-party manufacturers may expose us to different risks than if we were to manufacture product candidates ourselves. Under our collaboration agreements with AbbVie and Janssen, our collaborators will assume responsibility for the manufacturing according to the terms of those agreements for licensed products. There can be no assurance that our preclinical and clinical development product supplies will not be limited, interrupted, terminated or of satisfactory quality or continue to be available at acceptable prices. In particular, any replacement of our manufacturer could require significant effort and expertise because there may be a limited number of qualified replacements. If our third-party manufacturers and suppliers, or any third-party in the supply chain, are adversely impacted by restrictions resulting from the COVID-19 pandemic, we may be unable to secure the supply of product candidates required for our preclinical studies.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing process for a product candidate is subject to FDA and foreign regulatory authority review. We, and our suppliers and manufacturers, must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as current Good Manufacturing Practices, or cGMPs. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the FDA and foreign regulatory authorities. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable foreign regulatory authorities, we may not be able to rely on their manufacturing facilities for the manufacture of elements of our product candidates. Moreover, we do not control the manufacturing process at our contract manufacturers and are completely dependent on them for compliance with current regulatory requirements. In the event that any of our manufacturers fails to comply with such requirements or to perform its obligations in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such to another third party. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to enable us, or to have another third party, manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines; and we may be required to repeat some of the development program. The delays associated with the validation of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to rely on third-party manufacturers if we receive regulatory approval for any product candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. Any manufacturing facilities used to produce our products will be subject to periodic review and inspection by the FDA and foreign regulatory authorities, including for continued compliance with cGMP requirements, quality control, quality assurance and corresponding maintenance of records and documents. If we are unable to obtain or maintain third-party manufacturing for product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully. Our or a third party&#8217;s failure to execute on our </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing requirements, comply with cGMPs or maintain a compliance status acceptable to the FDA or foreign regulatory authorities could adversely affect our business in a number of ways, including:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an inability to initiate or continue clinical trials of product candidates under development;</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay in submitting regulatory applications, or receiving regulatory approvals, for product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of the cooperation of existing or future collaborators;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subjecting third-party manufacturing facilities to additional inspections by regulatory authorities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirements to cease distribution or to recall batches of our product candidates; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our contract manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes, unstable political environments, or medical pandemics such as the COVID-19 pandemic. If our contract manufacturers were to encounter any of these difficulties, our ability to provide our product candidates to patients in preclinical and clinical trials, or to provide product for treatment of patients once approved, would be jeopardized.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the United Kingdom formally left the European Union on January 31, 2020, often referred to as Brexit, and the transition period ended on December 31, 2020. Brexit has caused uncertainty in the current regulatory framework in Europe. For instance, Brexit has resulted in the European Medicines Agency, or the EMA, moving from the United Kingdom to the Netherlands. In the United Kingdom, Brexit may cause disruption in the administrative and medical scientific links between the EMA and MHRA. On December 31, 2020, the United Kingdom passed legislation giving effect to the trade and cooperation agreement with the E.U. expected to formally adopt the agreement in early 2021. The trade and cooperation agreement sets out certain procedures for approval and recognition of medical products in each jurisdiction. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of the trade and cooperation agreement or otherwise, could prevent us from commercializing any product candidates in the United Kingdom and/or the European Union and restrict our ability to generate revenue and achieve and sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom and/or European Union for any product candidates, which could significantly and materially harm our business. The current lack of detail and resolution with regard to the Brexit implementation may result in a disruption of the manufacturing and supply of components of our product candidates in the U.K. and we are unable to confidently predict the effects of such disruption to the regulatory framework in Europe. Any adjustments we make to our business and operations as a result of Brexit could result in significant delays and additional expense. Any of the foregoing factors could have a material adverse effect on our business, results of operations, or financial condition.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We, or our third-party contract research organizations, face risks related to health epidemics and other outbreaks, including the COVID-19 pandemic, which could significantly disrupt our operations. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be adversely impacted by the effects of the COVID-19 pandemic or other epidemics or pandemics. If there are closures or other restrictions in places where we or our vendors work or transport supply, we may experience disruptions to our operations. We have and may continue to experience impacts to certain of our suppliers as a result of the COVID-19 pandemic or other health epidemic or outbreak occurring in one or more of these locations, which may materially and adversely affect our business, financial condition and results of operations. Further, our operation has and may continue to experience disruptions, such as temporary closure of the offices of our suppliers and suspension of services, which may result in us having to procure the components for our product candidates from alternate suppliers, which may materially and adversely affect our development timelines, and our business, financial condition and results of operations. </span></div><div><span><br/></span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The manufacturing of small molecules is complex and our third-party manufacturers may encounter difficulties in production. If we or any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our product candidates for clinical trials, our ability to obtain marketing approval, or our ability to provide supply of our products for patients, if approved, could be delayed or stopped.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are biopharmaceuticals and the process of manufacturing biopharmaceuticals is complex, time-consuming, highly regulated and subject to multiple risks. Our contract manufacturers must comply with legal requirements, cGMPs and guidelines for the manufacturing of biopharmaceuticals used in clinical trials and, if approved, marketed products. Our contract manufacturers may have limited experience in the manufacturing of cGMP batches.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing biopharmaceuticals is highly susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered at our third-party manufacturers&#8217; facilities, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business. Moreover, if the FDA determines that our third-party manufacturers&#8217; facilities are not in compliance with FDA laws and regulations, including those governing cGMPs, the FDA may deny NDA approval until the deficiencies are corrected or we replace the manufacturer in our NDA with a manufacturer that is in compliance.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are risks associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, compliance with cGMPs, lot consistency and timely availability of raw materials. Even if our collaborators obtain regulatory approval for any of our product candidates, there is no assurance that manufacturers will be able to manufacture the approved product to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product or to meet potential future demand. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization, commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scaling up a biopharmaceutical manufacturing process is a difficult and uncertain task, and our third-party manufacturers may not have the necessary capabilities to complete the implementation, manufacturing and development process. If we are unable to adequately validate or scale-up the manufacturing process at our current manufacturers&#8217; facilities, we will need to transfer to another manufacturer and complete the manufacturing validation process, which can be lengthy. If we are able to adequately validate and scale-up the manufacturing process for our product candidates with a contract manufacturer, we will still need to negotiate with such contract manufacturer an agreement for commercial supply and it is not certain we will be able to come to agreement on terms acceptable to us.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that any stability or other issues relating to the manufacture of any of our product candidates or products will not occur in the future. If our third-party manufacturers were to encounter any of these difficulties, our ability to provide any product candidates to patients in planned clinical trials and products to patients, once approved, would be jeopardized. Any delay or interruption in the supply of clinical trial supplies could delay the completion of planned clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials completely. Any adverse developments affecting clinical or commercial manufacturing of our product candidates or products may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our product candidates or products. We may also have to take inventory write-offs and incur other charges and expenses for product candidates or products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Accordingly, failures or difficulties faced at any level of our supply chain could adversely affect our business and delay or impede the development and commercialization of any of our product candidates or products, if approved, and could have an adverse effect on our business, prospects, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our process development efforts, we also may make changes to the manufacturing processes at various points during development, for various reasons, such as controlling costs, achieving scale, decreasing processing time, increasing manufacturing success rate or other reasons. Such changes carry the risk that they will not achieve </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">their intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of our ongoing clinical trials or future clinical trials. In some circumstances, changes in the manufacturing process may require us to perform </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> comparability studies and to collect additional data from patients prior to undertaking more advanced clinical trials. For instance, changes in our process during the course of clinical development may require us to show the comparability of the product used in earlier clinical phases or at earlier portions of a trial to the product used in later clinical phases or later portions of the trial.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to obtain, maintain, and enforce patent protection for our technologies or product candidates, development and commercialization of our product candidates may be adversely affected.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in part on our ability to obtain and maintain patents and other forms of intellectual property rights, including in-licenses of intellectual property rights of others, for our product candidates, as well as our ability to preserve our trade secrets, to prevent third parties from infringing upon our proprietary rights and to operate without infringing upon the proprietary rights of others. As of September 30, 2021, we solely owned certain published and unpublished pending global patent applications including U.S. and ex-U.S. international counterpart patent filings protecting our integrin therapeutic compounds across multiple programs (including our product candidates). In addition, we hold an exclusive, worldwide license agreement with the Children&#8217;s Medical Center Corporation, or the CMCC Agreement, to one U.S. patent and a related pending U.S. patent application relating to modified integrin polypeptides, crystallizable dimers comprising a modified integrin polypeptide, and related methods. We may not be able to apply for patents on certain aspects of our product candidates in a timely fashion or at all. Further, we may not be able to prosecute all necessary or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may not have the right to control the preparation, filing and prosecution of all patent applications that we license from third parties, or to maintain the rights to patents licensed to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. Future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing products and technology. There is no guarantee that any of our pending patent applications will result in issued or granted patents, that any of our future issued or granted patents will not later be found to be invalid or unenforceable or that any future issued or granted patents will include claims that are sufficiently broad to cover our product candidates or to provide meaningful protection from our competitors. Moreover, the patent position of biotechnology and biopharmaceutical companies can be highly uncertain because it involves complex legal and factual questions. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our current and future proprietary technology and product candidates are covered by valid and enforceable patents, or are effectively maintained as trade secrets. If third parties disclose or misappropriate our proprietary rights, it may materially and adversely affect our position in the market.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Assuming the other requirements for patentability are met, currently, the first inventor to file&#160;a patent application is generally entitled to the patent. However, prior to March&#160;16, 2013, in the United States, the first to invent the claimed invention was entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. Therefore, we cannot be certain that we , our licensors or collaborators, or any future strategic partners were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we, our licensors or collaborators, or any future strategic partners were the first to file for patent protection of such inventions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Patent and Trademark Office, or USPTO, and various foreign governmental patent agencies require compliance with a large number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. The standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in biotechnology and biopharmaceutical patents. As such, we do not know the degree of future protection that we </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will have on our proprietary products and technology. The process of obtaining patents is time consuming, expensive and sometimes unpredictable.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once granted, for a given period after allowance or grant patents may remain open to opposition, interference, re-examination, post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, nullification, or derivation action in court or before patent offices or similar proceedings, during which time third parties can raise objections against such initial grant. Such proceedings may continue for a protracted period of time and an adverse determination in any such proceedings could reduce the scope of the allowed or granted claims thus attacked, or could result in our patents being invalidated in whole or in part, or being held unenforceable, which could allow third parties to commercialize our product candidates and compete directly with us without payment to us. In addition, there can be no assurance that:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others will not or may not be able to make, use or sell compounds that are the same as or similar to our product candidates but that are not covered by the claims of the patents that we own or license;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors, or our existing or future collaborators are the first to make the inventions covered by each of our issued patents and pending patent applications that we own or license;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors, or our existing or future collaborators are the first to file patent applications covering certain aspects of our inventions;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others will not independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a third party may not challenge our patents and, if challenged, a court would hold that our patents are valid, enforceable and infringed;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any issued patents that we own or have licensed or that we may license in the future will provide us with any competitive advantages, or will not be challenged by third parties;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may develop additional proprietary technologies that are patentable;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others will not have a material or adverse effect on our business, financial condition, results of operations and prospects; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors do not conduct research and development activities in countries where we do not have enforceable patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our licensors or collaborators fail to maintain the patents and patent applications covering our product candidates, our competitors might be able to enter the market, which could have a material and adverse effect on our business, financial condition, results of operations and prospects. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patent protection for certain aspects of our product candidates, we also consider trade secrets, including confidential and unpatented know-how, important to the maintenance of our competitive position. Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. We seek to protect trade secrets and confidential and unpatented know-how, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to such knowledge, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants that obligate them to maintain confidentiality and assign their inventions to us. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States and certain foreign jurisdictions are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. Furthermore, we expect that, over time, our trade secrets, know-how and proprietary information may be disseminated within the industry through independent development, the publication of journal articles and the movement of personnel to and from academic and industry scientific positions. Consequently, without costly efforts to protect our proprietary technology, we may be unable to prevent others from exploiting that technology, which could affect our ability to expand in domestic and international markets. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed which could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other companies or organizations may challenge our or our licensors&#8217; patent rights or may assert patent rights that prevent us from developing and commercializing our products, if approved.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oral integrin therapies in fibrosis and inflammatory bowel disease or other disease areas are a relatively new scientific field. We have applied for, and have obtained a license from, a third party on an exclusive basis to U.S. patent filings related to our MInT Platform. Other pending patent applications in the United States and in key markets around the world that we own or license claim many different methods, compositions and processes relating to the discovery, development, and manufacture of small-molecule integrin inhibitor-based and other therapeutics.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the field of small-molecule integrin inhibitor-based therapeutics continues to mature, patent applications are being processed by national patent offices around the world. There is uncertainty about which patents will issue and, if they do, as to when, to whom, and with what claims. In addition, third parties may attempt to invalidate our intellectual property rights. Even if our rights are not directly challenged, disputes could lead to the weakening of our intellectual property rights. Our defense against any attempt by third parties to circumvent or invalidate our intellectual property rights could be costly to us, could require significant time and attention of our management and could have a material and adverse effect on our business, financial condition, results of operations and prospects or our ability to successfully compete. If we are found to infringe a third party&#8217;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting, defending and enforcing patents covering our technology in the United States and in other jurisdictions worldwide would be extremely costly, and our or our licensors&#8217; or collaborators&#8217; intellectual property rights may not exist in some countries outside the United States or may be less extensive in some countries than in the United States. In jurisdictions where we or our licensors or collaborators have not obtained patent protection, competitors may seek to use our or our licensors&#8217; or collaborators&#8217; technology to develop competing products and further, may export otherwise infringing products to territories where we have patent protection, but where it is more difficult to enforce a patent as compared to the United States. Competitor products may compete with our future products in jurisdictions where we do not have issued or granted patents or where our or our licensors&#8217; or collaborators&#8217; issued or granted patent claims or other intellectual property rights are not sufficient to prevent competitor activities in these jurisdictions. The legal systems of certain countries, particularly certain developing countries, make it difficult to enforce patents and such countries may not recognize other types of intellectual property protection, particularly relating to pharmaceuticals or biopharmaceuticals. This could make it difficult for us or our licensors or collaborators to prevent the infringement of our or their patents or marketing of competing products in violation of our or their proprietary rights generally in certain jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our and our licensors&#8217; or collaborators&#8217; efforts and attention from other aspects of our business, could put our and our licensors&#8217; or collaborators&#8217; patents at risk of being invalidated or interpreted narrowly and our and our licensors&#8217; or collaborators&#8217; patent applications at risk of not issuing and could provoke third parties to assert claims against us or our licensors or collaborators. We or our licensors or collaborators may not prevail in any lawsuits that we or our licensors or collaborators initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we elect to pursue patent protection on an invention, we generally first file&#160;a U.S. provisional patent application (a priority filing) at the USPTO. An international patent application under the Patent Cooperation Treaty, or PCT, and/or a national application in a non-PCT country may then be filed within twelve&#160;months after the priority filing. Based on the PCT filing, national and regional patent applications may be filed in one or more PCT member countries. We have thus far not filed for patent protection in all national and regional jurisdictions where such </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">protection may be available. In addition, we may decide to abandon national and regional patent applications before grant. Finally, the grant proceeding of each national or regional patent office is an independent proceeding, which may lead to situations in which patent applications might in some jurisdictions be refused by the relevant registration authorities, while granted by others. It is also quite common that, depending on the country, different scopes of patent protection may be granted on the same product candidate or technology.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws in the United States, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. If we or our licensors or collaborators encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions. Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such a patent. If we or any of our licensors or collaborators are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our product candidates or we could lose certain rights to grant sublicenses.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on patents, know-how and proprietary technology, both our own and licensed from others. Any termination of our licenses could result in the loss of significant rights and could harm our ability to develop our product candidates. Our current licenses impose, and any future licenses we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement and/or other obligations on us. If we breach any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture and sell any future products that are covered by the licensed technology or enable a competitor to gain access to the licensed technology. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating a licensor&#8217;s rights. In addition, while we cannot determine currently the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our product candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sublicensing of patent and other rights under our collaborative development relationships;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the priority of invention of patented technology.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We, our licensors or collaborators, or any future strategic partners may need to resort to litigation to protect or enforce our patents, if and when granted, or other proprietary rights, all of which could be costly and time consuming, delay or prevent the development and commercialization of our product candidates, or put our patents, if and when granted, patent applications and other proprietary rights at risk.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our owned or licensed patents, if and when granted, patent applications or other intellectual property. If we were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates or our technology, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, lack of adequate written description, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that an individual connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity or unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our product candidates or certain aspects of our platform technology. Such a loss of patent protection could have a material and adverse effect on our business, financial condition, results of operations and prospects. Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the inventorship or priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. Patents and other intellectual property rights will not protect our technology if competitors design around our protected technology without legally infringing our patents or other intellectual property rights.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights of third parties could adversely affect our ability to commercialize our product candidates, and we, our licensors or collaborators, or any future strategic partners may become subject to third party claims or litigation alleging infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights. We might be required to litigate or obtain licenses from third parties in order to develop or market our product candidates. Such litigation or licenses could be costly or not available on commercially reasonable terms.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, our licensors or collaborators, or any future strategic partners, may be subject to third-party claims for infringement or misappropriation of patent or other proprietary rights. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, derivations, oppositions and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review proceedings before the USPTO, and corresponding foreign patent offices. There may be issued patents and pending patent applications that claim aspects of our targets, our MInT Platform, or our product candidates and modifications that we may need to apply to our product candidates. There may be issued patents that claim integrin inhibitors which may be relevant to the products we wish to develop. Thus, it is possible that one or more organizations will hold patent rights to which we will need a license. If those organizations refuse to grant us a license to such patent rights on reasonable terms, we may not be able to market products or perform research and development or other activities covered by these patents, which could have a material and adverse effect on our business, financial condition, results of operations and prospects. If we, our licensors or collaborators, </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or any future strategic partners are found to infringe a third-party patent or other intellectual property rights, we could be required to pay damages, potentially including treble damages and attorneys&#8217; fees if we or they are found to have infringed willfully. In addition, we, our licensors or collaborators, or any future strategic partners may choose to seek, or be required to seek, a license from a third party, which may not be available on acceptable terms, if at all. Even if a license can be obtained on acceptable terms, the rights may be non-exclusive, which could give our competitors access to the same technology or intellectual property rights licensed to us. If we fail to obtain a required license, we or our existing or future collaborators may be unable to effectively market product candidates based on our technology, which could limit our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations. In addition, we may find it necessary to pursue claims or initiate lawsuits to protect or enforce our patent or other intellectual property rights. The cost to us in defending or initiating any litigation or other proceeding relating to patent or other proprietary rights, even if resolved in our favor, could be substantial, and litigation could divert our management&#8217;s attention. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts and limit our ability to continue our operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the integrin-based therapeutics landscape is still evolving, it is difficult to conclusively assess our freedom to operate without infringing on third-party rights. There are numerous companies that have pending patent applications and issued patents broadly covering integrins generally, covering integrins directed against the same targets as, or targets similar to, those we are pursuing, or covering compounds similar to our product candidates. Failure to receive a license could delay commercialization of our product candidates. Our competitive position may suffer if patents issued to third parties or other third-party intellectual property rights cover our products, if approved, or product candidates or elements thereof, or our manufacture or uses relevant to our development plans. In such cases, we may not be in a position to develop or commercialize products or product candidates until such patents expire or unless we successfully pursue litigation to nullify or invalidate the third-party intellectual property right concerned, or enter into a license agreement with the intellectual property right holder, if available on commercially reasonable terms. There may be issued patents of which we are not aware, held by third parties that, if found to be valid and enforceable, could be alleged to be infringed by our MInT Platform and product candidates. There also may be pending patent applications of which we are not aware that may result in issued patents, which could be alleged to be infringed by our MInT Platform and product candidates. If such an infringement claim should be brought and be successful, we may be required to pay substantial damages, including potentially treble damages and attorneys&#8217; fees for willful infringement, and we may be forced to abandon our product candidates or seek a license from any patent holders. No assurances can be given that a license will be available on commercially reasonable terms, if at all.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is also possible that we have failed to identify relevant third-party patents or applications. For example, U.S. applications filed before November&#160;29, 2000, and certain U.S. applications filed after that date that will not be filed outside the United States remain confidential unless and until corresponding patents issue. Patent applications in the United States and elsewhere are published approximately 18&#160;months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our product candidates or MInT Platform could have been filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our MInT Platform, our product candidates or the use of our product candidates. Third-party intellectual property right holders may also actively bring infringement claims against us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing our products, if approved. Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing any of our product candidates that are held to be infringing. We might, if possible, also be forced to redesign product candidates so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">otherwise be able to devote to our business and could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation and other legal proceedings relating to intellectual property claims, with or without merit, are unpredictable and generally expensive and time consuming and are likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Moreover, such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating or from successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets of our employees&#8217; or consultants&#8217; former employers or their clients. These claims may be costly to defend and if we do not successfully do so, we may be required to pay monetary damages and may lose valuable intellectual property rights or personnel.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees, including our management, were previously employed at universities or biotechnology or biopharmaceutical companies, including our competitors or potential competitors. Some of these employees executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although no claims against us are currently pending, we may be subject to claims that these employees, employees of our licensors or collaborators or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If we or our licensors or collaborators fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel or their work product could hamper our ability to develop and ultimately commercialize, or prevent us from developing and commercializing, our product candidates, which could severely harm our business. Even if we or our licensors or collaborators are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent terms may be insufficient to protect our competitive position on our product candidates for an adequate amount of time.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest U.S. non-provisional filing date. Various patent term adjustments or extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ consultants and an outside firm and/or rely on our outside counsel to pay these fees due to the USPTO and non-U.S. patent agencies. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market and this circumstance would have a material adverse effect on our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent and ex-U.S. patent laws could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or interpretation of the patent laws in the United States or in other jurisdictions could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. In the United States, numerous recent changes to the patent laws and proposed changes to the rules&#160;of the USPTO may have a significant impact on our ability to protect our technology and enforce our intellectual property rights. We cannot assure you that subsequent rulings will not adversely impact our patents or patent applications. In addition to increasing uncertainty regarding to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once granted. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, and similar legislative and regulatory bodies in other countries in which may pursue patent protection, the laws and regulations governing patents could change in unpredictable ways, particularly with respect to pharmaceutical patent protection, that would weaken our ability to obtain new patents or to enforce our or our licensors&#8217; or collaborators&#8217; existing patents and patents that we might obtain in the future.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common law trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively which could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and/or our collaborators may be unable to obtain, or may be delayed in obtaining, U.S. or foreign regulatory approval and, as a result, unable to commercialize our product candidates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, post-approval monitoring, marketing and distribution of drugs. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process are required to be completed successfully in the United States and in many foreign jurisdictions before a new drug can be marketed. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. It is possible that none of the product candidates we may develop, either alone or with our collaborators, will obtain the regulatory approvals necessary for us or our existing or future collaborators to begin selling them.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no prior experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA. The time required to obtain FDA and other approvals is unpredictable but typically </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">takes many&#160;years following the commencement of clinical trials, depending upon the type, complexity and novelty of the product candidate. The standards that the FDA and its foreign counterparts use when regulating us require judgment and can change, which makes it difficult to predict with certainty their application. Any analysis we perform of data from preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We or our collaborators may also encounter unexpected delays or increased costs due to new government regulations, for example, from future legislation or administrative action, or from changes in FDA policy during the period of product development, clinical trials and FDA regulatory review. Further, infections and deaths related to COVID-19 are disrupting certain healthcare and healthcare regulatory systems globally. Such disruptions could divert healthcare resources away from, or materially delay review by, the FDA and comparable foreign regulatory agencies. As a result of the FDA&#8217;s updated industry guidance for conducting clinical trials issued on March 18, 2020 last updated on January 27, 2021, we may experience delays in of the enrollment of patients in our clinical trials, if any. It is unknown how long these disruptions could continue, were they to occur. Any elongation or de-prioritization of preclinical studies or clinical trials or delay in regulatory review resulting from such disruptions could materially affect the development and study of our product candidates. It is impossible to predict whether additional legislative changes will be enacted, or whether FDA or foreign regulations, guidance or interpretations will be changed, or the impact of such changes, if any.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given that the product candidates we are developing, either alone or with our collaborators, represent a new therapeutic approach, the FDA and its foreign counterparts may not have established any definitive policies, practices or guidelines in relation to these product candidates. Moreover, the FDA may respond to any NDA that we may submit by defining requirements that we do not anticipate. Such responses could delay clinical development of our product candidates. In addition, because there may be approved treatments for some of the diseases for which we may seek approval, in order to receive regulatory approval, we may need to demonstrate through clinical trials that the product candidates we develop to treat these diseases, if any, are not only safe and effective, but safer or more effective than existing products. Furthermore, in recent&#160;years, there has been increased public and political pressure on the FDA with respect to the approval process for new drugs, and FDA standards, especially regarding product safety.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay or failure in obtaining required approvals could have a material and adverse effect on our ability to generate revenues from the particular product candidate for which we are seeking approval. Furthermore, any regulatory approval to market a product may be subject to limitations on the approved uses for which we may market the product or on the labeling or other restrictions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to or may in the future become subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries and may include all of the risks associated with the FDA approval process described above, as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval. FDA approval does not ensure approval by regulatory authorities outside the United States and vice versa. Any delay or failure to obtain U.S. or foreign regulatory approval for a product candidate could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal. We may also be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approvals that we or our existing or future collaborators obtain for our product candidates may also be subject to limitations on the approved indicated uses for which a product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing and surveillance to monitor the safety and efficacy of the product candidate.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if the FDA or a comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, labeling, packaging, distribution, post-approval monitoring and adverse event reporting, storage, import, export, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. The FDA has significant post-market authority, including the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials to evaluate </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">safety risks related to the use of a product or to require withdrawal of the product from the market. The FDA also has the authority to require a REMS plan after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug. The manufacturing facilities we use to make a future product, if any, will also be subject to periodic review and inspection by the FDA and other regulatory agencies, including for continued compliance with cGMP requirements. The discovery of any new or previously unknown problems with our third-party manufacturers, manufacturing processes or facilities may result in restrictions on the product, manufacturer or facility, including withdrawal of the product from the market. If we rely on thirdparty manufacturers, we will not have control over compliance with applicable rules&#160;and regulations by such manufacturers. Any product promotion and advertising will also be subject to regulatory requirements and continuing regulatory review. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding use of their products. If we promote our product candidates in a manner inconsistent with FDA-approved labeling or otherwise not in compliance with FDA regulations, we may be subject to enforcement action. If we or our existing or future collaborators, manufacturers or service providers fail to comply with applicable continuing regulatory requirements in the United States or foreign jurisdictions in which we seek to market our products, we or they may be subject to, among other things, fines, warning letters, holds on clinical trials, delay of approval or refusal by the FDA or similar foreign regulatory bodies to approve pending applications or supplements to approved applications, suspension or withdrawal of regulatory approval, product recalls and seizures, administrative detention of products, refusal to permit the import or export of products, operating restrictions, injunction, civil penalties and criminal prosecution.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market or voluntary or mandatory product recalls;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning or untitled letters or holds on clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or our strategic partners;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or revocation of product license approvals;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention or refusal to permit the import or export of products; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. For example, in December&#160;2016, the 21st&#160;Century Cures Act, or Cures Act, was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and biologics and to spur innovation. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. Changes in FDA staffing could result in delays in the FDA&#8217;s responsiveness or in its ability to review submissions or applications, issue regulations or guidance, or implement or enforce regulatory requirements in a timely fashion or at all. Similar consequences would also result in the event of another significant shutdown of the federal government such as the one that occurred from December&#160;22, 2018 through January&#160;25, 2019. It is difficult to predict how these requirements will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If any legislation, executive orders, or lapses in agency funding impose constraints on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may face difficulties from healthcare legislative reform measures.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Existing regulatory policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March&#160;2010, the Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Reconciliation Act, or together, the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. The ACA, among other things, (i)&#160;subjected therapeutic biologics to potential competition by lower-cost biosimilars by creating a licensure framework for follow on biologic products, (ii)&#160;proscribed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs and therapeutic biologics that are inhaled, infused, instilled, implanted or injected, (iii)&#160;increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, (iv)&#160;established annual non-deductible fees and taxes on manufacturers of certain branded prescription drugs and therapeutic biologics apportioned among these entities according to their market share in certain government healthcare programs, (v)&#160;established a new Medicare Part&#160;D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs and therapeutic biologics to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs and therapeutic biologics to be covered under Medicare Part&#160;D, (vi)&#160;expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability, (vii)&#160;expanded the entities eligible for discounts under the Public Health program, (viii)&#160;created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research and (ix)&#160;established a Center for Medicare Innovation at the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been legislative and judicial efforts to modify, repeal, or otherwise invalidate all, or certain provisions of, the ACA, including measures taken during the Trump administration. The Tax Cuts and Jobs Act of 2017, or the Tax Reform Act, among other things, includes a provision that repealed, effective January&#160;1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a&#160;year that is commonly referred to as the &#8220;individual mandate.&#8221; In November 2020, the United States Supreme Court held oral arguments on the Fifth Circuit U.S. Court of Appeals decision that held that the individual mandate is unconstitutional. It is uncertain how the United States Supreme Court will rule on this case or how healthcare measures of the Biden administration will impact the ACA and our business. Additionally, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on certain high cost employer-sponsored insurance plans and the medical device excise tax on non-exempt medical devices, and effective January 1, 2021, also eliminates the health insurer tax. Further, the Bipartisan Budget Act of 2018, or the BBA, among other things, amended the ACA, effective January&#160;1, 2019, to increase from 50&#160;percent to 70&#160;percent the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part&#160;D and to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221; In addition, CMS published a final rule that would give states greater flexibility, effective January 1, 2020, in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted to reduce healthcare expenditures. On August&#160;2, 2011, the Budget Control Act of 2011 among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the&#160;years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal&#160;year, which went into effect on April&#160;1, 2013 and will remain in effect through 2030 unless additional Congressional action is taken. The Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, which was signed into law in March 2020 </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and is designed to provide financial support and resources to individuals and businesses affected by the COVID-19 pandemic, suspended the 2% Medicare sequester from May 1, 2020 through December 31, 2020, and extended the sequester by one year, through 2030. The Consolidated Appropriations Act, 2021 extended the suspension of the 2% Medicare sequester through March 31, 2021. Moreover, the American Taxpayer Relief Act of 2012 among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five&#160;years. If federal spending is further reduced, anticipated budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA or the National Institutes of Health to continue to function at current levels. Amounts allocated to federal grants and contracts may be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely review and approve research and development, manufacturing, and marketing activities, which may delay our ability to develop, market and sell any products we may develop.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement methodology based on average sales prices for physician-administered drugs. In addition, this legislation provided authority for limiting the number of drugs that will be covered in any therapeutic class. While the MMA only applies to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the MMA may result in a similar reduction in payments from private payors.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare, and reform government program reimbursement methodologies for drug products. At the federal level, the former Trump administration&#8217;s budget proposal for fiscal&#160;year 2021 included at $135 billion allowance to support legislative proposals seeking to reduce drug process, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower cost generic and biosimilar drugs. In particular, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that seek to implement several of the administration&#8217;s proposals. FDA also released a final rule in September 2020 providing guidance for states to build and submit importation plans for drugs from Canada. In July 2021, President Biden issued an executive order supporting the importation of drugs from Canada as an effort to reduce prescription drug costs, requesting that the Department of Health and Human Services develop a plan to address drug pricing by the end of the summer of 2021 and encouraging the Federal Trade Commission to use its rulemaking authority to combat unfair anticompetitive conduct related to the introduction of generic drugs and biosimilars to the market.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, in November 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. The CMS also issued an interim final rule implementing President Trump&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. In December 2020, CMS issued a final rule implementing significant manufacturer price reporting changes under the Medicaid Drug Rebate Program, including regulations that affect manufacturer-sponsored patient assistance programs subject to pharmacy benefit manager accumulator programs and Best Price reporting related to certain value-based purchasing arrangements. It is unclear to what extent these new regulations will be implemented and to what extent these regulations or any future legislation or regulations by the Biden administration will have on our business, including our ability to generate revenue and achieve profitability. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or companion diagnostics or additional pricing pressures.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations and relationships with healthcare providers, healthcare organizations, customers and third-party payors will be subject to applicable anti-bribery, anti-kickback, fraud and abuse, transparency and other healthcare and privacy laws and regulations, which could expose us to, among other things, enforcement actions, criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and future arrangements with healthcare providers, healthcare organizations, third-party payors and customers expose us to broadly applicable anti-bribery, fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we research, market, sell and distribute our product candidates. In addition, we may be subject to patient data privacy and security regulation by the U.S. federal government and the states and the foreign governments in which we conduct our business. Restrictions under applicable federal and state anti-bribery and healthcare laws and regulations, include the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, individuals and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal and state healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal criminal and civil false claims and civil monetary penalties laws, including the federal False Claims Act, which can be enforced through civil whistleblower or qui tam actions against individuals or entities, prohibits, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, certain marketing practices, including off-label promotion, may also violate false claims laws. Moreover, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, which imposes criminal and civil liability, prohibits, among other things, knowingly and willfully executing, or attempting to execute a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by HITECH, and their respective implementing regulations, including the Final Omnibus Rule&#160;published on January&#160;25, 2013, which impose obligations on certain healthcare providers, health plans, and healthcare clearinghouses, known as covered entities, as well as their business associates that perform certain services involving the storage, use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information; the federal legislation commonly referred to as Physician Payments Sunshine Act, enacted as part of the ACA, and its implementing regulations, which requires certain manufacturers of covered drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with certain exceptions, to report annually to CMS information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members, with the information made publicly available on a searchable website;</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state privacy laws and regulations, such as those of California and Massachusetts, that impose restrictive requirements regulating the use and disclosure of health information and other personally identifiable information (for example, in June&#160;2018, California enacted the California Consumer Privacy Act, or CCPA, which became effective on January&#160;1, 2020, and the California Privacy Rights Act, or CPRA, which modifies the CCPA and creates additional obligations beginning on January 1, 2022) that gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used, and provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation; resulting in increased compliance costs and potential liability);</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, that may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">certain state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures and drug pricing information, state and local laws that require the registration of pharmaceutical sales representatives, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our collaborators, manufacturers or service providers fail to comply with applicable federal, state or foreign laws or regulations, we could be subject to enforcement actions, which could affect our ability to develop, market and sell our products successfully and could harm our reputation and lead to reduced acceptance of our products by the market. These enforcement actions include, among others:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exclusion from participation in government-funded healthcare programs; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exclusion from eligibility for the award of government contracts for our products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our current and future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any such requirements, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, the curtailment or restructuring of our operations, loss of eligibility to obtain approvals from the FDA, exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, integrity oversight and reporting obligations, or reputational harm, any of which could adversely affect our financial results. These risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we are able to commercialize any product candidate, such product candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations that govern regulatory approvals, pricing and reimbursement for new drugs vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing approval is granted. In some foreign markets, prescription biopharmaceutical pricing remains subject to continuing governmental control even after initial </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval is granted. As a result, we might obtain regulatory approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain regulatory approval.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize any products successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from third-party payors including government authorities, such as Medicare and Medicaid, private health insurers and other organizations. Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Coverage and adequate reimbursement from third-party payors are critical to new product acceptance. Even if we succeed in bringing one or more products to the market, these products may not be considered cost-effective, and the amount reimbursed for any products may be insufficient to allow us to sell our products on a competitive basis. Because our programs are in the early stages of development, we are unable at this time to determine their cost effectiveness or the likely level or method of coverage and reimbursement. Increasingly, the third-party payors who reimburse patients or healthcare providers, such as government and private insurance plans, are requiring that drug companies provide them with predetermined discounts from list prices, and are seeking to reduce the prices charged or the amounts reimbursed for biopharmaceutical products. If the price we are able to charge for any products we develop, or the coverage and reimbursement provided for such products, is inadequate in light of our development and other costs, our return on investment could be affected adversely.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or similar foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug or therapeutic biologic will be reimbursed in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim reimbursement levels for new drugs, if applicable, may also be insufficient to cover our costs and may not be made permanent. Reimbursement rates may be based on payments allowed for lower cost drugs that are already reimbursed, may be incorporated into existing payments for other services and may reflect budgetary constraints or imperfections in Medicare data. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. As a result, obtaining coverage and reimbursement approval of a product from a third-party payor is a time consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost effectiveness data for the use of our products on a payor-by-payor basis, with no assurance that coverage and adequate reimbursement will be obtained. There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for new drugs that we develop and for which we obtain regulatory approval could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we decide to pursue a Fast Track Designation by the FDA, it may not lead to a faster development or regulatory review or approval process.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek Fast Track Designation for one or more of our product candidates. If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the product sponsor may apply for FDA Fast Track Designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we decide to seek Orphan Drug Designation for some of our product candidates, we may be unsuccessful or may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for supplemental market exclusivity.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business strategy, we may seek Orphan Drug Designation for one or more of our product candidates, and we may be unsuccessful. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, Orphan Drug Designation entitles a party to financial incentives such as opportunities for grant funding toward clinical trial costs, tax advantages and user fee waivers. In addition, if a product that has Orphan Drug Designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same product for the same indication for seven&#160;years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain Orphan Drug Designation for our product candidates in specific indications, we may not be the first to obtain marketing approval of these product candidates for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moiety can be approved for the same condition. Even after an orphan product is approved, the FDA can subsequently approve the same drug with the same active moiety for the same condition if the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. In addition, while we may seek Orphan Drug Designation for our product candidates, we may never receive such designations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax reform legislation, which was signed into law on December&#160;22, 2017, reduced the amount of the qualified clinical research costs for a designated orphan product that a sponsor may claim as a credit from 50% to 25%. Thus, further limiting the advantage and may impact our future business strategy of seeking the Orphan Drug Designation.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, or FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167;&#160;201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties to sell our products sell our products outside the United States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governments outside the United States tend to impose strict price controls, which may adversely affect our revenue, if any.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In some countries, particularly member states of the European Union, or EU, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. To obtain coverage and reimbursement or pricing approvals in some countries, we or current or future collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our therapeutic candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any product candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business, financial condition, results of operations or prospects could be materially and adversely affected. In addition, as a result of Brexit, there will be a transition period until a comprehensive trade agreement between the United Kingdom and EU is negotiated by year-end 2020. Beginning in 2021, the United Kingdom became a &#8220;third country&#8221; under the GDPR. We may, however, incur liabilities, expenses, costs, and other operational losses under GDPR and applicable EU Member States and the United Kingdom privacy laws in connection with any measures we take to comply with them.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">European data collection is governed by restrictive regulations governing the use, processing, and cross-border transfer of personal information.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collection and use of personal health data in the EU is governed by the provisions of the Data Protection Directive, and as of May&#160;2018, the General Data Protection Regulation, or GDPR. These directives impose several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, notification of data processing obligations to the competent national data protection authorities and the security and confidentiality of the personal data. The Data Protection Directive and GDPR also impose strict rules&#160;on the transfer of personal data out of the EU to the United States. In addition, the GDPR increases the scrutiny of transfers of personal data from clinical trial sites located in the European Economic Area to the United States and other jurisdictions that the European Commission does not recognize as having &#8220;adequate&#8221; data protection laws. For example, following a decision of the Court of Justice of the EU in October 2015, the transfer of personal data to U.S. companies that had certified as members of the U.S. Safe Harbor Scheme, was declared invalid. In July 2016, the European Commission adopted the EU-U.S. Privacy Shield Framework, or the Privacy Shield Framework, which replaced the U.S. Safe Harbor Scheme. On July 16, 2020, the Court of Justice of the European Union issued a decision that declared the Privacy Shield Framework invalid, and will also result in additional compliance obligations for companies that implement standard contractual clauses to ensure a valid basis for the transfer of personal data outside of Europe. On November 10, 2020, the European Data Protection Board, or EDPB, issued recommendations on the additional safeguards required for standard contractual clauses to be valid. It is possible that the ability to transfer personal data from the European Union to the United States will be restricted. We and many other companies may be required to adopt additional measures to accomplish and maintain legitimate means for the transfer and receipt of personal data from the European Union to the United States and other third-party countries. Failure to comply with the requirements of the Data Protection Directive, the GDPR, and the related national data protection laws of the EU Member States may result in fines (for example, of up to &#8364;20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial&#160;year (whichever is higher)) and other administrative penalties. The GDPR regulations may impose additional responsibility and liability in relation to personal data that we process and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. This may be onerous and adversely affect our business, financial condition, results of operations and prospects. As a result of the implementation of the GDPR, we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. There is significant uncertainty related to the manner in which data protection authorities will seek to enforce compliance with GDPR is not yet clear. For example, it is not clear if the authorities will conduct random audits of companies doing business in the EU, or if the authorities will wait for complaints to be filed by individuals who claim their rights have been violated. Enforcement uncertainty and the costs associated with ensuring GDPR compliance be onerous and adversely affect our business, financial condition, results of operations and prospects. Further, Brexit has created uncertainty with regard to data protection regulation in the United Kingdom. The United Kingdom enacted the Data Protection Act 2018 to directly enforce the GDPR.  </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in the level of expense related to the ongoing development of our MInT Platform, product candidates or future development programs;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of preclinical and clinical trials, or the addition or termination of existing or future clinical trials or funding support by us, or existing or future collaborators or licensing partners;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our execution of any additional collaboration, licensing or similar arrangements, and the timing of payments we may make or receive under existing or future arrangements or the termination or modification of any such existing or future arrangements;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any intellectual property infringement lawsuit or opposition, interference or cancellation proceeding in which we may become involved;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions and departures of key personnel;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic decisions by us, our collaborators or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if any of our product candidates receives regulatory approval, the terms of such approval and market acceptance and demand for such product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments affecting our product candidates or those of our competitors; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in general market and economic conditions, including due to global pandemics such as COVID-19.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our common stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our stock may be volatile, and you could lose all or part of your investment.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock may be highly volatile and subject to wide fluctuations in response to various factors, some of which we cannot control. The trading prices for our common stock and the common stock of other biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic. The market price for our common stock may be influenced by many factors, including the other risks described in this section and elsewhere in this report and the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of preclinical studies and clinical trials of our product candidates, or those of our competitors or our existing or future collaborators;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory or legal developments in the United States and other countries, especially changes in laws or regulations applicable to our product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competitive products or technologies;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introductions and announcements of new products by us, our future commercialization partners, or our competitors, and the timing of these introductions or announcements;</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actions taken by regulatory agencies with respect to our products, clinical studies, manufacturing process or sales and marketing terms;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our efforts to acquire or in-license additional technologies, products or product candidates;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments concerning any future collaborations, including but not limited to those with development and commercialization partners;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market conditions in the pharmaceutical and biotechnology sectors;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures or capital commitments;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our product candidates and products;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability or inability to raise additional capital and the terms on which we raise it;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the recruitment or departure of key personnel;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common stock, other comparable companies or our industry generally;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure or the failure of our competitors to meet analysts&#8217; projections or guidance that we or our competitors may give to the market;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcement and expectation of additional financing efforts;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">speculation in the press or investment community;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">share price and fluctuations of trading volume of our common stock, which may affect our trading liquidity and public float;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our common stock by us, insiders or our stockholders;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the concentrated ownership of our common stock;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting principles;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actions instituted by activist shareholders or others;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">terrorist acts, acts of war or periods of widespread civil unrest;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">natural disasters and other calamities, including global pandemics, such as COVID-19; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, industry and market conditions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme price and volume fluctuations that have been often unrelated or disproportionate to the operating performance of the issuer. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other risks, including those described in this &#8220;Risk Factors&#8221; section, </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could have a dramatic and adverse impact on the market price of our common stock. In addition, it may be more difficult for stockholders to sell a substantial number of shares for the same price at which stockholders could sell a smaller number of shares.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for biopharmaceutical companies, which have experienced significant stock price volatility in recent&#160;years. Additionally, market volatility arising from the COVID-19 pandemic may lead to increased shareholder activism if we experience a market valuation that they believe are not reflective of our stock&#8217;s intrinsic value. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors could have an adverse effect on our operating results and financial condition.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A sale of a substantial number of shares of our common stock may cause the price of our common stock to decline.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market the market price of our common stock could decline significantly. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict what effect, if any, sales of our shares in the public market or the availability of shares for sale will have on the market price of our common stock. However, future sales of substantial amounts of our common stock in the public market, including shares issued upon exercise of our outstanding warrant or options, or the perception that such sales may occur, could adversely affect the market price of our common stock.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also expect that significant additional capital may be needed in the future to continue our planned operations. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner that we determine from time to time. To the extent that additional capital is raised through the sale and issuance of shares or other securities convertible into shares, our stockholders will be diluted. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are party to an &#8220;at-the-market&#8221; offering of our common stock pursuant to a sales agreement, as amended from time to time, between us and Jefferies LLC (&#8220;Jefferies&#8221;). Subject to certain limitations in the sales agreement and compliance with applicable law, we may, in our sole discretion to deliver a placement notice to Jefferies at any time throughout the term of the sales agreement. The number of shares that are sold by Jefferies after delivering a placement notice will fluctuate based on the market price of our common stock during the sales period and limits we set with Jefferies. Because the price per share of each share sold will fluctuate based on the market price of our common stock during the sales period, it is not possible at this stage to predict the number of shares that will be ultimately issued, if any. Issuances of any shares sold pursuant to the sales agreement will have a dilutive effect on our existing stockholders. Further, if we sell common stock, preferred stock, convertible securities and other equity securities in other transactions pursuant to our shelf registration statement on Form S-3, existing investors may be materially diluted by such subsequent sales and new investors could gain rights superior to our existing stockholders.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders and management own a significant&#160;percentage of our stock and will be able to control matters subject to stockholder approval.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the beneficial ownership of our common stock as of September&#160;30, 2021, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 54% of our outstanding voting stock. As a result, these stockholders, if acting together, will continue to have control over the outcome of corporate actions requiring stockholder approval, including the election of directors, amendment of our organizational documents, any merger, consolidation or sale of all or substantially all of our assets and any other significant corporate transaction. The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could delay or prevent a change of control of our company, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company or our assets and might affect the prevailing market price of our common stock. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors&#8217; perception that conflicts of interest may exist or arise.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies or smaller reporting companies will make our common stock less attractive to investors.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act until December 31, 2021. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including (i)&#160;not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, (ii)&#160;reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and (iii)&#160;exemptions from the requirements of holding nonbinding advisory stockholder votes on executive compensation and stockholder approval of any golden parachute payments not approved previously. In addition, as an emerging growth company, we are only required to provide two&#160;years of audited financial statements and two&#160;years of selected financial data in this report.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also a &#8220;smaller reporting company,&#8221; meaning that as of the date of our initial public offering, the market value of our stock held by non-affiliates was less than $700.0&#160;million and our annual revenue was less than $100.0&#160;million during the most recently completed fiscal&#160;year. We may continue to be a smaller reporting company until (i)&#160;the market value of our stock held by non-affiliates is more than $250.0&#160;million as of the prior June 30</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or (ii)&#160;our annual revenue is more than $100.0&#160;million during the most recently completed fiscal&#160;year and the market value of our stock held by non-affiliates is less than $700.0&#160;million as of the prior June 30th. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal&#160;years of audited financial statements in our Annual Report on Form&#160;10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards. Until the date that we are no longer an &#8220;emerging growth company&#8221; or affirmatively and irrevocably opt out of the exemption provided by Section&#160;7(a)(2)(B)&#160;of the Securities Act, upon issuance of a new or revised accounting standard that applies to our financial statements and that has a different effective date for public and private companies, we will disclose the date on which adoption is required for non-emerging growth companies and the date on which we will adopt the recently issued accounting standard.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We will remain an emerging growth company until December 31, 2021. As of June 30, 2021, the market value of our common stock that was held by non-affiliates exceeded $700 million and therefore, we will no longer be considered an emerging growth company and smaller reporting company as of December 31, 2021 and will need to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and adopt new or revised accounting standards in the timeframe as required for non-emerging growth companies.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware law could prevent or delay an acquisition of us, which may be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restated certificate of incorporation and our restated bylaws, as amended, contain provisions that could delay or prevent a change in control of our company. These provisions could also make it difficult for stockholders to elect directors who are not nominated by current members of our board of directors or take other corporate actions, including effecting changes in our management. These provisions:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a classified board of directors so that not all members of our board are elected at one time;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">permit only the board of directors to establish the number of directors and fill vacancies on the board;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that directors may only be removed &#8220;for cause&#8221; and only with the approval of two-thirds of our stockholders;</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require super-majority voting to amend some provisions in our restated certificate of incorporation and restated bylaws;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize the issuance of &#8220;blank check&#8221; preferred stock that our board could use to implement a stockholder rights plan;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">eliminate the ability of our stockholders to call special meetings of stockholders;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibit cumulative voting; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The exclusive forum provision in our restated certificate of incorporation may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restated certificate of incorporation, to the fullest extent permitted by law, provides that the Court of Chancery of the State of Delaware is the exclusive forum for: any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, or the DGCL, our restated certificate of incorporation, or our restated bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. This exclusive forum provision does not apply to suits brought to enforce a duty or liability created by the Exchange Act. It could apply, however, to a suit that falls within one or more of the categories enumerated in the exclusive forum provision.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims. Alternatively, if a court were to find the choice of forum provisions contained in our restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations and financial condition.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Section&#160;203 of the DGCL may discourage, delay or prevent a change in control of our company. Section&#160;203 imposes certain restrictions on mergers, business combinations and other transactions between us and holders of 15% or more of our common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 22 of the Securities Act of 1933, as amended, or the &#8220;Securities Act&#8221;, creates concurrent jurisdiction for federal and state courts over all claims brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. In March 2020, we amended and restated our restated bylaws to provide that the federal district courts of the United States of America will, to the fullest extent permitted by law, be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, or a &#8220;Federal Forum Provision&#8221;. Our decision to adopt a Federal Forum Provision followed a decision by the Supreme Court of the State of Delaware holding that such provisions are facially valid under Delaware law. While there can be no assurance that federal or state courts will follow the holding of the Delaware Supreme Court or determine that the Federal Forum Provision should be enforced in a particular case, application of the Federal Forum Provision means that suits brought by our stockholders to enforce any duty or liability created by the Securities Act must be brought in federal court and cannot be brought in state court.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 27 of the Exchange Act creates exclusive federal jurisdiction over all claims brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. In addition, neither the exclusive forum provision nor the Federal Forum Provision applies to suits brought to enforce any duty or liability created by the Exchange Act. Accordingly, actions by our stockholders to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder must be brought in federal court. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stockholders will not be deemed to have waived our compliance with the federal securities laws and the regulations promulgated thereunder.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any person or entity purchasing or otherwise acquiring or holding any interest in any of our securities shall be deemed to have notice of and consented to our exclusive forum provisions, including the Federal Forum Provision. These provisions may limit a stockholders&#8217; ability to bring a claim in a judicial forum of their choosing for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees.</span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. We do not have any control over the industry or securities analysts, or the content and opinions included in their reports. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our preclinical studies and clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of such analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause a decline in our stock price or trading volume.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, and particularly after we are no longer an emerging growth company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Global Market and other applicable securities rules&#160;and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, we expect these rules&#160;and regulations to substantially increase our legal and financial compliance costs and to make some activities more time consuming and costly. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. The increased costs may require us to reduce costs in other areas of our business or increase the prices of our services. Moreover, these rules&#160;and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently required to comply with the SEC&#8217;s rules&#160;that implement Section&#160;404 of the Sarbanes-Oxley Act, and are therefore not required to make a formal assessment of the effectiveness of our internal control over financial reporting for that purpose. Pursuant to Section&#160;404, we will be required to furnish a report by our management on our internal control over financial reporting. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&#160;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for internal control over financial reporting. This process will be time-consuming, costly and complicated. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section&#160;404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. In addition, if we are not able to continue to meet these requirements, we may not be able to remain listed on the Nasdaq Global Market.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_121"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Item&#160;3. Defaults Upon Senior Securities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_124"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mine Safety Disclosures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable</span></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_127"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Information</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_130"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exhibits</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furnish the exhibits required by Item 601 of Regulation S-K (&#167; 229.601 of this chapter).</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.226%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Filing <br/>Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed/Furnished Herewith</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000167936321000051/exhibit13-jefferiesagreeme.htm">Amended and Restated Amendment No. 1 to the Open Market Sale Agreement</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline" href="https://www.sec.gov/Archives/edgar/data/1679363/000167936321000051/exhibit13-jefferiesagreeme.htm">SM</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline" href="https://www.sec.gov/Archives/edgar/data/1679363/000167936321000051/exhibit13-jefferiesagreeme.htm">,</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000167936321000051/exhibit13-jefferiesagreeme.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000167936321000051/exhibit13-jefferiesagreeme.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000167936321000051/exhibit13-jefferiesagreeme.htm">date</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000167936321000051/exhibit13-jefferiesagreeme.htm">d</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000167936321000051/exhibit13-jefferiesagreeme.htm"> July 1, 2020, by and between the Registrant and Jefferies LLC, as amended on August 11, 2021</a></span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000167936321000037/exhibit12-jefferiesagreeme.htm">S-3</a></span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000167936321000037/exhibit12-jefferiesagreeme.htm">333-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000167936321000037/exhibit12-jefferiesagreeme.htm">258703</a></span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679363/000167936321000037/exhibit12-jefferiesagreeme.htm">August 11, 2021</a></span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit101-rentamendment.htm">Amendment No. </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit101-rentamendment.htm">5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit101-rentamendment.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit101-rentamendment.htm">to lease dat</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit101-rentamendment.htm">ed August 17, 2021 b</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit101-rentamendment.htm">etween Astrazeneca Pharmaceuticals LP and Morphic Therapeutic</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit101-rentamendment.htm">, I</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit101-rentamendment.htm">nc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="morf-2021930x10qex311.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="morf-2021930x10qex312.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="morf-2021930x10qex321.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="morf-2021930x10qex322.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:22pt">The certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Form 10-Q and are not deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="i78343c0ada4c4eb7afb5039f4dd8197f_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i78343c0ada4c4eb7afb5039f4dd8197f_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:45.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.968%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MORPHIC HOLDING, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Praveen P. Tipirneni</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praveen P. Tipirneni, M.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director<br/>(Principal Executive Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Marc Schegerin</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marc Schegerin, M.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Chief Operating Officer<br/>(Principal Financial Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Robert E. Farrell Jr.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert E. Farrell Jr. CPA</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer and Assistant Treasurer<br/>(Principal Accounting Officer)</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101-rentamendment.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="iae04c2b1d1a54f6d94e7b9dcf4e3bd28_1"></div><div style="min-height:39.5pt;width:100%"><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">FIFTH AMENDMENT OF LEASE</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">THIS FIFTH AMENDMENT OF LEASE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) is made and entered into as of August 17, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">ASTRAZENECA PHARMACEUTICALS LP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">MORPHIC THERAPEUTIC, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> (f&#47;k&#47;a Morphic Rock Therapeutic, Inc., &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Tenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;).</font></div><div><font><br></font></div><div style="padding-right:-9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">RECITALS</font></div><div><font><br></font></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:11.81pt">Landlord and Tenant are parties to that certain Lease dated as of August 5, 2015 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Original Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), as amended by that certain First Amendment of Lease dated as of November 8, 2016 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">First Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), as further amended by that certain Second Amendment of Lease dated as of June 1, 2017 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Second Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), as further amended by that certain Third Amendment of Lease dated as of April 20, 2018 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Third Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) and as further amended by that certain Fourth Amendment of Lease dated as of February 11, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Fourth Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; and together with the Original Lease, the First Amendment, the Second Amendment and the Third Amendment, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Existing Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) whereby Tenant leases certain </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">space in the buildings and facilities commonly known as 35 Gatehouse Drive, Waltham, Massachusetts (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Landlord&#8217;s Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;), which leased space </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">currently </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">consists of approximately 11,166 square feet of rentable space located on Level 2 of Building A (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">A2 Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">12,147 square feet of rentable office space located on Level 2 of Building D (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Existing D2 Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">9,092 square feet of rentable laboratory space located on Level 3 of Building C (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">C3 Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, and together with the A2 Premises and the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Existing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">D2 Premises, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">all as more particularly set forth in the Existing Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div style="padding-left:9pt;text-indent:-27pt"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:11.5pt">The Term of Existing Lease is currently scheduled to expire on May 31, 2022, and Tenant desires to extend the Term of the Lease until May 31, 2025.</font></div><div style="padding-left:9pt;text-indent:-27pt"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:11.5pt">The Existing Lease, as amended by this Fifth Amendment of Lease, shall be referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;&#59; and capitalized terms not otherwise defined herein shall have their respective definitions set forth in the Existing Lease.</font></div><div style="padding-left:9pt;text-indent:-27pt"><font><br></font></div><div style="text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, in consideration of the above recitals which by this reference are incorporated herein, the mutual covenants and conditions contained herein and other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant agree as follows&#58;</font></div><div style="padding-left:9pt;text-indent:-27pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:18.75pt;text-decoration:underline">Extension of Term&#59; No Further Right of Extension</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  </font></div><div style="text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.68pt">Effective as of the date hereof, the Lease Term shall be extended until May 31, 2025. </font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:18.75pt">The parties acknowledge and agree that the Right of Extension shall be of no further force or effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:18.75pt;text-decoration:underline">Base Rent&#59; Security Deposit.</font></div><div style="text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:19.37pt">Effective as of June 1, 2022, the Base Rent for the A2 Premises and C3 Premises shall be as set forth in the following chart&#58;</font></div><div style="height:63.93pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:39.5pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Period</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Rent per rsf</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Annual Base Rent</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Monthly Base Rent</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">June 1, 2022 &#8211; May 31, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">$65.00</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">$1,316,770.00</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">$109,730.83</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">June 1, 2023 &#8211; May 31, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">$66.00<br></font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">$1,337,028.00</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">$111,419.00</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">June 1, 2024 &#8211; May 31, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">$67.00</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">$1,357,286.00</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">$113,107.17</font></div></td></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:35.84pt">Effective as of June 1, 2022, the Base Rent for the D2 Premises shall be as set forth in the following chart&#58;</font><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Effective as of June 1, 2022, the Base Rent for the D2 Premises shall be as set forth in the fo</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Period</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Rent per rsf</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Annual Base Rent</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Monthly Base Rent</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">June 1, 2022 &#8211; May 31, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">$30.00<br></font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">$364,410.00</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">$30,367.50</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">June 1, 2023 &#8211; May 31, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">$31.00<br></font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">$376,557.00</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">$31,379.75</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">June 1, 2024 &#8211; May 31, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">$32.00</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">$388,704.00</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">$32,392.00</font></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:18.45pt;text-decoration:underline">Security Deposit.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  Effective as of the Amendment Effective Date, Section 13 of the Summary of Basic Terms in the Original Lease and Section 13.3 of the Original Lease shall be amended to provide that the Security Deposit amount shall be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">$560,393.33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Tenant shall deliver to Landlord either (i) an amendment to its existing Letter of Credit increasing the same to $560,393.33, or (ii) an additional Letter of Credit complying with the terms and conditions of Section 13.3 of the Original Lease in the amount of $285,204.59.</font></div><div style="margin-top:12pt;padding-left:9pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:17.84pt;text-decoration:underline">Zero Carbon.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Tenant acknowledges and understands that Landlord has commenced a multi-year effort to provide that one hundred percent (100%) of the operational energy use associated with Landlord&#8217;s Property be offset by new on- or off-site renewable energy (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Zero Carbon Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;). Tenant acknowledges, agrees and covenants that (i) Tenant shall cooperate with Landlord&#8217;s policies and procedures adopted to reach the Zero Carbon Target (provided such policies and procedures shall be reasonable, shall be of uniform applicability to all tenants of the Building, and shall be enforced in a non-discriminatory manner with respect to similarly situated tenants), (ii) capital costs incurred by Landlord in connection with reaching the Zero Carbon Target shall be included in Operating Costs, provided that such capital costs incurred in connection with reaching the Zero Carbon Target shall be amortized as set forth in the Lease and (iii) non-capital costs (including without limitation the purchase of carbon credits) incurred by Landlord in connection with reaching the Zero Carbon Target shall be included in Operating Costs, provided that the cost of purchased carbon credits shall not be included in Operating Costs to the extent that such credits result in an on- or off-site renewable energy offset of more than 100% of the operational energy use associated with Landlord&#8217;s Property for the applicable calendar year.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:17.84pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">.</font></div><div style="text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:17.84pt">This Amendment sets forth the entire agreement between the parties with respect to the matters set forth herein.  There have been no additional oral or written representations or agreements.  Under no circumstances shall Tenant be entitled to any Rent abatement, improvement allowance, leasehold improvements, or other work to the Premises, or any similar economic incentives that may have been provided Tenant in connection with entering into the Existing Lease, unless specifically set forth in this Amendment.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:17.84pt">Except as is expressly modified or amended herein, the provisions, conditions and terms of the Existing Lease shall remain unchanged and in full force and effect.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:18.45pt">In the case of any inconsistency between the provisions of the Existing Lease and this Amendment, the provisions of this Amendment shall govern and control.</font></div><div style="height:63.93pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-2-</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:39.5pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:17.84pt">Landlord has delivered a copy of this Amendment to Tenant for Tenant&#8217;s review only and the delivery of it does not constitute an offer to Tenant or an option.  Landlord and Tenant shall not be bound by this Amendment until Landlord and Tenant have executed and delivered the same to the other party.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:17.84pt">The capitalized terms used in this Amendment shall have the same definitions as set forth in the Existing Lease to the extent that such capitalized terms are defined therein and not redefined in this Amendment.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:20.9pt">Tenant and Landlord hereby represent to each other that Landlord and Tenant have dealt with no broker in connection with this Amendment other than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">CBRE &#124; New England (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Broker</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Broker&#8217;s fees payable to Broker for this Amendment, if any, shall be payable by Landlord pursuant to the terms of a separate agreement between Landlord and Broker. Tenant and Landlord agree to indemnify and hold each other, its trustees, members, principals, beneficiaries, partners, officers, directors, employees, mortgagee(s) and agents, and the respective principals and members of any such agents harmless from all claims of any other brokers claiming to have represented Tenant and Landlord in connection with this Amendment.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:17.84pt">Each signatory of this Amendment represents hereby that he or she has the authority to execute and deliver the same on behalf of the party hereto for which such signatory is acting.</font></div><div style="padding-right:-9pt;text-align:center;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#91;SIGNATURES ARE ON FOLLOWING PAGE&#93;</font></div><div style="height:63.93pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-3-</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:39.5pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, Landlord and Tenant have duly executed this Fifth Amendment of Lease as of the Amendment Effective Date as a document under seal.</font></div><div style="padding-left:9pt;text-indent:-27pt"><font><br></font></div><div style="padding-left:9pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.151%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">LANDLORD&#58;</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">ASTRAZENECA PHARMACEUTICALS LP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, a Delaware </font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">limited partnership</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Stephen Fawell</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Name&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Stephen Fawell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">VP Head Oncology Discovery</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">TENANT&#58;</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">MORPHIC THERAPEUTIC, INC. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, a Delaware Corporation </font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Robert Farrell</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Name&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Robert Farrell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">SVB Finance and CAO</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:63.93pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-4-</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>morf-2021930x10qex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i83218a9cff15482e93f4bc9ebea58f80_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Praveen P. Tipirneni, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Morphic Holding, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:52.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.381%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 4, 2021</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Praveen P. Tipirneni</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praveen P. Tipirneni, M.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President, Chief Executive Officer and Director<br>(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>morf-2021930x10qex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i5f43770794b64ea8aa84329fa5ca4305_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Marc Schegerin, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Morphic Holding, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:52.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.381%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 4, 2021</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Marc Schegerin</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marc Schegerin</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer and Chief Operating Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:32.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>morf-2021930x10qex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i4d223b764976486080cb8c1a2e5f3422_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Praveen P. Tipirneni, Chief Executive Officer of Morphic Holding, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended September 30, 2021 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:52.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.381%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; November 4, 2021</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Praveen P. Tipirneni</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Praveen P. Tipirneni, M.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President, Chief Executive Officer and Director<br>(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>morf-2021930x10qex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ie540518896e4438eb6c0928b2edad2e2_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Marc Schegerin, Chief Financial Officer and Chief Operating Officer of Morphic Holding, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended September&#160;30, 2021 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:52.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.381%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; November 4, 2021</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Marc Schegerin</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marc Schegerin</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer and Chief Operating Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>morf-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a0fdcec5-f1a8-410f-b814-f85a654bede4,g:4b0f2f4e-5307-47a8-ad80-54240ea99d78-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:morf="http://morphictx.com/20210930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://morphictx.com/20210930">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="morf-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="morf-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="morf-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="morf-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://morphictx.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" roleURI="http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" roleURI="http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited" roleURI="http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" roleURI="http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" roleURI="http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" roleURI="http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited">
        <link:definition>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureoftheBusinessandBasisofPresentation" roleURI="http://morphictx.com/role/NatureoftheBusinessandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Nature of the Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureoftheBusinessandBasisofPresentationDetails" roleURI="http://morphictx.com/role/NatureoftheBusinessandBasisofPresentationDetails">
        <link:definition>2402401 - Disclosure - Nature of the Business and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPolicies" roleURI="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Basis of Presentation and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesPolicies" roleURI="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesDetails" roleURI="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails">
        <link:definition>2405402 - Disclosure - Basis of Presentation and Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialAssetsandLiabilities" roleURI="http://morphictx.com/role/FairValueofFinancialAssetsandLiabilities">
        <link:definition>2106103 - Disclosure - Fair Value of Financial Assets and Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialAssetsandLiabilitiesTables" roleURI="http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesTables">
        <link:definition>2307301 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialAssetsandLiabilitiesDetails" roleURI="http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails">
        <link:definition>2408403 - Disclosure - Fair Value of Financial Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Marketablesecurities" roleURI="http://morphictx.com/role/Marketablesecurities">
        <link:definition>2109104 - Disclosure - Marketable securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketablesecuritiesTables" roleURI="http://morphictx.com/role/MarketablesecuritiesTables">
        <link:definition>2310302 - Disclosure - Marketable securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketablesecuritiesDetails" roleURI="http://morphictx.com/role/MarketablesecuritiesDetails">
        <link:definition>2411404 - Disclosure - Marketable securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandRestrictedCash" roleURI="http://morphictx.com/role/CashCashEquivalentsandRestrictedCash">
        <link:definition>2112105 - Disclosure - Cash, Cash Equivalents, and Restricted Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandRestrictedCashTables" roleURI="http://morphictx.com/role/CashCashEquivalentsandRestrictedCashTables">
        <link:definition>2313303 - Disclosure - Cash, Cash Equivalents, and Restricted Cash (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandRestrictedCashDetails" roleURI="http://morphictx.com/role/CashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2414405 - Disclosure - Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://morphictx.com/role/AccruedExpenses">
        <link:definition>2115106 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://morphictx.com/role/AccruedExpensesTables">
        <link:definition>2316304 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://morphictx.com/role/AccruedExpensesDetails">
        <link:definition>2417406 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensation" roleURI="http://morphictx.com/role/EquityBasedCompensation">
        <link:definition>2118107 - Disclosure - Equity Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationTables" roleURI="http://morphictx.com/role/EquityBasedCompensationTables">
        <link:definition>2319305 - Disclosure - Equity Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensation2019equityincentiveplanDetails" roleURI="http://morphictx.com/role/EquityBasedCompensation2019equityincentiveplanDetails">
        <link:definition>2420407 - Disclosure - Equity Based Compensation - 2019 equity incentive plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationEquitybasedcompensationexpenseDetails" roleURI="http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails">
        <link:definition>2421408 - Disclosure - Equity Based Compensation - Equity based compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationRestrictedcommonstockactivityDetails" roleURI="http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails">
        <link:definition>2422409 - Disclosure - Equity Based Compensation - Restricted common stock activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationRestrictedstockunitsactivityDetails" roleURI="http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails">
        <link:definition>2423410 - Disclosure - Equity Based Compensation - Restricted stock units activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationStockoptionawardsDetails" roleURI="http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails">
        <link:definition>2424411 - Disclosure - Equity Based Compensation - Stock option awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationESPPDetails" roleURI="http://morphictx.com/role/EquityBasedCompensationESPPDetails">
        <link:definition>2425412 - Disclosure - Equity Based Compensation - ESPP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://morphictx.com/role/IncomeTaxes">
        <link:definition>2126108 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://morphictx.com/role/IncomeTaxesDetails">
        <link:definition>2427413 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://morphictx.com/role/CommitmentsandContingencies">
        <link:definition>2128109 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://morphictx.com/role/CommitmentsandContingenciesTables">
        <link:definition>2329306 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://morphictx.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>2430414 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofMinimumRentPaymentsDetails" roleURI="http://morphictx.com/role/CommitmentsandContingenciesScheduleofMinimumRentPaymentsDetails">
        <link:definition>2431415 - Disclosure - Commitments and Contingencies - Schedule of Minimum Rent Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OptionandLicenseAgreements" roleURI="http://morphictx.com/role/OptionandLicenseAgreements">
        <link:definition>2132110 - Disclosure - Option and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OpenOptionContractsWrittenTables" roleURI="http://morphictx.com/role/OpenOptionContractsWrittenTables">
        <link:definition>2333307 - Disclosure - Open Option Contracts Written (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OptionandLicenseAgreementsNarrativeDetails" roleURI="http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails">
        <link:definition>2434416 - Disclosure - Option and License Agreements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails" roleURI="http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails">
        <link:definition>2435417 - Disclosure - Option and License Agreements - Costs incurred and revenue recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomeperShare" roleURI="http://morphictx.com/role/NetLossIncomeperShare">
        <link:definition>2136111 - Disclosure - Net (Loss) Income per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomeperShareTables" roleURI="http://morphictx.com/role/NetLossIncomeperShareTables">
        <link:definition>2337308 - Disclosure - Net (Loss) Income per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomeperShareBasicnetincomelosspershareDetails" roleURI="http://morphictx.com/role/NetLossIncomeperShareBasicnetincomelosspershareDetails">
        <link:definition>2438418 - Disclosure - Net (Loss) Income per Share - Basic net income (loss) per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomeperShareCommonstockequivalentsharesDetails" roleURI="http://morphictx.com/role/NetLossIncomeperShareCommonstockequivalentsharesDetails">
        <link:definition>2439419 - Disclosure - Net (Loss) Income per Share - Common stock equivalent shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="morf_SecondaryOfferingMember" abstract="true" name="SecondaryOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="morf_ReimbursementRevenueMember" abstract="true" name="ReimbursementRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="morf_JanssenPharmaceuticalsIncMember" abstract="true" name="JanssenPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="morf_UpfrontPaymentRevenueMember" abstract="true" name="UpfrontPaymentRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="morf_AccruedResearchAndDevelopment" abstract="false" name="AccruedResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="morf_RestrictedCommonStockAndRestrictedStockUnitsMember" abstract="true" name="RestrictedCommonStockAndRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="morf_OfficeAndLaboratorySpaceMember" abstract="true" name="OfficeAndLaboratorySpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="morf_OpenMarketSaleAgreementMember" abstract="true" name="OpenMarketSaleAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee" abstract="false" name="EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="morf_TwoThousandNineteenStockIncentivePlanMember" abstract="true" name="TwoThousandNineteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="morf_AtMarketOfferingProgramMember" abstract="true" name="AtMarketOfferingProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="morf_CommonStockAvailableForIssuance" abstract="false" name="CommonStockAvailableForIssuance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock" abstract="false" name="ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="morf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" abstract="false" name="RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="morf_PercentageOfCommissionOnGrossSaleProceeds" abstract="false" name="PercentageOfCommissionOnGrossSaleProceeds" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="morf_AbbVieMember" abstract="true" name="AbbVieMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="morf_IncreaseDecreaseInDeferredRent" abstract="false" name="IncreaseDecreaseInDeferredRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="morf_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="morf_CollaborativeArrangementDisclosureAbstract" abstract="true" name="CollaborativeArrangementDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="morf_FollowOnPublicOfferingMember" abstract="true" name="FollowOnPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="morf_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="morf_IncomeTaxExpenseBenefitCARESAct" abstract="false" name="IncomeTaxExpenseBenefitCARESAct" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>morf-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a0fdcec5-f1a8-410f-b814-f85a654bede4,g:4b0f2f4e-5307-47a8-ad80-54240ea99d78-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="simple" xlink:href="morf-20210930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"/>
  <link:calculationLink xlink:role="http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c3b56a09-3966-45c2-97d3-829b8a81abf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_387852cb-613a-4170-a715-a5d5a05c60ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c3b56a09-3966-45c2-97d3-829b8a81abf5" xlink:to="loc_us-gaap_Liabilities_387852cb-613a-4170-a715-a5d5a05c60ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cb022827-5da7-46f9-a664-8d450e4f73c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c3b56a09-3966-45c2-97d3-829b8a81abf5" xlink:to="loc_us-gaap_StockholdersEquity_cb022827-5da7-46f9-a664-8d450e4f73c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_db91d99d-42d6-4d08-8984-59e4ea65f1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_328dae83-aec8-47b5-9356-5699ff9eb1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_db91d99d-42d6-4d08-8984-59e4ea65f1fc" xlink:to="loc_us-gaap_AssetsCurrent_328dae83-aec8-47b5-9356-5699ff9eb1e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fb823f9b-5dfd-46be-be5a-1c9a16d4f3e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_db91d99d-42d6-4d08-8984-59e4ea65f1fc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fb823f9b-5dfd-46be-be5a-1c9a16d4f3e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_bd03dc44-f74d-4562-a74c-f23104f482b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_db91d99d-42d6-4d08-8984-59e4ea65f1fc" xlink:to="loc_us-gaap_RestrictedCash_bd03dc44-f74d-4562-a74c-f23104f482b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_95ed4757-5bfd-4b8a-a9d6-a3dd06559284" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_db91d99d-42d6-4d08-8984-59e4ea65f1fc" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_95ed4757-5bfd-4b8a-a9d6-a3dd06559284" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_70b8dba7-aa37-4610-b196-5e7a7b194b42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_188d988e-8f0b-4bf0-97ff-d6cf2f9dc4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_70b8dba7-aa37-4610-b196-5e7a7b194b42" xlink:to="loc_us-gaap_AccountsPayableCurrent_188d988e-8f0b-4bf0-97ff-d6cf2f9dc4cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_0e758747-243e-4047-9747-d15eb022b1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_70b8dba7-aa37-4610-b196-5e7a7b194b42" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_0e758747-243e-4047-9747-d15eb022b1f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4e6046ae-145f-484c-b8b6-4953522b3619" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_70b8dba7-aa37-4610-b196-5e7a7b194b42" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4e6046ae-145f-484c-b8b6-4953522b3619" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRentCurrent_e87a5f31-353d-4d2c-bd9f-a76ca03961f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRentCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_70b8dba7-aa37-4610-b196-5e7a7b194b42" xlink:to="loc_us-gaap_AccruedRentCurrent_e87a5f31-353d-4d2c-bd9f-a76ca03961f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2c19c923-11d9-4e85-af9b-fd76e858c8e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_ab409e62-ed2d-44e6-8b56-b4f2b7c091c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2c19c923-11d9-4e85-af9b-fd76e858c8e2" xlink:to="loc_us-gaap_PreferredStockValue_ab409e62-ed2d-44e6-8b56-b4f2b7c091c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f0e943bd-8d00-4ef9-b63c-a5381c5d2ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2c19c923-11d9-4e85-af9b-fd76e858c8e2" xlink:to="loc_us-gaap_CommonStockValue_f0e943bd-8d00-4ef9-b63c-a5381c5d2ed6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_638b0e94-8fcc-42a9-bfd1-2ce5de75673c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2c19c923-11d9-4e85-af9b-fd76e858c8e2" xlink:to="loc_us-gaap_AdditionalPaidInCapital_638b0e94-8fcc-42a9-bfd1-2ce5de75673c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3d109313-3a3d-4ca0-9c21-b6d948915926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2c19c923-11d9-4e85-af9b-fd76e858c8e2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3d109313-3a3d-4ca0-9c21-b6d948915926" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8320c88c-0303-4e79-a82f-918a0810ea31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2c19c923-11d9-4e85-af9b-fd76e858c8e2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8320c88c-0303-4e79-a82f-918a0810ea31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1732a8dd-8c5b-4495-8506-4af80916edd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8a459edb-4115-471d-9faa-4e2b75d36ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1732a8dd-8c5b-4495-8506-4af80916edd2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8a459edb-4115-471d-9faa-4e2b75d36ffe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0bb03bfc-615e-45c3-ae1f-30ab1a6eceb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1732a8dd-8c5b-4495-8506-4af80916edd2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0bb03bfc-615e-45c3-ae1f-30ab1a6eceb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0b604b43-2a83-43fc-a48d-46b35b320a69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1732a8dd-8c5b-4495-8506-4af80916edd2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_0b604b43-2a83-43fc-a48d-46b35b320a69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3a1157df-9c8b-4e41-8465-4af42ef4093a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1732a8dd-8c5b-4495-8506-4af80916edd2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3a1157df-9c8b-4e41-8465-4af42ef4093a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8432251b-8645-47d6-8724-911ef86be864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e055d7a4-c7fc-4ba3-a1f8-402f392c38ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8432251b-8645-47d6-8724-911ef86be864" xlink:to="loc_us-gaap_LiabilitiesCurrent_e055d7a4-c7fc-4ba3-a1f8-402f392c38ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1874b219-5a95-48be-a32b-55f2333dc54e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8432251b-8645-47d6-8724-911ef86be864" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1874b219-5a95-48be-a32b-55f2333dc54e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRentNoncurrent_98c55aab-6607-417e-a780-d4534fef3ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRentNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8432251b-8645-47d6-8724-911ef86be864" xlink:to="loc_us-gaap_AccruedRentNoncurrent_98c55aab-6607-417e-a780-d4534fef3ed2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited" xlink:type="simple" xlink:href="morf-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited"/>
  <link:calculationLink xlink:role="http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_115b92db-f49c-4c30-ae2b-540c77368241" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_95d98087-28f8-47d3-ba95-b16baea2003f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_115b92db-f49c-4c30-ae2b-540c77368241" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_95d98087-28f8-47d3-ba95-b16baea2003f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e12278b5-07b6-4960-9dd1-ba34a64aa0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_115b92db-f49c-4c30-ae2b-540c77368241" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e12278b5-07b6-4960-9dd1-ba34a64aa0b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_84ba8d50-fc39-4d16-b5af-099f69568682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_87cab587-8ea8-4462-befe-94f708d7c960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_84ba8d50-fc39-4d16-b5af-099f69568682" xlink:to="loc_us-gaap_NetIncomeLoss_87cab587-8ea8-4462-befe-94f708d7c960" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b1a43867-0f8f-46d8-9acd-6c97318abbea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_84ba8d50-fc39-4d16-b5af-099f69568682" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b1a43867-0f8f-46d8-9acd-6c97318abbea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d81b3aef-46e0-42e9-ab2a-db9742cd1fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2833bf7d-ac70-42bd-9b73-e927da257f79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d81b3aef-46e0-42e9-ab2a-db9742cd1fd9" xlink:to="loc_us-gaap_OperatingIncomeLoss_2833bf7d-ac70-42bd-9b73-e927da257f79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_cfe5f7f1-db46-4644-b223-eae096739361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d81b3aef-46e0-42e9-ab2a-db9742cd1fd9" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_cfe5f7f1-db46-4644-b223-eae096739361" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_885b9fc4-54b7-4297-a124-4e0f7c804a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_24736e77-40a6-48f0-8a0e-2cd589ae7af1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_885b9fc4-54b7-4297-a124-4e0f7c804a7e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_24736e77-40a6-48f0-8a0e-2cd589ae7af1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_7e1c433d-5d25-4b0a-a3db-93bc00fa9caa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_885b9fc4-54b7-4297-a124-4e0f7c804a7e" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_7e1c433d-5d25-4b0a-a3db-93bc00fa9caa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6081bac0-9e14-48ee-8883-b400b045b8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_7430df1c-238b-43ae-bb4b-7ef4151c583b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6081bac0-9e14-48ee-8883-b400b045b8c6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_7430df1c-238b-43ae-bb4b-7ef4151c583b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d21ee94d-a5d9-4025-b66c-fda3b4e8d168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a16c4c5b-e688-4326-8106-0864f5449eae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d21ee94d-a5d9-4025-b66c-fda3b4e8d168" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a16c4c5b-e688-4326-8106-0864f5449eae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a650d7fa-02de-4d68-8b10-41245aec0a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d21ee94d-a5d9-4025-b66c-fda3b4e8d168" xlink:to="loc_us-gaap_CostsAndExpenses_a650d7fa-02de-4d68-8b10-41245aec0a4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a9b45f63-938b-4d1c-9eb0-622103bc568c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_50219096-2423-454b-b0df-5ccf1b79459d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_a9b45f63-938b-4d1c-9eb0-622103bc568c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_50219096-2423-454b-b0df-5ccf1b79459d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_6bada1b7-f0da-4376-b071-d0731479b94c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_a9b45f63-938b-4d1c-9eb0-622103bc568c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_6bada1b7-f0da-4376-b071-d0731479b94c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="simple" xlink:href="morf-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"/>
  <link:calculationLink xlink:role="http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1cc2b843-6245-46d9-9d7a-6f7fbe26291d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_0bbb693e-c0ab-445e-8563-85e4422e55bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1cc2b843-6245-46d9-9d7a-6f7fbe26291d" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_0bbb693e-c0ab-445e-8563-85e4422e55bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_71ce3673-b305-40d1-85ea-0f23072e6439" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1cc2b843-6245-46d9-9d7a-6f7fbe26291d" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_71ce3673-b305-40d1-85ea-0f23072e6439" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8daa6fdd-16ba-40d4-b7d4-a448cb755eab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1cc2b843-6245-46d9-9d7a-6f7fbe26291d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8daa6fdd-16ba-40d4-b7d4-a448cb755eab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a037c750-802e-40e9-87ca-6d7fff1395ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a52fd009-ad77-4cb7-ab3e-c04af2336096" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a037c750-802e-40e9-87ca-6d7fff1395ed" xlink:to="loc_us-gaap_ProfitLoss_a52fd009-ad77-4cb7-ab3e-c04af2336096" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_91fdc2d7-8380-4f47-a761-5335d6243cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a037c750-802e-40e9-87ca-6d7fff1395ed" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_91fdc2d7-8380-4f47-a761-5335d6243cbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_6b3e56fb-c3e6-4a09-a702-80200123676a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a037c750-802e-40e9-87ca-6d7fff1395ed" xlink:to="loc_us-gaap_DepreciationAndAmortization_6b3e56fb-c3e6-4a09-a702-80200123676a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_adbb1915-f0df-4cc0-9b25-e5eca137a346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a037c750-802e-40e9-87ca-6d7fff1395ed" xlink:to="loc_us-gaap_ShareBasedCompensation_adbb1915-f0df-4cc0-9b25-e5eca137a346" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1e8656af-bf16-44c6-9d16-d19609348640" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a037c750-802e-40e9-87ca-6d7fff1395ed" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1e8656af-bf16-44c6-9d16-d19609348640" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_de91d6c0-dabd-4256-9905-2a9df415c5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a037c750-802e-40e9-87ca-6d7fff1395ed" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_de91d6c0-dabd-4256-9905-2a9df415c5d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_530cc118-c0e3-4e38-885e-d68fb4b667c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a037c750-802e-40e9-87ca-6d7fff1395ed" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_530cc118-c0e3-4e38-885e-d68fb4b667c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7bf219aa-f4b9-4272-a605-a5dc204b3b70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a037c750-802e-40e9-87ca-6d7fff1395ed" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7bf219aa-f4b9-4272-a605-a5dc204b3b70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4d0d6946-56fa-4d25-b4e9-51572cfe1bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a037c750-802e-40e9-87ca-6d7fff1395ed" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4d0d6946-56fa-4d25-b4e9-51572cfe1bd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_0af9ba99-ea15-4298-8a4a-c20077a451d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a037c750-802e-40e9-87ca-6d7fff1395ed" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_0af9ba99-ea15-4298-8a4a-c20077a451d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_IncreaseDecreaseInDeferredRent_0fdf0c5f-16e0-4622-ac6c-aa7be3aa7611" xlink:href="morf-20210930.xsd#morf_IncreaseDecreaseInDeferredRent"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a037c750-802e-40e9-87ca-6d7fff1395ed" xlink:to="loc_morf_IncreaseDecreaseInDeferredRent_0fdf0c5f-16e0-4622-ac6c-aa7be3aa7611" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_7b28a20a-d3db-47e6-be47-e6f4ff2c56e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a037c750-802e-40e9-87ca-6d7fff1395ed" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_7b28a20a-d3db-47e6-be47-e6f4ff2c56e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_38549ff6-b2dd-4517-b8ba-5654a3485f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_054a8782-e5ed-4796-aa4f-cbd9d7d2f8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_38549ff6-b2dd-4517-b8ba-5654a3485f2f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_054a8782-e5ed-4796-aa4f-cbd9d7d2f8fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_42b333fe-0e6f-40b8-93fe-bc0e5fa65aec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_38549ff6-b2dd-4517-b8ba-5654a3485f2f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_42b333fe-0e6f-40b8-93fe-bc0e5fa65aec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_e004f8f7-2caf-425b-a21e-baf2b9146e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_38549ff6-b2dd-4517-b8ba-5654a3485f2f" xlink:to="loc_us-gaap_ProceedsFromStockPlans_e004f8f7-2caf-425b-a21e-baf2b9146e8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1de0913b-bee9-44e3-84d4-d94643aabddd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_38549ff6-b2dd-4517-b8ba-5654a3485f2f" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1de0913b-bee9-44e3-84d4-d94643aabddd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8bcefe19-5c02-4ca3-b048-b3a1277920c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3176f35f-fdb0-4450-972a-701eb7207324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8bcefe19-5c02-4ca3-b048-b3a1277920c3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3176f35f-fdb0-4450-972a-701eb7207324" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b0914cc2-73a7-4861-91f9-fa08b616565d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8bcefe19-5c02-4ca3-b048-b3a1277920c3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b0914cc2-73a7-4861-91f9-fa08b616565d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21be3bf1-1902-4cba-99ff-c31ad8a2fdf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8bcefe19-5c02-4ca3-b048-b3a1277920c3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21be3bf1-1902-4cba-99ff-c31ad8a2fdf3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#FairValueofFinancialAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_51337cbe-4af7-4fd3-bc2b-b25b4ec8a512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_aa0f84ef-6bc3-4bca-b7ff-0f2750565076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_51337cbe-4af7-4fd3-bc2b-b25b4ec8a512" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_aa0f84ef-6bc3-4bca-b7ff-0f2750565076" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0b55d420-43ba-4e33-bea8-b67e8e7ddb0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_51337cbe-4af7-4fd3-bc2b-b25b4ec8a512" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0b55d420-43ba-4e33-bea8-b67e8e7ddb0b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://morphictx.com/role/MarketablesecuritiesDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#MarketablesecuritiesDetails"/>
  <link:calculationLink xlink:role="http://morphictx.com/role/MarketablesecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_670b46f7-2214-49cc-9554-3f0df66ea00f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5b53b70b-e129-4907-bac2-fefb497d8714" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_670b46f7-2214-49cc-9554-3f0df66ea00f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5b53b70b-e129-4907-bac2-fefb497d8714" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5bff377a-a218-44df-a2bf-181f50f8ffea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_670b46f7-2214-49cc-9554-3f0df66ea00f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5bff377a-a218-44df-a2bf-181f50f8ffea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e395d6ca-993b-49eb-9910-55f120ef73cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_670b46f7-2214-49cc-9554-3f0df66ea00f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e395d6ca-993b-49eb-9910-55f120ef73cc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://morphictx.com/role/CashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#CashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://morphictx.com/role/CashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d40ce010-e340-40e7-b936-c81d82fc44c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5c00f470-0e2c-4ad7-b0cf-242188ac098e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d40ce010-e340-40e7-b936-c81d82fc44c0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5c00f470-0e2c-4ad7-b0cf-242188ac098e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_cae84cc6-7f76-4e79-b287-b3ad1d581412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d40ce010-e340-40e7-b936-c81d82fc44c0" xlink:to="loc_us-gaap_RestrictedCash_cae84cc6-7f76-4e79-b287-b3ad1d581412" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://morphictx.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#AccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://morphictx.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b48e1960-ebad-4173-b135-94c85f9e63ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c863812a-ce97-41c7-a03b-102e174e5858" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b48e1960-ebad-4173-b135-94c85f9e63ac" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c863812a-ce97-41c7-a03b-102e174e5858" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_efabd4ec-886d-46a5-86e8-cf3806a46cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b48e1960-ebad-4173-b135-94c85f9e63ac" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_efabd4ec-886d-46a5-86e8-cf3806a46cc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AccruedResearchAndDevelopment_6c9c2c7f-d833-409e-84ba-633e117eb797" xlink:href="morf-20210930.xsd#morf_AccruedResearchAndDevelopment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b48e1960-ebad-4173-b135-94c85f9e63ac" xlink:to="loc_morf_AccruedResearchAndDevelopment_6c9c2c7f-d833-409e-84ba-633e117eb797" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://morphictx.com/role/CommitmentsandContingenciesScheduleofMinimumRentPaymentsDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#CommitmentsandContingenciesScheduleofMinimumRentPaymentsDetails"/>
  <link:calculationLink xlink:role="http://morphictx.com/role/CommitmentsandContingenciesScheduleofMinimumRentPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_69f5b223-f4d6-47dd-8042-38ba0eed253f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0f452454-1cc8-4090-ae05-39bd8eedb344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_69f5b223-f4d6-47dd-8042-38ba0eed253f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0f452454-1cc8-4090-ae05-39bd8eedb344" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0d0f2e3e-fcc8-4b4e-8eb6-020bf4e8d015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_69f5b223-f4d6-47dd-8042-38ba0eed253f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0d0f2e3e-fcc8-4b4e-8eb6-020bf4e8d015" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_debd8a0a-be8d-4e85-9f97-b62fa27bc78e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_69f5b223-f4d6-47dd-8042-38ba0eed253f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_debd8a0a-be8d-4e85-9f97-b62fa27bc78e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bb83ee85-43c1-43a4-ace0-6331987998c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_69f5b223-f4d6-47dd-8042-38ba0eed253f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bb83ee85-43c1-43a4-ace0-6331987998c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d92932a5-541a-4c93-b58a-9c80cda8faba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_69f5b223-f4d6-47dd-8042-38ba0eed253f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d92932a5-541a-4c93-b58a-9c80cda8faba" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>morf-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a0fdcec5-f1a8-410f-b814-f85a654bede4,g:4b0f2f4e-5307-47a8-ad80-54240ea99d78-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="simple" xlink:href="morf-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="extended" id="i381c25fafae348c1a854c0605dfec415_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2f2777d0-8e60-4335-a07e-b7bd2cca8c44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2f2777d0-8e60-4335-a07e-b7bd2cca8c44" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3b605276-0854-4b9a-9ad7-97999647390a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:to="loc_us-gaap_StockholdersEquity_3b605276-0854-4b9a-9ad7-97999647390a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_57bd4f4c-e8a5-403e-a968-cf4c1e9f9798" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:to="loc_us-gaap_SharesOutstanding_57bd4f4c-e8a5-403e-a968-cf4c1e9f9798" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_b79adb7c-6798-48cc-b67b-74c3803c2a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_b79adb7c-6798-48cc-b67b-74c3803c2a4b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_f452822c-8496-4e10-ba7e-ab85c9e1668a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_f452822c-8496-4e10-ba7e-ab85c9e1668a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_35776e84-1c80-4dd7-9299-aed35b1a023a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_35776e84-1c80-4dd7-9299-aed35b1a023a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e0ac5814-9866-402b-8c78-155cf0256f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e0ac5814-9866-402b-8c78-155cf0256f9e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_10b5a54a-5f2d-449a-8290-1b84ea41b9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_10b5a54a-5f2d-449a-8290-1b84ea41b9d0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_a2a51994-a021-407f-b1b9-2b66942ff49f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_a2a51994-a021-407f-b1b9-2b66942ff49f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8d9c0feb-3473-4a82-baba-b29dd5d46a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8d9c0feb-3473-4a82-baba-b29dd5d46a8f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_aece3c12-9bea-4f32-8327-a621b5f97ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_aece3c12-9bea-4f32-8327-a621b5f97ece" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_419379a1-a062-4a48-b138-7961c26f25e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_419379a1-a062-4a48-b138-7961c26f25e7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_d5238999-f143-4590-b7fd-278e892234cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_d5238999-f143-4590-b7fd-278e892234cd" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c5804a89-046d-4a8f-9c6a-1b59190d9eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:to="loc_us-gaap_NetIncomeLoss_c5804a89-046d-4a8f-9c6a-1b59190d9eb8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_333299c5-cebe-4412-ae67-cdea2d5e8b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_d8a36b44-c1bd-4dd5-a752-e9188cf0fb99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e6a069ea-5fdf-4783-8536-987ca9fd65b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2f2777d0-8e60-4335-a07e-b7bd2cca8c44" xlink:to="loc_us-gaap_StatementTable_e6a069ea-5fdf-4783-8536-987ca9fd65b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2412335b-cc9a-47b4-9ad4-663e28e0e3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e6a069ea-5fdf-4783-8536-987ca9fd65b4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2412335b-cc9a-47b4-9ad4-663e28e0e3a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2412335b-cc9a-47b4-9ad4-663e28e0e3a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2412335b-cc9a-47b4-9ad4-663e28e0e3a8" xlink:to="loc_us-gaap_EquityComponentDomain_2412335b-cc9a-47b4-9ad4-663e28e0e3a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_745e714d-1fc4-4d27-b668-da30cbb15341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2412335b-cc9a-47b4-9ad4-663e28e0e3a8" xlink:to="loc_us-gaap_EquityComponentDomain_745e714d-1fc4-4d27-b668-da30cbb15341" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_915954a5-133e-43ab-8a51-26b5d6069d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_745e714d-1fc4-4d27-b668-da30cbb15341" xlink:to="loc_us-gaap_CommonStockMember_915954a5-133e-43ab-8a51-26b5d6069d4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4e8ca456-9292-4636-9e27-4fd69a8fb439" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_745e714d-1fc4-4d27-b668-da30cbb15341" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4e8ca456-9292-4636-9e27-4fd69a8fb439" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5c559763-258f-4969-83d7-7bd33bd3665a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_745e714d-1fc4-4d27-b668-da30cbb15341" xlink:to="loc_us-gaap_RetainedEarningsMember_5c559763-258f-4969-83d7-7bd33bd3665a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_43fbca09-f2d2-451d-abf6-f6cdaa5129f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_745e714d-1fc4-4d27-b668-da30cbb15341" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_43fbca09-f2d2-451d-abf6-f6cdaa5129f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3130a620-246b-4038-adad-c4af05da9e03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e6a069ea-5fdf-4783-8536-987ca9fd65b4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3130a620-246b-4038-adad-c4af05da9e03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3130a620-246b-4038-adad-c4af05da9e03_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3130a620-246b-4038-adad-c4af05da9e03" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3130a620-246b-4038-adad-c4af05da9e03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ff25fd23-cb36-434e-bf3e-6423c01bb45d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3130a620-246b-4038-adad-c4af05da9e03" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ff25fd23-cb36-434e-bf3e-6423c01bb45d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AtTheMarketOfferingMember_6f7cbdcd-92e2-4a99-bb2b-0de460597797" xlink:href="morf-20210930.xsd#morf_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ff25fd23-cb36-434e-bf3e-6423c01bb45d" xlink:to="loc_morf_AtTheMarketOfferingMember_6f7cbdcd-92e2-4a99-bb2b-0de460597797" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_SecondaryOfferingMember_57e53e8e-b67c-4f16-9216-423015de5832" xlink:href="morf-20210930.xsd#morf_SecondaryOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ff25fd23-cb36-434e-bf3e-6423c01bb45d" xlink:to="loc_morf_SecondaryOfferingMember_57e53e8e-b67c-4f16-9216-423015de5832" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="morf-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended" id="i4b1e4e52a589479d928ea6f38ed9ce5f_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a86e0b11-976a-416b-b33b-594bdf4f51d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_6b00fd5a-1aaa-47de-9b5a-cbd92960e83d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a86e0b11-976a-416b-b33b-594bdf4f51d9" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_6b00fd5a-1aaa-47de-9b5a-cbd92960e83d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_fdd627eb-7f49-4057-a39e-586baf42ae36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a86e0b11-976a-416b-b33b-594bdf4f51d9" xlink:to="loc_us-gaap_StatementTable_fdd627eb-7f49-4057-a39e-586baf42ae36" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_23eb5103-15c3-4bd1-9d4b-549efa47bed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_fdd627eb-7f49-4057-a39e-586baf42ae36" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_23eb5103-15c3-4bd1-9d4b-549efa47bed4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23eb5103-15c3-4bd1-9d4b-549efa47bed4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_23eb5103-15c3-4bd1-9d4b-549efa47bed4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23eb5103-15c3-4bd1-9d4b-549efa47bed4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_821fb596-a0a9-40a2-8fae-c238ab2dab5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_23eb5103-15c3-4bd1-9d4b-549efa47bed4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_821fb596-a0a9-40a2-8fae-c238ab2dab5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AtTheMarketOfferingMember_c5f81d49-8d80-453a-b135-6dc9810b42bd" xlink:href="morf-20210930.xsd#morf_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_821fb596-a0a9-40a2-8fae-c238ab2dab5d" xlink:to="loc_morf_AtTheMarketOfferingMember_c5f81d49-8d80-453a-b135-6dc9810b42bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_SecondaryOfferingMember_d8af61c7-cc1f-430f-acf4-b61ac53bbafe" xlink:href="morf-20210930.xsd#morf_SecondaryOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_821fb596-a0a9-40a2-8fae-c238ab2dab5d" xlink:to="loc_morf_SecondaryOfferingMember_d8af61c7-cc1f-430f-acf4-b61ac53bbafe" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/NatureoftheBusinessandBasisofPresentationDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#NatureoftheBusinessandBasisofPresentationDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/NatureoftheBusinessandBasisofPresentationDetails" xlink:type="extended" id="i4795990467214682b381b70cff0c94f6_NatureoftheBusinessandBasisofPresentationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_8452a784-cfcd-4598-9b5c-364e29188cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_fc8d340b-3d7f-4414-bd4a-15c9ce400d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_8452a784-cfcd-4598-9b5c-364e29188cf7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_fc8d340b-3d7f-4414-bd4a-15c9ce400d3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_PercentageOfCommissionOnGrossSaleProceeds_7266b942-7ab4-4755-9bf2-74c709400cc5" xlink:href="morf-20210930.xsd#morf_PercentageOfCommissionOnGrossSaleProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_8452a784-cfcd-4598-9b5c-364e29188cf7" xlink:to="loc_morf_PercentageOfCommissionOnGrossSaleProceeds_7266b942-7ab4-4755-9bf2-74c709400cc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1e5dffff-9f79-4ca6-b893-fb56cfcf8012" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_8452a784-cfcd-4598-9b5c-364e29188cf7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1e5dffff-9f79-4ca6-b893-fb56cfcf8012" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CommonStockAvailableForIssuance_01e52743-576e-4c81-b4da-c49a7564dbf3" xlink:href="morf-20210930.xsd#morf_CommonStockAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_8452a784-cfcd-4598-9b5c-364e29188cf7" xlink:to="loc_morf_CommonStockAvailableForIssuance_01e52743-576e-4c81-b4da-c49a7564dbf3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_b889456e-1655-413d-93b5-06388c6ee67a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_8452a784-cfcd-4598-9b5c-364e29188cf7" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_b889456e-1655-413d-93b5-06388c6ee67a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1bc5122c-3df5-4ec5-aeee-89a517dbde2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_8452a784-cfcd-4598-9b5c-364e29188cf7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1bc5122c-3df5-4ec5-aeee-89a517dbde2a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_0b0885f5-7601-4cf3-8178-ca11387a44ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_8452a784-cfcd-4598-9b5c-364e29188cf7" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_0b0885f5-7601-4cf3-8178-ca11387a44ec" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9ffb8240-2e74-479d-b6ab-e0e4ebd900ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_8452a784-cfcd-4598-9b5c-364e29188cf7" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9ffb8240-2e74-479d-b6ab-e0e4ebd900ef" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_7a9575a7-99ea-4055-8505-f17700565753" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_8452a784-cfcd-4598-9b5c-364e29188cf7" xlink:to="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_7a9575a7-99ea-4055-8505-f17700565753" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d7c20384-83f3-4c9b-9d5b-fbb7c12f992a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_7a9575a7-99ea-4055-8505-f17700565753" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d7c20384-83f3-4c9b-9d5b-fbb7c12f992a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d7c20384-83f3-4c9b-9d5b-fbb7c12f992a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d7c20384-83f3-4c9b-9d5b-fbb7c12f992a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d7c20384-83f3-4c9b-9d5b-fbb7c12f992a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81e5540d-bc12-4dc6-8932-113361cc664e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d7c20384-83f3-4c9b-9d5b-fbb7c12f992a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81e5540d-bc12-4dc6-8932-113361cc664e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AtMarketOfferingProgramMember_2dcf04ea-c3ed-40dd-bbc8-585eb7aee379" xlink:href="morf-20210930.xsd#morf_AtMarketOfferingProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81e5540d-bc12-4dc6-8932-113361cc664e" xlink:to="loc_morf_AtMarketOfferingProgramMember_2dcf04ea-c3ed-40dd-bbc8-585eb7aee379" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_FollowOnPublicOfferingMember_0719dd52-b78d-43d4-b2f9-e3a827c0d0cd" xlink:href="morf-20210930.xsd#morf_FollowOnPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81e5540d-bc12-4dc6-8932-113361cc664e" xlink:to="loc_morf_FollowOnPublicOfferingMember_0719dd52-b78d-43d4-b2f9-e3a827c0d0cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8ca69fe7-f135-44b0-ba86-ef39dbb13534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_7a9575a7-99ea-4055-8505-f17700565753" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8ca69fe7-f135-44b0-ba86-ef39dbb13534" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8ca69fe7-f135-44b0-ba86-ef39dbb13534_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8ca69fe7-f135-44b0-ba86-ef39dbb13534" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8ca69fe7-f135-44b0-ba86-ef39dbb13534_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_88f4eacd-87af-4390-8309-f12512f90f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8ca69fe7-f135-44b0-ba86-ef39dbb13534" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_88f4eacd-87af-4390-8309-f12512f90f0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_OpenMarketSaleAgreementMember_9c7c6ce0-aa6c-4c76-aa70-2e157ae9107b" xlink:href="morf-20210930.xsd#morf_OpenMarketSaleAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_88f4eacd-87af-4390-8309-f12512f90f0c" xlink:to="loc_morf_OpenMarketSaleAgreementMember_9c7c6ce0-aa6c-4c76-aa70-2e157ae9107b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#BasisofPresentationandSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" xlink:type="extended" id="ia67756db7c0b41c0aed1b6db04c23d98_BasisofPresentationandSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d86c5ac-c7aa-4834-ad11-5baddcc64433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_663726ee-bbe1-4905-b325-a79e6da06423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfLand"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d86c5ac-c7aa-4834-ad11-5baddcc64433" xlink:to="loc_us-gaap_AreaOfLand_663726ee-bbe1-4905-b325-a79e6da06423" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4741d8f3-6670-4c46-bb62-8765ea40a159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d86c5ac-c7aa-4834-ad11-5baddcc64433" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4741d8f3-6670-4c46-bb62-8765ea40a159" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_5dcb6f34-3fbb-42cb-b307-d15d7a3a518e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4741d8f3-6670-4c46-bb62-8765ea40a159" xlink:to="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_5dcb6f34-3fbb-42cb-b307-d15d7a3a518e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_5dcb6f34-3fbb-42cb-b307-d15d7a3a518e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_5dcb6f34-3fbb-42cb-b307-d15d7a3a518e" xlink:to="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_5dcb6f34-3fbb-42cb-b307-d15d7a3a518e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_b6a4e850-3f0e-4940-9b8e-bd51d0be4d6a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_5dcb6f34-3fbb-42cb-b307-d15d7a3a518e" xlink:to="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_b6a4e850-3f0e-4940-9b8e-bd51d0be4d6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_OfficeAndLaboratorySpaceMember_2e7d4e26-7595-4230-8a65-3d71da515755" xlink:href="morf-20210930.xsd#morf_OfficeAndLaboratorySpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_b6a4e850-3f0e-4940-9b8e-bd51d0be4d6a" xlink:to="loc_morf_OfficeAndLaboratorySpaceMember_2e7d4e26-7595-4230-8a65-3d71da515755" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#FairValueofFinancialAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="extended" id="iab19b0c42b3a494b820849fd4afadc02_FairValueofFinancialAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b79d173b-519b-4392-ae2c-08be589247a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_84e39525-b5b7-4bdf-bd5e-f5baa9a341ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b79d173b-519b-4392-ae2c-08be589247a0" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_84e39525-b5b7-4bdf-bd5e-f5baa9a341ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_21343e65-4d07-4745-afec-b3e3980e97c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_84e39525-b5b7-4bdf-bd5e-f5baa9a341ad" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_21343e65-4d07-4745-afec-b3e3980e97c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2b894a22-a394-4a20-ac3c-cdbfa438e459" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_84e39525-b5b7-4bdf-bd5e-f5baa9a341ad" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2b894a22-a394-4a20-ac3c-cdbfa438e459" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_976e14ea-0d87-48cf-98ab-cfee08193be2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_84e39525-b5b7-4bdf-bd5e-f5baa9a341ad" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_976e14ea-0d87-48cf-98ab-cfee08193be2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aa42795-953a-4b9f-bb7a-1af894b38386" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b79d173b-519b-4392-ae2c-08be589247a0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aa42795-953a-4b9f-bb7a-1af894b38386" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8247a275-3ea0-45ba-8fc9-480ddbf21ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aa42795-953a-4b9f-bb7a-1af894b38386" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8247a275-3ea0-45ba-8fc9-480ddbf21ff5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8247a275-3ea0-45ba-8fc9-480ddbf21ff5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8247a275-3ea0-45ba-8fc9-480ddbf21ff5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8247a275-3ea0-45ba-8fc9-480ddbf21ff5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_fb0a4aa0-a055-4b8b-ac3f-c3baec44e195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8247a275-3ea0-45ba-8fc9-480ddbf21ff5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_fb0a4aa0-a055-4b8b-ac3f-c3baec44e195" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_fbfd0088-ae33-4692-9f4d-36cf1bbcc56d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_fb0a4aa0-a055-4b8b-ac3f-c3baec44e195" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_fbfd0088-ae33-4692-9f4d-36cf1bbcc56d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_05ed4891-f25e-4d9d-aca1-16fddfeffd12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aa42795-953a-4b9f-bb7a-1af894b38386" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_05ed4891-f25e-4d9d-aca1-16fddfeffd12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_05ed4891-f25e-4d9d-aca1-16fddfeffd12_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_05ed4891-f25e-4d9d-aca1-16fddfeffd12" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_05ed4891-f25e-4d9d-aca1-16fddfeffd12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1c38ad6a-af8b-4f42-883f-51c8f36495a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_05ed4891-f25e-4d9d-aca1-16fddfeffd12" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1c38ad6a-af8b-4f42-883f-51c8f36495a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3c36e177-6dd2-413d-ba3b-8596108a1503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1c38ad6a-af8b-4f42-883f-51c8f36495a4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3c36e177-6dd2-413d-ba3b-8596108a1503" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6f2c8645-1045-4fb9-85f4-4c02ee8ad704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1c38ad6a-af8b-4f42-883f-51c8f36495a4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6f2c8645-1045-4fb9-85f4-4c02ee8ad704" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d759cd08-9361-4e44-b830-c09db5c82c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1c38ad6a-af8b-4f42-883f-51c8f36495a4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d759cd08-9361-4e44-b830-c09db5c82c1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_4259ef24-bf58-41e3-8b45-c1c84449634d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aa42795-953a-4b9f-bb7a-1af894b38386" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_4259ef24-bf58-41e3-8b45-c1c84449634d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4259ef24-bf58-41e3-8b45-c1c84449634d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_4259ef24-bf58-41e3-8b45-c1c84449634d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4259ef24-bf58-41e3-8b45-c1c84449634d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_bf4ce205-b695-4d75-a115-e7f0e5f7bfa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_4259ef24-bf58-41e3-8b45-c1c84449634d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_bf4ce205-b695-4d75-a115-e7f0e5f7bfa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_c950c6e0-d245-44fe-bbb0-658593aa316f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_bf4ce205-b695-4d75-a115-e7f0e5f7bfa5" xlink:to="loc_us-gaap_MoneyMarketFundsMember_c950c6e0-d245-44fe-bbb0-658593aa316f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7b6f9238-4cee-4ab8-9cb3-67f97dc4a834" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aa42795-953a-4b9f-bb7a-1af894b38386" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7b6f9238-4cee-4ab8-9cb3-67f97dc4a834" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7b6f9238-4cee-4ab8-9cb3-67f97dc4a834_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7b6f9238-4cee-4ab8-9cb3-67f97dc4a834" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7b6f9238-4cee-4ab8-9cb3-67f97dc4a834_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_11422d91-6b72-4489-89e1-8520072b09a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7b6f9238-4cee-4ab8-9cb3-67f97dc4a834" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_11422d91-6b72-4489-89e1-8520072b09a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_89ad74e8-9069-435b-b9fa-311ed1532636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_11422d91-6b72-4489-89e1-8520072b09a4" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_89ad74e8-9069-435b-b9fa-311ed1532636" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6c894066-ecb7-4fce-ad86-481355c29f75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_11422d91-6b72-4489-89e1-8520072b09a4" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6c894066-ecb7-4fce-ad86-481355c29f75" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/MarketablesecuritiesDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#MarketablesecuritiesDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/MarketablesecuritiesDetails" xlink:type="extended" id="i7f0a32ca77914bd9937b78fd1973ba71_MarketablesecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_61280188-b238-4abf-90a4-5f4afccc97a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_21d498c9-8aef-4fb2-8566-fcb5c7afce31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_61280188-b238-4abf-90a4-5f4afccc97a1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_21d498c9-8aef-4fb2-8566-fcb5c7afce31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f32505f2-5912-4c27-8423-dd81ee7e268a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_21d498c9-8aef-4fb2-8566-fcb5c7afce31" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f32505f2-5912-4c27-8423-dd81ee7e268a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8b3a9674-9df2-417b-a5a1-582faff9b69e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_21d498c9-8aef-4fb2-8566-fcb5c7afce31" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8b3a9674-9df2-417b-a5a1-582faff9b69e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_db5cc9e6-0c8a-46e7-b8ac-d3e089a9178f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_21d498c9-8aef-4fb2-8566-fcb5c7afce31" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_db5cc9e6-0c8a-46e7-b8ac-d3e089a9178f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0e92aae5-0eff-4388-be6c-2428598f633a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_21d498c9-8aef-4fb2-8566-fcb5c7afce31" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0e92aae5-0eff-4388-be6c-2428598f633a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7b5e5056-dfbb-4585-a845-df627d579ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_61280188-b238-4abf-90a4-5f4afccc97a1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7b5e5056-dfbb-4585-a845-df627d579ff0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8e0bbc69-da12-4fc8-9c5f-dc222a17c7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7b5e5056-dfbb-4585-a845-df627d579ff0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8e0bbc69-da12-4fc8-9c5f-dc222a17c7ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8e0bbc69-da12-4fc8-9c5f-dc222a17c7ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8e0bbc69-da12-4fc8-9c5f-dc222a17c7ba" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8e0bbc69-da12-4fc8-9c5f-dc222a17c7ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_050d398e-5189-43ea-88cc-6ec6d8ed031b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8e0bbc69-da12-4fc8-9c5f-dc222a17c7ba" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_050d398e-5189-43ea-88cc-6ec6d8ed031b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_ccf74423-6970-4ece-94a4-c7c0c5351324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_050d398e-5189-43ea-88cc-6ec6d8ed031b" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_ccf74423-6970-4ece-94a4-c7c0c5351324" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5e1e4ca9-00a5-4ab8-8139-a53ce8e4ddda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_050d398e-5189-43ea-88cc-6ec6d8ed031b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_5e1e4ca9-00a5-4ab8-8139-a53ce8e4ddda" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/EquityBasedCompensation2019equityincentiveplanDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#EquityBasedCompensation2019equityincentiveplanDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/EquityBasedCompensation2019equityincentiveplanDetails" xlink:type="extended" id="i207dfe7e56c74bc898a0efa46cafeefc_EquityBasedCompensation2019equityincentiveplanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5ff625e3-fafd-448c-bc60-4e881f7b20ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_464298f0-07aa-4d77-b030-641d4f65c60b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5ff625e3-fafd-448c-bc60-4e881f7b20ac" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_464298f0-07aa-4d77-b030-641d4f65c60b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_aa09f445-d9a0-4356-bf71-68aaeb386e41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5ff625e3-fafd-448c-bc60-4e881f7b20ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_aa09f445-d9a0-4356-bf71-68aaeb386e41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7e5936c-559f-45c1-a011-658ce4e7a7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5ff625e3-fafd-448c-bc60-4e881f7b20ac" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7e5936c-559f-45c1-a011-658ce4e7a7fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_16931b30-f79c-4900-b5f1-445fc6eda4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7e5936c-559f-45c1-a011-658ce4e7a7fe" xlink:to="loc_us-gaap_PlanNameAxis_16931b30-f79c-4900-b5f1-445fc6eda4fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_16931b30-f79c-4900-b5f1-445fc6eda4fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_16931b30-f79c-4900-b5f1-445fc6eda4fc" xlink:to="loc_us-gaap_PlanNameDomain_16931b30-f79c-4900-b5f1-445fc6eda4fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a7d0c022-192d-420b-baed-1c34ea5bfe15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_16931b30-f79c-4900-b5f1-445fc6eda4fc" xlink:to="loc_us-gaap_PlanNameDomain_a7d0c022-192d-420b-baed-1c34ea5bfe15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_TwoThousandNineteenStockIncentivePlanMember_b99ebeef-c00f-422a-9db6-af4274bfcedf" xlink:href="morf-20210930.xsd#morf_TwoThousandNineteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a7d0c022-192d-420b-baed-1c34ea5bfe15" xlink:to="loc_morf_TwoThousandNineteenStockIncentivePlanMember_b99ebeef-c00f-422a-9db6-af4274bfcedf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#EquityBasedCompensationEquitybasedcompensationexpenseDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails" xlink:type="extended" id="i64f7f8576be849ccab68db17bbcfbf35_EquityBasedCompensationEquitybasedcompensationexpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_eac6f9dc-dde6-4ccd-a69d-8058b1f96d29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_54083568-b347-4fcb-8261-038b8cf63dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_eac6f9dc-dde6-4ccd-a69d-8058b1f96d29" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_54083568-b347-4fcb-8261-038b8cf63dfc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5dec3ad5-bbb3-402c-829b-64189df3446b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_eac6f9dc-dde6-4ccd-a69d-8058b1f96d29" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5dec3ad5-bbb3-402c-829b-64189df3446b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_43ace14c-1d62-4095-8eef-288fe9c92174" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5dec3ad5-bbb3-402c-829b-64189df3446b" xlink:to="loc_us-gaap_AwardTypeAxis_43ace14c-1d62-4095-8eef-288fe9c92174" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_43ace14c-1d62-4095-8eef-288fe9c92174_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_43ace14c-1d62-4095-8eef-288fe9c92174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_43ace14c-1d62-4095-8eef-288fe9c92174_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eadcba89-e4ca-48b2-b4cf-cb9105392d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_43ace14c-1d62-4095-8eef-288fe9c92174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eadcba89-e4ca-48b2-b4cf-cb9105392d5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1727c675-cd8b-4477-bf98-4d51615c3985" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eadcba89-e4ca-48b2-b4cf-cb9105392d5f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1727c675-cd8b-4477-bf98-4d51615c3985" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_250096eb-9cc9-4dc0-aa2b-ad3d013abda6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eadcba89-e4ca-48b2-b4cf-cb9105392d5f" xlink:to="loc_us-gaap_RestrictedStockMember_250096eb-9cc9-4dc0-aa2b-ad3d013abda6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f71f688f-f646-4fda-a5e0-5e3350f48272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eadcba89-e4ca-48b2-b4cf-cb9105392d5f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f71f688f-f646-4fda-a5e0-5e3350f48272" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_20deb25f-95c3-40ed-bc22-5482a57ee566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eadcba89-e4ca-48b2-b4cf-cb9105392d5f" xlink:to="loc_us-gaap_EmployeeStockMember_20deb25f-95c3-40ed-bc22-5482a57ee566" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_11539290-1dbb-49ba-8eaf-85d2d8b2df24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5dec3ad5-bbb3-402c-829b-64189df3446b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_11539290-1dbb-49ba-8eaf-85d2d8b2df24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_11539290-1dbb-49ba-8eaf-85d2d8b2df24_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_11539290-1dbb-49ba-8eaf-85d2d8b2df24" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_11539290-1dbb-49ba-8eaf-85d2d8b2df24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5fa9f44f-7351-4fe9-aa4e-1928d20127eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_11539290-1dbb-49ba-8eaf-85d2d8b2df24" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5fa9f44f-7351-4fe9-aa4e-1928d20127eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_30ecd389-17a2-4370-97fd-56e1eaae67f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5fa9f44f-7351-4fe9-aa4e-1928d20127eb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_30ecd389-17a2-4370-97fd-56e1eaae67f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_19dcdf24-0661-4287-9aa8-7d7fd7e54b48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5fa9f44f-7351-4fe9-aa4e-1928d20127eb" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_19dcdf24-0661-4287-9aa8-7d7fd7e54b48" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#EquityBasedCompensationRestrictedcommonstockactivityDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails" xlink:type="extended" id="i29f9b6861d294ab1a7d3633163d8d990_EquityBasedCompensationRestrictedcommonstockactivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d425aa0-5946-47a1-b423-2ca378f4876f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_976b576c-24a1-4cb7-aeb8-658cdb191105" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d425aa0-5946-47a1-b423-2ca378f4876f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_976b576c-24a1-4cb7-aeb8-658cdb191105" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7e3b2156-bcdc-45bd-86ee-68e491447294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_976b576c-24a1-4cb7-aeb8-658cdb191105" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7e3b2156-bcdc-45bd-86ee-68e491447294" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f3ab5733-96ca-4f56-87dd-ae5a89938d10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_976b576c-24a1-4cb7-aeb8-658cdb191105" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f3ab5733-96ca-4f56-87dd-ae5a89938d10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b9da25f1-f446-4d8a-a576-f797acfa35c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_976b576c-24a1-4cb7-aeb8-658cdb191105" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b9da25f1-f446-4d8a-a576-f797acfa35c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_60613f1a-7172-49cc-906e-128b29b44abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_976b576c-24a1-4cb7-aeb8-658cdb191105" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_60613f1a-7172-49cc-906e-128b29b44abe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d119d313-f7d8-42e8-a67f-f89d84122cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_227b7f69-94c1-4280-bed5-70ecaf22c579" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d425aa0-5946-47a1-b423-2ca378f4876f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_227b7f69-94c1-4280-bed5-70ecaf22c579" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f8ebccac-7632-4bbc-a522-60408c354ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_227b7f69-94c1-4280-bed5-70ecaf22c579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f8ebccac-7632-4bbc-a522-60408c354ad9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fb7ec4bb-3ea1-4207-bbf5-ea13fd087031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_227b7f69-94c1-4280-bed5-70ecaf22c579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fb7ec4bb-3ea1-4207-bbf5-ea13fd087031" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2d40cc71-beb4-403f-aab0-b58f2c99ec56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_227b7f69-94c1-4280-bed5-70ecaf22c579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2d40cc71-beb4-403f-aab0-b58f2c99ec56" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c23501f0-eb0f-4bbd-80c8-f20376d6ceb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_227b7f69-94c1-4280-bed5-70ecaf22c579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c23501f0-eb0f-4bbd-80c8-f20376d6ceb1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_87bb26b3-19d9-4df1-88c7-f18b265478f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_62971360-e990-41cb-846b-522ba7e8fcaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d425aa0-5946-47a1-b423-2ca378f4876f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_62971360-e990-41cb-846b-522ba7e8fcaf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_88c8f5f7-9a86-43f7-9fda-719466733d94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d425aa0-5946-47a1-b423-2ca378f4876f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_88c8f5f7-9a86-43f7-9fda-719466733d94" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e87ef1f6-46fa-4933-aa67-ed734c590720" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d425aa0-5946-47a1-b423-2ca378f4876f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e87ef1f6-46fa-4933-aa67-ed734c590720" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_670955ab-f5cd-459e-8851-0a520d2a1b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e87ef1f6-46fa-4933-aa67-ed734c590720" xlink:to="loc_us-gaap_PlanNameAxis_670955ab-f5cd-459e-8851-0a520d2a1b4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_670955ab-f5cd-459e-8851-0a520d2a1b4e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_670955ab-f5cd-459e-8851-0a520d2a1b4e" xlink:to="loc_us-gaap_PlanNameDomain_670955ab-f5cd-459e-8851-0a520d2a1b4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e59048a0-a2e9-4b3c-be52-9b1a85cab6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_670955ab-f5cd-459e-8851-0a520d2a1b4e" xlink:to="loc_us-gaap_PlanNameDomain_e59048a0-a2e9-4b3c-be52-9b1a85cab6ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_TwoThousandNineteenStockIncentivePlanMember_bd518120-f83e-486b-aef2-2ec9ca1d4b44" xlink:href="morf-20210930.xsd#morf_TwoThousandNineteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e59048a0-a2e9-4b3c-be52-9b1a85cab6ea" xlink:to="loc_morf_TwoThousandNineteenStockIncentivePlanMember_bd518120-f83e-486b-aef2-2ec9ca1d4b44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1feb3b74-c47c-4868-8aad-7c8db6263938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e87ef1f6-46fa-4933-aa67-ed734c590720" xlink:to="loc_us-gaap_AwardTypeAxis_1feb3b74-c47c-4868-8aad-7c8db6263938" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1feb3b74-c47c-4868-8aad-7c8db6263938_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1feb3b74-c47c-4868-8aad-7c8db6263938" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1feb3b74-c47c-4868-8aad-7c8db6263938_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a2a70e9-a5fd-43fe-a2d6-240c35885417" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1feb3b74-c47c-4868-8aad-7c8db6263938" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a2a70e9-a5fd-43fe-a2d6-240c35885417" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_74c686ab-6165-47a1-b36b-936c66190544" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a2a70e9-a5fd-43fe-a2d6-240c35885417" xlink:to="loc_us-gaap_RestrictedStockMember_74c686ab-6165-47a1-b36b-936c66190544" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#EquityBasedCompensationRestrictedstockunitsactivityDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails" xlink:type="extended" id="i1fbc8da1c3a64f7c981d2603b5e3ae1c_EquityBasedCompensationRestrictedstockunitsactivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e7d20397-4671-403d-b90b-9c5f1c378e84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97cbb6a6-fe60-497d-b537-39940b2f947d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e7d20397-4671-403d-b90b-9c5f1c378e84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97cbb6a6-fe60-497d-b537-39940b2f947d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4ae7cea3-0f0e-4456-89c4-b47dd3b33c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97cbb6a6-fe60-497d-b537-39940b2f947d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4ae7cea3-0f0e-4456-89c4-b47dd3b33c0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a9aa4b8a-ff74-4ff1-b0e3-e5d3e9889380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97cbb6a6-fe60-497d-b537-39940b2f947d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a9aa4b8a-ff74-4ff1-b0e3-e5d3e9889380" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5b36fe3c-b1f5-49c6-a42a-6672493e8f37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97cbb6a6-fe60-497d-b537-39940b2f947d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5b36fe3c-b1f5-49c6-a42a-6672493e8f37" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9b4a3c8a-27da-4c86-a919-2150d4e44904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97cbb6a6-fe60-497d-b537-39940b2f947d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9b4a3c8a-27da-4c86-a919-2150d4e44904" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_354b046e-ca2c-4367-9183-8ba2a0b509c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6218039f-3c5e-4ad5-9e77-7f52d9c5ff08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e7d20397-4671-403d-b90b-9c5f1c378e84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6218039f-3c5e-4ad5-9e77-7f52d9c5ff08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0e14b2b8-12b8-47d3-9fc8-f4433e396710" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6218039f-3c5e-4ad5-9e77-7f52d9c5ff08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0e14b2b8-12b8-47d3-9fc8-f4433e396710" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a10ec7b5-8bb1-47cc-a96a-616bc91b3a60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6218039f-3c5e-4ad5-9e77-7f52d9c5ff08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a10ec7b5-8bb1-47cc-a96a-616bc91b3a60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1be903a2-8260-41ea-9352-01afe4ddab9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6218039f-3c5e-4ad5-9e77-7f52d9c5ff08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1be903a2-8260-41ea-9352-01afe4ddab9a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_daad0dc6-1817-449e-b5ff-0291007bb73c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6218039f-3c5e-4ad5-9e77-7f52d9c5ff08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_daad0dc6-1817-449e-b5ff-0291007bb73c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d2e6c711-c7a3-470c-9b55-fa5960affff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ce5a01c7-7c71-43ef-b94a-76d30783430a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e7d20397-4671-403d-b90b-9c5f1c378e84" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ce5a01c7-7c71-43ef-b94a-76d30783430a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6a785795-e946-43a3-9687-1fb42938bab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e7d20397-4671-403d-b90b-9c5f1c378e84" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6a785795-e946-43a3-9687-1fb42938bab7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19a99378-0ea3-4c04-8f52-bf53a1060e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e7d20397-4671-403d-b90b-9c5f1c378e84" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19a99378-0ea3-4c04-8f52-bf53a1060e5c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_edda2658-5751-41b0-b5eb-c715acb34ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19a99378-0ea3-4c04-8f52-bf53a1060e5c" xlink:to="loc_us-gaap_PlanNameAxis_edda2658-5751-41b0-b5eb-c715acb34ace" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_edda2658-5751-41b0-b5eb-c715acb34ace_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_edda2658-5751-41b0-b5eb-c715acb34ace" xlink:to="loc_us-gaap_PlanNameDomain_edda2658-5751-41b0-b5eb-c715acb34ace_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_75035377-3a7e-4e7a-b7e1-bc1176176c37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_edda2658-5751-41b0-b5eb-c715acb34ace" xlink:to="loc_us-gaap_PlanNameDomain_75035377-3a7e-4e7a-b7e1-bc1176176c37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_TwoThousandNineteenStockIncentivePlanMember_ca451ee6-5077-4685-b147-04bfbb326bc8" xlink:href="morf-20210930.xsd#morf_TwoThousandNineteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_75035377-3a7e-4e7a-b7e1-bc1176176c37" xlink:to="loc_morf_TwoThousandNineteenStockIncentivePlanMember_ca451ee6-5077-4685-b147-04bfbb326bc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0abf3799-d77b-4f16-8309-7b8815c5b041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19a99378-0ea3-4c04-8f52-bf53a1060e5c" xlink:to="loc_us-gaap_AwardTypeAxis_0abf3799-d77b-4f16-8309-7b8815c5b041" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0abf3799-d77b-4f16-8309-7b8815c5b041_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0abf3799-d77b-4f16-8309-7b8815c5b041" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0abf3799-d77b-4f16-8309-7b8815c5b041_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6e65279-6f49-43d4-84d8-1069bfd01356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0abf3799-d77b-4f16-8309-7b8815c5b041" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6e65279-6f49-43d4-84d8-1069bfd01356" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_626f7ee0-a900-45da-9a90-215ca02ceb63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6e65279-6f49-43d4-84d8-1069bfd01356" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_626f7ee0-a900-45da-9a90-215ca02ceb63" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#EquityBasedCompensationStockoptionawardsDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails" xlink:type="extended" id="i1906fb18288a4f6ab66dfb58f89db8ee_EquityBasedCompensationStockoptionawardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff61e11b-5ceb-4a8d-bf9c-64b38040553f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5f181749-4d1d-4db9-8438-ec881f8a74b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff61e11b-5ceb-4a8d-bf9c-64b38040553f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5f181749-4d1d-4db9-8438-ec881f8a74b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f9a17a9f-4b99-4916-95c5-d6f8f00aa865" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5f181749-4d1d-4db9-8438-ec881f8a74b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f9a17a9f-4b99-4916-95c5-d6f8f00aa865" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019a3eb6-2d15-4699-bd48-5b988dc79185" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5f181749-4d1d-4db9-8438-ec881f8a74b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019a3eb6-2d15-4699-bd48-5b988dc79185" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4ec71b44-79e6-4b79-8d7a-7fd24eacf86c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5f181749-4d1d-4db9-8438-ec881f8a74b3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4ec71b44-79e6-4b79-8d7a-7fd24eacf86c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d946d7a0-11f9-4f19-bb79-96441737958b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5f181749-4d1d-4db9-8438-ec881f8a74b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d946d7a0-11f9-4f19-bb79-96441737958b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_25765250-a54e-40a6-9733-6bc343be4dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ab4d30fe-f616-44ef-933c-bbb211ea8c11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff61e11b-5ceb-4a8d-bf9c-64b38040553f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ab4d30fe-f616-44ef-933c-bbb211ea8c11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5dcc55ab-48eb-4336-a0db-5c4c7a5a3a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff61e11b-5ceb-4a8d-bf9c-64b38040553f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5dcc55ab-48eb-4336-a0db-5c4c7a5a3a7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bd2784af-36fa-4279-825c-9972d8fb156c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5dcc55ab-48eb-4336-a0db-5c4c7a5a3a7b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bd2784af-36fa-4279-825c-9972d8fb156c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cf6a1690-ac66-40a6-890e-df6d70ce9d56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5dcc55ab-48eb-4336-a0db-5c4c7a5a3a7b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cf6a1690-ac66-40a6-890e-df6d70ce9d56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_73a7d612-0f94-449a-9493-82d65486ffd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5dcc55ab-48eb-4336-a0db-5c4c7a5a3a7b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_73a7d612-0f94-449a-9493-82d65486ffd2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f4648a3d-b9b0-4ea9-a85d-a3b70ac1d4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5dcc55ab-48eb-4336-a0db-5c4c7a5a3a7b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f4648a3d-b9b0-4ea9-a85d-a3b70ac1d4a4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f0f2611f-8dff-4668-a765-4bd7b46dcca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c38182cf-aa12-47f1-a7a9-7235db4c9b31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff61e11b-5ceb-4a8d-bf9c-64b38040553f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c38182cf-aa12-47f1-a7a9-7235db4c9b31" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ab175b42-3749-4e35-aa40-8947ebe0c6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff61e11b-5ceb-4a8d-bf9c-64b38040553f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ab175b42-3749-4e35-aa40-8947ebe0c6ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8b6154ef-8e62-41d9-8287-f6ae2b62811c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ab175b42-3749-4e35-aa40-8947ebe0c6ec" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8b6154ef-8e62-41d9-8287-f6ae2b62811c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6979b22f-4d36-4139-9280-8be1c468d4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ab175b42-3749-4e35-aa40-8947ebe0c6ec" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6979b22f-4d36-4139-9280-8be1c468d4b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_12c96601-e5b4-40a3-a8c2-394e4c54877f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ab175b42-3749-4e35-aa40-8947ebe0c6ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_12c96601-e5b4-40a3-a8c2-394e4c54877f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6b4d6828-388f-44ef-9c2a-73992c984c61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f33e588c-b4de-4884-8c33-dd45dd94a7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ab175b42-3749-4e35-aa40-8947ebe0c6ec" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f33e588c-b4de-4884-8c33-dd45dd94a7e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b27c27f7-cedc-413e-bd84-82c8320afc7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ab175b42-3749-4e35-aa40-8947ebe0c6ec" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b27c27f7-cedc-413e-bd84-82c8320afc7a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dc207030-f214-4761-8e6d-83fb07064a72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ab175b42-3749-4e35-aa40-8947ebe0c6ec" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dc207030-f214-4761-8e6d-83fb07064a72" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea5ecbd3-5e87-49a0-901d-97b758397a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff61e11b-5ceb-4a8d-bf9c-64b38040553f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea5ecbd3-5e87-49a0-901d-97b758397a5f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_31254e97-b82b-4254-b91d-0c623df53315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea5ecbd3-5e87-49a0-901d-97b758397a5f" xlink:to="loc_us-gaap_PlanNameAxis_31254e97-b82b-4254-b91d-0c623df53315" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_31254e97-b82b-4254-b91d-0c623df53315_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_31254e97-b82b-4254-b91d-0c623df53315" xlink:to="loc_us-gaap_PlanNameDomain_31254e97-b82b-4254-b91d-0c623df53315_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fc783f2f-9ccf-4a1b-9a58-fb02537d8d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_31254e97-b82b-4254-b91d-0c623df53315" xlink:to="loc_us-gaap_PlanNameDomain_fc783f2f-9ccf-4a1b-9a58-fb02537d8d7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_TwoThousandNineteenStockIncentivePlanMember_d3eaf0d4-e443-4272-94d8-156bda8ad745" xlink:href="morf-20210930.xsd#morf_TwoThousandNineteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_fc783f2f-9ccf-4a1b-9a58-fb02537d8d7a" xlink:to="loc_morf_TwoThousandNineteenStockIncentivePlanMember_d3eaf0d4-e443-4272-94d8-156bda8ad745" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c65969d4-34b1-480b-89d5-18ecf4e204dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea5ecbd3-5e87-49a0-901d-97b758397a5f" xlink:to="loc_us-gaap_AwardTypeAxis_c65969d4-34b1-480b-89d5-18ecf4e204dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c65969d4-34b1-480b-89d5-18ecf4e204dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c65969d4-34b1-480b-89d5-18ecf4e204dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c65969d4-34b1-480b-89d5-18ecf4e204dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84bb0580-3842-48bb-b224-331755276320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c65969d4-34b1-480b-89d5-18ecf4e204dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84bb0580-3842-48bb-b224-331755276320" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e525cb05-5ca7-461b-b323-c55b8f5ab5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84bb0580-3842-48bb-b224-331755276320" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e525cb05-5ca7-461b-b323-c55b8f5ab5dc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/EquityBasedCompensationESPPDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#EquityBasedCompensationESPPDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/EquityBasedCompensationESPPDetails" xlink:type="extended" id="i16fe2d59b1dd415596b4323b5a19759e_EquityBasedCompensationESPPDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50e4e8cb-bee3-4ddb-a492-9427554be6df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ca37415d-1dc9-465a-9f17-24ca3b7d8cab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50e4e8cb-bee3-4ddb-a492-9427554be6df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ca37415d-1dc9-465a-9f17-24ca3b7d8cab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a7354206-0254-4418-a3fe-5a411692d649" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50e4e8cb-bee3-4ddb-a492-9427554be6df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a7354206-0254-4418-a3fe-5a411692d649" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee_1f2b6c9b-3d24-4ac7-b397-c11bd7fdb638" xlink:href="morf-20210930.xsd#morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50e4e8cb-bee3-4ddb-a492-9427554be6df" xlink:to="loc_morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee_1f2b6c9b-3d24-4ac7-b397-c11bd7fdb638" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock_89fb27bd-4fce-45c3-a0a7-e9f35a8dc6af" xlink:href="morf-20210930.xsd#morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50e4e8cb-bee3-4ddb-a492-9427554be6df" xlink:to="loc_morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock_89fb27bd-4fce-45c3-a0a7-e9f35a8dc6af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_210e722f-389b-40fc-9fe7-5bd9db5049d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50e4e8cb-bee3-4ddb-a492-9427554be6df" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_210e722f-389b-40fc-9fe7-5bd9db5049d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_48492998-5cf2-47a9-a549-52b6e57542aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_210e722f-389b-40fc-9fe7-5bd9db5049d8" xlink:to="loc_us-gaap_PlanNameAxis_48492998-5cf2-47a9-a549-52b6e57542aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_48492998-5cf2-47a9-a549-52b6e57542aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_48492998-5cf2-47a9-a549-52b6e57542aa" xlink:to="loc_us-gaap_PlanNameDomain_48492998-5cf2-47a9-a549-52b6e57542aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9ae499ce-575a-4136-9d67-34d5e17a7e35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_48492998-5cf2-47a9-a549-52b6e57542aa" xlink:to="loc_us-gaap_PlanNameDomain_9ae499ce-575a-4136-9d67-34d5e17a7e35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_EmployeeStockPurchasePlanMember_fdb49ec5-2271-4815-9918-ece98c65e84b" xlink:href="morf-20210930.xsd#morf_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9ae499ce-575a-4136-9d67-34d5e17a7e35" xlink:to="loc_morf_EmployeeStockPurchasePlanMember_fdb49ec5-2271-4815-9918-ece98c65e84b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e97a15de-4ed2-4c4e-a8da-1ad918eb1afc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_210e722f-389b-40fc-9fe7-5bd9db5049d8" xlink:to="loc_srt_RangeAxis_e97a15de-4ed2-4c4e-a8da-1ad918eb1afc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e97a15de-4ed2-4c4e-a8da-1ad918eb1afc_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e97a15de-4ed2-4c4e-a8da-1ad918eb1afc" xlink:to="loc_srt_RangeMember_e97a15de-4ed2-4c4e-a8da-1ad918eb1afc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_154b7ebb-cf6e-4329-9a5a-d25bad5b5912" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e97a15de-4ed2-4c4e-a8da-1ad918eb1afc" xlink:to="loc_srt_RangeMember_154b7ebb-cf6e-4329-9a5a-d25bad5b5912" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a5100f67-c4de-4cd3-a80b-4c1a230cab30" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_154b7ebb-cf6e-4329-9a5a-d25bad5b5912" xlink:to="loc_srt_MaximumMember_a5100f67-c4de-4cd3-a80b-4c1a230cab30" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="ifa7991f00e8b4a86bde63d48a471444c_CommitmentsandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_563344ad-3f53-4fe6-96c4-a185e1f07260" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_d423f8f9-8942-4dce-b462-3592111ed051" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfLand"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_563344ad-3f53-4fe6-96c4-a185e1f07260" xlink:to="loc_us-gaap_AreaOfLand_d423f8f9-8942-4dce-b462-3592111ed051" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_e2275348-b9e2-44c4-a491-47efb005e008" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_563344ad-3f53-4fe6-96c4-a185e1f07260" xlink:to="loc_us-gaap_OtherCommitmentsTable_e2275348-b9e2-44c4-a491-47efb005e008" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_0ef9ea2e-8427-4c1e-b692-2dc73e9d9fbc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_e2275348-b9e2-44c4-a491-47efb005e008" xlink:to="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_0ef9ea2e-8427-4c1e-b692-2dc73e9d9fbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_0ef9ea2e-8427-4c1e-b692-2dc73e9d9fbc_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_0ef9ea2e-8427-4c1e-b692-2dc73e9d9fbc" xlink:to="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_0ef9ea2e-8427-4c1e-b692-2dc73e9d9fbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_ac23e6ac-2d61-4114-a84d-7399111918e0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_0ef9ea2e-8427-4c1e-b692-2dc73e9d9fbc" xlink:to="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_ac23e6ac-2d61-4114-a84d-7399111918e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_OfficeAndLaboratorySpaceMember_33aeb115-7744-4644-9521-9ba03024dfd9" xlink:href="morf-20210930.xsd#morf_OfficeAndLaboratorySpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_ac23e6ac-2d61-4114-a84d-7399111918e0" xlink:to="loc_morf_OfficeAndLaboratorySpaceMember_33aeb115-7744-4644-9521-9ba03024dfd9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#OptionandLicenseAgreementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails" xlink:type="extended" id="i28f23db271f34e418918332073178015_OptionandLicenseAgreementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8966931-469e-4b4d-b87c-7d6fcb2424ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f1562b2a-6236-4d6b-aa89-4646d5da6bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8966931-469e-4b4d-b87c-7d6fcb2424ec" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f1562b2a-6236-4d6b-aa89-4646d5da6bc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_ea89718f-5458-46e4-82e7-2729a4a44470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8966931-469e-4b4d-b87c-7d6fcb2424ec" xlink:to="loc_us-gaap_ContractWithCustomerLiability_ea89718f-5458-46e4-82e7-2729a4a44470" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_3cfe2927-261a-4bb3-b65e-b5512af8dd60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8966931-469e-4b4d-b87c-7d6fcb2424ec" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_3cfe2927-261a-4bb3-b65e-b5512af8dd60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0cb898b9-b370-4b13-ae3d-4283bff6efe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8966931-469e-4b4d-b87c-7d6fcb2424ec" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0cb898b9-b370-4b13-ae3d-4283bff6efe0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d2de72b8-a8c1-46be-aabc-ab591307ad3f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0cb898b9-b370-4b13-ae3d-4283bff6efe0" xlink:to="loc_srt_CounterpartyNameAxis_d2de72b8-a8c1-46be-aabc-ab591307ad3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d2de72b8-a8c1-46be-aabc-ab591307ad3f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d2de72b8-a8c1-46be-aabc-ab591307ad3f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d2de72b8-a8c1-46be-aabc-ab591307ad3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_70ffd935-ece2-4340-bc05-e3a285f70c49" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d2de72b8-a8c1-46be-aabc-ab591307ad3f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_70ffd935-ece2-4340-bc05-e3a285f70c49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AbbVieMember_c3662e3a-6b3f-49eb-893b-0b111867e108" xlink:href="morf-20210930.xsd#morf_AbbVieMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_70ffd935-ece2-4340-bc05-e3a285f70c49" xlink:to="loc_morf_AbbVieMember_c3662e3a-6b3f-49eb-893b-0b111867e108" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_JanssenPharmaceuticalsIncMember_12909a33-ce8c-4ccd-bc92-0be8843a5d2e" xlink:href="morf-20210930.xsd#morf_JanssenPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_70ffd935-ece2-4340-bc05-e3a285f70c49" xlink:to="loc_morf_JanssenPharmaceuticalsIncMember_12909a33-ce8c-4ccd-bc92-0be8843a5d2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_43569f68-2ce3-4a15-a26e-503883357d6e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0cb898b9-b370-4b13-ae3d-4283bff6efe0" xlink:to="loc_srt_ProductOrServiceAxis_43569f68-2ce3-4a15-a26e-503883357d6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_43569f68-2ce3-4a15-a26e-503883357d6e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_43569f68-2ce3-4a15-a26e-503883357d6e" xlink:to="loc_srt_ProductsAndServicesDomain_43569f68-2ce3-4a15-a26e-503883357d6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c00edc74-0150-44e5-bc96-5bec84406df0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_43569f68-2ce3-4a15-a26e-503883357d6e" xlink:to="loc_srt_ProductsAndServicesDomain_c00edc74-0150-44e5-bc96-5bec84406df0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_UpfrontPaymentRevenueMember_4442aa1e-8874-4483-a668-da0074f69ed5" xlink:href="morf-20210930.xsd#morf_UpfrontPaymentRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c00edc74-0150-44e5-bc96-5bec84406df0" xlink:to="loc_morf_UpfrontPaymentRevenueMember_4442aa1e-8874-4483-a668-da0074f69ed5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_3ae27cf1-5efd-4088-87bd-878f74dd6c20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c00edc74-0150-44e5-bc96-5bec84406df0" xlink:to="loc_us-gaap_LicenseMember_3ae27cf1-5efd-4088-87bd-878f74dd6c20" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails" xlink:type="extended" id="i25e8b2549d1e4f3cb388cfc5520eb1b9_OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7fde0b0c-b3b6-42f5-b68f-fc5dd3a2f165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5d2f5ed8-d346-4457-bdfd-c1449f4626ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7fde0b0c-b3b6-42f5-b68f-fc5dd3a2f165" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5d2f5ed8-d346-4457-bdfd-c1449f4626ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_616be0dd-0329-49e2-9b24-18d0499d201a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7fde0b0c-b3b6-42f5-b68f-fc5dd3a2f165" xlink:to="loc_us-gaap_CostsAndExpenses_616be0dd-0329-49e2-9b24-18d0499d201a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f18b8493-784f-4cdd-bde4-1acde8775c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7fde0b0c-b3b6-42f5-b68f-fc5dd3a2f165" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f18b8493-784f-4cdd-bde4-1acde8775c15" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0f413d18-33c3-44d1-9278-c3f1597dc0bb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f18b8493-784f-4cdd-bde4-1acde8775c15" xlink:to="loc_srt_CounterpartyNameAxis_0f413d18-33c3-44d1-9278-c3f1597dc0bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0f413d18-33c3-44d1-9278-c3f1597dc0bb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0f413d18-33c3-44d1-9278-c3f1597dc0bb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0f413d18-33c3-44d1-9278-c3f1597dc0bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c8d2e1ab-c5d6-4f7f-99fd-78f7b13587fb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0f413d18-33c3-44d1-9278-c3f1597dc0bb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c8d2e1ab-c5d6-4f7f-99fd-78f7b13587fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AbbVieMember_e460878f-2fdb-44f3-a0b4-415ab28b6844" xlink:href="morf-20210930.xsd#morf_AbbVieMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c8d2e1ab-c5d6-4f7f-99fd-78f7b13587fb" xlink:to="loc_morf_AbbVieMember_e460878f-2fdb-44f3-a0b4-415ab28b6844" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_JanssenPharmaceuticalsIncMember_163886b3-58c1-4c9f-ab10-d6088a9d609c" xlink:href="morf-20210930.xsd#morf_JanssenPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c8d2e1ab-c5d6-4f7f-99fd-78f7b13587fb" xlink:to="loc_morf_JanssenPharmaceuticalsIncMember_163886b3-58c1-4c9f-ab10-d6088a9d609c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c4d2a18a-791c-4c92-8916-15f45f6eee1e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f18b8493-784f-4cdd-bde4-1acde8775c15" xlink:to="loc_srt_ProductOrServiceAxis_c4d2a18a-791c-4c92-8916-15f45f6eee1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c4d2a18a-791c-4c92-8916-15f45f6eee1e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c4d2a18a-791c-4c92-8916-15f45f6eee1e" xlink:to="loc_srt_ProductsAndServicesDomain_c4d2a18a-791c-4c92-8916-15f45f6eee1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0c495a37-40d3-463f-95a6-c5e12f1a9b5a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c4d2a18a-791c-4c92-8916-15f45f6eee1e" xlink:to="loc_srt_ProductsAndServicesDomain_0c495a37-40d3-463f-95a6-c5e12f1a9b5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_78f5c3a8-d22b-464e-aeec-46d02ef63806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0c495a37-40d3-463f-95a6-c5e12f1a9b5a" xlink:to="loc_us-gaap_LicenseMember_78f5c3a8-d22b-464e-aeec-46d02ef63806" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_ReimbursementRevenueMember_7aa60ae8-6b9f-4afe-9d55-7e09c7f1c710" xlink:href="morf-20210930.xsd#morf_ReimbursementRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0c495a37-40d3-463f-95a6-c5e12f1a9b5a" xlink:to="loc_morf_ReimbursementRevenueMember_7aa60ae8-6b9f-4afe-9d55-7e09c7f1c710" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_UpfrontPaymentRevenueMember_d68920e5-cb61-4c51-8021-d1ad2ff5ca71" xlink:href="morf-20210930.xsd#morf_UpfrontPaymentRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0c495a37-40d3-463f-95a6-c5e12f1a9b5a" xlink:to="loc_morf_UpfrontPaymentRevenueMember_d68920e5-cb61-4c51-8021-d1ad2ff5ca71" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/NetLossIncomeperShareBasicnetincomelosspershareDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#NetLossIncomeperShareBasicnetincomelosspershareDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/NetLossIncomeperShareBasicnetincomelosspershareDetails" xlink:type="extended" id="i0a6121d10ad44a1280e3dcc73fc64168_NetLossIncomeperShareBasicnetincomelosspershareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_107da403-b00f-4580-91f4-dd9bffc59bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2eda6a79-fd18-4130-b156-3adbfafab332" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_107da403-b00f-4580-91f4-dd9bffc59bd6" xlink:to="loc_us-gaap_NetIncomeLoss_2eda6a79-fd18-4130-b156-3adbfafab332" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_da84ca02-f6b6-4646-98cd-5f42c2757673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_107da403-b00f-4580-91f4-dd9bffc59bd6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_da84ca02-f6b6-4646-98cd-5f42c2757673" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_307d3d37-2cbf-4cff-b75d-32a4e7d6ff9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_107da403-b00f-4580-91f4-dd9bffc59bd6" xlink:to="loc_us-gaap_EarningsPerShareBasic_307d3d37-2cbf-4cff-b75d-32a4e7d6ff9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d974021c-704c-464c-9d27-fdf47ce3f6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_107da403-b00f-4580-91f4-dd9bffc59bd6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d974021c-704c-464c-9d27-fdf47ce3f6e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_02a8a636-3f48-4f26-bef6-37feb9d044c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_107da403-b00f-4580-91f4-dd9bffc59bd6" xlink:to="loc_us-gaap_EarningsPerShareDiluted_02a8a636-3f48-4f26-bef6-37feb9d044c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4714daa2-ff32-4b32-9ebe-7cc696592082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_107da403-b00f-4580-91f4-dd9bffc59bd6" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4714daa2-ff32-4b32-9ebe-7cc696592082" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_91452b98-8a86-4e79-93ed-6477f9dfa697" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4714daa2-ff32-4b32-9ebe-7cc696592082" xlink:to="loc_us-gaap_AwardTypeAxis_91452b98-8a86-4e79-93ed-6477f9dfa697" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91452b98-8a86-4e79-93ed-6477f9dfa697_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_91452b98-8a86-4e79-93ed-6477f9dfa697" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91452b98-8a86-4e79-93ed-6477f9dfa697_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3da260c0-e2b1-4357-8870-4cd525bbe300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_91452b98-8a86-4e79-93ed-6477f9dfa697" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3da260c0-e2b1-4357-8870-4cd525bbe300" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7dc7a0c3-b6d9-43e0-9a7e-3d8fa66eb89c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3da260c0-e2b1-4357-8870-4cd525bbe300" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7dc7a0c3-b6d9-43e0-9a7e-3d8fa66eb89c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_RestrictedCommonStockAndRestrictedStockUnitsMember_f745e533-85f2-4476-add6-ccfb33e8fb2d" xlink:href="morf-20210930.xsd#morf_RestrictedCommonStockAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3da260c0-e2b1-4357-8870-4cd525bbe300" xlink:to="loc_morf_RestrictedCommonStockAndRestrictedStockUnitsMember_f745e533-85f2-4476-add6-ccfb33e8fb2d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://morphictx.com/role/NetLossIncomeperShareCommonstockequivalentsharesDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#NetLossIncomeperShareCommonstockequivalentsharesDetails"/>
  <link:definitionLink xlink:role="http://morphictx.com/role/NetLossIncomeperShareCommonstockequivalentsharesDetails" xlink:type="extended" id="i5a0481d0163141f9bc60eb97d277380f_NetLossIncomeperShareCommonstockequivalentsharesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_045807d5-0434-4033-b417-632348e0f7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_38c093e9-89d7-4dca-9a9d-afafeabc763f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_045807d5-0434-4033-b417-632348e0f7a6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_38c093e9-89d7-4dca-9a9d-afafeabc763f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1e983ec9-263c-4f00-b3d2-8a678cb5d1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_045807d5-0434-4033-b417-632348e0f7a6" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1e983ec9-263c-4f00-b3d2-8a678cb5d1c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b503c681-bbcc-41d6-9777-ab47875895a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1e983ec9-263c-4f00-b3d2-8a678cb5d1c9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b503c681-bbcc-41d6-9777-ab47875895a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b503c681-bbcc-41d6-9777-ab47875895a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b503c681-bbcc-41d6-9777-ab47875895a9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b503c681-bbcc-41d6-9777-ab47875895a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0c89a915-187c-4f8f-8912-6143ff267115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b503c681-bbcc-41d6-9777-ab47875895a9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0c89a915-187c-4f8f-8912-6143ff267115" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_46b5710b-19ae-48f0-9ec0-6b8033467884" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0c89a915-187c-4f8f-8912-6143ff267115" xlink:to="loc_us-gaap_RestrictedStockMember_46b5710b-19ae-48f0-9ec0-6b8033467884" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d93c0667-b008-4765-9f02-6cb2d2902993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0c89a915-187c-4f8f-8912-6143ff267115" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d93c0667-b008-4765-9f02-6cb2d2902993" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_01ebad91-df07-443c-aabc-55a5a87abe4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0c89a915-187c-4f8f-8912-6143ff267115" xlink:to="loc_us-gaap_EmployeeStockOptionMember_01ebad91-df07-443c-aabc-55a5a87abe4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_EmployeeStockPurchasePlanMember_c8ccb155-246e-4523-a9ef-7328d95c8a0a" xlink:href="morf-20210930.xsd#morf_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0c89a915-187c-4f8f-8912-6143ff267115" xlink:to="loc_morf_EmployeeStockPurchasePlanMember_c8ccb155-246e-4523-a9ef-7328d95c8a0a" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>morf-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a0fdcec5-f1a8-410f-b814-f85a654bede4,g:4b0f2f4e-5307-47a8-ad80-54240ea99d78-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_01641026-56d3-4c21-a935-9f263d09d48a_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_7507bd00-39fe-472d-b88f-378a8a780b79_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_96fffe72-f9f0-4821-8b35-2e808f69dba4_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_750793b9-13e1-4436-9797-07333e8e1019_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_dec1feeb-e7f3-4614-a792-2c85e1c3ef50_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_e1119855-1593-4e64-bba1-68fa5438159d_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_0586f5b8-abbd-4a7a-a4c0-d4e85a2f4118_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_CommonStockAvailableForIssuance_1abb7cab-c85e-4d07-9c20-69c5feaf3643_terseLabel_en-US" xlink:label="lab_morf_CommonStockAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of shares remaining available for sale</link:label>
    <link:label id="lab_morf_CommonStockAvailableForIssuance_label_en-US" xlink:label="lab_morf_CommonStockAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Available For Issuance</link:label>
    <link:label id="lab_morf_CommonStockAvailableForIssuance_documentation_en-US" xlink:label="lab_morf_CommonStockAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of common stock available for issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CommonStockAvailableForIssuance" xlink:href="morf-20210930.xsd#morf_CommonStockAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_CommonStockAvailableForIssuance" xlink:to="lab_morf_CommonStockAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_0c9b6ff5-bb10-4669-b98a-8f71541aa544_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_1ef1817e-e353-4c74-973d-d0274321c6f8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_28204531-3fc5-4b04-83ee-57a03cfb6372_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll and related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_add6f4a1-6d1c-4576-a327-3ed5889353e3_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_ec1c895c-c811-4b4b-bfef-337b0407f841_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_0f1e3fb8-9d13-482f-82e6-dcb7c5c9bbdd_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_6528c3e1-9362-451e-af63-3abff0d64726_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_f37470b0-fc72-4c31-bfbb-ff0fea60515d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_d4f943f4-341b-4d06-a6db-119571097b26_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_e8860d42-1ad3-450e-848b-474df593390d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_17da4c1c-4d1e-4c04-a6f4-c299f22c3f63_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_4db17999-e72c-430d-8072-b0ae5dcfb28c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Subsidiary or Equity Method Investee [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Subsidiary or Equity Method Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="lab_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_37ff08f0-a0fa-4731-88b1-15a2de669cca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_2b047aa0-51d0-4cfc-ad0c-201dc12a42de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reconciled cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_3cc61c4b-762d-42da-81d4-78e526efe573_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_2f4f2934-3876-42c8-89ba-9d01b0bbff93_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_b0fbb27d-4f5b-421b-8214-5469b5c050a4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_89f738e4-c73c-48e1-ae23-88f22400b63b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_ca7898a7-a4fa-4ac6-bd07-4dce012546db_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_44fc64a6-b6b7-477a-8d8a-06dd0481d6eb_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_3a529c47-83d8-4ff3-a92e-c846c38094dc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_38ad61c2-1f7c-4219-8b86-64130abe2d1e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_e424ce11-61f2-4660-9991-473bd2cd5c76_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common shares upon stock option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7ff78f45-0261-4f54-aa69-ae931fb26701_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_20db81fe-d58e-4449-abe5-7c9bd9babd4e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_584927a6-576a-4caf-bf51-01d8c106d013_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7402cd78-fc31-4262-8f59-330285dee0d3_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b3155beb-b447-4205-847d-830dcc877425_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_dc37d402-4460-458b-9e05-11dd691eedf8_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_5ba81556-fe7b-4a13-b388-f1d22956380c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under the Employee Stock Purchase Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Ownership Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_8623ce86-f46a-4612-9ef6-d6ab0676d23f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_3b5914fa-ec6f-40bc-a846-c874c74c55f2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_CollaborativeArrangementDisclosureAbstract_6b45a422-5e5f-4fb3-9dd6-cc757214a2ae_terseLabel_en-US" xlink:label="lab_morf_CollaborativeArrangementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option and License Agreements</link:label>
    <link:label id="lab_morf_CollaborativeArrangementDisclosureAbstract_label_en-US" xlink:label="lab_morf_CollaborativeArrangementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option and License Agreements</link:label>
    <link:label id="lab_morf_CollaborativeArrangementDisclosureAbstract_documentation_en-US" xlink:label="lab_morf_CollaborativeArrangementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementDisclosureAbstract" xlink:href="morf-20210930.xsd#morf_CollaborativeArrangementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_CollaborativeArrangementDisclosureAbstract" xlink:to="lab_morf_CollaborativeArrangementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_0634bf6c-9f95-4791-a9e5-dc1ef1833e15_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of investments in marketable securities classified as available for sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_4e95aeb5-288a-4d89-aaab-cd4cea7467b3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ca91662c-af74-4b6d-9262-69015a6ec51e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_9ecaec31-8e6c-4d6b-8f18-6e97b4c2d327_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_424c6b5a-084c-48b3-afd4-70bfe239b697_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e228bb8e-5d09-4e62-b113-56bd7edee525_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_72f48a42-7cc0-4cff-997a-b177aaf5322f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_da730d00-86e3-432b-b969-c0a7e0150763_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3efa71e4-ff93-407b-83e3-170d4ebcf436_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_IncreaseDecreaseInDeferredRent_d28e8e0d-230b-409f-af1a-79a567ff8375_terseLabel_en-US" xlink:label="lab_morf_IncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_morf_IncreaseDecreaseInDeferredRent_label_en-US" xlink:label="lab_morf_IncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Rent</link:label>
    <link:label id="lab_morf_IncreaseDecreaseInDeferredRent_documentation_en-US" xlink:label="lab_morf_IncreaseDecreaseInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of increase (decrease) in deferred income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_IncreaseDecreaseInDeferredRent" xlink:href="morf-20210930.xsd#morf_IncreaseDecreaseInDeferredRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_IncreaseDecreaseInDeferredRent" xlink:to="lab_morf_IncreaseDecreaseInDeferredRent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c98ae4bd-ea49-4496-9b7f-9665da3b1aeb_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c6f1516a-4f32-47af-a282-a01410ecc400_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_c99950aa-850b-45ed-8397-41587398eb0c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a806c6e8-985d-43e6-a12b-dce232686e29_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti&#8209;dilutive securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4a529386-3b6b-48e3-9bdc-a9341d236267_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized equity based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_5f814174-14a1-40a3-82df-4d043c20b622_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_477b8371-a742-4673-88d3-312464b97934_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_c2bee3e3-4c09-423c-bf13-e8d8ed954e16_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares under the Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Ownership Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_AtTheMarketOfferingMember_e972878a-bb0a-4dde-b1fa-f67c11164858_terseLabel_en-US" xlink:label="lab_morf_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Offering</link:label>
    <link:label id="lab_morf_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_morf_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Offering [Member]</link:label>
    <link:label id="lab_morf_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_morf_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AtTheMarketOfferingMember" xlink:href="morf-20210930.xsd#morf_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_AtTheMarketOfferingMember" xlink:to="lab_morf_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_a507e066-3242-4e1f-9b2f-6bb369959f23_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_31a0aaef-c8b6-46d0-89f6-bfacb2264e9e_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_47e2f3af-4010-458d-9f29-7adaf93b7597_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_OpenMarketSaleAgreementMember_5b3b2d47-37cc-44f7-9bab-804384708457_terseLabel_en-US" xlink:label="lab_morf_OpenMarketSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sale Agreement</link:label>
    <link:label id="lab_morf_OpenMarketSaleAgreementMember_label_en-US" xlink:label="lab_morf_OpenMarketSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sale Agreement [Member]</link:label>
    <link:label id="lab_morf_OpenMarketSaleAgreementMember_documentation_en-US" xlink:label="lab_morf_OpenMarketSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents Open Market Sale Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_OpenMarketSaleAgreementMember" xlink:href="morf-20210930.xsd#morf_OpenMarketSaleAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_OpenMarketSaleAgreementMember" xlink:to="lab_morf_OpenMarketSaleAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_c9382713-b644-4323-95f5-22dc2d34d8cc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_0cc05624-340b-47fd-9a0e-574780564b85_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized equity based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dd51b337-0ae4-43c0-85c2-92edfe1b64f6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_7b8961b9-f094-4809-bb3e-a909c099991d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_075388d0-be85-4156-b4e3-5ebc341a9ccf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding gains (losses) on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_57a43ace-0464-4adf-8e74-6224a9020472_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding losses on marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a6549bb3-d3a0-49a1-ba07-25f20959ddda_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_OfficeAndLaboratorySpaceMember_475eb724-ff41-4f51-b918-0d4a19ac3aeb_terseLabel_en-US" xlink:label="lab_morf_OfficeAndLaboratorySpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Laboratory Space</link:label>
    <link:label id="lab_morf_OfficeAndLaboratorySpaceMember_label_en-US" xlink:label="lab_morf_OfficeAndLaboratorySpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Laboratory Space [Member]</link:label>
    <link:label id="lab_morf_OfficeAndLaboratorySpaceMember_documentation_en-US" xlink:label="lab_morf_OfficeAndLaboratorySpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Laboratory Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_OfficeAndLaboratorySpaceMember" xlink:href="morf-20210930.xsd#morf_OfficeAndLaboratorySpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_OfficeAndLaboratorySpaceMember" xlink:to="lab_morf_OfficeAndLaboratorySpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_37cd0b41-6d89-4dcd-b9e8-22e4fab0ac90_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_242aa007-71ee-4b8c-9449-d7d39ed3dd49_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_190c7e2e-2f59-41e1-a2e1-b602cb6711c2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_726da834-d782-4c8f-b748-59095b2195ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6538e26c-0e5b-43b7-9761-999b29390ff6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable at the end (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_fc186bb3-cf73-488b-9504-ecdb4db1e35f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAbstract_80ae4de4-6a9e-4852-be22-17635373a53e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAbstract_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAbstract" xlink:to="lab_us-gaap_RestrictedCashAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_70316df7-43ae-4d80-8717-e1f12e77e7c0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7a1a6bc5-23e9-4704-aff8-787e271b147a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_0dcc8511-c4a6-4fd7-8c9e-4710edb68c7b_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of September&#160;30, 2021 and December&#160;31, 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e9c2660e-ee49-427b-afc2-22c5e2697310_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cfc5e2a5-1c0e-4881-9ab1-36aa0e35dd4f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_8c3900fe-1186-4241-88a5-f4ceae48917b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_ab72f98f-7778-46f8-bf52-68dab3eac07e_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6f02e40b-12f6-4b78-9022-1b59afd49c69_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_effa3256-faf7-43cd-b458-d4fdebe83dd5_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_cc130483-2969-443d-8a3c-127b9a597c1c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_8413bd94-cbb0-48bb-9f61-eb3782aa5ff9_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c18199bb-3bdf-47e1-b67e-3f4979cd06f1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_ReimbursementRevenueMember_71e90d77-6427-4c74-96a9-dd6dbdda1947_terseLabel_en-US" xlink:label="lab_morf_ReimbursementRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement revenue</link:label>
    <link:label id="lab_morf_ReimbursementRevenueMember_label_en-US" xlink:label="lab_morf_ReimbursementRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Revenue [Member]</link:label>
    <link:label id="lab_morf_ReimbursementRevenueMember_documentation_en-US" xlink:label="lab_morf_ReimbursementRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_ReimbursementRevenueMember" xlink:href="morf-20210930.xsd#morf_ReimbursementRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_ReimbursementRevenueMember" xlink:to="lab_morf_ReimbursementRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_181abc42-9d63-41d4-8772-dae089ef6af3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_b46c864b-d64c-43bb-bc4a-235be82b5045_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_f29b2d8c-b6b9-4268-b2ff-9ad57ab3d90e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_a85d3959-7f4e-45c4-8261-eb5f00c523bb_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a3ae5aad-822f-42f9-a628-f3985c817f72_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_92f53943-b45f-4969-a84b-45cdc3ef3ce8_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) Income before benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_c97dc6f7-daa7-4648-b5fa-13aab01f05f1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_TwoThousandNineteenStockIncentivePlanMember_0f446bf2-5c92-4afd-a880-0726122ad718_terseLabel_en-US" xlink:label="lab_morf_TwoThousandNineteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Equity Incentive Plan</link:label>
    <link:label id="lab_morf_TwoThousandNineteenStockIncentivePlanMember_label_en-US" xlink:label="lab_morf_TwoThousandNineteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_morf_TwoThousandNineteenStockIncentivePlanMember_documentation_en-US" xlink:label="lab_morf_TwoThousandNineteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the 2019 stock incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_TwoThousandNineteenStockIncentivePlanMember" xlink:href="morf-20210930.xsd#morf_TwoThousandNineteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_TwoThousandNineteenStockIncentivePlanMember" xlink:to="lab_morf_TwoThousandNineteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e3eb4f6f-654e-4a5f-bea8-65757ff1f851_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_1df21f0b-19c4-4018-8c6d-bed3a8f42d39_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_97b94f37-ad36-400c-8f3a-64bf9097aa5f_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_27f6de48-25df-4c76-b915-612e515d1efb_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_30852961-6530-406d-b497-4ca71711a515_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_f9667d37-62ee-48b3-bf91-d5b2702b95ad_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7d20fce9-8a34-410c-bb9b-c537140e3422_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_17879705-175d-4e07-96b0-8a91170999f5_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3686f94a-9a3c-4b0b-9de3-d3335ba4fe9a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_00f96049-bef8-4005-9d32-387dbe0debaf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of equity based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_928b4aee-d74c-4c3e-ace3-9f0c22e5b39a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_51f0fbe6-0886-4364-bab1-7269abdaa556_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_d0f99068-ce67-4115-b239-8ce17550751a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from at-the-market offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_9f40b113-9c44-461e-9558-7e39e0ae5fec_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_785135e8-e7c4-48c4-b8a4-6cfa56100f12_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_8decac35-1048-4df9-bb58-2504b7e93aa8_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_754cb908-2c03-4392-b43e-c23cc3f82a03_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_13e06298-04b2-4477-bf45-069b68b69022_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Based Compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_362627cb-fccb-4453-ba80-b9c84aaaa8a3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income per share, basic (in dollars Per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d9bfd72c-f550-4db4-9e26-d75e045c4872_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_01ab02f7-4d96-4083-82d3-8d6ccd781cff_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_4c33f029-a76d-476b-9c09-fbacd3a6ac3d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of restricted stock units</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_9ecde0b7-4dab-41a0-a75e-43e0c02a8324_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_10bbcbbd-29f7-4e90-9632-8aa98937b537_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_72989afe-c801-4d0e-8097-45d57b38fa97_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_8e61ff32-2586-494a-b6f5-e88e41d6dea9_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_e039c5fa-c4cd-4e2f-b528-cbf420e7adca_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_86f8a1b0-54e8-452d-8b56-534bbb03d60f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e5b42a7e-0d35-4c03-8b2a-2f0d0127818f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_2bafb3ae-b10f-42c9-a957-ba5757c09a8a_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_a548b87f-f464-497f-8967-ec204531eea9_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of restricted common stock</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_528fe7e5-e727-4a88-93b6-2273fa48354f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4c7178ae-6604-42cc-8095-aa9d99b4c561_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_5747595a-cf82-4580-922b-a73adbd0d96a_terseLabel_en-US" xlink:label="lab_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate [Domain]</link:label>
    <link:label id="lab_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_label_en-US" xlink:label="lab_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="lab_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_682a6ab9-bd22-4469-8af3-607cac4772d6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_1368a0e2-4d95-426d-84cd-e2bcd2194c87_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3e649a57-0f30-4f17-ad78-f0da63dcf3a0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_PercentageOfCommissionOnGrossSaleProceeds_19aa0f55-9a44-43d9-9d4e-d1d864c0962d_terseLabel_en-US" xlink:label="lab_morf_PercentageOfCommissionOnGrossSaleProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission (as a percent)</link:label>
    <link:label id="lab_morf_PercentageOfCommissionOnGrossSaleProceeds_label_en-US" xlink:label="lab_morf_PercentageOfCommissionOnGrossSaleProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Commission on Gross sale Proceeds</link:label>
    <link:label id="lab_morf_PercentageOfCommissionOnGrossSaleProceeds_documentation_en-US" xlink:label="lab_morf_PercentageOfCommissionOnGrossSaleProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of commission on gross sale proceeds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_PercentageOfCommissionOnGrossSaleProceeds" xlink:href="morf-20210930.xsd#morf_PercentageOfCommissionOnGrossSaleProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_PercentageOfCommissionOnGrossSaleProceeds" xlink:to="lab_morf_PercentageOfCommissionOnGrossSaleProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_31de396f-1d80-4298-9982-8aa36664262c_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_84b032db-3be5-4fcd-abc4-2b3425617280_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income per share, diluted (in dollars Per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_6b28d133-f6a9-4cb9-9ae4-6724dea94f7e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_094f6991-2458-4736-9135-7a491a79da10_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of basic net income (loss) per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_25ef7231-a30a-4f6f-9867-0cb790899a6e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_7ead5867-186d-46f2-abba-770d9e5e633f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_02faa364-3970-4bba-9669-e6c13279adba_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_3e3659bf-6ec3-436a-a2ac-1e541a5ca6e7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_7e1f2d47-57ca-4fb5-91af-84bac23c766c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_4a01cb7d-a637-4e5e-a980-02d479966edc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9608bb60-422b-496e-99b5-a4df56a7d469_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_78090d81-a3b3-48d0-aa9b-5ca470c9191f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_5f697eb6-ae26-42ee-acf7-599efef4ba45_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_68e89353-5476-4ad8-b921-d258a5735308_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_343fcb6e-0530-42b1-b955-93fabe5f3ac1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock_a0c414b0-ffdf-4eed-b48b-3132febe040d_terseLabel_en-US" xlink:label="lab_morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate to purchase common stock</link:label>
    <link:label id="lab_morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock_label_en-US" xlink:label="lab_morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement, Percentage Of Discount On Purchase Of Common Stock</link:label>
    <link:label id="lab_morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock_documentation_en-US" xlink:label="lab_morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of discount provided to employees to purchase common stock under the employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock" xlink:href="morf-20210930.xsd#morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock" xlink:to="lab_morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_d4f08b54-1985-434f-8dc1-225f5a40bc1a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a265e8c3-7fd7-4827-b0ca-bbd8e86caae8_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_ac1e593c-5aee-4b05-ba17-66eb6c0439b1_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_ba5ef9ee-025c-4954-b767-db1feb43c9a6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_2fdea1cf-13cc-4ab5-bbda-3165939f513d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_d6d003c2-4d08-4b15-945f-d8eb888bcc54_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_be05dfd4-b607-4590-8e48-9b999c4417b7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_c8f94847-6028-4fb4-8d09-c955eccbfe43_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_486fb6a8-48a2-4d92-9238-b8d103cc12a7_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_69a9463d-7cd0-4db7-bf89-a5cc0dacc9a8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid&#8209;in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1abf0bc0-8a34-403e-adba-7abecd61e779_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of financial assets measured at fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f698f7e6-22a5-425b-9915-021cc0f8939c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_71c65f2c-91ff-47fe-8cbd-fab273a6dcd0_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from secondary offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_c746a10c-5890-46d8-89ed-e14ab47f5c67_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a7994638-2c03-4f93-a404-7c3861228847_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b50062a3-c79e-4712-9325-851d2fa12b7b_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4959689a-3d4d-4668-abd2-1de723391016_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_90bce75c-840b-48f1-9fcf-e6d0bbc9b907_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (Loss) Income per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01f078c1-9b17-40f7-b37e-c4b156a2cb53_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2116165f-a8ae-4265-a730-4814a4b1ad32_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_ffa51781-eaad-43e1-90f9-68f775795c6c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_IncomeTaxExpenseBenefitCARESAct_8efaf31a-fe0c-4f50-9ec2-49ce3cbb318f_negatedLabel_en-US" xlink:label="lab_morf_IncomeTaxExpenseBenefitCARESAct" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit, CARES Act</link:label>
    <link:label id="lab_morf_IncomeTaxExpenseBenefitCARESAct_label_en-US" xlink:label="lab_morf_IncomeTaxExpenseBenefitCARESAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), CARES Act</link:label>
    <link:label id="lab_morf_IncomeTaxExpenseBenefitCARESAct_documentation_en-US" xlink:label="lab_morf_IncomeTaxExpenseBenefitCARESAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_IncomeTaxExpenseBenefitCARESAct" xlink:href="morf-20210930.xsd#morf_IncomeTaxExpenseBenefitCARESAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_IncomeTaxExpenseBenefitCARESAct" xlink:to="lab_morf_IncomeTaxExpenseBenefitCARESAct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_9465944c-54f7-4c90-b495-359745443dea_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_32815682-14dd-41d5-a7d2-4e360613937c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5b62672c-7e5e-4692-ae89-3c169a80495d_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares upon stock option exercises</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_0076cdda-f67a-4cfe-b51d-ccefe0ce42a0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_4a4af66b-1259-4552-98ac-077adc2890e6_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of the Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9339a43a-b4e1-460a-8d31-bccc78e6b656_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e93d3368-9282-4b94-af05-1618dbaf96f2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2fc8bc46-46c8-48f7-9f72-f6bf58e648a6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_AccruedResearchAndDevelopment_315aa07d-64fb-4189-916c-497d6ed2f823_terseLabel_en-US" xlink:label="lab_morf_AccruedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development activities</link:label>
    <link:label id="lab_morf_AccruedResearchAndDevelopment_label_en-US" xlink:label="lab_morf_AccruedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development</link:label>
    <link:label id="lab_morf_AccruedResearchAndDevelopment_documentation_en-US" xlink:label="lab_morf_AccruedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AccruedResearchAndDevelopment" xlink:href="morf-20210930.xsd#morf_AccruedResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_AccruedResearchAndDevelopment" xlink:to="lab_morf_AccruedResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_f8be1596-2890-42a6-afeb-36372e96ceda_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_6e448fd6-1119-4125-9995-2c260f39aef8_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_81a4e924-471d-4e31-b7dc-77da6339ae55_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_4af4de3c-4dca-4b85-8600-6921f23adfb0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of letter of credit (in years)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3c662c91-f9aa-4cdc-bf7e-ec957fec8a10_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized holding gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_a90f0f3c-ef49-4eab-9fd0-22ccaff896e7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_cd2bcf92-cd39-4ab3-bc4d-b7a3140feaaa_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_105703ed-14f2-4038-bc7c-c08eadf664b6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_e970cad3-2259-44d7-8cd9-470da8bbae83_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_558c75b3-f851-4194-8068-4b5e0aa53cbc_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares/stock, net of offering/issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRentCurrent_5caa2b4e-03e9-4159-830d-6233aaa93807_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent, current portion</link:label>
    <link:label id="lab_us-gaap_AccruedRentCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rent, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRentCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRentCurrent" xlink:to="lab_us-gaap_AccruedRentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_77b59822-33f5-4e30-a701-1d5eb867a5a4_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bec2097a-e56b-4daf-bb4f-264f41111541_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_a9f56a1c-bd52-4e63-b1a4-f3a96e7243ef_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_28dcf908-4674-47b8-9ac2-f2a882f54202_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period ( in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_eae1db94-4635-4e39-9533-208416401ff2_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period ( in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_SecondaryOfferingMember_1fc49af5-bad9-4bcf-b7fd-92014c05c881_terseLabel_en-US" xlink:label="lab_morf_SecondaryOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secondary Offering</link:label>
    <link:label id="lab_morf_SecondaryOfferingMember_label_en-US" xlink:label="lab_morf_SecondaryOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secondary Offering [Member]</link:label>
    <link:label id="lab_morf_SecondaryOfferingMember_documentation_en-US" xlink:label="lab_morf_SecondaryOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secondary Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_SecondaryOfferingMember" xlink:href="morf-20210930.xsd#morf_SecondaryOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_SecondaryOfferingMember" xlink:to="lab_morf_SecondaryOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_420ae6d0-3a64-4076-9438-8798c8d28db5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable at the end (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f1e86eec-2683-40a7-b943-ef9662c8710d_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_EmployeeStockPurchasePlanMember_f0e23141-0ce9-4a38-92ab-3ae0cd0eb55c_terseLabel_en-US" xlink:label="lab_morf_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_morf_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_morf_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_morf_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_morf_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents Employee Stock Purchase Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_EmployeeStockPurchasePlanMember" xlink:href="morf-20210930.xsd#morf_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_EmployeeStockPurchasePlanMember" xlink:to="lab_morf_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_e9866336-e218-423c-a85e-844fbc74b12c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_90a51ac7-c9c2-4d7d-a0eb-c539c886d330_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_e5114c6a-4a4e-4ee4-b0af-8f69776d6726_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_87f99436-9c7f-4890-8828-f2c3c844da85_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c44579ae-d80f-41f9-bd76-8fd9f2d6db8b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_05bc10ef-4c60-4a46-af24-854ae2e813c3_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8097d5f0-7668-404d-994d-cc97f17955f8_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares/stock, net of offering/issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_263ae57f-f2be-4502-a117-7b0218daf8de_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of common shares sold in IPO, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_adb88d28-3a0c-4185-927f-05eaf479d57b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_f8386da3-c462-406d-9a52-044c0714b2ab_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_73168f85-d570-4002-8048-3b9986cd51c4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7bc0d0fa-2691-4eb5-96f7-a56e0085fef8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_47a19be2-df34-4cc2-a29c-8df74a37945e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_452a43c6-5584-4c96-91a6-cd5e375f70a4_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, $0.0001 par value, 400,000,000 shares authorized, 36,892,411 shares issued and outstanding as of September&#160;30, 2021 and 32,037,686 shares issued and outstanding as of December&#160;31, 2020</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_8e4f3cdf-75ca-41f7-a4e3-65226a7d4235_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_89c635ca-e3a1-41df-afe1-31dd01ee9675_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_70a72bc6-9b19-4f22-aa31-0db7959d65a1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized equity based compensation expense expected period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_996e01b8-f593-4fec-8d0a-8365c8986f6b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b5e6106c-f940-4c7b-931d-c2660e5b242a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_db60f4fa-e82d-45a2-8aaf-c20fdb020c98_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0c32b86c-7305-4163-a2a5-2877b4abb1c6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_d5bfa0b9-199f-4996-9bcf-8e7d6372f1ee_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable at the end (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_56278a6c-6b46-4d0b-b081-63675e156444_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a9d2f245-c262-43d0-8dfb-e45c393fa759_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_f7abc472-ef0b-47c0-8cf7-4e522aa6d478_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_c5675869-cb0f-4fc8-ac59-8cb72e00bb1a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted common stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_d4358ccb-051f-4d24-9400-7adbc80b9514_terseLabel_en-US" xlink:label="lab_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate, Type of Property [Axis]</link:label>
    <link:label id="lab_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_label_en-US" xlink:label="lab_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate, Type of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="lab_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_5d04cb65-999a-4adc-8b22-8b70d3548488_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_f1de6a1c-72a1-4f43-b358-a0d2b9f274be_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a55e29ae-559c-4519-92f8-06b74600313e_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium amortization and discount accretion on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_27a4fd11-3832-437f-a928-65e88129a1c2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_46c20d89-032f-4a1b-b42e-7db36f1618eb_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2e4c3a3a-c961-4fa2-803a-b03b66b11fc5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_adeffd70-308e-4cf7-8bb7-481bb5f87a5a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_b8fad296-5302-4436-9bca-341caa844662_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_a75f2ef2-b1c0-4fe5-b55a-c93244d87fb4_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5fff5b10-e33d-40ea-a1f3-ec991bcd4df3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_d3cd06c4-cc2d-4451-83ee-9f8656b4eb74_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Janssen</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_78233092-c9ec-4958-8e59-9feeb810d768_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3077be63-23fe-4bb3-bbf0-e725d9b78591_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ba14946f-4cd6-4bfa-b98c-27d998deb116_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRentNoncurrent_43d63a14-0865-4f96-8b18-f669c0595474_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent, net of current portion</link:label>
    <link:label id="lab_us-gaap_AccruedRentNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rent, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRentNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRentNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRentNoncurrent" xlink:to="lab_us-gaap_AccruedRentNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_430fe9a6-bae6-4c57-88e4-219536df120f_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_0309e45d-12b0-4e91-8a62-437c28ecf568_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs incurred</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_54b81f22-b8e4-4511-833e-d2e9ddbe2e0a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_ecaf7c23-8625-4ced-befa-35045bea4298_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_e267d752-1435-4513-ac6c-16143d26f384_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_fa72fd5a-4ba9-47b7-a2bd-fe6c85fd260c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b0794bd0-a5a1-4640-8ea3-35d056605d83_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_8725600f-f826-4cc6-af3c-36226182a154_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_738d262d-3529-4aae-a147-a67cffeaa0c1_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7c795fc0-d1f5-4be3-9479-be3556aef6d1_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from secondary offering</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_7d75822e-f257-4d2a-b794-d67118b37b4d_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_JanssenPharmaceuticalsIncMember_a0e66619-43ed-4744-9a25-3f2d6993cbc7_terseLabel_en-US" xlink:label="lab_morf_JanssenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen</link:label>
    <link:label id="lab_morf_JanssenPharmaceuticalsIncMember_label_en-US" xlink:label="lab_morf_JanssenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Pharmaceuticals Inc [Member]</link:label>
    <link:label id="lab_morf_JanssenPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_morf_JanssenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents Janssen Pharmaceuticals Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_JanssenPharmaceuticalsIncMember" xlink:href="morf-20210930.xsd#morf_JanssenPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_JanssenPharmaceuticalsIncMember" xlink:to="lab_morf_JanssenPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f7110b2c-76b0-4ebd-b383-11e22d3e7e84_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds, included in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_98c4d0a2-cf09-4c32-89e1-fe76dfdbeebc_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares upon stock option exercises (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b8633a0b-f04e-44c1-ad67-eba7fa35bb8f_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_62f44fdf-115d-404a-9b0c-5eeb0be9fa3f_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_3c9cbcd4-bffc-4d00-ab9a-df85a87b2018_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive (loss) income:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_60c9365a-1f99-481c-b7c9-e41276d2d952_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_afe588f0-d1dd-446b-bf2a-574cc237e916_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_3feed337-528c-42bb-b558-5abbc03b2a40_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b309d20e-f7f2-4285-886c-d12831aeafbc_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_18cc6665-6896-4c8b-947b-414f655ea059_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_02d21882-440b-4581-9c5d-178673e35b8b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_d3ae2663-ffdf-4294-87f2-d264bade1cab_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_1cec6815-ce86-49f6-a85c-5fe586e68994_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_9b2a5e8b-f3ae-4fcd-9820-df6fd8e9ff0d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate offering price of placement shares</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_53e79fcd-7ae4-4cc9-b9cc-19ff85d699d3_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3d61d277-fb64-4acd-91cd-71792976df42_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of stock option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_38bd43d2-8420-4b9d-b96b-0aceca63ab4b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3aee367a-4a0b-4e87-b4f9-a0721a8b116d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of common stock equivalent shares</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_FollowOnPublicOfferingMember_7934ce26-9b1f-4c42-9d65-a929c5928efe_terseLabel_en-US" xlink:label="lab_morf_FollowOnPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secondary Offering</link:label>
    <link:label id="lab_morf_FollowOnPublicOfferingMember_label_en-US" xlink:label="lab_morf_FollowOnPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow-On Public Offering [Member]</link:label>
    <link:label id="lab_morf_FollowOnPublicOfferingMember_documentation_en-US" xlink:label="lab_morf_FollowOnPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow-On Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_FollowOnPublicOfferingMember" xlink:href="morf-20210930.xsd#morf_FollowOnPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_FollowOnPublicOfferingMember" xlink:to="lab_morf_FollowOnPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_51f7813a-183c-4560-a283-5ce29baf7dce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering costs incurred</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_ad9675fc-6af2-4efa-af89-b2e11828b368_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_190c1def-df2b-443e-85b3-ef2bca079490_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_0201351f-2ede-4acb-9bbf-689fd0728fd6_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_aeacb2dd-a086-4c74-8cd1-1b9b7b17d67d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfLand_fe64ef3c-5459-42cb-ae00-a18fa9a2150a_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of land (square feet)</link:label>
    <link:label id="lab_us-gaap_AreaOfLand_label_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfLand"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfLand" xlink:to="lab_us-gaap_AreaOfLand" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_d164d56f-a23b-449c-8042-7d2b651b5d3f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eb8519bf-d6d7-4524-97e5-19f5480183ce_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_0ebcf0a9-17a9-4078-a0c8-1de733deb7fe_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_38b66b6e-1514-4ab1-903a-adb8dcc58825_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ccb66882-fc17-44e6-90f9-b063a378015d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested as of the Reorganization</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_001ef7ef-a32a-4270-9f82-faccf1c61254_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_2588cb7a-a7b1-4838-ac19-404fbd7f7b27_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_abaedcaa-3cfd-4721-be9e-b0adf952391f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_316d91b9-0170-4135-8d26-0c75c897d8e1_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized holding losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_1a6e51b5-db29-4cf1-ac9e-413c4d5003b9_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_3a3f19a4-0829-4321-bb70-f27f08dc2730_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_3dc4985b-9847-4f6f-942c-f03407908568_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff69b3e6-9710-4bdf-b850-754cecf07698_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_AbbVieMember_039e7ed8-064b-4560-bd6d-4bc8bfa5d0c9_terseLabel_en-US" xlink:label="lab_morf_AbbVieMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie</link:label>
    <link:label id="lab_morf_AbbVieMember_label_en-US" xlink:label="lab_morf_AbbVieMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie [Member]</link:label>
    <link:label id="lab_morf_AbbVieMember_documentation_en-US" xlink:label="lab_morf_AbbVieMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents AbbVie Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AbbVieMember" xlink:href="morf-20210930.xsd#morf_AbbVieMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_AbbVieMember" xlink:to="lab_morf_AbbVieMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_38009a49-0113-41f7-b236-cecacc6c9d9c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity&#8209;based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_d129c32c-5d85-4e2e-8d57-6252431d12e4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_fc2ce332-f06b-41d3-bb3a-01382bc5bbb8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid&#8209;in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e9c57590-4871-41ba-867f-5923444db2ef_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_029f2d69-1275-4118-a12a-9bb431abc3de_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_b8a6b8e7-80a7-4259-85c3-6911887dcfa4_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_11d35762-7de9-4199-b581-525f1f07b445_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_RestrictedCommonStockAndRestrictedStockUnitsMember_d2e9b318-024f-49a4-943f-ba5cc543d3fa_terseLabel_en-US" xlink:label="lab_morf_RestrictedCommonStockAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted common stock and stock units</link:label>
    <link:label id="lab_morf_RestrictedCommonStockAndRestrictedStockUnitsMember_label_en-US" xlink:label="lab_morf_RestrictedCommonStockAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Common Stock And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_morf_RestrictedCommonStockAndRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_morf_RestrictedCommonStockAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to restricted common stock and restricted stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_RestrictedCommonStockAndRestrictedStockUnitsMember" xlink:href="morf-20210930.xsd#morf_RestrictedCommonStockAndRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_RestrictedCommonStockAndRestrictedStockUnitsMember" xlink:to="lab_morf_RestrictedCommonStockAndRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_1873a232-8c04-497a-8deb-d547b0048f4d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4d87b075-9401-446e-acfd-e7607eeb02cc_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_be62d9b2-fa2f-4cf5-8e1b-1b13aa99b178_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_aa142744-c127-4640-9082-04c13c22a3ef_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_efbdec67-b2af-4a9b-9e75-ac0a4db18586_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common shares under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_c5e01adf-b9ba-4f74-9d45-337b6c5e9620_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_24cdc551-9336-49b0-9d9e-4b4124916311_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c5e756c1-76bd-4ca4-8ba1-dcaec2daca0b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_31d6bb17-2bc5-4e44-bf47-aeaf55d5daab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_e608188d-54f6-4004-b780-6c29b1771f90_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_535953ff-7da4-4409-98b0-3f1402a6c125_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_0aab762d-539f-463d-8080-74907f2d4929_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_faa5e0d9-1b27-4635-a15a-11a1245b46c1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of costs incurred and revenue recognized</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_ce84b91e-d9cc-45af-92db-5a88635223f3_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_53012a12-4f36-4fe9-9f7c-0bc087f20685_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2073979d-c252-4cd0-86b3-7c4e69e8ac44_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accrued expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_14704002-014e-4b63-aa8d-21e8db7cb03e_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_61818f5d-ceec-43b8-96ca-84c32bf347ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_2635f00d-d22b-4839-8295-8d4ac506c5fe_terseLabel_en-US" xlink:label="lab_morf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued Accounting Pronouncements not yet Adopted</link:label>
    <link:label id="lab_morf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_label_en-US" xlink:label="lab_morf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued Accounting Pronouncements Not Yet Adopted [Policy Text Block]</link:label>
    <link:label id="lab_morf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_documentation_en-US" xlink:label="lab_morf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policies for Pro forma financial information.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:href="morf-20210930.xsd#morf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="lab_morf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7f703d96-6298-4f93-baaa-e42e8ef4ff37_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_UpfrontPaymentRevenueMember_be2c582f-ff3a-49e9-b160-a11b478d0090_terseLabel_en-US" xlink:label="lab_morf_UpfrontPaymentRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment revenue</link:label>
    <link:label id="lab_morf_UpfrontPaymentRevenueMember_label_en-US" xlink:label="lab_morf_UpfrontPaymentRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment Revenue [Member]</link:label>
    <link:label id="lab_morf_UpfrontPaymentRevenueMember_documentation_en-US" xlink:label="lab_morf_UpfrontPaymentRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_UpfrontPaymentRevenueMember" xlink:href="morf-20210930.xsd#morf_UpfrontPaymentRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_UpfrontPaymentRevenueMember" xlink:to="lab_morf_UpfrontPaymentRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b6328d13-3e16-4348-8bad-797b503f04ea_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_decd4991-3cea-45b6-9a1f-1f5b8a99ed44_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4eddc7a2-36fd-443e-a66c-f096dff55a8d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of minimum annual rent payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_8250296f-a5aa-417b-b7c6-5d8c1524957a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_1fd08a26-ed82-4fe3-acb0-b08d9bba9138_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_7d547291-7f58-46ab-8d6f-6cb870355a57_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_99bdc417-499b-4b45-b29e-bc6d86a8657e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_e31bd60c-9508-42f4-b70c-ee375bc4859f_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_730e53b5-3709-4ceb-b668-39f227fc3d88_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1b6085a1-c40f-40f1-ada5-e10dafae3076_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable at the end</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0ba85cd5-bad3-4aa6-a4c9-5f28cc0339ba_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee_dbcb57f7-9e4f-4fd1-aacf-6d5202ffb5cb_terseLabel_en-US" xlink:label="lab_morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of common shares available for purchase per employee per year</link:label>
    <link:label id="lab_morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee_label_en-US" xlink:label="lab_morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan Annual Value Of Shares Available For Purchase Per Employee</link:label>
    <link:label id="lab_morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee_documentation_en-US" xlink:label="lab_morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual value of shares available for purchase per employee from employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee" xlink:href="morf-20210930.xsd#morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee" xlink:to="lab_morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_2344a55f-9822-4d23-9615-56061f732ba9_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_morf_AtMarketOfferingProgramMember_b813032b-96e1-4696-a55a-7ae911b2cae2_terseLabel_en-US" xlink:label="lab_morf_AtMarketOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM</link:label>
    <link:label id="lab_morf_AtMarketOfferingProgramMember_label_en-US" xlink:label="lab_morf_AtMarketOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At Market Offering Program [Member]</link:label>
    <link:label id="lab_morf_AtMarketOfferingProgramMember_documentation_en-US" xlink:label="lab_morf_AtMarketOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents at-the-market offering program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AtMarketOfferingProgramMember" xlink:href="morf-20210930.xsd#morf_AtMarketOfferingProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_morf_AtMarketOfferingProgramMember" xlink:to="lab_morf_AtMarketOfferingProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_96c475a7-cb17-4a00-bb19-cb43dc201d6a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82b0b7d1-d644-4a26-aa25-b953065793dd_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0adc3703-d72f-455a-a717-4b3ba7c0eb8a_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>morf-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a0fdcec5-f1a8-410f-b814-f85a654bede4,g:4b0f2f4e-5307-47a8-ad80-54240ea99d78-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://morphictx.com/role/CoverPage" xlink:type="simple" xlink:href="morf-20210930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_4b31bb3b-3f98-4883-8173-15eb330bdcfd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:to="loc_dei_DocumentType_4b31bb3b-3f98-4883-8173-15eb330bdcfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_d4ffbdc0-beec-4a6b-8967-a256c9c5bdb6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:to="loc_dei_DocumentQuarterlyReport_d4ffbdc0-beec-4a6b-8967-a256c9c5bdb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_fb872ead-6e64-43ed-8916-5ddaa55d213d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:to="loc_dei_DocumentPeriodEndDate_fb872ead-6e64-43ed-8916-5ddaa55d213d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_319a4726-e894-46a3-be1f-d6258b27b2c4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:to="loc_dei_DocumentTransitionReport_319a4726-e894-46a3-be1f-d6258b27b2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_00615ebb-7f63-457a-a20d-4b75145450f4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:to="loc_dei_EntityFileNumber_00615ebb-7f63-457a-a20d-4b75145450f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_3c36dd92-41b7-4ec5-b446-0ff955b9404f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:to="loc_dei_EntityRegistrantName_3c36dd92-41b7-4ec5-b446-0ff955b9404f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_71879f12-83ec-46ba-b03b-48d146188491" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_71879f12-83ec-46ba-b03b-48d146188491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_7bdade31-ae3a-446f-8fb5-f966650b2361" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:to="loc_dei_EntityTaxIdentificationNumber_7bdade31-ae3a-446f-8fb5-f966650b2361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_31c6c818-a71c-460c-8544-1f69c53d5096" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:to="loc_dei_EntityAddressAddressLine1_31c6c818-a71c-460c-8544-1f69c53d5096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_07e8f1fd-bd08-46da-b979-999bf17939d0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:to="loc_dei_EntityAddressAddressLine2_07e8f1fd-bd08-46da-b979-999bf17939d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f7863c18-e4c3-41e0-af81-66797268a78e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:to="loc_dei_EntityAddressCityOrTown_f7863c18-e4c3-41e0-af81-66797268a78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_8bbc433f-e3c1-453b-9c24-a2e1cb781c83" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:to="loc_dei_EntityAddressStateOrProvince_8bbc433f-e3c1-453b-9c24-a2e1cb781c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b04237e2-5d6d-4794-904a-8be27ae49dd0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:to="loc_dei_EntityAddressPostalZipCode_b04237e2-5d6d-4794-904a-8be27ae49dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_06a045f4-647e-459b-b98d-78660b830629" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:to="loc_dei_CityAreaCode_06a045f4-647e-459b-b98d-78660b830629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_19063207-8294-4da6-a863-cdb545f64f27" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:to="loc_dei_LocalPhoneNumber_19063207-8294-4da6-a863-cdb545f64f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_51864b7a-6149-49d1-bf27-96d319586bcf" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:to="loc_dei_Security12bTitle_51864b7a-6149-49d1-bf27-96d319586bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f5ba9d95-d0da-4601-9f27-856789058e31" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:to="loc_dei_TradingSymbol_f5ba9d95-d0da-4601-9f27-856789058e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_bfd89f03-7b10-4af3-9635-84152e8eda57" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:to="loc_dei_SecurityExchangeName_bfd89f03-7b10-4af3-9635-84152e8eda57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_e9d9c0e9-12c3-41da-ab06-2c84c3101862" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:to="loc_dei_EntityCurrentReportingStatus_e9d9c0e9-12c3-41da-ab06-2c84c3101862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_bef25511-07a7-466f-a3bd-c3d0235eeefb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:to="loc_dei_EntityInteractiveDataCurrent_bef25511-07a7-466f-a3bd-c3d0235eeefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e1a85a8a-760b-4b1a-ac5e-1c06e5d30509" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:to="loc_dei_EntityFilerCategory_e1a85a8a-760b-4b1a-ac5e-1c06e5d30509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_57bc4826-d66e-4792-b5c4-df735bff16cc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:to="loc_dei_EntitySmallBusiness_57bc4826-d66e-4792-b5c4-df735bff16cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_602897e2-6125-4487-bbae-590498985091" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:to="loc_dei_EntityEmergingGrowthCompany_602897e2-6125-4487-bbae-590498985091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_c21d97f7-4061-4933-bbf4-4b5bbb3e90e9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:to="loc_dei_EntityExTransitionPeriod_c21d97f7-4061-4933-bbf4-4b5bbb3e90e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_f581ece7-1e18-4371-a6ca-95f58cea8e33" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:to="loc_dei_EntityShellCompany_f581ece7-1e18-4371-a6ca-95f58cea8e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6a6fe4f3-1b53-40be-9a24-a3bd86e69e01" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6a6fe4f3-1b53-40be-9a24-a3bd86e69e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_70314c2e-daa1-44e2-98c2-b878b17b8381" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:to="loc_dei_EntityCentralIndexKey_70314c2e-daa1-44e2-98c2-b878b17b8381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_3868402c-bd8d-4d6a-b3c0-87cc18ae054c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:to="loc_dei_CurrentFiscalYearEndDate_3868402c-bd8d-4d6a-b3c0-87cc18ae054c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_994d479d-9e21-4369-8cab-af0863cc94ea" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:to="loc_dei_DocumentFiscalYearFocus_994d479d-9e21-4369-8cab-af0863cc94ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_ed3ff7b8-8452-48e7-9b84-83aaceb07d79" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:to="loc_dei_DocumentFiscalPeriodFocus_ed3ff7b8-8452-48e7-9b84-83aaceb07d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d55bbfb5-9065-4c1f-8dd0-9d97d721838d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9d7bd83b-9f0a-4b2c-9ab0-dc95c8f9eb0c" xlink:to="loc_dei_AmendmentFlag_d55bbfb5-9065-4c1f-8dd0-9d97d721838d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="simple" xlink:href="morf-20210930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_917dd420-0042-4797-a3d1-e24b46666d07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_a2073980-f745-4b40-a534-308f1cb93438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_917dd420-0042-4797-a3d1-e24b46666d07" xlink:to="loc_us-gaap_AssetsAbstract_a2073980-f745-4b40-a534-308f1cb93438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2bd2e9b5-967b-45a4-9feb-b1aa8e7f95bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a2073980-f745-4b40-a534-308f1cb93438" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2bd2e9b5-967b-45a4-9feb-b1aa8e7f95bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b3aeb698-3631-4e0a-a0c7-36dce523576a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2bd2e9b5-967b-45a4-9feb-b1aa8e7f95bc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b3aeb698-3631-4e0a-a0c7-36dce523576a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e40bc4df-627b-4f52-a2da-2e1a6a03f192" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2bd2e9b5-967b-45a4-9feb-b1aa8e7f95bc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e40bc4df-627b-4f52-a2da-2e1a6a03f192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_622229c1-5f4a-451c-8d11-0e57745abcf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2bd2e9b5-967b-45a4-9feb-b1aa8e7f95bc" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_622229c1-5f4a-451c-8d11-0e57745abcf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_307d167d-3f2b-4332-b73a-2b95e6f38e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2bd2e9b5-967b-45a4-9feb-b1aa8e7f95bc" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_307d167d-3f2b-4332-b73a-2b95e6f38e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e9c18140-8cb2-4645-ad2a-861489bc5996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2bd2e9b5-967b-45a4-9feb-b1aa8e7f95bc" xlink:to="loc_us-gaap_AssetsCurrent_e9c18140-8cb2-4645-ad2a-861489bc5996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_018fd27a-2606-4d8c-a6d9-cf3a7ff2f895" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a2073980-f745-4b40-a534-308f1cb93438" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_018fd27a-2606-4d8c-a6d9-cf3a7ff2f895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_66715dbc-2308-408b-9144-05b933a09cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a2073980-f745-4b40-a534-308f1cb93438" xlink:to="loc_us-gaap_RestrictedCash_66715dbc-2308-408b-9144-05b933a09cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_43ef56cd-dd25-4195-a54f-7aa025119770" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a2073980-f745-4b40-a534-308f1cb93438" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_43ef56cd-dd25-4195-a54f-7aa025119770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9bea7562-96cb-42c9-9cf1-613f456f82e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a2073980-f745-4b40-a534-308f1cb93438" xlink:to="loc_us-gaap_Assets_9bea7562-96cb-42c9-9cf1-613f456f82e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_baf4c975-b5a3-4be2-af60-f3da7dda6825" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_917dd420-0042-4797-a3d1-e24b46666d07" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_baf4c975-b5a3-4be2-af60-f3da7dda6825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_90cdc3da-da8f-4b83-976d-ed6d5705dff1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_baf4c975-b5a3-4be2-af60-f3da7dda6825" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_90cdc3da-da8f-4b83-976d-ed6d5705dff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3e08bbaa-c5da-4fce-aaa5-8103955cfdd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_90cdc3da-da8f-4b83-976d-ed6d5705dff1" xlink:to="loc_us-gaap_AccountsPayableCurrent_3e08bbaa-c5da-4fce-aaa5-8103955cfdd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_43246183-1f08-4504-873d-1540e6717150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_90cdc3da-da8f-4b83-976d-ed6d5705dff1" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_43246183-1f08-4504-873d-1540e6717150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_bf6708a9-2117-4506-ada6-7c7fa8d03304" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_90cdc3da-da8f-4b83-976d-ed6d5705dff1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_bf6708a9-2117-4506-ada6-7c7fa8d03304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRentCurrent_a1018001-5177-46fa-8bfa-a94fb3cd8abc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRentCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_90cdc3da-da8f-4b83-976d-ed6d5705dff1" xlink:to="loc_us-gaap_AccruedRentCurrent_a1018001-5177-46fa-8bfa-a94fb3cd8abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b30f8f96-ebef-4bc0-a154-679b891dc823" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_90cdc3da-da8f-4b83-976d-ed6d5705dff1" xlink:to="loc_us-gaap_LiabilitiesCurrent_b30f8f96-ebef-4bc0-a154-679b891dc823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_13fc4461-eb4f-4201-91c2-96e87e775a53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_baf4c975-b5a3-4be2-af60-f3da7dda6825" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_13fc4461-eb4f-4201-91c2-96e87e775a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3ea57156-7fb4-4809-9674-3c54cea39964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_13fc4461-eb4f-4201-91c2-96e87e775a53" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3ea57156-7fb4-4809-9674-3c54cea39964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRentNoncurrent_855a3a8a-d5ff-43f5-96cf-72c9fa86f1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRentNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_13fc4461-eb4f-4201-91c2-96e87e775a53" xlink:to="loc_us-gaap_AccruedRentNoncurrent_855a3a8a-d5ff-43f5-96cf-72c9fa86f1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e748d988-13db-45a3-ad3c-1674af7219ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_13fc4461-eb4f-4201-91c2-96e87e775a53" xlink:to="loc_us-gaap_Liabilities_e748d988-13db-45a3-ad3c-1674af7219ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_6b7793e3-5219-4f12-849d-c868ec691f88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_baf4c975-b5a3-4be2-af60-f3da7dda6825" xlink:to="loc_us-gaap_StockholdersEquityAbstract_6b7793e3-5219-4f12-849d-c868ec691f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_52b0ac21-52c7-4880-b865-a6aa71e3a24b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6b7793e3-5219-4f12-849d-c868ec691f88" xlink:to="loc_us-gaap_PreferredStockValue_52b0ac21-52c7-4880-b865-a6aa71e3a24b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a0696a2f-7d67-455a-9c86-39a81709f810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6b7793e3-5219-4f12-849d-c868ec691f88" xlink:to="loc_us-gaap_CommonStockValue_a0696a2f-7d67-455a-9c86-39a81709f810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_456a23b1-0bd2-4e29-b7c4-2cce8f4bdaa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6b7793e3-5219-4f12-849d-c868ec691f88" xlink:to="loc_us-gaap_AdditionalPaidInCapital_456a23b1-0bd2-4e29-b7c4-2cce8f4bdaa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f5e2a47d-aa9f-4557-b558-070f5ca0adc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6b7793e3-5219-4f12-849d-c868ec691f88" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f5e2a47d-aa9f-4557-b558-070f5ca0adc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8a41dbaf-8ff5-495f-b504-6dbb35842359" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6b7793e3-5219-4f12-849d-c868ec691f88" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8a41dbaf-8ff5-495f-b504-6dbb35842359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_381763fb-d491-4f6e-8a60-e341266ff91e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6b7793e3-5219-4f12-849d-c868ec691f88" xlink:to="loc_us-gaap_StockholdersEquity_381763fb-d491-4f6e-8a60-e341266ff91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b8fbafe4-e8f9-47f1-b6b0-58f405660dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6b7793e3-5219-4f12-849d-c868ec691f88" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_b8fbafe4-e8f9-47f1-b6b0-58f405660dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:type="simple" xlink:href="morf-20210930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b356f715-078a-4987-884f-d1c94c9bb2ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f80fde82-1d3e-41e5-bb97-59bb79ea2296" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b356f715-078a-4987-884f-d1c94c9bb2ec" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f80fde82-1d3e-41e5-bb97-59bb79ea2296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_e48c1c3e-14ba-41ec-89eb-3fd7643a5f42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b356f715-078a-4987-884f-d1c94c9bb2ec" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_e48c1c3e-14ba-41ec-89eb-3fd7643a5f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_265918e0-c0fd-477c-a277-0a7ac0b076e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b356f715-078a-4987-884f-d1c94c9bb2ec" xlink:to="loc_us-gaap_PreferredStockSharesIssued_265918e0-c0fd-477c-a277-0a7ac0b076e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_a62035cf-2dec-434c-8669-118f42b2c1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b356f715-078a-4987-884f-d1c94c9bb2ec" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_a62035cf-2dec-434c-8669-118f42b2c1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_989bd402-6f60-4543-941a-7a0dd5225bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b356f715-078a-4987-884f-d1c94c9bb2ec" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_989bd402-6f60-4543-941a-7a0dd5225bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_808084e9-2a5f-4706-a6db-d827f2ce0cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b356f715-078a-4987-884f-d1c94c9bb2ec" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_808084e9-2a5f-4706-a6db-d827f2ce0cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_cdfbda42-8033-4677-8c9a-db8813caafd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b356f715-078a-4987-884f-d1c94c9bb2ec" xlink:to="loc_us-gaap_CommonStockSharesIssued_cdfbda42-8033-4677-8c9a-db8813caafd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3692a742-d5cd-43e9-9d7e-011459852f55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b356f715-078a-4987-884f-d1c94c9bb2ec" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3692a742-d5cd-43e9-9d7e-011459852f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited" xlink:type="simple" xlink:href="morf-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_b8a5c59b-23b8-4fba-82aa-a547d33599a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_254746eb-2416-43aa-893b-ea07edbe8c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b8a5c59b-23b8-4fba-82aa-a547d33599a6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_254746eb-2416-43aa-893b-ea07edbe8c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_cc6cef1b-2513-4408-98be-4ea8dfd8bcc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b8a5c59b-23b8-4fba-82aa-a547d33599a6" xlink:to="loc_us-gaap_OperatingExpensesAbstract_cc6cef1b-2513-4408-98be-4ea8dfd8bcc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6b857b44-ad08-4682-a357-8bf4d39d9b57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_cc6cef1b-2513-4408-98be-4ea8dfd8bcc2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6b857b44-ad08-4682-a357-8bf4d39d9b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_f44d8bbb-4b9a-494e-b33b-7a48730a9168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_cc6cef1b-2513-4408-98be-4ea8dfd8bcc2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_f44d8bbb-4b9a-494e-b33b-7a48730a9168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f7aa1825-c2c1-4dcd-a4a6-105491d73fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_cc6cef1b-2513-4408-98be-4ea8dfd8bcc2" xlink:to="loc_us-gaap_CostsAndExpenses_f7aa1825-c2c1-4dcd-a4a6-105491d73fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_33a126bf-f9de-4552-8448-4c2ba6503615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b8a5c59b-23b8-4fba-82aa-a547d33599a6" xlink:to="loc_us-gaap_OperatingIncomeLoss_33a126bf-f9de-4552-8448-4c2ba6503615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_822feca8-af82-434d-8072-936e281d2fce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b8a5c59b-23b8-4fba-82aa-a547d33599a6" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_822feca8-af82-434d-8072-936e281d2fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_4c4de96c-c1f9-475a-9a63-e8e0b846ee01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_822feca8-af82-434d-8072-936e281d2fce" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_4c4de96c-c1f9-475a-9a63-e8e0b846ee01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c258cbc2-df3f-47af-bebe-e5b10af733fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_822feca8-af82-434d-8072-936e281d2fce" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c258cbc2-df3f-47af-bebe-e5b10af733fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_77a7dfa1-0456-4933-aa27-a71e93d77f28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_822feca8-af82-434d-8072-936e281d2fce" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_77a7dfa1-0456-4933-aa27-a71e93d77f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a510af2f-db80-4757-8dd4-627f3ad091c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b8a5c59b-23b8-4fba-82aa-a547d33599a6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a510af2f-db80-4757-8dd4-627f3ad091c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f025a87e-ea1d-4f92-b2ab-4bb0ec639f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b8a5c59b-23b8-4fba-82aa-a547d33599a6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f025a87e-ea1d-4f92-b2ab-4bb0ec639f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0bfa15af-acbf-43ee-8786-e0de5d856fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b8a5c59b-23b8-4fba-82aa-a547d33599a6" xlink:to="loc_us-gaap_NetIncomeLoss_0bfa15af-acbf-43ee-8786-e0de5d856fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_57f88e0d-a3a3-48b9-be9e-6e43da69f0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b8a5c59b-23b8-4fba-82aa-a547d33599a6" xlink:to="loc_us-gaap_EarningsPerShareBasic_57f88e0d-a3a3-48b9-be9e-6e43da69f0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_05ef6687-7b7a-4410-9c3b-f7b1ce2acd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b8a5c59b-23b8-4fba-82aa-a547d33599a6" xlink:to="loc_us-gaap_EarningsPerShareDiluted_05ef6687-7b7a-4410-9c3b-f7b1ce2acd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3ea484b3-cf27-4690-a332-b9026d0d7103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b8a5c59b-23b8-4fba-82aa-a547d33599a6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3ea484b3-cf27-4690-a332-b9026d0d7103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3d218bb0-3898-4517-9b7b-21ab3e2028fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b8a5c59b-23b8-4fba-82aa-a547d33599a6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3d218bb0-3898-4517-9b7b-21ab3e2028fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_9b15615f-130f-4f04-8d71-c23f8caf2ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b8a5c59b-23b8-4fba-82aa-a547d33599a6" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_9b15615f-130f-4f04-8d71-c23f8caf2ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1cb11b3d-0f9e-4b23-bf82-81ba6a41aec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_9b15615f-130f-4f04-8d71-c23f8caf2ff0" xlink:to="loc_us-gaap_NetIncomeLoss_1cb11b3d-0f9e-4b23-bf82-81ba6a41aec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_3afdc3eb-6810-4bc8-8ccd-2b46ccc8d070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_9b15615f-130f-4f04-8d71-c23f8caf2ff0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_3afdc3eb-6810-4bc8-8ccd-2b46ccc8d070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_fd7be2a0-d5a8-4903-99ba-344a2fab78f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_3afdc3eb-6810-4bc8-8ccd-2b46ccc8d070" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_fd7be2a0-d5a8-4903-99ba-344a2fab78f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2be824dc-25ac-4b24-9fce-2d51c7963fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_3afdc3eb-6810-4bc8-8ccd-2b46ccc8d070" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2be824dc-25ac-4b24-9fce-2d51c7963fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_be9ffa14-df99-49f6-95fb-adb54f92a564" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_9b15615f-130f-4f04-8d71-c23f8caf2ff0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_be9ffa14-df99-49f6-95fb-adb54f92a564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="simple" xlink:href="morf-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_060bc0f0-b3bf-4408-8bd6-4a9cf27cea81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e6a069ea-5fdf-4783-8536-987ca9fd65b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_060bc0f0-b3bf-4408-8bd6-4a9cf27cea81" xlink:to="loc_us-gaap_StatementTable_e6a069ea-5fdf-4783-8536-987ca9fd65b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2412335b-cc9a-47b4-9ad4-663e28e0e3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e6a069ea-5fdf-4783-8536-987ca9fd65b4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2412335b-cc9a-47b4-9ad4-663e28e0e3a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_745e714d-1fc4-4d27-b668-da30cbb15341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2412335b-cc9a-47b4-9ad4-663e28e0e3a8" xlink:to="loc_us-gaap_EquityComponentDomain_745e714d-1fc4-4d27-b668-da30cbb15341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_915954a5-133e-43ab-8a51-26b5d6069d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_745e714d-1fc4-4d27-b668-da30cbb15341" xlink:to="loc_us-gaap_CommonStockMember_915954a5-133e-43ab-8a51-26b5d6069d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4e8ca456-9292-4636-9e27-4fd69a8fb439" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_745e714d-1fc4-4d27-b668-da30cbb15341" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4e8ca456-9292-4636-9e27-4fd69a8fb439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5c559763-258f-4969-83d7-7bd33bd3665a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_745e714d-1fc4-4d27-b668-da30cbb15341" xlink:to="loc_us-gaap_RetainedEarningsMember_5c559763-258f-4969-83d7-7bd33bd3665a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_43fbca09-f2d2-451d-abf6-f6cdaa5129f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_745e714d-1fc4-4d27-b668-da30cbb15341" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_43fbca09-f2d2-451d-abf6-f6cdaa5129f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3130a620-246b-4038-adad-c4af05da9e03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e6a069ea-5fdf-4783-8536-987ca9fd65b4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3130a620-246b-4038-adad-c4af05da9e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ff25fd23-cb36-434e-bf3e-6423c01bb45d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3130a620-246b-4038-adad-c4af05da9e03" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ff25fd23-cb36-434e-bf3e-6423c01bb45d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AtTheMarketOfferingMember_6f7cbdcd-92e2-4a99-bb2b-0de460597797" xlink:href="morf-20210930.xsd#morf_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ff25fd23-cb36-434e-bf3e-6423c01bb45d" xlink:to="loc_morf_AtTheMarketOfferingMember_6f7cbdcd-92e2-4a99-bb2b-0de460597797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_SecondaryOfferingMember_57e53e8e-b67c-4f16-9216-423015de5832" xlink:href="morf-20210930.xsd#morf_SecondaryOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ff25fd23-cb36-434e-bf3e-6423c01bb45d" xlink:to="loc_morf_SecondaryOfferingMember_57e53e8e-b67c-4f16-9216-423015de5832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2f2777d0-8e60-4335-a07e-b7bd2cca8c44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e6a069ea-5fdf-4783-8536-987ca9fd65b4" xlink:to="loc_us-gaap_StatementLineItems_2f2777d0-8e60-4335-a07e-b7bd2cca8c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2f2777d0-8e60-4335-a07e-b7bd2cca8c44" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3b605276-0854-4b9a-9ad7-97999647390a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:to="loc_us-gaap_StockholdersEquity_3b605276-0854-4b9a-9ad7-97999647390a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_57bd4f4c-e8a5-403e-a968-cf4c1e9f9798" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:to="loc_us-gaap_SharesOutstanding_57bd4f4c-e8a5-403e-a968-cf4c1e9f9798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_b79adb7c-6798-48cc-b67b-74c3803c2a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_b79adb7c-6798-48cc-b67b-74c3803c2a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_f452822c-8496-4e10-ba7e-ab85c9e1668a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_f452822c-8496-4e10-ba7e-ab85c9e1668a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_35776e84-1c80-4dd7-9299-aed35b1a023a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_35776e84-1c80-4dd7-9299-aed35b1a023a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e0ac5814-9866-402b-8c78-155cf0256f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e0ac5814-9866-402b-8c78-155cf0256f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_10b5a54a-5f2d-449a-8290-1b84ea41b9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_10b5a54a-5f2d-449a-8290-1b84ea41b9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_a2a51994-a021-407f-b1b9-2b66942ff49f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_a2a51994-a021-407f-b1b9-2b66942ff49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8d9c0feb-3473-4a82-baba-b29dd5d46a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8d9c0feb-3473-4a82-baba-b29dd5d46a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_aece3c12-9bea-4f32-8327-a621b5f97ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_aece3c12-9bea-4f32-8327-a621b5f97ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_419379a1-a062-4a48-b138-7961c26f25e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_419379a1-a062-4a48-b138-7961c26f25e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_d5238999-f143-4590-b7fd-278e892234cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_d5238999-f143-4590-b7fd-278e892234cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c5804a89-046d-4a8f-9c6a-1b59190d9eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:to="loc_us-gaap_NetIncomeLoss_c5804a89-046d-4a8f-9c6a-1b59190d9eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_333299c5-cebe-4412-ae67-cdea2d5e8b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:to="loc_us-gaap_StockholdersEquity_333299c5-cebe-4412-ae67-cdea2d5e8b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_d8a36b44-c1bd-4dd5-a752-e9188cf0fb99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcd2e2a9-3e4d-4a67-8267-866a8dd70b12" xlink:to="loc_us-gaap_SharesOutstanding_d8a36b44-c1bd-4dd5-a752-e9188cf0fb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="morf-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_9486ac92-ae10-4e8b-921d-27109724dbc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_fdd627eb-7f49-4057-a39e-586baf42ae36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_9486ac92-ae10-4e8b-921d-27109724dbc8" xlink:to="loc_us-gaap_StatementTable_fdd627eb-7f49-4057-a39e-586baf42ae36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_23eb5103-15c3-4bd1-9d4b-549efa47bed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fdd627eb-7f49-4057-a39e-586baf42ae36" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_23eb5103-15c3-4bd1-9d4b-549efa47bed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_821fb596-a0a9-40a2-8fae-c238ab2dab5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_23eb5103-15c3-4bd1-9d4b-549efa47bed4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_821fb596-a0a9-40a2-8fae-c238ab2dab5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AtTheMarketOfferingMember_c5f81d49-8d80-453a-b135-6dc9810b42bd" xlink:href="morf-20210930.xsd#morf_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_821fb596-a0a9-40a2-8fae-c238ab2dab5d" xlink:to="loc_morf_AtTheMarketOfferingMember_c5f81d49-8d80-453a-b135-6dc9810b42bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_SecondaryOfferingMember_d8af61c7-cc1f-430f-acf4-b61ac53bbafe" xlink:href="morf-20210930.xsd#morf_SecondaryOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_821fb596-a0a9-40a2-8fae-c238ab2dab5d" xlink:to="loc_morf_SecondaryOfferingMember_d8af61c7-cc1f-430f-acf4-b61ac53bbafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a86e0b11-976a-416b-b33b-594bdf4f51d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fdd627eb-7f49-4057-a39e-586baf42ae36" xlink:to="loc_us-gaap_StatementLineItems_a86e0b11-976a-416b-b33b-594bdf4f51d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_6b00fd5a-1aaa-47de-9b5a-cbd92960e83d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a86e0b11-976a-416b-b33b-594bdf4f51d9" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_6b00fd5a-1aaa-47de-9b5a-cbd92960e83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="simple" xlink:href="morf-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_8073d6d1-f6e6-49f9-972d-74697f3eb9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7bf7dde7-6f20-4b39-a72c-bbc3b6d1cd5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8073d6d1-f6e6-49f9-972d-74697f3eb9bd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7bf7dde7-6f20-4b39-a72c-bbc3b6d1cd5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_774e30d6-f9c7-4a18-ac37-858063689caf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7bf7dde7-6f20-4b39-a72c-bbc3b6d1cd5a" xlink:to="loc_us-gaap_ProfitLoss_774e30d6-f9c7-4a18-ac37-858063689caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f14d6b62-b20d-46fa-9122-99b4f31b5169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7bf7dde7-6f20-4b39-a72c-bbc3b6d1cd5a" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f14d6b62-b20d-46fa-9122-99b4f31b5169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_dd2fde61-8d82-4b0f-97a4-8cbbf7663517" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f14d6b62-b20d-46fa-9122-99b4f31b5169" xlink:to="loc_us-gaap_DepreciationAndAmortization_dd2fde61-8d82-4b0f-97a4-8cbbf7663517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a359d06a-23b8-4d99-b7fb-89a102998f90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f14d6b62-b20d-46fa-9122-99b4f31b5169" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a359d06a-23b8-4d99-b7fb-89a102998f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a3789a08-c8c8-41df-92d6-3cbe785d27ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f14d6b62-b20d-46fa-9122-99b4f31b5169" xlink:to="loc_us-gaap_ShareBasedCompensation_a3789a08-c8c8-41df-92d6-3cbe785d27ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_e697acb0-9c44-41bc-b4fa-6ffc1b151d60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f14d6b62-b20d-46fa-9122-99b4f31b5169" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_e697acb0-9c44-41bc-b4fa-6ffc1b151d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_48d11d44-60d1-448c-8f47-6597de8ae19f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7bf7dde7-6f20-4b39-a72c-bbc3b6d1cd5a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_48d11d44-60d1-448c-8f47-6597de8ae19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9525fb2d-c9ab-43a8-8726-90339a52d7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_48d11d44-60d1-448c-8f47-6597de8ae19f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9525fb2d-c9ab-43a8-8726-90339a52d7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_bbbed998-52b0-4cf4-9f27-8396aed17b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_48d11d44-60d1-448c-8f47-6597de8ae19f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_bbbed998-52b0-4cf4-9f27-8396aed17b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_55a1ed95-7943-49cd-ac72-e5f679d52139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_48d11d44-60d1-448c-8f47-6597de8ae19f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_55a1ed95-7943-49cd-ac72-e5f679d52139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_70c049ce-8f0b-457b-9e29-d8e946e3e798" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_48d11d44-60d1-448c-8f47-6597de8ae19f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_70c049ce-8f0b-457b-9e29-d8e946e3e798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_84ab1261-7574-4a76-b3cb-d1cc6c9096ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_48d11d44-60d1-448c-8f47-6597de8ae19f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_84ab1261-7574-4a76-b3cb-d1cc6c9096ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_fa4c9cb8-f4fc-4546-bcdf-684d75984889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_48d11d44-60d1-448c-8f47-6597de8ae19f" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_fa4c9cb8-f4fc-4546-bcdf-684d75984889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_IncreaseDecreaseInDeferredRent_9d5c8578-e20a-46e5-ab23-7ec322930533" xlink:href="morf-20210930.xsd#morf_IncreaseDecreaseInDeferredRent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_48d11d44-60d1-448c-8f47-6597de8ae19f" xlink:to="loc_morf_IncreaseDecreaseInDeferredRent_9d5c8578-e20a-46e5-ab23-7ec322930533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7287b899-6b35-47db-8bd2-ad5eac3c08c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_48d11d44-60d1-448c-8f47-6597de8ae19f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7287b899-6b35-47db-8bd2-ad5eac3c08c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a19bc892-f400-4782-b6ab-41b975acad72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8073d6d1-f6e6-49f9-972d-74697f3eb9bd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a19bc892-f400-4782-b6ab-41b975acad72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_cdd5b1b7-577e-4d08-a4f3-f6a7291d819b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a19bc892-f400-4782-b6ab-41b975acad72" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_cdd5b1b7-577e-4d08-a4f3-f6a7291d819b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_54eaace4-088c-4f5a-8797-66c6d5f7e046" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a19bc892-f400-4782-b6ab-41b975acad72" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_54eaace4-088c-4f5a-8797-66c6d5f7e046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c633a2aa-2cb5-496c-9550-a059d8d97873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a19bc892-f400-4782-b6ab-41b975acad72" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c633a2aa-2cb5-496c-9550-a059d8d97873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_853a9be7-b353-407c-b1de-8a77e50a36b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a19bc892-f400-4782-b6ab-41b975acad72" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_853a9be7-b353-407c-b1de-8a77e50a36b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bae309f9-d611-47e8-9cc9-ae5aa487f698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8073d6d1-f6e6-49f9-972d-74697f3eb9bd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bae309f9-d611-47e8-9cc9-ae5aa487f698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_c64ad920-0689-4655-932d-52ad2d2dd58f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bae309f9-d611-47e8-9cc9-ae5aa487f698" xlink:to="loc_us-gaap_ProceedsFromStockPlans_c64ad920-0689-4655-932d-52ad2d2dd58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7636e2b4-283c-425d-a74d-41ce23802a01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bae309f9-d611-47e8-9cc9-ae5aa487f698" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7636e2b4-283c-425d-a74d-41ce23802a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_93d9fb75-9d0c-4647-aed2-ed3c8b55ad8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bae309f9-d611-47e8-9cc9-ae5aa487f698" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_93d9fb75-9d0c-4647-aed2-ed3c8b55ad8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_e6559f07-4afd-40ba-8b84-cb2c6e08b066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bae309f9-d611-47e8-9cc9-ae5aa487f698" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_e6559f07-4afd-40ba-8b84-cb2c6e08b066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_230e3a55-0e9c-43e6-bd6d-0da3b46232ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bae309f9-d611-47e8-9cc9-ae5aa487f698" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_230e3a55-0e9c-43e6-bd6d-0da3b46232ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7e1cfd69-4056-4987-9106-8a9910038db6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8073d6d1-f6e6-49f9-972d-74697f3eb9bd" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7e1cfd69-4056-4987-9106-8a9910038db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c56b1ba0-a8d8-4d8e-9b62-20a40341d941" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8073d6d1-f6e6-49f9-972d-74697f3eb9bd" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c56b1ba0-a8d8-4d8e-9b62-20a40341d941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6aff8c0a-b65f-4420-8fcb-c0161763fe07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8073d6d1-f6e6-49f9-972d-74697f3eb9bd" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6aff8c0a-b65f-4420-8fcb-c0161763fe07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_03a97e47-a307-4f0c-9d81-2a6f2179bb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8073d6d1-f6e6-49f9-972d-74697f3eb9bd" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_03a97e47-a307-4f0c-9d81-2a6f2179bb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_06b39acb-36a9-4bd7-ae1e-4b794d96f184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_03a97e47-a307-4f0c-9d81-2a6f2179bb5d" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_06b39acb-36a9-4bd7-ae1e-4b794d96f184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_7a1fe61b-6bcc-4554-ae9b-76fd98aad158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8073d6d1-f6e6-49f9-972d-74697f3eb9bd" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_7a1fe61b-6bcc-4554-ae9b-76fd98aad158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_187fb841-9f2c-405b-bce9-09fc08075c21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7a1fe61b-6bcc-4554-ae9b-76fd98aad158" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_187fb841-9f2c-405b-bce9-09fc08075c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/NatureoftheBusinessandBasisofPresentation" xlink:type="simple" xlink:href="morf-20210930.xsd#NatureoftheBusinessandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/NatureoftheBusinessandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a20513a6-7a81-4619-aa33-da4fd4765b03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8b2ea5f2-cf49-4425-89f6-e856d8f9c858" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a20513a6-7a81-4619-aa33-da4fd4765b03" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8b2ea5f2-cf49-4425-89f6-e856d8f9c858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/NatureoftheBusinessandBasisofPresentationDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#NatureoftheBusinessandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/NatureoftheBusinessandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ddfb6da3-b86d-4686-a9a4-1eed447ad833" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_7a9575a7-99ea-4055-8505-f17700565753" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ddfb6da3-b86d-4686-a9a4-1eed447ad833" xlink:to="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_7a9575a7-99ea-4055-8505-f17700565753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d7c20384-83f3-4c9b-9d5b-fbb7c12f992a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_7a9575a7-99ea-4055-8505-f17700565753" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d7c20384-83f3-4c9b-9d5b-fbb7c12f992a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81e5540d-bc12-4dc6-8932-113361cc664e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d7c20384-83f3-4c9b-9d5b-fbb7c12f992a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81e5540d-bc12-4dc6-8932-113361cc664e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AtMarketOfferingProgramMember_2dcf04ea-c3ed-40dd-bbc8-585eb7aee379" xlink:href="morf-20210930.xsd#morf_AtMarketOfferingProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81e5540d-bc12-4dc6-8932-113361cc664e" xlink:to="loc_morf_AtMarketOfferingProgramMember_2dcf04ea-c3ed-40dd-bbc8-585eb7aee379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_FollowOnPublicOfferingMember_0719dd52-b78d-43d4-b2f9-e3a827c0d0cd" xlink:href="morf-20210930.xsd#morf_FollowOnPublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81e5540d-bc12-4dc6-8932-113361cc664e" xlink:to="loc_morf_FollowOnPublicOfferingMember_0719dd52-b78d-43d4-b2f9-e3a827c0d0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8ca69fe7-f135-44b0-ba86-ef39dbb13534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_7a9575a7-99ea-4055-8505-f17700565753" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8ca69fe7-f135-44b0-ba86-ef39dbb13534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_88f4eacd-87af-4390-8309-f12512f90f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8ca69fe7-f135-44b0-ba86-ef39dbb13534" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_88f4eacd-87af-4390-8309-f12512f90f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_OpenMarketSaleAgreementMember_9c7c6ce0-aa6c-4c76-aa70-2e157ae9107b" xlink:href="morf-20210930.xsd#morf_OpenMarketSaleAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_88f4eacd-87af-4390-8309-f12512f90f0c" xlink:to="loc_morf_OpenMarketSaleAgreementMember_9c7c6ce0-aa6c-4c76-aa70-2e157ae9107b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_8452a784-cfcd-4598-9b5c-364e29188cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_7a9575a7-99ea-4055-8505-f17700565753" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_8452a784-cfcd-4598-9b5c-364e29188cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_fc8d340b-3d7f-4414-bd4a-15c9ce400d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_8452a784-cfcd-4598-9b5c-364e29188cf7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_fc8d340b-3d7f-4414-bd4a-15c9ce400d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_PercentageOfCommissionOnGrossSaleProceeds_7266b942-7ab4-4755-9bf2-74c709400cc5" xlink:href="morf-20210930.xsd#morf_PercentageOfCommissionOnGrossSaleProceeds"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_8452a784-cfcd-4598-9b5c-364e29188cf7" xlink:to="loc_morf_PercentageOfCommissionOnGrossSaleProceeds_7266b942-7ab4-4755-9bf2-74c709400cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1e5dffff-9f79-4ca6-b893-fb56cfcf8012" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_8452a784-cfcd-4598-9b5c-364e29188cf7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1e5dffff-9f79-4ca6-b893-fb56cfcf8012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_CommonStockAvailableForIssuance_01e52743-576e-4c81-b4da-c49a7564dbf3" xlink:href="morf-20210930.xsd#morf_CommonStockAvailableForIssuance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_8452a784-cfcd-4598-9b5c-364e29188cf7" xlink:to="loc_morf_CommonStockAvailableForIssuance_01e52743-576e-4c81-b4da-c49a7564dbf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_b889456e-1655-413d-93b5-06388c6ee67a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_8452a784-cfcd-4598-9b5c-364e29188cf7" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_b889456e-1655-413d-93b5-06388c6ee67a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1bc5122c-3df5-4ec5-aeee-89a517dbde2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_8452a784-cfcd-4598-9b5c-364e29188cf7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1bc5122c-3df5-4ec5-aeee-89a517dbde2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_0b0885f5-7601-4cf3-8178-ca11387a44ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_8452a784-cfcd-4598-9b5c-364e29188cf7" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_0b0885f5-7601-4cf3-8178-ca11387a44ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9ffb8240-2e74-479d-b6ab-e0e4ebd900ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_8452a784-cfcd-4598-9b5c-364e29188cf7" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9ffb8240-2e74-479d-b6ab-e0e4ebd900ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="morf-20210930.xsd#BasisofPresentationandSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_32cb1f1b-411d-46d5-bacf-882cffadb64e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_7075353a-1402-45a3-9875-2ff8e5f3b2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_32cb1f1b-411d-46d5-bacf-882cffadb64e" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_7075353a-1402-45a3-9875-2ff8e5f3b2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="morf-20210930.xsd#BasisofPresentationandSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bff9f550-0da1-4e11-8689-6897f4444186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_b7114b18-725a-4d9f-a20b-5ebf1a8636ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bff9f550-0da1-4e11-8689-6897f4444186" xlink:to="loc_us-gaap_UseOfEstimates_b7114b18-725a-4d9f-a20b-5ebf1a8636ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_d35b420e-8e6a-45a1-8f74-489d97729ea8" xlink:href="morf-20210930.xsd#morf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bff9f550-0da1-4e11-8689-6897f4444186" xlink:to="loc_morf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_d35b420e-8e6a-45a1-8f74-489d97729ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#BasisofPresentationandSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d2e49417-845e-47f7-a6de-dd7b1cf1101e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4741d8f3-6670-4c46-bb62-8765ea40a159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d2e49417-845e-47f7-a6de-dd7b1cf1101e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4741d8f3-6670-4c46-bb62-8765ea40a159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_5dcb6f34-3fbb-42cb-b307-d15d7a3a518e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4741d8f3-6670-4c46-bb62-8765ea40a159" xlink:to="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_5dcb6f34-3fbb-42cb-b307-d15d7a3a518e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_b6a4e850-3f0e-4940-9b8e-bd51d0be4d6a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_5dcb6f34-3fbb-42cb-b307-d15d7a3a518e" xlink:to="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_b6a4e850-3f0e-4940-9b8e-bd51d0be4d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_OfficeAndLaboratorySpaceMember_2e7d4e26-7595-4230-8a65-3d71da515755" xlink:href="morf-20210930.xsd#morf_OfficeAndLaboratorySpaceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_b6a4e850-3f0e-4940-9b8e-bd51d0be4d6a" xlink:to="loc_morf_OfficeAndLaboratorySpaceMember_2e7d4e26-7595-4230-8a65-3d71da515755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d86c5ac-c7aa-4834-ad11-5baddcc64433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4741d8f3-6670-4c46-bb62-8765ea40a159" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d86c5ac-c7aa-4834-ad11-5baddcc64433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_663726ee-bbe1-4905-b325-a79e6da06423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfLand"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7d86c5ac-c7aa-4834-ad11-5baddcc64433" xlink:to="loc_us-gaap_AreaOfLand_663726ee-bbe1-4905-b325-a79e6da06423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/FairValueofFinancialAssetsandLiabilities" xlink:type="simple" xlink:href="morf-20210930.xsd#FairValueofFinancialAssetsandLiabilities"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/FairValueofFinancialAssetsandLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_40813a30-2481-46d4-968c-3b7b828f4a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_e03a013e-f49c-4717-83e9-63fa6b7c1b19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_40813a30-2481-46d4-968c-3b7b828f4a5c" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_e03a013e-f49c-4717-83e9-63fa6b7c1b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesTables" xlink:type="simple" xlink:href="morf-20210930.xsd#FairValueofFinancialAssetsandLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_bded1691-2553-4ed4-9775-06890f313319" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_acacd7f0-b0c3-4f9a-9069-296ea616942e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bded1691-2553-4ed4-9775-06890f313319" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_acacd7f0-b0c3-4f9a-9069-296ea616942e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#FairValueofFinancialAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_33020e99-21e8-4c10-a4b4-b10116902b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aa42795-953a-4b9f-bb7a-1af894b38386" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_33020e99-21e8-4c10-a4b4-b10116902b3d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aa42795-953a-4b9f-bb7a-1af894b38386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8247a275-3ea0-45ba-8fc9-480ddbf21ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aa42795-953a-4b9f-bb7a-1af894b38386" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8247a275-3ea0-45ba-8fc9-480ddbf21ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_fb0a4aa0-a055-4b8b-ac3f-c3baec44e195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8247a275-3ea0-45ba-8fc9-480ddbf21ff5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_fb0a4aa0-a055-4b8b-ac3f-c3baec44e195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_fbfd0088-ae33-4692-9f4d-36cf1bbcc56d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_fb0a4aa0-a055-4b8b-ac3f-c3baec44e195" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_fbfd0088-ae33-4692-9f4d-36cf1bbcc56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_05ed4891-f25e-4d9d-aca1-16fddfeffd12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aa42795-953a-4b9f-bb7a-1af894b38386" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_05ed4891-f25e-4d9d-aca1-16fddfeffd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1c38ad6a-af8b-4f42-883f-51c8f36495a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_05ed4891-f25e-4d9d-aca1-16fddfeffd12" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1c38ad6a-af8b-4f42-883f-51c8f36495a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3c36e177-6dd2-413d-ba3b-8596108a1503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1c38ad6a-af8b-4f42-883f-51c8f36495a4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3c36e177-6dd2-413d-ba3b-8596108a1503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6f2c8645-1045-4fb9-85f4-4c02ee8ad704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1c38ad6a-af8b-4f42-883f-51c8f36495a4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6f2c8645-1045-4fb9-85f4-4c02ee8ad704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d759cd08-9361-4e44-b830-c09db5c82c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1c38ad6a-af8b-4f42-883f-51c8f36495a4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d759cd08-9361-4e44-b830-c09db5c82c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_4259ef24-bf58-41e3-8b45-c1c84449634d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aa42795-953a-4b9f-bb7a-1af894b38386" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_4259ef24-bf58-41e3-8b45-c1c84449634d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_bf4ce205-b695-4d75-a115-e7f0e5f7bfa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_4259ef24-bf58-41e3-8b45-c1c84449634d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_bf4ce205-b695-4d75-a115-e7f0e5f7bfa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_c950c6e0-d245-44fe-bbb0-658593aa316f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_bf4ce205-b695-4d75-a115-e7f0e5f7bfa5" xlink:to="loc_us-gaap_MoneyMarketFundsMember_c950c6e0-d245-44fe-bbb0-658593aa316f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7b6f9238-4cee-4ab8-9cb3-67f97dc4a834" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aa42795-953a-4b9f-bb7a-1af894b38386" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7b6f9238-4cee-4ab8-9cb3-67f97dc4a834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_11422d91-6b72-4489-89e1-8520072b09a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7b6f9238-4cee-4ab8-9cb3-67f97dc4a834" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_11422d91-6b72-4489-89e1-8520072b09a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_89ad74e8-9069-435b-b9fa-311ed1532636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_11422d91-6b72-4489-89e1-8520072b09a4" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_89ad74e8-9069-435b-b9fa-311ed1532636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6c894066-ecb7-4fce-ad86-481355c29f75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_11422d91-6b72-4489-89e1-8520072b09a4" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6c894066-ecb7-4fce-ad86-481355c29f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b79d173b-519b-4392-ae2c-08be589247a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4aa42795-953a-4b9f-bb7a-1af894b38386" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b79d173b-519b-4392-ae2c-08be589247a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_84e39525-b5b7-4bdf-bd5e-f5baa9a341ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b79d173b-519b-4392-ae2c-08be589247a0" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_84e39525-b5b7-4bdf-bd5e-f5baa9a341ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_21343e65-4d07-4745-afec-b3e3980e97c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_84e39525-b5b7-4bdf-bd5e-f5baa9a341ad" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_21343e65-4d07-4745-afec-b3e3980e97c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2b894a22-a394-4a20-ac3c-cdbfa438e459" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_84e39525-b5b7-4bdf-bd5e-f5baa9a341ad" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2b894a22-a394-4a20-ac3c-cdbfa438e459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_976e14ea-0d87-48cf-98ab-cfee08193be2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_84e39525-b5b7-4bdf-bd5e-f5baa9a341ad" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_976e14ea-0d87-48cf-98ab-cfee08193be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/Marketablesecurities" xlink:type="simple" xlink:href="morf-20210930.xsd#Marketablesecurities"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/Marketablesecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_200059f7-899f-4eac-a76d-e0ea3f42ce23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_22881cc4-860b-4857-82d9-82c2cb4d87ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_200059f7-899f-4eac-a76d-e0ea3f42ce23" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_22881cc4-860b-4857-82d9-82c2cb4d87ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/MarketablesecuritiesTables" xlink:type="simple" xlink:href="morf-20210930.xsd#MarketablesecuritiesTables"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/MarketablesecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b864132a-a07a-42ff-80e4-f6de148bba7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_fdb1e71f-b088-4c10-9004-1905d103745b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b864132a-a07a-42ff-80e4-f6de148bba7e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_fdb1e71f-b088-4c10-9004-1905d103745b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/MarketablesecuritiesDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#MarketablesecuritiesDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/MarketablesecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_03f08101-23f9-4781-aaca-1b1d50fd3388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7b5e5056-dfbb-4585-a845-df627d579ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_03f08101-23f9-4781-aaca-1b1d50fd3388" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7b5e5056-dfbb-4585-a845-df627d579ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8e0bbc69-da12-4fc8-9c5f-dc222a17c7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7b5e5056-dfbb-4585-a845-df627d579ff0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8e0bbc69-da12-4fc8-9c5f-dc222a17c7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_050d398e-5189-43ea-88cc-6ec6d8ed031b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8e0bbc69-da12-4fc8-9c5f-dc222a17c7ba" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_050d398e-5189-43ea-88cc-6ec6d8ed031b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_ccf74423-6970-4ece-94a4-c7c0c5351324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_050d398e-5189-43ea-88cc-6ec6d8ed031b" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_ccf74423-6970-4ece-94a4-c7c0c5351324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5e1e4ca9-00a5-4ab8-8139-a53ce8e4ddda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_050d398e-5189-43ea-88cc-6ec6d8ed031b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_5e1e4ca9-00a5-4ab8-8139-a53ce8e4ddda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_61280188-b238-4abf-90a4-5f4afccc97a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7b5e5056-dfbb-4585-a845-df627d579ff0" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_61280188-b238-4abf-90a4-5f4afccc97a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_21d498c9-8aef-4fb2-8566-fcb5c7afce31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_61280188-b238-4abf-90a4-5f4afccc97a1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_21d498c9-8aef-4fb2-8566-fcb5c7afce31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f32505f2-5912-4c27-8423-dd81ee7e268a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_21d498c9-8aef-4fb2-8566-fcb5c7afce31" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f32505f2-5912-4c27-8423-dd81ee7e268a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8b3a9674-9df2-417b-a5a1-582faff9b69e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_21d498c9-8aef-4fb2-8566-fcb5c7afce31" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8b3a9674-9df2-417b-a5a1-582faff9b69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_db5cc9e6-0c8a-46e7-b8ac-d3e089a9178f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_21d498c9-8aef-4fb2-8566-fcb5c7afce31" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_db5cc9e6-0c8a-46e7-b8ac-d3e089a9178f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0e92aae5-0eff-4388-be6c-2428598f633a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_21d498c9-8aef-4fb2-8566-fcb5c7afce31" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0e92aae5-0eff-4388-be6c-2428598f633a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/CashCashEquivalentsandRestrictedCash" xlink:type="simple" xlink:href="morf-20210930.xsd#CashCashEquivalentsandRestrictedCash"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/CashCashEquivalentsandRestrictedCash" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAbstract_e521ed03-e512-4400-9991-e1aa56b3ba4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_679dd553-3292-4cbf-b777-f4c42d5a343d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAbstract_e521ed03-e512-4400-9991-e1aa56b3ba4e" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_679dd553-3292-4cbf-b777-f4c42d5a343d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/CashCashEquivalentsandRestrictedCashTables" xlink:type="simple" xlink:href="morf-20210930.xsd#CashCashEquivalentsandRestrictedCashTables"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/CashCashEquivalentsandRestrictedCashTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAbstract_c802aca2-529a-4c2a-bc1c-be665f507f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_db4583d0-20c0-4cad-a94f-a428d59770d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAbstract_c802aca2-529a-4c2a-bc1c-be665f507f2f" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_db4583d0-20c0-4cad-a94f-a428d59770d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/CashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#CashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/CashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAbstract_ab1c7e42-53fd-421f-af02-c22e6894f326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_f3fc1e0c-d07a-4a2a-b23f-19ec798e4471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAbstract_ab1c7e42-53fd-421f-af02-c22e6894f326" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_f3fc1e0c-d07a-4a2a-b23f-19ec798e4471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_8f4ad589-2ff9-4b75-bcf2-4905bcc81df6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAbstract_ab1c7e42-53fd-421f-af02-c22e6894f326" xlink:to="loc_us-gaap_DebtInstrumentTerm_8f4ad589-2ff9-4b75-bcf2-4905bcc81df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7e54fa1d-fdd3-4be5-ba10-5f995a5fd079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAbstract_ab1c7e42-53fd-421f-af02-c22e6894f326" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7e54fa1d-fdd3-4be5-ba10-5f995a5fd079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_bb762e05-8d2e-4b2f-8732-d98d711de912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAbstract_ab1c7e42-53fd-421f-af02-c22e6894f326" xlink:to="loc_us-gaap_RestrictedCash_bb762e05-8d2e-4b2f-8732-d98d711de912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4a36b2d4-b5c8-41ec-b333-ece1a1086f05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAbstract_ab1c7e42-53fd-421f-af02-c22e6894f326" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4a36b2d4-b5c8-41ec-b333-ece1a1086f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/AccruedExpenses" xlink:type="simple" xlink:href="morf-20210930.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_9193f9eb-4b2d-4810-a839-f1dd8775eefb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_7938dad7-c448-4370-9081-837b2cc1d91c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_9193f9eb-4b2d-4810-a839-f1dd8775eefb" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_7938dad7-c448-4370-9081-837b2cc1d91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="morf-20210930.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_c14d9d63-40a9-4297-a957-f1ff96ba0dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ec5d3acb-7ef9-4a4a-8a84-a30c76e47b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_c14d9d63-40a9-4297-a957-f1ff96ba0dd1" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ec5d3acb-7ef9-4a4a-8a84-a30c76e47b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#AccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_7e8a622a-db3b-4b34-ab83-2ba409734509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b2f77f19-6720-4f20-b327-55083f575c05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7e8a622a-db3b-4b34-ab83-2ba409734509" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b2f77f19-6720-4f20-b327-55083f575c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AccruedResearchAndDevelopment_b795fbd1-83f1-4ae7-be1c-f099ad7a0020" xlink:href="morf-20210930.xsd#morf_AccruedResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7e8a622a-db3b-4b34-ab83-2ba409734509" xlink:to="loc_morf_AccruedResearchAndDevelopment_b795fbd1-83f1-4ae7-be1c-f099ad7a0020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_16e5e218-85a7-43aa-b94e-1a08b68a735c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7e8a622a-db3b-4b34-ab83-2ba409734509" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_16e5e218-85a7-43aa-b94e-1a08b68a735c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b2d74dae-b3f8-49a8-84a2-24d7c061b0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7e8a622a-db3b-4b34-ab83-2ba409734509" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b2d74dae-b3f8-49a8-84a2-24d7c061b0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/EquityBasedCompensation" xlink:type="simple" xlink:href="morf-20210930.xsd#EquityBasedCompensation"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/EquityBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f021f476-3add-45c4-b969-4476cd1e15a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_21c2184e-d20a-4cf9-8e29-a04e410f04b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f021f476-3add-45c4-b969-4476cd1e15a2" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_21c2184e-d20a-4cf9-8e29-a04e410f04b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/EquityBasedCompensationTables" xlink:type="simple" xlink:href="morf-20210930.xsd#EquityBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/EquityBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_133e5015-a924-4e87-863c-91030f2eb379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e65f347d-4a2a-46d5-a920-7d6fbcf05896" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_133e5015-a924-4e87-863c-91030f2eb379" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e65f347d-4a2a-46d5-a920-7d6fbcf05896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_73829794-8c84-4276-9483-04e23cd46865" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_133e5015-a924-4e87-863c-91030f2eb379" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_73829794-8c84-4276-9483-04e23cd46865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_1d54d64a-462e-4bcb-9346-8981474b233c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_133e5015-a924-4e87-863c-91030f2eb379" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_1d54d64a-462e-4bcb-9346-8981474b233c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_115e415d-8ee8-42a0-80e6-d33ea780d77f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_133e5015-a924-4e87-863c-91030f2eb379" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_115e415d-8ee8-42a0-80e6-d33ea780d77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/EquityBasedCompensation2019equityincentiveplanDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#EquityBasedCompensation2019equityincentiveplanDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/EquityBasedCompensation2019equityincentiveplanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32c2b36c-55c2-43f1-8c84-b56d660fda1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7e5936c-559f-45c1-a011-658ce4e7a7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32c2b36c-55c2-43f1-8c84-b56d660fda1a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7e5936c-559f-45c1-a011-658ce4e7a7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_16931b30-f79c-4900-b5f1-445fc6eda4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7e5936c-559f-45c1-a011-658ce4e7a7fe" xlink:to="loc_us-gaap_PlanNameAxis_16931b30-f79c-4900-b5f1-445fc6eda4fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a7d0c022-192d-420b-baed-1c34ea5bfe15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_16931b30-f79c-4900-b5f1-445fc6eda4fc" xlink:to="loc_us-gaap_PlanNameDomain_a7d0c022-192d-420b-baed-1c34ea5bfe15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_TwoThousandNineteenStockIncentivePlanMember_b99ebeef-c00f-422a-9db6-af4274bfcedf" xlink:href="morf-20210930.xsd#morf_TwoThousandNineteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a7d0c022-192d-420b-baed-1c34ea5bfe15" xlink:to="loc_morf_TwoThousandNineteenStockIncentivePlanMember_b99ebeef-c00f-422a-9db6-af4274bfcedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5ff625e3-fafd-448c-bc60-4e881f7b20ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7e5936c-559f-45c1-a011-658ce4e7a7fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5ff625e3-fafd-448c-bc60-4e881f7b20ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_464298f0-07aa-4d77-b030-641d4f65c60b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5ff625e3-fafd-448c-bc60-4e881f7b20ac" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_464298f0-07aa-4d77-b030-641d4f65c60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_aa09f445-d9a0-4356-bf71-68aaeb386e41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5ff625e3-fafd-448c-bc60-4e881f7b20ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_aa09f445-d9a0-4356-bf71-68aaeb386e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#EquityBasedCompensationEquitybasedcompensationexpenseDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3411daa5-d70f-484c-811e-e2e359395264" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5dec3ad5-bbb3-402c-829b-64189df3446b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3411daa5-d70f-484c-811e-e2e359395264" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5dec3ad5-bbb3-402c-829b-64189df3446b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_43ace14c-1d62-4095-8eef-288fe9c92174" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5dec3ad5-bbb3-402c-829b-64189df3446b" xlink:to="loc_us-gaap_AwardTypeAxis_43ace14c-1d62-4095-8eef-288fe9c92174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eadcba89-e4ca-48b2-b4cf-cb9105392d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_43ace14c-1d62-4095-8eef-288fe9c92174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eadcba89-e4ca-48b2-b4cf-cb9105392d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1727c675-cd8b-4477-bf98-4d51615c3985" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eadcba89-e4ca-48b2-b4cf-cb9105392d5f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1727c675-cd8b-4477-bf98-4d51615c3985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_250096eb-9cc9-4dc0-aa2b-ad3d013abda6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eadcba89-e4ca-48b2-b4cf-cb9105392d5f" xlink:to="loc_us-gaap_RestrictedStockMember_250096eb-9cc9-4dc0-aa2b-ad3d013abda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f71f688f-f646-4fda-a5e0-5e3350f48272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eadcba89-e4ca-48b2-b4cf-cb9105392d5f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f71f688f-f646-4fda-a5e0-5e3350f48272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_20deb25f-95c3-40ed-bc22-5482a57ee566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eadcba89-e4ca-48b2-b4cf-cb9105392d5f" xlink:to="loc_us-gaap_EmployeeStockMember_20deb25f-95c3-40ed-bc22-5482a57ee566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_11539290-1dbb-49ba-8eaf-85d2d8b2df24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5dec3ad5-bbb3-402c-829b-64189df3446b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_11539290-1dbb-49ba-8eaf-85d2d8b2df24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5fa9f44f-7351-4fe9-aa4e-1928d20127eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_11539290-1dbb-49ba-8eaf-85d2d8b2df24" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5fa9f44f-7351-4fe9-aa4e-1928d20127eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_30ecd389-17a2-4370-97fd-56e1eaae67f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5fa9f44f-7351-4fe9-aa4e-1928d20127eb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_30ecd389-17a2-4370-97fd-56e1eaae67f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_19dcdf24-0661-4287-9aa8-7d7fd7e54b48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5fa9f44f-7351-4fe9-aa4e-1928d20127eb" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_19dcdf24-0661-4287-9aa8-7d7fd7e54b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_eac6f9dc-dde6-4ccd-a69d-8058b1f96d29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5dec3ad5-bbb3-402c-829b-64189df3446b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_eac6f9dc-dde6-4ccd-a69d-8058b1f96d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_54083568-b347-4fcb-8261-038b8cf63dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_eac6f9dc-dde6-4ccd-a69d-8058b1f96d29" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_54083568-b347-4fcb-8261-038b8cf63dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#EquityBasedCompensationRestrictedcommonstockactivityDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_41f356e4-b5fa-4e19-85ce-6851467a2982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e87ef1f6-46fa-4933-aa67-ed734c590720" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_41f356e4-b5fa-4e19-85ce-6851467a2982" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e87ef1f6-46fa-4933-aa67-ed734c590720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_670955ab-f5cd-459e-8851-0a520d2a1b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e87ef1f6-46fa-4933-aa67-ed734c590720" xlink:to="loc_us-gaap_PlanNameAxis_670955ab-f5cd-459e-8851-0a520d2a1b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e59048a0-a2e9-4b3c-be52-9b1a85cab6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_670955ab-f5cd-459e-8851-0a520d2a1b4e" xlink:to="loc_us-gaap_PlanNameDomain_e59048a0-a2e9-4b3c-be52-9b1a85cab6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_TwoThousandNineteenStockIncentivePlanMember_bd518120-f83e-486b-aef2-2ec9ca1d4b44" xlink:href="morf-20210930.xsd#morf_TwoThousandNineteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e59048a0-a2e9-4b3c-be52-9b1a85cab6ea" xlink:to="loc_morf_TwoThousandNineteenStockIncentivePlanMember_bd518120-f83e-486b-aef2-2ec9ca1d4b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1feb3b74-c47c-4868-8aad-7c8db6263938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e87ef1f6-46fa-4933-aa67-ed734c590720" xlink:to="loc_us-gaap_AwardTypeAxis_1feb3b74-c47c-4868-8aad-7c8db6263938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a2a70e9-a5fd-43fe-a2d6-240c35885417" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1feb3b74-c47c-4868-8aad-7c8db6263938" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a2a70e9-a5fd-43fe-a2d6-240c35885417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_74c686ab-6165-47a1-b36b-936c66190544" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a2a70e9-a5fd-43fe-a2d6-240c35885417" xlink:to="loc_us-gaap_RestrictedStockMember_74c686ab-6165-47a1-b36b-936c66190544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d425aa0-5946-47a1-b423-2ca378f4876f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e87ef1f6-46fa-4933-aa67-ed734c590720" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d425aa0-5946-47a1-b423-2ca378f4876f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_976b576c-24a1-4cb7-aeb8-658cdb191105" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d425aa0-5946-47a1-b423-2ca378f4876f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_976b576c-24a1-4cb7-aeb8-658cdb191105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7e3b2156-bcdc-45bd-86ee-68e491447294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_976b576c-24a1-4cb7-aeb8-658cdb191105" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7e3b2156-bcdc-45bd-86ee-68e491447294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f3ab5733-96ca-4f56-87dd-ae5a89938d10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_976b576c-24a1-4cb7-aeb8-658cdb191105" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f3ab5733-96ca-4f56-87dd-ae5a89938d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b9da25f1-f446-4d8a-a576-f797acfa35c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_976b576c-24a1-4cb7-aeb8-658cdb191105" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b9da25f1-f446-4d8a-a576-f797acfa35c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_60613f1a-7172-49cc-906e-128b29b44abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_976b576c-24a1-4cb7-aeb8-658cdb191105" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_60613f1a-7172-49cc-906e-128b29b44abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d119d313-f7d8-42e8-a67f-f89d84122cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_976b576c-24a1-4cb7-aeb8-658cdb191105" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d119d313-f7d8-42e8-a67f-f89d84122cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_227b7f69-94c1-4280-bed5-70ecaf22c579" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d425aa0-5946-47a1-b423-2ca378f4876f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_227b7f69-94c1-4280-bed5-70ecaf22c579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f8ebccac-7632-4bbc-a522-60408c354ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_227b7f69-94c1-4280-bed5-70ecaf22c579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f8ebccac-7632-4bbc-a522-60408c354ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fb7ec4bb-3ea1-4207-bbf5-ea13fd087031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_227b7f69-94c1-4280-bed5-70ecaf22c579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fb7ec4bb-3ea1-4207-bbf5-ea13fd087031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2d40cc71-beb4-403f-aab0-b58f2c99ec56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_227b7f69-94c1-4280-bed5-70ecaf22c579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2d40cc71-beb4-403f-aab0-b58f2c99ec56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c23501f0-eb0f-4bbd-80c8-f20376d6ceb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_227b7f69-94c1-4280-bed5-70ecaf22c579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c23501f0-eb0f-4bbd-80c8-f20376d6ceb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_87bb26b3-19d9-4df1-88c7-f18b265478f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_227b7f69-94c1-4280-bed5-70ecaf22c579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_87bb26b3-19d9-4df1-88c7-f18b265478f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_62971360-e990-41cb-846b-522ba7e8fcaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d425aa0-5946-47a1-b423-2ca378f4876f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_62971360-e990-41cb-846b-522ba7e8fcaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_88c8f5f7-9a86-43f7-9fda-719466733d94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d425aa0-5946-47a1-b423-2ca378f4876f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_88c8f5f7-9a86-43f7-9fda-719466733d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#EquityBasedCompensationRestrictedstockunitsactivityDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3ebf7b45-e51c-4a59-8128-1a0da46507b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19a99378-0ea3-4c04-8f52-bf53a1060e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3ebf7b45-e51c-4a59-8128-1a0da46507b5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19a99378-0ea3-4c04-8f52-bf53a1060e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_edda2658-5751-41b0-b5eb-c715acb34ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19a99378-0ea3-4c04-8f52-bf53a1060e5c" xlink:to="loc_us-gaap_PlanNameAxis_edda2658-5751-41b0-b5eb-c715acb34ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_75035377-3a7e-4e7a-b7e1-bc1176176c37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_edda2658-5751-41b0-b5eb-c715acb34ace" xlink:to="loc_us-gaap_PlanNameDomain_75035377-3a7e-4e7a-b7e1-bc1176176c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_TwoThousandNineteenStockIncentivePlanMember_ca451ee6-5077-4685-b147-04bfbb326bc8" xlink:href="morf-20210930.xsd#morf_TwoThousandNineteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_75035377-3a7e-4e7a-b7e1-bc1176176c37" xlink:to="loc_morf_TwoThousandNineteenStockIncentivePlanMember_ca451ee6-5077-4685-b147-04bfbb326bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0abf3799-d77b-4f16-8309-7b8815c5b041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19a99378-0ea3-4c04-8f52-bf53a1060e5c" xlink:to="loc_us-gaap_AwardTypeAxis_0abf3799-d77b-4f16-8309-7b8815c5b041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6e65279-6f49-43d4-84d8-1069bfd01356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0abf3799-d77b-4f16-8309-7b8815c5b041" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6e65279-6f49-43d4-84d8-1069bfd01356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_626f7ee0-a900-45da-9a90-215ca02ceb63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b6e65279-6f49-43d4-84d8-1069bfd01356" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_626f7ee0-a900-45da-9a90-215ca02ceb63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e7d20397-4671-403d-b90b-9c5f1c378e84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19a99378-0ea3-4c04-8f52-bf53a1060e5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e7d20397-4671-403d-b90b-9c5f1c378e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97cbb6a6-fe60-497d-b537-39940b2f947d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e7d20397-4671-403d-b90b-9c5f1c378e84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97cbb6a6-fe60-497d-b537-39940b2f947d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4ae7cea3-0f0e-4456-89c4-b47dd3b33c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97cbb6a6-fe60-497d-b537-39940b2f947d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4ae7cea3-0f0e-4456-89c4-b47dd3b33c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a9aa4b8a-ff74-4ff1-b0e3-e5d3e9889380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97cbb6a6-fe60-497d-b537-39940b2f947d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a9aa4b8a-ff74-4ff1-b0e3-e5d3e9889380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5b36fe3c-b1f5-49c6-a42a-6672493e8f37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97cbb6a6-fe60-497d-b537-39940b2f947d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5b36fe3c-b1f5-49c6-a42a-6672493e8f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9b4a3c8a-27da-4c86-a919-2150d4e44904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97cbb6a6-fe60-497d-b537-39940b2f947d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9b4a3c8a-27da-4c86-a919-2150d4e44904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_354b046e-ca2c-4367-9183-8ba2a0b509c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97cbb6a6-fe60-497d-b537-39940b2f947d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_354b046e-ca2c-4367-9183-8ba2a0b509c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6218039f-3c5e-4ad5-9e77-7f52d9c5ff08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e7d20397-4671-403d-b90b-9c5f1c378e84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6218039f-3c5e-4ad5-9e77-7f52d9c5ff08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0e14b2b8-12b8-47d3-9fc8-f4433e396710" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6218039f-3c5e-4ad5-9e77-7f52d9c5ff08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0e14b2b8-12b8-47d3-9fc8-f4433e396710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a10ec7b5-8bb1-47cc-a96a-616bc91b3a60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6218039f-3c5e-4ad5-9e77-7f52d9c5ff08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a10ec7b5-8bb1-47cc-a96a-616bc91b3a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1be903a2-8260-41ea-9352-01afe4ddab9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6218039f-3c5e-4ad5-9e77-7f52d9c5ff08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1be903a2-8260-41ea-9352-01afe4ddab9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_daad0dc6-1817-449e-b5ff-0291007bb73c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6218039f-3c5e-4ad5-9e77-7f52d9c5ff08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_daad0dc6-1817-449e-b5ff-0291007bb73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d2e6c711-c7a3-470c-9b55-fa5960affff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6218039f-3c5e-4ad5-9e77-7f52d9c5ff08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d2e6c711-c7a3-470c-9b55-fa5960affff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ce5a01c7-7c71-43ef-b94a-76d30783430a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e7d20397-4671-403d-b90b-9c5f1c378e84" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ce5a01c7-7c71-43ef-b94a-76d30783430a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6a785795-e946-43a3-9687-1fb42938bab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e7d20397-4671-403d-b90b-9c5f1c378e84" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6a785795-e946-43a3-9687-1fb42938bab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#EquityBasedCompensationStockoptionawardsDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4848310c-8ea8-4e86-a0f8-013b0c3e6c45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea5ecbd3-5e87-49a0-901d-97b758397a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4848310c-8ea8-4e86-a0f8-013b0c3e6c45" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea5ecbd3-5e87-49a0-901d-97b758397a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_31254e97-b82b-4254-b91d-0c623df53315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea5ecbd3-5e87-49a0-901d-97b758397a5f" xlink:to="loc_us-gaap_PlanNameAxis_31254e97-b82b-4254-b91d-0c623df53315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fc783f2f-9ccf-4a1b-9a58-fb02537d8d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_31254e97-b82b-4254-b91d-0c623df53315" xlink:to="loc_us-gaap_PlanNameDomain_fc783f2f-9ccf-4a1b-9a58-fb02537d8d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_TwoThousandNineteenStockIncentivePlanMember_d3eaf0d4-e443-4272-94d8-156bda8ad745" xlink:href="morf-20210930.xsd#morf_TwoThousandNineteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_fc783f2f-9ccf-4a1b-9a58-fb02537d8d7a" xlink:to="loc_morf_TwoThousandNineteenStockIncentivePlanMember_d3eaf0d4-e443-4272-94d8-156bda8ad745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c65969d4-34b1-480b-89d5-18ecf4e204dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea5ecbd3-5e87-49a0-901d-97b758397a5f" xlink:to="loc_us-gaap_AwardTypeAxis_c65969d4-34b1-480b-89d5-18ecf4e204dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84bb0580-3842-48bb-b224-331755276320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c65969d4-34b1-480b-89d5-18ecf4e204dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84bb0580-3842-48bb-b224-331755276320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e525cb05-5ca7-461b-b323-c55b8f5ab5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84bb0580-3842-48bb-b224-331755276320" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e525cb05-5ca7-461b-b323-c55b8f5ab5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff61e11b-5ceb-4a8d-bf9c-64b38040553f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea5ecbd3-5e87-49a0-901d-97b758397a5f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff61e11b-5ceb-4a8d-bf9c-64b38040553f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5f181749-4d1d-4db9-8438-ec881f8a74b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff61e11b-5ceb-4a8d-bf9c-64b38040553f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5f181749-4d1d-4db9-8438-ec881f8a74b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f9a17a9f-4b99-4916-95c5-d6f8f00aa865" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5f181749-4d1d-4db9-8438-ec881f8a74b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f9a17a9f-4b99-4916-95c5-d6f8f00aa865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019a3eb6-2d15-4699-bd48-5b988dc79185" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5f181749-4d1d-4db9-8438-ec881f8a74b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_019a3eb6-2d15-4699-bd48-5b988dc79185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4ec71b44-79e6-4b79-8d7a-7fd24eacf86c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5f181749-4d1d-4db9-8438-ec881f8a74b3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4ec71b44-79e6-4b79-8d7a-7fd24eacf86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d946d7a0-11f9-4f19-bb79-96441737958b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5f181749-4d1d-4db9-8438-ec881f8a74b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d946d7a0-11f9-4f19-bb79-96441737958b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_25765250-a54e-40a6-9733-6bc343be4dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5f181749-4d1d-4db9-8438-ec881f8a74b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_25765250-a54e-40a6-9733-6bc343be4dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ab4d30fe-f616-44ef-933c-bbb211ea8c11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff61e11b-5ceb-4a8d-bf9c-64b38040553f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ab4d30fe-f616-44ef-933c-bbb211ea8c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5dcc55ab-48eb-4336-a0db-5c4c7a5a3a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff61e11b-5ceb-4a8d-bf9c-64b38040553f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5dcc55ab-48eb-4336-a0db-5c4c7a5a3a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bd2784af-36fa-4279-825c-9972d8fb156c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5dcc55ab-48eb-4336-a0db-5c4c7a5a3a7b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bd2784af-36fa-4279-825c-9972d8fb156c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cf6a1690-ac66-40a6-890e-df6d70ce9d56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5dcc55ab-48eb-4336-a0db-5c4c7a5a3a7b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cf6a1690-ac66-40a6-890e-df6d70ce9d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_73a7d612-0f94-449a-9493-82d65486ffd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5dcc55ab-48eb-4336-a0db-5c4c7a5a3a7b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_73a7d612-0f94-449a-9493-82d65486ffd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f4648a3d-b9b0-4ea9-a85d-a3b70ac1d4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5dcc55ab-48eb-4336-a0db-5c4c7a5a3a7b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f4648a3d-b9b0-4ea9-a85d-a3b70ac1d4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f0f2611f-8dff-4668-a765-4bd7b46dcca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5dcc55ab-48eb-4336-a0db-5c4c7a5a3a7b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f0f2611f-8dff-4668-a765-4bd7b46dcca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c38182cf-aa12-47f1-a7a9-7235db4c9b31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff61e11b-5ceb-4a8d-bf9c-64b38040553f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c38182cf-aa12-47f1-a7a9-7235db4c9b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ab175b42-3749-4e35-aa40-8947ebe0c6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff61e11b-5ceb-4a8d-bf9c-64b38040553f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ab175b42-3749-4e35-aa40-8947ebe0c6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8b6154ef-8e62-41d9-8287-f6ae2b62811c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ab175b42-3749-4e35-aa40-8947ebe0c6ec" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8b6154ef-8e62-41d9-8287-f6ae2b62811c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6979b22f-4d36-4139-9280-8be1c468d4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ab175b42-3749-4e35-aa40-8947ebe0c6ec" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6979b22f-4d36-4139-9280-8be1c468d4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_12c96601-e5b4-40a3-a8c2-394e4c54877f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ab175b42-3749-4e35-aa40-8947ebe0c6ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_12c96601-e5b4-40a3-a8c2-394e4c54877f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6b4d6828-388f-44ef-9c2a-73992c984c61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ab175b42-3749-4e35-aa40-8947ebe0c6ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6b4d6828-388f-44ef-9c2a-73992c984c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f33e588c-b4de-4884-8c33-dd45dd94a7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ab175b42-3749-4e35-aa40-8947ebe0c6ec" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f33e588c-b4de-4884-8c33-dd45dd94a7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b27c27f7-cedc-413e-bd84-82c8320afc7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ab175b42-3749-4e35-aa40-8947ebe0c6ec" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b27c27f7-cedc-413e-bd84-82c8320afc7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dc207030-f214-4761-8e6d-83fb07064a72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ab175b42-3749-4e35-aa40-8947ebe0c6ec" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dc207030-f214-4761-8e6d-83fb07064a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/EquityBasedCompensationESPPDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#EquityBasedCompensationESPPDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/EquityBasedCompensationESPPDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d1137a99-3651-48b5-a479-834fcf07a86d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_210e722f-389b-40fc-9fe7-5bd9db5049d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d1137a99-3651-48b5-a479-834fcf07a86d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_210e722f-389b-40fc-9fe7-5bd9db5049d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_48492998-5cf2-47a9-a549-52b6e57542aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_210e722f-389b-40fc-9fe7-5bd9db5049d8" xlink:to="loc_us-gaap_PlanNameAxis_48492998-5cf2-47a9-a549-52b6e57542aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9ae499ce-575a-4136-9d67-34d5e17a7e35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_48492998-5cf2-47a9-a549-52b6e57542aa" xlink:to="loc_us-gaap_PlanNameDomain_9ae499ce-575a-4136-9d67-34d5e17a7e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_EmployeeStockPurchasePlanMember_fdb49ec5-2271-4815-9918-ece98c65e84b" xlink:href="morf-20210930.xsd#morf_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9ae499ce-575a-4136-9d67-34d5e17a7e35" xlink:to="loc_morf_EmployeeStockPurchasePlanMember_fdb49ec5-2271-4815-9918-ece98c65e84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e97a15de-4ed2-4c4e-a8da-1ad918eb1afc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_210e722f-389b-40fc-9fe7-5bd9db5049d8" xlink:to="loc_srt_RangeAxis_e97a15de-4ed2-4c4e-a8da-1ad918eb1afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_154b7ebb-cf6e-4329-9a5a-d25bad5b5912" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e97a15de-4ed2-4c4e-a8da-1ad918eb1afc" xlink:to="loc_srt_RangeMember_154b7ebb-cf6e-4329-9a5a-d25bad5b5912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a5100f67-c4de-4cd3-a80b-4c1a230cab30" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_154b7ebb-cf6e-4329-9a5a-d25bad5b5912" xlink:to="loc_srt_MaximumMember_a5100f67-c4de-4cd3-a80b-4c1a230cab30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50e4e8cb-bee3-4ddb-a492-9427554be6df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_210e722f-389b-40fc-9fe7-5bd9db5049d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50e4e8cb-bee3-4ddb-a492-9427554be6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ca37415d-1dc9-465a-9f17-24ca3b7d8cab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50e4e8cb-bee3-4ddb-a492-9427554be6df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ca37415d-1dc9-465a-9f17-24ca3b7d8cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a7354206-0254-4418-a3fe-5a411692d649" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50e4e8cb-bee3-4ddb-a492-9427554be6df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a7354206-0254-4418-a3fe-5a411692d649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee_1f2b6c9b-3d24-4ac7-b397-c11bd7fdb638" xlink:href="morf-20210930.xsd#morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50e4e8cb-bee3-4ddb-a492-9427554be6df" xlink:to="loc_morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee_1f2b6c9b-3d24-4ac7-b397-c11bd7fdb638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock_89fb27bd-4fce-45c3-a0a7-e9f35a8dc6af" xlink:href="morf-20210930.xsd#morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50e4e8cb-bee3-4ddb-a492-9427554be6df" xlink:to="loc_morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock_89fb27bd-4fce-45c3-a0a7-e9f35a8dc6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/IncomeTaxes" xlink:type="simple" xlink:href="morf-20210930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d194486d-7d13-44f9-a080-e4d3bbf61f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_a5e564bf-f670-429f-b3a5-5a97bf889fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d194486d-7d13-44f9-a080-e4d3bbf61f9e" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_a5e564bf-f670-429f-b3a5-5a97bf889fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e3bdda19-7941-42b9-aa5e-36a61f54de2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_IncomeTaxExpenseBenefitCARESAct_ff337d99-8913-4810-9f53-5ecc81fa22b4" xlink:href="morf-20210930.xsd#morf_IncomeTaxExpenseBenefitCARESAct"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e3bdda19-7941-42b9-aa5e-36a61f54de2f" xlink:to="loc_morf_IncomeTaxExpenseBenefitCARESAct_ff337d99-8913-4810-9f53-5ecc81fa22b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="morf-20210930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0260bc0e-65af-4a90-b45c-582a212e7d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0857a1bd-e579-40f3-8b59-49b32f798246" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0260bc0e-65af-4a90-b45c-582a212e7d9c" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0857a1bd-e579-40f3-8b59-49b32f798246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="morf-20210930.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f360baf3-c0d2-432f-a2b1-d9fedea3d757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a5882611-41af-479f-aa65-4883cc230420" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f360baf3-c0d2-432f-a2b1-d9fedea3d757" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a5882611-41af-479f-aa65-4883cc230420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8d32c846-2816-4f3b-8b2e-72102acde1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_e2275348-b9e2-44c4-a491-47efb005e008" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8d32c846-2816-4f3b-8b2e-72102acde1e9" xlink:to="loc_us-gaap_OtherCommitmentsTable_e2275348-b9e2-44c4-a491-47efb005e008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_0ef9ea2e-8427-4c1e-b692-2dc73e9d9fbc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_e2275348-b9e2-44c4-a491-47efb005e008" xlink:to="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_0ef9ea2e-8427-4c1e-b692-2dc73e9d9fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_ac23e6ac-2d61-4114-a84d-7399111918e0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_0ef9ea2e-8427-4c1e-b692-2dc73e9d9fbc" xlink:to="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_ac23e6ac-2d61-4114-a84d-7399111918e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_OfficeAndLaboratorySpaceMember_33aeb115-7744-4644-9521-9ba03024dfd9" xlink:href="morf-20210930.xsd#morf_OfficeAndLaboratorySpaceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_ac23e6ac-2d61-4114-a84d-7399111918e0" xlink:to="loc_morf_OfficeAndLaboratorySpaceMember_33aeb115-7744-4644-9521-9ba03024dfd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_563344ad-3f53-4fe6-96c4-a185e1f07260" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_e2275348-b9e2-44c4-a491-47efb005e008" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_563344ad-3f53-4fe6-96c4-a185e1f07260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_d423f8f9-8942-4dce-b462-3592111ed051" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfLand"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_563344ad-3f53-4fe6-96c4-a185e1f07260" xlink:to="loc_us-gaap_AreaOfLand_d423f8f9-8942-4dce-b462-3592111ed051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/CommitmentsandContingenciesScheduleofMinimumRentPaymentsDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#CommitmentsandContingenciesScheduleofMinimumRentPaymentsDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/CommitmentsandContingenciesScheduleofMinimumRentPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dc0918c1-eb73-4959-a460-02ce76e5b662" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b85333f9-715a-4052-bed1-b609d4cd5b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dc0918c1-eb73-4959-a460-02ce76e5b662" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b85333f9-715a-4052-bed1-b609d4cd5b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_33a1497a-8e76-4f98-ba8a-0511272dd762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b85333f9-715a-4052-bed1-b609d4cd5b1b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_33a1497a-8e76-4f98-ba8a-0511272dd762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_074119dd-4b75-43eb-adca-55de7e01d789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b85333f9-715a-4052-bed1-b609d4cd5b1b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_074119dd-4b75-43eb-adca-55de7e01d789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_895def8a-cd0a-4d7f-8db0-9d2fada8fc08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b85333f9-715a-4052-bed1-b609d4cd5b1b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_895def8a-cd0a-4d7f-8db0-9d2fada8fc08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f27ea7f5-be99-469b-b4c7-a4fa9da1765b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b85333f9-715a-4052-bed1-b609d4cd5b1b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f27ea7f5-be99-469b-b4c7-a4fa9da1765b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_701c3d50-3757-4ce4-9782-8229ac263929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b85333f9-715a-4052-bed1-b609d4cd5b1b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_701c3d50-3757-4ce4-9782-8229ac263929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0d031573-1a2e-4945-bff3-491913311a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b85333f9-715a-4052-bed1-b609d4cd5b1b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0d031573-1a2e-4945-bff3-491913311a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/OptionandLicenseAgreements" xlink:type="simple" xlink:href="morf-20210930.xsd#OptionandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/OptionandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementDisclosureAbstract_3b44d781-0415-46cb-9e2a-761f9eb511d2" xlink:href="morf-20210930.xsd#morf_CollaborativeArrangementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_8a618ed0-b785-4802-91e7-75d3f65d55a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_morf_CollaborativeArrangementDisclosureAbstract_3b44d781-0415-46cb-9e2a-761f9eb511d2" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_8a618ed0-b785-4802-91e7-75d3f65d55a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/OpenOptionContractsWrittenTables" xlink:type="simple" xlink:href="morf-20210930.xsd#OpenOptionContractsWrittenTables"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/OpenOptionContractsWrittenTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementDisclosureAbstract_4ce7a1a1-0245-403d-b373-6a312b97e958" xlink:href="morf-20210930.xsd#morf_CollaborativeArrangementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_fcb2c7f0-4ac3-4b58-ad3a-b1ebdbb3c6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_morf_CollaborativeArrangementDisclosureAbstract_4ce7a1a1-0245-403d-b373-6a312b97e958" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_fcb2c7f0-4ac3-4b58-ad3a-b1ebdbb3c6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#OptionandLicenseAgreementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementDisclosureAbstract_96212e7b-2057-489d-a00a-7105b258f1c1" xlink:href="morf-20210930.xsd#morf_CollaborativeArrangementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0cb898b9-b370-4b13-ae3d-4283bff6efe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_morf_CollaborativeArrangementDisclosureAbstract_96212e7b-2057-489d-a00a-7105b258f1c1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0cb898b9-b370-4b13-ae3d-4283bff6efe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d2de72b8-a8c1-46be-aabc-ab591307ad3f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0cb898b9-b370-4b13-ae3d-4283bff6efe0" xlink:to="loc_srt_CounterpartyNameAxis_d2de72b8-a8c1-46be-aabc-ab591307ad3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_70ffd935-ece2-4340-bc05-e3a285f70c49" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d2de72b8-a8c1-46be-aabc-ab591307ad3f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_70ffd935-ece2-4340-bc05-e3a285f70c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AbbVieMember_c3662e3a-6b3f-49eb-893b-0b111867e108" xlink:href="morf-20210930.xsd#morf_AbbVieMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_70ffd935-ece2-4340-bc05-e3a285f70c49" xlink:to="loc_morf_AbbVieMember_c3662e3a-6b3f-49eb-893b-0b111867e108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_JanssenPharmaceuticalsIncMember_12909a33-ce8c-4ccd-bc92-0be8843a5d2e" xlink:href="morf-20210930.xsd#morf_JanssenPharmaceuticalsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_70ffd935-ece2-4340-bc05-e3a285f70c49" xlink:to="loc_morf_JanssenPharmaceuticalsIncMember_12909a33-ce8c-4ccd-bc92-0be8843a5d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_43569f68-2ce3-4a15-a26e-503883357d6e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0cb898b9-b370-4b13-ae3d-4283bff6efe0" xlink:to="loc_srt_ProductOrServiceAxis_43569f68-2ce3-4a15-a26e-503883357d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c00edc74-0150-44e5-bc96-5bec84406df0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_43569f68-2ce3-4a15-a26e-503883357d6e" xlink:to="loc_srt_ProductsAndServicesDomain_c00edc74-0150-44e5-bc96-5bec84406df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_UpfrontPaymentRevenueMember_4442aa1e-8874-4483-a668-da0074f69ed5" xlink:href="morf-20210930.xsd#morf_UpfrontPaymentRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c00edc74-0150-44e5-bc96-5bec84406df0" xlink:to="loc_morf_UpfrontPaymentRevenueMember_4442aa1e-8874-4483-a668-da0074f69ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_3ae27cf1-5efd-4088-87bd-878f74dd6c20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c00edc74-0150-44e5-bc96-5bec84406df0" xlink:to="loc_us-gaap_LicenseMember_3ae27cf1-5efd-4088-87bd-878f74dd6c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8966931-469e-4b4d-b87c-7d6fcb2424ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0cb898b9-b370-4b13-ae3d-4283bff6efe0" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8966931-469e-4b4d-b87c-7d6fcb2424ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f1562b2a-6236-4d6b-aa89-4646d5da6bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8966931-469e-4b4d-b87c-7d6fcb2424ec" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f1562b2a-6236-4d6b-aa89-4646d5da6bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_ea89718f-5458-46e4-82e7-2729a4a44470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8966931-469e-4b4d-b87c-7d6fcb2424ec" xlink:to="loc_us-gaap_ContractWithCustomerLiability_ea89718f-5458-46e4-82e7-2729a4a44470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_3cfe2927-261a-4bb3-b65e-b5512af8dd60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8966931-469e-4b4d-b87c-7d6fcb2424ec" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_3cfe2927-261a-4bb3-b65e-b5512af8dd60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_morf_CollaborativeArrangementDisclosureAbstract_0b89f997-780d-4ec6-b1d2-92755e21e8b6" xlink:href="morf-20210930.xsd#morf_CollaborativeArrangementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f18b8493-784f-4cdd-bde4-1acde8775c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_morf_CollaborativeArrangementDisclosureAbstract_0b89f997-780d-4ec6-b1d2-92755e21e8b6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f18b8493-784f-4cdd-bde4-1acde8775c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0f413d18-33c3-44d1-9278-c3f1597dc0bb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f18b8493-784f-4cdd-bde4-1acde8775c15" xlink:to="loc_srt_CounterpartyNameAxis_0f413d18-33c3-44d1-9278-c3f1597dc0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c8d2e1ab-c5d6-4f7f-99fd-78f7b13587fb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0f413d18-33c3-44d1-9278-c3f1597dc0bb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c8d2e1ab-c5d6-4f7f-99fd-78f7b13587fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_AbbVieMember_e460878f-2fdb-44f3-a0b4-415ab28b6844" xlink:href="morf-20210930.xsd#morf_AbbVieMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c8d2e1ab-c5d6-4f7f-99fd-78f7b13587fb" xlink:to="loc_morf_AbbVieMember_e460878f-2fdb-44f3-a0b4-415ab28b6844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_JanssenPharmaceuticalsIncMember_163886b3-58c1-4c9f-ab10-d6088a9d609c" xlink:href="morf-20210930.xsd#morf_JanssenPharmaceuticalsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c8d2e1ab-c5d6-4f7f-99fd-78f7b13587fb" xlink:to="loc_morf_JanssenPharmaceuticalsIncMember_163886b3-58c1-4c9f-ab10-d6088a9d609c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c4d2a18a-791c-4c92-8916-15f45f6eee1e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f18b8493-784f-4cdd-bde4-1acde8775c15" xlink:to="loc_srt_ProductOrServiceAxis_c4d2a18a-791c-4c92-8916-15f45f6eee1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0c495a37-40d3-463f-95a6-c5e12f1a9b5a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c4d2a18a-791c-4c92-8916-15f45f6eee1e" xlink:to="loc_srt_ProductsAndServicesDomain_0c495a37-40d3-463f-95a6-c5e12f1a9b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_78f5c3a8-d22b-464e-aeec-46d02ef63806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0c495a37-40d3-463f-95a6-c5e12f1a9b5a" xlink:to="loc_us-gaap_LicenseMember_78f5c3a8-d22b-464e-aeec-46d02ef63806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_ReimbursementRevenueMember_7aa60ae8-6b9f-4afe-9d55-7e09c7f1c710" xlink:href="morf-20210930.xsd#morf_ReimbursementRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0c495a37-40d3-463f-95a6-c5e12f1a9b5a" xlink:to="loc_morf_ReimbursementRevenueMember_7aa60ae8-6b9f-4afe-9d55-7e09c7f1c710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_UpfrontPaymentRevenueMember_d68920e5-cb61-4c51-8021-d1ad2ff5ca71" xlink:href="morf-20210930.xsd#morf_UpfrontPaymentRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0c495a37-40d3-463f-95a6-c5e12f1a9b5a" xlink:to="loc_morf_UpfrontPaymentRevenueMember_d68920e5-cb61-4c51-8021-d1ad2ff5ca71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7fde0b0c-b3b6-42f5-b68f-fc5dd3a2f165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f18b8493-784f-4cdd-bde4-1acde8775c15" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7fde0b0c-b3b6-42f5-b68f-fc5dd3a2f165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5d2f5ed8-d346-4457-bdfd-c1449f4626ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7fde0b0c-b3b6-42f5-b68f-fc5dd3a2f165" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5d2f5ed8-d346-4457-bdfd-c1449f4626ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_616be0dd-0329-49e2-9b24-18d0499d201a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7fde0b0c-b3b6-42f5-b68f-fc5dd3a2f165" xlink:to="loc_us-gaap_CostsAndExpenses_616be0dd-0329-49e2-9b24-18d0499d201a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/NetLossIncomeperShare" xlink:type="simple" xlink:href="morf-20210930.xsd#NetLossIncomeperShare"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/NetLossIncomeperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_168e316c-d7cc-4268-bb57-4b051a25c3e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_30d7e5d4-6989-405b-98a2-751521a856d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_168e316c-d7cc-4268-bb57-4b051a25c3e3" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_30d7e5d4-6989-405b-98a2-751521a856d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/NetLossIncomeperShareTables" xlink:type="simple" xlink:href="morf-20210930.xsd#NetLossIncomeperShareTables"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/NetLossIncomeperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_318a74e0-6266-4edb-a3ea-5bb24515b7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_5fe80498-1f77-4d0e-9b7e-ed504a49e04f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_318a74e0-6266-4edb-a3ea-5bb24515b7e8" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_5fe80498-1f77-4d0e-9b7e-ed504a49e04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_fa33f6eb-8851-4289-ae1c-92c95fb99ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_318a74e0-6266-4edb-a3ea-5bb24515b7e8" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_fa33f6eb-8851-4289-ae1c-92c95fb99ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/NetLossIncomeperShareBasicnetincomelosspershareDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#NetLossIncomeperShareBasicnetincomelosspershareDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/NetLossIncomeperShareBasicnetincomelosspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7b8c6f89-d21f-4946-9abd-93ef5260fff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4714daa2-ff32-4b32-9ebe-7cc696592082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7b8c6f89-d21f-4946-9abd-93ef5260fff5" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4714daa2-ff32-4b32-9ebe-7cc696592082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_91452b98-8a86-4e79-93ed-6477f9dfa697" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4714daa2-ff32-4b32-9ebe-7cc696592082" xlink:to="loc_us-gaap_AwardTypeAxis_91452b98-8a86-4e79-93ed-6477f9dfa697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3da260c0-e2b1-4357-8870-4cd525bbe300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_91452b98-8a86-4e79-93ed-6477f9dfa697" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3da260c0-e2b1-4357-8870-4cd525bbe300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7dc7a0c3-b6d9-43e0-9a7e-3d8fa66eb89c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3da260c0-e2b1-4357-8870-4cd525bbe300" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7dc7a0c3-b6d9-43e0-9a7e-3d8fa66eb89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_RestrictedCommonStockAndRestrictedStockUnitsMember_f745e533-85f2-4476-add6-ccfb33e8fb2d" xlink:href="morf-20210930.xsd#morf_RestrictedCommonStockAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3da260c0-e2b1-4357-8870-4cd525bbe300" xlink:to="loc_morf_RestrictedCommonStockAndRestrictedStockUnitsMember_f745e533-85f2-4476-add6-ccfb33e8fb2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_107da403-b00f-4580-91f4-dd9bffc59bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4714daa2-ff32-4b32-9ebe-7cc696592082" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_107da403-b00f-4580-91f4-dd9bffc59bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2eda6a79-fd18-4130-b156-3adbfafab332" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_107da403-b00f-4580-91f4-dd9bffc59bd6" xlink:to="loc_us-gaap_NetIncomeLoss_2eda6a79-fd18-4130-b156-3adbfafab332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_da84ca02-f6b6-4646-98cd-5f42c2757673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_107da403-b00f-4580-91f4-dd9bffc59bd6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_da84ca02-f6b6-4646-98cd-5f42c2757673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_307d3d37-2cbf-4cff-b75d-32a4e7d6ff9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_107da403-b00f-4580-91f4-dd9bffc59bd6" xlink:to="loc_us-gaap_EarningsPerShareBasic_307d3d37-2cbf-4cff-b75d-32a4e7d6ff9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d974021c-704c-464c-9d27-fdf47ce3f6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_107da403-b00f-4580-91f4-dd9bffc59bd6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d974021c-704c-464c-9d27-fdf47ce3f6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_02a8a636-3f48-4f26-bef6-37feb9d044c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_107da403-b00f-4580-91f4-dd9bffc59bd6" xlink:to="loc_us-gaap_EarningsPerShareDiluted_02a8a636-3f48-4f26-bef6-37feb9d044c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://morphictx.com/role/NetLossIncomeperShareCommonstockequivalentsharesDetails" xlink:type="simple" xlink:href="morf-20210930.xsd#NetLossIncomeperShareCommonstockequivalentsharesDetails"/>
  <link:presentationLink xlink:role="http://morphictx.com/role/NetLossIncomeperShareCommonstockequivalentsharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2e1afa97-2e8e-4928-abdc-d02c4e1ad636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1e983ec9-263c-4f00-b3d2-8a678cb5d1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2e1afa97-2e8e-4928-abdc-d02c4e1ad636" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1e983ec9-263c-4f00-b3d2-8a678cb5d1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b503c681-bbcc-41d6-9777-ab47875895a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1e983ec9-263c-4f00-b3d2-8a678cb5d1c9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b503c681-bbcc-41d6-9777-ab47875895a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0c89a915-187c-4f8f-8912-6143ff267115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b503c681-bbcc-41d6-9777-ab47875895a9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0c89a915-187c-4f8f-8912-6143ff267115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_46b5710b-19ae-48f0-9ec0-6b8033467884" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0c89a915-187c-4f8f-8912-6143ff267115" xlink:to="loc_us-gaap_RestrictedStockMember_46b5710b-19ae-48f0-9ec0-6b8033467884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d93c0667-b008-4765-9f02-6cb2d2902993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0c89a915-187c-4f8f-8912-6143ff267115" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d93c0667-b008-4765-9f02-6cb2d2902993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_01ebad91-df07-443c-aabc-55a5a87abe4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0c89a915-187c-4f8f-8912-6143ff267115" xlink:to="loc_us-gaap_EmployeeStockOptionMember_01ebad91-df07-443c-aabc-55a5a87abe4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_morf_EmployeeStockPurchasePlanMember_c8ccb155-246e-4523-a9ef-7328d95c8a0a" xlink:href="morf-20210930.xsd#morf_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0c89a915-187c-4f8f-8912-6143ff267115" xlink:to="loc_morf_EmployeeStockPurchasePlanMember_c8ccb155-246e-4523-a9ef-7328d95c8a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_045807d5-0434-4033-b417-632348e0f7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1e983ec9-263c-4f00-b3d2-8a678cb5d1c9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_045807d5-0434-4033-b417-632348e0f7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_38c093e9-89d7-4dca-9a9d-afafeabc763f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_045807d5-0434-4033-b417-632348e0f7a6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_38c093e9-89d7-4dca-9a9d-afafeabc763f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>morf-20210930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:morf="http://morphictx.com/20210930"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="morf-20210930.xsd" xlink:type="simple"/>
    <context id="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i418fd438d137415fa9b558a67ab1fce8_I20211101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6a068fad94154f33aaa0ea27a826b0e1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8c604eb326ec497187ef28434af427bf_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9d6197cbb2f545b7ab683c1901d4ea29_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i243f3682abd5424ba05ed1db40ccb97c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i27ecd01750ae41fab6b59da5854ce971_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic197e04f10c7408ba4ef7db9f441c28a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i66ab197779d14e8b9af5bcb81478b4c6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i901f8ecd744645b8a45d1b64a74c0f58_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9be65219686545cf83e7c3cd5542dd20_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1d3e2328ff2041f58dcaeaaebb4233bc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia01ec15ac72b4497a0496ccada0d94dc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4efb9d0eda5b4f64829d51d0b07ac1b0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i06ca94fcd1b246778b2f5c3579ac9473_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:SecondaryOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i58aa03ecfdd643a5894ce9870d82dbf6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:SecondaryOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6e6d9c7159174b0789e9ced5c520204e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:SecondaryOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if5690066625a42e3b87d0384affb2d01_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib800117992e243cf8a7585686b33a363_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i515d2c5350ad4f2d83c7a0bdffb1c873_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifc97a27759e34d4cb8df378b38cdacaf_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1553aca7f70042e7abd871d77d833356_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i58cda165edf34fb0b54d026018e62af0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0f81b65df28e4c0eb8e87eb238682f6f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idbabfe222fdf4273a3a4864d3c46bb31_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if6b9e0cfb6c842a3a3373453c72b93c0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib6533246bc7740bfb131bb0f31d5ebce_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie4bbeefbdf784a4a86d7368751611e4d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic3a28dfdb1574133a31c2bbdc51e68b2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id787d30e67454f57ad1994ca3038b201_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib159d5476c2447b29c76c974f6a73e16_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie78e1f680612471088c63f49b5dd8a18_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6938de3cb6cf4fa7806a42ee8d41f58e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i045fb029fd9f4fd3ba7809ee012e5352_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5c8425c2e88641d2abdbb94c5d478327_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib378bf3c290247ed8a0dcf860e280f0f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie46f079ac4224779be66b7117f7c7607_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6a9a17e2241e4a3f9bf48a8a07ea581f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i93e1933f2bc44d94bea2dcf014ef6034_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if47513e8e86f49968b6af3544f6b81c9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i02e02a526a804154b6839aa55df1b6cb_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i525829a7d9e441d0ba3b4b60e68895fc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i67cb7e787c6f404fba5246e0f6e89ee6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5674ed6b01654ebeaed47a14ff3407ec_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2a0cdc60fdbc4ada914dbb870ef3b65e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie0289611dea94928a98cb550c8c5397a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5b404164f5bb4d7ca737270c6e265def_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if6bb096c70634192838a382eb5887887_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ided2a95523e74652809cc83e76cc2c1c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia2e37d454f86483da5d113ba5bb9c6ae_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i28b354f9bb8d47e8a80d9ddf5b84ae8c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i678eec9b2b244447b18fc4ba9a55fb5d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id44003b9b0fc4840a4b1164b5acc2433_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia0b42c7d7a4a4d258150923a53914e00_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i47ae904392494a1691f66d44af867fd5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib198e32eebb44ca09f321ba259b29ce2_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id62a5c373f8043a49ac6d4b6edcb5f03_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="idcc27241cea443418ead40c7a7f13130_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i3f787d6a671940b0a2ba97e900ceeba5_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i831afc5715a74d2ebfcc35bdfd047f7f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ibd4b367ccae649d798f837bc4bae25cf_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1b9b5c829b794265abbba640d8790b61_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie820eb1d183044f29008086e76bb8abb_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ieaa73485876b4e858b467fc72c87dc11_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia2b9993359cb456984780b6ee2dcb181_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i44de926c8806430b8699f3779b9c08b1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7c86edc9380f4e658d4c9376a669e0d9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie08a82cfc7f24fbbad0fe77f2bfe3618_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i22f2eddba4d5410b914c1f3b00fc8918_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i61f47238d1b44b2a9637c0aa85dc0ee4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i49f954fe973a4718a7bb027c7e112f91_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i763837ff1bfa4e4395a5c9985fb3ea1d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibb907e28eb904c5abe8778dff7854225_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7c337f23b5d94bce847216e32970fc13_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8ce691e108d44f41854e25c5b8aa249f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i58e35bd616704d81933f455f82a367b9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8e417c1626c0447da3ff198c9dbd9029_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifecee13ba23d4d56894bc6a643e63e62_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5762a65d06864432a626e61cf3346d84_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ifdf49025fcce47b8a9f8b80534c93448_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4d5c7026852d4a94bec2b79ab34bc87d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i64b5dd8c546640129471ee97d4f9028f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5f1bf035ce6148889916ac0580538d5b_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtMarketOfferingProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">morf:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i3a3fb30525ad4997ad257edca9bb1309_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">morf:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i2c1c09e4655f462d8172c3fed16c5d41_D20210811-20210811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtMarketOfferingProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">morf:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-11</startDate>
            <endDate>2021-08-11</endDate>
        </period>
    </context>
    <context id="i8539e76f9660442e9d169db576c8aedd_D20210811-20210811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">morf:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-11</startDate>
            <endDate>2021-08-11</endDate>
        </period>
    </context>
    <context id="i16001d4e30b441e1808c258ac136a45a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6a6c3241ca9141c9bbb04c6d0c0c55fa_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i77369a4a13ef44fa8daace2f7956ce2a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:AtMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie84d1725167c4a75be6380089ca4347a_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8cf597d615c64759b8f60cb2d5d4e180_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">morf:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i196c1e6bf66247b98fa293ce7ce21c10_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">morf:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="i385155a063a54593b7698266553fa968_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic691b1bab6064f3d9b9e1c90394f4e2d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id40e4cfd2a8045e1a1e666498fe4e815_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i037043297a254ed9b5cf0826c9db9fa9_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="icb831f5a17f54f7584aa402e76bb36fe_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i486fa776a3f04f34ac576895fc27dad7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0fb8ba20056d490189b4417c8db4fc8b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia8565d342aa34348b2d8b3de28ae62d2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i64b03ce48904405aa038b9b8f79e221c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i79dd709730de462484976109499248c0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3093e8eb0fbf40cfaf61a51b86743dfc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if0460516fcd64ec5939869a8cc9083fc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia7a2b23055c14610b9b9f0122e0bc83c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i57619922f2b04e87b375de9b0c6abf2f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1f4e846feef646b38404ae6f8ed330dc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="icd960eb27fba42f3a7c083248ce24430_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i488d3d9e7497417dae3338d286bf285c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1efba4c0bfa64c24912b8e57773d8914_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4a595f6291d745078296fee41e88b0b5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if06a28dfa4674c8da99858f333e14322_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iddb9c72e419f4eadbe5c615a694858f7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i078df3d57b71434481ab87bd4712a953_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8f25b4bb5f1f4854b5ecb14766c3ca49_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i12b799caa9b242aabc2dbefff0e5f757_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib207c5a6d64c4722b33aa55f1f923141_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib8109e4aa5a0416e9392220462770a8c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie493a72a05bd4a50bb01b9136293db44_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic0f1e91996364358920d91dc6eedb07f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1f5553a6ec7c411da7d58ef985358ba5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i103b3b3fd13b4d969b9f99f276f756be_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie233b4a2750a4b268a177be345cf1c52_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9fa385b09a9947cbaaa1c35bef4b2881_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="i1d81d7faa05e4d72ba315f45f8ca2b93_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i9b8872a576284d399ea67d6b51d01d5b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iccd54f681834442eb165955240d9e74a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idcf0ba2ceaab4483a2bfe533ce701a43_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia79f1a27faad4ee0b5c7c77ea717ed13_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic423ff5ccdca4effbe4d4211fa5e77f6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaf513a6144654bceada542de288df958_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1f9166bb425c44ada5c593577d00e22a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2eee8a4601534a4a917d268a6e6ed3c0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iad4849d4849a4887af432c78ad0245a8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i24c99804fc6044a5a6faa8fb23d4c212_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifa63b4b83d8c4eaca119ea3ed2510c96_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0f2f1b5251e94bbe8ef420f9ff484d6e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i65aaf5db173b49e9ab4c31517132d9ec_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i039b981d5def4df5ac1cd4a91d5e0229_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie9b7b224fe294b00affdcc71cba4f7d6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i28dbbd4689134d678129e0ec4c7edb79_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if4d1f97a11f54bcb896bca14bdcd10f2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if1efef8ae596461dbbceea676d6cf299_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibf03edf7a50641cfb11f3e5cc6746127_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i673a34526db04381a03c0b2e761aca2a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if9e3e64d44494241956eb0fdacb21e56_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i21ee8d1c8ad34b4e80c662e251e209ae_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i71df2423ac2c4debbc999ef809fd11c1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4bcc85b10d794d0c98147f0f99a5a07a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5998a9c8f16249a5a5aed5bd18c1e529_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i55558d3807264cfebb3cf65d4a4463df_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie3b3a9e7b9604013adda880bf9c86908_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic35b086f16144f27b108d50ef91c71d5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3306469c42b0426c851e95ee8d3af6bf_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i19b2674b6d5149d0b8ee34f673c706f2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iafc120c8b5bb4f488b7898393d9badba_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id827d0b4de4c40aebffdd742a897d8e7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i336ef268b2b54d5a8d41335f5521475d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie1bba300f18d4aa9a80235013244a2ca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i41bca88497e24b96b89b016e9cea4fe6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i500b2548238d418785e416f8b2eb9f96_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="idecb2791d4e644adac2b17f62a0ffc4d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9f2623aae9e042109d449218c4a952e2_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="if4fd934abc1c47eeb0364ac66d1ad27d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i933ed6a72813427384dce0d77c868663_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">morf:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2cb15e50535f4e87b974bc0af2a7bb9c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifd339294a59643f7b3b5f6dd55384718_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaacbf9b146694148984076cec6a6afd1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i291b9147c1ae41379197349d37bd173b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i230a2ca85b2a4dccb1eb0099d20ad182_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iae18ebb70c3c4104ab905dae334545e6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iccbf9f78a6bf4f6d936be01c6bdf3bde_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idf1288ac2081418ea5506b9b964c318e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3686e9bb301546d3b3f298fb3add79a3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if51ea1a4ae7b4814bdd7be74ca589c83_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icf36089b555c48e58d97c007d1218b7e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i04814fa766f14a87b1a4f5090088feac_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8b5652f4187946c99d351a84522e3224_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="id854b4ee36ae41358df7d8160430d227_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:ReimbursementRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia72ac23116b546868709c55972ad7552_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:ReimbursementRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifd2abd0024994ee09ba37323fe37f011_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:ReimbursementRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id12aad613d2c4493984ca5f33bb35df9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:ReimbursementRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i01c98160846146719189240b8058862e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie9354f5fe43946dc8a9f666176548cf0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9f177f36d3854a15b812deee9a7d9bdb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1757a9161a324b048e54e4ae0d303a19_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">morf:UpfrontPaymentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7428ecf2c9c2487f9fb6cb0173822e37_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i95e6d1a476764b22afd007e50518a6b3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib185e590ec714546bf7f6029f9dbac37_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i38ff992e2599451b9c12dca8f4da6c0e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idfcdd8be7e094adb844410ae8c290692_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id6809bfeafd44664a693a85e7e121e7a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">morf:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8bf19a2caf8b4d509a379811f8a3c1ea_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">morf:RestrictedCommonStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i12795b2676c0493781d9a5bdadfbf6cc_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">morf:RestrictedCommonStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1a64c5a4066049d08858e72736c24a45_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">morf:RestrictedCommonStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i20a672c9e2164a1480e1ae0fd1133627_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">morf:RestrictedCommonStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1117ebd626644baebf8cd85f62f25c00_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8ec79f5f2c2143ed87b1024777fbb963_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id77ac29ae1c946708d972f4329a5fd16_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ieb5f82106070482cae1bfd5c69ed3333_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4ea8f4ed8fbc4550aa703adec2e38d33_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icccb7da2fdfc4873a395a07afd73be7c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iea0a178c00d24c538b17f43b4a9992b0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i79f148df7d7a454d8deed12b42736ccb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8a342db77baf4dcc9e4c05d95f989378_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i33b959e99b544061a1ad9375c42039bd_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ica73f41d57df4863906446bbbec208e0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibc431739b79043079a7eb95d72fdb304_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4299c25bbef841838f8943aab9d90e62_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001679363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">morf:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80L2ZyYWc6ZjhhOGQzNzUzYTQ3NDI5MDkwMDA4ZGNjOWM1MjkwMGEvdGFibGU6NDkxMmU0M2FiMmY4NDhjNzlkZjgxNGIyY2U4YjY0MGMvdGFibGVyYW5nZTo0OTEyZTQzYWIyZjg0OGM3OWRmODE0YjJjZThiNjQwY18yLTEtMS0xLTIxMzY_ba55f4c5-edf1-403b-8a7c-9496144ea607">0001679363</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80L2ZyYWc6ZjhhOGQzNzUzYTQ3NDI5MDkwMDA4ZGNjOWM1MjkwMGEvdGFibGU6NDkxMmU0M2FiMmY4NDhjNzlkZjgxNGIyY2U4YjY0MGMvdGFibGVyYW5nZTo0OTEyZTQzYWIyZjg0OGM3OWRmODE0YjJjZThiNjQwY18zLTEtMS0xLTIxMzY_ef24286f-bad5-4e6e-9195-a7c6eac70cd8">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80L2ZyYWc6ZjhhOGQzNzUzYTQ3NDI5MDkwMDA4ZGNjOWM1MjkwMGEvdGFibGU6NDkxMmU0M2FiMmY4NDhjNzlkZjgxNGIyY2U4YjY0MGMvdGFibGVyYW5nZTo0OTEyZTQzYWIyZjg0OGM3OWRmODE0YjJjZThiNjQwY180LTEtMS0xLTIxMzY_be288f6d-ec81-4e46-91d8-3c79a76ba994">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80L2ZyYWc6ZjhhOGQzNzUzYTQ3NDI5MDkwMDA4ZGNjOWM1MjkwMGEvdGFibGU6NDkxMmU0M2FiMmY4NDhjNzlkZjgxNGIyY2U4YjY0MGMvdGFibGVyYW5nZTo0OTEyZTQzYWIyZjg0OGM3OWRmODE0YjJjZThiNjQwY181LTEtMS0xLTIxMzY_a6f4cf1c-c9d8-4678-8fd7-7db29e0fd4b7">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80L2ZyYWc6ZjhhOGQzNzUzYTQ3NDI5MDkwMDA4ZGNjOWM1MjkwMGEvdGFibGU6NDkxMmU0M2FiMmY4NDhjNzlkZjgxNGIyY2U4YjY0MGMvdGFibGVyYW5nZTo0OTEyZTQzYWIyZjg0OGM3OWRmODE0YjJjZThiNjQwY182LTEtMS0xLTIxMzY_874bc3f9-9325-4e20-bf10-47831ffc32d0">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGV4dHJlZ2lvbjowZjUxMGQ0MTQyOGU0ZWI3OWJlMjQ3ODkyODllYzMxZF8yMDMx_2921aeaa-3241-4df8-8797-f297d725b4c5">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGFibGU6MjE0MjM5NzEwNWU4NDA5YTgwMGQwYjhhODRiNzViMjkvdGFibGVyYW5nZToyMTQyMzk3MTA1ZTg0MDlhODAwZDBiOGE4NGI3NWIyOV8xLTAtMS0xLTIxMzY_5f922287-f87f-4553-bc65-67d367eebaae">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGV4dHJlZ2lvbjowZjUxMGQ0MTQyOGU0ZWI3OWJlMjQ3ODkyODllYzMxZF82NTk3MDY5NzY4NzE1_d4a949a5-8ae6-49ff-b622-9d274d5faf47">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGFibGU6NGYxYjgzNjg5YmI1NGFlOWFiZDkxMGY1OGFhNzJiNmUvdGFibGVyYW5nZTo0ZjFiODM2ODliYjU0YWU5YWJkOTEwZjU4YWE3MmI2ZV8wLTAtMS0xLTIxMzY_95e3b9c9-9435-48bd-9ddc-a55fac32c4e4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGV4dHJlZ2lvbjowZjUxMGQ0MTQyOGU0ZWI3OWJlMjQ3ODkyODllYzMxZF8yMDI2_a4acd4c5-6467-47f2-a515-431e960e85ca">001-38940</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGV4dHJlZ2lvbjowZjUxMGQ0MTQyOGU0ZWI3OWJlMjQ3ODkyODllYzMxZF8yMDI3_43f44aa8-f689-4c69-a5d9-7def64e8c354">MORPHIC HOLDING,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGFibGU6ZjQ4OTcwMGVlNTY2NDY5N2EzYWE3ZjRlMTg5NjU1ZDAvdGFibGVyYW5nZTpmNDg5NzAwZWU1NjY0Njk3YTNhYTdmNGUxODk2NTVkMF8wLTAtMS0xLTIxMzYvdGV4dHJlZ2lvbjpkYzI3NTE2ZDE3MjI0ZGY5OTExOWMyZDUwZTA2YWIwOV81_2e360f39-35d8-415c-8790-db32162a8618">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGFibGU6ZjQ4OTcwMGVlNTY2NDY5N2EzYWE3ZjRlMTg5NjU1ZDAvdGFibGVyYW5nZTpmNDg5NzAwZWU1NjY0Njk3YTNhYTdmNGUxODk2NTVkMF8wLTEtMS0xLTIxMzYvdGV4dHJlZ2lvbjoyZjc1ZjMzNDljNGM0ODg1YmQ4ZTgyOGZmM2I2YTkyNF81_7090f37d-c55b-4135-9281-02ff67edd567">47-3878772</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGFibGU6ZjQ4OTcwMGVlNTY2NDY5N2EzYWE3ZjRlMTg5NjU1ZDAvdGFibGVyYW5nZTpmNDg5NzAwZWU1NjY0Njk3YTNhYTdmNGUxODk2NTVkMF8xLTAtMS0xLTIxMzYvdGV4dHJlZ2lvbjoxMDcxMGQ5MjQ4ZjM0ZTIyODI2NjBjNDI3ZDkzNmQ2MV83_34e05301-376b-4c52-8e60-3cf295ff2395">35 Gatehouse Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGFibGU6ZjQ4OTcwMGVlNTY2NDY5N2EzYWE3ZjRlMTg5NjU1ZDAvdGFibGVyYW5nZTpmNDg5NzAwZWU1NjY0Njk3YTNhYTdmNGUxODk2NTVkMF8xLTAtMS0xLTIxMzYvdGV4dHJlZ2lvbjoxMDcxMGQ5MjQ4ZjM0ZTIyODI2NjBjNDI3ZDkzNmQ2MV8xMQ_0866ba64-6b98-462f-95b4-5253c824d824">A2</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGFibGU6ZjQ4OTcwMGVlNTY2NDY5N2EzYWE3ZjRlMTg5NjU1ZDAvdGFibGVyYW5nZTpmNDg5NzAwZWU1NjY0Njk3YTNhYTdmNGUxODk2NTVkMF8xLTAtMS0xLTIxMzYvdGV4dHJlZ2lvbjoxMDcxMGQ5MjQ4ZjM0ZTIyODI2NjBjNDI3ZDkzNmQ2MV8xNA_b9578f5e-377b-4618-859f-4662ddb8c645">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGFibGU6ZjQ4OTcwMGVlNTY2NDY5N2EzYWE3ZjRlMTg5NjU1ZDAvdGFibGVyYW5nZTpmNDg5NzAwZWU1NjY0Njk3YTNhYTdmNGUxODk2NTVkMF8xLTAtMS0xLTIxMzYvdGV4dHJlZ2lvbjoxMDcxMGQ5MjQ4ZjM0ZTIyODI2NjBjNDI3ZDkzNmQ2MV8xOA_b9d0588b-4fda-48a2-94c5-586e3b6964e5">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGFibGU6ZjQ4OTcwMGVlNTY2NDY5N2EzYWE3ZjRlMTg5NjU1ZDAvdGFibGVyYW5nZTpmNDg5NzAwZWU1NjY0Njk3YTNhYTdmNGUxODk2NTVkMF8xLTEtMS0xLTIxMzYvdGV4dHJlZ2lvbjpkNThhNWU0YTU1NWI0YzQ4YTljNzZjZWM5ZjkyZGZmY183_c59bf62d-e4e6-46c5-acfb-c012eda16f55">02451</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGV4dHJlZ2lvbjowZjUxMGQ0MTQyOGU0ZWI3OWJlMjQ3ODkyODllYzMxZF8yMDI4_759909dc-d755-4185-9f1f-fb15335b90e1">781</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGV4dHJlZ2lvbjowZjUxMGQ0MTQyOGU0ZWI3OWJlMjQ3ODkyODllYzMxZF8yMDMy_dd3ae3db-bc66-4a21-877a-1d5fb0a2747b">996-0955</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGFibGU6MzYwN2YyMmJiMmNkNDFhNDk3YmUzOTIwNmY1MWM4MjkvdGFibGVyYW5nZTozNjA3ZjIyYmIyY2Q0MWE0OTdiZTM5MjA2ZjUxYzgyOV8xLTAtMS0xLTIxMzY_d26e27f9-3c67-444c-9ad6-e19056d5b9f8">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGFibGU6MzYwN2YyMmJiMmNkNDFhNDk3YmUzOTIwNmY1MWM4MjkvdGFibGVyYW5nZTozNjA3ZjIyYmIyY2Q0MWE0OTdiZTM5MjA2ZjUxYzgyOV8xLTEtMS0xLTIxMzY_44503a68-c6c1-4fa1-b020-2935c3ae8690">MORF</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGFibGU6MzYwN2YyMmJiMmNkNDFhNDk3YmUzOTIwNmY1MWM4MjkvdGFibGVyYW5nZTozNjA3ZjIyYmIyY2Q0MWE0OTdiZTM5MjA2ZjUxYzgyOV8xLTItMS0xLTIxMzY_462e9603-2b25-4057-b679-16a5e1dfc077">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGV4dHJlZ2lvbjowZjUxMGQ0MTQyOGU0ZWI3OWJlMjQ3ODkyODllYzMxZF8yMDI5_cf25db3d-048f-488a-8398-987bdea010fe">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGV4dHJlZ2lvbjowZjUxMGQ0MTQyOGU0ZWI3OWJlMjQ3ODkyODllYzMxZF8yMDMz_084295da-446d-4903-88f9-15ab1b2cc6b9">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGFibGU6MGM4NzFhZjFiYzlhNDQzMmE3YzVjNWMyYzYxOGVlNTkvdGFibGVyYW5nZTowYzg3MWFmMWJjOWE0NDMyYTdjNWM1YzJjNjE4ZWU1OV8xLTAtMS0xLTIxMzYvdGV4dHJlZ2lvbjoyOGQ2MDFjM2JlMjE0MDAzYmFhYjBmMzdkNzE1MDdmY180_e953fe14-6d7f-4138-8d34-1f429a8ef447">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGFibGU6MGM4NzFhZjFiYzlhNDQzMmE3YzVjNWMyYzYxOGVlNTkvdGFibGVyYW5nZTowYzg3MWFmMWJjOWE0NDMyYTdjNWM1YzJjNjE4ZWU1OV8xLTEtMS0xLTIxMzYvdGV4dHJlZ2lvbjo5ZGJlODdlNDZiN2Y0NDFkYWFjNzUyOTI3ZTViOTAzMl8zMA_e59e941d-7195-4fe9-a2f0-1ffbc4f43c9f">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGFibGU6MGM4NzFhZjFiYzlhNDQzMmE3YzVjNWMyYzYxOGVlNTkvdGFibGVyYW5nZTowYzg3MWFmMWJjOWE0NDMyYTdjNWM1YzJjNjE4ZWU1OV8yLTEtMS0xLTIxMzYvdGV4dHJlZ2lvbjo2MWExMzNkYTlmNDQ0ZDlmYjkxZjk0MGRjYjMwYTQyNl8yOA_b379d844-7a8f-4cd0-8a84-492d3f76ff90">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGV4dHJlZ2lvbjowZjUxMGQ0MTQyOGU0ZWI3OWJlMjQ3ODkyODllYzMxZF8yMDM0_320c535a-b033-4d96-81a7-b4904c03f71f">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGV4dHJlZ2lvbjowZjUxMGQ0MTQyOGU0ZWI3OWJlMjQ3ODkyODllYzMxZF8yMDMw_c9f44b82-16d1-4725-9821-ad933ea73ee4">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i418fd438d137415fa9b558a67ab1fce8_I20211101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xL2ZyYWc6MGY1MTBkNDE0MjhlNGViNzliZTI0Nzg5Mjg5ZWMzMWQvdGV4dHJlZ2lvbjowZjUxMGQ0MTQyOGU0ZWI3OWJlMjQ3ODkyODllYzMxZF8xNjQ5MjY3NDQzNzUw_f449de5e-1908-4e6e-b0b2-b7199312f474"
      unitRef="shares">36961618</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfNC0xLTEtMS0yMTM2_55baceaf-cfa0-48a1-97dd-591c33405fc4"
      unitRef="usd">184159000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfNC0zLTEtMS0yMTM2_2039d01e-220e-4382-9378-873dcb926218"
      unitRef="usd">102047000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfNS0xLTEtMS0yMTM2_a7c2ae64-b720-4da1-9b26-e95151524b5c"
      unitRef="usd">243417000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfNS0zLTEtMS0yMTM2_7b673c2c-d0f8-4770-92a8-a5d3ab9d759e"
      unitRef="usd">126217000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfNi0xLTEtMS0yMTM2_3bf3de25-f3e5-4e5e-a9b5-4a3231df563f"
      unitRef="usd">2618000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfNi0zLTEtMS0yMTM2_2de0a58d-1671-4e68-ad18-fafbb86dce00"
      unitRef="usd">7314000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfNy0xLTEtMS0yMTM2_a5016b74-ae79-4f4c-8e63-a59eee1e22b2"
      unitRef="usd">5210000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfNy0zLTEtMS0yMTM2_30ad188d-8d6d-4060-8582-7b8a21a8bcc3"
      unitRef="usd">3857000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfOC0xLTEtMS0yMTM2_079f7d26-05c7-4efb-82d0-0735db0f3fcb"
      unitRef="usd">435404000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfOC0zLTEtMS0yMTM2_086adf4c-8068-420a-96ac-481ded64f101"
      unitRef="usd">239435000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTAtMS0xLTEtMjEzNg_ad5ff557-abb8-464f-ba86-9f369dcc3816"
      unitRef="usd">2584000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTAtMy0xLTEtMjEzNg_f507da0b-71cc-409c-991e-533f23558f68"
      unitRef="usd">2606000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCash
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTEtMS0xLTEtMjEzNg_bbac4bb2-4de8-424d-8465-aa72ffcc0db7"
      unitRef="usd">560000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTEtMy0xLTEtMjEzNg_1d11643f-05ad-41aa-a5c6-f39c82520850"
      unitRef="usd">275000</us-gaap:RestrictedCash>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTItMS0xLTEtMjEzNg_efab2516-d2bb-4596-877b-a81736523aeb"
      unitRef="usd">15000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTItMy0xLTEtMjEzNg_f170ce0f-0922-4f78-8b9e-3ca937d7d5bd"
      unitRef="usd">66000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTMtMS0xLTEtMjEzNg_8af1b418-f6e3-40e1-94e7-21183ed58e28"
      unitRef="usd">438563000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTMtMy0xLTEtMjEzNg_a4bfd9dd-caa5-48c8-8da3-9c0b9b99458a"
      unitRef="usd">242382000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTYtMS0xLTEtMjEzNg_65d20e6a-8a08-4aa8-a8b5-0148f6fdd0df"
      unitRef="usd">3176000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTYtMy0xLTEtMjEzNg_67a76c98-b69b-4837-863c-0b69cc6b67ed"
      unitRef="usd">3845000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTctMS0xLTEtMjEzNg_df96444e-8856-4920-bc58-ea1d6b24da34"
      unitRef="usd">8417000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTctMy0xLTEtMjEzNg_828e0c9a-378a-4774-a7a3-a4183d9e9f3f"
      unitRef="usd">10160000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTgtMS0xLTEtMjEzNg_891018ea-6606-4f1a-9252-c57a90b26b31"
      unitRef="usd">30148000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTgtMy0xLTEtMjEzNg_901e4ce4-abdb-4865-b70d-20fb2b1fc85a"
      unitRef="usd">25266000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:AccruedRentCurrent
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTktMS0xLTEtMjEzNg_ce1c189c-2d3b-4c1c-850a-2407b53a5e33"
      unitRef="usd">23000</us-gaap:AccruedRentCurrent>
    <us-gaap:AccruedRentCurrent
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMTktMy0xLTEtMjEzNg_ed6950da-46a5-4c8c-b2b4-7c9b35a831c6"
      unitRef="usd">167000</us-gaap:AccruedRentCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjAtMS0xLTEtMjEzNg_9c4b9b9b-6b37-4fe8-95e3-33003dd505ee"
      unitRef="usd">41764000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjAtMy0xLTEtMjEzNg_b68229ae-db0e-4c73-ad32-b208e0836a9d"
      unitRef="usd">39438000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjMtMS0xLTEtMjEzNg_9f5976ea-e76b-4856-b9cb-6c86e73f1a85"
      unitRef="usd">46495000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjMtMy0xLTEtMjEzNg_f6c3bec7-afe3-4074-bad4-b75b03356064"
      unitRef="usd">57672000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:AccruedRentNoncurrent
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjQtMS0xLTEtMjEzNg_2af37f65-2677-4ec5-a039-3694c62794dc"
      unitRef="usd">139000</us-gaap:AccruedRentNoncurrent>
    <us-gaap:AccruedRentNoncurrent
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjQtMy0xLTEtMjEzNg_2fe54e83-e60b-4222-a1d6-a744d857be62"
      unitRef="usd">75000</us-gaap:AccruedRentNoncurrent>
    <us-gaap:Liabilities
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjUtMS0xLTEtMjEzNg_e8b91b35-a72c-47fd-bb1a-7311d141703b"
      unitRef="usd">88398000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjUtMy0xLTEtMjEzNg_531d767f-af16-4d4b-8476-48c3f0b4d101"
      unitRef="usd">97185000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjgtMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjE2YWI2OTlmZDZlOTQ4N2ZiNTZjZDMxODUzYTgzOWM5XzIy_67afc8ef-84cb-416f-a833-d7ad3a057327"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjgtMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjE2YWI2OTlmZDZlOTQ4N2ZiNTZjZDMxODUzYTgzOWM5XzIy_79989d10-ba84-4f3d-a6a1-d45223b82ef7"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjgtMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjE2YWI2OTlmZDZlOTQ4N2ZiNTZjZDMxODUzYTgzOWM5XzM2_9d1a745b-4295-4a7e-ba28-23dc4ed9fac0"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjgtMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjE2YWI2OTlmZDZlOTQ4N2ZiNTZjZDMxODUzYTgzOWM5XzM2_b63c0acd-7d8b-48ee-aec8-d77b4824998e"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjgtMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjE2YWI2OTlmZDZlOTQ4N2ZiNTZjZDMxODUzYTgzOWM5XzU4_00ebd298-6be6-487b-a4f4-04333e30b95c"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjgtMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjE2YWI2OTlmZDZlOTQ4N2ZiNTZjZDMxODUzYTgzOWM5XzU4_d9e560f9-c330-49c7-9469-aa844b466a4c"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjgtMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjE2YWI2OTlmZDZlOTQ4N2ZiNTZjZDMxODUzYTgzOWM5XzU4_dc436d9e-72d7-4aca-bb4a-c48ca95be2f0"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjgtMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjE2YWI2OTlmZDZlOTQ4N2ZiNTZjZDMxODUzYTgzOWM5XzU4_de90c241-d92b-42a2-b1b2-52fa62153acd"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjgtMS0xLTEtMjEzNg_1fd8c36c-ece4-40f5-824f-e7bee70af4d3"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjgtMy0xLTEtMjEzNg_535e26fe-2f36-454c-8642-7513d5451d1e"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjktMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjVjNjY4NWFlMWEwMjQxOTc4OGU1ZDc5YmU5YTdiNTkyXzE5_30d283d0-c022-4db5-bfdd-9f98bf088b89"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjktMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjVjNjY4NWFlMWEwMjQxOTc4OGU1ZDc5YmU5YTdiNTkyXzE5_8794d62c-a340-465f-acce-6ee0e2827585"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjktMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjVjNjY4NWFlMWEwMjQxOTc4OGU1ZDc5YmU5YTdiNTkyXzMz_ccdc694a-88e5-4927-ab27-f4274fa6e0c9"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjktMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjVjNjY4NWFlMWEwMjQxOTc4OGU1ZDc5YmU5YTdiNTkyXzMz_d5faebca-7736-45cc-aae6-04fc226a6228"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjktMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjVjNjY4NWFlMWEwMjQxOTc4OGU1ZDc5YmU5YTdiNTkyXzU1_fa3d4711-34b2-4c81-86a9-7e1ad65f2341"
      unitRef="shares">36892411</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjktMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjVjNjY4NWFlMWEwMjQxOTc4OGU1ZDc5YmU5YTdiNTkyXzU1_ff253210-0bc7-480d-9998-25a51b5cde14"
      unitRef="shares">36892411</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjktMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjVjNjY4NWFlMWEwMjQxOTc4OGU1ZDc5YmU5YTdiNTkyXzExMg_88c3e55e-03d0-4785-a17e-163a91d3a674"
      unitRef="shares">32037686</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjktMC0xLTEtMjEzNi90ZXh0cmVnaW9uOjVjNjY4NWFlMWEwMjQxOTc4OGU1ZDc5YmU5YTdiNTkyXzExMg_dea8e94a-7055-4199-8a81-bb12da741c77"
      unitRef="shares">32037686</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjktMS0xLTEtMjEzNg_40bfab6b-bbc4-4a84-86a4-2415b1fc0049"
      unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMjktMy0xLTEtMjEzNg_e297d95d-53f9-460b-a40b-e310c386c0e1"
      unitRef="usd">3000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMzAtMS0xLTEtMjEzNg_ce598f43-2e39-4e36-9dec-b1aae36892a5"
      unitRef="usd">566906000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMzAtMy0xLTEtMjEzNg_06129725-30b2-45d1-9d0a-aead5eb34aa2"
      unitRef="usd">287727000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMzEtMS0xLTEtMjEzNg_7bbe30df-2eb0-4632-b1cb-d81b2e19485f"
      unitRef="usd">-216652000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMzEtMy0xLTEtMjEzNg_dea98e0d-93a8-436c-8e6f-0c9184a261e8"
      unitRef="usd">-142512000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMzItMS0xLTEtMjEzNg_341ee3c7-67d8-415f-ac4d-2d7d29a24fe7"
      unitRef="usd">-93000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMzItMy0xLTEtMjEzNg_8331cd71-7372-4cee-95c4-df0567106818"
      unitRef="usd">-21000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMzMtMS0xLTEtMjEzNg_8eb42156-3275-4202-9fe2-9f35d8b72abd"
      unitRef="usd">350165000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMzMtMy0xLTEtMjEzNg_a6e9d18c-811e-4b6a-a555-ef763aebb8cb"
      unitRef="usd">145197000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMzQtMS0xLTEtMjEzNg_4cc02510-2c28-4439-ac0a-2a9fc7585044"
      unitRef="usd">438563000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xNi9mcmFnOjk5NWJlNWE2NmZmYzRmYzNiMDE4ODhlNGFmNmEzMTExL3RhYmxlOjdjNDViMTQ5ZjFmODQzZWM5OThiNDRiZmU3NDg4NjNkL3RhYmxlcmFuZ2U6N2M0NWIxNDlmMWY4NDNlYzk5OGI0NGJmZTc0ODg2M2RfMzQtMy0xLTEtMjEzNg_ab4e263e-1bd6-460e-ad1d-1d391f3e7303"
      unitRef="usd">242382000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMy0xLTEtMS0yMTM2_63f762d8-191e-4a85-9dee-3d3ca9822a91"
      unitRef="usd">3124000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMy0zLTEtMS0yMTM2_5152ff84-e2fb-4cd5-9ea2-114dea4ec602"
      unitRef="usd">25757000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMy01LTEtMS0yMTM2_4a321af0-18c3-43a3-bcc8-eb806255c6a2"
      unitRef="usd">10238000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMy03LTEtMS0yMTM2_81a95ea7-fd35-4dd3-9acd-f4bd881b23aa"
      unitRef="usd">39044000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfNS0xLTEtMS0yMTM2_ee0aca43-dda3-437e-935c-7cc5acdf73ae"
      unitRef="usd">20966000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfNS0zLTEtMS0yMTM2_9bc06629-7e87-4340-8385-71ff0fe271d4"
      unitRef="usd">15998000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfNS01LTEtMS0yMTM2_b41ce81c-362a-4c5e-8198-d3d8248903a9"
      unitRef="usd">64131000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfNS03LTEtMS0yMTM2_d7e0b0c9-9fc3-4aa1-91ab-d586692dbb15"
      unitRef="usd">54877000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfNi0xLTEtMS0yMTM2_bffeaba1-f139-4efe-8e9f-efd1edde00e6"
      unitRef="usd">7276000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfNi0zLTEtMS0yMTM2_92244266-585f-4f3d-849d-30af894260cc"
      unitRef="usd">4751000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfNi01LTEtMS0yMTM2_3da80be0-0579-416c-afa4-78d4aa74b04f"
      unitRef="usd">20367000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfNi03LTEtMS0yMTM2_b0118d9a-77aa-483f-810d-e29397e81475"
      unitRef="usd">13368000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfNy0xLTEtMS0yMTM2_4944b808-1f59-42b0-862b-d5bc8cb5c69b"
      unitRef="usd">28242000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfNy0zLTEtMS0yMTM2_63822278-5bbc-4379-86ec-c28c781aed33"
      unitRef="usd">20749000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfNy01LTEtMS0yMTM2_16e3c4ad-1089-49e5-94c9-a9245570cfe5"
      unitRef="usd">84498000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfNy03LTEtMS0yMTM2_6c11339d-ab0a-4b26-864b-ff041d4dcdc6"
      unitRef="usd">68245000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfOC0xLTEtMS0yMTM2_0b33c897-0ce6-46aa-88e3-cb56f192697b"
      unitRef="usd">-25118000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfOC0zLTEtMS0yMTM2_5ed6c4ed-3607-45fd-8c11-7f49f856704c"
      unitRef="usd">5008000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfOC01LTEtMS0yMTM2_f4461b44-78ac-4cf7-98d5-314ac465a152"
      unitRef="usd">-74260000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfOC03LTEtMS0yMTM2_96fa0e4c-7c38-4776-814f-92d5165474a9"
      unitRef="usd">-29201000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTAtMS0xLTEtMjEzNg_0a41c4b4-d2ce-48c2-910b-770e895cce8a"
      unitRef="usd">77000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTAtMy0xLTEtMjEzNg_250caf89-1a80-48e5-83c0-ab5017ae765c"
      unitRef="usd">237000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTAtNS0xLTEtMjEzNg_65442dca-89f6-4f0a-b902-99ba4c8b36c9"
      unitRef="usd">140000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTAtNy0xLTEtMjEzNg_109654b4-7230-4401-ad04-9f2f56b74dfd"
      unitRef="usd">1536000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTEtMS0xLTEtMjEzNg_78fc9dfb-074f-4c6f-abff-b92ccd1ecbbf"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTEtMy0xLTEtMjEzNg_7c38c159-435e-4963-8f79-795085968105"
      unitRef="usd">-6000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTEtNS0xLTEtMjEzNg_85ea44a1-4935-4d09-b6a3-162ea42185c8"
      unitRef="usd">-20000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTEtNy0xLTEtMjEzNg_fd933df3-5e6f-4a4e-8a69-68b547dc89b6"
      unitRef="usd">-12000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTItMS0xLTEtMjEzNg_3da67055-4260-4b7e-9d6d-be3d115ba538"
      unitRef="usd">77000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTItMy0xLTEtMjEzNg_11aeb642-5d4a-4330-bf52-08cdc72dcf0b"
      unitRef="usd">231000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTItNS0xLTEtMjEzNg_16c30221-68d9-45c6-b3b9-4b8dc79d2c4c"
      unitRef="usd">120000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTItNy0xLTEtMjEzNg_19c61240-9c14-4715-92db-ddedd29a2c0e"
      unitRef="usd">1524000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTMtMS0xLTEtMjEzNg_6330bab7-e623-4f16-9b7b-2c21d7bf322f"
      unitRef="usd">-25041000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTMtMy0xLTEtMjEzNg_2dab9a37-70fb-4e50-b751-02b0b62637c3"
      unitRef="usd">5239000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTMtNS0xLTEtMjEzNg_c2ef99bf-b9e2-4ca3-b11c-442de8bb711e"
      unitRef="usd">-74140000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTMtNy0xLTEtMjEzNg_47658af0-af19-44b0-ad09-30c78fd54086"
      unitRef="usd">-27677000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTQtMS0xLTEtMjEzNg_c7f30281-30b7-4109-9a3e-b27780f1e711"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTQtMy0xLTEtMjEzNg_86b1b654-1780-455e-88e6-3b4218cbec0c"
      unitRef="usd">-115000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTQtNS0xLTEtMjEzNg_6a14587b-eeec-4c2a-996e-8585364d6ad0"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTQtNy0xLTEtMjEzNg_fa80066e-19b8-44fa-b6fc-2824e1a7ccba"
      unitRef="usd">-427000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTUtMS0xLTEtMjEzNg_172f3ede-705c-40e5-9068-b1501d12816e"
      unitRef="usd">-25041000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTUtMy0xLTEtMjEzNg_9e1ccf23-fc2d-4bb0-8a75-820d5156b1c7"
      unitRef="usd">5354000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTUtNS0xLTEtMjEzNg_23b29a7f-d182-47cd-8ca8-040601c2cc74"
      unitRef="usd">-74140000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTUtNy0xLTEtMjEzNg_7d8eeb7a-2df7-4356-a390-235b7513d136"
      unitRef="usd">-27250000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTYtMS0xLTEtMjEzNg_f2eab23e-37c7-41d2-b99a-c10b9cad2e42"
      unitRef="usdPerShare">-0.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTYtMy0xLTEtMjEzNg_b1f014c5-1d96-44ff-92f1-af428e2439e2"
      unitRef="usdPerShare">0.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTYtNS0xLTEtMjEzNg_7086749f-f604-4cbb-a151-cd0dddbde57d"
      unitRef="usdPerShare">-2.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTYtNy0xLTEtMjEzNg_92d4f044-2677-4ce2-bba4-9724ed66a46a"
      unitRef="usdPerShare">-0.90</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTctMS0xLTEtMzIzMw_79806467-afcf-4b8c-be86-3d2ad5dca9e3"
      unitRef="usdPerShare">-0.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTctMS0xLTEtMzIzMw_804d6c04-826f-4040-8267-7f8f30485929"
      unitRef="usdPerShare">-0.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTctMy0xLTEtMzIzMw_b831b3c0-dd7e-4681-8b13-4c29ea9d0613"
      unitRef="usdPerShare">0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTctNS0xLTEtMzIzMw_54816111-70ae-48ef-b789-f7061e8dff0c"
      unitRef="usdPerShare">-2.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTctNy0xLTEtMzIzMw_547eb4aa-908b-4ab6-afc9-062c05893440"
      unitRef="usdPerShare">-0.90</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTgtMS0xLTEtMjEzNg_16b61173-78ef-471f-bf7d-89aebd053823"
      unitRef="shares">36547222</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTgtMy0xLTEtMjEzNg_1e3618e5-2c38-4d59-97a6-f03baac82b93"
      unitRef="shares">30533847</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTgtNS0xLTEtMjEzNg_60a728ed-2999-4329-9ef7-9c5af11c7f1b"
      unitRef="shares">35392153</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMTgtNy0xLTEtMjEzNg_83ea6809-8076-4794-861f-f1c055f8acc8"
      unitRef="shares">30368437</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjAtMS0xLTEtMzI0NQ_433664a5-964d-421d-a6d9-3b9c8a5c36a0"
      unitRef="shares">36547222</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjAtMy0xLTEtMzI0NQ_13de2d2e-096f-4544-821d-21af080aeaad"
      unitRef="shares">32366141</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjAtNS0xLTEtMzI0NQ_518b28e4-710d-4034-bcac-cfe20c9b80fe"
      unitRef="shares">35392153</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjAtNy0xLTEtMzI0NQ_5a01372b-5e08-410f-9aea-6bc74b16ff4d"
      unitRef="shares">30368437</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjEtMS0xLTEtMjEzNg_535ed7dd-dba4-408b-953e-7236683dfe81"
      unitRef="usd">-25041000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjEtMy0xLTEtMjEzNg_28c9ee6a-5a18-4be1-8811-2c81ee59867a"
      unitRef="usd">5354000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjEtNS0xLTEtMjEzNg_d93c3c83-8743-40ce-b4db-82b6e32cb1ec"
      unitRef="usd">-74140000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjEtNy0xLTEtMjEzNg_adbf4fc0-2659-4e02-aa2f-8c1cd330a6c1"
      unitRef="usd">-27250000</us-gaap:NetIncomeLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjMtMS0xLTEtMjEzNg_6c815e8b-c655-43a0-af03-f76134abe9d1"
      unitRef="usd">-73000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjMtMy0xLTEtMjEzNg_30867330-5aef-40f3-bd56-af643405044d"
      unitRef="usd">-190000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjMtNS0xLTEtMjEzNg_1b723a48-b3ad-48ac-8594-55845c2fdb8d"
      unitRef="usd">-72000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjMtNy0xLTEtMjEzNg_400be2da-c306-49a3-9ed1-fecca4ffa89d"
      unitRef="usd">-10000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjQtMS0xLTEtMjEzNg_8d182329-3e11-4895-8451-50a8202fc1c5"
      unitRef="usd">-73000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjQtMy0xLTEtMjEzNg_51442c91-5d6b-407a-85de-d38397de5375"
      unitRef="usd">-190000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjQtNS0xLTEtMjEzNg_b6a0ca9a-87c1-44c4-8cf9-f844c7736f79"
      unitRef="usd">-72000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjQtNy0xLTEtMjEzNg_d044492f-d5c4-46b7-8e3f-1d731855cf0a"
      unitRef="usd">-10000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjUtMS0xLTEtMjEzNg_32488dd4-1d8c-4054-8a76-4a78c87fa647"
      unitRef="usd">-25114000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjUtMy0xLTEtMjEzNg_007f5ece-d7fe-49cf-9ed1-0883c82b2ee6"
      unitRef="usd">5164000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjUtNS0xLTEtMjEzNg_3e1d5d21-aeb3-491f-bfe5-97d53c56f5e7"
      unitRef="usd">-74212000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xOS9mcmFnOmNkNjUwNmNjMDNlYzQyYjdhMTZhMmVmOGNiYzE0NGYzL3RhYmxlOjU5NjQ4NjQ3OWFhNTQzOWM4M2EwZGM4Y2NkOTM4MjdjL3RhYmxlcmFuZ2U6NTk2NDg2NDc5YWE1NDM5YzgzYTBkYzhjY2Q5MzgyN2NfMjUtNy0xLTEtMjEzNg_a121666b-e786-403e-9835-f8dfc02ad1b9"
      unitRef="usd">-27260000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i9d6197cbb2f545b7ab683c1901d4ea29_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMi0xLTEtMS00NjM4_7afc5e57-5669-4298-922a-afd3735c3604"
      unitRef="shares">32037686</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9d6197cbb2f545b7ab683c1901d4ea29_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMi0zLTEtMS00NjM4_7a795159-d5e1-4628-9bae-a9f2b5567c44"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i243f3682abd5424ba05ed1db40ccb97c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMi01LTEtMS00NjM4_58062c7f-b912-416f-b806-641dc5c4584b"
      unitRef="usd">287727000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i27ecd01750ae41fab6b59da5854ce971_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMi03LTEtMS00NjM4_6d4e867e-4de9-425d-8f0e-05fb144b843f"
      unitRef="usd">-142512000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic197e04f10c7408ba4ef7db9f441c28a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMi05LTEtMS00NjM4_0afc3498-95fe-418c-812a-c6840b74a4fa"
      unitRef="usd">-21000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMi0xMS0xLTEtNDYzOA_0c347755-9915-4dac-92ac-251d26a79e6a"
      unitRef="usd">145197000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i66ab197779d14e8b9af5bcb81478b4c6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMy01LTEtMS00NjM4_299b9e05-824b-4cf7-b799-a9a838858986"
      unitRef="usd">4442000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i901f8ecd744645b8a45d1b64a74c0f58_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMy0xMS0xLTEtNDYzOA_2702d7be-849d-4f90-b16a-3889ec93b5dd"
      unitRef="usd">4442000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i9be65219686545cf83e7c3cd5542dd20_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfNC0xLTEtMS00NjM4_2414c3be-b99c-4807-b443-a7c33813088b"
      unitRef="shares">46893</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i9be65219686545cf83e7c3cd5542dd20_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfNS0xLTEtMS00NjM4_5258e136-fc96-4569-a436-08aeba5e9eab"
      unitRef="shares">279431</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i66ab197779d14e8b9af5bcb81478b4c6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfNS01LTEtMS00NjM4_33063866-68dc-4c32-b45d-eab89980686b"
      unitRef="usd">2657000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i901f8ecd744645b8a45d1b64a74c0f58_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfNS0xMS0xLTEtNDYzOA_5a47f397-8f3d-45b1-9127-160194f341df"
      unitRef="usd">2657000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="i9be65219686545cf83e7c3cd5542dd20_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfNi0xLTEtMS00NjM4_80e46cd5-d00c-4f33-a47c-ed3ace038c1f"
      unitRef="shares">26561</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="i66ab197779d14e8b9af5bcb81478b4c6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfNi01LTEtMS00NjM4_34055cc2-577b-4348-9b01-f6ee2d2e7f67"
      unitRef="usd">613000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="i901f8ecd744645b8a45d1b64a74c0f58_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfNi0xMS0xLTEtNDYzOA_5dd77d55-0d53-42cd-a322-d33ea2547c5c"
      unitRef="usd">613000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i1d3e2328ff2041f58dcaeaaebb4233bc_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfNy0wLTEtMS00NjE3L3RleHRyZWdpb246ZmI2NTQ1MGRiMzQ3NDU4OTk5Mzk1MDJjNmU5ZGE3NWFfMTA5OTUxMTYyNzg4OQ_b947f005-f868-4e70-a4ad-5a8433d5f377"
      unitRef="usd">200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia01ec15ac72b4497a0496ccada0d94dc_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfNy0xLTEtMS00NjM4_224b5060-36b8-4d59-9eeb-557750a6e343"
      unitRef="shares">240704</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4efb9d0eda5b4f64829d51d0b07ac1b0_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfNy01LTEtMS00NjM4_61212a5a-4966-4a75-b8ff-bc8f7cd56f98"
      unitRef="usd">7231000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1d3e2328ff2041f58dcaeaaebb4233bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfNy0xMS0xLTEtNDYzOA_aae3a9de-3ce5-4283-9e85-e67270e311dd"
      unitRef="usd">7231000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i06ca94fcd1b246778b2f5c3579ac9473_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfOC0wLTEtMS00NjE3L3RleHRyZWdpb246MTQxM2UyYTM1YTBhNDg1MGI3YjRiY2ExMDI5NmQ5YzNfMTA5OTUxMTYyNzg4MA_721e518c-8966-4480-bf1f-a964096575a8"
      unitRef="usd">15000000.0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i58aa03ecfdd643a5894ce9870d82dbf6_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfOC0xLTEtMS00NjM4_04a71261-c059-4778-b932-0a5dd6183c34"
      unitRef="shares">3500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i58aa03ecfdd643a5894ce9870d82dbf6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfOC0zLTEtMS00NjM4_227f67e3-68e2-4fea-8c98-a98cb09b9bdc"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6e6d9c7159174b0789e9ced5c520204e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfOC01LTEtMS00NjM4_0fa24971-c290-4bbe-8f5b-037ef269a59e"
      unitRef="usd">230030000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i06ca94fcd1b246778b2f5c3579ac9473_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfOC0xMS0xLTEtNDYzOA_5af7b58a-88c6-41a4-9a59-e6d75ed457f6"
      unitRef="usd">230031000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="if5690066625a42e3b87d0384affb2d01_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfOS05LTEtMS00NjM4_a926911c-1638-4535-85f1-93a2d7910613"
      unitRef="usd">5000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i901f8ecd744645b8a45d1b64a74c0f58_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfOS0xMS0xLTEtNDYzOA_4cebe9d1-2ff7-4d5d-8e04-00f34311aa3a"
      unitRef="usd">5000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ib800117992e243cf8a7585686b33a363_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTAtNy0xLTEtNDYzOA_6df3906f-23bb-4a81-957a-478b5c696ac0"
      unitRef="usd">-21284000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i901f8ecd744645b8a45d1b64a74c0f58_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTAtMTEtMS0xLTQ2Mzg_c0f9a14f-6a20-4cef-9737-c00ca27bfff8"
      unitRef="usd">-21284000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i515d2c5350ad4f2d83c7a0bdffb1c873_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTEtMS0xLTEtNDYzOA_49b75cca-c304-4993-81b5-9e49b0ba15ef"
      unitRef="shares">36131275</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i515d2c5350ad4f2d83c7a0bdffb1c873_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTEtMy0xLTEtNDYzOA_3797cea2-1f12-429d-905e-792264c66a71"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifc97a27759e34d4cb8df378b38cdacaf_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTEtNS0xLTEtNDYzOA_369da7f5-5f06-49d2-b9d4-736d9ab14456"
      unitRef="usd">532700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1553aca7f70042e7abd871d77d833356_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTEtNy0xLTEtNDYzOA_ea220ec0-383f-4336-be24-7bb2a41a7a61"
      unitRef="usd">-163796000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i58cda165edf34fb0b54d026018e62af0_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTEtOS0xLTEtNDYzOA_068ae29b-1510-4f5b-84ae-62be8bcb01b8"
      unitRef="usd">-16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0f81b65df28e4c0eb8e87eb238682f6f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTEtMTEtMS0xLTQ2Mzg_872074ef-fa45-48f7-adca-0993df2479a6"
      unitRef="usd">368892000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="idbabfe222fdf4273a3a4864d3c46bb31_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTItNS0xLTEtNDYzOA_0b861568-0919-4471-8d76-ce416f464ae8"
      unitRef="usd">5308000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="if6b9e0cfb6c842a3a3373453c72b93c0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTItMTEtMS0xLTQ2Mzg_a234f25f-9334-449c-977c-6fd138af9efe"
      unitRef="usd">5308000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ib6533246bc7740bfb131bb0f31d5ebce_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTMtMS0xLTEtNDYzOA_85202987-aece-49f4-bd9d-5dfd2dd3b0fd"
      unitRef="shares">24080</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ib6533246bc7740bfb131bb0f31d5ebce_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTQtMS0xLTEtNDYzOA_230d7fd8-6f87-450d-b2d9-06d66fd60694"
      unitRef="shares">122156</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="idbabfe222fdf4273a3a4864d3c46bb31_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTQtNS0xLTEtNDYzOA_6ac8e6ca-0f5f-4591-869b-738dd49d69d6"
      unitRef="usd">1577000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if6b9e0cfb6c842a3a3373453c72b93c0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTQtMTEtMS0xLTQ2Mzg_09cad903-fe2e-43d4-8d11-baedcd1e8d97"
      unitRef="usd">1577000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie4bbeefbdf784a4a86d7368751611e4d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTUtOS0xLTEtNDYzOA_3c52e657-15fb-407a-b8d5-f13802fa701a"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="if6b9e0cfb6c842a3a3373453c72b93c0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTUtMTEtMS0xLTQ2Mzg_e166d4d1-6974-49fa-a2a1-b55985195ce4"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="idbabfe222fdf4273a3a4864d3c46bb31_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTYtNS0xLTEtNDYzOA_8ac38698-3b10-4245-9e9c-515a8e3f6e9a"
      unitRef="usd">49000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="if6b9e0cfb6c842a3a3373453c72b93c0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTYtMTEtMS0xLTQ2Mzg_3b119725-1eab-4ea7-a5fa-6c8809e51ff4"
      unitRef="usd">49000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:NetIncomeLoss
      contextRef="ic3a28dfdb1574133a31c2bbdc51e68b2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTctNy0xLTEtNDYzOA_12318f83-0ced-4118-87ee-9ee526d2d805"
      unitRef="usd">-27815000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if6b9e0cfb6c842a3a3373453c72b93c0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTctMTEtMS0xLTQ2Mzg_35c2c8ab-855e-4c70-b0b5-0f6050b60320"
      unitRef="usd">-27815000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="id787d30e67454f57ad1994ca3038b201_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTgtMS0xLTEtNDYzOA_73a11cf7-2e64-4172-80fb-76ec652e1c0e"
      unitRef="shares">36277511</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id787d30e67454f57ad1994ca3038b201_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTgtMy0xLTEtNDYzOA_45e60c1d-9a16-4e63-af0e-d028d6ad8fec"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib159d5476c2447b29c76c974f6a73e16_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTgtNS0xLTEtNDYzOA_b7014998-d0a6-4c1e-adab-fc00530eb4c8"
      unitRef="usd">539536000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie78e1f680612471088c63f49b5dd8a18_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTgtNy0xLTEtNDYzOA_5b057c47-2f27-45dc-9a20-1b047f0ca7fd"
      unitRef="usd">-191611000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6938de3cb6cf4fa7806a42ee8d41f58e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTgtOS0xLTEtNDYzOA_02ea91bc-6293-49a7-abb7-892c2efd3563"
      unitRef="usd">-20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i045fb029fd9f4fd3ba7809ee012e5352_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTgtMTEtMS0xLTQ2Mzg_1ed94494-3b82-46b6-b9b7-c198ae14111b"
      unitRef="usd">347909000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i5c8425c2e88641d2abdbb94c5d478327_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTktNS0xLTEtNDYzOA_1c522ff3-5661-49c2-ad61-4ff01bba9337"
      unitRef="usd">5791000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMTktMTEtMS0xLTQ2Mzg_ebd0b159-267f-4e99-a3bc-305a8f30fc34"
      unitRef="usd">5791000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ib378bf3c290247ed8a0dcf860e280f0f_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjAtMS0xLTEtNDYzOA_645f7f6c-6cd7-4a17-8cda-86216368f7ac"
      unitRef="shares">34204</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ib378bf3c290247ed8a0dcf860e280f0f_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjEtMS0xLTEtNDYzOA_cd53783f-65b3-4b4d-909a-20d39d6425bc"
      unitRef="shares">273624</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5c8425c2e88641d2abdbb94c5d478327_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjEtNS0xLTEtNDYzOA_4b37f146-e58d-440d-a9c6-08e1d822453d"
      unitRef="usd">3683000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjEtMTEtMS0xLTQ2Mzg_738f806f-6ce6-4d30-9172-9cfe50802b8a"
      unitRef="usd">3683000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="ib378bf3c290247ed8a0dcf860e280f0f_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjItMS0xLTEtNDYzOA_09b518eb-7802-409c-b7cd-1ef88301937a"
      unitRef="shares">9002</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="i5c8425c2e88641d2abdbb94c5d478327_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjItNS0xLTEtNDYzOA_001f6979-f0de-499b-8f36-f68b52aac4a3"
      unitRef="usd">482000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjItMTEtMS0xLTQ2Mzg_b530c3e0-97d2-4254-8be6-1e8d5c2014ea"
      unitRef="usd">482000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ie46f079ac4224779be66b7117f7c7607_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjMtMC0xLTEtMjI2MDYvdGV4dHJlZ2lvbjozZmFlMDA5NGQ3ZTc0ZThhYjc2MTFlNWUxZGNlN2U5NF8xMDk5NTExNjI3ODg5_ded46afb-d10b-4953-bb3f-f1ba371ee60f"
      unitRef="usd">900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i6a9a17e2241e4a3f9bf48a8a07ea581f_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjMtMS0xLTEtMjExMDU_7e1b45c2-d2b3-4098-a235-9aa46229b6a1"
      unitRef="shares">298070</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i93e1933f2bc44d94bea2dcf014ef6034_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjMtNS0xLTEtMjExMDU_81815a19-cbb7-4430-9d9c-446d8fe959f0"
      unitRef="usd">17414000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie46f079ac4224779be66b7117f7c7607_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjMtMTEtMS0xLTIxMTA1_3e914668-af4a-42d5-81c0-9aa583e8e4af"
      unitRef="usd">17414000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="if47513e8e86f49968b6af3544f6b81c9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjMtOS0xLTEtNDYzOA_ecfd7268-fbb2-4b58-8e29-4458156fff5e"
      unitRef="usd">-73000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjMtMTEtMS0xLTQ2Mzg_fa29055c-49b9-4d70-8172-fc18c025fef1"
      unitRef="usd">-73000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i02e02a526a804154b6839aa55df1b6cb_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjQtNy0xLTEtNDYzOA_b0c504db-e4d4-4e92-a2dd-727ee956e8be"
      unitRef="usd">-25041000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjQtMTEtMS0xLTQ2Mzg_0cca5336-764c-4ad7-9a42-b35683ece295"
      unitRef="usd">-25041000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i525829a7d9e441d0ba3b4b60e68895fc_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjUtMS0xLTEtNDYzOA_8d6f9da6-7a6a-420b-a602-45179ff09b1e"
      unitRef="shares">36892411</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i525829a7d9e441d0ba3b4b60e68895fc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjUtMy0xLTEtNDYzOA_685985e7-7016-43a7-935d-5e5f8f37e93c"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i67cb7e787c6f404fba5246e0f6e89ee6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjUtNS0xLTEtNDYzOA_5612fa77-1cb8-4382-af1f-e9167223c2dc"
      unitRef="usd">566906000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5674ed6b01654ebeaed47a14ff3407ec_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjUtNy0xLTEtNDYzOA_2b75b3ef-792e-48dc-b088-998eb3a242c5"
      unitRef="usd">-216652000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2a0cdc60fdbc4ada914dbb870ef3b65e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjUtOS0xLTEtNDYzOA_1b11f4ae-8205-40e6-938a-a71e07589113"
      unitRef="usd">-93000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOjNjOTdkZGUzMDNhYTRkMTFhZDUwZDA5NmJkODRjZmVlL3RhYmxlcmFuZ2U6M2M5N2RkZTMwM2FhNGQxMWFkNTBkMDk2YmQ4NGNmZWVfMjUtMTEtMS0xLTQ2Mzg_0dba3706-f3ed-4ca3-89e1-d9be687bc921"
      unitRef="usd">350165000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ie0289611dea94928a98cb550c8c5397a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMi0yLTEtMS0yMTM2_af997c29-3b49-4626-be8c-cd9600e6f551"
      unitRef="shares">30110251</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie0289611dea94928a98cb550c8c5397a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMi00LTEtMS0yMTM2_161f9603-e9ce-47bc-915d-c8522db4e67f"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5b404164f5bb4d7ca737270c6e265def_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMi02LTEtMS0yMTM2_0ee9bfdf-7bd7-4a0d-b725-cec67d88f480"
      unitRef="usd">238384000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if6bb096c70634192838a382eb5887887_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMi04LTEtMS0yMTM2_99185c6d-3b39-45f0-93c2-48271c3e9698"
      unitRef="usd">-97513000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ided2a95523e74652809cc83e76cc2c1c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMi0xMC0xLTEtMjEzNg_06f946f1-8d01-4c34-8e6d-85b7da4cc88d"
      unitRef="usd">44000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia2e37d454f86483da5d113ba5bb9c6ae_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMi0xMi0xLTEtMjEzNg_711794d8-b5fc-401b-89c8-7199c7e5a5fe"
      unitRef="usd">140918000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i28b354f9bb8d47e8a80d9ddf5b84ae8c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMy02LTEtMS0yNDY0_19b1c719-0b28-4ccb-832e-b7c8de9ae33c"
      unitRef="usd">2544000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i678eec9b2b244447b18fc4ba9a55fb5d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMy0xMi0xLTEtMjQ2NA_24a778d8-646c-4f9f-a778-69a5b0f5c39d"
      unitRef="usd">2544000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="id44003b9b0fc4840a4b1164b5acc2433_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfNC0yLTEtMS0yNDY0_2f29d0f3-5cb8-4087-a058-a14bb491e980"
      unitRef="shares">84247</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id44003b9b0fc4840a4b1164b5acc2433_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfNS0yLTEtMS0yNDY0_b615109d-7ca1-4ac1-b302-6a2ebe30f8a9"
      unitRef="shares">35822</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i28b354f9bb8d47e8a80d9ddf5b84ae8c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfNS02LTEtMS0yNDY0_de82c479-76e8-4b98-8f45-a2954e79bb62"
      unitRef="usd">167000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i678eec9b2b244447b18fc4ba9a55fb5d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfNS0xMi0xLTEtMjQ2NA_dc3d2782-f2ad-48d0-a2dc-d2f291553e86"
      unitRef="usd">167000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="id44003b9b0fc4840a4b1164b5acc2433_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfNi0yLTEtMS0yNDY0_378b6e21-54b8-437a-aad2-b3d4cffd024c"
      unitRef="shares">53405</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="i28b354f9bb8d47e8a80d9ddf5b84ae8c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfNi02LTEtMS0yNDY0_9530b313-27cd-47cf-8cc9-dc2d6b87828c"
      unitRef="usd">681000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="i678eec9b2b244447b18fc4ba9a55fb5d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfNi0xMi0xLTEtMjQ2NA_9ffb2ce7-ab18-408d-964c-caf4ce68622c"
      unitRef="usd">681000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia0b42c7d7a4a4d258150923a53914e00_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfNy0xMC0xLTEtMjQ2NA_5e7c07cd-10ad-4089-af18-05cb5d64834e"
      unitRef="usd">571000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i678eec9b2b244447b18fc4ba9a55fb5d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfNy0xMi0xLTEtMjQ2NA_86b5126d-4bfe-44fd-8202-595dbe187b5a"
      unitRef="usd">571000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i47ae904392494a1691f66d44af867fd5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfOC04LTEtMS0yNDY0_737469ca-1989-47e1-b687-7c5f9c942db1"
      unitRef="usd">-16746000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i678eec9b2b244447b18fc4ba9a55fb5d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfOC0xMi0xLTEtMjQ2NA_30ed7b30-fa95-455b-88fb-71f6b4dfed99"
      unitRef="usd">-16746000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ib198e32eebb44ca09f321ba259b29ce2_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfOS0yLTEtMS0yMTM2_d4c39390-163c-4220-8145-1db90e3ee7e5"
      unitRef="shares">30283725</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib198e32eebb44ca09f321ba259b29ce2_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfOS00LTEtMS0yMTM2_509dcc1b-d162-49cb-a89f-eab8de6e559a"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id62a5c373f8043a49ac6d4b6edcb5f03_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfOS02LTEtMS0yMTM2_9e11a98f-95d6-48da-b45e-4219f94def15"
      unitRef="usd">241776000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idcc27241cea443418ead40c7a7f13130_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfOS04LTEtMS0yMTM2_4d6fea99-1924-47c0-aac1-6e8b64511557"
      unitRef="usd">-114259000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3f787d6a671940b0a2ba97e900ceeba5_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfOS0xMC0xLTEtMjEzNg_d2180c88-9a0c-42d2-b86b-91427946e264"
      unitRef="usd">615000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i831afc5715a74d2ebfcc35bdfd047f7f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfOS0xMi0xLTEtMjEzNg_1e31a1ab-2688-4dca-a840-b97035997165"
      unitRef="usd">128135000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="ibd4b367ccae649d798f837bc4bae25cf_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTAtNi0xLTEtMjEzNg_e46cbaab-dc95-45fb-9558-34ceebea770f"
      unitRef="usd">2489000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i1b9b5c829b794265abbba640d8790b61_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTAtMTItMS0xLTIxMzY_46a428d8-f946-4159-a96b-f369fda3a436"
      unitRef="usd">2489000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ie820eb1d183044f29008086e76bb8abb_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTEtMi0xLTEtMjEzNg_83a037da-2ea6-4de1-b608-a0657bd24b75"
      unitRef="shares">57490</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie820eb1d183044f29008086e76bb8abb_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTItMi0xLTEtMjEzNg_224b7372-59de-4ec5-ac82-7ccf73b27a0a"
      unitRef="shares">80560</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ibd4b367ccae649d798f837bc4bae25cf_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTItNi0xLTEtMjEzNg_549c71b8-8ec5-4455-bb48-e906df1d8b22"
      unitRef="usd">542000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1b9b5c829b794265abbba640d8790b61_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTItMTItMS0xLTIxMzY_f9f107cd-1184-458c-a130-a8bb3dd3a168"
      unitRef="usd">542000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ieaa73485876b4e858b467fc72c87dc11_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTMtMTAtMS0xLTIxMzY_a0693995-eb23-497e-8ae2-fa20c98fcd79"
      unitRef="usd">-391000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1b9b5c829b794265abbba640d8790b61_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTMtMTItMS0xLTIxMzY_823f72ea-2f76-497f-8d2e-8c83e9959cab"
      unitRef="usd">-391000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ia2b9993359cb456984780b6ee2dcb181_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTQtOC0xLTEtMjEzNg_4d5711ff-9bd8-4d98-9dca-2485868eb12c"
      unitRef="usd">-15858000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1b9b5c829b794265abbba640d8790b61_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTQtMTItMS0xLTIxMzY_667469ad-d80b-4ed7-a590-7836724b9be7"
      unitRef="usd">-15858000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i44de926c8806430b8699f3779b9c08b1_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTUtMi0xLTEtMjEzNg_23726da2-8075-4fbb-a38c-8028281c929a"
      unitRef="shares">30421775</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i44de926c8806430b8699f3779b9c08b1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTUtNC0xLTEtMjEzNg_7cabbed0-47dc-41d1-a48e-fda4ec87cc75"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7c86edc9380f4e658d4c9376a669e0d9_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTUtNi0xLTEtMjEzNg_2e276488-ddde-4df0-ba62-b7112688d5aa"
      unitRef="usd">244807000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie08a82cfc7f24fbbad0fe77f2bfe3618_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTUtOC0xLTEtMjEzNg_1d3c10e6-ee98-45b1-90f1-c5f0a175ce5e"
      unitRef="usd">-130117000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i22f2eddba4d5410b914c1f3b00fc8918_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTUtMTAtMS0xLTIxMzY_509d2182-ffa4-4de7-b680-ec77f8cca439"
      unitRef="usd">224000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i61f47238d1b44b2a9637c0aa85dc0ee4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTUtMTItMS0xLTIxMzY_212a314b-0aa1-43cb-9e79-2094a4182876"
      unitRef="usd">114917000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i49f954fe973a4718a7bb027c7e112f91_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTYtNi0xLTEtMjQyMg_dde0b266-f5d4-486c-9322-89a5c7325094"
      unitRef="usd">2996000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTYtMTItMS0xLTI0MjI_dfece723-c33b-41e6-bcdc-04e58723288e"
      unitRef="usd">2996000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i763837ff1bfa4e4395a5c9985fb3ea1d_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTctMi0xLTEtMjQyMg_f20c7ca7-7e8a-4ca0-9332-97a6c52cd6fc"
      unitRef="shares">56991</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ibb907e28eb904c5abe8778dff7854225_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTgtMC0xLTEtMjQyMi90ZXh0cmVnaW9uOjk4MzU1NzUwNmU3YTQzNjc5NWViNWJiNTAzMGQ0ZmY1XzEwOTk1MTE2Mjc4ODc_cd6019be-2bab-4d82-bb9c-19b394df3469"
      unitRef="usd">600000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i7c337f23b5d94bce847216e32970fc13_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTgtMi0xLTEtMjQyMg_46118cb2-b7fa-4572-bc5d-f39b16b1e1ad"
      unitRef="shares">256879</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8ce691e108d44f41854e25c5b8aa249f_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTgtNi0xLTEtMjQyMg_52446dd5-2744-44f2-b4f2-7052f57049d6"
      unitRef="usd">6319000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibb907e28eb904c5abe8778dff7854225_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTgtMTItMS0xLTI0MjI_2330bc43-a807-4193-aec2-0bff44fadb2a"
      unitRef="usd">6319000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i763837ff1bfa4e4395a5c9985fb3ea1d_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTktMi0xLTEtMjQyMg_662cc422-d6ee-4ae1-98ea-07f392a0a7d5"
      unitRef="shares">60115</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i49f954fe973a4718a7bb027c7e112f91_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTktNi0xLTEtMjQyMg_8cef2b48-3af5-44ba-ba3c-393aedcbefbe"
      unitRef="usd">477000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMTktMTItMS0xLTI0MjI_2087a929-6cae-435c-ac4d-bd78ece93ac6"
      unitRef="usd">477000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="i763837ff1bfa4e4395a5c9985fb3ea1d_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMjAtMi0xLTEtMjQyMg_4d72a67f-e893-40f1-9c4d-7d709782ca52"
      unitRef="shares">31893</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="i49f954fe973a4718a7bb027c7e112f91_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMjAtNi0xLTEtMjQyMg_30b131be-fb79-4d5c-931a-d1496ed868d0"
      unitRef="usd">431000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMjAtMTItMS0xLTI0MjI_2f8713a1-8699-48e6-a2fd-ea9ccefc58ad"
      unitRef="usd">431000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i58e35bd616704d81933f455f82a367b9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMjEtMTAtMS0xLTI0MjI_29bd91a6-5644-496c-bc0c-e4c0260301ab"
      unitRef="usd">-190000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMjEtMTItMS0xLTI0MjI_ea3ea892-d956-4bf5-8e69-ebec4ae33818"
      unitRef="usd">-190000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i8e417c1626c0447da3ff198c9dbd9029_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMjItOC0xLTEtMjQyMg_ebdc12a5-26a3-465b-a50f-2a30f10ec04b"
      unitRef="usd">5354000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMjItMTItMS0xLTI0MjI_34290133-a832-46de-bfac-0a22d531864d"
      unitRef="usd">5354000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ifecee13ba23d4d56894bc6a643e63e62_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMjMtMi0xLTEtMjQyMg_8126afb7-da62-4bdc-9e70-ce8790ffa5d1"
      unitRef="shares">30827653</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ifecee13ba23d4d56894bc6a643e63e62_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMjMtNC0xLTEtMjQyMg_562c743a-63f4-403f-8853-28dc1855119e"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5762a65d06864432a626e61cf3346d84_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMjMtNi0xLTEtMjQyMg_a4ca7f87-6fd7-455e-8695-82cc8a5fb7b9"
      unitRef="usd">255030000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifdf49025fcce47b8a9f8b80534c93448_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMjMtOC0xLTEtMjQyMg_7b20c463-7d70-43c8-a1a4-830faaefddc7"
      unitRef="usd">-124763000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4d5c7026852d4a94bec2b79ab34bc87d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMjMtMTAtMS0xLTI0MjI_0ab077dd-29d2-43d1-95ad-db5cdada28ae"
      unitRef="usd">34000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i64b5dd8c546640129471ee97d4f9028f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yMi9mcmFnOjBiY2NiMTg4OTBlZjRiY2ZiNWU5ZGRkN2U1ZWMzZGRiL3RhYmxlOmNiMzZjZjkxMjRiODQ0Njg4ODYzNWZlYmJmMWRmNThjL3RhYmxlcmFuZ2U6Y2IzNmNmOTEyNGI4NDQ2ODg4NjM1ZmViYmYxZGY1OGNfMjMtMTItMS0xLTI0MjI_2dc56f72-fe01-45ba-9d1b-5a235e9e2a58"
      unitRef="usd">130304000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMy0xLTEtMS0yMTM2_af48b730-0286-41c6-92a3-0d0c0d7c04e0"
      unitRef="usd">-74140000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMy0zLTEtMS0yMTM2_26ca0ea9-476b-4489-a78a-42e7f524b595"
      unitRef="usd">-27250000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfNS0xLTEtMS0yMTM2_161e4172-05b0-4d56-be34-99a08a13c8c9"
      unitRef="usd">754000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfNS0zLTEtMS0yMTM2_a4fedf39-0cdb-458b-803d-6be1ff252992"
      unitRef="usd">852000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfNi0xLTEtMS0yMTM2_43e38b5a-ca4f-4ec7-99c1-4563e9eb0b09"
      unitRef="usd">-531000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfNi0zLTEtMS0yMTM2_08eb3691-902e-4692-bced-a6f28bc8934b"
      unitRef="usd">-429000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfNy0xLTEtMS0yMTM2_b103b699-feef-4bef-833c-3b0e03db7622"
      unitRef="usd">15541000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfNy0zLTEtMS0yMTM2_eb28147a-4ab0-4758-801f-66916f00651a"
      unitRef="usd">8029000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfOC0xLTEtMS0yMTM2_87255541-c661-459e-8ad8-c988c02b0c43"
      unitRef="usd">-4000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfOC0zLTEtMS0yMTM2_d3c6e15f-895a-49a3-a9b6-820094acab03"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTAtMS0xLTEtMjEzNg_54396d2c-c11b-4a1d-a1d4-bff038292197"
      unitRef="usd">-4696000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTAtMy0xLTEtMjEzNg_19dd40fa-6e04-4e60-b681-79306ced5da2"
      unitRef="usd">-1832000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTEtMS0xLTEtMjEzNg_71fba497-8741-499d-a788-839f73074376"
      unitRef="usd">1353000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTEtMy0xLTEtMjEzNg_a0dcaf8c-39dd-4a90-be11-3c88a92fc614"
      unitRef="usd">530000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTItMS0xLTEtMjEzNg_6f901ab4-5236-4ed3-9e41-9e02cadedaf4"
      unitRef="usd">-51000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTItMy0xLTEtMjEzNg_93e3c5b8-af53-4efc-91a3-f9e87e7da4c0"
      unitRef="usd">-55000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTMtMS0xLTEtMjEzNg_9a577dcc-ec90-4410-ab11-5e4c274428fe"
      unitRef="usd">-842000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTMtMy0xLTEtMjEzNg_6492b82d-f882-4ba6-9b20-d7f0b41b51d5"
      unitRef="usd">-1893000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTQtMS0xLTEtMjEzNg_0978443c-1377-49dd-9349-6a5754148b3e"
      unitRef="usd">-1743000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTQtMy0xLTEtMjEzNg_9d88f8ba-4818-4c4d-aa56-a40a56a610ba"
      unitRef="usd">818000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTUtMS0xLTEtMjEzNg_15fe41ca-693d-4538-9d67-fc695a4c6205"
      unitRef="usd">-6295000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTUtMy0xLTEtMjEzNg_4927448c-4ae8-4a61-8375-eb20082bf1c5"
      unitRef="usd">-13878000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <morf:IncreaseDecreaseInDeferredRent
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTYtMS0xLTEtMjEzNg_811f1099-14d4-4f5b-8ae3-3e0db32dcf77"
      unitRef="usd">-80000</morf:IncreaseDecreaseInDeferredRent>
    <morf:IncreaseDecreaseInDeferredRent
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTYtMy0xLTEtMjEzNg_72200d81-89d9-49d1-9093-614ebb821735"
      unitRef="usd">-36000</morf:IncreaseDecreaseInDeferredRent>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTgtMS0xLTEtMjEzNg_1a9e3bc8-aac6-4709-a0a5-585d3ce9183c"
      unitRef="usd">-62876000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMTgtMy0xLTEtMjEzNg_6f26bfcc-af4f-40e2-b7d1-3d07979f943f"
      unitRef="usd">-31572000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjAtMS0xLTEtMjEzNg_715d052d-8222-4102-ba0a-49b0899139e5"
      unitRef="usd">223803000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjAtMy0xLTEtMjEzNg_f80f0387-79f2-4866-bf6a-6cb4e01d9bb4"
      unitRef="usd">95049000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjEtMS0xLTEtMjEzNg_5ca3c9ad-1136-435a-b9fb-aedbf7029480"
      unitRef="usd">106000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjEtMy0xLTEtMjEzNg_1264482a-2513-4102-83e3-cd9bfb3ffe21"
      unitRef="usd">115000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjItMS0xLTEtMjEzNg_caae0bec-57fb-4b71-8024-afb5cd7cbfb8"
      unitRef="usd">563000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjItMy0xLTEtMjEzNg_1c0f6aa7-8563-44ce-9c64-e1028de05406"
      unitRef="usd">475000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjMtMS0xLTEtMjEzNg_5f1821a3-32bb-4dfd-b5d7-5b8d40c54535"
      unitRef="usd">-118366000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjMtMy0xLTEtMjEzNg_c450de47-64c3-4a15-b5ff-2c6d86b4740f"
      unitRef="usd">19476000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjYtMS0xLTEtMjEzNg_6fd786e8-30cd-421c-9240-334c6f890d0b"
      unitRef="usd">1095000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjYtMy0xLTEtMjEzNg_1746a628-e370-452e-9236-800fdc0042e5"
      unitRef="usd">1112000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjctMS0xLTEtMjEzNg_9a2f5813-27cd-48ab-8f5b-aa8222a33a98"
      unitRef="usd">24645000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjctMy0xLTEtMjEzNg_ef3775f1-5380-485a-8a17-59d7051e85ab"
      unitRef="usd">6319000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjgtMS0xLTEtMjEzNg_c4edbae5-f553-4a4f-8c1d-b5bc960285e2"
      unitRef="usd">229982000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjgtMy0xLTEtMjEzNg_ca810c78-b910-4f44-8985-fc5491828652"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjktMS0xLTEtMjEzNg_e7f127b3-c4d4-4f0b-883b-f36c607fd6e6"
      unitRef="usd">7917000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMjktMy0xLTEtMjEzNg_c78c088b-e8b4-4760-a890-64fb6bf15f07"
      unitRef="usd">1186000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMzAtMS0xLTEtMjEzNg_8e01a05b-98b2-4307-9ed4-e278acaa480e"
      unitRef="usd">263639000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMzAtMy0xLTEtMjEzNg_42e41ed4-cdf8-47fd-af6d-41e3e9ee8a7d"
      unitRef="usd">8617000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMzEtMS0xLTEtMjEzNg_f39d381f-d348-4d15-8715-83d4b4ab64ef"
      unitRef="usd">82397000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMzEtMy0xLTEtMjEzNg_f7e5580c-7c22-4e78-afe5-d21851c231a9"
      unitRef="usd">-3479000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMzItMS0xLTEtMjEzNg_c63cf0da-5393-460d-99e5-9b09870bd6a7"
      unitRef="usd">102322000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia2e37d454f86483da5d113ba5bb9c6ae_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMzItMy0xLTEtMjEzNg_b9e84d4a-40c0-4502-8532-330bad465e4c"
      unitRef="usd">101834000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMzMtMS0xLTEtMjEzNg_221370d5-e9dc-4f94-ab3c-b2cd01a58979"
      unitRef="usd">184719000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i64b5dd8c546640129471ee97d4f9028f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMzMtMy0xLTEtMjEzNg_447a9ee8-7b1c-4c4a-8011-83e789ee5671"
      unitRef="usd">98355000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMzYtMS0xLTEtMjEzNg_4189e854-395d-4d1f-a9af-b40f7f566549"
      unitRef="usd">173000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfMzYtMy0xLTEtMjEzNg_57fc9c4b-34f8-4d82-bf17-ef23efafe325"
      unitRef="usd">15000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfNDEtMS0xLTEtMjEzNg_1223b470-cfe7-4bd5-bcf5-64e0d5c789d5"
      unitRef="usd">130000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8yNS9mcmFnOjFmMWFlNWRhMTFiNjQ1OGFhNzBiZmZiOWQ1MDdkOThkL3RhYmxlOmNmZWI3MWZmN2YwMzQ0Nzk5N2IzNDc0YzYwN2FiYjY1L3RhYmxlcmFuZ2U6Y2ZlYjcxZmY3ZjAzNDQ3OTk3YjM0NzRjNjA3YWJiNjVfNDEtMy0xLTEtMjEzNg_8c526979-02fe-405d-bdf4-0d34cecce9e1"
      unitRef="usd">480000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zMS9mcmFnOmU3OGNjZWI4NzVlYjQ0MGU4ZGIxNmJlMGQ3MDkwZDYzL3RleHRyZWdpb246ZTc4Y2NlYjg3NWViNDQwZThkYjE2YmUwZDcwOTBkNjNfNDE1OA_c82455e4-c016-48bf-9f6e-44cf33d12c34">Nature of the Business and Basis of Presentation&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization and Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Morphic Holding, Inc. (the &#x201c;Company&#x201d;) was formed under the laws of the State of Delaware in August 2014. The Company is a biopharmaceutical company applying proprietary insights into integrin medicine to discover and develop first-in-class oral small molecule integrin therapeutics. Integrins are a validated target class with multiple approved drugs for the treatment of serious chronic diseases. Despite significant biopharmaceutical industry investment, no oral integrin therapies have been approved. The Company has created the Morphic integrin technology platform, or MInT Platform, by leveraging its unique understanding of integrin structure and biology, to develop a pipeline of novel product candidates designed to achieve potency, high selectivity, and the pharmaceutical properties required for oral administration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#x2019;s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.&#160;The Company expects to continue to incur losses from operations for the foreseeable future. The Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements through at least the next 12 months from the date these financial statements were issued.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2020, the Company entered into an Open Market Sale Agreement (&#x201c;the Original Agreement&#x201d;) with Jefferies LLC (&#x201c;Jefferies&#x201d;) with respect to an at-the-market (&#x201c;ATM&#x201d;) offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of our common stock, having an aggregate offering price of up to $75,000,000, referred to as Placement Shares, through Jefferies as its sales agent. The Company paid Jefferies a commission equal to 3.0% of the gross sales proceeds of any Placement Shares sold through Jefferies under the Original Agreement, and also has provided Jefferies with customary indemnification and contribution rights. On August 11, 2021, the Company entered into an Amendment No. 1 to the Open Market Sale Agreement with Jefferies, establishing a new at-the-market offering (&#x201c;New ATM&#x201d;) with an aggregate offering price of up to $150,000,000, also subject to a commission equal to 3.0% of gross sales proceeds from Placement Shares sold through Jefferies.  Under the New ATM, the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, referred to as Placement Shares, through Jefferies as its sales agent.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the three months ended September&#160;30, 2021, 298,070 shares under the ATM were sold for net proceeds of $17.4 million after deducting offering commissions and offering expenses paid by the Company. During the nine months ended September&#160;30, 2021, the Company issued and sold 538,774 shares for net proceeds of $24.6 million after deducting offering commissions and offering expenses paid by the Company. As of September&#160;30, 2021, the Company had approximately $138.9 million of common stock remaining available for sale under the ATM.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, the Company completed an underwritten follow-on public offering of 3,500,000 shares of its common stock at a price to the public of $70.00 per share. Gross proceeds from the secondary offering were approximately $245.0&#160;million, before deducting underwriting discounts, commissions and other offering expenses of approximately $15.0&#160;million, paid by the Company, resulting in net proceeds of approximately $230.0&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="i5f1bf035ce6148889916ac0580538d5b_D20200701-20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zMS9mcmFnOmU3OGNjZWI4NzVlYjQ0MGU4ZGIxNmJlMGQ3MDkwZDYzL3RleHRyZWdpb246ZTc4Y2NlYjg3NWViNDQwZThkYjE2YmUwZDcwOTBkNjNfNDk0NzgwMjMzNDE0OQ_a6240f26-a8cc-4881-bb03-ddcf919635ce"
      unitRef="usd">75000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <morf:PercentageOfCommissionOnGrossSaleProceeds
      contextRef="i3a3fb30525ad4997ad257edca9bb1309_D20200701-20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zMS9mcmFnOmU3OGNjZWI4NzVlYjQ0MGU4ZGIxNmJlMGQ3MDkwZDYzL3RleHRyZWdpb246ZTc4Y2NlYjg3NWViNDQwZThkYjE2YmUwZDcwOTBkNjNfNDk0NzgwMjMzNDE2Mg_335dc75e-9ab7-4698-a641-71cc54e0f943"
      unitRef="number">0.030</morf:PercentageOfCommissionOnGrossSaleProceeds>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="i2c1c09e4655f462d8172c3fed16c5d41_D20210811-20210811"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zMS9mcmFnOmU3OGNjZWI4NzVlYjQ0MGU4ZGIxNmJlMGQ3MDkwZDYzL3RleHRyZWdpb246ZTc4Y2NlYjg3NWViNDQwZThkYjE2YmUwZDcwOTBkNjNfMTA5OTUxMTY0MDczNA_d964b5b2-3655-470e-b780-dc0fd5956edf"
      unitRef="usd">150000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <morf:PercentageOfCommissionOnGrossSaleProceeds
      contextRef="i8539e76f9660442e9d169db576c8aedd_D20210811-20210811"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zMS9mcmFnOmU3OGNjZWI4NzVlYjQ0MGU4ZGIxNmJlMGQ3MDkwZDYzL3RleHRyZWdpb246ZTc4Y2NlYjg3NWViNDQwZThkYjE2YmUwZDcwOTBkNjNfNDk0NzgwMjMzNzk1OQ_23592277-6c27-4957-9346-adc19f1b279e"
      unitRef="number">0.030</morf:PercentageOfCommissionOnGrossSaleProceeds>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i16001d4e30b441e1808c258ac136a45a_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zMS9mcmFnOmU3OGNjZWI4NzVlYjQ0MGU4ZGIxNmJlMGQ3MDkwZDYzL3RleHRyZWdpb246ZTc4Y2NlYjg3NWViNDQwZThkYjE2YmUwZDcwOTBkNjNfMTA5OTUxMTYzMjAzNg_94c25b78-c44b-44fb-b32a-872d9fbfafdc"
      unitRef="shares">298070</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="i16001d4e30b441e1808c258ac136a45a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zMS9mcmFnOmU3OGNjZWI4NzVlYjQ0MGU4ZGIxNmJlMGQ3MDkwZDYzL3RleHRyZWdpb246ZTc4Y2NlYjg3NWViNDQwZThkYjE2YmUwZDcwOTBkNjNfMTA5OTUxMTYzMjA2MQ_0066da11-ae98-4f6d-b6ed-00eabbe8e57d"
      unitRef="usd">17400000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i6a6c3241ca9141c9bbb04c6d0c0c55fa_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zMS9mcmFnOmU3OGNjZWI4NzVlYjQ0MGU4ZGIxNmJlMGQ3MDkwZDYzL3RleHRyZWdpb246ZTc4Y2NlYjg3NWViNDQwZThkYjE2YmUwZDcwOTBkNjNfMTA5OTUxMTYzMjMyOA_a90b2c43-7019-40b2-a2f9-618afad2a39f"
      unitRef="shares">538774</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="i6a6c3241ca9141c9bbb04c6d0c0c55fa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zMS9mcmFnOmU3OGNjZWI4NzVlYjQ0MGU4ZGIxNmJlMGQ3MDkwZDYzL3RleHRyZWdpb246ZTc4Y2NlYjg3NWViNDQwZThkYjE2YmUwZDcwOTBkNjNfMTA5OTUxMTYzMjMzMg_a67faba0-bf52-4250-a068-2469168898e5"
      unitRef="usd">24600000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <morf:CommonStockAvailableForIssuance
      contextRef="i77369a4a13ef44fa8daace2f7956ce2a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zMS9mcmFnOmU3OGNjZWI4NzVlYjQ0MGU4ZGIxNmJlMGQ3MDkwZDYzL3RleHRyZWdpb246ZTc4Y2NlYjg3NWViNDQwZThkYjE2YmUwZDcwOTBkNjNfMTA5OTUxMTYzMjM0MA_c9cf1e75-1888-43a3-a9c2-1bbea0953916"
      unitRef="usd">138900000</morf:CommonStockAvailableForIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ie84d1725167c4a75be6380089ca4347a_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zMS9mcmFnOmU3OGNjZWI4NzVlYjQ0MGU4ZGIxNmJlMGQ3MDkwZDYzL3RleHRyZWdpb246ZTc4Y2NlYjg3NWViNDQwZThkYjE2YmUwZDcwOTBkNjNfMzg1Mg_a4d7e1a9-c699-41e9-b3e5-04e2022ae2bb"
      unitRef="shares">3500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i8cf597d615c64759b8f60cb2d5d4e180_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zMS9mcmFnOmU3OGNjZWI4NzVlYjQ0MGU4ZGIxNmJlMGQ3MDkwZDYzL3RleHRyZWdpb246ZTc4Y2NlYjg3NWViNDQwZThkYjE2YmUwZDcwOTBkNjNfMzkxMA_131bfb69-6433-4d87-8385-aec14bd62f8d"
      unitRef="usdPerShare">70.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ie84d1725167c4a75be6380089ca4347a_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zMS9mcmFnOmU3OGNjZWI4NzVlYjQ0MGU4ZGIxNmJlMGQ3MDkwZDYzL3RleHRyZWdpb246ZTc4Y2NlYjg3NWViNDQwZThkYjE2YmUwZDcwOTBkNjNfMzk4Ng_50747fde-2af2-4f9b-b62a-2c95c5c679cb"
      unitRef="usd">245000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ie84d1725167c4a75be6380089ca4347a_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zMS9mcmFnOmU3OGNjZWI4NzVlYjQ0MGU4ZGIxNmJlMGQ3MDkwZDYzL3RleHRyZWdpb246ZTc4Y2NlYjg3NWViNDQwZThkYjE2YmUwZDcwOTBkNjNfNDA4OA_7ee159e7-c938-4121-846a-2656e5a23755"
      unitRef="usd">15000000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ie84d1725167c4a75be6380089ca4347a_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zMS9mcmFnOmU3OGNjZWI4NzVlYjQ0MGU4ZGIxNmJlMGQ3MDkwZDYzL3RleHRyZWdpb246ZTc4Y2NlYjg3NWViNDQwZThkYjE2YmUwZDcwOTBkNjNfNDE1Ng_c92276fa-5038-4d52-9a03-352356e34e54"
      unitRef="usd">230000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNC9mcmFnOjMyZGVhNWI1NDQzMzQ0MjhiODBiZmIwYzkyYjBlY2ZlL3RleHRyZWdpb246MzJkZWE1YjU0NDMzNDQyOGI4MGJmYjBjOTJiMGVjZmVfNzkwNQ_98acac90-e37f-421a-9d19-616ea63a0af9">Basis of Presentation and Significant Accounting Policies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited interim condensed consolidated financial statements include the accounts of Morphic Holding, Inc. and its wholly owned subsidiaries, Morphic Therapeutic, Inc. and a Massachusetts Security Corporation, organized in December 2019 to take advantage of the favorable tax treatment of income earned on securities held within such entity. All intercompany balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). Certain information and footnote disclosures normally included in the Company&#x2019;s annual financial statements have been &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;condensed or omitted. These unaudited interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company&#x2019;s financial position and results of operations for the interim periods ended September&#160;30, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December&#160;31, 2020, and the notes thereto, which are included in the Company&#x2019;s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on March 1, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates and Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in accordance with GAAP requires management to make estimates and judgments that may affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the related reporting of revenues and expenses during the reporting period. Significant estimates of accounting reflected in these consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued research and development expenses, the valuation of equity-based compensation, and income taxes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant accounting policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant accounting policies used in preparation of these condensed consolidated financial statements as of and for the three and nine months ended September&#160;30, 2021 are consistent with those discussed in Note 2 to the consolidated financial statements in the Company&#x2019;s 2020 Annual Report on Form 10-K, except as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements not yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At IPO, as an &#x201c;emerging growth company,&#x201d; or EGC, under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, the Company has made an election under Section 107 of the JOBS Act to take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards and has been following requirements applicable to the private companies for adopting new and updated accounting standards. Based on the value of the Company's common stock held by non-affiliates on June 30, 2021, the Company will become a large accelerated filer for the year ending December 31, 2021 and will follow adoption guidance mandated for non-EGC entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, Financial Instruments Credit Losses (Topic 326) (&#x201c;ASU 2016-13&#x201d;), which requires consideration of a broader range of reasonable and supportable information in developing credit loss estimates. In April 2019, the FASB issued ASU 2019-04, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments (&#x201c;ASU 2019-04&#x201d;). Certain provisions of ASU 2019-04 amend the guidance of ASU 2016-13, are applicable to the Company&#x2019;s investments portfolio, and allow the Company to make certain accounting policy elections regarding establishing allowance for credit losses for the accrued interest receivable and the corresponding disclosures. In November 2019, the FASB issued ASU No. 2019-11, Codification Improvements to Topic 326, Financial Instruments &#x2013; Credit Losses (&#x201c;ASU 2019-11&#x201d;), which clarifies certain areas of the guidance to ensure all companies and organizations can make a smoother transition to the standard. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the Company will become a large accelerated filer and as a result, the guidance under ASU 2019-04, ASU 2016-13 and ASU 2019-11 is effective for the Company's Annual Report on Form 10-K to be filed for the year ended December 31, 2021. The Company will record a cumulative effect adjustment to retained earnings retroactive to January 1, 2021, the date of adoption. The Company is currently evaluating the impact of ASU 2019-11 and the related ASU 2019-04 and ASU 2016-13 on its consolidated financial statements, including the impact of the available accounting policy elections. The Company does not expect this guidance to have a material impact on its consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), with guidance regarding the accounting for and disclosure of leases. In general, for lease arrangements exceeding a twelve-month term, these arrangements must now be recognized as assets and liabilities on the balance sheet of the lessee. Under ASU 2016-02, a right-of-use asset and lease obligation will be recorded for all leases, whether operating or financing, while the income statement will reflect lease expense for operating leases and amortization/interest expense for financing leases. The balance sheet amount recorded for existing leases at the date of adoption of ASU 2016-02 must be calculated using the applicable incremental borrowing rate at the date of adoption. This update also requires lessees and lessors to disclose key information about their leasing transactions. In July 2018, the FASB issued ASU 2018-11, Leases - Targeted Improvements, intended to ease the implementation of the new lease &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;standard for financial statement preparers by, among other things, allowing for an additional transition method. In lieu of presenting transition requirements to comparative periods, as previously required, an entity may now elect to show a cumulative effect adjustment on the date of adoption without the requirement to recast prior period financial statements or disclosures presented in accordance with ASU 2016-02.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently expects to elect the available package of practical expedients which allows the Company to not reassess previous accounting conclusions around whether arrangements are or contain leases, the classification of leases, and the treatment of initial direct costs. The Company also expects it will make an accounting policy election to keep leases with an initial term of 12 months or less off of the balance sheet. &lt;/span&gt;&lt;/div&gt;In August 2021, the Company exercised its one-time extension right for its existing lease for 35,000 square feet of office and laboratory space through May 2025, as provided for under the terms of the lease. The Company is currently evaluating the effect of adopting the requirements of ASU 2016-02 as it relates to its facility lease, as amended in August 2021, and discussed in Note 10 to the consolidated financial statements appearing in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2020. The Company is also performing an evaluation of other material contracts to determine if any contain embedded leases, and has not identified any to date. As of December 31, 2021, the Company will become a large accelerated filer and as a result, the guidance under ASU 2016-02 is effective for the Company's Annual Report on Form 10-K to be filed for the year ended December 31, 2021, with an effective date of adoption of January 1, 2021.</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNC9mcmFnOjMyZGVhNWI1NDQzMzQ0MjhiODBiZmIwYzkyYjBlY2ZlL3RleHRyZWdpb246MzJkZWE1YjU0NDMzNDQyOGI4MGJmYjBjOTJiMGVjZmVfNzkwNg_846128c6-6b84-46fe-908a-b8582535750d">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates and Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in accordance with GAAP requires management to make estimates and judgments that may affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the related reporting of revenues and expenses during the reporting period. Significant estimates of accounting reflected in these consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued research and development expenses, the valuation of equity-based compensation, and income taxes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <morf:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNC9mcmFnOjMyZGVhNWI1NDQzMzQ0MjhiODBiZmIwYzkyYjBlY2ZlL3RleHRyZWdpb246MzJkZWE1YjU0NDMzNDQyOGI4MGJmYjBjOTJiMGVjZmVfNzkwNw_fd0079d0-bca3-464f-9623-2d7dd71c6c8a">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements not yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At IPO, as an &#x201c;emerging growth company,&#x201d; or EGC, under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, the Company has made an election under Section 107 of the JOBS Act to take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards and has been following requirements applicable to the private companies for adopting new and updated accounting standards. Based on the value of the Company's common stock held by non-affiliates on June 30, 2021, the Company will become a large accelerated filer for the year ending December 31, 2021 and will follow adoption guidance mandated for non-EGC entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, Financial Instruments Credit Losses (Topic 326) (&#x201c;ASU 2016-13&#x201d;), which requires consideration of a broader range of reasonable and supportable information in developing credit loss estimates. In April 2019, the FASB issued ASU 2019-04, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments (&#x201c;ASU 2019-04&#x201d;). Certain provisions of ASU 2019-04 amend the guidance of ASU 2016-13, are applicable to the Company&#x2019;s investments portfolio, and allow the Company to make certain accounting policy elections regarding establishing allowance for credit losses for the accrued interest receivable and the corresponding disclosures. In November 2019, the FASB issued ASU No. 2019-11, Codification Improvements to Topic 326, Financial Instruments &#x2013; Credit Losses (&#x201c;ASU 2019-11&#x201d;), which clarifies certain areas of the guidance to ensure all companies and organizations can make a smoother transition to the standard. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the Company will become a large accelerated filer and as a result, the guidance under ASU 2019-04, ASU 2016-13 and ASU 2019-11 is effective for the Company's Annual Report on Form 10-K to be filed for the year ended December 31, 2021. The Company will record a cumulative effect adjustment to retained earnings retroactive to January 1, 2021, the date of adoption. The Company is currently evaluating the impact of ASU 2019-11 and the related ASU 2019-04 and ASU 2016-13 on its consolidated financial statements, including the impact of the available accounting policy elections. The Company does not expect this guidance to have a material impact on its consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), with guidance regarding the accounting for and disclosure of leases. In general, for lease arrangements exceeding a twelve-month term, these arrangements must now be recognized as assets and liabilities on the balance sheet of the lessee. Under ASU 2016-02, a right-of-use asset and lease obligation will be recorded for all leases, whether operating or financing, while the income statement will reflect lease expense for operating leases and amortization/interest expense for financing leases. The balance sheet amount recorded for existing leases at the date of adoption of ASU 2016-02 must be calculated using the applicable incremental borrowing rate at the date of adoption. This update also requires lessees and lessors to disclose key information about their leasing transactions. In July 2018, the FASB issued ASU 2018-11, Leases - Targeted Improvements, intended to ease the implementation of the new lease &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;standard for financial statement preparers by, among other things, allowing for an additional transition method. In lieu of presenting transition requirements to comparative periods, as previously required, an entity may now elect to show a cumulative effect adjustment on the date of adoption without the requirement to recast prior period financial statements or disclosures presented in accordance with ASU 2016-02.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently expects to elect the available package of practical expedients which allows the Company to not reassess previous accounting conclusions around whether arrangements are or contain leases, the classification of leases, and the treatment of initial direct costs. The Company also expects it will make an accounting policy election to keep leases with an initial term of 12 months or less off of the balance sheet. &lt;/span&gt;&lt;/div&gt;In August 2021, the Company exercised its one-time extension right for its existing lease for 35,000 square feet of office and laboratory space through May 2025, as provided for under the terms of the lease. The Company is currently evaluating the effect of adopting the requirements of ASU 2016-02 as it relates to its facility lease, as amended in August 2021, and discussed in Note 10 to the consolidated financial statements appearing in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2020. The Company is also performing an evaluation of other material contracts to determine if any contain embedded leases, and has not identified any to date. As of December 31, 2021, the Company will become a large accelerated filer and as a result, the guidance under ASU 2016-02 is effective for the Company's Annual Report on Form 10-K to be filed for the year ended December 31, 2021, with an effective date of adoption of January 1, 2021.</morf:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock>
    <us-gaap:AreaOfLand
      contextRef="i196c1e6bf66247b98fa293ce7ce21c10_I20210831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNC9mcmFnOjMyZGVhNWI1NDQzMzQ0MjhiODBiZmIwYzkyYjBlY2ZlL3RleHRyZWdpb246MzJkZWE1YjU0NDMzNDQyOGI4MGJmYjBjOTJiMGVjZmVfNDk0NzgwMjMzMzI1Mg_8f5ee994-3cc8-4d10-9a38-c69b13d1b85b"
      unitRef="sqft">35000</us-gaap:AreaOfLand>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RleHRyZWdpb246YjZmM2VmNzM3MDhmNGI4N2FhZTYyNDYzYjMxZmQxN2ZfMjQ0Ng_00c86c13-304a-4f46-afed-67243d296bc0">Fair Value of Financial Assets and Liabilities&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has certain financial assets and liabilities that are recorded at fair value which have been classified as Level&#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 &#x2014; Quoted market prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 &#x2014; Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 &#x2014; Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;At September&#160;30, 2021, investments also include corporate debt securities which are valued either based on recent trades of securities in inactive markets or based on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below present information about the Company&#x2019;s financial assets that are measured at fair value on a recurring basis as of September&#160;30, 2021 and December&#160;31, 2020 (in thousands) and indicate the level within the fair value hierarchy where each measurement is classified.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The money market funds included in the tables above invest in U.S. government securities that are valued using quoted market prices. Accordingly, money market funds are categorized as Level 1 as of September&#160;30, 2021 and December&#160;31, 2020. Marketable securities included in the tables above consist of U.S. Treasury securities and corporate debt securities, and these securities are categorized as Level 2 as of September&#160;30, 2021 and December&#160;31, 2020. During the nine months ended September&#160;30, 2021, no assets were transferred between the fair value hierarchy categories. The Company had no liabilities measured at fair value on a recurring basis at September&#160;30, 2021 or December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that the carrying amounts of the Company&#x2019;s condensed consolidated financial instruments, including prepaid expenses and other current assets, accounts receivable, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RleHRyZWdpb246YjZmM2VmNzM3MDhmNGI4N2FhZTYyNDYzYjMxZmQxN2ZfMjQ0Nw_20e1e410-492e-49a7-bc3c-c1572f9f0a73">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below present information about the Company&#x2019;s financial assets that are measured at fair value on a recurring basis as of September&#160;30, 2021 and December&#160;31, 2020 (in thousands) and indicate the level within the fair value hierarchy where each measurement is classified.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i385155a063a54593b7698266553fa968_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfNC0xLTEtMS0yMTM2_4df7d99c-570c-4c12-a22a-1e1ac1f855ee"
      unitRef="usd">143883000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic691b1bab6064f3d9b9e1c90394f4e2d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfNC0zLTEtMS0yMTM2_5a7579ff-e22d-4ba0-b83f-1406284fe19a"
      unitRef="usd">143883000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id40e4cfd2a8045e1a1e666498fe4e815_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfNC01LTEtMS0yMTM2_86354921-b4e9-409a-804e-81b4f802c08d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i037043297a254ed9b5cf0826c9db9fa9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfNC03LTEtMS0yMTM2_b6b6d7c7-a76e-4bbb-8360-d8998ef7e929"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icb831f5a17f54f7584aa402e76bb36fe_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfNS0xLTEtMS0yMTM2_373a7a83-db9f-423b-98e1-70ddfe9b1588"
      unitRef="usd">32087000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i486fa776a3f04f34ac576895fc27dad7_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfNS0zLTEtMS0yMTM2_8d7eec36-0ff2-41ec-96ad-2a9b39fef5a5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0fb8ba20056d490189b4417c8db4fc8b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfNS01LTEtMS0yMTM2_3d6af515-fffd-499d-ab9d-cb627a3306f3"
      unitRef="usd">32087000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia8565d342aa34348b2d8b3de28ae62d2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfNS03LTEtMS0yMTM2_1bba3481-4620-4f9f-89ed-64f495c5306a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i64b03ce48904405aa038b9b8f79e221c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfOC0xLTEtMS0yMDI2OA_8e26636e-ed9f-4795-8213-397d4cdf2461"
      unitRef="usd">211330000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i79dd709730de462484976109499248c0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfOC0zLTEtMS0yMDI2OA_178befd4-fe3b-4606-ae1a-b5221125d741"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3093e8eb0fbf40cfaf61a51b86743dfc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfOC01LTEtMS0yMDI2OA_cb16671a-0991-4814-a4e9-cbd795694a19"
      unitRef="usd">211330000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if0460516fcd64ec5939869a8cc9083fc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfOC03LTEtMS0yMDI2OA_c619f01b-b89f-4636-8c7e-b16cd144574f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia7a2b23055c14610b9b9f0122e0bc83c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfNi0xLTEtMS0yMTM2_272c9d88-6504-4f16-b6ba-45b0ca611c43"
      unitRef="usd">387300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i57619922f2b04e87b375de9b0c6abf2f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfNi0zLTEtMS0yMTM2_8028e8cb-2468-4c5e-9fda-c6f98270805d"
      unitRef="usd">143883000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1f4e846feef646b38404ae6f8ed330dc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfNi01LTEtMS0yMTM2_16483793-242c-4dc4-a27f-36e0a25f4fe6"
      unitRef="usd">243417000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icd960eb27fba42f3a7c083248ce24430_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjQwMTQ1NTU4MWMwOTQ0M2RiZTg2NDU4YTlkZTk5NGNlL3RhYmxlcmFuZ2U6NDAxNDU1NTgxYzA5NDQzZGJlODY0NThhOWRlOTk0Y2VfNi03LTEtMS0yMTM2_d483d9e7-b624-4eba-8bcd-e92fadcfb7f8"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i488d3d9e7497417dae3338d286bf285c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjgxMDdmNGM3M2JhYjQ3ZGI4YmUyOGQyNjZkMTJiMzFlL3RhYmxlcmFuZ2U6ODEwN2Y0YzczYmFiNDdkYjhiZTI4ZDI2NmQxMmIzMWVfNC0xLTEtMS0yMTM2_f412186d-9931-40b7-834a-e070cb57313f"
      unitRef="usd">101760000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1efba4c0bfa64c24912b8e57773d8914_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjgxMDdmNGM3M2JhYjQ3ZGI4YmUyOGQyNjZkMTJiMzFlL3RhYmxlcmFuZ2U6ODEwN2Y0YzczYmFiNDdkYjhiZTI4ZDI2NmQxMmIzMWVfNC0zLTEtMS0yMTM2_80f1b08f-7131-4c77-8c4d-7d9bfc763aae"
      unitRef="usd">101760000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4a595f6291d745078296fee41e88b0b5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjgxMDdmNGM3M2JhYjQ3ZGI4YmUyOGQyNjZkMTJiMzFlL3RhYmxlcmFuZ2U6ODEwN2Y0YzczYmFiNDdkYjhiZTI4ZDI2NmQxMmIzMWVfNC01LTEtMS0yMTM2_27fb7d78-630a-4392-a194-986395899522"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if06a28dfa4674c8da99858f333e14322_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjgxMDdmNGM3M2JhYjQ3ZGI4YmUyOGQyNjZkMTJiMzFlL3RhYmxlcmFuZ2U6ODEwN2Y0YzczYmFiNDdkYjhiZTI4ZDI2NmQxMmIzMWVfNC03LTEtMS0yMTM2_674e7d30-116e-4413-b815-bbc45eeaa25c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iddb9c72e419f4eadbe5c615a694858f7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjgxMDdmNGM3M2JhYjQ3ZGI4YmUyOGQyNjZkMTJiMzFlL3RhYmxlcmFuZ2U6ODEwN2Y0YzczYmFiNDdkYjhiZTI4ZDI2NmQxMmIzMWVfNi0xLTEtMS0yMTM2_14486803-c3b3-4236-86c2-518ffd93ed12"
      unitRef="usd">126217000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i078df3d57b71434481ab87bd4712a953_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjgxMDdmNGM3M2JhYjQ3ZGI4YmUyOGQyNjZkMTJiMzFlL3RhYmxlcmFuZ2U6ODEwN2Y0YzczYmFiNDdkYjhiZTI4ZDI2NmQxMmIzMWVfNi0zLTEtMS0yMTM2_5501f123-2c78-40d8-bfd3-3eeaa27e09c3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8f25b4bb5f1f4854b5ecb14766c3ca49_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjgxMDdmNGM3M2JhYjQ3ZGI4YmUyOGQyNjZkMTJiMzFlL3RhYmxlcmFuZ2U6ODEwN2Y0YzczYmFiNDdkYjhiZTI4ZDI2NmQxMmIzMWVfNi01LTEtMS0yMTM2_91ea2ada-f545-4b17-a0d7-f6bcab2d8a0f"
      unitRef="usd">126217000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i12b799caa9b242aabc2dbefff0e5f757_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjgxMDdmNGM3M2JhYjQ3ZGI4YmUyOGQyNjZkMTJiMzFlL3RhYmxlcmFuZ2U6ODEwN2Y0YzczYmFiNDdkYjhiZTI4ZDI2NmQxMmIzMWVfNi03LTEtMS0yMTM2_240ebd08-9ee8-4083-8130-dd71aa7dfa4f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib207c5a6d64c4722b33aa55f1f923141_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjgxMDdmNGM3M2JhYjQ3ZGI4YmUyOGQyNjZkMTJiMzFlL3RhYmxlcmFuZ2U6ODEwN2Y0YzczYmFiNDdkYjhiZTI4ZDI2NmQxMmIzMWVfNy0xLTEtMS0yMTM2_831257e0-3f4b-4759-a046-ff63aab8afb7"
      unitRef="usd">227977000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib8109e4aa5a0416e9392220462770a8c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjgxMDdmNGM3M2JhYjQ3ZGI4YmUyOGQyNjZkMTJiMzFlL3RhYmxlcmFuZ2U6ODEwN2Y0YzczYmFiNDdkYjhiZTI4ZDI2NmQxMmIzMWVfNy0zLTEtMS0yMTM2_81f79176-81c6-4f67-99fe-c07d7838b179"
      unitRef="usd">101760000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie493a72a05bd4a50bb01b9136293db44_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjgxMDdmNGM3M2JhYjQ3ZGI4YmUyOGQyNjZkMTJiMzFlL3RhYmxlcmFuZ2U6ODEwN2Y0YzczYmFiNDdkYjhiZTI4ZDI2NmQxMmIzMWVfNy01LTEtMS0yMTM2_6445ccc3-1440-452f-ad35-94d638c7c639"
      unitRef="usd">126217000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic0f1e91996364358920d91dc6eedb07f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8zNy9mcmFnOmI2ZjNlZjczNzA4ZjRiODdhYWU2MjQ2M2IzMWZkMTdmL3RhYmxlOjgxMDdmNGM3M2JhYjQ3ZGI4YmUyOGQyNjZkMTJiMzFlL3RhYmxlcmFuZ2U6ODEwN2Y0YzczYmFiNDdkYjhiZTI4ZDI2NmQxMmIzMWVfNy03LTEtMS0yMTM2_9f8594b5-e12d-4d72-80e2-29be10891467"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RleHRyZWdpb246OTAyNzM3YTgwZDAyNDY2NTk3YzY0OWM5MzJhMjdjNTRfMTA5OTUxMTYyNzk0MDk_559ace01-8e07-45cc-892d-953a7e6aae92">Marketable securities&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s investments in marketable securities classified as available for sale (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized &lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;within 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized &lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company&#x2019;s investments are classified as available-for-sale and are carried at fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income (loss). The Company considers all available-for-sale securities, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs and therefore classifies all securities with maturity dates beyond 90 days at the date of purchase as current assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RleHRyZWdpb246OTAyNzM3YTgwZDAyNDY2NTk3YzY0OWM5MzJhMjdjNTRfMTY2_36079d3b-a18c-4ce8-a2fa-72f3cf15452b">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s investments in marketable securities classified as available for sale (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized &lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;within 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized &lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;estimated&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1f5553a6ec7c411da7d58ef985358ba5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOjJmNGQ5N2E1NjQ2NTQxZjRhMTViZWE2NWVmMzZjYTMwL3RhYmxlcmFuZ2U6MmY0ZDk3YTU2NDY1NDFmNGExNWJlYTY1ZWYzNmNhMzBfMi0zLTEtMS0yMTM2_9fed219f-dd67-4ae0-9ed1-992842bdab4f"
      unitRef="usd">32084000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1f5553a6ec7c411da7d58ef985358ba5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOjJmNGQ5N2E1NjQ2NTQxZjRhMTViZWE2NWVmMzZjYTMwL3RhYmxlcmFuZ2U6MmY0ZDk3YTU2NDY1NDFmNGExNWJlYTY1ZWYzNmNhMzBfMi01LTEtMS0yMTM2_565d7be6-a24f-42c6-bc46-0280624c8fc3"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1f5553a6ec7c411da7d58ef985358ba5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOjJmNGQ5N2E1NjQ2NTQxZjRhMTViZWE2NWVmMzZjYTMwL3RhYmxlcmFuZ2U6MmY0ZDk3YTU2NDY1NDFmNGExNWJlYTY1ZWYzNmNhMzBfMi03LTEtMS0yMTM2_5f90ec35-cc23-428f-b8d5-23c11c3a83f8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1f5553a6ec7c411da7d58ef985358ba5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOjJmNGQ5N2E1NjQ2NTQxZjRhMTViZWE2NWVmMzZjYTMwL3RhYmxlcmFuZ2U6MmY0ZDk3YTU2NDY1NDFmNGExNWJlYTY1ZWYzNmNhMzBfMi05LTEtMS0yMTM2_ddb9c492-63e3-403a-baf2-bce9c2dc60df"
      unitRef="usd">32087000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i103b3b3fd13b4d969b9f99f276f756be_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOjJmNGQ5N2E1NjQ2NTQxZjRhMTViZWE2NWVmMzZjYTMwL3RhYmxlcmFuZ2U6MmY0ZDk3YTU2NDY1NDFmNGExNWJlYTY1ZWYzNmNhMzBfNS0zLTEtMS0yMDM5MQ_3cb1c6ea-f40b-4ba3-935f-e5ddb37141b7"
      unitRef="usd">211400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i103b3b3fd13b4d969b9f99f276f756be_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOjJmNGQ5N2E1NjQ2NTQxZjRhMTViZWE2NWVmMzZjYTMwL3RhYmxlcmFuZ2U6MmY0ZDk3YTU2NDY1NDFmNGExNWJlYTY1ZWYzNmNhMzBfNS01LTEtMS0yMDM5MQ_6313bac9-dedf-49a0-86b2-edf50e01252d"
      unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i103b3b3fd13b4d969b9f99f276f756be_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOjJmNGQ5N2E1NjQ2NTQxZjRhMTViZWE2NWVmMzZjYTMwL3RhYmxlcmFuZ2U6MmY0ZDk3YTU2NDY1NDFmNGExNWJlYTY1ZWYzNmNhMzBfNS03LTEtMS0yMDM5MQ_2d75cdb2-ad1e-408c-b710-96da5c200954"
      unitRef="usd">83000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i103b3b3fd13b4d969b9f99f276f756be_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOjJmNGQ5N2E1NjQ2NTQxZjRhMTViZWE2NWVmMzZjYTMwL3RhYmxlcmFuZ2U6MmY0ZDk3YTU2NDY1NDFmNGExNWJlYTY1ZWYzNmNhMzBfNS05LTEtMS0yMDM5MQ_d043ac46-e06c-48c8-a714-e4612c269da4"
      unitRef="usd">211330000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOjJmNGQ5N2E1NjQ2NTQxZjRhMTViZWE2NWVmMzZjYTMwL3RhYmxlcmFuZ2U6MmY0ZDk3YTU2NDY1NDFmNGExNWJlYTY1ZWYzNmNhMzBfOC0zLTEtMS0yMDM5MQ_e09ada1c-140c-4a56-a0b3-ee9d02403c71"
      unitRef="usd">243484000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOjJmNGQ5N2E1NjQ2NTQxZjRhMTViZWE2NWVmMzZjYTMwL3RhYmxlcmFuZ2U6MmY0ZDk3YTU2NDY1NDFmNGExNWJlYTY1ZWYzNmNhMzBfOC01LTEtMS0yMDM5MQ_2ec72347-0a23-4313-ac1e-fcc1c83d7088"
      unitRef="usd">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOjJmNGQ5N2E1NjQ2NTQxZjRhMTViZWE2NWVmMzZjYTMwL3RhYmxlcmFuZ2U6MmY0ZDk3YTU2NDY1NDFmNGExNWJlYTY1ZWYzNmNhMzBfOC03LTEtMS0yMDM5MQ_cdbb96f5-bd3a-4cc7-9197-5b2cd8ce3655"
      unitRef="usd">83000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOjJmNGQ5N2E1NjQ2NTQxZjRhMTViZWE2NWVmMzZjYTMwL3RhYmxlcmFuZ2U6MmY0ZDk3YTU2NDY1NDFmNGExNWJlYTY1ZWYzNmNhMzBfOC05LTEtMS0yMDM5MQ_7d9eb4f3-8289-4e1d-9e3e-78f8a9f1e3a1"
      unitRef="usd">243417000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie233b4a2750a4b268a177be345cf1c52_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOmUzYWFjNGJkYjFmODQ3ODQ5NTQzYTY2NTJmNzU5ZGY3L3RhYmxlcmFuZ2U6ZTNhYWM0YmRiMWY4NDc4NDk1NDNhNjY1MmY3NTlkZjdfMi0zLTEtMS0yMTM2_181b4cf0-1bbe-44d4-ab9a-c374c4ef7bea"
      unitRef="usd">126212000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie233b4a2750a4b268a177be345cf1c52_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOmUzYWFjNGJkYjFmODQ3ODQ5NTQzYTY2NTJmNzU5ZGY3L3RhYmxlcmFuZ2U6ZTNhYWM0YmRiMWY4NDc4NDk1NDNhNjY1MmY3NTlkZjdfMi01LTEtMS0yMTM2_efb2faec-1e21-4a10-9ea3-50a7ed207aa0"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie233b4a2750a4b268a177be345cf1c52_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOmUzYWFjNGJkYjFmODQ3ODQ5NTQzYTY2NTJmNzU5ZGY3L3RhYmxlcmFuZ2U6ZTNhYWM0YmRiMWY4NDc4NDk1NDNhNjY1MmY3NTlkZjdfMi03LTEtMS0yMTM2_96acfb7d-9f5b-4705-b94e-fe1ddb96ddc0"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie233b4a2750a4b268a177be345cf1c52_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOmUzYWFjNGJkYjFmODQ3ODQ5NTQzYTY2NTJmNzU5ZGY3L3RhYmxlcmFuZ2U6ZTNhYWM0YmRiMWY4NDc4NDk1NDNhNjY1MmY3NTlkZjdfMi05LTEtMS0yMTM2_3d496245-7c67-4edc-bc52-45d38e3fb0a9"
      unitRef="usd">126217000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOmUzYWFjNGJkYjFmODQ3ODQ5NTQzYTY2NTJmNzU5ZGY3L3RhYmxlcmFuZ2U6ZTNhYWM0YmRiMWY4NDc4NDk1NDNhNjY1MmY3NTlkZjdfNC0zLTEtMS0yMDQxNA_44598178-49fd-46e6-9e66-193a7f3b1dd0"
      unitRef="usd">126212000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOmUzYWFjNGJkYjFmODQ3ODQ5NTQzYTY2NTJmNzU5ZGY3L3RhYmxlcmFuZ2U6ZTNhYWM0YmRiMWY4NDc4NDk1NDNhNjY1MmY3NTlkZjdfNC01LTEtMS0yMDQxNA_f55aeb7a-45eb-4f5a-8034-ce9ece3dedd4"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOmUzYWFjNGJkYjFmODQ3ODQ5NTQzYTY2NTJmNzU5ZGY3L3RhYmxlcmFuZ2U6ZTNhYWM0YmRiMWY4NDc4NDk1NDNhNjY1MmY3NTlkZjdfNC03LTEtMS0yMDQxNA_5d8fdf15-e267-4660-a6ac-601b12269e23"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80MC9mcmFnOjkwMjczN2E4MGQwMjQ2NjU5N2M2NDljOTMyYTI3YzU0L3RhYmxlOmUzYWFjNGJkYjFmODQ3ODQ5NTQzYTY2NTJmNzU5ZGY3L3RhYmxlcmFuZ2U6ZTNhYWM0YmRiMWY4NDc4NDk1NDNhNjY1MmY3NTlkZjdfNC05LTEtMS0yMDQxNA_bd4a5663-12eb-4428-8e35-eb4931c43fe7"
      unitRef="usd">126217000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RleHRyZWdpb246YjdlZTdjOWE4MDhhNDM5ZGJiZjFkNDA0NmYyNTYxMmVfMzc0_f5dd6fc1-15cb-48c4-b31e-39934078eaa6">Cash, Cash Equivalents and Restricted CashRestricted cash consists of a letter of credit in the amount of $560,000 issued to the landlord of the Company&#x2019;s facility lease as of September 30, 2021. The letter of credit increased from $275,000 in August 2021 due to the operating lease extension discussed further in Note 2. The terms of the letter of credit extend beyond one year. The following table reconciles cash, cash equivalents and restricted cash per the balance sheet to the statements of cash flows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RleHRyZWdpb246YjdlZTdjOWE4MDhhNDM5ZGJiZjFkNDA0NmYyNTYxMmVfMTEz_aa45083a-f6e1-45e4-8024-f1b59c4fb229"
      unitRef="usd">560000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i9fa385b09a9947cbaaa1c35bef4b2881_I20210831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RleHRyZWdpb246YjdlZTdjOWE4MDhhNDM5ZGJiZjFkNDA0NmYyNTYxMmVfNDk0NzgwMjMyNTYxMA_4ae2dc2f-3133-4f25-bd79-7fb1f3d3934e"
      unitRef="usd">275000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RleHRyZWdpb246YjdlZTdjOWE4MDhhNDM5ZGJiZjFkNDA0NmYyNTYxMmVfMjIw_d1a9e565-0794-44a8-8f15-45fbb1c6b079">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RleHRyZWdpb246YjdlZTdjOWE4MDhhNDM5ZGJiZjFkNDA0NmYyNTYxMmVfMzc1_5e543b18-1292-4bcc-93cb-ab4f76bce87b">The following table reconciles cash, cash equivalents and restricted cash per the balance sheet to the statements of cash flows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RhYmxlOjkxMjY3MjAxM2FmNjRlNjI4YmNhZTFlNmRjODk2NjcyL3RhYmxlcmFuZ2U6OTEyNjcyMDEzYWY2NGU2MjhiY2FlMWU2ZGM4OTY2NzJfMy0xLTEtMS0yMTM2_dc082eef-8366-4b4b-a9ee-35e8617bcbdb"
      unitRef="usd">184159000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RhYmxlOjkxMjY3MjAxM2FmNjRlNjI4YmNhZTFlNmRjODk2NjcyL3RhYmxlcmFuZ2U6OTEyNjcyMDEzYWY2NGU2MjhiY2FlMWU2ZGM4OTY2NzJfMy0zLTEtMS0yMTM2_0d480679-5d63-4a76-ac7e-aaa750988aad"
      unitRef="usd">102047000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i64b5dd8c546640129471ee97d4f9028f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RhYmxlOjkxMjY3MjAxM2FmNjRlNjI4YmNhZTFlNmRjODk2NjcyL3RhYmxlcmFuZ2U6OTEyNjcyMDEzYWY2NGU2MjhiY2FlMWU2ZGM4OTY2NzJfMy01LTEtMS0yMTM2_e8130edb-f347-49a3-a519-0595c9b75a34"
      unitRef="usd">98080000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia2e37d454f86483da5d113ba5bb9c6ae_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RhYmxlOjkxMjY3MjAxM2FmNjRlNjI4YmNhZTFlNmRjODk2NjcyL3RhYmxlcmFuZ2U6OTEyNjcyMDEzYWY2NGU2MjhiY2FlMWU2ZGM4OTY2NzJfMy03LTEtMS0yMTM2_c05044e8-7d0b-4e1c-8cce-870ceee4204a"
      unitRef="usd">101559000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RhYmxlOjkxMjY3MjAxM2FmNjRlNjI4YmNhZTFlNmRjODk2NjcyL3RhYmxlcmFuZ2U6OTEyNjcyMDEzYWY2NGU2MjhiY2FlMWU2ZGM4OTY2NzJfNC0xLTEtMS0yMTM2_f6dcd046-848a-44f1-8634-0a1210e3dd90"
      unitRef="usd">560000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RhYmxlOjkxMjY3MjAxM2FmNjRlNjI4YmNhZTFlNmRjODk2NjcyL3RhYmxlcmFuZ2U6OTEyNjcyMDEzYWY2NGU2MjhiY2FlMWU2ZGM4OTY2NzJfNC0zLTEtMS0yMTM2_201df9b6-a364-4ddd-b578-474662c1689d"
      unitRef="usd">275000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i64b5dd8c546640129471ee97d4f9028f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RhYmxlOjkxMjY3MjAxM2FmNjRlNjI4YmNhZTFlNmRjODk2NjcyL3RhYmxlcmFuZ2U6OTEyNjcyMDEzYWY2NGU2MjhiY2FlMWU2ZGM4OTY2NzJfNC01LTEtMS0yMTM2_eb4f1c9a-159e-41a5-ac1a-9d98b1e35d6f"
      unitRef="usd">275000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="ia2e37d454f86483da5d113ba5bb9c6ae_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RhYmxlOjkxMjY3MjAxM2FmNjRlNjI4YmNhZTFlNmRjODk2NjcyL3RhYmxlcmFuZ2U6OTEyNjcyMDEzYWY2NGU2MjhiY2FlMWU2ZGM4OTY2NzJfNC03LTEtMS0yMTM2_d7b29593-b59b-4acf-a1a4-f94d8f53a5fa"
      unitRef="usd">275000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RhYmxlOjkxMjY3MjAxM2FmNjRlNjI4YmNhZTFlNmRjODk2NjcyL3RhYmxlcmFuZ2U6OTEyNjcyMDEzYWY2NGU2MjhiY2FlMWU2ZGM4OTY2NzJfNS0xLTEtMS0yMTM2_592f20b7-2abd-4448-b781-0b4861f18fcb"
      unitRef="usd">184719000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RhYmxlOjkxMjY3MjAxM2FmNjRlNjI4YmNhZTFlNmRjODk2NjcyL3RhYmxlcmFuZ2U6OTEyNjcyMDEzYWY2NGU2MjhiY2FlMWU2ZGM4OTY2NzJfNS0zLTEtMS0yMTM2_c893b16a-dd26-42c4-9e59-a598ed01457d"
      unitRef="usd">102322000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i64b5dd8c546640129471ee97d4f9028f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RhYmxlOjkxMjY3MjAxM2FmNjRlNjI4YmNhZTFlNmRjODk2NjcyL3RhYmxlcmFuZ2U6OTEyNjcyMDEzYWY2NGU2MjhiY2FlMWU2ZGM4OTY2NzJfNS01LTEtMS0yMTM2_e1d65f70-b879-4db7-a4c6-9a6fded745ca"
      unitRef="usd">98355000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia2e37d454f86483da5d113ba5bb9c6ae_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80My9mcmFnOmI3ZWU3YzlhODA4YTQzOWRiYmYxZDQwNDZmMjU2MTJlL3RhYmxlOjkxMjY3MjAxM2FmNjRlNjI4YmNhZTFlNmRjODk2NjcyL3RhYmxlcmFuZ2U6OTEyNjcyMDEzYWY2NGU2MjhiY2FlMWU2ZGM4OTY2NzJfNS03LTEtMS0yMTM2_0acf0c33-bc6e-466f-8e75-5f6f93a12af7"
      unitRef="usd">101834000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80Ni9mcmFnOjU2YjRhZjlmYzc1MjRjMmQ4OWQ3YTZkYTY5YmRlYTYwL3RleHRyZWdpb246NTZiNGFmOWZjNzUyNGMyZDg5ZDdhNmRhNjliZGVhNjBfOTU_23cbae94-3f00-46b2-8dcf-f27a2357ab18">Accrued Expenses&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2021 and December&#160;31, 2020 accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80Ni9mcmFnOjU2YjRhZjlmYzc1MjRjMmQ4OWQ3YTZkYTY5YmRlYTYwL3RleHRyZWdpb246NTZiNGFmOWZjNzUyNGMyZDg5ZDdhNmRhNjliZGVhNjBfOTY_4c111b3f-2616-497f-a891-994d6996df89">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2021 and December&#160;31, 2020 accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80Ni9mcmFnOjU2YjRhZjlmYzc1MjRjMmQ4OWQ3YTZkYTY5YmRlYTYwL3RhYmxlOjI0NjM4Y2I3OTc0MTQ0OGQ4NzBiZjc2ZGMzZDZlNWNkL3RhYmxlcmFuZ2U6MjQ2MzhjYjc5NzQxNDQ4ZDg3MGJmNzZkYzNkNmU1Y2RfMy0xLTEtMS0yMTM2_f0e1b785-de51-47db-8e51-2dcb3b52ad11"
      unitRef="usd">4390000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80Ni9mcmFnOjU2YjRhZjlmYzc1MjRjMmQ4OWQ3YTZkYTY5YmRlYTYwL3RhYmxlOjI0NjM4Y2I3OTc0MTQ0OGQ4NzBiZjc2ZGMzZDZlNWNkL3RhYmxlcmFuZ2U6MjQ2MzhjYjc5NzQxNDQ4ZDg3MGJmNzZkYzNkNmU1Y2RfMy0zLTEtMS0yMTM2_10d9d109-00bb-4fad-a39b-36627ee65e3b"
      unitRef="usd">5148000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <morf:AccruedResearchAndDevelopment
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80Ni9mcmFnOjU2YjRhZjlmYzc1MjRjMmQ4OWQ3YTZkYTY5YmRlYTYwL3RhYmxlOjI0NjM4Y2I3OTc0MTQ0OGQ4NzBiZjc2ZGMzZDZlNWNkL3RhYmxlcmFuZ2U6MjQ2MzhjYjc5NzQxNDQ4ZDg3MGJmNzZkYzNkNmU1Y2RfNC0xLTEtMS0yMTM2_0a172fc6-bd33-4d06-b86e-bc1fcfdd8cd9"
      unitRef="usd">3019000</morf:AccruedResearchAndDevelopment>
    <morf:AccruedResearchAndDevelopment
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80Ni9mcmFnOjU2YjRhZjlmYzc1MjRjMmQ4OWQ3YTZkYTY5YmRlYTYwL3RhYmxlOjI0NjM4Y2I3OTc0MTQ0OGQ4NzBiZjc2ZGMzZDZlNWNkL3RhYmxlcmFuZ2U6MjQ2MzhjYjc5NzQxNDQ4ZDg3MGJmNzZkYzNkNmU1Y2RfNC0zLTEtMS0yMTM2_ad4c6cbf-682b-45db-85c9-0b38b51e8518"
      unitRef="usd">4335000</morf:AccruedResearchAndDevelopment>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80Ni9mcmFnOjU2YjRhZjlmYzc1MjRjMmQ4OWQ3YTZkYTY5YmRlYTYwL3RhYmxlOjI0NjM4Y2I3OTc0MTQ0OGQ4NzBiZjc2ZGMzZDZlNWNkL3RhYmxlcmFuZ2U6MjQ2MzhjYjc5NzQxNDQ4ZDg3MGJmNzZkYzNkNmU1Y2RfNS0xLTEtMS0yMTM2_06ec2ca3-923b-4ff5-996f-2b85a3a9787c"
      unitRef="usd">1008000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80Ni9mcmFnOjU2YjRhZjlmYzc1MjRjMmQ4OWQ3YTZkYTY5YmRlYTYwL3RhYmxlOjI0NjM4Y2I3OTc0MTQ0OGQ4NzBiZjc2ZGMzZDZlNWNkL3RhYmxlcmFuZ2U6MjQ2MzhjYjc5NzQxNDQ4ZDg3MGJmNzZkYzNkNmU1Y2RfNS0zLTEtMS0yMTM2_c218bef9-56fa-4c57-86ac-4ddcced984af"
      unitRef="usd">677000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80Ni9mcmFnOjU2YjRhZjlmYzc1MjRjMmQ4OWQ3YTZkYTY5YmRlYTYwL3RhYmxlOjI0NjM4Y2I3OTc0MTQ0OGQ4NzBiZjc2ZGMzZDZlNWNkL3RhYmxlcmFuZ2U6MjQ2MzhjYjc5NzQxNDQ4ZDg3MGJmNzZkYzNkNmU1Y2RfNi0xLTEtMS0yMTM2_fbd77782-e825-4d68-81d2-264d7bce8be6"
      unitRef="usd">8417000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i6a068fad94154f33aaa0ea27a826b0e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80Ni9mcmFnOjU2YjRhZjlmYzc1MjRjMmQ4OWQ3YTZkYTY5YmRlYTYwL3RhYmxlOjI0NjM4Y2I3OTc0MTQ0OGQ4NzBiZjc2ZGMzZDZlNWNkL3RhYmxlcmFuZ2U6MjQ2MzhjYjc5NzQxNDQ4ZDg3MGJmNzZkYzNkNmU1Y2RfNi0zLTEtMS0yMTM2_79a30603-47c4-47a4-9070-0d0df0762e8d"
      unitRef="usd">10160000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfMzA4OQ_902a82b1-0f3d-4d1a-9d49-5b487792904d">Equity Based Compensation&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Company&#x2019;s initial public offering in July 2019, the Company adopted the 2019 Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;) in June 2019, which replaced the 2018 Stock Incentive Plan. The 2019 Plan provides for the grant of stock options, restricted stock awards, stock bonus awards, cash awards, stock appreciation right, RSUs, and performance awards to directors, officers and employees of the Company, as well as consultants and advisors of the Company.  As a result of the automatic increase provision of the 2019 Plan, the number of shares of common stock available for issuance under the 2019 Plan increased by 1.3&#160;million shares on January 2021. As of&#160;September&#160;30, 2021, there were a total of&#160;1.3&#160;million shares available for future award grants under the 2019 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized equity-based compensation expense in the condensed consolidated statements of operations and comprehensive loss, by award type, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the allocation of equity-based compensation expense in the condensed consolidated statements of operations and comprehensive loss, by expense category (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Restricted Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the restricted stock awards activity during the nine months ended September&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average Fair&lt;br/&gt;Value per Share&lt;br/&gt;at Issuance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted common stock as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted common stock as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, the Company had unrecognized equity-based compensation expense of $0.1&#160;million related to the restricted stock awards, which is expected to be recognized over a weighted average period of 0.3 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The following table summarizes the restricted stock units activity during the nine months ended September&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average Fair&lt;br/&gt;Value per Share&lt;br/&gt;at Issuance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units as of  December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, the Company had unrecognized equity-based compensation expense of $0.5&#160;million related to the restricted stock units, which is expected to be recognized over a weighted average period of 2.2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity during the nine months ended September&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,352,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,550,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(675,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140,722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,086,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,729,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, the Company had unrecognized equity-based compensation expense of $50.3&#160;million related to stock options issued to employees and non-employees, which is expected to be recognized over a weighted average period of 2.4 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;ESPP&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the Company adopted the 2019 Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;), which became effective on June 26, 2019. The Company initially reserved 300,000 shares of common stock for sale under the ESPP. As a result of the automatic increase provision of the ESPP, the number of shares of common stock available for issuance under the ESPP increased by 0.3&#160;million &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shares on January 1, 2021. The ESPP is a qualified, compensatory plan under Section 423 of the Internal Revenue Code and offers substantially all employees opportunity to purchase up to $25,000 of common stock per year at 15% discount to the lower of the beginning of the offering period price or the end of the offering period price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation expense for discounted purchases under the ESPP is measured using the Black-Scholes model to compute the fair value of the lookback provision plus the purchase discount and is recognized as compensation expense over the course of the offering period.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i1d81d7faa05e4d72ba315f45f8ca2b93_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfNjY0_84c03127-8054-4be8-b981-79e580b8fd39"
      unitRef="shares">1300000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i9b8872a576284d399ea67d6b51d01d5b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfNzIz_2735c360-edac-4511-9ec5-df9b39b02458"
      unitRef="shares">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfMzA5MA_9f06a47e-2d0c-48b0-90a2-c453b906ef86">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized equity-based compensation expense in the condensed consolidated statements of operations and comprehensive loss, by award type, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the allocation of equity-based compensation expense in the condensed consolidated statements of operations and comprehensive loss, by expense category (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iccd54f681834442eb165955240d9e74a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfMi0xLTEtMS0yMTM2_cb83b2ad-a2d3-474b-9543-0c94da15dcc8"
      unitRef="usd">5403000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idcf0ba2ceaab4483a2bfe533ce701a43_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfMi0zLTEtMS0yMTM2_842802ee-598d-47a0-9157-451c51623572"
      unitRef="usd">2672000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia79f1a27faad4ee0b5c7c77ea717ed13_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfMi01LTEtMS0yMTM2_f6ca46e7-86fd-48c8-b699-e318bffa71ae"
      unitRef="usd">14448000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic423ff5ccdca4effbe4d4211fa5e77f6_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfMi03LTEtMS0yMTM2_daa3aa2a-ab87-405e-a7b7-27b5ea43c3db"
      unitRef="usd">6734000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaf513a6144654bceada542de288df958_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfMy0xLTEtMS0yMTM2_ff6eec6d-7def-4370-9ca8-e890d5e3b261"
      unitRef="usd">71000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1f9166bb425c44ada5c593577d00e22a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfMy0zLTEtMS0yMTM2_f0dd558a-f3c3-4dd0-aea2-c2c7373d77a1"
      unitRef="usd">147000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2eee8a4601534a4a917d268a6e6ed3c0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfMy01LTEtMS0yMTM2_01f152df-d951-4a5f-a9e5-8ef5ffe2762a"
      unitRef="usd">224000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iad4849d4849a4887af432c78ad0245a8_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfMy03LTEtMS0yMTM2_b287a99f-dfdf-45c5-b614-4b6cb0ac4311"
      unitRef="usd">832000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i24c99804fc6044a5a6faa8fb23d4c212_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfNC0xLTEtMS0yMTM2_3d966332-ca55-4a3f-b147-708f526bcb5e"
      unitRef="usd">163000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifa63b4b83d8c4eaca119ea3ed2510c96_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfNC0zLTEtMS0yMTM2_4a1c9326-18c5-47bf-a8d1-2e5f5654d42b"
      unitRef="usd">55000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0f2f1b5251e94bbe8ef420f9ff484d6e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfNC01LTEtMS0yMTM2_c6a7a476-6646-4bde-a2c4-87434895cfb7"
      unitRef="usd">385000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i65aaf5db173b49e9ab4c31517132d9ec_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfNC03LTEtMS0yMTM2_83cbb4d9-ac70-4b6b-96dd-804f7d667363"
      unitRef="usd">124000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i039b981d5def4df5ac1cd4a91d5e0229_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfNS0xLTEtMS0yMTM2_ed888c89-6643-4b3c-83c9-92cb6d9cfac3"
      unitRef="usd">154000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie9b7b224fe294b00affdcc71cba4f7d6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfNS0zLTEtMS0yMTM2_b4f742ca-2632-4be8-a768-dcf2e0867f12"
      unitRef="usd">122000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i28dbbd4689134d678129e0ec4c7edb79_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfNS01LTEtMS0yMTM2_25bca380-007f-4807-9fe9-36cb82f985cf"
      unitRef="usd">484000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if4d1f97a11f54bcb896bca14bdcd10f2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfNS03LTEtMS0yMTM2_2555c467-0d32-452c-a34c-2b795d1b069b"
      unitRef="usd">339000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfNi0xLTEtMS0yMTM2_364026d8-eb43-4228-a9b3-ae64964033e7"
      unitRef="usd">5791000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfNi0zLTEtMS0yMTM2_f8dc7294-20a3-4a6d-8d1e-c566a5af4b08"
      unitRef="usd">2996000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfNi01LTEtMS0yMTM2_a65a26d0-8618-4ee6-916e-1387951ea11a"
      unitRef="usd">15541000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmRhZjg2NTQxNWUxYzQyYjU5MGQyNzk4NDdkMDZhNzk3L3RhYmxlcmFuZ2U6ZGFmODY1NDE1ZTFjNDJiNTkwZDI3OTg0N2QwNmE3OTdfNi03LTEtMS0yMTM2_8dc3ef1d-4ba0-484b-8840-3a8dba8332a0"
      unitRef="usd">8029000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if1efef8ae596461dbbceea676d6cf299_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjg0MjUxNGRiYjViNDQ5NGFhZmY3NDBmZTY5NTZjYzhiL3RhYmxlcmFuZ2U6ODQyNTE0ZGJiNWI0NDk0YWFmZjc0MGZlNjk1NmNjOGJfMi0xLTEtMS0yMTM2_485d1837-8cfc-4bb0-90fa-962ed3c81766"
      unitRef="usd">2599000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibf03edf7a50641cfb11f3e5cc6746127_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjg0MjUxNGRiYjViNDQ5NGFhZmY3NDBmZTY5NTZjYzhiL3RhYmxlcmFuZ2U6ODQyNTE0ZGJiNWI0NDk0YWFmZjc0MGZlNjk1NmNjOGJfMi0zLTEtMS0yMTM2_a40f548c-7fc9-4bf4-95cc-7bccc9d66e95"
      unitRef="usd">1480000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i673a34526db04381a03c0b2e761aca2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjg0MjUxNGRiYjViNDQ5NGFhZmY3NDBmZTY5NTZjYzhiL3RhYmxlcmFuZ2U6ODQyNTE0ZGJiNWI0NDk0YWFmZjc0MGZlNjk1NmNjOGJfMi01LTEtMS0yMTM2_b5e1a6d1-42a0-47e0-804f-8036c5dcfdf3"
      unitRef="usd">7406000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if9e3e64d44494241956eb0fdacb21e56_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjg0MjUxNGRiYjViNDQ5NGFhZmY3NDBmZTY5NTZjYzhiL3RhYmxlcmFuZ2U6ODQyNTE0ZGJiNWI0NDk0YWFmZjc0MGZlNjk1NmNjOGJfMi03LTEtMS0yMTM2_9f6602d4-d519-498e-97dc-fb444954caaa"
      unitRef="usd">4623000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i21ee8d1c8ad34b4e80c662e251e209ae_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjg0MjUxNGRiYjViNDQ5NGFhZmY3NDBmZTY5NTZjYzhiL3RhYmxlcmFuZ2U6ODQyNTE0ZGJiNWI0NDk0YWFmZjc0MGZlNjk1NmNjOGJfMy0xLTEtMS0yMTM2_f79e7d80-ffb8-4b8b-8264-fa9d5f960e80"
      unitRef="usd">3192000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i71df2423ac2c4debbc999ef809fd11c1_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjg0MjUxNGRiYjViNDQ5NGFhZmY3NDBmZTY5NTZjYzhiL3RhYmxlcmFuZ2U6ODQyNTE0ZGJiNWI0NDk0YWFmZjc0MGZlNjk1NmNjOGJfMy0zLTEtMS0yMTM2_164c8422-2360-463c-9fff-e85efec9ed18"
      unitRef="usd">1516000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4bcc85b10d794d0c98147f0f99a5a07a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjg0MjUxNGRiYjViNDQ5NGFhZmY3NDBmZTY5NTZjYzhiL3RhYmxlcmFuZ2U6ODQyNTE0ZGJiNWI0NDk0YWFmZjc0MGZlNjk1NmNjOGJfMy01LTEtMS0yMTM2_ff23ace3-79a0-411e-a9a1-d585397419e7"
      unitRef="usd">8135000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5998a9c8f16249a5a5aed5bd18c1e529_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjg0MjUxNGRiYjViNDQ5NGFhZmY3NDBmZTY5NTZjYzhiL3RhYmxlcmFuZ2U6ODQyNTE0ZGJiNWI0NDk0YWFmZjc0MGZlNjk1NmNjOGJfMy03LTEtMS0yMTM2_1ff71ccd-6d7e-45ad-824e-ef3a2d6e356a"
      unitRef="usd">3406000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjg0MjUxNGRiYjViNDQ5NGFhZmY3NDBmZTY5NTZjYzhiL3RhYmxlcmFuZ2U6ODQyNTE0ZGJiNWI0NDk0YWFmZjc0MGZlNjk1NmNjOGJfNC0xLTEtMS0yMTM2_2f044201-ca11-490e-a67f-faf19c03229d"
      unitRef="usd">5791000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjg0MjUxNGRiYjViNDQ5NGFhZmY3NDBmZTY5NTZjYzhiL3RhYmxlcmFuZ2U6ODQyNTE0ZGJiNWI0NDk0YWFmZjc0MGZlNjk1NmNjOGJfNC0zLTEtMS0yMTM2_eea67926-8bce-48e7-aec9-4637622459a3"
      unitRef="usd">2996000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjg0MjUxNGRiYjViNDQ5NGFhZmY3NDBmZTY5NTZjYzhiL3RhYmxlcmFuZ2U6ODQyNTE0ZGJiNWI0NDk0YWFmZjc0MGZlNjk1NmNjOGJfNC01LTEtMS0yMTM2_dd211850-cb6e-4b57-b428-c0904014b0b7"
      unitRef="usd">15541000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjg0MjUxNGRiYjViNDQ5NGFhZmY3NDBmZTY5NTZjYzhiL3RhYmxlcmFuZ2U6ODQyNTE0ZGJiNWI0NDk0YWFmZjc0MGZlNjk1NmNjOGJfNC03LTEtMS0yMTM2_0f90033c-bba8-44ff-ab1a-96541da56144"
      unitRef="usd">8029000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfMzA5MQ_6b67c9ac-4953-4610-9da2-4d370928f437">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the restricted stock awards activity during the nine months ended September&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average Fair&lt;br/&gt;Value per Share&lt;br/&gt;at Issuance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted common stock as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted common stock as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i55558d3807264cfebb3cf65d4a4463df_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjI0NTU2NTRhMGQ4NzQ2ODFhZDRhM2U0MzU4MmY5ZjMwL3RhYmxlcmFuZ2U6MjQ1NTY1NGEwZDg3NDY4MWFkNGEzZTQzNTgyZjlmMzBfMS0xLTEtMS0yMTM2_dc10cc38-5478-4c72-9c82-b8016927a3b5"
      unitRef="shares">100989</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i55558d3807264cfebb3cf65d4a4463df_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjI0NTU2NTRhMGQ4NzQ2ODFhZDRhM2U0MzU4MmY5ZjMwL3RhYmxlcmFuZ2U6MjQ1NTY1NGEwZDg3NDY4MWFkNGEzZTQzNTgyZjlmMzBfMS0zLTEtMS0yMTM2_d99f67ae-fdc8-40cf-8885-75e1b2981418"
      unitRef="usdPerShare">4.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie3b3a9e7b9604013adda880bf9c86908_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjI0NTU2NTRhMGQ4NzQ2ODFhZDRhM2U0MzU4MmY5ZjMwL3RhYmxlcmFuZ2U6MjQ1NTY1NGEwZDg3NDY4MWFkNGEzZTQzNTgyZjlmMzBfMi0xLTEtMS0yMTM2_08694e21-fcf4-47c6-ba0f-dc31b8f29820"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie3b3a9e7b9604013adda880bf9c86908_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjI0NTU2NTRhMGQ4NzQ2ODFhZDRhM2U0MzU4MmY5ZjMwL3RhYmxlcmFuZ2U6MjQ1NTY1NGEwZDg3NDY4MWFkNGEzZTQzNTgyZjlmMzBfMi0zLTEtMS0yMTM2_34b5a0ba-54a8-4025-938a-d17ba2908ccd"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ie3b3a9e7b9604013adda880bf9c86908_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjI0NTU2NTRhMGQ4NzQ2ODFhZDRhM2U0MzU4MmY5ZjMwL3RhYmxlcmFuZ2U6MjQ1NTY1NGEwZDg3NDY4MWFkNGEzZTQzNTgyZjlmMzBfMy0xLTEtMS0yMTM2_3a3962cc-047b-42db-ae4c-8b30edf8b2ba"
      unitRef="shares">73056</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie3b3a9e7b9604013adda880bf9c86908_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjI0NTU2NTRhMGQ4NzQ2ODFhZDRhM2U0MzU4MmY5ZjMwL3RhYmxlcmFuZ2U6MjQ1NTY1NGEwZDg3NDY4MWFkNGEzZTQzNTgyZjlmMzBfMy0zLTEtMS0yMTM2_3ecf0786-bc93-4414-b20d-d6acaeda6db0"
      unitRef="usdPerShare">4.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ie3b3a9e7b9604013adda880bf9c86908_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjI0NTU2NTRhMGQ4NzQ2ODFhZDRhM2U0MzU4MmY5ZjMwL3RhYmxlcmFuZ2U6MjQ1NTY1NGEwZDg3NDY4MWFkNGEzZTQzNTgyZjlmMzBfNC0xLTEtMS0yMTM2_b7617c8b-b990-4c9a-b0bd-ec445a19616a"
      unitRef="shares">3540</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ie3b3a9e7b9604013adda880bf9c86908_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjI0NTU2NTRhMGQ4NzQ2ODFhZDRhM2U0MzU4MmY5ZjMwL3RhYmxlcmFuZ2U6MjQ1NTY1NGEwZDg3NDY4MWFkNGEzZTQzNTgyZjlmMzBfNC0zLTEtMS0yMTM2_159c0f54-fc50-42a4-acb5-cabb339e956e"
      unitRef="usdPerShare">4.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ic35b086f16144f27b108d50ef91c71d5_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjI0NTU2NTRhMGQ4NzQ2ODFhZDRhM2U0MzU4MmY5ZjMwL3RhYmxlcmFuZ2U6MjQ1NTY1NGEwZDg3NDY4MWFkNGEzZTQzNTgyZjlmMzBfNS0xLTEtMS0yMTM2_245e86d0-4aaf-4c22-9c7f-e10637b09d74"
      unitRef="shares">24393</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ic35b086f16144f27b108d50ef91c71d5_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjI0NTU2NTRhMGQ4NzQ2ODFhZDRhM2U0MzU4MmY5ZjMwL3RhYmxlcmFuZ2U6MjQ1NTY1NGEwZDg3NDY4MWFkNGEzZTQzNTgyZjlmMzBfNS0zLTEtMS0yMTM2_eccbc7b5-4b99-4a51-ab64-4c9707b4f354"
      unitRef="usdPerShare">4.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i3306469c42b0426c851e95ee8d3af6bf_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfMTM3Ng_3d4c3427-46d0-49c8-857c-44c676c7b606"
      unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i2eee8a4601534a4a917d268a6e6ed3c0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfMTQ4OA_514071eb-b290-4570-8f06-0d32e6acae4e">P0Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfMzA5Mg_1fc40d89-fe7f-4676-8f75-ff1729a4bbff">The following table summarizes the restricted stock units activity during the nine months ended September&#160;30, 2021:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average Fair&lt;br/&gt;Value per Share&lt;br/&gt;at Issuance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units as of  December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i19b2674b6d5149d0b8ee34f673c706f2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmY5OGVmZDMyZWQxNzQyYThhMGJiMGYyYWMyZDllMzE5L3RhYmxlcmFuZ2U6Zjk4ZWZkMzJlZDE3NDJhOGEwYmIwZjJhYzJkOWUzMTlfMS0xLTEtMS0yMTM2_7d7d1811-98d9-4b99-be72-26eab711f736"
      unitRef="shares">66216</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i19b2674b6d5149d0b8ee34f673c706f2_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmY5OGVmZDMyZWQxNzQyYThhMGJiMGYyYWMyZDllMzE5L3RhYmxlcmFuZ2U6Zjk4ZWZkMzJlZDE3NDJhOGEwYmIwZjJhYzJkOWUzMTlfMS0zLTEtMS0yMTM2_ae3e061d-4580-43ce-bf5a-fab0d11cfa58"
      unitRef="usdPerShare">10.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iafc120c8b5bb4f488b7898393d9badba_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmY5OGVmZDMyZWQxNzQyYThhMGJiMGYyYWMyZDllMzE5L3RhYmxlcmFuZ2U6Zjk4ZWZkMzJlZDE3NDJhOGEwYmIwZjJhYzJkOWUzMTlfMi0xLTEtMS0yMTM2_db455384-6b41-4296-acfa-3898e04d0a38"
      unitRef="shares">7000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iafc120c8b5bb4f488b7898393d9badba_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmY5OGVmZDMyZWQxNzQyYThhMGJiMGYyYWMyZDllMzE5L3RhYmxlcmFuZ2U6Zjk4ZWZkMzJlZDE3NDJhOGEwYmIwZjJhYzJkOWUzMTlfMi0zLTEtMS0yMTM2_6464165f-dc87-4958-9dd9-db76ea0bcd8b"
      unitRef="usdPerShare">57.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="iafc120c8b5bb4f488b7898393d9badba_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmY5OGVmZDMyZWQxNzQyYThhMGJiMGYyYWMyZDllMzE5L3RhYmxlcmFuZ2U6Zjk4ZWZkMzJlZDE3NDJhOGEwYmIwZjJhYzJkOWUzMTlfMy0xLTEtMS0yMTM2_f40d24e3-a87b-4276-a92e-0b3cab6e4f09"
      unitRef="shares">32121</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="iafc120c8b5bb4f488b7898393d9badba_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmY5OGVmZDMyZWQxNzQyYThhMGJiMGYyYWMyZDllMzE5L3RhYmxlcmFuZ2U6Zjk4ZWZkMzJlZDE3NDJhOGEwYmIwZjJhYzJkOWUzMTlfMy0zLTEtMS0yMTM2_4f6e5797-adc2-4757-a69b-aea8a4b776ae"
      unitRef="usdPerShare">10.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="iafc120c8b5bb4f488b7898393d9badba_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmY5OGVmZDMyZWQxNzQyYThhMGJiMGYyYWMyZDllMzE5L3RhYmxlcmFuZ2U6Zjk4ZWZkMzJlZDE3NDJhOGEwYmIwZjJhYzJkOWUzMTlfNC0xLTEtMS0yMTM2_4e603e0f-f43c-499c-94a3-f7964bf7f1f0"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="iafc120c8b5bb4f488b7898393d9badba_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmY5OGVmZDMyZWQxNzQyYThhMGJiMGYyYWMyZDllMzE5L3RhYmxlcmFuZ2U6Zjk4ZWZkMzJlZDE3NDJhOGEwYmIwZjJhYzJkOWUzMTlfNC0zLTEtMS0yMTM2_e046e5dc-d71c-4c22-855c-a97edf842511"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id827d0b4de4c40aebffdd742a897d8e7_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmY5OGVmZDMyZWQxNzQyYThhMGJiMGYyYWMyZDllMzE5L3RhYmxlcmFuZ2U6Zjk4ZWZkMzJlZDE3NDJhOGEwYmIwZjJhYzJkOWUzMTlfNS0xLTEtMS0yMTM2_98b69057-22c7-42cf-b305-8fecb2e3d5e6"
      unitRef="shares">41095</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="id827d0b4de4c40aebffdd742a897d8e7_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOmY5OGVmZDMyZWQxNzQyYThhMGJiMGYyYWMyZDllMzE5L3RhYmxlcmFuZ2U6Zjk4ZWZkMzJlZDE3NDJhOGEwYmIwZjJhYzJkOWUzMTlfNS0zLTEtMS0yMTM2_9b5b3ae5-8713-42f3-b31c-8ab30704659a"
      unitRef="usdPerShare">18.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i336ef268b2b54d5a8d41335f5521475d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfMTY5Mg_808fc3dc-e284-47bf-ba29-59be72257ea0"
      unitRef="usd">500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i0f2f1b5251e94bbe8ef420f9ff484d6e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfMTgwMw_dcefc73c-e88e-4d51-be8f-479d42802dd2">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfMzA5Mw_ebed68e6-0101-45ad-a626-18ef11fcd4c0">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity during the nine months ended September&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,352,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,550,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(675,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140,722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,086,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,729,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie1bba300f18d4aa9a80235013244a2ca_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfMi0xLTEtMS0yMTM2_350492d3-88ac-495b-b8fc-43fe1bbeb7b0"
      unitRef="shares">4352095</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ie1bba300f18d4aa9a80235013244a2ca_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfMi0zLTEtMS0yMTM2_10fb899d-0726-4dcd-8d8f-f76040d13a97"
      unitRef="usdPerShare">12.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i41bca88497e24b96b89b016e9cea4fe6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfMi01LTEtMS0yMTM2_dd1fe5b8-83b4-4183-a57d-085c7f51bc1a">P8Y8M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ie1bba300f18d4aa9a80235013244a2ca_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfMi03LTEtMS0yMTM2_fe226740-6ccd-4c87-9a81-1470c737d80f"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ia79f1a27faad4ee0b5c7c77ea717ed13_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfMy0xLTEtMS0yMTM2_0f14578b-cc39-41dd-9c79-61e3f3b348e1"
      unitRef="shares">1550333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ia79f1a27faad4ee0b5c7c77ea717ed13_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfMy0zLTEtMS0yMTM2_df4524d0-ea3d-46cb-8339-09daf1a85675"
      unitRef="usdPerShare">35.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia79f1a27faad4ee0b5c7c77ea717ed13_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfNC0xLTEtMS0yMTM2_3584355d-8f60-4b15-b9ed-fb33d8193517"
      unitRef="shares">675211</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ia79f1a27faad4ee0b5c7c77ea717ed13_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfNC0zLTEtMS0yMTM2_7497101d-15cd-4f92-9894-1f4979760cc4"
      unitRef="usdPerShare">11.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ia79f1a27faad4ee0b5c7c77ea717ed13_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfNS0xLTEtMS0yMTM2_bf546d4a-94cf-456d-a1d5-0c2140ce7d84"
      unitRef="shares">140722</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ia79f1a27faad4ee0b5c7c77ea717ed13_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfNS0zLTEtMS0yMTM2_1111b202-abdf-4607-a938-bf98db36a0f1"
      unitRef="usdPerShare">17.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i500b2548238d418785e416f8b2eb9f96_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfNi0xLTEtMS0yMTM2_adbb93de-571e-41d4-b3c7-873f67710a30"
      unitRef="shares">5086495</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i500b2548238d418785e416f8b2eb9f96_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfNi0zLTEtMS0yMTM2_07bac347-8e71-452a-af7e-ed4a5df0278c"
      unitRef="usdPerShare">19.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ia79f1a27faad4ee0b5c7c77ea717ed13_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfNi01LTEtMS0yMTM2_50c52e1b-db18-483e-98fa-9395b5dbea91">P8Y4M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i500b2548238d418785e416f8b2eb9f96_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfNi03LTEtMS0yMTM2_55b7b803-a37d-4fa1-bce9-aec7a35e9d14"
      unitRef="usd">191512000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i500b2548238d418785e416f8b2eb9f96_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfNy0xLTEtMS0yMTM2_c0f2dd0a-372a-410e-9014-d2b83e6659c1"
      unitRef="shares">1729711</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i500b2548238d418785e416f8b2eb9f96_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfNy0zLTEtMS0yMTM2_fe4b6311-860d-4a8c-a152-85417d78d519"
      unitRef="usdPerShare">12.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ia79f1a27faad4ee0b5c7c77ea717ed13_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfNy01LTEtMS0yMTM2_e318ff44-440a-444a-8873-5faaa7c469d2">P7Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i500b2548238d418785e416f8b2eb9f96_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RhYmxlOjgxZWM4OTUxYmQzMTQ0OTE5ZWUyOTQ3ZmY0MjNhM2NiL3RhYmxlcmFuZ2U6ODFlYzg5NTFiZDMxNDQ5MTllZTI5NDdmZjQyM2EzY2JfNy03LTEtMS0yMTM2_835eef8a-5b61-4d3c-8c6c-edc8b42b6f54"
      unitRef="usd">75513000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfMTk5OQ_ee1a6eb7-e7b6-4d1c-a5b6-a00aa8f6d413"
      unitRef="usd">50300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfMjEzNQ_e819192e-3fee-468c-8d55-35101aff5df1">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="idecb2791d4e644adac2b17f62a0ffc4d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfMjI5Mw_0ef47d46-7dd4-46a6-8dc0-9dd5957c29be"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i9f2623aae9e042109d449218c4a952e2_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfMjQ5Mw_8cd8fb53-ef7e-4f12-a01c-e2e9ebb423f1"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <morf:EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee
      contextRef="if4fd934abc1c47eeb0364ac66d1ad27d_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfMjY4Mg_76551ab3-d3de-46c6-8f59-7cfdae248b19"
      unitRef="usd">25000</morf:EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee>
    <morf:ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock
      contextRef="i933ed6a72813427384dce0d77c868663_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl80OS9mcmFnOmIyYjI1NTA0Y2JiNTQzMmI5NDU0NDNhOTdjMjY1N2ZiL3RleHRyZWdpb246YjJiMjU1MDRjYmI1NDMyYjk0NTQ0M2E5N2MyNjU3ZmJfMjcxMw_6c96dd82-53e1-4d63-baea-337316fe4056"
      unitRef="number">0.15</morf:ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl81NS9mcmFnOjNmMWIwZDhiN2FlZDQ2YTFhNDAwMzAxN2UwNTFiMDBkL3RleHRyZWdpb246M2YxYjBkOGI3YWVkNDZhMWE0MDAzMDE3ZTA1MWIwMGRfMjAzOQ_bae97fa0-fe5d-474e-a6e2-37d632db4f6c">Income Taxes&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to use its operating loss carryforwards and tax credits to offset future taxable income is subject to restrictions under Sections&#160;382 and 383 of the United States Internal Revenue Code, or the Internal Revenue Code. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50 percent, as defined under Sections 382 and 383 of the Internal Revenue Code. Such changes would limit the Company&#x2019;s use of its operating loss carryforwards and tax credits. In such a situation, the Company may be required to pay income taxes, even though significant operating loss carryforwards and tax credits exist.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 27, 2020, the Coronavirus Aid Relief and Economic Security (&#x201c;CARES&#x201d;) Act was signed into law.&#160;The CARES Act included several income tax changes, included allowing for the carryback of net operating losses, expanding interest deductibility, and allowing for accelerated expensing of certain capital improvements.&#160;&lt;/span&gt;&lt;/div&gt;The Company records a provision or benefit for income taxes on ordinary pre-tax income or loss based on its estimated effective tax rate for the year. As of September&#160;30, 2021, the Company forecasts an ordinary pre-tax loss for the year ended December 31, 2021 and, since it maintains a full valuation allowance on its deferred tax assets, the Company did not record an income tax benefit in 2021. Based on the carryback allowance under the CARES Act, the Company recorded an income tax benefit of $0.1&#160;million and $0.4&#160;million for the three and nine months ended September&#160;30, 2020, respectively.</us-gaap:IncomeTaxDisclosureTextBlock>
    <morf:IncomeTaxExpenseBenefitCARESAct
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl81NS9mcmFnOjNmMWIwZDhiN2FlZDQ2YTFhNDAwMzAxN2UwNTFiMDBkL3RleHRyZWdpb246M2YxYjBkOGI3YWVkNDZhMWE0MDAzMDE3ZTA1MWIwMGRfODc5NjA5MzAyNDMxNw_c487a4ee-7a81-409e-b31b-df4cb0ed41d6"
      unitRef="usd">-100000</morf:IncomeTaxExpenseBenefitCARESAct>
    <morf:IncomeTaxExpenseBenefitCARESAct
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl81NS9mcmFnOjNmMWIwZDhiN2FlZDQ2YTFhNDAwMzAxN2UwNTFiMDBkL3RleHRyZWdpb246M2YxYjBkOGI3YWVkNDZhMWE0MDAzMDE3ZTA1MWIwMGRfODc5NjA5MzAyNDMwMg_aa8ec002-8212-4a29-91c0-0742f4f1feb7"
      unitRef="usd">-400000</morf:IncomeTaxExpenseBenefitCARESAct>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl81OC9mcmFnOmQ3NjVjYmNmZDlkODQ5NTI5Y2ZkOTI1OWVkZmRkZGYzL3RleHRyZWdpb246ZDc2NWNiY2ZkOWQ4NDk1MjljZmQ5MjU5ZWRmZGRkZjNfMjA5MA_3563f5ab-8cd4-4b41-ae77-0df19a8b41aa">Commitments and Contingencies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Guarantees and Indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered, and intends to continue to enter, into separate indemnification agreements with directors, officers, and certain of key employees, in addition to the indemnification provided for in the restated certificate of incorporation and restated bylaws. These agreements, among other things, require the Company to indemnify directors, officers, and key employees for certain expenses, including attorneys' fees, judgments, penalties, fines, and settlement amounts actually incurred by these individuals in any action or proceeding arising out of their service to the Company or any of its subsidiaries or any other company or enterprise to which these individuals provide services at the Company&#x2019;s request. Subject to certain limitations, the indemnification agreements also require the Company to advance expenses incurred by directors, officers, and key employees for the defense of any action for which indemnification is required or permitted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has standard indemnification arrangements in its leases for laboratory and office space that require it to indemnify the landlord against any liability for injury, loss, accident, or damage from any claims, actions, proceedings, or costs resulting from certain acts, breaches, violations, or non-performance under the Company&#x2019;s lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through September&#160;30, 2021, the Company had not experienced any losses related to these indemnification obligations, and no material claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2021, the Company exercised its one-time extension right for its existing lease for 35,000 square feet of office and laboratory space through May 2025, as provided for under the terms of the lease. During the three and nine months ended September&#160;30, 2021, there were no other material changes to our contractual obligations and commitments previously disclosed in Note 10 to the consolidated financial statements appearing in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Minimum annual rent payments after the exercise of the lease extension right, excluding operating expenses and taxes, which are not fixed for future periods, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Minimum Lease Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is not currently a party to any material legal proceedings.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfLand
      contextRef="i196c1e6bf66247b98fa293ce7ce21c10_I20210831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl81OC9mcmFnOmQ3NjVjYmNmZDlkODQ5NTI5Y2ZkOTI1OWVkZmRkZGYzL3RleHRyZWdpb246ZDc2NWNiY2ZkOWQ4NDk1MjljZmQ5MjU5ZWRmZGRkZjNfNDk0NzgwMjMyNzQ5MA_73ee5a7c-27d3-4eb7-b1c2-cdfba2cd75e6"
      unitRef="sqft">35000</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl81OC9mcmFnOmQ3NjVjYmNmZDlkODQ5NTI5Y2ZkOTI1OWVkZmRkZGYzL3RleHRyZWdpb246ZDc2NWNiY2ZkOWQ4NDk1MjljZmQ5MjU5ZWRmZGRkZjNfMTA5OTUxMTYyODA2NTA_848a2e5e-2274-4b65-afd8-c7e752c91b83">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Minimum annual rent payments after the exercise of the lease extension right, excluding operating expenses and taxes, which are not fixed for future periods, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Minimum Lease Payments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl81OC9mcmFnOmQ3NjVjYmNmZDlkODQ5NTI5Y2ZkOTI1OWVkZmRkZGYzL3RhYmxlOjAwNGM5NjdmOGQ3MzRmMjM4YTMyNzBmZDI4YjM4YjliL3RhYmxlcmFuZ2U6MDA0Yzk2N2Y4ZDczNGYyMzhhMzI3MGZkMjhiMzhiOWJfMS0yLTEtMS0yMjczNg_5c4956e4-2270-4155-a17f-923ae65ba059"
      unitRef="usd">316000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl81OC9mcmFnOmQ3NjVjYmNmZDlkODQ5NTI5Y2ZkOTI1OWVkZmRkZGYzL3RhYmxlOjAwNGM5NjdmOGQ3MzRmMjM4YTMyNzBmZDI4YjM4YjliL3RhYmxlcmFuZ2U6MDA0Yzk2N2Y4ZDczNGYyMzhhMzI3MGZkMjhiMzhiOWJfMi0yLTEtMS0yMjczNg_7563604f-c6cb-44c7-8c58-ab841b728caf"
      unitRef="usd">1507000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl81OC9mcmFnOmQ3NjVjYmNmZDlkODQ5NTI5Y2ZkOTI1OWVkZmRkZGYzL3RhYmxlOjAwNGM5NjdmOGQ3MzRmMjM4YTMyNzBmZDI4YjM4YjliL3RhYmxlcmFuZ2U6MDA0Yzk2N2Y4ZDczNGYyMzhhMzI3MGZkMjhiMzhiOWJfMy0yLTEtMS0yMjczNg_56885635-0c7e-4857-9897-ffcc793931e1"
      unitRef="usd">1700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl81OC9mcmFnOmQ3NjVjYmNmZDlkODQ5NTI5Y2ZkOTI1OWVkZmRkZGYzL3RhYmxlOjAwNGM5NjdmOGQ3MzRmMjM4YTMyNzBmZDI4YjM4YjliL3RhYmxlcmFuZ2U6MDA0Yzk2N2Y4ZDczNGYyMzhhMzI3MGZkMjhiMzhiOWJfNC0yLTEtMS0yMjczNg_a93ac5fd-7477-4cea-aa4c-753cb79181d3"
      unitRef="usd">1733000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl81OC9mcmFnOmQ3NjVjYmNmZDlkODQ5NTI5Y2ZkOTI1OWVkZmRkZGYzL3RhYmxlOjAwNGM5NjdmOGQ3MzRmMjM4YTMyNzBmZDI4YjM4YjliL3RhYmxlcmFuZ2U6MDA0Yzk2N2Y4ZDczNGYyMzhhMzI3MGZkMjhiMzhiOWJfNS0yLTEtMS0yMjczNg_46e3e4c8-1cd5-49d8-bf54-7254dfe16661"
      unitRef="usd">727000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl81OC9mcmFnOmQ3NjVjYmNmZDlkODQ5NTI5Y2ZkOTI1OWVkZmRkZGYzL3RhYmxlOjAwNGM5NjdmOGQ3MzRmMjM4YTMyNzBmZDI4YjM4YjliL3RhYmxlcmFuZ2U6MDA0Yzk2N2Y4ZDczNGYyMzhhMzI3MGZkMjhiMzhiOWJfNi0yLTEtMS0yMjczNg_2a0ba46f-e01b-4881-9698-3ed6d8216822"
      unitRef="usd">5983000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RleHRyZWdpb246MjgxZjNiZTQzYzhmNGJiMWI3ZWZhY2YyZjBkZTBhYWJfNDUzMw_ed328f9f-3a43-4903-899f-7a653cb5bc4e">Option and License Agreements&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Detailed description of contractual terms and the Company&#x2019;s accounting for agreements described below were included in the Company&#x2019;s audited financial statements and notes in the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AbbVie Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September 30, 2021, the Company continued to perform under its agreement with AbbVie, (the &#x201c;AbbVie Agreement&#x201d;) pursuant to which the Company recognizes revenues in proportion to the costs incurred. As a result, the Company recognizes as revenue the $100.0 million up-front payment as research and development services are performed, which is expected to be completed through 2024. The following table summarizes research and development costs incurred and revenue recognized in connection with Company's performance under the AbbVie Agreement during the three and nine months ended September 30, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costs incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 25, 2020, AbbVie exercised its option to license and control further development and commercialization of Morphic&#x2019;s &#x3b1;v&#x3b2;6&#x2013;specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications. In connection with the exercise of the option, AbbVie paid the Company $20.0 million, which was recognized as revenue during the three and nine months ended September 30, 2021. The Company is eligible to receive potential milestones and royalties on future development and commercialization of Morphic&#x2019;s &#x3b1;v&#x3b2;6&#x2013;specific integrin inhibitors, as further described in the Company&#x2019;s audited financial statements and notes in the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2021, all of which have been fully constrained as of September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, the Company had $66.7 million of deferred revenue, which is classified as either current or long-term deferred revenue in the accompanying condensed consolidated balance sheets based on the period over which the revenue is expected to be recognized. This deferred revenue balance represents the aggregate amount of the transaction price allocated to the performance obligations that are partially unsatisfied as of September&#160;30, 2021.&lt;/span&gt;&lt;span style="color:#1d1c1d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company had $29 thousand and  $0.9&#160;million recorded as accounts receivable from AbbVie &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the condensed consolidated balance sheet &lt;/span&gt;&lt;span style="color:#1d1c1d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September&#160;30, 2021 and &lt;/span&gt;&lt;span style="color:#1d1c1d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31. 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As the Company progresses towards satisfaction of performance obligations under the AbbVie Agreement, the estimated costs associated with the remaining effort required to complete the performance obligations may change, which may materially impact revenue recognition. The Company regularly evaluates and, when necessary, updates the costs associated with the remaining effort pursuant to each performance obligation under the AbbVie Agreement. Accordingly, revenue may fluctuate from period to period due to revisions to estimated costs, resulting in a change in the measure of progress for a performance &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;obligation. Such changes can also impact the allocation of deferred revenue between current and long term based on changes in expected timing of the satisfaction of performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Janssen Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September 30, 2021, the Company continued to perform under its agreement with Janssen (the "Janssen Agreement"), pursuant to which the Company recognizes revenue in proportion to the costs incurred to date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, Janssen paid the Company an upfront fee of $10.0&#160;million for the first two research programs in 2019 and in December 2020 the Company reached an agreement with Janssen to commence work on the third research program, and Janssen paid to the Company $5.0&#160;million for the third research program commencement fee in February 2021. The Company expects to provide research services and recognize revenue through 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes research and development costs incurred and revenue recognized in connection with Company's performance under the Janssen Agreement during three and nine months ended September 30, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Upfront payment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costs incurred&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had $2.6 million and $6.4&#160;million due from Janssen included in accounts receivable on the condensed consolidated balance sheets as of September&#160;30, 2021 and December&#160;31, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, $10.0 million of deferred revenue is classified as either current or long-term deferred revenue in the accompanying condensed consolidated balance sheet based on the period over which the revenue is expected to be recognized. This deferred revenue balance represents the portion of the upfront payment received allocated to the performance obligations that are partially unsatisfied as of September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2cb15e50535f4e87b974bc0af2a7bb9c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RleHRyZWdpb246MjgxZjNiZTQzYzhmNGJiMWI3ZWZhY2YyZjBkZTBhYWJfNTcz_2e51d973-6a93-4fdc-bc64-1a924078165e"
      unitRef="usd">100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd339294a59643f7b3b5f6dd55384718_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RleHRyZWdpb246MjgxZjNiZTQzYzhmNGJiMWI3ZWZhY2YyZjBkZTBhYWJfNTcz_82c51b0f-0ffd-4dce-89ee-7d5d0eb00a04"
      unitRef="usd">100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RleHRyZWdpb246MjgxZjNiZTQzYzhmNGJiMWI3ZWZhY2YyZjBkZTBhYWJfNDUzMQ_6bc5c83b-7ace-4dc3-9a3a-095caceee51e">The following table summarizes research and development costs incurred and revenue recognized in connection with Company's performance under the AbbVie Agreement during the three and nine months ended September 30, 2021 and 2020 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costs incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes research and development costs incurred and revenue recognized in connection with Company's performance under the Janssen Agreement during three and nine months ended September 30, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reimbursement revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Upfront payment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Costs incurred&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaacbf9b146694148984076cec6a6afd1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOjVhNmViMzFhZGE5YzQzZTA5MGVhNmQ1NDRhMTdlYWU2L3RhYmxlcmFuZ2U6NWE2ZWIzMWFkYTljNDNlMDkwZWE2ZDU0NGExN2VhZTZfMi0xLTEtMS0yMTM2_9c29801f-8cdf-49a2-ad22-128e61f24989"
      unitRef="usd">1476000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i291b9147c1ae41379197349d37bd173b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOjVhNmViMzFhZGE5YzQzZTA5MGVhNmQ1NDRhMTdlYWU2L3RhYmxlcmFuZ2U6NWE2ZWIzMWFkYTljNDNlMDkwZWE2ZDU0NGExN2VhZTZfMi0zLTEtMS0yMTM2_d2a98ec1-4ce3-46f2-9e0e-c47cacf6dcf9"
      unitRef="usd">23647000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i230a2ca85b2a4dccb1eb0099d20ad182_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOjVhNmViMzFhZGE5YzQzZTA5MGVhNmQ1NDRhMTdlYWU2L3RhYmxlcmFuZ2U6NWE2ZWIzMWFkYTljNDNlMDkwZWE2ZDU0NGExN2VhZTZfMi01LTEtMS0yMTM2_7206334f-a0a6-4421-97ad-03bf26b03011"
      unitRef="usd">5043000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae18ebb70c3c4104ab905dae334545e6_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOjVhNmViMzFhZGE5YzQzZTA5MGVhNmQ1NDRhMTdlYWU2L3RhYmxlcmFuZ2U6NWE2ZWIzMWFkYTljNDNlMDkwZWE2ZDU0NGExN2VhZTZfMi03LTEtMS0yMTM2_f1bc2b27-86a5-4e97-b2b8-c5aaf656a340"
      unitRef="usd">32328000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostsAndExpenses
      contextRef="iaacbf9b146694148984076cec6a6afd1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOjVhNmViMzFhZGE5YzQzZTA5MGVhNmQ1NDRhMTdlYWU2L3RhYmxlcmFuZ2U6NWE2ZWIzMWFkYTljNDNlMDkwZWE2ZDU0NGExN2VhZTZfMy0xLTEtMS0yMTM2_39fc118b-45ff-411d-917d-559a3be3bf2d"
      unitRef="usd">1206000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i291b9147c1ae41379197349d37bd173b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOjVhNmViMzFhZGE5YzQzZTA5MGVhNmQ1NDRhMTdlYWU2L3RhYmxlcmFuZ2U6NWE2ZWIzMWFkYTljNDNlMDkwZWE2ZDU0NGExN2VhZTZfMy0zLTEtMS0yMTM2_b3c9d2db-552e-40fd-9707-8dfdb65f1a61"
      unitRef="usd">2480000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i230a2ca85b2a4dccb1eb0099d20ad182_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOjVhNmViMzFhZGE5YzQzZTA5MGVhNmQ1NDRhMTdlYWU2L3RhYmxlcmFuZ2U6NWE2ZWIzMWFkYTljNDNlMDkwZWE2ZDU0NGExN2VhZTZfMy01LTEtMS0yMTM2_25330732-94a9-4a22-8f6a-d6e04f3b32e1"
      unitRef="usd">4374000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="iae18ebb70c3c4104ab905dae334545e6_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOjVhNmViMzFhZGE5YzQzZTA5MGVhNmQ1NDRhMTdlYWU2L3RhYmxlcmFuZ2U6NWE2ZWIzMWFkYTljNDNlMDkwZWE2ZDU0NGExN2VhZTZfMy03LTEtMS0yMTM2_ef515178-a57d-420e-9798-8043baaa63e8"
      unitRef="usd">10150000</us-gaap:CostsAndExpenses>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iccbf9f78a6bf4f6d936be01c6bdf3bde_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RleHRyZWdpb246MjgxZjNiZTQzYzhmNGJiMWI3ZWZhY2YyZjBkZTBhYWJfMTI0Mg_455fb57d-896c-47f5-95ac-864a2fb76d2d"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf1288ac2081418ea5506b9b964c318e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RleHRyZWdpb246MjgxZjNiZTQzYzhmNGJiMWI3ZWZhY2YyZjBkZTBhYWJfMTI0Mg_acfd753b-05e0-48a2-a1b3-38a51cc500b2"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i3686e9bb301546d3b3f298fb3add79a3_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RleHRyZWdpb246MjgxZjNiZTQzYzhmNGJiMWI3ZWZhY2YyZjBkZTBhYWJfMTczNw_67289270-6174-484d-8b50-70a9fb8a3b09"
      unitRef="usd">66700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i3686e9bb301546d3b3f298fb3add79a3_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RleHRyZWdpb246MjgxZjNiZTQzYzhmNGJiMWI3ZWZhY2YyZjBkZTBhYWJfMTA5OTUxMTYzMjMxMw_00903fc3-503e-494b-951b-9db32320e356"
      unitRef="usd">29000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="if51ea1a4ae7b4814bdd7be74ca589c83_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RleHRyZWdpb246MjgxZjNiZTQzYzhmNGJiMWI3ZWZhY2YyZjBkZTBhYWJfMjE0Ng_8f03b7a6-9d5b-4528-a4b5-95842a8e78c1"
      unitRef="usd">900000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf36089b555c48e58d97c007d1218b7e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RleHRyZWdpb246MjgxZjNiZTQzYzhmNGJiMWI3ZWZhY2YyZjBkZTBhYWJfMzQ0MQ_3a76551b-d41c-4167-833b-726ace7ff014"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04814fa766f14a87b1a4f5090088feac_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RleHRyZWdpb246MjgxZjNiZTQzYzhmNGJiMWI3ZWZhY2YyZjBkZTBhYWJfMzQ0MQ_59885763-d4ab-42b7-921b-cd970336b2f9"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b5652f4187946c99d351a84522e3224_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RleHRyZWdpb246MjgxZjNiZTQzYzhmNGJiMWI3ZWZhY2YyZjBkZTBhYWJfMzYzNQ_005bb37f-1973-4632-8971-eec2ab35f39c"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id854b4ee36ae41358df7d8160430d227_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfMi0xLTEtMS0yMTM2_004cbe6b-74c5-4a58-9d51-58a0fcf09d06"
      unitRef="usd">1276000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia72ac23116b546868709c55972ad7552_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfMi0zLTEtMS0yMTM2_9da1b157-5840-4aca-a6dd-17c894b51f5e"
      unitRef="usd">1634000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd2abd0024994ee09ba37323fe37f011_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfMi01LTEtMS0yMTM2_70fb1bbd-de21-4faa-a770-198edf364ea2"
      unitRef="usd">3914000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id12aad613d2c4493984ca5f33bb35df9_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfMi03LTEtMS0yMTM2_554767b1-1d0e-4acf-809b-ec988ccb54a0"
      unitRef="usd">5165000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i01c98160846146719189240b8058862e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfMy0xLTEtMS0yMTM2_9ed4cf34-d990-4741-acba-d3474b111c31"
      unitRef="usd">372000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9354f5fe43946dc8a9f666176548cf0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfMy0zLTEtMS0yMTM2_165a7d68-cffa-4ca8-9965-39a8af23afe4"
      unitRef="usd">476000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f177f36d3854a15b812deee9a7d9bdb_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfMy01LTEtMS0yMTM2_5c682e7e-25e4-4aa9-9279-c0acf37426e1"
      unitRef="usd">1281000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1757a9161a324b048e54e4ae0d303a19_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfMy03LTEtMS0yMTM2_77228490-1e76-499b-854f-3b2a4bb030e8"
      unitRef="usd">1551000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7428ecf2c9c2487f9fb6cb0173822e37_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfNC0xLTEtMS0yMTM2_f8960ebd-dba3-45c3-9a79-4a8a4970e2b7"
      unitRef="usd">1648000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i95e6d1a476764b22afd007e50518a6b3_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfNC0zLTEtMS0yMTM2_a731defd-78c2-41db-addb-e4dad80a4442"
      unitRef="usd">2110000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib185e590ec714546bf7f6029f9dbac37_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfNC01LTEtMS0yMTM2_3576ba43-ed91-429f-83ba-a2917abd6e0c"
      unitRef="usd">5195000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38ff992e2599451b9c12dca8f4da6c0e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfNC03LTEtMS0yMTM2_1013b282-4937-45ce-8cca-2a2d646a6b36"
      unitRef="usd">6716000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostsAndExpenses
      contextRef="i7428ecf2c9c2487f9fb6cb0173822e37_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfNS0xLTEtMS0yMTM2_faa6c9ed-9135-496e-a771-59697d64cfcd"
      unitRef="usd">1118000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i95e6d1a476764b22afd007e50518a6b3_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfNS0zLTEtMS0yMTM2_352b3d63-c270-4ae5-94a6-d97ae06804fa"
      unitRef="usd">1439000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ib185e590ec714546bf7f6029f9dbac37_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfNS01LTEtMS0yMTM2_bb7c0da1-1ff7-4277-85cf-5a3ab05b6351"
      unitRef="usd">3388000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i38ff992e2599451b9c12dca8f4da6c0e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RhYmxlOmM1NGNjMTRmNzc0YzQ5YmViNmM1NDFjMjcxY2JjYmEyL3RhYmxlcmFuZ2U6YzU0Y2MxNGY3NzRjNDliZWI2YzU0MWMyNzFjYmNiYTJfNS03LTEtMS0yMTM2_3c01e473-0be5-4350-b6f7-a75cfd6dee08"
      unitRef="usd">4540000</us-gaap:CostsAndExpenses>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="idfcdd8be7e094adb844410ae8c290692_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RleHRyZWdpb246MjgxZjNiZTQzYzhmNGJiMWI3ZWZhY2YyZjBkZTBhYWJfNDAwNA_1c790e34-9e7f-4f1a-a762-edead266dd6e"
      unitRef="usd">2600000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="id6809bfeafd44664a693a85e7e121e7a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RleHRyZWdpb246MjgxZjNiZTQzYzhmNGJiMWI3ZWZhY2YyZjBkZTBhYWJfNDAxMQ_fbbae9ea-3b99-466b-838e-19e29538bd4e"
      unitRef="usd">6400000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="idfcdd8be7e094adb844410ae8c290692_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82MS9mcmFnOjI4MWYzYmU0M2M4ZjRiYjFiN2VmYWNmMmYwZGUwYWFiL3RleHRyZWdpb246MjgxZjNiZTQzYzhmNGJiMWI3ZWZhY2YyZjBkZTBhYWJfNDE1MA_6bcccc95-009a-4bbc-9937-5163eb30320c"
      unitRef="usd">10000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RleHRyZWdpb246NWZlZjg0Y2JhMTM0NGZlMmFiMDIyMTc5NTM5OTE0NWZfMTYyMw_3ede08d0-bb84-4555-88e7-9650f20e1b00">Net (Loss) Income per Share&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income (loss) per share is calculated by dividing net income (loss) allocable to common stockholders by the weighted-average common shares outstanding during the period, without consideration of common stock equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For periods with net income, diluted net income per share is calculated by adjusting the weighted-average shares outstanding for the dilutive effect of common stock equivalents, including stock options and restricted common stock and stock units outstanding for the period as determined using the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation if their effect would be anti-dilutive. As such, basic and diluted net loss per share applicable to common stockholders are the same for periods with a net loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables illustrate the determination of basic and diluted loss per share for each period presented (in thousands, except share data):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74,140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,547,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,533,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,392,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,368,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income per share, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74,140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,547,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,533,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,392,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,368,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive impact from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,605,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted common stock and stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,547,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,366,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,392,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,368,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income per share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the outstanding common stock equivalents, presented based on amounts outstanding at each period end, that have been excluded from the calculation of diluted net loss per share for the periods indicated because their inclusion would have been anti-dilutive (in common stock equivalent shares, as applicable):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,086,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,086,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,685,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,151,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,151,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,918,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the securities listed in the table above, as of September&#160;30, 2021 the Company had reserved 801,622 shares of common stock for sale under the ESPP, which, if issued, would be anti-dilutive if included in calculation of diluted net loss per share for the nine months ended September&#160;30, 2021.&lt;/span&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RleHRyZWdpb246NWZlZjg0Y2JhMTM0NGZlMmFiMDIyMTc5NTM5OTE0NWZfMTYyMQ_343a888c-f609-4468-a457-64c0b33fe8e3">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables illustrate the determination of basic and diluted loss per share for each period presented (in thousands, except share data):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74,140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,547,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,533,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,392,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,368,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income per share, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74,140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,547,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,533,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,392,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,368,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive impact from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,605,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted common stock and stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,547,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,366,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,392,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,368,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income per share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjdiMDUzZTQwY2FjMzRiYjJhZmJjMmNlMzg5MjFjZTc0L3RhYmxlcmFuZ2U6N2IwNTNlNDBjYWMzNGJiMmFmYmMyY2UzODkyMWNlNzRfMi0xLTEtMS0yMTM2_0fde3029-a8e6-4d25-989b-79f320d1b6d4"
      unitRef="usd">-25041000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjdiMDUzZTQwY2FjMzRiYjJhZmJjMmNlMzg5MjFjZTc0L3RhYmxlcmFuZ2U6N2IwNTNlNDBjYWMzNGJiMmFmYmMyY2UzODkyMWNlNzRfMi0zLTEtMS0yMTM2_c0d412a2-5502-4a42-9c65-1882a0f4af61"
      unitRef="usd">5354000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjdiMDUzZTQwY2FjMzRiYjJhZmJjMmNlMzg5MjFjZTc0L3RhYmxlcmFuZ2U6N2IwNTNlNDBjYWMzNGJiMmFmYmMyY2UzODkyMWNlNzRfMi01LTEtMS0yMTM2_d4a75067-aea3-4a39-b6f4-e03ff35c3df3"
      unitRef="usd">-74140000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjdiMDUzZTQwY2FjMzRiYjJhZmJjMmNlMzg5MjFjZTc0L3RhYmxlcmFuZ2U6N2IwNTNlNDBjYWMzNGJiMmFmYmMyY2UzODkyMWNlNzRfMi03LTEtMS0yMTM2_dbb7e303-9ef3-4ea3-b0a5-e505f0d5d756"
      unitRef="usd">-27250000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjdiMDUzZTQwY2FjMzRiYjJhZmJjMmNlMzg5MjFjZTc0L3RhYmxlcmFuZ2U6N2IwNTNlNDBjYWMzNGJiMmFmYmMyY2UzODkyMWNlNzRfMy0xLTEtMS0yMTM2_a66f0772-14f7-4b77-8d85-2064549ba1cd"
      unitRef="shares">36547222</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjdiMDUzZTQwY2FjMzRiYjJhZmJjMmNlMzg5MjFjZTc0L3RhYmxlcmFuZ2U6N2IwNTNlNDBjYWMzNGJiMmFmYmMyY2UzODkyMWNlNzRfMy0zLTEtMS0yMTM2_f4e3d2c8-70c1-4b0a-aac0-7d041bef324c"
      unitRef="shares">30533847</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjdiMDUzZTQwY2FjMzRiYjJhZmJjMmNlMzg5MjFjZTc0L3RhYmxlcmFuZ2U6N2IwNTNlNDBjYWMzNGJiMmFmYmMyY2UzODkyMWNlNzRfMy01LTEtMS0yMTM2_b66dccaa-ed39-4a8e-b7b4-56e6506c5878"
      unitRef="shares">35392153</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjdiMDUzZTQwY2FjMzRiYjJhZmJjMmNlMzg5MjFjZTc0L3RhYmxlcmFuZ2U6N2IwNTNlNDBjYWMzNGJiMmFmYmMyY2UzODkyMWNlNzRfMy03LTEtMS0yMTM2_04a9e057-dfe9-41c2-a7aa-d23833f11ca6"
      unitRef="shares">30368437</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjdiMDUzZTQwY2FjMzRiYjJhZmJjMmNlMzg5MjFjZTc0L3RhYmxlcmFuZ2U6N2IwNTNlNDBjYWMzNGJiMmFmYmMyY2UzODkyMWNlNzRfNC0xLTEtMS0yMTM2_0e2bf4d6-6e5d-4002-8be9-12da550ac230"
      unitRef="usdPerShare">-0.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjdiMDUzZTQwY2FjMzRiYjJhZmJjMmNlMzg5MjFjZTc0L3RhYmxlcmFuZ2U6N2IwNTNlNDBjYWMzNGJiMmFmYmMyY2UzODkyMWNlNzRfNC0zLTEtMS0yMTM2_c4869766-9cd3-4425-a6ce-d5b824f3d774"
      unitRef="usdPerShare">0.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjdiMDUzZTQwY2FjMzRiYjJhZmJjMmNlMzg5MjFjZTc0L3RhYmxlcmFuZ2U6N2IwNTNlNDBjYWMzNGJiMmFmYmMyY2UzODkyMWNlNzRfNC01LTEtMS0yMTM2_73b54b2f-73b7-4354-8c04-413f90271fca"
      unitRef="usdPerShare">-2.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjdiMDUzZTQwY2FjMzRiYjJhZmJjMmNlMzg5MjFjZTc0L3RhYmxlcmFuZ2U6N2IwNTNlNDBjYWMzNGJiMmFmYmMyY2UzODkyMWNlNzRfNC03LTEtMS0yMTM2_a0573c3c-41b9-457c-bcf9-ad28be92dd8d"
      unitRef="usdPerShare">-0.90</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfMi0xLTEtMS00MjEy_186af6e8-3234-4e70-9c58-31b97920ca1f"
      unitRef="usd">-25041000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfMi0zLTEtMS00MjEy_870ed8bc-42f9-4a1b-a945-e133aa0d72ff"
      unitRef="usd">5354000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfMi01LTEtMS00MjEy_1973f8ab-38c4-4138-89f2-458afacf4feb"
      unitRef="usd">-74140000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfMi03LTEtMS00MjEy_a1ab0a3f-349b-430b-b9f0-d84b88210394"
      unitRef="usd">-27250000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfMy0xLTEtMS00MjEy_fbdd521c-fe58-4697-afc6-1d794424a61e"
      unitRef="shares">36547222</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfMy0zLTEtMS00MjEy_4877f692-f1c6-4d0d-ac36-929dab21f84c"
      unitRef="shares">30533847</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfMy01LTEtMS00MjEy_93071084-2da0-400b-a51e-5687eef30a1a"
      unitRef="shares">35392153</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfMy03LTEtMS00MjEy_8d98d37c-b8d9-4e19-8e03-2aadae72d471"
      unitRef="shares">30368437</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iccd54f681834442eb165955240d9e74a_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfNi0xLTEtMS00MjEy_71006b49-ebe4-4a75-8e97-463acd57a787"
      unitRef="shares">0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="idcf0ba2ceaab4483a2bfe533ce701a43_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfNi0zLTEtMS00MjEy_4f001b1d-c39d-4eb8-be24-85f68a862c73"
      unitRef="shares">1605663</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia79f1a27faad4ee0b5c7c77ea717ed13_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfNi01LTEtMS00MjEy_31d005fe-640f-49df-aa77-697f5852d50d"
      unitRef="shares">0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic423ff5ccdca4effbe4d4211fa5e77f6_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfNi03LTEtMS00MjEy_e505c02a-59aa-4868-bc5b-4ffb26666e3c"
      unitRef="shares">0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8bf19a2caf8b4d509a379811f8a3c1ea_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfNy0xLTEtMS00MjEy_911cf9c8-c083-4428-a8d1-b6979c936fe8"
      unitRef="shares">0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i12795b2676c0493781d9a5bdadfbf6cc_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfNy0zLTEtMS00MjEy_303b2ab1-7876-40a5-9da5-c902e8eaa683"
      unitRef="shares">226631</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1a64c5a4066049d08858e72736c24a45_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfNy01LTEtMS00MjEy_0b11bdf2-3781-4992-bc6a-d7fe003bd8ae"
      unitRef="shares">0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i20a672c9e2164a1480e1ae0fd1133627_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfNy03LTEtMS00MjEy_40a9bc1e-9023-4fab-84e8-b3959ee7dee4"
      unitRef="shares">0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfOC0xLTEtMS00MjEy_5e115bd8-0882-4140-aaf6-e6696a361c1b"
      unitRef="shares">36547222</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfOC0zLTEtMS00MjEy_2a1dc011-47d1-4f6b-a731-8e6a01d83c45"
      unitRef="shares">32366141</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfOC01LTEtMS00MjEy_0f9e522f-81c0-47f3-ad06-07884ca1a2ed"
      unitRef="shares">35392153</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfOC03LTEtMS00MjEy_69fcb58e-4210-42c0-ba4f-e9f629e83348"
      unitRef="shares">30368437</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfMTAtMS0xLTEtNDIxMg_393f65a9-1e97-4f69-b0c2-b93a24a15c87"
      unitRef="usdPerShare">-0.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfMTAtMy0xLTEtNDIxMg_62c8280f-c481-45be-b779-ad87619de494"
      unitRef="usdPerShare">0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfMTAtNS0xLTEtNDIxMg_cf78680c-2a9e-45ce-8a9f-09f0b26ae7b2"
      unitRef="usdPerShare">-2.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjg5MDJhMTk4NDEzMzRkOWNhMWRkZDBkZjMwNGUyYWRhL3RhYmxlcmFuZ2U6ODkwMmExOTg0MTMzNGQ5Y2ExZGRkMGRmMzA0ZTJhZGFfMTAtNy0xLTEtNDIxMg_1d120151-d4b1-4f84-8a4e-1ac69607a726"
      unitRef="usdPerShare">-0.90</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RleHRyZWdpb246NWZlZjg0Y2JhMTM0NGZlMmFiMDIyMTc5NTM5OTE0NWZfMTYyMg_ca12cacc-df40-4a8d-90e5-f8e4bce6a9b8">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the outstanding common stock equivalents, presented based on amounts outstanding at each period end, that have been excluded from the calculation of diluted net loss per share for the periods indicated because their inclusion would have been anti-dilutive (in common stock equivalent shares, as applicable):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,086,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,086,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,685,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,151,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,151,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,918,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1117ebd626644baebf8cd85f62f25c00_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfMi0xLTEtMS0yMTM2_044fe011-956f-43ea-8180-7dedacfe56f4"
      unitRef="shares">24393</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8ec79f5f2c2143ed87b1024777fbb963_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfMi0zLTEtMS0yMTM2_a038fca5-ab8b-4c3f-9db9-2dbcc8df17b0"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id77ac29ae1c946708d972f4329a5fd16_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfMi01LTEtMS0yMDY0Nw_85f33374-421d-42ad-a4e5-2b7e73f50a44"
      unitRef="shares">24393</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ieb5f82106070482cae1bfd5c69ed3333_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfMi03LTEtMS0yMDY0Nw_992d4759-6436-450e-bb25-9544b5f80113"
      unitRef="shares">167240</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4ea8f4ed8fbc4550aa703adec2e38d33_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfMy0xLTEtMS0yMTM2_32903f5d-f9aa-4cd2-aa5f-0ba6599edd41"
      unitRef="shares">41095</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icccb7da2fdfc4873a395a07afd73be7c_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfMy0zLTEtMS0yMTM2_5ccec520-1afa-4bc9-ba45-6cc08a843412"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iea0a178c00d24c538b17f43b4a9992b0_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfMy01LTEtMS0yMDY0Nw_60803e6a-eb28-4e76-b7c8-a8bc9ae46f73"
      unitRef="shares">41095</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i79f148df7d7a454d8deed12b42736ccb_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfMy03LTEtMS0yMDY0Nw_019493fd-2d3d-4d0f-863d-6f0ef66a2bf1"
      unitRef="shares">66216</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8a342db77baf4dcc9e4c05d95f989378_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfNC0xLTEtMS0yMTM2_e2f16d03-29eb-4c4c-9ac8-44499b41971e"
      unitRef="shares">5086495</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i33b959e99b544061a1ad9375c42039bd_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfNC0zLTEtMS0yMTM2_5622343a-ab3b-4be5-aa62-fcf7c24268d7"
      unitRef="shares">553502</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ica73f41d57df4863906446bbbec208e0_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfNC01LTEtMS0yMDY0Nw_829c11d9-ab78-4a2f-969a-3bbdc1308267"
      unitRef="shares">5086495</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibc431739b79043079a7eb95d72fdb304_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfNC03LTEtMS0yMDY0Nw_dbd33bda-2ac9-43b8-b356-509a6b7ad764"
      unitRef="shares">4685276</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfNS0xLTEtMS0yMTM2_e76b5149-9aad-4805-81d5-914e432b1b12"
      unitRef="shares">5151983</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8c604eb326ec497187ef28434af427bf_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfNS0zLTEtMS0yMTM2_052c194f-1ced-46f2-a48b-c260b61e05f1"
      unitRef="shares">553502</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfNS01LTEtMS0yMDY0Nw_05a14e17-a58a-4497-8acb-b4c5d80aa9fa"
      unitRef="shares">5151983</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia1145b0d5b7d4f3da1b359d80c6fad9a_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RhYmxlOjkxNTFiY2JiNThlOTQxYTFiZTQ3MDc1YTIwNzFjMmE5L3RhYmxlcmFuZ2U6OTE1MWJjYmI1OGU5NDFhMWJlNDcwNzVhMjA3MWMyYTlfNS03LTEtMS0yMDY0Nw_8e6494f7-08d4-45d2-87b2-1db6ee1234b8"
      unitRef="shares">4918732</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4299c25bbef841838f8943aab9d90e62_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl82Ny9mcmFnOjVmZWY4NGNiYTEzNDRmZTJhYjAyMjE3OTUzOTkxNDVmL3RleHRyZWdpb246NWZlZjg0Y2JhMTM0NGZlMmFiMDIyMTc5NTM5OTE0NWZfMTQ0NA_6f97e100-4008-44ae-bd00-4a265971d0e7"
      unitRef="shares">801622</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AreaOfLand
      contextRef="i196c1e6bf66247b98fa293ce7ce21c10_I20210831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc4MzQzYzBhZGE0YzRlYjdhZmI1MDM5ZjRkZDgxOTdmL3NlYzo3ODM0M2MwYWRhNGM0ZWI3YWZiNTAzOWY0ZGQ4MTk3Zl8xMDAvZnJhZzo3MTc2MTdiZmY2NDA0MDhhOTdlMGM4MDI4ZTNjNzYxZi90ZXh0cmVnaW9uOjcxNzYxN2JmZjY0MDQwOGE5N2UwYzgwMjhlM2M3NjFmXzIxOTkwMjMyNTg3NTg_73ee5a7c-27d3-4eb7-b1c2-cdfba2cd75e6"
      unitRef="sqft">35000</us-gaap:AreaOfLand>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557558837048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Nov. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MORPHIC HOLDING,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-3878772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">35 Gatehouse Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">A2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">996-0955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MORF<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,961,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001679363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557558936200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 184,159<span></span>
</td>
<td class="nump">$ 102,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities</a></td>
<td class="nump">243,417<span></span>
</td>
<td class="nump">126,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">2,618<span></span>
</td>
<td class="nump">7,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,210<span></span>
</td>
<td class="nump">3,857<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">435,404<span></span>
</td>
<td class="nump">239,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,584<span></span>
</td>
<td class="nump">2,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">560<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">438,563<span></span>
</td>
<td class="nump">242,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,176<span></span>
</td>
<td class="nump">3,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued expenses</a></td>
<td class="nump">8,417<span></span>
</td>
<td class="nump">10,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current portion</a></td>
<td class="nump">30,148<span></span>
</td>
<td class="nump">25,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRentCurrent', window );">Deferred rent, current portion</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">41,764<span></span>
</td>
<td class="nump">39,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">46,495<span></span>
</td>
<td class="nump">57,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRentNoncurrent', window );">Deferred rent, net of current portion</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">88,398<span></span>
</td>
<td class="nump">97,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred shares, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of September&#160;30, 2021 and December&#160;31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares, $0.0001 par value, 400,000,000 shares authorized, 36,892,411 shares issued and outstanding as of September&#160;30, 2021 and 32,037,686 shares issued and outstanding as of December&#160;31, 2020</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid&#8209;in capital</a></td>
<td class="nump">566,906<span></span>
</td>
<td class="nump">287,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(216,652)<span></span>
</td>
<td class="num">(142,512)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(93)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">350,165<span></span>
</td>
<td class="nump">145,197<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 438,563<span></span>
</td>
<td class="nump">$ 242,382<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(1),(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer) for contractual rent under lease arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRentNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557558593528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred shares, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="nump">36,892,411<span></span>
</td>
<td class="nump">32,037,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding</a></td>
<td class="nump">36,892,411<span></span>
</td>
<td class="nump">32,037,686<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557470625784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 3,124<span></span>
</td>
<td class="nump">$ 25,757<span></span>
</td>
<td class="nump">$ 10,238<span></span>
</td>
<td class="nump">$ 39,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">20,966<span></span>
</td>
<td class="nump">15,998<span></span>
</td>
<td class="nump">64,131<span></span>
</td>
<td class="nump">54,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">7,276<span></span>
</td>
<td class="nump">4,751<span></span>
</td>
<td class="nump">20,367<span></span>
</td>
<td class="nump">13,368<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">28,242<span></span>
</td>
<td class="nump">20,749<span></span>
</td>
<td class="nump">84,498<span></span>
</td>
<td class="nump">68,245<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(Loss) Income from operations</a></td>
<td class="num">(25,118)<span></span>
</td>
<td class="nump">5,008<span></span>
</td>
<td class="num">(74,260)<span></span>
</td>
<td class="num">(29,201)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="nump">1,536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">231<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="nump">1,524<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) Income before benefit from income taxes</a></td>
<td class="num">(25,041)<span></span>
</td>
<td class="nump">5,239<span></span>
</td>
<td class="num">(74,140)<span></span>
</td>
<td class="num">(27,677)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">427<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (25,041)<span></span>
</td>
<td class="nump">$ 5,354<span></span>
</td>
<td class="num">$ (74,140)<span></span>
</td>
<td class="num">$ (27,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (loss) income per share, basic (in dollars Per share)</a></td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="nump">$ 0.18<span></span>
</td>
<td class="num">$ (2.09)<span></span>
</td>
<td class="num">$ (0.90)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net (loss) income per share, diluted (in dollars Per share)</a></td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="num">$ (2.09)<span></span>
</td>
<td class="num">$ (0.90)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">36,547,222<span></span>
</td>
<td class="nump">30,533,847<span></span>
</td>
<td class="nump">35,392,153<span></span>
</td>
<td class="nump">30,368,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">36,547,222<span></span>
</td>
<td class="nump">32,366,141<span></span>
</td>
<td class="nump">35,392,153<span></span>
</td>
<td class="nump">30,368,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (25,041)<span></span>
</td>
<td class="nump">$ 5,354<span></span>
</td>
<td class="num">$ (74,140)<span></span>
</td>
<td class="num">$ (27,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Unrealized holding losses on marketable securities</a></td>
<td class="num">(73)<span></span>
</td>
<td class="num">(190)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive loss</a></td>
<td class="num">(73)<span></span>
</td>
<td class="num">(190)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) income</a></td>
<td class="num">$ (25,114)<span></span>
</td>
<td class="nump">$ 5,164<span></span>
</td>
<td class="num">$ (74,212)<span></span>
</td>
<td class="num">$ (27,260)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557458754824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>At-The-Market Offering</div></th>
<th class="th"><div>Secondary Offering</div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th">
<div>Common Shares </div>
<div>At-The-Market Offering</div>
</th>
<th class="th">
<div>Common Shares </div>
<div>Secondary Offering</div>
</th>
<th class="th"><div>Additional Paid&#8209;in Capital</div></th>
<th class="th">
<div>Additional Paid&#8209;in Capital </div>
<div>At-The-Market Offering</div>
</th>
<th class="th">
<div>Additional Paid&#8209;in Capital </div>
<div>Secondary Offering</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2019</a></td>
<td class="nump">$ 140,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 238,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (97,513)<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period ( in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,110,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Equity-based compensation expense</a></td>
<td class="nump">2,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common shares upon stock option exercises</a></td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common shares upon stock option exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan', window );">Issuance of common shares under the Employee Stock Purchase Plan</a></td>
<td class="nump">681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Issuance of common stock under the Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gains (losses) on marketable securities</a></td>
<td class="nump">571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(16,746)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,746)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Mar. 31, 2020</a></td>
<td class="nump">128,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(114,259)<span></span>
</td>
<td class="nump">615<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period ( in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,283,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2019</a></td>
<td class="nump">140,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(97,513)<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period ( in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,110,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(27,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Sep. 30, 2020</a></td>
<td class="nump">130,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(124,763)<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period ( in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,827,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Mar. 31, 2020</a></td>
<td class="nump">128,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(114,259)<span></span>
</td>
<td class="nump">615<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period ( in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,283,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Equity-based compensation expense</a></td>
<td class="nump">2,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common shares upon stock option exercises</a></td>
<td class="nump">542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common shares upon stock option exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gains (losses) on marketable securities</a></td>
<td class="num">(391)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(391)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(15,858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Jun. 30, 2020</a></td>
<td class="nump">114,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(130,117)<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period ( in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,421,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Equity-based compensation expense</a></td>
<td class="nump">2,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common shares upon stock option exercises</a></td>
<td class="nump">477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common shares upon stock option exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan', window );">Issuance of common shares under the Employee Stock Purchase Plan</a></td>
<td class="nump">431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Issuance of common stock under the Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares/stock, net of offering/issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares/stock, net of offering/issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gains (losses) on marketable securities</a></td>
<td class="num">(190)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(190)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="nump">5,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Sep. 30, 2020</a></td>
<td class="nump">130,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(124,763)<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period ( in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,827,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2020</a></td>
<td class="nump">145,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">287,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(142,512)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period ( in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,037,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Equity-based compensation expense</a></td>
<td class="nump">4,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common shares upon stock option exercises</a></td>
<td class="nump">2,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common shares upon stock option exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan', window );">Issuance of common shares under the Employee Stock Purchase Plan</a></td>
<td class="nump">613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Issuance of common stock under the Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares/stock, net of offering/issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,231<span></span>
</td>
<td class="nump">$ 230,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,231<span></span>
</td>
<td class="nump">$ 230,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares/stock, net of offering/issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,704<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gains (losses) on marketable securities</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(21,284)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,284)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Mar. 31, 2021</a></td>
<td class="nump">368,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">532,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(163,796)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period ( in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,131,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2020</a></td>
<td class="nump">145,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">287,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(142,512)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period ( in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,037,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(74,140)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Sep. 30, 2021</a></td>
<td class="nump">350,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">566,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(216,652)<span></span>
</td>
<td class="num">(93)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period ( in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,892,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Mar. 31, 2021</a></td>
<td class="nump">368,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">532,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(163,796)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period ( in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,131,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Equity-based compensation expense</a></td>
<td class="nump">5,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common shares upon stock option exercises</a></td>
<td class="nump">1,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common shares upon stock option exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gains (losses) on marketable securities</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering costs incurred</a></td>
<td class="num">(49)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(27,815)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,815)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Jun. 30, 2021</a></td>
<td class="nump">347,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">539,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(191,611)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period ( in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,277,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Equity-based compensation expense</a></td>
<td class="nump">5,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common shares upon stock option exercises</a></td>
<td class="nump">3,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common shares upon stock option exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan', window );">Issuance of common shares under the Employee Stock Purchase Plan</a></td>
<td class="nump">482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Issuance of common stock under the Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares/stock, net of offering/issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares/stock, net of offering/issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gains (losses) on marketable securities</a></td>
<td class="num">(73)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(25,041)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,041)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Sep. 30, 2021</a></td>
<td class="nump">$ 350,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 566,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (216,652)<span></span>
</td>
<td class="num">$ (93)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period ( in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,892,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109244457&amp;loc=d3e16649-113920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109244457&amp;loc=d3e16649-113920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557469975096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=morf_AtTheMarketOfferingMember', window );">At-The-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=morf_SecondaryOfferingMember', window );">Secondary Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=morf_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=morf_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=morf_SecondaryOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=morf_SecondaryOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557471243304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (74,140)<span></span>
</td>
<td class="num">$ (27,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">754<span></span>
</td>
<td class="nump">852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Premium amortization and discount accretion on marketable securities</a></td>
<td class="nump">531<span></span>
</td>
<td class="nump">429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity&#8209;based compensation</a></td>
<td class="nump">15,541<span></span>
</td>
<td class="nump">8,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of equipment</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">4,696<span></span>
</td>
<td class="nump">1,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,353)<span></span>
</td>
<td class="num">(530)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(842)<span></span>
</td>
<td class="num">(1,893)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(1,743)<span></span>
</td>
<td class="nump">818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(6,295)<span></span>
</td>
<td class="num">(13,878)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_morf_IncreaseDecreaseInDeferredRent', window );">Deferred rent</a></td>
<td class="num">(80)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(62,876)<span></span>
</td>
<td class="num">(31,572)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(223,803)<span></span>
</td>
<td class="num">(95,049)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">106,000<span></span>
</td>
<td class="nump">115,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(563)<span></span>
</td>
<td class="num">(475)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(118,366)<span></span>
</td>
<td class="nump">19,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common shares under Employee Stock Purchase Plan</a></td>
<td class="nump">1,095<span></span>
</td>
<td class="nump">1,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from at-the-market offering, net of issuance costs</a></td>
<td class="nump">24,645<span></span>
</td>
<td class="nump">6,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from secondary offering, net of issuance costs</a></td>
<td class="nump">229,982<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common shares upon stock option exercises</a></td>
<td class="nump">7,917<span></span>
</td>
<td class="nump">1,186<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">263,639<span></span>
</td>
<td class="nump">8,617<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">82,397<span></span>
</td>
<td class="num">(3,479)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">102,322<span></span>
</td>
<td class="nump">101,834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">184,719<span></span>
</td>
<td class="nump">98,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued expenses</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="nump">$ 130<span></span>
</td>
<td class="nump">$ 480<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_IncreaseDecreaseInDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_IncreaseDecreaseInDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557467587576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of the Business and Basis of Presentation</a></td>
<td class="text">Nature of the Business and Basis of Presentation<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization and Liquidity</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Morphic Holding, Inc. (the &#8220;Company&#8221;) was formed under the laws of the State of Delaware in August 2014. The Company is a biopharmaceutical company applying proprietary insights into integrin medicine to discover and develop first-in-class oral small molecule integrin therapeutics. Integrins are a validated target class with multiple approved drugs for the treatment of serious chronic diseases. Despite significant biopharmaceutical industry investment, no oral integrin therapies have been approved. The Company has created the Morphic integrin technology platform, or MInT Platform, by leveraging its unique understanding of integrin structure and biology, to develop a pipeline of novel product candidates designed to achieve potency, high selectivity, and the pharmaceutical properties required for oral administration.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.&#160;The Company expects to continue to incur losses from operations for the foreseeable future. The Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements through at least the next 12 months from the date these financial statements were issued.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2020, the Company entered into an Open Market Sale Agreement (&#8220;the Original Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;) with respect to an at-the-market (&#8220;ATM&#8221;) offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of our common stock, having an aggregate offering price of up to $75,000,000, referred to as Placement Shares, through Jefferies as its sales agent. The Company paid Jefferies a commission equal to 3.0% of the gross sales proceeds of any Placement Shares sold through Jefferies under the Original Agreement, and also has provided Jefferies with customary indemnification and contribution rights. On August 11, 2021, the Company entered into an Amendment No. 1 to the Open Market Sale Agreement with Jefferies, establishing a new at-the-market offering (&#8220;New ATM&#8221;) with an aggregate offering price of up to $150,000,000, also subject to a commission equal to 3.0% of gross sales proceeds from Placement Shares sold through Jefferies.  Under the New ATM, the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, referred to as Placement Shares, through Jefferies as its sales agent.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended September&#160;30, 2021, 298,070 shares under the ATM were sold for net proceeds of $17.4 million after deducting offering commissions and offering expenses paid by the Company. During the nine months ended September&#160;30, 2021, the Company issued and sold 538,774 shares for net proceeds of $24.6 million after deducting offering commissions and offering expenses paid by the Company. As of September&#160;30, 2021, the Company had approximately $138.9 million of common stock remaining available for sale under the ATM.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company completed an underwritten follow-on public offering of 3,500,000 shares of its common stock at a price to the public of $70.00 per share. Gross proceeds from the secondary offering were approximately $245.0&#160;million, before deducting underwriting discounts, commissions and other offering expenses of approximately $15.0&#160;million, paid by the Company, resulting in net proceeds of approximately $230.0&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557467028120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Significant Accounting Policies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements include the accounts of Morphic Holding, Inc. and its wholly owned subsidiaries, Morphic Therapeutic, Inc. and a Massachusetts Security Corporation, organized in December 2019 to take advantage of the favorable tax treatment of income earned on securities held within such entity. All intercompany balances have been eliminated in consolidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). Certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements have been </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condensed or omitted. These unaudited interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company&#8217;s financial position and results of operations for the interim periods ended September&#160;30, 2021 and 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December&#160;31, 2020, and the notes thereto, which are included in the Company&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 1, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates and Summary of Significant Accounting Policies</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP requires management to make estimates and judgments that may affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the related reporting of revenues and expenses during the reporting period. Significant estimates of accounting reflected in these consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued research and development expenses, the valuation of equity-based compensation, and income taxes. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant accounting policies</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant accounting policies used in preparation of these condensed consolidated financial statements as of and for the three and nine months ended September&#160;30, 2021 are consistent with those discussed in Note 2 to the consolidated financial statements in the Company&#8217;s 2020 Annual Report on Form 10-K, except as described below.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements not yet Adopted</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At IPO, as an &#8220;emerging growth company,&#8221; or EGC, under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, the Company has made an election under Section 107 of the JOBS Act to take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards and has been following requirements applicable to the private companies for adopting new and updated accounting standards. Based on the value of the Company's common stock held by non-affiliates on June 30, 2021, the Company will become a large accelerated filer for the year ending December 31, 2021 and will follow adoption guidance mandated for non-EGC entities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, Financial Instruments Credit Losses (Topic 326) (&#8220;ASU 2016-13&#8221;), which requires consideration of a broader range of reasonable and supportable information in developing credit loss estimates. In April 2019, the FASB issued ASU 2019-04, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments (&#8220;ASU 2019-04&#8221;). Certain provisions of ASU 2019-04 amend the guidance of ASU 2016-13, are applicable to the Company&#8217;s investments portfolio, and allow the Company to make certain accounting policy elections regarding establishing allowance for credit losses for the accrued interest receivable and the corresponding disclosures. In November 2019, the FASB issued ASU No. 2019-11, Codification Improvements to Topic 326, Financial Instruments &#8211; Credit Losses (&#8220;ASU 2019-11&#8221;), which clarifies certain areas of the guidance to ensure all companies and organizations can make a smoother transition to the standard. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company will become a large accelerated filer and as a result, the guidance under ASU 2019-04, ASU 2016-13 and ASU 2019-11 is effective for the Company's Annual Report on Form 10-K to be filed for the year ended December 31, 2021. The Company will record a cumulative effect adjustment to retained earnings retroactive to January 1, 2021, the date of adoption. The Company is currently evaluating the impact of ASU 2019-11 and the related ASU 2019-04 and ASU 2016-13 on its consolidated financial statements, including the impact of the available accounting policy elections. The Company does not expect this guidance to have a material impact on its consolidated financial statements. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), with guidance regarding the accounting for and disclosure of leases. In general, for lease arrangements exceeding a twelve-month term, these arrangements must now be recognized as assets and liabilities on the balance sheet of the lessee. Under ASU 2016-02, a right-of-use asset and lease obligation will be recorded for all leases, whether operating or financing, while the income statement will reflect lease expense for operating leases and amortization/interest expense for financing leases. The balance sheet amount recorded for existing leases at the date of adoption of ASU 2016-02 must be calculated using the applicable incremental borrowing rate at the date of adoption. This update also requires lessees and lessors to disclose key information about their leasing transactions. In July 2018, the FASB issued ASU 2018-11, Leases - Targeted Improvements, intended to ease the implementation of the new lease </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">standard for financial statement preparers by, among other things, allowing for an additional transition method. In lieu of presenting transition requirements to comparative periods, as previously required, an entity may now elect to show a cumulative effect adjustment on the date of adoption without the requirement to recast prior period financial statements or disclosures presented in accordance with ASU 2016-02.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently expects to elect the available package of practical expedients which allows the Company to not reassess previous accounting conclusions around whether arrangements are or contain leases, the classification of leases, and the treatment of initial direct costs. The Company also expects it will make an accounting policy election to keep leases with an initial term of 12 months or less off of the balance sheet. </span></div>In August 2021, the Company exercised its one-time extension right for its existing lease for 35,000 square feet of office and laboratory space through May 2025, as provided for under the terms of the lease. The Company is currently evaluating the effect of adopting the requirements of ASU 2016-02 as it relates to its facility lease, as amended in August 2021, and discussed in Note 10 to the consolidated financial statements appearing in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2020. The Company is also performing an evaluation of other material contracts to determine if any contain embedded leases, and has not identified any to date. As of December 31, 2021, the Company will become a large accelerated filer and as a result, the guidance under ASU 2016-02 is effective for the Company's Annual Report on Form 10-K to be filed for the year ended December 31, 2021, with an effective date of adoption of January 1, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557467012936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Assets and Liabilities</a></td>
<td class="text">Fair Value of Financial Assets and Liabilities<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has certain financial assets and liabilities that are recorded at fair value which have been classified as Level&#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8212; Quoted market prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8212; Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8212; Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At September&#160;30, 2021, investments also include corporate debt securities which are valued either based on recent trades of securities in inactive markets or based on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about the Company&#8217;s financial assets that are measured at fair value on a recurring basis as of September&#160;30, 2021 and December&#160;31, 2020 (in thousands) and indicate the level within the fair value hierarchy where each measurement is classified.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387,300&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,883&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,417&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,977&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,760&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,217&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The money market funds included in the tables above invest in U.S. government securities that are valued using quoted market prices. Accordingly, money market funds are categorized as Level 1 as of September&#160;30, 2021 and December&#160;31, 2020. Marketable securities included in the tables above consist of U.S. Treasury securities and corporate debt securities, and these securities are categorized as Level 2 as of September&#160;30, 2021 and December&#160;31, 2020. During the nine months ended September&#160;30, 2021, no assets were transferred between the fair value hierarchy categories. The Company had no liabilities measured at fair value on a recurring basis at September&#160;30, 2021 or December&#160;31, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that the carrying amounts of the Company&#8217;s condensed consolidated financial instruments, including prepaid expenses and other current assets, accounts receivable, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557467024472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable securities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable securities</a></td>
<td class="text">Marketable securities<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s investments in marketable securities classified as available for sale (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:32.282%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less than 1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">within 2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,484&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,417&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:32.282%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less than 1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,212&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,217&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s investments are classified as available-for-sale and are carried at fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income (loss). The Company considers all available-for-sale securities, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs and therefore classifies all securities with maturity dates beyond 90 days at the date of purchase as current assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557465757560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, and Restricted Cash<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAbstract', window );"><strong>Restricted Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents and Restricted CashRestricted cash consists of a letter of credit in the amount of $560,000 issued to the landlord of the Company&#8217;s facility lease as of September 30, 2021. The letter of credit increased from $275,000 in August 2021 due to the operating lease extension discussed further in Note 2. The terms of the letter of credit extend beyond one year. The following table reconciles cash, cash equivalents and restricted cash per the balance sheet to the statements of cash flows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,719&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,322&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,355&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,834&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557573127240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2021 and December&#160;31, 2020 accrued expenses consist of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related expenses</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,390&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,148&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,417&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,160&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557465635304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Based Compensation</a></td>
<td class="text">Equity Based Compensation<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company&#8217;s initial public offering in July 2019, the Company adopted the 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;) in June 2019, which replaced the 2018 Stock Incentive Plan. The 2019 Plan provides for the grant of stock options, restricted stock awards, stock bonus awards, cash awards, stock appreciation right, RSUs, and performance awards to directors, officers and employees of the Company, as well as consultants and advisors of the Company.  As a result of the automatic increase provision of the 2019 Plan, the number of shares of common stock available for issuance under the 2019 Plan increased by 1.3&#160;million shares on January 2021. As of&#160;September&#160;30, 2021, there were a total of&#160;1.3&#160;million shares available for future award grants under the 2019 Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized equity-based compensation expense in the condensed consolidated statements of operations and comprehensive loss, by award type, as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,403&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,672&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,448&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,734&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,791&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,996&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,541&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,029&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the allocation of equity-based compensation expense in the condensed consolidated statements of operations and comprehensive loss, by expense category (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,599&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,406&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,623&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,791&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,996&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,541&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,029&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Restricted Common Stock</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the restricted stock awards activity during the nine months ended September&#160;30, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of&#160;Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average Fair<br/>Value per Share<br/>at Issuance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted common stock as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,989&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,056)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,540)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted common stock as of September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,393&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the Company had unrecognized equity-based compensation expense of $0.1&#160;million related to the restricted stock awards, which is expected to be recognized over a weighted average period of 0.3 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Restricted Stock Units</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The following table summarizes the restricted stock units activity during the nine months ended September&#160;30, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:72.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of&#160;Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average Fair<br/>Value per Share<br/>at Issuance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units as of  December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units as of September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,095&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the Company had unrecognized equity-based compensation expense of $0.5&#160;million related to the restricted stock units, which is expected to be recognized over a weighted average period of 2.2 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Stock Options</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity during the nine months ended September&#160;30, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:45.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,352,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.68</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,550,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(675,211)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140,722)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,086,495&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.20&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.38</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,512&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729,711&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.98&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.97</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,513&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the Company had unrecognized equity-based compensation expense of $50.3&#160;million related to stock options issued to employees and non-employees, which is expected to be recognized over a weighted average period of 2.4 years.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">ESPP</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company adopted the 2019 Employee Stock Purchase Plan (&#8220;ESPP&#8221;), which became effective on June 26, 2019. The Company initially reserved 300,000 shares of common stock for sale under the ESPP. As a result of the automatic increase provision of the ESPP, the number of shares of common stock available for issuance under the ESPP increased by 0.3&#160;million </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares on January 1, 2021. The ESPP is a qualified, compensatory plan under Section 423 of the Internal Revenue Code and offers substantially all employees opportunity to purchase up to $25,000 of common stock per year at 15% discount to the lower of the beginning of the offering period price or the end of the offering period price.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense for discounted purchases under the ESPP is measured using the Black-Scholes model to compute the fair value of the lookback provision plus the purchase discount and is recognized as compensation expense over the course of the offering period.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557470744456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to use its operating loss carryforwards and tax credits to offset future taxable income is subject to restrictions under Sections&#160;382 and 383 of the United States Internal Revenue Code, or the Internal Revenue Code. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50 percent, as defined under Sections 382 and 383 of the Internal Revenue Code. Such changes would limit the Company&#8217;s use of its operating loss carryforwards and tax credits. In such a situation, the Company may be required to pay income taxes, even though significant operating loss carryforwards and tax credits exist.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the Coronavirus Aid Relief and Economic Security (&#8220;CARES&#8221;) Act was signed into law.&#160;The CARES Act included several income tax changes, included allowing for the carryback of net operating losses, expanding interest deductibility, and allowing for accelerated expensing of certain capital improvements.&#160;</span></div>The Company records a provision or benefit for income taxes on ordinary pre-tax income or loss based on its estimated effective tax rate for the year. As of September&#160;30, 2021, the Company forecasts an ordinary pre-tax loss for the year ended December 31, 2021 and, since it maintains a full valuation allowance on its deferred tax assets, the Company did not record an income tax benefit in 2021. Based on the carryback allowance under the CARES Act, the Company recorded an income tax benefit of $0.1&#160;million and $0.4&#160;million for the three and nine months ended September&#160;30, 2020, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557467032376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guarantees and Indemnifications</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered, and intends to continue to enter, into separate indemnification agreements with directors, officers, and certain of key employees, in addition to the indemnification provided for in the restated certificate of incorporation and restated bylaws. These agreements, among other things, require the Company to indemnify directors, officers, and key employees for certain expenses, including attorneys' fees, judgments, penalties, fines, and settlement amounts actually incurred by these individuals in any action or proceeding arising out of their service to the Company or any of its subsidiaries or any other company or enterprise to which these individuals provide services at the Company&#8217;s request. Subject to certain limitations, the indemnification agreements also require the Company to advance expenses incurred by directors, officers, and key employees for the defense of any action for which indemnification is required or permitted.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has standard indemnification arrangements in its leases for laboratory and office space that require it to indemnify the landlord against any liability for injury, loss, accident, or damage from any claims, actions, proceedings, or costs resulting from certain acts, breaches, violations, or non-performance under the Company&#8217;s lease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through September&#160;30, 2021, the Company had not experienced any losses related to these indemnification obligations, and no material claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2021, the Company exercised its one-time extension right for its existing lease for 35,000 square feet of office and laboratory space through May 2025, as provided for under the terms of the lease. During the three and nine months ended September&#160;30, 2021, there were no other material changes to our contractual obligations and commitments previously disclosed in Note 10 to the consolidated financial statements appearing in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Minimum annual rent payments after the exercise of the lease extension right, excluding operating expenses and taxes, which are not fixed for future periods, are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Minimum Lease Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,983&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not currently a party to any material legal proceedings.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557465671192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Option and License Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_morf_CollaborativeArrangementDisclosureAbstract', window );"><strong>Option and License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Option and License Agreements</a></td>
<td class="text">Option and License Agreements<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Detailed description of contractual terms and the Company&#8217;s accounting for agreements described below were included in the Company&#8217;s audited financial statements and notes in the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2021, the Company continued to perform under its agreement with AbbVie, (the &#8220;AbbVie Agreement&#8221;) pursuant to which the Company recognizes revenues in proportion to the costs incurred. As a result, the Company recognizes as revenue the $100.0 million up-front payment as research and development services are performed, which is expected to be completed through 2024. The following table summarizes research and development costs incurred and revenue recognized in connection with Company's performance under the AbbVie Agreement during the three and nine months ended September 30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,647&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,043&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,328&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs incurred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 25, 2020, AbbVie exercised its option to license and control further development and commercialization of Morphic&#8217;s &#945;v&#946;6&#8211;specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications. In connection with the exercise of the option, AbbVie paid the Company $20.0 million, which was recognized as revenue during the three and nine months ended September 30, 2021. The Company is eligible to receive potential milestones and royalties on future development and commercialization of Morphic&#8217;s &#945;v&#946;6&#8211;specific integrin inhibitors, as further described in the Company&#8217;s audited financial statements and notes in the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2021, all of which have been fully constrained as of September&#160;30, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the Company had $66.7 million of deferred revenue, which is classified as either current or long-term deferred revenue in the accompanying condensed consolidated balance sheets based on the period over which the revenue is expected to be recognized. This deferred revenue balance represents the aggregate amount of the transaction price allocated to the performance obligations that are partially unsatisfied as of September&#160;30, 2021.</span><span style="color:#1d1c1d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company had $29 thousand and  $0.9&#160;million recorded as accounts receivable from AbbVie </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheet </span><span style="color:#1d1c1d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2021 and </span><span style="color:#1d1c1d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31. 2020, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As the Company progresses towards satisfaction of performance obligations under the AbbVie Agreement, the estimated costs associated with the remaining effort required to complete the performance obligations may change, which may materially impact revenue recognition. The Company regularly evaluates and, when necessary, updates the costs associated with the remaining effort pursuant to each performance obligation under the AbbVie Agreement. Accordingly, revenue may fluctuate from period to period due to revisions to estimated costs, resulting in a change in the measure of progress for a performance </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">obligation. Such changes can also impact the allocation of deferred revenue between current and long term based on changes in expected timing of the satisfaction of performance obligations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2021, the Company continued to perform under its agreement with Janssen (the "Janssen Agreement"), pursuant to which the Company recognizes revenue in proportion to the costs incurred to date. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Janssen paid the Company an upfront fee of $10.0&#160;million for the first two research programs in 2019 and in December 2020 the Company reached an agreement with Janssen to commence work on the third research program, and Janssen paid to the Company $5.0&#160;million for the third research program commencement fee in February 2021. The Company expects to provide research services and recognize revenue through 2024. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes research and development costs incurred and revenue recognized in connection with Company's performance under the Janssen Agreement during three and nine months ended September 30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement revenue</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,276&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,634&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,914&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,165&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront payment revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue recognized</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,110&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,195&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,716&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs incurred</span></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,439&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,388&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,540&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had $2.6 million and $6.4&#160;million due from Janssen included in accounts receivable on the condensed consolidated balance sheets as of September&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, $10.0 million of deferred revenue is classified as either current or long-term deferred revenue in the accompanying condensed consolidated balance sheet based on the period over which the revenue is expected to be recognized. This deferred revenue balance represents the portion of the upfront payment received allocated to the performance obligations that are partially unsatisfied as of September&#160;30, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_CollaborativeArrangementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_CollaborativeArrangementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557467131720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net (Loss) Income per Share</a></td>
<td class="text">Net (Loss) Income per Share<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share is calculated by dividing net income (loss) allocable to common stockholders by the weighted-average common shares outstanding during the period, without consideration of common stock equivalents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods with net income, diluted net income per share is calculated by adjusting the weighted-average shares outstanding for the dilutive effect of common stock equivalents, including stock options and restricted common stock and stock units outstanding for the period as determined using the treasury stock method.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation if their effect would be anti-dilutive. As such, basic and diluted net loss per share applicable to common stockholders are the same for periods with a net loss.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables illustrate the determination of basic and diluted loss per share for each period presented (in thousands, except share data):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:45.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.775%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,041)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,140)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,250)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,547,222&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,533,847&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,392,153&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,368,437&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share, basic</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.69)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.18&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.09)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.90)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,041)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,354&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,140)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,250)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,547,222&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,533,847&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,392,153&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,368,437&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive impact from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,605,663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted common stock and stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,547,222&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,366,141&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,392,153&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,368,437&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share, diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.69)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.17&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.09)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.90)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding common stock equivalents, presented based on amounts outstanding at each period end, that have been excluded from the calculation of diluted net loss per share for the periods indicated because their inclusion would have been anti-dilutive (in common stock equivalent shares, as applicable):</span></div><div style="margin-top:12pt;text-align:center;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,393&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,393&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,240&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,086,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,086,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,685,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,151,983&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553,502&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,151,983&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,918,732&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the securities listed in the table above, as of September&#160;30, 2021 the Company had reserved 801,622 shares of common stock for sale under the ESPP, which, if issued, would be anti-dilutive if included in calculation of diluted net loss per share for the nine months ended September&#160;30, 2021.</span><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557465692984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates and Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates and Summary of Significant Accounting Policies</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP requires management to make estimates and judgments that may affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the related reporting of revenues and expenses during the reporting period. Significant estimates of accounting reflected in these consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued research and development expenses, the valuation of equity-based compensation, and income taxes. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_morf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock', window );">Recently Issued Accounting Pronouncements not yet Adopted</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements not yet Adopted</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At IPO, as an &#8220;emerging growth company,&#8221; or EGC, under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, the Company has made an election under Section 107 of the JOBS Act to take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards and has been following requirements applicable to the private companies for adopting new and updated accounting standards. Based on the value of the Company's common stock held by non-affiliates on June 30, 2021, the Company will become a large accelerated filer for the year ending December 31, 2021 and will follow adoption guidance mandated for non-EGC entities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, Financial Instruments Credit Losses (Topic 326) (&#8220;ASU 2016-13&#8221;), which requires consideration of a broader range of reasonable and supportable information in developing credit loss estimates. In April 2019, the FASB issued ASU 2019-04, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments (&#8220;ASU 2019-04&#8221;). Certain provisions of ASU 2019-04 amend the guidance of ASU 2016-13, are applicable to the Company&#8217;s investments portfolio, and allow the Company to make certain accounting policy elections regarding establishing allowance for credit losses for the accrued interest receivable and the corresponding disclosures. In November 2019, the FASB issued ASU No. 2019-11, Codification Improvements to Topic 326, Financial Instruments &#8211; Credit Losses (&#8220;ASU 2019-11&#8221;), which clarifies certain areas of the guidance to ensure all companies and organizations can make a smoother transition to the standard. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company will become a large accelerated filer and as a result, the guidance under ASU 2019-04, ASU 2016-13 and ASU 2019-11 is effective for the Company's Annual Report on Form 10-K to be filed for the year ended December 31, 2021. The Company will record a cumulative effect adjustment to retained earnings retroactive to January 1, 2021, the date of adoption. The Company is currently evaluating the impact of ASU 2019-11 and the related ASU 2019-04 and ASU 2016-13 on its consolidated financial statements, including the impact of the available accounting policy elections. The Company does not expect this guidance to have a material impact on its consolidated financial statements. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), with guidance regarding the accounting for and disclosure of leases. In general, for lease arrangements exceeding a twelve-month term, these arrangements must now be recognized as assets and liabilities on the balance sheet of the lessee. Under ASU 2016-02, a right-of-use asset and lease obligation will be recorded for all leases, whether operating or financing, while the income statement will reflect lease expense for operating leases and amortization/interest expense for financing leases. The balance sheet amount recorded for existing leases at the date of adoption of ASU 2016-02 must be calculated using the applicable incremental borrowing rate at the date of adoption. This update also requires lessees and lessors to disclose key information about their leasing transactions. In July 2018, the FASB issued ASU 2018-11, Leases - Targeted Improvements, intended to ease the implementation of the new lease </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">standard for financial statement preparers by, among other things, allowing for an additional transition method. In lieu of presenting transition requirements to comparative periods, as previously required, an entity may now elect to show a cumulative effect adjustment on the date of adoption without the requirement to recast prior period financial statements or disclosures presented in accordance with ASU 2016-02.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently expects to elect the available package of practical expedients which allows the Company to not reassess previous accounting conclusions around whether arrangements are or contain leases, the classification of leases, and the treatment of initial direct costs. The Company also expects it will make an accounting policy election to keep leases with an initial term of 12 months or less off of the balance sheet. </span></div>In August 2021, the Company exercised its one-time extension right for its existing lease for 35,000 square feet of office and laboratory space through May 2025, as provided for under the terms of the lease. The Company is currently evaluating the effect of adopting the requirements of ASU 2016-02 as it relates to its facility lease, as amended in August 2021, and discussed in Note 10 to the consolidated financial statements appearing in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2020. The Company is also performing an evaluation of other material contracts to determine if any contain embedded leases, and has not identified any to date. As of December 31, 2021, the Company will become a large accelerated filer and as a result, the guidance under ASU 2016-02 is effective for the Company's Annual Report on Form 10-K to be filed for the year ended December 31, 2021, with an effective date of adoption of January 1, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policies for Pro forma financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557467503320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of financial assets measured at fair value on recurring basis</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about the Company&#8217;s financial assets that are measured at fair value on a recurring basis as of September&#160;30, 2021 and December&#160;31, 2020 (in thousands) and indicate the level within the fair value hierarchy where each measurement is classified.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387,300&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,883&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,417&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,977&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,760&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,217&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557465647688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of investments in marketable securities classified as available for sale</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s investments in marketable securities classified as available for sale (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:32.282%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less than 1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">within 2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,484&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,417&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:32.282%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>unrealized<br/>holding losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less than 1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,212&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,217&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557464543032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, and Restricted Cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAbstract', window );"><strong>Restricted Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of reconciled cash, cash equivalents, and restricted cash</a></td>
<td class="text">The following table reconciles cash, cash equivalents and restricted cash per the balance sheet to the statements of cash flows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,719&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,322&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,355&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,834&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557466958152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2021 and December&#160;31, 2020 accrued expenses consist of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related expenses</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,390&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,148&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,417&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,160&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557465670632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of equity based compensation expense</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized equity-based compensation expense in the condensed consolidated statements of operations and comprehensive loss, by award type, as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,403&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,672&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,448&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,734&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,791&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,996&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,541&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,029&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the allocation of equity-based compensation expense in the condensed consolidated statements of operations and comprehensive loss, by expense category (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,599&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,406&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,623&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,791&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,996&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,541&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,029&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Summary of restricted common stock</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the restricted stock awards activity during the nine months ended September&#160;30, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of&#160;Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average Fair<br/>Value per Share<br/>at Issuance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted common stock as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,989&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,056)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,540)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted common stock as of September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,393&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of restricted stock units</a></td>
<td class="text">The following table summarizes the restricted stock units activity during the nine months ended September&#160;30, 2021:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:72.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of&#160;Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average Fair<br/>Value per Share<br/>at Issuance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units as of  December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units as of September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,095&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option activity</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity during the nine months ended September&#160;30, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:45.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,352,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.68</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,550,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(675,211)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140,722)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,086,495&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.20&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.38</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,512&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729,711&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.98&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.97</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,513&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557465658184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of minimum annual rent payments</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Minimum annual rent payments after the exercise of the lease extension right, excluding operating expenses and taxes, which are not fixed for future periods, are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Minimum Lease Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,983&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557467082728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Open Option Contracts Written (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_morf_CollaborativeArrangementDisclosureAbstract', window );"><strong>Option and License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Summary of costs incurred and revenue recognized</a></td>
<td class="text">The following table summarizes research and development costs incurred and revenue recognized in connection with Company's performance under the AbbVie Agreement during the three and nine months ended September 30, 2021 and 2020 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,647&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,043&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,328&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs incurred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes research and development costs incurred and revenue recognized in connection with Company's performance under the Janssen Agreement during three and nine months ended September 30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reimbursement revenue</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,276&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,634&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,914&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,165&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront payment revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue recognized</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,110&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,195&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,716&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs incurred</span></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,439&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,388&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,540&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_CollaborativeArrangementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_CollaborativeArrangementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557467112008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock', window );">Schedule of basic net income (loss) per share</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables illustrate the determination of basic and diluted loss per share for each period presented (in thousands, except share data):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:45.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.775%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,041)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,140)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,250)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,547,222&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,533,847&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,392,153&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,368,437&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share, basic</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.69)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.18&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.09)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.90)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,041)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,354&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,140)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,250)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,547,222&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,533,847&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,392,153&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,368,437&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive impact from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,605,663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted common stock and stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,547,222&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,366,141&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,392,153&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,368,437&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share, diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.69)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.17&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.09)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.90)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of common stock equivalent shares</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding common stock equivalents, presented based on amounts outstanding at each period end, that have been excluded from the calculation of diluted net loss per share for the periods indicated because their inclusion would have been anti-dilutive (in common stock equivalent shares, as applicable):</span></div><div style="margin-top:12pt;text-align:center;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,393&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,393&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,240&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,086,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,086,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,685,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,151,983&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553,502&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,151,983&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,918,732&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of income (loss) on basic earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557470943720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 11, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from at-the-market offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,645,000<span></span>
</td>
<td class="nump">$ 6,319,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=morf_OpenMarketSaleAgreementMember', window );">Open Market Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_morf_PercentageOfCommissionOnGrossSaleProceeds', window );">Commission (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=morf_AtMarketOfferingProgramMember', window );">ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Aggregate offering price of placement shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,400,000<span></span>
</td>
<td class="nump">$ 24,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sales of common shares sold in IPO, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298,070<span></span>
</td>
<td class="nump">538,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_morf_CommonStockAvailableForIssuance', window );">Amount of shares remaining available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138,900,000<span></span>
</td>
<td class="nump">$ 138,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=morf_AtMarketOfferingProgramMember', window );">ATM | Open Market Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Aggregate offering price of placement shares</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=morf_FollowOnPublicOfferingMember', window );">Secondary Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sales of common shares sold in IPO, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Public offering price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from at-the-market offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from secondary offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_CommonStockAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock available for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_CommonStockAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_PercentageOfCommissionOnGrossSaleProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission on gross sale proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_PercentageOfCommissionOnGrossSaleProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=morf_OpenMarketSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=morf_OpenMarketSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=morf_AtMarketOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=morf_AtMarketOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=morf_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=morf_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557467014504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Details)<br> ft&#178; in Thousands</strong></div></th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=morf_OfficeAndLaboratorySpaceMember', window );">Office and Laboratory Space</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land (square feet)</a></td>
<td class="nump">35<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=morf_OfficeAndLaboratorySpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=morf_OfficeAndLaboratorySpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557559054264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities</a></td>
<td class="nump">$ 243,417<span></span>
</td>
<td class="nump">$ 126,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities</a></td>
<td class="nump">32,087<span></span>
</td>
<td class="nump">126,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities</a></td>
<td class="nump">211,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">387,300<span></span>
</td>
<td class="nump">227,977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities</a></td>
<td class="nump">32,087<span></span>
</td>
<td class="nump">126,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities</a></td>
<td class="nump">211,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">143,883<span></span>
</td>
<td class="nump">101,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">143,883<span></span>
</td>
<td class="nump">101,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Level 1 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">143,883<span></span>
</td>
<td class="nump">101,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">243,417<span></span>
</td>
<td class="nump">126,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Level 2 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities</a></td>
<td class="nump">32,087<span></span>
</td>
<td class="nump">126,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities</a></td>
<td class="nump">211,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Level 3 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on a recurring basis | Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557467874104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 243,484<span></span>
</td>
<td class="nump">$ 126,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized holding gains</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized holding losses</a></td>
<td class="num">(83)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate estimated fair value</a></td>
<td class="nump">243,417<span></span>
</td>
<td class="nump">126,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">32,084<span></span>
</td>
<td class="nump">126,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized holding gains</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized holding losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate estimated fair value</a></td>
<td class="nump">32,087<span></span>
</td>
<td class="nump">$ 126,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">211,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized holding gains</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized holding losses</a></td>
<td class="num">(83)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate estimated fair value</a></td>
<td class="nump">$ 211,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557559411928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAbstract', window );"><strong>Restricted Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit</a></td>
<td class="nump">$ 560<span></span>
</td>
<td class="nump">$ 275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of letter of credit (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 184,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,047<span></span>
</td>
<td class="nump">$ 98,080<span></span>
</td>
<td class="nump">$ 101,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 184,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,322<span></span>
</td>
<td class="nump">$ 98,355<span></span>
</td>
<td class="nump">$ 101,834<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557469876824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related expenses</a></td>
<td class="nump">$ 4,390<span></span>
</td>
<td class="nump">$ 5,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_morf_AccruedResearchAndDevelopment', window );">Research and development activities</a></td>
<td class="nump">3,019<span></span>
</td>
<td class="nump">4,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Other expenses</a></td>
<td class="nump">1,008<span></span>
</td>
<td class="nump">677<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 8,417<span></span>
</td>
<td class="nump">$ 10,160<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_AccruedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_AccruedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557465572872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity Based Compensation - 2019 equity incentive plan (Details) - 2019 Equity Incentive Plan - shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance (in shares)</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=morf_TwoThousandNineteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=morf_TwoThousandNineteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557467877000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Based Compensation - Equity based compensation expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation expense</a></td>
<td class="nump">$ 5,791<span></span>
</td>
<td class="nump">$ 2,996<span></span>
</td>
<td class="nump">$ 15,541<span></span>
</td>
<td class="nump">$ 8,029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation expense</a></td>
<td class="nump">2,599<span></span>
</td>
<td class="nump">1,480<span></span>
</td>
<td class="nump">7,406<span></span>
</td>
<td class="nump">4,623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation expense</a></td>
<td class="nump">3,192<span></span>
</td>
<td class="nump">1,516<span></span>
</td>
<td class="nump">8,135<span></span>
</td>
<td class="nump">3,406<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation expense</a></td>
<td class="nump">5,403<span></span>
</td>
<td class="nump">2,672<span></span>
</td>
<td class="nump">14,448<span></span>
</td>
<td class="nump">6,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation expense</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="nump">224<span></span>
</td>
<td class="nump">832<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation expense</a></td>
<td class="nump">163<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">385<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Equity Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation expense</a></td>
<td class="nump">$ 154<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
<td class="nump">$ 484<span></span>
</td>
<td class="nump">$ 339<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557470802280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Based Compensation - Restricted common stock activity (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized equity based compensation expense expected period for recognition</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized equity based compensation expense | $</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized equity based compensation expense expected period for recognition</a></td>
<td class="text">3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=morf_TwoThousandNineteenStockIncentivePlanMember', window );">2019 Equity Incentive Plan | Restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at the beginning (in shares) | shares</a></td>
<td class="nump">100,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(73,056)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(3,540)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at the end (in shares) | shares</a></td>
<td class="nump">24,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at the beginning (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested as of the Reorganization | $ / shares</a></td>
<td class="nump">4.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">4.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at the end (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=morf_TwoThousandNineteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=morf_TwoThousandNineteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557471035512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Based Compensation - Restricted stock units activity (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized equity based compensation expense expected period for recognition</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized equity based compensation expense | $</a></td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized equity based compensation expense expected period for recognition</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=morf_TwoThousandNineteenStockIncentivePlanMember', window );">2019 Equity Incentive Plan | Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at the beginning (in shares) | shares</a></td>
<td class="nump">66,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(32,121)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at the end (in shares) | shares</a></td>
<td class="nump">41,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at the beginning (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">57.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">10.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at the end (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 18.83<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=morf_TwoThousandNineteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=morf_TwoThousandNineteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557471310728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Based Compensation - Stock option awards (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized equity based compensation expense | $</a></td>
<td class="nump">$ 50,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized equity based compensation expense expected period for recognition</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning (in shares) | shares</a></td>
<td class="nump">4,352,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,550,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(675,211)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(140,722)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end (in shares) | shares</a></td>
<td class="nump">5,086,495<span></span>
</td>
<td class="nump">4,352,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable at the end (in shares) | shares</a></td>
<td class="nump">1,729,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 12.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">35.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">11.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">17.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end (in dollars per share) | $ / shares</a></td>
<td class="nump">19.20<span></span>
</td>
<td class="nump">$ 12.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable at the end (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 12.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Expected term (in years)</a></td>
<td class="text">8 years 4 months 17 days<span></span>
</td>
<td class="text">8 years 8 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable at the end (in years)</a></td>
<td class="text">7 years 11 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at the beginning | $</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at the end | $</a></td>
<td class="nump">191,512<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable at the end | $</a></td>
<td class="nump">$ 75,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557471429832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Based Compensation - ESPP (Details) - ESPP - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock', window );">Discount rate to purchase common stock</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=morf_EmployeeStockPurchasePlanMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee', window );">Amount of common shares available for purchase per employee per year</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual value of shares available for purchase per employee from employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of discount provided to employees to purchase common stock under the employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=morf_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=morf_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557559904744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_morf_IncomeTaxExpenseBenefitCARESAct', window );">Income tax benefit, CARES Act</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_morf_IncomeTaxExpenseBenefitCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Expense (Benefit), CARES Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">morf_IncomeTaxExpenseBenefitCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>morf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557467234648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details)<br> ft&#178; in Thousands</strong></div></th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=morf_OfficeAndLaboratorySpaceMember', window );">Office and Laboratory Space</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land (square feet)</a></td>
<td class="nump">35<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=morf_OfficeAndLaboratorySpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=morf_OfficeAndLaboratorySpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557465494936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Minimum Rent Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, Payment, Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2021</a></td>
<td class="nump">$ 316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">1,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">1,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">1,733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">727<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">$ 5,983<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557471346072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Option and License Agreements - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,124<span></span>
</td>
<td class="nump">$ 25,757<span></span>
</td>
<td class="nump">$ 10,238<span></span>
</td>
<td class="nump">$ 39,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=morf_AbbVieMember', window );">AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=morf_AbbVieMember', window );">AbbVie | Upfront payment revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=morf_AbbVieMember', window );">AbbVie | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,476<span></span>
</td>
<td class="nump">23,647<span></span>
</td>
<td class="nump">5,043<span></span>
</td>
<td class="nump">32,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Due from Janssen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=morf_JanssenPharmaceuticalsIncMember', window );">Janssen | Upfront payment revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">372<span></span>
</td>
<td class="nump">476<span></span>
</td>
<td class="nump">1,281<span></span>
</td>
<td class="nump">1,551<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=morf_JanssenPharmaceuticalsIncMember', window );">Janssen | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,648<span></span>
</td>
<td class="nump">$ 2,110<span></span>
</td>
<td class="nump">5,195<span></span>
</td>
<td class="nump">$ 6,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Due from Janssen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=morf_AbbVieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=morf_AbbVieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=morf_UpfrontPaymentRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=morf_UpfrontPaymentRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=morf_JanssenPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=morf_JanssenPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557559538744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Option and License Agreements - Costs incurred and revenue recognized (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,124<span></span>
</td>
<td class="nump">$ 25,757<span></span>
</td>
<td class="nump">$ 10,238<span></span>
</td>
<td class="nump">$ 39,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,242<span></span>
</td>
<td class="nump">20,749<span></span>
</td>
<td class="nump">84,498<span></span>
</td>
<td class="nump">68,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=morf_AbbVieMember', window );">AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=morf_AbbVieMember', window );">AbbVie | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,476<span></span>
</td>
<td class="nump">23,647<span></span>
</td>
<td class="nump">5,043<span></span>
</td>
<td class="nump">32,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,206<span></span>
</td>
<td class="nump">2,480<span></span>
</td>
<td class="nump">4,374<span></span>
</td>
<td class="nump">10,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=morf_AbbVieMember', window );">AbbVie | Upfront payment revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=morf_JanssenPharmaceuticalsIncMember', window );">Janssen | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,648<span></span>
</td>
<td class="nump">2,110<span></span>
</td>
<td class="nump">5,195<span></span>
</td>
<td class="nump">6,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,118<span></span>
</td>
<td class="nump">1,439<span></span>
</td>
<td class="nump">3,388<span></span>
</td>
<td class="nump">4,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=morf_JanssenPharmaceuticalsIncMember', window );">Janssen | Reimbursement revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,276<span></span>
</td>
<td class="nump">1,634<span></span>
</td>
<td class="nump">3,914<span></span>
</td>
<td class="nump">5,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=morf_JanssenPharmaceuticalsIncMember', window );">Janssen | Upfront payment revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 372<span></span>
</td>
<td class="nump">$ 476<span></span>
</td>
<td class="nump">$ 1,281<span></span>
</td>
<td class="nump">$ 1,551<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=morf_AbbVieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=morf_AbbVieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=morf_UpfrontPaymentRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=morf_UpfrontPaymentRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=morf_JanssenPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=morf_JanssenPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=morf_ReimbursementRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=morf_ReimbursementRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557471363752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income per Share - Basic net income (loss) per share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (25,041)<span></span>
</td>
<td class="num">$ (27,815)<span></span>
</td>
<td class="num">$ (21,284)<span></span>
</td>
<td class="nump">$ 5,354<span></span>
</td>
<td class="num">$ (15,858)<span></span>
</td>
<td class="num">$ (16,746)<span></span>
</td>
<td class="num">$ (74,140)<span></span>
</td>
<td class="num">$ (27,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">36,547,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,533,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,392,153<span></span>
</td>
<td class="nump">30,368,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (loss) income per share, basic (in dollars Per share)</a></td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.09)<span></span>
</td>
<td class="num">$ (0.90)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">36,547,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,366,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,392,153<span></span>
</td>
<td class="nump">30,368,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net (loss) income per share, diluted (in dollars Per share)</a></td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.09)<span></span>
</td>
<td class="num">$ (0.90)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,605,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=morf_RestrictedCommonStockAndRestrictedStockUnitsMember', window );">Restricted common stock and stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=morf_RestrictedCommonStockAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=morf_RestrictedCommonStockAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140557468208248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income per Share - Common stock equivalent shares (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti&#8209;dilutive securities</a></td>
<td class="nump">5,151,983<span></span>
</td>
<td class="nump">553,502<span></span>
</td>
<td class="nump">5,151,983<span></span>
</td>
<td class="nump">4,918,732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti&#8209;dilutive securities</a></td>
<td class="nump">24,393<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,393<span></span>
</td>
<td class="nump">167,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti&#8209;dilutive securities</a></td>
<td class="nump">41,095<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">41,095<span></span>
</td>
<td class="nump">66,216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti&#8209;dilutive securities</a></td>
<td class="nump">5,086,495<span></span>
</td>
<td class="nump">553,502<span></span>
</td>
<td class="nump">5,086,495<span></span>
</td>
<td class="nump">4,685,276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=morf_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti&#8209;dilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">801,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=morf_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=morf_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>59
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( "6%9%,'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  EA613+.1EJNX    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2L0P$(=?17)O)^FN"J';B^))07!!\1:2V=U@\X=DI-VW-ZV[740?P&-F?OGF
M&YA61ZE#PN<4(B:RF*]&U_LL==RP U&4 %D?T*E<EX0OS5U(3E%YICU$I3_4
M'J'A_ 8<DC**%$S *BY$UK5&2YU044@GO-$+/GZF?H89#=BC0T\91"V ==/$
M>!S[%BZ "4:87/XNH%F(<_5/[-P!=DJ.V2ZI81CJ837GR@X"WIX>7^9U*^LS
M*:^Q_,I6TC'BAITGOZ[N[K</K&MX(RHA*K[>-ERNN;R^?9]<?_A=A%TP=F?_
ML?%9L&OAUUUT7U!+ P04    "  EA613F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M "6%9%,HU.C$8P4  )<6   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MI9AK;Z-&%(8_;W_%R*VJ5HH##+YN'4N.<[.:.-XX[6I;]<,8Q@8%&#H,=O+O
M>P9L<")\0-TO";?S^N',\)Z9,]H)^9)XG"OR&@91<M'RE(H_&T;B>#QDR;F(
M>01WUD*&3,&IW!A)+#ESLZ P,*AI]HR0^5%K/,JN+>1X)%(5^!%?2)*D8<CD
MVR4/Q.ZB9;4.%Y[\C:?T!6,\BMF&+[GZ(UY(.#,*%=</>93X(B*2KR]:$^OS
MU.[H@.R)/WV^2XZ.B7Z5E1 O^F3F7K1,3<0#[B@MP>#?ED]Y$&@EX/AW+]HJ
M?E,''A\?U&^REX>76;&$3T7PU7>5=]$:M(C+URP-U)/8W?']"W6UGB.")/M+
M=OFSG4Z+.&FB1+@/!H+0C_+_['6?B., >B* [@/HAP#KU"_8^P [>]&<+'NM
M*Z;8>"3%CDC]-*CI@RPW632\C1_I85PJ"7=]B%/CJ=AR218P8J1-$H])GHP,
M!<+ZMN'L12YS$7I"9$@>1*2\A%Q'+G??QQL 5%#1 ]4E1067/#XGMGE&J$FM
M"IXI'CX7VW-B6E7A[W#L(DEVIF>C2?I[LDJ4A'GW#R+9*20[F63GA.25<%+X
M&A1Y?HMY5<;Q<,ML?T$HN@5%MQG%EY1)Q67P1IYX+*2J(L*EE$PY0M0KB'K-
MB!9<^L+5,XK Q*Y,$:YTF$,_?/I4,PWZ!5N_X9A)!CZ6V=#I=.%::Q8D6+X&
M!=, U;F.E*_>R(T?<#)/PQ6752RXAFE:;7LP[)@(S[#@&3;A>>(;7W\LD*PY
M"RM'#]=Y>'Q:W,VFY.[Q_FHVOSW[^4>K9_XVFT_/$4C++%W/;((YBQPA80"9
M'LLSLE0PTXB09"K22,DW^.]6LM>H7UUCD$?6;#6!?&:O9.;"O//7OI.1(B-=
M(]GIPTCW!_T^Q0AI24B;$$Y<%^I&<G8X(/?P''F,JG.'2]I=<@NCX(DTX>1*
M0HW'2$L'M^S_3_J\$Y6DN.0$S6%9""S<RC^23?49S,%GL8LJJ7"YKRQ0'@LQ
MM+(Z6+BG?T0KOH^%%%L_<JK'%]=\F&!H99FP<'?_B+80B6(!^<N/3W^TN*))
M.UVL2EAEF;!P;\]&< *+ZM,HN$!_@(*4M<'"C?U>.)"3A2<BK#C4B R'O;8Y
M['8QHK(Z6+BM/_L*"I58$XO^LOJ5++F32LA6)1:N-!5A"$ZX5,)Y.2,QDV3+
M@I23G\QS$PH:B6'%EJUGL>5H62\H[NA0\5T_VI#E6[@2015NC0#4LQN,I"P*
M%'?P0\K(]:OCL0C6[:<*;(W0?+*\FF"+2%J6 =JH#$Q3*?7R*%\39>D"PT@K
M-Q0UBM\^;D/>DY6V3QO9_BR"Q6V^8]2K279 K23#%6O(2MNGC6Q?+]Q@O0&^
MNA&R\CNHT9F+J,T<!_;%L(KA;BZ($9;N3QNY_S)D04 NTP1N)]5C^5T[ UIZ
M/FWD^=<AEQL]NVY!07E@LF',HNK<X8)U9*7C4]RP#V2OQUN#? =3B?5]>P-:
M%@#::'>P]#@,(98G7*86J/1_VFA[\-Z\EUG;@3RF"FIXI'VV<LN?*W<S9=V=
MVH[MWK!G]:S!R-A64-FEN]N-=@-3< 0)!7,6N?R5_,XK4U4CI6M/KS^T>S;6
M=RC=WL9-^F"I-WZB2_DW#G4.VQ+7R+7;%FW;:$ND-'T;M^AB-WS,=@,7*SVB
M1JRN47/4J<'M^2/5OHUPF@N7^X(.8VGV-F[2$T!R<ZR 5<WNRQJ!DU^@<=3Z
MT[Z8=403XN@-;-X%+*X67==)UFLTRL?SENT#T[::D("O(=0\[\.G)O,N:'ZB
M1)PU$E="*1%FAQYG+I?Z ;B_%D(=3O0/%+WH\7]02P,$%     @ )85D4SK\
MTWBI!0  'Q8  !@   !X;"]W;W)K<VAE971S+W-H965T,BYX;6RE6-MNVS@0
M_17"6Q0MX,0B=6\= ZF=10MTVZ!.=Y\9B8Z%2*)+4DFS7[]#69$4D5)=[$-B
M7<Z,#H?#.1PN'[FXEWO&%/I9Y*6\F.V5.KQ;+&2R9P65Y_S 2GBSXZ*@"F[%
MW4(>!*-I;53D"^(XP:*@63E;+>MGUV*UY)7*LY)="R2KHJ#BZ0/+^>/%#,^>
M'WS+[O9*/UBLE@=ZQ[9,?3]<"[A;M%[2K&"ES'B)!-M=S"[QNS6)M4&-^#MC
MC[)WC?10;CF_US>?THN9HQFQG"5*NZ#P\\#6+,^U)^#QHW$Z:[^I#?O7S][_
MK </@[FEDJUY_D^6JOW%+)JAE.UHE:MO_/$C:P;D:W\)SV7]'STV6&>&DDHJ
M7C3&P*#(RN,O_=D$HF> O1$#TAB04PW<QL"M!WID5@]K0Q5=+05_1$*CP9N^
MJ&-36\-HLE)/XU8)>)N!G5JMOW[97'W97FT07&V_?OZTN;R!FP^7GR^_K*_0
M]N/5U<T6O?E>TBK-%$O?HC/T?;M!;UZ]1:]05J*;/:\D+5.Y7"C@H[TNDN;;
M'X[?)B/?WK+#.7*=.2(.P1;S];3YAB5@CFMSYZ7Y J+0AH*TH2"U/W<L%)40
MK%2(2LF4?#?AT6T]NK5';\PCE7L$L4&)OF _JNR!YO ):ZR.KH+:E5Y\#RL<
M>=B/EXN'?DPL,!B^%[:P%TR]EJDWR72[YT*=*28*2"YQSQ2]S1F2+*E$IC)F
M)7STZ/>8$,_U<#@@;,(P"0@>(>RWA/U)PI=)PBN())22A$%8@:Z-HV]R#' T
M8&B"0A=[=GY!RR^8Y'<MV(%F*6(_H>!*)NLTX&K/!*SJ?I[96 <&(9]@9\#:
M!+F1/Q+5L&4=3K*^X8KF)Q ,C6][KN\YWH"B"2-N#$@[R:@E&?TBM"!B0CW5
M(=6+Z@"RHN:H9,K&-3))^-&0J044.(&=9]SRC"=Y?F-2B2R!HEFO?QNWV)SH
M8#C/)H:$(Q'$3E?UG4EN7^M,')_@QOS%JO4'Q"R88"1DN"='^(0,G""&+:D7
M^8$[)&?BB$?<B(P0[$0"GZ82>49OL[PNCE-2@3NMP--BT5:T WT:*V>-BQ>+
M'H?!<.P65.2-Y4PG$7A:(X"@J%A7TJP$S6H?F9)@06$']S+_)<-.$_"T*&S8
MCL'LI" *#ZRLV+PM90>0-]@U6BF;Y=]UL#<4"0N,^&0TX3N=P--"T>.LB]@I
MA,W*3XST-S$X&!$'W*D#_AUYZ*T *TV+2$"N#BNO!:8U(AKAVHD$CB;7Z6=>
MWATW-*>NU*ZNX^G";J892 _BNY,FSRSG7N#%1FVU*$,8A"/5BW1UGTS7_4&V
MG<Z;6 3!'>Y-+: QJ2*=(I!3%.$7R4;,<A]%;CQ<Q!98'.)HC&.O<Y@6A:WB
MR?V>YRD3\O4?$>QNWZ,KV)FHIZF^I),&,BT-L)ELIDWNJ6!RCEXYYX[C8- *
M@:"GT#F(G3D\TG\-"M%*P;8^^Y>E,-/\^6DFI:[B]7ZT4E+!15;>@>3J3("6
M3+'BEHG7?T ]?O_<G-5HZ+?ZKZR-5S,;I@ -=S63D)=AZ@2*3 O4FA<%+Z=B
MY#F307*#>123N8?Q_PZ62^:.&\Z#*#C)U6_$UM3.84FU0-R1V';22G[1;Z70
M_D-M@*6H^QJ=Y$[\'OK_A!XR6*!6JJ9D^D$0.\/]B@5'HC D(WI%.FTET]H*
M.Y:JJ'*JM^ IVV5)9NT0B"F69P0'@4^&1"U [!$?C]7E3EG)M++VF39=(B\.
M@NWU@=D#0SF7]KIGJN=9/-P,V$#ZP,5*N1-8,MV&'>NRM%0^9JE\#5VSSW)]
MV/D-Y<^"PYZ/X[&,Z*2;3$NW(2;U>OS-0<3&$8RU!;'@K"W(HG=ZIX]._Z+B
M+BLERMD.#)WS$,(@CJ>1QQO%#_6!WBU7BA?UY9Y1(*\!\'['N7J^T6>$[9GP
MZC]02P,$%     @ )85D4XH+L,;N @  E@D  !@   !X;"]W;W)K<VAE971S
M+W-H965T,RYX;6REEEMOVC 4Q[^*%>VAE3KB)%PK0*) U4E=BTJ[/4Q[<),#
ML>K8F>U MT\_.TDS:,.E'0_$E_,_YW<.)]C]M9!/*@;0Z#EA7 V<6.OTW'55
M&$-"5$.DP,W.0LB$:#.52U>E$DB4BQ+F^ABWW810[@S[^=I,#OLBTXQRF$FD
MLB0A\O<%,+$>.)[SLG!'E[&V"^ZPGY(ES$$_I#-I9F[E):()<$4%1Q(6 V?D
MG8\]; 6YQ3<*:[4Q1C:51R&>[.1+-'"P)0(&H;8NB'FL8 R,64^&XU?IU*EB
M6N'F^,7[99Z\2>:1*!@+]IU&.AXX70=%L" 9TW=B?05E0BWK+Q1,Y=]H7=AV
M>@X*,Z5%4HH-04)Y\23/92$V!%YSA\ O!?ZQ@J 4!'FB!5F>UH1H,NQ+L4;2
M6AMO=I#7)E>;;"BW/^-<2[-+C4X/Q[<WD^G-?#I!9C2_O?XR&=V;R<7H>G0S
MGJ+YU71Z/T<G#YQD$=40G:*3&9' =0R:AH2=HL_H$W*1BLVJZKO:,%G/;EC&
MORCB^SOBSR%MH "?(1_[7HU\O%\^@=#(O5R.M^6NJ415#K\JAY_["W;A:*+!
M=*E&8H$N*2<\I(2AF5 T[[H?HT>EI>F]GWN"!56P( _6W!%L9CH6I(2HK-X9
M2HE$*\(R0">4HT@P1J1"*<C"XK2NOD6,3A[#OK2K(6Y@C$TQ5YMU/&BVE4*S
M2J'YSA2*)R*9CH6D?R"J8RZ<MC9@/%Q\7E$?8;C%W:JX6Q_CIDIE]<RM-RBO
M8?=9;%&V*\KVQRC-_['2A$>4+^M0VP=1]UELH78JU,Y>U+%($O-^_$\C=XYK
MY(-F6_S=BK][%+\6X=.13=Q]4\,FKN_B8RRWJ'L5=>\]53_8P[TW($&[V_.;
MWNLBUQCZ..BTN^UZ8 __.V_P!Y /-'3I\PCP.LMZ<G?CT+0WEJ]$+BE7B,'"
M2'&C8WS(XA)03+1(\W/T46AS*N?#V%R<0%H#L[\00K],[-%<7<6&?P%02P,$
M%     @ )85D4]#:?J0N!@  4AH  !@   !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6RM65UOXC@4_2L6VH=6FBFQ\T4JBM1"9@=I^J'2SCRL]B& @6B2F'4,
M[>ZO7SM)"=@WGL[L]J'DX]Q[?4Z<ZY-D^,+X]W)#J4"O>5:45[V-$-O+?K]<
M;&B>E!=L2PMY9L5XG@BYR]?]<LMILJR"\JQ/'"?HYTE:]$;#ZM@#'PW93F1I
M01\X*G=YGO"_;VC&7JYZN/=VX#%=;X0ZT!\-M\F:SJAXWCYPN=<_9%FF.2W*
ME!6(T]55[QI?QB10 17B:TI?RJ-MI*C,&?NN=J;+JYZC1D0SNA J12)_]G1,
MLTQEDN/XJTG:.]14@<?;;]D_5>0EF7E2TC'+OJ5+L;GJ#7IH25?)+A./[.4S
M;0CY*M^"967U'[TT6*>'%KM2L+P)EB/(TZ+^35X;(8X"9!XX@#0!1 _P.@+<
M)L!];P6O"?#>6\%O BKJ_9I[)=PD$<EHR-D+X@HMLZF-2OTJ6NJ5%FJBS 27
M9U,9)T;C^[M)?#>+)TANS>Z_3"?73W)G]B1_;N.[IQFZ_X3N'^+'ZZ>I!*#K
M.X6\?7B,/\NPZ=<83>_D?HS.OMS/9N?H[+E(=LM4T.4Y^HB>9Q-T]MLY^@VE
M!7K:L%V9%,MRV!=RY*I^?]&,\J8>)>D8I8MN62$V)8J+)5T"\1-[?&2)[TO%
M#K*1-]ENB#7AC&XOD.M\0,0A&!C/^/WA#D3GOU6/?[GZB1CN80ZY53ZW(]^T
M6+"<HIE(!)4]1* _KN>EX+('_&G)[AVR>U5VKVN&LBQ+YHPGHNY->UKL*#2%
MZC1!E4;UQ_W(Q<0;]O?'U\4$$3_TPU/4Q$1AA[B#4U0,%(P<KZUX0M<_T/6M
M8MYOJ:):K!%]E:M!2<M+BXC!(6M@%?&1EC3ABPV2]Y_LHWNY0&S5I8)TK#/Y
MQQ(Y41!H0IHH[$>1)M'$1 4>=K$FI(GRO4$8PD*&!\JAE?+OM)!*9A7C9"E;
M9ZKFI%J6(-*A,820A#IG$^2%OD9F8H*(XP;:#(M-%';=8 !3'APH#ZR4GYB0
MA)DQ@R#" W.8 ^(1C3& <D(OTBB;J('GZ7,A-E&!K.C#E*,#Y<A*^>P+*\MS
MU+2@%6?Y&W]6@+PC8Q0?B8^Q-MBQ"?,=1Y_=0*[0(X&C$8=*1L3!,'/LM$NW
M8V\58D.Y7%D5=5N3P$=F %O5G!:"<EJ*)ND'5%"P131I3FX7;8:/ 0QQ]48+
M@+"GZP>!?#?HD(^T9(F5;"U?<X^ +(E1U]%)FI"/@<X1P!"#(P#"I(-BNS!C
M]ST-X6B>=%]2]QV7U,00O9E/ ! VZ0(@GW0LG;BU"MCN%4Z[P9S*!RGU4]!5
M*NKF4*N 1/(*M\6F@-8?' _K4I@XG[AZ8X2RA1XPPZ&J8="U!.+63&#?*LC-
M3W'W?SS?30C&OL[ZAWEB .*1+K:MR<%VEW,G'ZS/LFH*U%Q!EH%AV^ K;.)\
MU_=TKD V\ I#54-9MX-SZW*PW>88G)%<_E"Y2;B\U^4C=+I 9_+A:ZE<-"_1
MP]O)<U";NM;@>)3.13"(3OYTH<P@YT)?4"=0:G+A1+I.X BB#I5:8X3MSLBJ
MTC+-=O*!]6=T&OR*3F:0U,E8$8'4D$[@"+IT:MT4MMNI;]6+%:E%LI<F:DV1
MU"J7CUV5%"5B.U$*::BEN3R>7/596"G3_+B![X6$Z%830CJ^ZPX\0R( Z;L1
MD:9 5PG**6VVYW;T&M*:+^+\;TH=3S"+5DW%=V@%(8D;!%CO8A,("6L%(>U:
MM;:28*M1';-\R^E&O5[<T]/[T.9;26OEB-W*O:OQ-SE^V/@!'-#XH6Q0XP>K
M=C=^TGH[8G_K4MO7Q8FT2@*KHJV3(G8G]5QPFF3I/W+6;EBFIG&57,WL N4)
M_TY%,L\H*NEBQU.1PHZ"0/['U?4&0#AR=+VA5$07&TK5I71KHHC=1!V[:%-O
MD+=I;P#>  C@#:4R>$.INGBW=HK8[93EM@5)@\8*8_T5'(#S<6#<7Z"Q(MB@
M#ANK0&??/WI'GE.^KCY.E/)Z[@I1O^H\'#U\ +FN7OMKQV_PY1@#QR?X,JX_
M;[3IZZ\MMPE?IT6),KJ2I9R+4%XG7G_ J'<$VU9OZ.=,")97FQN:+"E7 'E^
MQ9AXVU$%#I^11O\"4$L#!!0    ( "6%9%/\,"2Z@PL  ,=+   8    >&PO
M=V]R:W-H965T<R]S:&5E=#4N>&ULQ9QK;]LX%H;_BI =S+; N!;OU$P:H$W<
M)DW:9.IT%HO%?E!M)39J6QY);MK]]4LYBFF1AY1\:_NA\>4E>7A]SCF2?/R0
M9E_R49(4P;?I9):_/!H5Q?SW;C<?C))IG+](Y\E,?7.79M.X4&^S^VX^SY)X
MN"PTG71Q&/+N-![/CDZ.EY_=9"?'Z:*8C&?)31;DB^DTSKZ_3B;IP\LC=/3T
MP<?Q_:@H/^B>',_C^Z2?%)_F-YEZUUW5,AQ/DUD^3F=!EMR]/'J%?K^*PK+
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MV QVSBI5_=:V,#1U;P&=(;EHU> [5X,.MY*MW=VU98"^'\^> <BFH3#=NK>
MCK"P_.?HH*8Q\]-XOR$  Y+;AE/AE=0[H3G-_%%]*^>?V1&X\F:P=:V^65>W
M4N.<^7'>]G84!%H/A.)<RL@ >Z_2U>X#-<](NRI&L C-  #0=1 GPDS87<%"
MQW!I7X)M>3G<=P$0&KL> ZX_*RH@[,K"<NU<\-:9]6TC  [DUZ$(@#?GUX&J
MP @ T,$1 "1T10!<^S)\IZOB&T< ',BR>R, KAT9_A.R[%P['MSO>+0ZV#@0
MJ N*J(,-7/L/?,L8W B[P0.+ V$W"Q$W[UO@-KK- PNHBG$>A>9]"X!.K5;.
MF;6L :$KT.#:5^"MLP'M4Q;@@<4!W*M0"%/DVGMK-X#O%'VW01$' FX(197.
M.[. ,P"A"-#!*(*%CD'3_@7W^Q<[W)$"SZ_M8C0 23L97/Z$ TM#F_NAO57*
M@MM\9B24YEII4-6?/] $%WZ"[Y*R$-#U[% Z#EZA 2D.$.R#3T4 -X\QZ[I@
MDZK>"\U.L7428/N4A; #?(0Q8HX]+C1JA1^U^PV$!,!DX_"[\FOJW=#,%GYF
M/SW/5\6?RFM89%DR!&T$*$C-^\ :1'4K-2J%'Y6M_!H!I9^%1(8'<=FLJUNI
M62E:L])[VPQ(20%0DHHH- :X)YHI"53%2,2(Z?\ N@Z*$$?FS5"0$+M.K;5'
MN5I3LOUM,R ?!<1'+ 1S^3]"\U'\!#X*S4=Q #X*@'S"O,/MO$E5?[Y-\U$>
MCH\2N+.:XM!QR$G-1_F#^"B!R)%+,ZQN4M5[H?DH?P(?I<U'+-3F<8VYYJ/<
M/ >^:TI?V@2DTKQ4U2"J=T=S4FZ>&]]C2E_:V(S"T&6UYJ8\:#H:RNA+^\(R
M*K,'1AZ^45;OD6:LW/+NL?TDV*5-.AS)4#A@)S7LI!]V^W47)9!S%N9]%@VB
M>D?6'F#>PS-/$GKFB8748-!ELZYNI>:FW,^S4: K)H%GGJ!4%* S73%  J:B
M !V<BH*$KE14I*$='>#A*- 5BP"$PZFH[MK/])0_<?4^SN[+#3%)[E31\$7I
MIF>/OQKU^*9(Y\M?[OF<%D4Z7;X<);$Z?4N!^OXN38NG-^6/ :U^N^OD_U!+
M P04    "  EA613R=3WPHP"  "'!@  &    'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;*55:V_:,!3]*U963:VTDA >?0PB :%JM5)80S?MHYO<$*N)S6P#
MW;_?M1,R6@&JM"^QKWW/\3W7R4EO(^2+R@ T>2URKOI.IO7RVG55G$%!54,L
M@>-.*F1!-89RX:JE!)I84)&[ON=UW8(R[@0]NS:304^L=,XXS"11JZ*@\L\0
M<K'I.TUGN_#(%IDV"V[06](%1*"?EC.)D5NS)*P KIC@1$+:=P;-Z[!K\FW"
M#P8;M3,G1LFS$"\FN$OZCF<*@AQB;1@H#FL809X;(BSC=\7IU$<:X.Y\RWYC
MM:.69ZI@)/*?+-%9W[ET2 (I7>7Z46QNH=+3,7RQR)5]DDV5ZSDD7BDMB@J,
M%12,ER-]K?JP T">_0"_ OCO >T#@%8%:'T4T*X ;=N94HKM0T@U#7I2;(@T
MV<AF)K:9%HWR&3?7'FF)NPQQ.AA-'\+Q0S0."<ZBZ?U=.)AC$,UQF(P?YA&9
MWF T'7V[G=Z'X\?H\Z=+OWGQE8R_/]W-?Y'3&97 =0::Q30_(^?D*0K)Z<D9
M.2&,DPG+<[Q>U7,U%FN.=..JL&%9F'^@L!:9".159,P32-[B7119*_6W2H?^
M4<((E@W2\KX0W_.;>^H9'8=/J$1X\R \_/CIWA$UK?K>6I:O?8!OH,_G&9QC
M52_H#=,T!<GXX@AQNR9N'R7>4I%8*+WWWDK\E<4;5UD'7N.JYZYW>[DOQW^;
M$^[+Z=8Y;XKOU,5WCA8?02QX@O;UD8YT:]+N_W5D5.*[.TJ:G7="W)U/M "Y
ML%:GD'+%=?D.UZNUFPZLB;Q;'Z++EJ;XCZ:T:'P7%HPKDD.*E%[C GLE2]LK
M RV6U@B>A49;L=,,_Q0@30+NIT+H;6 .J/\]P5]02P,$%     @ )85D4VSC
MQ;K)!@  Q1H  !@   !X;"]W;W)K<VAE971S+W-H965T-RYX;6R=66UOVS80
M_BN$-PPM$-<BJ=<N"9 F*5J@38*YW3XS$AUKE42-I/*R7[\CY4JV1"G)@**1
MY"/U/,>[>X[B\8.0/]26<XT>RZ)2)XNMUO7[U4JE6UXR]4[4O()?-D*63,.M
MO%NI6G*6V4%EL2*>%ZY*EE>+TV/[[$:>'HM&%WG%;R1235DR^?2!%^+A9($7
M/Q_\D=]MM7FP.CVNV1U?<_V]OI%PM^IFR?*25RH7%9)\<[(XP^_/:6@&6(L_
M<_Z@]JZ1H7(KQ ]S\SD[67@&$2]XJLT4#/[<\W->%&8FP/'/;M)%]TXS</_Z
MY^P?+7D@<\L4/Q?%7WFFMR>+>($ROF%-H?\0#Y_XCE!@YDM%H>S_Z&%GZRU0
MVB@MRMU@0%#F5?N7/>X<L3< YG$/(+L!9#C GQA =P.H)=HBL[0NF&:GQU(\
M(&FL839S87UC1P.;O#++N-82?LUAG#X]O[ZZN+Q:7UX@N%I??_E\<?8-;M;?
MX,_7RZMO:W3]$9V?K3^ACU^N_UJC-]\KUF2YYME;M$3?UQ?HS:]OT:\HK]"W
MK6@4JS)UO-* S,R_2G<H/K0HR 2*!'T5E=XJ=%EE/#L<OP)&'2WRD]8',COA
MFM?O$/6.$/$(=N Y?_EP;P8.[;Q,[7QTRLM,;=$&4D:AC10E@BR43.?571O&
MN<ZY>C_S'K][CV_?XT^\YPKROA#*N0+MR-".-,E]?[J,?.P#O?M]QSC,2$2"
MWNP 6- !"V8=<);]#;$,Z:\5T@+R/Q55FA<<53O$YJFY3HVG&L4S$U&O=5/8
MH0EGW73!H>2E.6L+294A5@JI\W_M Y?OVNF"/:=$@3]PW-@F#HC;:U&',YK%
M>2-YF3?E 3R+-\M5*II*@U]2R>UC^ =U^ ?7[!;<JGC:2.LO%YUH!#6@>$!G
M;..3Q$TG[NC$LW0N_VER_?3;+S'QDM]-[<U0*DH0)#7I^'B$ @>!/\0ZMHJ]
M*;!)!S:9!?O%!"4X%5Q="\4*)#:( X':!+$+:C)VV #FV&(BJ[#75V]OOK!L
M677'![FB%(<T,W%2Y.PV+Y[-&[RG%GC6*V>IC3ME,ICG]R;6G-4>CYT1)N'
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M+6?0%!D#^'TCA/YY8U[0G5R=_@=02P,$%     @ )85D4]4-!;R3"   Y14
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M%>9S3POP?N5PKNIO2,'P9??B_U!+ P04    "  EA613#]!EYBD,  !P(0
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MRB_U#?8O*IBB[U0"/B:RD![#1E\;970@=>&V**>27]>F*E'Q:8V38ENL%?9
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ME_-9!+9_"OH!F3:4WXTA+N:A6_/KB=8;\'IE^-0- T\POL?K?P!02P,$%
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MU7/G\<0^I_2-1M;F47(E&R2;^=P*#F>3 ,;74C9]@R887JDO_P102P,$%
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MK"6C'F>#;5_=[8N?P>R%H&,)+_25<HND1>H'O%$":4P-[UJ5*K0%5FT;<;C
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M #!2R'6U&?/G^0?EO/K^AXNQ:L#$GM/U4U/6J!L?U:?&J_,FP.H0U#6]:NI
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M+<#W%4;7]H$4=']?.?TO4$L#!!0    ( "6%9%--I4>6<@,  ( (   9
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M4D)%.VXV<O<%AGQ2BU=(KMU(=KWOY=0C1:>-;(9@5- PT7_IZW .!P&S\$A
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M66HY?EI1CT?M!.A\H93=+)R![5_#[ ]02P,$%     @ )85D4R]E>IQ"!
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M9?BG$LA62:PH-()8'R8BI&R=!1:(Q?,"+&C,&.ZS?^3!ZX(40K86"N)XO-)
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MN&*T[;J_"\@TH>/6AKA_P[3B!P.M3^#]PAC:![Z)AR<H^P=02P,$%     @
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MYT][N]:?""!,@'Z^XER]#<PAM/KHF/P!4$L#!!0    ( "6%9%,@#Z62#0,
M -0)   9    >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;(U676_:,!3]*U;4
MAU9BS7<(%2!1/K1)JU25=GN8]F"2"[&:Q-0VI?WWLYV0AA R7L!VSCF^Y]Z;
MV,,]9:\\ 1#H(TMS/C(2(;9WILFC!#+,;^D6<OED35F&A9RRC<FW#'"L25EJ
M.I85F!DFN3$>ZK5'-A[2G4A)#H\,\5V68?9Y#RG=CPS;."P\D4TBU((Y'F[Q
M!I8@7K:/3,[,2B4F&>2<T!PQ6(^,B7VW"!5> WX1V//:&"DG*TI?U>1'/#(L
M%1"D$ FE@.7?.TPA3960#..MU#2J+16Q/CZH+[1WZ66%.4QI^IO$(AD9H8%B
M6.-=*I[H_CN4?GRE%]&4ZU^T+[#]@8&B'1<T*\DR@HSDQ3_^*/-0(TB==H)3
M$IPFP3M#<$N">RG!*PG>I02_)/B7$H*2$.C<%\G2F9YA@<=#1O>(*;144P-=
M+LV6"2:Y:JRE8/(ID3PQGF*>])#Z1?.W'7G'*>2"]Q#.8_0$7# 2"8@+P/4,
M!"8IOT'?T,MRAJZO;M 5(CEZ3NB.2P8?FD+&I)3-J-S_OMC?.;/_ #W07"0<
MS?,8XF.^*;U4AIR#H7NG4W )VUOD6CWD6([=$L^TFS[9;23=/DN?==-G$%5T
MJX4^OSSX-OKBXMWM04<NW:HY7*WGGM%K-L"?R4HNR(_!WPYQKQ+WM+AW1OPG
M" $,T36*&,1$M/5.H1!H!?6)?!_[@<S+>[V>IQBG[U>8H]#\*C2_,[1G8)D*
M+&V$B*YELW\"9ORF+=IN45LS.Q(75-$%G4*Z%.K]C-0 OM[:MIB"D^S8H6?[
M@^,DSEI@L@.]_C%L?@H;A%;8J,BB3<SV:WL>V>Y7MON=MFO-J(RWF2T$_*YV
MF9UBZNU2V+P L^C&'#D,*X=A=]M1@5-MKG=26UUP]O\4A&WU[MO->K? +,=U
MG$8B3F&#T/6;J6@3LT/7:V3#K)U2&;"-OD]P%-%=+HH#JUJMKBP3?5*;7_#B
MOO. V8;D7+Z@:TFU;ONR#JRX0Q030;?ZS%M1(4]0/4SDM0N8 LCG:TK%8:(V
MJ"YRXW]02P,$%     @ )85D4ZC1X"!S @  208  !D   !X;"]W;W)K<VAE
M971S+W-H965T,S,N>&ULC57);MLP$/T50L@A 5IKEYW %I#8+=I#4,-.VD/1
M RV-+2*4J)+TDK_OD)(%QQMZL;C,>_/>2#,>;H5\4P6 )KN25VKD%%K7#ZZK
ML@)*JGJBA@IOED*65.-6KEQ52Z"Y!97<#3PO<4O**B<=VK.I3(=BK3FK8"J)
M6I<EE>]/P,5VY/C._F#&5H4V!VXZK.D*YJ!?ZZG$G=NQY*R$2C%1$0G+D?/H
M/XP3$V\#?C+8JH,U,4X60KR9S?=\Y'A&$'#(M&&@^-C &#@W1"CC;\OI="D-
M\'"]9_]JO:.7!54P%OP7RW4Q<@8.R6%)UUS/Q/8;M'YBPY<)KNPOV3:Q<>"0
M;*VT*%LP*BA9U3SIKJW# <"/+@""%A#\+R!L :$UVBBSMB94TW0HQ99($XUL
M9F%K8]'HAE7F+<ZUQ%N&.)T^9IE<0TZ^[/"[4*#([00T95S=D<_D=3XAMS=W
MY(:PBKP48JUHE:NAJS&Q@;M9F^2I21)<2#*'ND="[Q,)O, _ Q]?AT\@0[AO
MX=Y'N(MV.\]!YSFP?.$%OBE]IPN.7M$-L06@7)'?CPNE)7Y6?ZZD"+L4H4T1
M74XA!><V@P1.-988VA*?JU_#EE@VTWB;- KOT>OFL$JG0;$?#;J@#T*C3FAT
M5>@,%%"9%59I#AMLZQJ;5#?]Q30[K[<AC0^DA)Y_?Z3W-"@*P_B\WKC3&U_5
M^T,7(*^6,C[)ZGO>X$C::5#2[Y]7EG3*DJO*7H2F_)R@Y.2U#2*_?R3H-,CW
M_,0[DN0>-+H9LL]4KEBE"(<EXKQ>'QW)9G U&RUJV_L+H7&2V&6!LQZD"<#[
MI1!ZOS'CI/OW2/\!4$L#!!0    ( "6%9%,-@_/C+ (  #4%   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;)54RV[;,!#\E85."=!8+Z>/0!90.RV:
M BF,&&W/M+2RB%"D0E)V\O=94K+@ K;A7D0NN3.<'7&9[91^-C6BA==&2#,+
M:FO;NS T18T-,Q/5HJ2=2NF&60KU)C2M1E9Z4"/")(H^A@WC,L@SO[;4>:8Z
M*[C$I0;3-0W3;W,4:C<+XF"_\,0WM74+89ZU;(,KM+_;I:8H'%E*WJ T7$G0
M6,V"K_'=8NKR?<(?CCMS, =7R5JI9Q<\E+,@<H)08&$= Z-ABPL4PA&1C)>!
M,QB/=,##^9[]NZ^=:EDS@PLE_O+2UK/@<P E5JP3]DGM?N!0SZWC*Y0P_@N[
M(3<*H.B,5<T )@4-E_W(7@<?#@#Q] 0@&0#)I8!T *2^T%Z9+^N>699G6NU
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M5#3Y=!N [INT#ZQJ_3U?*TM=XZ<UO6NH70+M5TK9?>!:9WPI\W=02P,$%
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MDP*-GQ3K[68S]F+=EEL$KZX2:DLO0K=2J68^?PTT-L5R"(3,TC@ \D)S>PV
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M"9GC=2H?V.874CH4:+R8I<+\@DTYUG- O!:29:6Q8I#1O/C'KV4@&@9^V&&
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MA2IBO+C6*AXD6YF;H1F3DF6FN20X(5P/4._GC,G=@YZ@NER<_ 502P,$%
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MR,L JB5+XO@=J[E049Z%LZ7),]V2% J7!FQ;U]S\N$.I=Y/H*MH?/(IM1?Z
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M6;G[CL8GN/-2:SH%?@:[/TCV%U!+ P04    "  EA613#J1Q^H "  !'!@
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M%EPGQH)LVE8ST:)RK6(MM&D\;EB83H_2!ICW6R'T<6*[3_??D?T%4$L#!!0
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M-K=W][DQ3S@JK8$97PFA'QIV@O91./D+4$L#!!0    ( "6%9%.+'ZR')P,
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M>CZMFH%MV*CU!0[[R&UU^1',QV%^!# L#J8 \W%>6)S_:3X#=#X.P[0-O,@
M]1F@/L[+ATRJ&XOC]TGLY9]IDD11'&,K.IEX%4RP=8MC^/C9,&W@@<6!2'^V
MUGBV\0HY7 =83@]5"#93O!*QF>)K#8A_W< C2?S9QN* !Y8%K'8@OC\.U)3?
M)XH@JY@V[ W&D23!$*A%?XW&,;(Z,=S^_&!O210EB1\!S*\@BC $WD8<P12
M!@R)HFH?W-N/PLT^%;;_@(U_ U!+ P04    "  EA613EXJ[',     3 @
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M"P_R+0+Y-B[D@MI6,Z(VQ.X8N6H-E\P80F5-KJCA'N0% GD1%]*1&,>XTLQ
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M0[V-0&]#O8U ;T.]C4!O0[V-0&]#O8U ;X]Z>P*]/>KM"?3VJ+<GT-NCWIY
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M<F]P<R]A<' N>&UL4$L! A0#%     @ )85D4RSD9:KN    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ )85D
M4YE<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    "  EA613*-3HQ&,%  "7%@  &
M@($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ )85D
M4SK\TWBI!0  'Q8  !@              ("!I@T  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( "6%9%.*"[#&[@(  )8)   8
M      " @843  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M"  EA613T-I^I"X&  !2&@  &               @(&I%@  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ )85D4_PP)+J#"P  QTL  !@
M             ("!#1T  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( "6%9%/)U/?"C (  (<&   8              " @<8H  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  EA613;./%NLD&  #%
M&@  &               @(&(*P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ )85D4]4-!;R3"   Y14  !@              ("!AS(
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( "6%9%,/T&7F
M*0P  ' A   8              " @5 [  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    "  EA613@?G"&VP&   !$@  &0
M@(&O1P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( "6%
M9%/2-P=]O@,  .L(   9              " @5).  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ )85D4Z%J S]# P  FP<  !D
M         ("!1U(  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    "  EA613#J/G%7T"  !Y!0  &0              @('!50  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( "6%9%-84OTUS@<  +$6
M   9              " @758  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ )85D4[]+PC&"!   (@H  !D              ("!>F
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  EA613)WN2
MKE4&   1#P  &0              @($S90  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( "6%9%.<]W0$+P@  (@9   9
M  " @;]K  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
M)85D4\2GHDY5!0  -P\  !D              ("!)70  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    "  EA613J=+[EM )  !K&0  &0
M            @(&Q>0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( "6%9%--I4>6<@,  ( (   9              " @;B#  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ )85D4^.(H&L' P
M.@<  !D              ("!88<  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    "  EA613)!)HFK0"   Y!@  &0              @(&?
MB@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( "6%9%-1
M]P^VC (  'T%   9              " @8J-  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ )85D4X14XA('!0  U X  !D
M     ("!39   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "6%9%-U<V--- (  (X$   9              "
M@>.D  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ )85D
M4[]R)K3T!   +1X  !D              ("!3J<  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    "  EA61384UB6# #  " #   &0
M        @(%YK   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( "6%9%,@#Z62#0,  -0)   9              " @>"O  !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ )85D4ZC1X"!S @  208
M !D              ("!)+,  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    "  EA613#8/SXRP"   U!0  &0              @('.M0
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( "6%9%-_M^>D
MX@,  !01   9              " @3&X  !X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ )85D4S/1US$:!   TP\  !D
M ("!2KP  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    "  E
MA613P9/)QQD$  #8#P  &0              @(&;P   >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( "6%9%-[.D^,T 0  &@4   9
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M970T,BYX;6Q02P$"% ,4    "  EA613<'QUMUT$  #$%   &0
M    @(%2U   >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M "6%9%.Q]YE)J00  +T6   9              " @>;8  !X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ )85D4PII<2=<!   !Q(  !D
M             ("!QMT  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    "  EA613-9TV!70#   @#@  &0              @(%9X@  >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( "6%9%.+'ZR')P,
M  X3   -              "  03F  !X;"]S='EL97,N>&UL4$L! A0#%
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K  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     V #8 L0X   CR      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>212</ContextCount>
  <ElementCount>266</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>36</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Nature of the Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/NatureoftheBusinessandBasisofPresentation</Role>
      <ShortName>Nature of the Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Basis of Presentation and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/BasisofPresentationandSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Fair Value of Financial Assets and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/FairValueofFinancialAssetsandLiabilities</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2109104 - Disclosure - Marketable securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/Marketablesecurities</Role>
      <ShortName>Marketable securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2112105 - Disclosure - Cash, Cash Equivalents, and Restricted Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/CashCashEquivalentsandRestrictedCash</Role>
      <ShortName>Cash, Cash Equivalents, and Restricted Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2115106 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2118107 - Disclosure - Equity Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/EquityBasedCompensation</Role>
      <ShortName>Equity Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2126108 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2128109 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2132110 - Disclosure - Option and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/OptionandLicenseAgreements</Role>
      <ShortName>Option and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2136111 - Disclosure - Net (Loss) Income per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/NetLossIncomeperShare</Role>
      <ShortName>Net (Loss) Income per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://morphictx.com/role/BasisofPresentationandSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesTables</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://morphictx.com/role/FairValueofFinancialAssetsandLiabilities</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - Marketable securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/MarketablesecuritiesTables</Role>
      <ShortName>Marketable securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://morphictx.com/role/Marketablesecurities</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Cash, Cash Equivalents, and Restricted Cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/CashCashEquivalentsandRestrictedCashTables</Role>
      <ShortName>Cash, Cash Equivalents, and Restricted Cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://morphictx.com/role/CashCashEquivalentsandRestrictedCash</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2316304 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://morphictx.com/role/AccruedExpenses</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2319305 - Disclosure - Equity Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/EquityBasedCompensationTables</Role>
      <ShortName>Equity Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://morphictx.com/role/EquityBasedCompensation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2329306 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://morphictx.com/role/CommitmentsandContingencies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2333307 - Disclosure - Open Option Contracts Written (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/OpenOptionContractsWrittenTables</Role>
      <ShortName>Open Option Contracts Written (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2337308 - Disclosure - Net (Loss) Income per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/NetLossIncomeperShareTables</Role>
      <ShortName>Net (Loss) Income per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://morphictx.com/role/NetLossIncomeperShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Nature of the Business and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/NatureoftheBusinessandBasisofPresentationDetails</Role>
      <ShortName>Nature of the Business and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://morphictx.com/role/NatureoftheBusinessandBasisofPresentation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Basis of Presentation and Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Fair Value of Financial Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Marketable securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/MarketablesecuritiesDetails</Role>
      <ShortName>Marketable securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://morphictx.com/role/MarketablesecuritiesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2414405 - Disclosure - Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/CashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://morphictx.com/role/CashCashEquivalentsandRestrictedCashTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2417406 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://morphictx.com/role/AccruedExpensesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2420407 - Disclosure - Equity Based Compensation - 2019 equity incentive plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/EquityBasedCompensation2019equityincentiveplanDetails</Role>
      <ShortName>Equity Based Compensation - 2019 equity incentive plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2421408 - Disclosure - Equity Based Compensation - Equity based compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails</Role>
      <ShortName>Equity Based Compensation - Equity based compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2422409 - Disclosure - Equity Based Compensation - Restricted common stock activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails</Role>
      <ShortName>Equity Based Compensation - Restricted common stock activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2423410 - Disclosure - Equity Based Compensation - Restricted stock units activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails</Role>
      <ShortName>Equity Based Compensation - Restricted stock units activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - Equity Based Compensation - Stock option awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails</Role>
      <ShortName>Equity Based Compensation - Stock option awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Equity Based Compensation - ESPP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/EquityBasedCompensationESPPDetails</Role>
      <ShortName>Equity Based Compensation - ESPP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://morphictx.com/role/IncomeTaxes</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2430414 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2431415 - Disclosure - Commitments and Contingencies - Schedule of Minimum Rent Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/CommitmentsandContingenciesScheduleofMinimumRentPaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Minimum Rent Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2434416 - Disclosure - Option and License Agreements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails</Role>
      <ShortName>Option and License Agreements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2435417 - Disclosure - Option and License Agreements - Costs incurred and revenue recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails</Role>
      <ShortName>Option and License Agreements - Costs incurred and revenue recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2438418 - Disclosure - Net (Loss) Income per Share - Basic net income (loss) per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/NetLossIncomeperShareBasicnetincomelosspershareDetails</Role>
      <ShortName>Net (Loss) Income per Share - Basic net income (loss) per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://morphictx.com/role/NetLossIncomeperShareTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="morf-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2439419 - Disclosure - Net (Loss) Income per Share - Common stock equivalent shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://morphictx.com/role/NetLossIncomeperShareCommonstockequivalentsharesDetails</Role>
      <ShortName>Net (Loss) Income per Share - Common stock equivalent shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://morphictx.com/role/NetLossIncomeperShareTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="morf-20210930.htm">morf-20210930.htm</File>
    <File>exhibit101-rentamendment.htm</File>
    <File>morf-20210930.xsd</File>
    <File>morf-20210930_cal.xml</File>
    <File>morf-20210930_def.xml</File>
    <File>morf-20210930_lab.xml</File>
    <File>morf-20210930_pre.xml</File>
    <File>morf-2021930x10qex311.htm</File>
    <File>morf-2021930x10qex312.htm</File>
    <File>morf-2021930x10qex321.htm</File>
    <File>morf-2021930x10qex322.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>64
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "morf-20210930.htm": {
   "axisCustom": 0,
   "axisStandard": 15,
   "contextCount": 212,
   "dts": {
    "calculationLink": {
     "local": [
      "morf-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "morf-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "morf-20210930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "morf-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "morf-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "morf-20210930.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 323,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 5
   },
   "keyCustom": 8,
   "keyStandard": 258,
   "memberCustom": 13,
   "memberStandard": 19,
   "nsprefix": "morf",
   "nsuri": "http://morphictx.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://morphictx.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Fair Value of Financial Assets and Liabilities",
     "role": "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilities",
     "shortName": "Fair Value of Financial Assets and Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109104 - Disclosure - Marketable securities",
     "role": "http://morphictx.com/role/Marketablesecurities",
     "shortName": "Marketable securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112105 - Disclosure - Cash, Cash Equivalents, and Restricted Cash",
     "role": "http://morphictx.com/role/CashCashEquivalentsandRestrictedCash",
     "shortName": "Cash, Cash Equivalents, and Restricted Cash",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115106 - Disclosure - Accrued Expenses",
     "role": "http://morphictx.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118107 - Disclosure - Equity Based Compensation",
     "role": "http://morphictx.com/role/EquityBasedCompensation",
     "shortName": "Equity Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126108 - Disclosure - Income Taxes",
     "role": "http://morphictx.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128109 - Disclosure - Commitments and Contingencies",
     "role": "http://morphictx.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132110 - Disclosure - Option and License Agreements",
     "role": "http://morphictx.com/role/OptionandLicenseAgreements",
     "shortName": "Option and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136111 - Disclosure - Net (Loss) Income per Share",
     "role": "http://morphictx.com/role/NetLossIncomeperShare",
     "shortName": "Net (Loss) Income per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)",
     "role": "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "role": "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)",
     "role": "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesTables",
     "shortName": "Fair Value of Financial Assets and Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - Marketable securities (Tables)",
     "role": "http://morphictx.com/role/MarketablesecuritiesTables",
     "shortName": "Marketable securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Cash, Cash Equivalents, and Restricted Cash (Tables)",
     "role": "http://morphictx.com/role/CashCashEquivalentsandRestrictedCashTables",
     "shortName": "Cash, Cash Equivalents, and Restricted Cash (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316304 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://morphictx.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319305 - Disclosure - Equity Based Compensation (Tables)",
     "role": "http://morphictx.com/role/EquityBasedCompensationTables",
     "shortName": "Equity Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329306 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://morphictx.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333307 - Disclosure - Open Option Contracts Written (Tables)",
     "role": "http://morphictx.com/role/OpenOptionContractsWrittenTables",
     "shortName": "Open Option Contracts Written (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337308 - Disclosure - Net (Loss) Income per Share (Tables)",
     "role": "http://morphictx.com/role/NetLossIncomeperShareTables",
     "shortName": "Net (Loss) Income per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Nature of the Business and Basis of Presentation (Details)",
     "role": "http://morphictx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
     "shortName": "Nature of the Business and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "i8539e76f9660442e9d169db576c8aedd_D20210811-20210811",
      "decimals": "INF",
      "lang": "en-US",
      "name": "morf:PercentageOfCommissionOnGrossSaleProceeds",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "i196c1e6bf66247b98fa293ce7ce21c10_I20210831",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AreaOfLand",
      "reportCount": 1,
      "unitRef": "sqft",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Basis of Presentation and Significant Accounting Policies (Details)",
     "role": "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "role": "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Fair Value of Financial Assets and Liabilities (Details)",
     "role": "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails",
     "shortName": "Fair Value of Financial Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ia7a2b23055c14610b9b9f0122e0bc83c_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411404 - Disclosure - Marketable securities (Details)",
     "role": "http://morphictx.com/role/MarketablesecuritiesDetails",
     "shortName": "Marketable securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LettersOfCreditOutstandingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414405 - Disclosure - Cash, Cash Equivalents, and Restricted Cash (Details)",
     "role": "http://morphictx.com/role/CashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LettersOfCreditOutstandingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417406 - Disclosure - Accrued Expenses (Details)",
     "role": "http://morphictx.com/role/AccruedExpensesDetails",
     "shortName": "Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "i1d81d7faa05e4d72ba315f45f8ca2b93_I20210101",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420407 - Disclosure - Equity Based Compensation - 2019 equity incentive plan (Details)",
     "role": "http://morphictx.com/role/EquityBasedCompensation2019equityincentiveplanDetails",
     "shortName": "Equity Based Compensation - 2019 equity incentive plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "i1d81d7faa05e4d72ba315f45f8ca2b93_I20210101",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421408 - Disclosure - Equity Based Compensation - Equity based compensation expense (Details)",
     "role": "http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails",
     "shortName": "Equity Based Compensation - Equity based compensation expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422409 - Disclosure - Equity Based Compensation - Restricted common stock activity (Details)",
     "role": "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
     "shortName": "Equity Based Compensation - Restricted common stock activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "i3306469c42b0426c851e95ee8d3af6bf_I20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423410 - Disclosure - Equity Based Compensation - Restricted stock units activity (Details)",
     "role": "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails",
     "shortName": "Equity Based Compensation - Restricted stock units activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "i336ef268b2b54d5a8d41335f5521475d_I20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - Equity Based Compensation - Stock option awards (Details)",
     "role": "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails",
     "shortName": "Equity Based Compensation - Stock option awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "idecb2791d4e644adac2b17f62a0ffc4d_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Equity Based Compensation - ESPP (Details)",
     "role": "http://morphictx.com/role/EquityBasedCompensationESPPDetails",
     "shortName": "Equity Based Compensation - ESPP (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "idecb2791d4e644adac2b17f62a0ffc4d_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited)",
     "role": "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "i8c604eb326ec497187ef28434af427bf_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "morf:IncomeTaxExpenseBenefitCARESAct",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Income Taxes (Details)",
     "role": "http://morphictx.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "i8c604eb326ec497187ef28434af427bf_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "morf:IncomeTaxExpenseBenefitCARESAct",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "i196c1e6bf66247b98fa293ce7ce21c10_I20210831",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AreaOfLand",
      "reportCount": 1,
      "unitRef": "sqft",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430414 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "role": "http://morphictx.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431415 - Disclosure - Commitments and Contingencies - Schedule of Minimum Rent Payments (Details)",
     "role": "http://morphictx.com/role/CommitmentsandContingenciesScheduleofMinimumRentPaymentsDetails",
     "shortName": "Commitments and Contingencies - Schedule of Minimum Rent Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "i33b4fdba1f9a45cfad52bcc6e9877d20_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434416 - Disclosure - Option and License Agreements - Narrative (Details)",
     "role": "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails",
     "shortName": "Option and License Agreements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "if51ea1a4ae7b4814bdd7be74ca589c83_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435417 - Disclosure - Option and License Agreements - Costs incurred and revenue recognized (Details)",
     "role": "http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails",
     "shortName": "Option and License Agreements - Costs incurred and revenue recognized (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "iaacbf9b146694148984076cec6a6afd1_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostsAndExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438418 - Disclosure - Net (Loss) Income per Share - Basic net income (loss) per share (Details)",
     "role": "http://morphictx.com/role/NetLossIncomeperShareBasicnetincomelosspershareDetails",
     "shortName": "Net (Loss) Income per Share - Basic net income (loss) per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "iccd54f681834442eb165955240d9e74a_D20210701-20210930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439419 - Disclosure - Net (Loss) Income per Share - Common stock equivalent shares (Details)",
     "role": "http://morphictx.com/role/NetLossIncomeperShareCommonstockequivalentsharesDetails",
     "shortName": "Net (Loss) Income per Share - Common stock equivalent shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ib152258fcd6e459f8a623da04c7f31d0_D20210701-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ia2e37d454f86483da5d113ba5bb9c6ae_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (Unaudited)",
     "role": "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "i678eec9b2b244447b18fc4ba9a55fb5d_D20200101-20200331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ie46f079ac4224779be66b7117f7c7607_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (Parenthetical)",
     "role": "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ie46f079ac4224779be66b7117f7c7607_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "role": "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Nature of the Business and Basis of Presentation",
     "role": "http://morphictx.com/role/NatureoftheBusinessandBasisofPresentation",
     "shortName": "Nature of the Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Basis of Presentation and Significant Accounting Policies",
     "role": "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "morf-20210930.htm",
      "contextRef": "ic874f44e59414867ad3a7dfee6a24ec3_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 36,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://morphictx.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "morf_AbbVieMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents AbbVie Inc.",
        "label": "AbbVie [Member]",
        "terseLabel": "AbbVie"
       }
      }
     },
     "localname": "AbbVieMember",
     "nsuri": "http://morphictx.com/20210930",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails",
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "morf_AccruedResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://morphictx.com/role/AccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Research And Development",
        "terseLabel": "Research and development activities"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopment",
     "nsuri": "http://morphictx.com/20210930",
     "presentation": [
      "http://morphictx.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "morf_AtMarketOfferingProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents at-the-market offering program.",
        "label": "At Market Offering Program [Member]",
        "terseLabel": "ATM"
       }
      }
     },
     "localname": "AtMarketOfferingProgramMember",
     "nsuri": "http://morphictx.com/20210930",
     "presentation": [
      "http://morphictx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "morf_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-The-Market Offering",
        "label": "At-The-Market Offering [Member]",
        "terseLabel": "At-The-Market Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://morphictx.com/20210930",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "morf_CollaborativeArrangementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Option and License Agreements",
        "terseLabel": "Option and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureAbstract",
     "nsuri": "http://morphictx.com/20210930",
     "xbrltype": "stringItemType"
    },
    "morf_CommonStockAvailableForIssuance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of common stock available for issuance.",
        "label": "Common Stock Available For Issuance",
        "terseLabel": "Amount of shares remaining available for sale"
       }
      }
     },
     "localname": "CommonStockAvailableForIssuance",
     "nsuri": "http://morphictx.com/20210930",
     "presentation": [
      "http://morphictx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "morf_EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual value of shares available for purchase per employee from employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan Annual Value Of Shares Available For Purchase Per Employee",
        "terseLabel": "Amount of common shares available for purchase per employee per year"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanAnnualValueOfSharesAvailableForPurchasePerEmployee",
     "nsuri": "http://morphictx.com/20210930",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationESPPDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "morf_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Employee Stock Purchase Plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://morphictx.com/20210930",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationESPPDetails",
      "http://morphictx.com/role/NetLossIncomeperShareCommonstockequivalentsharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "morf_FollowOnPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow-On Public Offering",
        "label": "Follow-On Public Offering [Member]",
        "terseLabel": "Secondary Offering"
       }
      }
     },
     "localname": "FollowOnPublicOfferingMember",
     "nsuri": "http://morphictx.com/20210930",
     "presentation": [
      "http://morphictx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "morf_IncomeTaxExpenseBenefitCARESAct": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Expense (Benefit), CARES Act",
        "label": "Income Tax Expense (Benefit), CARES Act",
        "negatedLabel": "Income tax benefit, CARES Act"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitCARESAct",
     "nsuri": "http://morphictx.com/20210930",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "morf_IncreaseDecreaseInDeferredRent": {
     "auth_ref": [],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income.",
        "label": "Increase (Decrease) in Deferred Rent",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRent",
     "nsuri": "http://morphictx.com/20210930",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "morf_JanssenPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Janssen Pharmaceuticals Inc.",
        "label": "Janssen Pharmaceuticals Inc [Member]",
        "terseLabel": "Janssen"
       }
      }
     },
     "localname": "JanssenPharmaceuticalsIncMember",
     "nsuri": "http://morphictx.com/20210930",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails",
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "morf_OfficeAndLaboratorySpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and Laboratory Space",
        "label": "Office and Laboratory Space [Member]",
        "terseLabel": "Office and Laboratory Space"
       }
      }
     },
     "localname": "OfficeAndLaboratorySpaceMember",
     "nsuri": "http://morphictx.com/20210930",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://morphictx.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "morf_OpenMarketSaleAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Open Market Sale Agreement.",
        "label": "Open Market Sale Agreement [Member]",
        "terseLabel": "Open Market Sale Agreement"
       }
      }
     },
     "localname": "OpenMarketSaleAgreementMember",
     "nsuri": "http://morphictx.com/20210930",
     "presentation": [
      "http://morphictx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "morf_PercentageOfCommissionOnGrossSaleProceeds": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of commission on gross sale proceeds.",
        "label": "Percentage of Commission on Gross sale Proceeds",
        "terseLabel": "Commission (as a percent)"
       }
      }
     },
     "localname": "PercentageOfCommissionOnGrossSaleProceeds",
     "nsuri": "http://morphictx.com/20210930",
     "presentation": [
      "http://morphictx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "morf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of accounting policies for Pro forma financial information.",
        "label": "Recently Issued Accounting Pronouncements Not Yet Adopted [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements not yet Adopted"
       }
      }
     },
     "localname": "RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock",
     "nsuri": "http://morphictx.com/20210930",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "morf_ReimbursementRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement Revenue",
        "label": "Reimbursement Revenue [Member]",
        "terseLabel": "Reimbursement revenue"
       }
      }
     },
     "localname": "ReimbursementRevenueMember",
     "nsuri": "http://morphictx.com/20210930",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "morf_RestrictedCommonStockAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to restricted common stock and restricted stock units.",
        "label": "Restricted Common Stock And Restricted Stock Units [Member]",
        "terseLabel": "Restricted common stock and stock units"
       }
      }
     },
     "localname": "RestrictedCommonStockAndRestrictedStockUnitsMember",
     "nsuri": "http://morphictx.com/20210930",
     "presentation": [
      "http://morphictx.com/role/NetLossIncomeperShareBasicnetincomelosspershareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "morf_SecondaryOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secondary Offering",
        "label": "Secondary Offering [Member]",
        "terseLabel": "Secondary Offering"
       }
      }
     },
     "localname": "SecondaryOfferingMember",
     "nsuri": "http://morphictx.com/20210930",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "morf_ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of discount provided to employees to purchase common stock under the employee stock purchase plan.",
        "label": "Share Based Compensation Arrangement, Percentage Of Discount On Purchase Of Common Stock",
        "terseLabel": "Discount rate to purchase common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementPercentageOfDiscountOnPurchaseOfCommonStock",
     "nsuri": "http://morphictx.com/20210930",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationESPPDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "morf_TwoThousandNineteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2019 stock incentive plan.",
        "label": "Two Thousand Nineteen Stock Incentive Plan [Member]",
        "terseLabel": "2019 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenStockIncentivePlanMember",
     "nsuri": "http://morphictx.com/20210930",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensation2019equityincentiveplanDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "morf_UpfrontPaymentRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront Payment Revenue",
        "label": "Upfront Payment Revenue [Member]",
        "terseLabel": "Upfront payment revenue"
       }
      }
     },
     "localname": "UpfrontPaymentRevenueMember",
     "nsuri": "http://morphictx.com/20210930",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails",
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r35",
      "r37",
      "r82",
      "r83",
      "r184",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails",
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r183",
      "r190",
      "r211",
      "r212",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r330",
      "r363",
      "r365",
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationESPPDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": {
     "auth_ref": [
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate, Type of Property [Axis]",
        "terseLabel": "Real Estate, Type of Property [Axis]"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://morphictx.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": {
     "auth_ref": [
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate [Domain]",
        "terseLabel": "Real Estate [Domain]"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://morphictx.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r134",
      "r199",
      "r201",
      "r332",
      "r362",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails",
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r134",
      "r199",
      "r201",
      "r332",
      "r362",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails",
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r183",
      "r190",
      "r202",
      "r211",
      "r212",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r330",
      "r363",
      "r365",
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationESPPDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r183",
      "r190",
      "r202",
      "r211",
      "r212",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r330",
      "r363",
      "r365",
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationESPPDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r36",
      "r37",
      "r82",
      "r83",
      "r184",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails",
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://morphictx.com/role/AccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r339",
      "r355"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.",
        "label": "Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r25",
      "r299"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r14",
      "r137",
      "r138"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Premium amortization and discount accretion on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://morphictx.com/role/AccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Other expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRentCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r29"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Rent, Current",
        "terseLabel": "Deferred rent, current portion"
       }
      }
     },
     "localname": "AccruedRentCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRentNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer) for contractual rent under lease arrangements.",
        "label": "Accrued Rent, Noncurrent",
        "terseLabel": "Deferred rent, net of current portion"
       }
      }
     },
     "localname": "AccruedRentNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r17",
      "r40",
      "r41",
      "r42",
      "r351",
      "r370",
      "r371"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r39",
      "r42",
      "r49",
      "r50",
      "r51",
      "r85",
      "r86",
      "r87",
      "r269",
      "r366",
      "r367",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r15",
      "r242",
      "r299"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid\u2011in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r239",
      "r240",
      "r241",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid\u2011in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition",
        "terseLabel": "Equity-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r193",
      "r194"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "negatedTerseLabel": "Offering costs incurred"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r214",
      "r235",
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total equity-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti\u2011dilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/NetLossIncomeperShareCommonstockequivalentsharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/NetLossIncomeperShareCommonstockequivalentsharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/NetLossIncomeperShareBasicnetincomelosspershareDetails",
      "http://morphictx.com/role/NetLossIncomeperShareCommonstockequivalentsharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/NetLossIncomeperShareCommonstockequivalentsharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area of Land",
        "terseLabel": "Area of land (square feet)"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://morphictx.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r78",
      "r123",
      "r126",
      "r132",
      "r152",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r265",
      "r270",
      "r287",
      "r297",
      "r299",
      "r336",
      "r349"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r34",
      "r78",
      "r152",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r265",
      "r270",
      "r287",
      "r297",
      "r299"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://morphictx.com/role/MarketablesecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized holding gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/MarketablesecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://morphictx.com/role/MarketablesecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross unrealized holding losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/MarketablesecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r142",
      "r159"
     ],
     "calculation": {
      "http://morphictx.com/role/MarketablesecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/MarketablesecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r140",
      "r143",
      "r159",
      "r338"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://morphictx.com/role/MarketablesecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Short-term marketable securities",
        "verboseLabel": "Aggregate estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails",
      "http://morphictx.com/role/MarketablesecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/MarketablesecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r215",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails",
      "http://morphictx.com/role/NetLossIncomeperShareBasicnetincomelosspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r23",
      "r72"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://morphictx.com/role/CashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://morphictx.com/role/CashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.",
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "verboseLabel": "Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CashCashEquivalentsandRestrictedCash"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds, included in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r67",
      "r72",
      "r77"
     ],
     "calculation": {
      "http://morphictx.com/role/CashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
      "http://morphictx.com/role/CashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r67",
      "r288"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r260",
      "r261",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Option and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails",
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r171",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares available for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensation2019equityincentiveplanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r85",
      "r86",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common shares, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common shares, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r13",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common shares, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r13",
      "r299"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common shares, $0.0001 par value, 400,000,000 shares authorized, 36,892,411 shares issued and outstanding as of September\u00a030, 2021 and 32,037,686 shares issued and outstanding as of December\u00a031, 2020"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r45",
      "r47",
      "r48",
      "r56",
      "r343",
      "r358"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive (loss) income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive (loss) income:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r195",
      "r197",
      "r200"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "terseLabel": "Due from Janssen"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r195",
      "r196",
      "r200"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r195",
      "r196",
      "r200"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue, current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r195",
      "r196",
      "r200"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r203",
      "r210",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails",
      "http://morphictx.com/role/MarketablesecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "terseLabel": "Costs incurred",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited",
      "http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Term of letter of credit (in years)"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/MarketablesecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Schedule of investments in marketable securities classified as available for sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/MarketablesecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Unrealized Gain (Loss)",
        "verboseLabel": "Unrealized holding losses on marketable securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r70",
      "r164"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Equity Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r57",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r98",
      "r100",
      "r103",
      "r104",
      "r105",
      "r109",
      "r110",
      "r277",
      "r278",
      "r344",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net (loss) income per share, basic (in dollars Per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited",
      "http://morphictx.com/role/NetLossIncomeperShareBasicnetincomelosspershareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r57",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r100",
      "r103",
      "r104",
      "r105",
      "r109",
      "r110",
      "r277",
      "r278",
      "r344",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net (loss) income per share, diluted (in dollars Per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited",
      "http://morphictx.com/role/NetLossIncomeperShareBasicnetincomelosspershareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net (Loss) Income per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/NetLossIncomeperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://morphictx.com/role/AccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Equity Based Compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized equity based compensation expense expected period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized equity based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized equity based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails",
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails",
      "http://morphictx.com/role/NetLossIncomeperShareBasicnetincomelosspershareDetails",
      "http://morphictx.com/role/NetLossIncomeperShareCommonstockequivalentsharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r49",
      "r50",
      "r51",
      "r85",
      "r86",
      "r87",
      "r89",
      "r95",
      "r97",
      "r112",
      "r153",
      "r193",
      "r194",
      "r239",
      "r240",
      "r241",
      "r251",
      "r252",
      "r276",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r366",
      "r367",
      "r368",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r279",
      "r280",
      "r281",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r185",
      "r187",
      "r188",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r280",
      "r303",
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r279",
      "r280",
      "r282",
      "r283",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Assets and Liabilities"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r185",
      "r203",
      "r204",
      "r209",
      "r210",
      "r280",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r185",
      "r187",
      "r188",
      "r203",
      "r204",
      "r209",
      "r210",
      "r280",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r185",
      "r187",
      "r188",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r280",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r185",
      "r187",
      "r188",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r303",
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r284",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair value on a recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r146",
      "r147",
      "r149",
      "r150",
      "r151",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r160",
      "r161",
      "r162",
      "r163",
      "r186",
      "r192",
      "r275",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails",
      "http://morphictx.com/role/MarketablesecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Loss on disposal of equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r53",
      "r123",
      "r125",
      "r128",
      "r131",
      "r133",
      "r333",
      "r340",
      "r345",
      "r360"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "(Loss) Income before benefit from income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r166",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r79",
      "r248",
      "r249",
      "r250",
      "r253",
      "r255",
      "r257",
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r80",
      "r96",
      "r97",
      "r122",
      "r247",
      "r254",
      "r256",
      "r361"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Benefit from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r73"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r148",
      "r334",
      "r347",
      "r373",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/Marketablesecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of minimum annual rent payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r296"
     ],
     "calculation": {
      "http://morphictx.com/role/CommitmentsandContingenciesScheduleofMinimumRentPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CommitmentsandContingenciesScheduleofMinimumRentPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r296"
     ],
     "calculation": {
      "http://morphictx.com/role/CommitmentsandContingenciesScheduleofMinimumRentPaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CommitmentsandContingenciesScheduleofMinimumRentPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r296"
     ],
     "calculation": {
      "http://morphictx.com/role/CommitmentsandContingenciesScheduleofMinimumRentPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CommitmentsandContingenciesScheduleofMinimumRentPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r296"
     ],
     "calculation": {
      "http://morphictx.com/role/CommitmentsandContingenciesScheduleofMinimumRentPaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CommitmentsandContingenciesScheduleofMinimumRentPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r296"
     ],
     "calculation": {
      "http://morphictx.com/role/CommitmentsandContingenciesScheduleofMinimumRentPaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CommitmentsandContingenciesScheduleofMinimumRentPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r296"
     ],
     "calculation": {
      "http://morphictx.com/role/CommitmentsandContingenciesScheduleofMinimumRentPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CommitmentsandContingenciesScheduleofMinimumRentPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of credit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r28",
      "r78",
      "r127",
      "r152",
      "r172",
      "r173",
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r266",
      "r270",
      "r271",
      "r287",
      "r297",
      "r298"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r20",
      "r78",
      "r152",
      "r287",
      "r299",
      "r337",
      "r353"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r30",
      "r78",
      "r152",
      "r172",
      "r173",
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r266",
      "r270",
      "r271",
      "r287",
      "r297",
      "r298",
      "r299"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails",
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r67",
      "r68",
      "r71"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r43",
      "r46",
      "r51",
      "r54",
      "r71",
      "r78",
      "r88",
      "r90",
      "r91",
      "r92",
      "r93",
      "r96",
      "r97",
      "r102",
      "r123",
      "r125",
      "r128",
      "r131",
      "r133",
      "r152",
      "r172",
      "r173",
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r278",
      "r287",
      "r341",
      "r356"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net (loss) income",
        "totalLabel": "Net (loss) income",
        "verboseLabel": "Net (loss) income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited",
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://morphictx.com/role/NetLossIncomeperShareBasicnetincomelosspershareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "verboseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Summary of restricted common stock"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r123",
      "r125",
      "r128",
      "r131",
      "r133"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "(Loss) Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CommitmentsandContingenciesScheduleofMinimumRentPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Nature of the Business and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/NatureoftheBusinessandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r44",
      "r47",
      "r49",
      "r50",
      "r52",
      "r55",
      "r193",
      "r289",
      "r294",
      "r295",
      "r342",
      "r357"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Total other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r38",
      "r40"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized holding gains (losses) on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
      "http://morphictx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r141"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r215",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensation2019equityincentiveplanDetails",
      "http://morphictx.com/role/EquityBasedCompensationESPPDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensation2019equityincentiveplanDetails",
      "http://morphictx.com/role/EquityBasedCompensationESPPDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r12",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred shares, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred shares, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r12",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred shares, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred shares, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r12",
      "r299"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred shares, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of September\u00a030, 2021 and December\u00a031, 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r21",
      "r22"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "verboseLabel": "Proceeds from secondary offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from at-the-market offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
      "http://morphictx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Aggregate offering price of placement shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r64",
      "r238"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common shares upon stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of common shares under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r43",
      "r46",
      "r51",
      "r66",
      "r78",
      "r88",
      "r96",
      "r97",
      "r123",
      "r125",
      "r128",
      "r131",
      "r133",
      "r152",
      "r172",
      "r173",
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r264",
      "r267",
      "r268",
      "r272",
      "r273",
      "r278",
      "r287",
      "r345"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r165",
      "r299",
      "r348",
      "r354"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r246",
      "r331",
      "r387"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r77",
      "r335",
      "r350"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://morphictx.com/role/CashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://morphictx.com/role/CashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash [Abstract]",
        "terseLabel": "Restricted Cash [Abstract]"
       }
      }
     },
     "localname": "RestrictedCashAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted common stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/NetLossIncomeperShareCommonstockequivalentsharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails",
      "http://morphictx.com/role/NetLossIncomeperShareCommonstockequivalentsharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r16",
      "r194",
      "r242",
      "r299",
      "r352",
      "r369",
      "r371"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r85",
      "r86",
      "r87",
      "r89",
      "r95",
      "r97",
      "r153",
      "r239",
      "r240",
      "r241",
      "r251",
      "r252",
      "r276",
      "r366",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r120",
      "r121",
      "r124",
      "r129",
      "r130",
      "r134",
      "r135",
      "r136",
      "r198",
      "r199",
      "r332"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited",
      "http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails",
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds from secondary offering"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://morphictx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/NetLossIncomeperShareBasicnetincomelosspershareDetails",
      "http://morphictx.com/role/NetLossIncomeperShareCommonstockequivalentsharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of common stock equivalent shares"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/NetLossIncomeperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/MarketablesecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
      "http://morphictx.com/role/OptionandLicenseAgreementsCostsincurredandrevenuerecognizedDetails",
      "http://morphictx.com/role/OptionandLicenseAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Summary of costs incurred and revenue recognized"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/OpenOptionContractsWrittenTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock": {
     "auth_ref": [
      "r101",
      "r105",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effect of income (loss) on basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]",
        "terseLabel": "Schedule of basic net income (loss) per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/NetLossIncomeperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r214",
      "r234",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r214",
      "r234",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of equity based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of financial assets measured at fair value on recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Summary of restricted stock units"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r9",
      "r77",
      "r335",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of reconciled cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CashCashEquivalentsandRestrictedCashTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r215",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensation2019equityincentiveplanDetails",
      "http://morphictx.com/role/EquityBasedCompensationESPPDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r219",
      "r230",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of subsidiary's sales of previously unissued stock made to investors outside the consolidated group. This includes stock issued in a business combination in exchange for shares of an acquired entity.",
        "label": "Schedule of Subsidiary or Equity Method Investee [Table]",
        "terseLabel": "Schedule of Subsidiary or Equity Method Investee [Table]"
       }
      }
     },
     "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Equity\u2011based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding at the end (in shares)",
        "periodStartLabel": "Outstanding at the beginning (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "verboseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding at the end (in dollars per share)",
        "periodStartLabel": "Outstanding at the beginning (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested as of the Reorganization",
        "verboseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Equity Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensation2019equityincentiveplanDetails",
      "http://morphictx.com/role/EquityBasedCompensationESPPDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationESPPDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grants (in shares)",
        "verboseLabel": "Number of shares available for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensation2019equityincentiveplanDetails",
      "http://morphictx.com/role/EquityBasedCompensationESPPDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable at the end (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable at the end (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Outstanding at the end",
        "periodStartLabel": "Outstanding at the beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r221",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at the end (in shares)",
        "periodStartLabel": "Outstanding at the beginning (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at the end (in dollars per share)",
        "periodStartLabel": "Outstanding at the beginning (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r213",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationEquitybasedcompensationexpenseDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedcommonstockactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationRestrictedstockunitsactivityDetails",
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails",
      "http://morphictx.com/role/NetLossIncomeperShareBasicnetincomelosspershareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable at the end"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable at the end (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Public offering price (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance at end of period ( in shares)",
        "periodStartLabel": "Balance at beginning of period ( in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r33",
      "r49",
      "r50",
      "r51",
      "r85",
      "r86",
      "r87",
      "r89",
      "r95",
      "r97",
      "r112",
      "r153",
      "r193",
      "r194",
      "r239",
      "r240",
      "r241",
      "r251",
      "r252",
      "r276",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r366",
      "r367",
      "r368",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r112",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan": {
     "auth_ref": [
      "r12",
      "r13",
      "r193",
      "r194",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Ownership Plan",
        "terseLabel": "Issuance of common stock under the Employee Stock Purchase Plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r12",
      "r13",
      "r193",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Sales of common shares sold in IPO, net of offering costs (in shares)",
        "verboseLabel": "Issuance of common shares/stock, net of offering/issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://morphictx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r12",
      "r13",
      "r193",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r12",
      "r13",
      "r193",
      "r194",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "verboseLabel": "Issuance of common shares upon stock option exercises (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://morphictx.com/role/EquityBasedCompensationStockoptionawardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan": {
     "auth_ref": [
      "r12",
      "r13",
      "r193",
      "r194",
      "r244"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Value, Employee Stock Ownership Plan",
        "terseLabel": "Issuance of common shares under the Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r12",
      "r13",
      "r193",
      "r194"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common shares/stock, net of offering/issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r33",
      "r193",
      "r194"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "verboseLabel": "Issuance of common shares upon stock option exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r13",
      "r18",
      "r19",
      "r78",
      "r139",
      "r152",
      "r287",
      "r299"
     ],
     "calculation": {
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary or Equity Method Investee [Line Items]",
        "terseLabel": "Subsidiary or Equity Method Investee [Line Items]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://morphictx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r146",
      "r147",
      "r149",
      "r150",
      "r151",
      "r186",
      "r192",
      "r275",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails",
      "http://morphictx.com/role/MarketablesecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r81",
      "r203",
      "r210",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury securities",
        "verboseLabel": "U.S. Treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/FairValueofFinancialAssetsandLiabilitiesDetails",
      "http://morphictx.com/role/MarketablesecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r99",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited",
      "http://morphictx.com/role/NetLossIncomeperShareBasicnetincomelosspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r98",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Weighted average common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://morphictx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSUnaudited",
      "http://morphictx.com/role/NetLossIncomeperShareBasicnetincomelosspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "40",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244457&loc=d3e16649-113920"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(1),(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r388": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r389": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r390": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r391": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r392": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r393": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r394": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r395": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r396": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r397": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r398": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r399": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r400": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r401": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r402": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>65
<FILENAME>0001679363-21-000067-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001679363-21-000067-xbrl.zip
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M+KEDU&?$5N'7G$=11X?"K.?&H;@&;N<0<VJ*\R"\!@)&T<\![,"EF,/UC$L
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M 5U".'3HA+8F_%H+)U::PH<9),%7S:\">0TYOT("6&H(KO[6E5>75I1G3B7
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M3C=W0OL=;[3VSKM\<ZU.ZJS^=6]WZ[#QMD[V=S?XWNY^L[&S>KZYNT?VWWZ
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M"-@HDXZ!8RQ1&7U%>WXQ+Q:,)-$QE9P%EKA5'NE.CCDC ^#S%7@ND@+-"^T
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MT2*3H-Q*"B!%/I_8!BN Y<H9.B0C]/S[R*V(P5'3#V*8Q,' 4_&/-!DJI7/
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MLBO;95O-@\ZK?"!;["U=%=5#!N3:>*A;QF/I9J._:9/M':!"#;K'K[(FW=;
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MK+/]-0P#CS:P?WL"0\/3S=WZV?[:QZ_[.ZML;W?CZ^;?FGYBD4N2N"FX"+H
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MX4).>DA1.$5"P4ARS-'DM<BS_6*9/7[=:)7U>"C?R#4GQD$VGD5\-*Y-)*.
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M;!!<2;273W\S2V CR=@("2BAG.C! FU5=>IYSG[.:"_MNX^5I>9BJ>UITT,
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MA=(1M'N%U8OW]=+LYK]<]<HL>O=<"!Y=W<]J]^4K =NK+.Y<TKK6>W39Z#)
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MC8C $^QCZ;LL 0$7CWK]WG T:-HBUVRT;&MC F<2ROST<$(^E:*N05&]J:B
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M>>W^\]HU:&W!0".O;'8C;#9I>'J6*(,@"8M6E11VV;.9&"DR,LA!6&S8C-W
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M!/&QK/),*HN32@JE8(DM8Y!2A7(;H;S,:&&%\JU">2IFR+SFPH$A7KA(P+A
M3)8JD=* ##Q%;S*4]6RC4T7RO4#R,@-L%<FWB^1)I9SO!8\\.A($502L$\1B
M9"1A" Y2<L86I=P2G;P.(;;]XY$[[!Q?$FA;4@?V=Q>;WT/"NKEX0!,1G2B.
M_9H#V,717MIW'RM)S452SZ9C "8RP\N<&(&,97/#2I+M#$8D=2:+*P46Y((Q
M@#DALIHM4.N&^IN+'534WP3J)TT3R0!XL!GF47D"5+OL9$0D41AA=40IM%PT
M7E!A?P]A?W-QA@K[&X#]5&S!*T>#LQGL.F1E#P&("<F29/)CK85*VBX86ZBH
MOX>HO[F81$7]3:!^4ME'"@"6)Q)E!CPHKXE!D0B+6C C94C4+1B'N"74K\/P
M^N\T@UYSY\7X=&;*0A;BL]9=MNNNR5GTXMP?DK^CQKQOD'\E_FL1_\OIV([@
M8$R,D)G>A.SER6SNN3(NU&F3#?GD%.BF32^K]Z5MV%D04"TO7*^4NNZ4VMJF
MPDJD2R3220LZRRA)#$BB3DC AC3.Y%%C1-F>P!%5:3%D:EDMAI5,*YFN 9FN
M0$-DI=7ET>I4.%(@BS)R1EQ6DIE6F_U3*(G548H@5>9<W;1'<K:$<J=*J952
M*Z6VH9FS4NH2*76JM9-QII3R!+519< M$FN$),G$%"AWD7D[;NU4RUNJ>T>4
MVD2#?VXZM_*_L??/YG_RC_.#/G*#M[U^\^V,3S)9P(R!P10^;Z[[[,M5O>XA
M;O['#WZN'[,"'W/;C8W[!]AQH90RNOZGTM;8/Q[E3W>#_.=^IY>/[.W '79.
MW&#4.4Z=T0$.RRZ:?LS<B\4BZ3>8=&553>KU73_T\LN'H_R'HWQ>PP>77I&S
MPP#^0&=H_WIR/.P5#OEE@(=NE&G]UP^].#HXCYE<>.,96="O;W$^'\3IZ/*W
MM.5JB\FK<?%G.=I&7VDC0 3JHH, Z+5+7E)A$\1HF-7I#><;YV\Z^#*(]\2]
M1>('Z-X3E_()_N(./[A/PXV?)^_"? M.7??I2W;IA4GIQB[,& U9UQ\/7"/0
MK"AP4%Z5C\FUYE@Z!X-B]/S/CT64G8[]IA\X0^91L9<R$O[SLYNEA\NYX\)+
MSEJ+S^_^1B?FBW'H3H;XR_F#7V-O>'+H/OW2ZS>GU+SIUS/:.8-,D?>40FS.
M=OSTV:U@[0-C6;D;SO*D9U]\=J,\&"ND2?U^]D[SP-++GZ8/V/^:T+S?R<->
MKOB_H?M;XF/H;UK3.WO/G_ZQ_:CSQ]Z?C[=WGW0[V[N/'C3R?K2W^WAK]\76
MXTY^]&+OS^W'#_?S+R_V\S\[6[O[+SI[O^??]A[][_+>K><O_K__,9SI7SM;
MSUYN[[_J_/2R[TYC+S/OOYO/^VF[G_GY^#0?;1QV._@Q8+ER9;1[)Q.TFS3.
M)FR?.S)C;OO6SA)Y0,=WZ+SWMK /]!7O[7D^UCP03%[K4[__G(#KO;,>:SW6
M>W2L?"YM-&69"OJ=I08_K >T,R_]AK8:&Z.WHZ_,E=35H_&:R?%"D._-#1H<
M?Y@N?+S*%)KOO&TEKL_#?*S%+'2'C<Y]ZGJQJ&5J?^WUQUK=G?1&^=EZZ68N
M70BG1Z>'Q55LKM1C3+W0&]4K]<,KU=2XCN^NB=J^<>2S\U.I=9T)O=7K..[6
M;*[;B]%Q>%\F-^%@>&9&-W_?^K^GO=&G6<-X=L,-+*(,KN39?,^M:=^U_;&&
MF..,U^G"/3PZ/NV/OG7+W715\E$OQD.\(S_X-W?H^@$[;M1YC '+^K&.8-U.
M20LM,BMM^4T5=WJ9YELA9Z-B5@?O>9(@O79>&1&8I2P".F[?;)?+R[A@%[-N
MV[N_SY5M:^UVN$\[O;,<V[O?>J_X;F]G_RWL[?]VF#\W_Y[?\_=+^?K)\_>[
M_"5[_??.Y_RX]S7'MOLN?^_[UT]>?MYYO'OP:O_Y^YW]WP]>/W[YX?7CAW+W
MZ+_O]QX_?_?ZZ*_#Z1Q;/CZYR_.Q[^]\V.&_Y^-\]G'G[]_?[^[_]G[G\7O^
MZN@9[#[9/7K]]U]IIW>67WM!Z>Z['7BC70H2I292*4N 6T,LYXZX%(4692$U
MA6;3+!6ZJXR:R;*=P^4NDL,+%:,M,9'W!:1W4!NQO.J'.Z6:ZU8_+*&^H9T4
M.UO><#U^+54-4PQZP?P<FYQM*5-8%0K]/$6AVDHF+8D2&0'%,X5ZA\39Q+V4
M2@> )MM6F;,R9V7..V!.#B()9;CS40('[ZC$R*('&H+/E'HY<\YCF%9:79!6
MV02M2D,5#SH1;QDGP%1^E/]$%+ 89 !IP&]L<J.[FL^N+*[D6LFUDNNUSWN>
MLENN,43*M*0.@:5LEGIIHY-&0D"KV>7L>IUJVTJSB]*LF*!9E9T'HS02B%@"
M #(2DR@2*I-G -YDW;FQR8!WY1+;%BK+M0GME>6NT*^5?6^DD!@-NJR(=8!)
M1V\3  O<N"NP7"6RY1*9G" RZE(04.*7LG2U,A.(8=R1H Q0K\%!<ME>7,(&
MW\IAE<-:<]YS4)AR5)G2"05,0A+".4?1<>T,5Y[B=PRU:I_=9H+F?.[)[N-7
MG_<>OJ&9UK26DEC+9#;37""6YQ]<LLB5TQ95&7@%LIM55'6$?TBO2QH-WGRW
M;DW!][<E,$;@65&8=^,NF:,3[ ^;?H(.?BR/9T9QS3-(L-5Y[<ON2\,9_W7.
MV_,[M\%-:?@ESGNL8JIBNO,10DHYGY64UC8R0..M2](';QAHXR&HZ:$78B%3
MY&%\=SH<-9U_^\=?:V5+F>QV_ZPTMBDG^:T0XZ,+O-@8,7LGY>'P.68.'?9&
M^ ('__0"/LU7Z3@^QW#\MM]\8K5OYK%O/DV%^;FUWB*5Q'#P!$+2Q&MKB;/.
M"&.DL49M;$(78#;Z5)FAW<Q0";R*J8KI#O2LI2P9#%$#*)#>.)"1>05.0Z!)
MFJIGUT#/3L<1N*8\:H_$@(T$DJ7$,^5(UK(6@Q5>QM@^3;O,S=YZ/&6@'6',
M;X/\+QR.RN2+X]09Y(>#7BC#+(;?[V^XL36#[>2[;U>?>U22,ZN,DB!#,@)U
M$"%*"3Q&3G] >7.7H1?FVAX.3S$^/AWD*SNFJW%U^O,ODFM>]O"#&\1F)-3O
MQX.$O=%I<_BU;/W*;+;[:*ILG0.#(#*7>6L# 4.SUP @B,LR%X8):HS/7*:Z
MQLX67EXO+-FBS,X]!_[U[-$JIBJF*J8JIBJF*J9[+*:E9B_;[P\5$[MIU<T.
M41B/ QF;_YW3D_*XV->=XY.S9"8.0F]X34?I'@:&6N\H78S_;)U)+U;/:![/
MZ,649R2Y-,B$(BE814 J2QSD7ZEQZ)U$BZZT36C;!3%;"U=CP.V&>@W5KX28
M6IL2OX2-_W*'I_A],JY!]RN1\61R6PBJA%&**!,#@2 X\2 CR1QLK#4TZ^!"
MQETE9POW*L;;C?%*Q55,54SW/KE=->9-NR]3:6KI0"=A-3%)Q.S >$8LXYID
M_#(+20"+J7TZ<\W2U-\)RY0)]64U0V?KZ.3P^!-BIX%)Y^GI(!RX(7:>'KI^
M366O2(3F7(ACJOO0Q\'PH'=21%C#-//PW/3<-4,15!8IB91FSR )03+O!8)1
MN(!4F, *RZFN5 M':6J28"5LSBJFMK#RC41IKFY67H%SJVUY)<Z=BL8 E3($
M3J36GH" ,J@M2RPI1!XYZJ3TQJ9BM6)HU9!<";>*J8II-6,Q52_>@2\R'7.)
M4>OL7Q(:I2# 0R1.<$ZB$.BXS(Z)#&W3C$LJA+ERF.7"YL*SCR#E];^HAAK:
M%809'>0S?WO0<2,R.D!RY ;OL:S,3%@@U>WTF]\ZO?,/",?#T;#\Y5]S8)]%
M@5QPDQ*GP#+88W#H''H/7 @??H1].8W]I^Y3TT2TE[ZP0#FZ1^7@OB!<583_
M&.&?Z(>OEN^6R)]UB'\\__3Z[WCB.:A\+?CN_C.VDX\M7RNQ^_AE/H?W<N?S
M^WR-_OMN]ZB<PY;8_?OWM+/_4.[MO_RXL__JT^[G?*[/WG@+.E%:UC K0P U
M)0Y<)-(9$"+*)'2VH^F#V3:B3D;!87XPM5URS5,<WPP".LHP,.F"YA[ :D?!
MJA!<=#1:B#]"UU*#@/D"-$_5II4Y43C5M,+!2ZHH$<IGW$1IB47T1&9_5%*G
M4(#8V.1 NYI"BW(;-8-9$\WW1DQS&#B R=M(,3KI(2DPW$;)(O54N\#\C_(P
M2TPTSQ)P=72N1,"3 4#%,D*=="2K4D6RDRJ)S^8K\<$D':)4R9J-3=WEM3)V
MY7!=Z;>*J8KI#K3DHF& JB7O7$M.AP.S](2S$8D(* EP([*C8B1!I;FF*!@K
MDT+:IB=O>W'E*@4$>_D19MA&-_@T&P<\_\/UXH!4!6<AA<A*;$EK4Q:4!2&U
M=<&"%C4.>%?0WGOT_3C@SGY^+W_YZ=7^#GNU_]O![N.W;.=)/N?F'+8^[CS>
MSL?R3+[ZO#L3!]QY^$9SAK*9L]Z8TV H\8DEXJP":I74TF5SFLD']"8"@?<P
MO_;-0* TSE&!(<6H0#AI;%FK8C2-AD>??E1Z4@.!;8#A9""09M>3<<5(H-(2
MR)1)O!6<4">SD)D1092-@5U):3??BBU*NM4$^I*MYP71/5\"O1K(UX3OYZDX
M?JD40T&404X@H2,F6)/UG@F>6F]]#%GO5=C>7]@J5-$&S:1E&CS5QJ(-&&60
M984&8'5Z6X_IR= P38Z#U5DE<TL)^#(F,TE/J-"8N+).VGQ;<I$5LJ@*>=60
M70L/JYBJF.Y 3RX:&ZIZ\L[UY&Q_;M(^NRW$F* (, >D:$>2+2(M,8+,QO&Y
MIFR3#;QF@]->]@>8#^,SQD[9QE:BNV]=KS_L9,".ZT&=/\02%<Y(&?76;FA:
M3416,54Q53%5,54QM4U,<QC822I+J5**2P<<A3<Z4F' I>1YI&SN^/'>Z  '
M94?+  ^P/^S]@]O]<'R$7^V)/\;FQ)-L3?QY/!SN]5]\L2$>#GK#_-1%X[O9
M>[#O/E:S>QZS^\74<FMGN;*,!<*4, 2DD,3(Q(@5CD=M&55,;&S*%E5C5*2W
MO=6R(KT=2)]VL"&@1QNS&%/2I4TD$H,4"*5)@&#,.>':A?4U&WZ5;_3.8<;#
MF@VQJM'9*J8JIBJFM1+33W-8:-Y0RIBVEB,'$9)Q6AI99CP+X82Z2K)CF$\X
M/YHKZY'5T=AP*S9:-;[F69*Y_W!TWJ5[9GRIF(2E*A$NO"?@3/:QI':DS/F2
M05GE MW8Y*S+S6R+[K\KCMN*XTJW*R&F>>AV"0YQI=O;IMN=<50K4^XSOO/Y
M[9LL*>L8)*(<IR2[OHE8+30)E ;'M<\NJFD7W][2W"%_/!H=']TX#/4W8?B;
M.VSZB-RHL^,&X: C6+=30+1(DM@?#R(.R.CXY!?Z(/OXG>'Q82]VRME<DZKN
M]!K-V<7!9.1!"DE=A,2C$4$[ZF-*G@6CQ9OMI31O-%^]=SH:CER_7-#:IS$7
M/YUST]=8G/5:AN!($!0(6"N(85X2B_D9ZAV3F#8VA>JRC!"N9X-RYX"Y&YOG
M.@'!J\+TZOSY!:;+3 S<*-NTCI#_=5-2G$-ZK2+9;W327(MA+VF@*253.!AN
M_=_3WNA3-?+F)=%)GUIHJP,Z3EABG "WD5@JD6C+N8*@E--L8W/6O*O<6;FS
M<N=M<&<*5F=O2TN+ B($;V(2VGAA0G3!I<NY<][J[$JLBQ#K[J1U*I2-3B=)
M9*(J6Z>1$V\C$"U4M,XS *DV-J7@7?V-+N)*KY5>*[U>^[SG"54R*47F49WR
M1P%'[7PTFI69VT8((=7E_'J="&4EVL6)=M*"S<8KIQ@H$48D D(HXI%GHO6>
M.V!..Y4M6*9$5UNU0)BR\ESEN57F.5GL1:8D9O,1DJ=>0J1<4690<9?H%7BN
M4MF2J6QOTF:DRCCDUA,F&250>MP-."2*>S0^>,I\&=I46:RRV'UBL7EZEI-A
M7LF8N$$(%+U!H]%S893A255GN"7$-IU*-II3#9CR#022@$F:N!@<H=:*+$S0
MUJF2JS%=8V=74U1O>)I?UZRJ>XS"4B=$[:_>#;&<]=$)]H>N80S\6!YC+?JN
M=5-53%5,-]WN%;WS"3GG*2;@6CCAP"B((H#R7IPW=L)Y=9L2= %SY&%\=SH<
M-5-W]X\?YNM:#L\=/G6]N-U_Y$YZ(W?8%)?\5HCQT05>'"_C.RD/A\\Q<^BP
M-\(7./BG%W#<%_8<P_';?O.)U<:9R\;9G@[X4V\4D\IDFX99 J 9,5$K$A"8
M2J"R(Y>=-]D5U+1H\DKEADKA54Q53"W5M$EYBS0DKX(!GO6L$%J %&7SGA6!
M5DV[#IIV.IK@N(#$92)6",BJU@9BM0Y$I<B$<<EBPO:IVC4;<O87#D=ELMEQ
MZ@SRPT$OC++;/B[ 7K-Y9O.5HWLEA>#9DPA: _7),\&\ITFP*-$'_ 'G+76I
MP/,ODFM>]O"#&XQG2?Q^/$C8&YT.ZKZ!.>EL9[J.W92YU-9HXC @ 9N ^&@C
MD3%%'J/(HH]E]6B7FH6G&]<A,BMADE8Q53%5,54Q53%5,=UC,:U9%O/R%8"G
M)^5QL; [QR=G&4T<A-[PFJ[2/8P-M=Y5NA@"VCJ37JR^T5R^T;-IWX@+&G6*
MAJB4'220-!+/HR541:525%19V-ADG'>9G"V+JX'@=H.]QNM70DRMS8Q_;Z?(
M]^FX1MZO1L=3.6[E@D%5ZO:23)F.+2-&64^T,#&"C2K_E^FX*[6N9+QB**]D
M7,54Q73O<]Q59]ZX"S.5K:8VN&BI(-DP0@(B C&1,>(=QA 9FFAU^Y3FFF6K
MO[&2JXP1Q[J3JRW!PAK3K6*J8JIBJF*J8EJ@#1[+_G!,/B9MP($S*FJAC)9,
M,880KV!M7](/7W?VM,( ?SG=52^"Y*BD)DPF3X!J1[R)DB0F#.7):<K<MT;<
MS=U47P'?1L OP;VN@&\WX*<];F1*18B,**O+9.#DB.,N>]Q26B.9E0&A-8A?
MLR*(O92PW/+Y7(>C8:?7SX 88%RS,H<:Q:UBJF*Z"W-@"1GJ:S2-?0VZGQ>!
M/2KT5S7]7)K^U70^VK@@C+*&"%\&9G$HT_]M()))9U DA;:8]K8=VTDJF"OG
M5C%5,;55-2[!4ZZJ\<Y4X[03G%4BLYI+PM!Y N@T<3)[PEFXAEJ4+"5HCVY<
MLW3S0FNJ5S=N5_,I54Q53%5,:R6F>4RP(!PW,47/I 965E.SP+V/03)4QO-Y
MDA5U;^JM6%YA>B$!XX*99 2A 2,!Q@PQ&I%81,E5Y-%0N;')==>PV9V$->G8
M6AQ7NET),=U5;KC2[2W1[8RC*P,/)ONX1DHD$#0E9;L%H4E12;VB@M-V\>V2
M4KZM7F9P84WU?T_[V!%TO*6ZLTBF=ZW75$=M=!04E08)26H7F;40G* B6X:4
MG>T^6+3'O:ZI7HB?WDZWL&OA& M)$XX*LCFH.3$T>:(5!B4YLD"Q65/-M>Y*
MQE9Y^\&<,+WI[3(_"/W?*-NTCI"OOEUFWM-?49+]1FW M1BVKJF^"1*=]*E!
MHJ*!16(=4P10">(211(I-U&Y:!*&%5]37;FS<N<*<Z=GTD8)6@4.H#VW(3^T
M&I)R6B!3EW-GW<QUF\0Z54'E-65@K<E,ZC*Q!H;$Q>Q+IT"IS*K00RA;*X3M
M2C$[8*G2:Z772J^WLKX5M4&6E*&*<=",&A.42&"]C-$X9B[GU[JF^FZ(=M*"
ME9Y*'4 3GGB99!=#MF4Y)<Q3T(F6!>1Q8Y-9UE7?B ',79-3>:[R7&O.>QZ>
M4U:8B")X%1(DIS/A.>"()@)+TN 5>*Y2V9*I;'I--4=GF0]$<2L(V%)9Z+TF
MQO+ ,44AE=C8Y+/+"BJ+519;71:;9TTUR.0IMRG:3&)1^,)C%I$RCE)(7IWA
M=A#;="J98;0 %HCPAA-07A%O,[,%9HU#!HPQO[$I0'<MG2V<KM[PPFNJOU?5
MW1I:O/T=U:M;C5.+IJJ8JICN8*JH+!5M,MOCQBA@D3L?O;<09 1M!-=GI6WZ
MO+3-ULV9]\[ >3\=[6=!<IZ2(%(IECVWP(F+Y5%*E'GOK!"Z+,[4=C8$5;FA
MW=Q0*;R*J8KI#C2M9YE4I4DA*@1IDW&*B^@H!%T6$=&J:==!T\[,(/.1EIH(
MPI5.!-!:XH0/1%#I3!(T!0'M4[5+'4;6\A[LI2^H7MTI$7-N71/:^"0"MY2#
MQF@<C2$919$;FFCZ >'5!=6MYK)W#Z<KV!7(I),*1(6H"3BFB0G1$:,X4T*9
MI%TH4=$NI[,5F'5 3+NA7^?X5#%5,54Q53%5,54QW>14JI:[0[>WG?H>1H5:
M[R?5[=2+.T9;TXY1B#*+6"2BI!<$/$1BJ759FE'8J(!+'\KD =%5?&'/J(:
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M\X1VI=* 4?ELLTE CPXC:,<@)0%4XW?LZ>M$="N%+T[ADU8W]UIZ@8EHRY&
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MLR81*Z,JO?^.>)"8;51FDX6(B67+E /K:CWK>U=RK>1:R?56UMUGXX?KC,.
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M,4&),]Z+&(5CRK1-*ZY9VKLN56NK;JJQX2JF*J8JIBJF*J:;$],\TU+0.2W
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M4KXI^9TI2;T'NKYJ_7"4I%;KE:CU(CL)D16%B 0)IH"=*&&0,J1 ,*4%%B3
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M*+QIG/7[5[.GP .NO//#:0Z0G]WS82XV.[]PFDU[]0/^Z,,_T_O?;+__8_*
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MV=[OU?.>2E[DT4RU,A9V]G:[N?AB93OW&U-9OVXN\V#"(K6D(\LS3,BR7CC
M+'AO4HS)B";IGU8BF4QM*O77&^:":YW.'#+G6,^YZJ:I>%BOG"+3&';[91SH
MW#)4"<$$J;<NIXFO%VR5B4J7T/I'EH$LT:G23VD%;RZ.<+G<+^#!G#*5&[NS
M>4SEYT+VI23']41L9TO;-QRPI2.[=,-^PR<\[>IBV:*JG%WR"Z5R%^/NN-P[
MK5HSM\E1.AV23*7CELT@Y>\DI1P!W);-A@O^--#.P7EC85@GKIK)"GBI).RL
M3&*H7!*5%Z8-EY2L:WZLECT["S#66UA\TE"5.10WV F:5%)<?'/&CVF:TC<
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M(HFP*',K@K.$%U(ZY@S7]1*]QCJ]Z!_5)!AJO$%1<(&X)04RV!<H2NM,.B?
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M_^#B .]];(KFQ9_'S1-_TMK_)S;WM\7>_H>OS?T#N.<S;NY\_B2$-B[ V*N
M"Y0L:P1<WB,M8)9@BDS0M*3^H&G!;R?B;IW&)D8JH_:@8-(4EC);,*F3"4#=
M1B, 1S^%"03E#==D5UPNEWM9I.^+D%U9S?6[O?S94K\8A;(<K;*??G^^DGQ
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MF4MQI8KUP(60:FBMH74-H+5V@#XXI)(E2(U"F& + ^P]6,2C,$AAQI$+.KC
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MUPXK28!HXL"#X=HZ$:S'#"NF/07:,C=N+HUKAOSA**=PFT8GC$:P8,#O;A
M>0'D,TZ:+G"6O+K\S[J5D_DK-WFX%U_E%N^-1\,1" A@Q79N])0-X^>FI?NO
M+SX9&'B8>X.B#"2Y63E2F'(4B17:\6@IU8#L$F_B*T[(:K2'0Q"MM$XG*>C
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M[AQV6A];GY>=>>ELM>;%\<G!B1.MBW=?6SOO./2#-=^F\]+@?1>MSZWN!W)
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M?YYE_&PWZ3?CJ=&8I$S%G1 WEB(;*$6$ZBA)HMQHDS/8N5J6PNJ:0J(&PL<
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MJ-;64ZP)!SUKA<#2&6<D]PQ^KXO GWG%K4]!">80%A&CW+D.6>(88MH*XKW
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M& $)G,U7]*KO5ZTQ&SUP/"Z0Q)P]Y!*YPCDP9TQM#RX/;/*T?CS*Y?,9>\I
M]_;Z<0_&T[#=S+DT,12'YZP'C:-^Z<?=Z?2\'3]R/,:S2OF+_:V'^W98D4+8
M?L9M )81W&O8'DQF]!; <@5JD$ \"8^(&E/:Z(EPX1)5]%6BGRV<82L._ZBV
MX+)'&>X! &?]>4^;!\V?S>-O&!O,DF=(8!81-]R!C4O@G^ 8911')B18/.8R
M%$RH%XKRG&NIDR#1$LMM5(Z#)>Q@A5U4W%NAC=?54F-"&7E@%7#=/GAUBN#@
M+6[M?=,),Z>LA,46^?25:F2YRTZ.YM3JJ+0G*^MX[?+B5Z S4089//NA@J8Q
M]=Q@;'X6PHL$'LC$8WX:#LJK\6FL&VZC3GXUSD?'T0KAGW.FKM$N1=2?<V8N
M-!)>&\>R0!EG30Z>3N=D@<WJTD5\8S!E.A_U>V \9.\;3()CVP^#1J7FQQ *
MF^ Z&^%Z9IW*.@<_K]TMV[JB] %[K >NT_"B_],O+4A+[_&4LK/4C_\S:O<K
M V7"-O5+2Z5KP><I3M/$^,M_F=#Q@MW2AA?UPUD.H?SE:=<53*A1Q_;A&_&'
M[8SLL/+)\EW!N3J$51\,;/]DM3$Z"N7#<P:_6[W91<[ :&&<5[_1+Z9UK;'A
M,\K!33LGJV=OE-\W=4:9E',X!KJQZ5GQ'N:?PFCLC_]H#RH#KS>[/JMCYL$2
MR3QLV/&L3JSA;K29K[9LB/&>J8@]I][C-ES'XPT_WI6<KJE,)734&Y1%>=./
MG4+?=<X@]+^G&5+'_$/X_"O6 82.AM=_Y5(E^C/YM(3/3-"%?_?[YRP&>Q&Y
M?K3?D4TPV#>V<VQ/!BO_GH83P)*9.9Q]_6M?,J5'>\GJX"5D=5S6_$W9S_DJ
M&)-=F+$T]OO9#OS'S:3;:F6]4,;EG9\-NHHUV%[F]JIF>_T_KO_O]:N6^4J&
MKR4C!RXJY!RLUAJ?1X!D%5* SPUC 3NY-\'<XIQ6+N<U#COXO</C'+R:>.99
MNV?7O+ +G_O3DR< &)U[S>UNQJJQLWM+K;4 ZKG<\?;DO7_"W<#7K]E[?\7>
M.YFDPMZ[<FG*5OZU.C=G[VTH>_-?LS&PUECP1?ER9E14K-UCH;'G%MMDSBX=
M)]K,*5I1BJ984'"N \;$)-;&"2$\UU'H8)3'6 5"B7:J'#<1,SYN(N:>#G=]
MW#2' W[Z$3<_?F-629&C+8$3CSB1"FF6F4&I!$6D4L*$SW7 B',X)<%=92+<
M:N4(*#:!#<9:)S!\J^P=V)95]DZ]XD^]XL)H+91DL.+6(4Z=0H;"!O @FI@Q
MZ6BN(">W.F"<#L),,B92NS\ G#WNG;.\%I_!=HL&SX)>M +\?.9-%SK5:42V
MF?8WX\\U8%^YB/!W4/''O?[W2>!]N-_NATN/7BV/G(:YWIT3)[034M#$B5:&
M2V],8()8S06ED5'*Q\?H='*,3JFN=_D3[?*=T];';Q@+YYA***?P(RX91=HH
M@F+TU#HF$C-^95U<L<FOWM-7;ZJS#5AV9]:/L*??1=<?Y=R?R^?CE?%:W&^X
MPX]VB.>W/"?C+I3'8WOD MO_%./VS7U*;D$&O'!VRL*11E\R)<\S)1Z(,?K6
M=F/-W%PS-]?,S?,P-]>,R#4C\MT9D6OVXIIKMF8OKG?4@DX;G@>L7@@K<+OK
M1OU!98>/[?N:&+@F/_IUP8,6W/$8F2PU_4*'I((&%Y\S'"A5-3'P@Q0<=IND
M];YUT-S^U&V=>AC;1['3_;O=RG_??'?0// _=^B?!SO=MR>S!8<[IU_P#FW^
M;+W?8:W33P>MS4X;QDGSWYM?<ROQ=[DM>7MG^\_+Q, 8<^^B=$AQ+Q"W0N=4
M,H*$MCCYA$W LC!WU,3 -1"^:B"TBEI/&2'2"2ZUU H;+X2!/P<E!*V)@9<,
M"*?Y3TRPQ!&A /DX!B#T%ED9 B+*:\.=("FW#R6KDMV;/*$&PAH(EQ@(4Z#6
M!8PI-P8,0VR<98I1EB)3"1-2\P(O&1#.\ +CY(AS 1:$$L23!2!4"B-B= R)
M21XM75EGJX;40%@#X6L&PD"HM4$2%JCGW#"C<_U38LPY)D(R-2_PD@'A-!>/
M$%Q)Y0@B <=L$2:D0=FAZ(W6.1& 6YP)THD42P*$KX%N]\O1=/_V:^*<-5W8
M6<(A@?T,NU5S2;A4Q!!M*,=.8Z&UI#=RV%PJWZV!ZI&!:I9]U\3 ?6(<!6/
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MC/' <"<3QV<FLWAPD[5XO8!XD *B"]5XO8"X&0'1#J*,IZ'OC29\X(!<AS]
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M<R[".4C9?H9W=[@9X!O4LGD=UI*;$I)=RCSTJ#B(O2H, O8S"A=8JSXM;G2
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M@!+(7=90YQ=2<'QZVY(1ZVS\^:0VN=J %"PI8IM-^&T0(>O+DHZMJ+WZ2<[
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M5LKN(O&+5"6L]*:R6Q6 X^EX:#4%X"E%#RJA#%H1F!%XJWHGU52 :*>H!/P
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MFXNU$&0>H6L;5C<7:;6*'ZD; KSX2BO)] DZ,7E\TCD7P?\!AL.7&^Z'\',
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M]GK+ V<M)VG=\J<[)4IJ;[4WJFS^NKW#LK+_KQR5GUC=C<J_D_DG]V\@[FD
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M_L@+[5E,43*AGJ]HHLF.[C8@/TA+'*2SVM#=?*P^V?5 TVV&N6;P[%J@.8R
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M5U)(/@D?J>^:NGMBY('FNQX@FJX\_:U'T9VE%@..^M:VW44/_.>NT7. ^OR
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M*Z2<HS'])Q>.G0A9Y @/J7K 8*W$;8+@V2QM5]Q2!:/U(.+KG^2+E4RD2#N
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M,^TKHE*$V8#)&NT,M:^T6?$DHA:/U2)P()BX](N2CNDQ.KH $IP=%T:"F3-
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MKYZOZ#9,,]KZ2B,5V>>TSEF0!<.J_ZFN+1A(0!;#9VD8YKS D8\,CM $*[!
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MWK&&[@AMXC2/4!>\)#<%],ZK\R@H9C+HT/RA#+,8]4^8EZ=Q66S_22.@@H$
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MQ):!F>IU*YJPR(ANE('[_4V(+=6@L=IIPI&:Y:0%3#I&L@)8J@H41+(4@2I
MC*6> P\D8!@5HE4H0F<6+:C4/\WSB+H/;C[NGF; $19R7$^=W*_9\S,U>)1I
M"_-U_<UK_?WL8O6V14FM*+$U)?=<;P3699O,.H]=HUYGZGX\4I?3^G7>*()
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M59UF9%'B"DL1K5&S3W>.&W9'\'^AVR;"\[XB=GP_Y]@^5US09"Y/)+A-76S
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M\^GC3./UXC7+T+KPR1V:U0T"J..RZJ_*PX$=637'%,04QA?,$6Z3<[<CM.9
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M1LV/U09HR[=.D72<B-,8U8REF& \N- ^&MPG'^RZF41Z3.=Q2GV5<]2FBH2
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M]-LN>RK\%=8Z;AYA,AA \N3;1O$'*6?G ZLJ2J[.<OYE%@;0)#I"7&[69"H
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M3WTEY,-#LBW>)Y)MOFY$!WO&\J;>?>V\08*!$@YJ;-S9I[8*]?Y8P.[[;PL
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MP_5TL-U$3R:+*YQ643-IAS!FS0C4((R>/"SH97@91UTXVK?=LI%4BNF0.G%
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MQ7GP@R926>B>!==^&@8!"_)SAOT8?/F<L;FK*^&E"K[C,_+M./D0-F88$$E
M@$?%A1"ZZB6#U6BX*\YQU E@0B;BW<TR%(@Q+09^)V3Y[N6X5D77;-JX2PP0
M)ZC1"* #!82/;E53&2G>[GT7C)<U<\! R(.YU+4%0@Q%I+R/^S0^O#FKR%\
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MR\Z9T&8K;GGN!+J>PKO]O+RJ&2FD9_Y#\'*S\<A>VF%V+$3GZN+ J8(=>\>
M9E4"*.=ZJ<#@^^V4R$>G;)-BZOMH_A96N+Y,B13A(4GP)<]QF89AX<SU;C+7
M2Q&;N9/&8/X>_ZHJU5Q%?"H!NA+@[YY*@(_B69Y*@%B/RZF-=>*"(5606+#*
M&]K@F9V('M3AL'H?\UZVY9=(9*RW@P4E+/U'^\&= 4^*MC^9\@?8:YT[*K1,
M=9(N+H!X"\<'4X8Y7_I)KO;G$P]2<!$2>"?ADO/^<ZMYK35'J^1CS[\%+WM<
M+_@I3P)0'W(.M23-L%'#7"&M=X?NQ=/$?,B)<02]%SS[&#FE[%,Q!AJ7BP%/
M$_@A)S!)_U)6 FF]'!2 % 5QBZTVU0F];8M)]">%L@\]98U/^WMN(J23P9TQ
MCW.+*M*YQX/Z7_Q=<&#""^QF%%4?0Y4U9?:^4)X1+$>X"SKF4\N5\&[L-%?'
M/3/(2H4K-E+.R #).(&4>).HMDAN")""GFPAN9!U=],,?7<P:,H!+4.MU<NC
M6'RQG'Y7R4^A)Y%01.I#G)/S+[?.<[':_[:0'W&D4>1:+<(YM'='"DMR4;T@
M*G6D;J\@"KMFCU24D.&M8T=PU')])%3DEVDL/46'(P'[[["V=CVJ?@?DL6A_
MXPM?3L3X&YXT?)-,;T?0GHD*/9^]6*\^_>333\)8[D,H'E8:56\X#QD6R.<#
MT8!%/L4Y#I.51\*_OP@.+J))O>1S^34(^X!"V26T06)P"O7(_5 =:H)RTG?X
MV9F81,6UUO[2G@LP>=EO:-VCY?;E55BL9],]^?*;E^O5H;])8"79($K _3<0
M\K5DKZPRFG[3G@70-8!M',N'/%.U@U#>21F5"2DANW($$)&JX*LPU>_'1(,T
M/"F^_,U?OGWY?/6Z,,K%%7 DBHL=]>$THU16KSCXD(8$Q6 -U4YSL]']S:J;
M>([GWSV/_5&4R-<U5NWZ(R^R^+/PTG5%@A'A 5](Q]\==V)&CBGV=[L"UMXS
M7W)B?MM?=8U!'=2^::X<]P\6[OM@;L==(\PVE'N/+2'((6N%(C^Q^%,&9,U1
M'"!TG6E.WO6&:1V[S*#M#U?E 5H6E<PF/7S^G[K T_TN/9F,JL@LLE"AUTJ$
M+CU#S!_$V*Y1)V3?G.27QD1O9C_,'=?9%61=**+'9]#F',:L,:"8&&5+%:B+
M;YN]Z6*U*J,N=[BY5NG!#,1+Q*.9Z-4[9ZC::ON>WGM7@R=(&UZ%.EL!18ZB
M3.Q#QEB4B[NFU$ % *7B[&:8A[O$1PT%.ZND6+]72T-&VXBWLI$&[(WK7Y]-
MWNDN:\UM6<0R)54]>IWW<QE#H,A<LU.ZKV3D<G6!A)1:"L@ 7EL(* P]_!RY
M**RA#A;ZM^[HW2JV:<&,%+JZ'H<[\>". (/>%V'7JFJ=,A\01\:V%JBR*XE>
MUT25LZJ/C7B?L9,_& V49;*::AGCN;A]/=M7G)'G\T+9S^.NO;Y#T\YC7[/-
M5QR*"'**0TK)0_7NA>R$O'0 Q%@RP&&C$H M67:"^X[443. &T*F/AP'.\;F
MA*T-ESH, @':Q0R9C7=Q3C04AO'S,_+W6B$V<Z2_NPJ/B"0.$KH7!S:=G\ 7
M1BI;@_R*O/;XP!+=BH)PR4BM*Y;)C90'#^GZ*#9\ZLDQ-R;!V64-[W4Z@G!W
M[Q@[-P,1PDK2#/U _GXF(-%3K!;S+BF6-YS\D+3B$RE*W<0QB"9Y(E[N&X'W
MD^^FV&MW4"U+UPE;I/2OU1Y/_K !+W9E1:SRCYZ/'U=G^246Y'__5)!_%,_R
MRRG(/]"YF3=*D'&C8#98_;;>3B2; *U:D*";[;BC;\N283FIKEB[1N2[^'QU
MB.KEZ\9KBA-^C\1:C!"6+&V) R>[F "LYI&ON87WO3/?+Q+!-WN7?ILQIU#S
MYZD_'C^*+-SK!=8_ZBO,A4QB:X."^V<=&H7?Q$6XSA1+F!BUM=J6L,XX;."!
MULFQ%7=<M2[*J6KJT?'@%*9OR< K *RD&."%3K_P:H670?J/6)IRP@V1FHG+
M@I==TOIWZ>D5A:[X?N]'=N7' X112DX?P4K[YAX+1=9#<-D(,M1(?*_K$X5N
M97,-]ZL.(KFR!CTO^TN". 2U+ 3B.-W:MI%B,ZF0ZP_7$BG$;U!^>ACZ 5&=
M@FRWR+N=F[JEYJJ;:FC4B$0C">9="H8&JKYOE10Y-:AC>&>GL2;&57?6\]67
MI"P;7I ICQO)+,##[)"U+/?;&&XJ.K6J*^/NHL]O*G(U!VLQIA4[Z/QPV/T0
M=0S]IB$;>M,,3!TI'-E^0MB J-XJ[>O3Y5-" *.N&BYNORN/ [I:<S2^X8A0
M.E] JWSB'+XD])6 #E EI8-27K=#O5.UOF05S94<"_O<N>R%%%M"P:]8MUW-
MK;?:QO# H3 >?=##I3AFNGQ;W6JGMC4ZS.'=5_18X&J&%8SM<V"^J\-1_C?"
M6&N^,AS932M=#TPSL-5' 0)Z*UU( -XC]L[[R@8E+:+K<E]&^K%*=2:O]1%8
ML@+-!]IEF'DXZP%A&2C:[;D)+_@PJ3RH_,HF,I$I A23Z#AOJ D,DJ[&[QNF
M,)C.0U1\P&&-JSV;CFO[2Y@X& #I>2?B [-FXS@I/T".FR<%:^[],YL(QX#;
M$J1;O%'JK81Y0.Q:4Q!X57_M4OO&!:%4HUN9]]1GA5]I08AB9K$G"@6@7&6,
MLOI9A^<2HE4S4^7>!-<4T7 &N,C@H5@#3E 7N 'C1+?5U#&9GF^PY7HRKC%3
M$&/4@A7'LV[,)*VNSUI^RH75NT]6L"15UP7&::V96/6:J>!1T'8JY9)H^QFH
MR!Z-N7DKGL)T# 9TKBY8;KL%[Y#Y'-*1KFG(4S6^7]\S)$S8<[N:+HX,7'4T
M00AKG:V%"CJM$97$5[)..G9Y2ETRU2[L@ J-P=))Q\SS8LONT7@L]:X[W0WM
MSE(70YM ?>_GK($T>>WT.5SCGSR2YVPBDHZZNSI=G_U[7WIKA$9WO_:%]*2<
MP<40)+Y_<)7<**CT9.VZHHL72!N*]]E!QMXD6KM.;*1CC=QUC<:*'KMNKNZL
MDI6I[9T^A@V\K)4#A1P[<^T X<-7^LDCUTS6LW_Q0%SU>=<=J)"H2)"RA]^#
M&^6G@$HM8 !RJ%1+/8T%^M<NQM&I)M]]L% .,^';YAVPQ56D4Z)08]?)Q15D
MXTL4N?#<3C#H%*4),P=1>V?@F6<TI<K.B_0"MXWR2:"JWA;LX,G663<Y=B -
M$#1:\S$]%4K-*:U__I/(TK#(6#I*'2-YF]08S!(9]UC!:9F&R AA%;ALOD:(
MUS'S27"W3A5D;\A'E6R "W5IS(GG6_P51NYZ\BN_/L;Y KG[84VK##0I?':&
M#4RX@?B<+.;3[_>C-+S2QDS4IHP""6K6Y<:*9(Q8?4L$'N#]I6[KVHFWT%)$
MXHU01ZE#1J<K@5A0/)3O90=X9&@DZEHO)Z/CS4)*+N-!176D <@0@(TNJ=8)
MH=*]>K[8?]#=?#C6ID1PES+]0XQFEL[C"S[$(S47\Z%ENL=_H+T<T>;K!A*N
MAY\ 64UP*[ /N/;YOC8=IMFAEF:QPE*A[!HQ)QU[P(AW CN.=^%^(_V:,9\8
MY1$W<L-Y%@TMAH2!UH-<*3*J,-#NWCAPH:HNQIO;O/U32@/T:A!O-&%>>;YZ
M"R=)7I/IX1'+->/[591 L$-986I/!5A7@/W#4P'V43S++Z< >W$],A,'J_!0
MWI,;NVX4E9'XP[;S<5PPEOI"IX!P?1A+I@)#!.*<$NT#2-,Q_J^4?9$>OYEN
ME-(P-<-V.AA'J)/$6PXHYUJ9^L@?N/=GL2)>GJ+ZA]5-<]/_? U)_^O_&HM;
M(\Q$40D!WGC;TI0ZKQL""*CI6!1T#(?9P,J;[*SA^.F99Y+F;19EY$T%;E:3
MTUDE.,BK(T+5)-SQ9_=\QH-7?6MA3WS!+.^HQ5%"S3>U2P\>KXG^2RB']5-(
M28@\8"4!C_@$^06I-ER\''_@KW1248]'Y4:5,1S?HF#P;<28?AWL"]8(<?>\
M0?7R='X4[_% =,K71?EG[4?0B)=M9]T!6D\[0+*!)Z'^T5265W!=%>.@]?V<
M_\L<<@6-FT<Q]G?B-]0=Y00!)U+@GG<+D!@&7PIE!X^[K_TRN25X/-UZ/,IZ
M=*(KD:?ZF?#5W?DS3(/4KY93E6LOR3/+*-4$XN0SE=M51G+B3UIA4<I'3ZH%
M&]MT>S*!ED&1>QM=H#RAF&OE"U?!]OS78JCR7]O[@< __.MM?3Q)L],G:'9Z
M@: H..+@-;M%WDC;A:9-VXS7 H29NOAO3?U<M?T&39#8+)Z?P<W'=\_?/I?T
MP3/\-W(:G>HA218/:T0NM&\H2AIM]XGZF.CJX&6'ZHB2 V-A)UIHU78@2(:A
M="Q?]:OX+.4)_G4FED",:SU%_E3)#S\=&U*&O>V'=G=+Z4.E0RPT=;VZ;MI=
M<)R,<^H;::1ZQ8QMK_KAZ*7'\9MO7KU:O=1K8=T09!ICI4-+/I@U .CP)]^(
M@Y^D:@_]CBFH;?2.?7L^$J!E!Z]K. .0$@P3&<9= _EB&M40(2*_<OD2:\D=
M\),=ZK \=S'IE)%[54BN"'Q-ND=MN3D)PN7>&^.;VU?CM4!HE-[3 -YE9C%*
M@3#I5X62@A:/>E&BX);?^5)>>TZAM9T0]-JV$"B?+&\D15XI6CO*S.*EZ=D]
M-QI7T8<"M5Y8HRA6('\18F@6-$ODD#7=QG)3>WTF)DM/1]?:3?+Z5S NQXG&
MC5I[I#YRZGLX-\YHS\['9,JM1 <SI @II>8-1I'<-MX#O->M#$H3I,FQMFQ9
M])434M*,W%"*SI'*3M6Y)%^/F3(^?#AZ[O?"BT\CL)8PRI]+R=.XA68+;.==
M"=9!6^)'I"?;U% X#^8!I-N9B#VM:Y8BD$<@M*N"2>W>L2P>%LQFZ*N=/WY$
M"@<C-8UJ"!W/+45K]*&L!,Y1096RB[H-?!;9CU0]@%$.5U.8TO .]2JG-U9K
M59I++-N82L>6 9#G"A?;Z4NO9U>5X'+Q%S&CQ6XYFB:G3O%:38=2)FM,RDQQ
MOF"(M[K?/?ATH3BW:@ZR/,G9+$\),&@7,KZN2G6H*ZK#D"BG]T-5_M/)AGJD
M%W:8[$[)M E\U,TWS>2\>(]XJD.!B8O"@H",M7J5/@!B1/2)%-0=%0KW0OCY
MCXF@;MJEE)=5Y9V6'!]>K)U@5OY)C>ZDO7!>Y?*9K5$K>]947VW',TVJYQ$)
MF=/Q6  >*VAP(]5OO[?=D2$R#8.FX)D]5RT0F80Q]0^EI2S1\&Q&X AQX#0C
M\OWA:9'7+0[2>B4]\O?IX['58 F6QZ-Y?C<J_((1D7)V6%IF<JLK(G#._6[1
MF]3$@YM_[%TVU9RO]]>?NE8K/8Q#K/0QI#0>SWC_.W*Y&5K.;6&2EL\@5'I$
MBQH#T?O7I,:K.CZ\H??-@#.""W8@"VC:^O_\?R]^]\F?JI(+&(QRE $E;^#4
MUM8\S=]_OOI+?UO#9EB:YQOR"?BR+WY'\<&+S]99L_C;DT'<Y+$$U=IQ?C .
M)?T)[=O5N/@(;RBFT(&FRK&@=)N8"$S('$X4!C'D@*@UVNHJS/MU(YT *G0;
M+\+N:3E F;^5"SL]SP$;@M/Y2%:RY3,W!D.\)E[\@8?M$);S-=6=Z=!AYV8M
M#EWDGN=$A+BMSM>(XL$$*59\E/@[C&9@IZ4?!)WI((NF$R.F#LP8]548-EK_
M7<1.^(GC!O+K.D[7Z#>#Z';SZ1?U@]1YO[@OUW:6WM8?Y-EI"[@]Y ]);;*/
M;_41V+EWUQ+TO8E!WSLZ,LA2KUZCK10#]=W;-^]>\\K6<J.RES*N&FBWZ#U?
M"5Q:TZ@YC+827'"D+E6F$(+6*W-T.':"NU[3WCU;9HLW"SR6$8O')7;CM&R5
M\$' R>$@FN(V9!Q:UW?NN<@!<4P.FW OIE_B1.N1$\9F^N(B<"LPTR''*6#X
M#P;**5NA_%A<#XT8ZK:^(3Z$E//D:STC.B;V6GM/3-359_*2\<"UE#.4QQ@B
M%*6M$3EME*J&C 4393A= 6" K+,=:R$A(]<AD3;D\#)P6^,NC1!^KE#:):>N
MH6Q;>^:\)K@KPFN<.:?OZ9',[9>?N.0(D69MST+7$6^*X=!FJN"NG&K5( P&
MOC]*_A\>=+"*_2V^3Q[G/?Q6>2WDN&AJO";,^TZ*!;N:,BQTF^@*JKE0$_M4
M]'9%[S\^%;T?Q;,\%;VQ'A$^PCP6DN674A2^/]0HJLP44GJ+6K-<'RC#W)13
MC+RV$UYDZJ)-_!@Z@U[302HIB[5(UETUU/$B2$UV4MG<0C)",APV.%Q[/8 L
MY%AW7(A04R9ZCL )D&,RU,_HB+#^M?"]TS.^'HMIK!]9C1Z/#[>@'G_60KT.
M3S>UK2$DUYR8'IH;83W;:O!.!7.X/)*DS0Y\@DPVX3$KJ;;7= I349(],_:V
MN!TQB8[A<E7DA B@!(&/!-+B33?PH#"I@BQSMT@I5$PB$>C\>2\D(U4<:E>1
MOO*60*/G=]!N4K0");X#PC]:R6FFSI)R1/U_.E7;][07^JCYJ2XF+(HL^TW-
M+J-V.^S82^TY/2BNY)IG@+YY7;>[-(V8=F_BN58S89U[R9MH7P=YJ[N&.AVU
MI7P:K1JH'CGW()24OY<D7I=%"9[X?_]U_E_)N\>.AZ%4F*(8?(WL)M#.;>N*
MFI9-QF*O:-\D.UP(H0H+9S.=XJ]9'=$2F9:G,91*4KVB"@/+5$O(_T3L_2%7
M2:0'LP2)D8+<Q9EO:^-R1B=./4@\I88BA0U?V[J49WU:&Q_[VD#&K)A"1[J4
MJG[E8GQ<2T_3_>\\,&BD1( 68K2LC:;&GSRLV/TR0Z;M)I[A.J%&\E\JH(D4
M:+,$F7J:_P\J;.2\Q+/Y"MOKX$'6I'CJO51E^;%/J3%(@@-I5R<0DU5#??(/
MGNTZ*6-RXQ?60;U[FN4/*U]USL_>[&P5]B6IM\0Z"I:$ E^2SEFV&0H=F+2_
MNCM;=AH)#4)M2T<BT:6HG=G4;AG-BNQ/J^$#'_%,>B/"EQ&07P0K-+6+"F)N
M_6F./N0<^1#),+5Q^^1TUW0P?R"*D"?1G@_N@Z78*BTDT31-GJ@[1TY2@NZF
M448UP)H!8S .:+D0BSG/ $0)X/NZ[I 0X#@.PA#(B[7AUE2-=XB3>%>GGNMM
M?D(;.3*'D]#M?)_WPE.!\F,HE1OIYV5806Q ]TC0)-Z]% PMM0/D*^3.FF^:
M#IR1XT?$UD_/*)0F X4&C@IVN],UDX,.8'Z1JK]61,61@"^0.9UE- T=2J0/
M5'?DAW+UMZVC%J!H60"Q)O05Y (1("["#D6P0V<0Z6I)=891%;_'VFM2)@?*
MH2K@+P;$\^E['*O[1[<P)8Q8)VW*--&)IM)>N$)#RHRX(#$3"@\TUA(JLG\4
M;4=NB:OJB<MA93U<]VXWB&P! &V33&PVGK&OQ(^_=LO@[F$'$0+AV75_"Q)0
MX@/I3"LHTVOW=L5/"9.U#K5@8_HNJR4(KF>T_DA:*(7Y9R.D+#"CT+=1)X'T
M,\&M=*:-/1R%T]'W#Q:,S*YO -\4NKIC]@U&MNZ ! :CAU_!R65X8=YK/+42
MLSFSR>6R#1%%]=TSN2=9@?R2@%IJPXT2$\I@WEX+34K%?6PTH'30TFW;>G=5
M1TH').$.Q[8_U\Q.R+T]61J.]MUI!)US1#)FWWCU[6M<H$3'N^;:=$L+A_",
MNYL&AUV$7V7-"W^79<NG$,9C]O*=!V@Z]-1(,B#LSF3CD[RLCJ@^EBR)3<O$
MIE@H_M@MW9_OM=)F=DM62Q'KBWH\-GPM/A>9P2-I;M<Y0\_D@-3VR:MF*=FM
MPJHSU(#SK/QF+NP<4?HI%&^TB5$XTH3$1CARL%#XP6ABOH33QTU5*+_HCN-T
M3]@^!*%GHELAE)TAP7=H3XX/1R>O<=ODV(6<X5H9L^4PIM^FH(;46V# *B64
MQB=HE#MO?O?)$S3J43S+$S1*@"P+4';U=10:.@>UPT6G@UOJ2%.G_U@ZG[U,
M7<$'$'8^8I2L;O<363,VD6S,B@4-#C.\X\$$D#%:ZOK82AA[JL,AXUK:F,PH
MZ6GSH;/0@M9*'CE%2:"#@N]9C1%76J_8Y0'W4N%$4"]$PZW2H:*]_!3IU,QB
MQS1[,F%A,*80?Y'C-?33U;4?G919"IY:;)6@L?\^/!0E">D(W+:U)0Y(A+,V
ME=;@/_1=5[?,&RJ)@VI;L603NP'R$,X[49,<ABALEC$<;=*+H@4C86)S4H-+
MW5QQ0KQ^H8]BYBV*81K:OCD5)C7#U<3F)M>2'W[-[[7:D7CBR=[3=YUKJN.^
MBSF>R'3F/V =+_GT>9CU\V4('D5\]\!X^#5S$UKB $H)3C>/H6A)V2Q/%BGK
M;II]$X0.:;U&/@)M'::UF,N+NH[9G.DC2R&E)'Z/8]@OXT<'*(4FI N2W=PW
MF[!^&J6+W+?5X< <XYO^MD;("*)1HZ/3/U04>C*[\$I=1.JH"D_L[,^>%"&<
MM)WT)^QI0]$=&0:LQTJ5M()3$=074<%N&'D<5IMJ1$M[PIZ@C!-.8I%F[INO
MNW>K-^%/9-)#%,[-+A<@,HLG<?C@?:W"MS0 W(M\77/GQ *V1J*$ UDHH^12
MD@7N.U%+K9M:" MSMEZ-X<_K]&!A\I6$R1>Z3<]4MRDN@*:[;C9DU)Z%(90>
M=XT_C8_CD9B3NP@C&15#L,T'O+!_3<.Y,D,^>A+7Q24!\:+:TTGBE+"3*$/O
MYBO#==E[H>]J0\<PGQEI-SI8)Q0; &['70\&F_"<M]=UM^;_P$;IA/7WEE8?
M P)GZ%&?:()I/)'RH79]&@OZ';"15&I!2QV"3#1<JX<RA!5[G$[&7-?6E36/
MWH:8JNX<7^_E.[^&B.%>*%L8STP[2M]DUE-.KB*XZ6XDF?R %XT*7.(C(9VA
MPES:@>?5=B,:^G32A(SI(808TK%(_;M]@X(TF= [L6<O#K4GC3>2!<62I.;8
M>'$NLSG=UG$<N:7;)V@V9\/ [T!Y0)JF5:1^1JXC(W8>9D>SU-84^#1+ #MR
MK\=AU!ZL.+S @F-^^L5U+#%)/YV<,7H4XW#1N'\E+==&)D/_P.[?J8]66QI.
M+6=2\7,AY*7CO-0F'KL@S;NO?SA12A";940,I4H72PYI7L34OU^<+9UI8$)C
ML[D5H34%/7\=\7@WD@L AP8<I?E%T+%:&A,<&ME09,K'%XJT$N&?HD<WJ]QD
M/;;A>;6&H'RF#QU--\OSNGE.>K-79BF19B;!YMBS.S<BS"==#P,];X(!P+L6
M7F^#T[PVRB5P;$;%%-24A7<JYNJ% #.R*F23\BH6<A+N^B0/XLAT[$O-XFQZ
M#,,R+PY5CO"+'[7.%RYK'0N>&W]Q0ZAOX?2"7+;!E;A2V ;7%9*7YR9"9K<9
MS^.IYJX)S:W9]EBS_Q#FJQIHN\OG":62?14H_>94GF)?;!>-$]V"NL^#P]0'
M%^*?RBMR.A\OT1WZI98\I8\3<@E$ZF^:"2/2:#3JY<S?@JH>TWB/39\F\LQ;
MT,25+!PN#KEE%?53:0KFNS4,^$W3MY5WH^)UYBQ#D22EB4QTV?2_<0UH;I8B
M+,+Q!I0SK7FSV3AMJ*'_Q![9>)(RU0WE'.!OR1%Q[SVCB;C4C62J**R/K-H=
M74-^-*)\^U$WMJ5Z8D9Y8IJ:=<_UHF,1)IS^V57#T-\*5=&_<-<LSHI/ .1\
ML"(Q*8-W'/J;_GW>]7CJ-=FC[ ,2(=QG%2-%<?=:UTU+"YX 2=+=2$J)4^/!
MOW=>B3LP3W4LY>VJ \%Y/?&_%""KVRJXQZ($VYW7WAN,OC"15!G/V$?@W_V=
MH'&4JF]%E?<X#13Q%CA@D/BQPC*"BKC=N2?&LRAQ/DB93(JTIJM?5<R51,$0
MYXQ^O6()!2;B("6:+--<N H*6/B1,+V\ZJ,,[#M"49T!SW[SZATF^C_12FM7
M3'B>B%N0T [ANW),<-\ ((04/36M*SK<UNU-72 J8EK&Y,6>KSY'UD/(9>GZ
M2F<4GX1E/I=>U,B,^2'(:>Z8W(R\&[KB@;EH[7R+.3]T[.ZK 2N6?U^F^J$1
M(!AN\9E*7@Q.U*=RMBMGOW@J9S^*9WDJ9V,]NLVM9.BLXCH#J%CKQ!:Q;:]$
M40^P4,*A()0&7S4=G0Y<<!4N#//^H-!-&".[>C_,+LYY7!#U=DD]-UY'BYCH
MY9&T9HD1JVA04077T#PU;QM"'^VG,?9X&X,5/24XU< DX65@PZU:8PD!VE?X
MPAW;\#^FYL0^@W E>?DW.1_D[%F[.@6X&3R]UGQB];YR$32X%Q-QCM/E\?LH
MB!=)!IN*"_-YDAA:,W&7LW!]'!BA-ZVX?($;E*D9I:AS=@52:3H0LO7P79^!
MSM7@'>\Z-SEH]@Q'9PQV\,\L6+HO,C_*-R[?W2A58ZXEN-!@VQ4D@^=:];_C
MD/+"N$8HKO+^&S"Z^&)\R1#23'6$'[K<&R "X?"+?/EBFTAJSO=T&18@B<]D
M)OMY[N$;GD>-_S&/=(TI;,Q!>P%I;K >V+-D\Q')\6Z[VI)\N'\K3)QLX4PM
M8<Z#G5C;0_HH;7A?=GVMF<6$6"PLE& JTA)&-D)*\,0_*_854=77FHAQ&1/'
M*!A?2/HD#UC^&OFD(!%'C:LSE,XEHWF-D=06L(.%7%C'7/, Z:P-:"Q(YR/*
M*;>A'H\2O7CF>+/64GV.0?HBB.024Z'.N$I96YC]$]2%'KE(R8_JKM!>(9!#
MGF-R5%#-0@6\$\%9:T9Q[2H,I9:$BV&0/>Y)ZG],SDZ>BT3O,4L!H/(=A1DE
M=3$)@SVHHA(@2J:=428;MS(;[JKIKWCT\'(> 3R#B7@<TWN7OG$%:7EUO'I3
ME;F VO,0L_ .U\I\ZV4>=MY@L^:LYZQ*;$4]3_KAT!:^47_ZNKX_K? .A[SL
M:BU/Q;GD&K=V/]D3T"$WUE$43M+\]CFE46*/ ."@S?N::];Z6R6835 C,SVC
M8$JFCGW;,*7U> J!?K D_;EJ3_ )PQ9BECA;3/AR.!R8C&KM?$03@7!,ZUH$
M_T_;8'Y;4D[%? ]I!$@:!=R7X53$WLK21O/"$!/+CG0I%3VK.=QW9V/FY0B)
MQ];)ZV-$F>/XY8Q%+*ZD22G*(HQ2IL>7O86^$+I%<?)3@=Z,X-[=>Y=!:6N^
M5=(=1!8"S0_6*;-P :]/D)ZG-!J">5*)D/*<X'&OJU$RF,3]G<X2("^$+9.!
M\I.CO+-DW9'E+70H-F%J@L4YK2T=2X/CF5$&YX=*D0&M'/HVAFU0X$D:JR+0
MB@S?2GA71ZYW;EXYD,^C;9.RA9+5?NO*R_FR"SN!6GS'E.?6P0\["6[Y-G:2
M.X/$]:[X&*Y 6'P:M(C!VFH8EQ'VEB?TML8N9(??+<G;.L68&"]"AJZL]7T2
M!O5:4$;WOHH;GA(\6>5P^R@!1+_8-TK9_Q&<B''O&:8*0*Z!%G+D:2Y/D]LZ
ME8LVJBA79;B<)R[!#TU!86R76KV4]$DL*,RER2),TVIPV+G/%.O*(A9/_"$?
M>O)4G::74WVIZW@N2R.87D/4]=W"9I5#PWP-&-1F%""$;>3XG60K/RV!#[Y_
MG?/K\J)QB\J^YOW,4;]%ES=U0C?"%:EP E\WQZ?=^\$982R$*>0#E@TO@-4.
M832&WXW[LZ3ZBM=\FLH/O0M51HEV#N\]RB?B7P!062<Z?689@Z@E(H*#]>K[
MOJ',)17L)?<SL2Y)V3H+E4H,?D!L,%I>3J5NGBB>_BUT7@IW\',>C7(:OSY^
M)S_G_/8D"+XJ<.OCS<@D6/0F$BST7&93L@=0_ULG_<9.#\@4U>+C6% ^;DE#
M5EFP5;<W=5,%?AEV'X$I9(JX$"%D&>GW*<:)-MC$6#G8X40*X\_8-E.^J&X1
MXG&C9^)FNUX5<9LLTWZ/(1/=+V9;6;@=@FO+PA>36_&,L9N[Z*MN^ ?[RPVD
M=S2(/,%A'!SFTR<XS*-XEB<X#-;C_8MTZYS[+69^FGU,_H#8X$*65=L4HMZ?
M]N@/4DS,JQ.6&NMG90A$F,-0";:;%;\]^I22QT>6!Z.$Z$(>[I[)/!Q\4HHL
M4WK]"T:R,!'C/6?B4?@/#^X?^PE4&X$YKCD_36?X<&(FOY,<;TE+VE# UFO:
M>H?FU2AG9$=E2167 *'9B1@;,I48:>6(D7;A/%/5.^M)2,@]LZ66E/R*')&#
M@>HOOT@1R^Z5%?.6!0&Z/XXU==%RO<IZMF("ZY*LZ /&Z7(KD!8$E<9#P?/2
MR^-UA:PM.*$.*'5=Q5;!KEZ>?P5 >6>0EQ1!J:I..3 % ^7(P%Q723.NEF3*
M45N2K[G-5(:#)3>UVT%GL;YRO1H-.[#N1E&4F,%_Q[;:AGO_>6!Q&I9XLM]&
MO@W;<E7'=Z':>=6T$T_$H:Y-RWTD!6+JK H/.X%!PDLD^Z[?<&_I[@C;DJK*
M^@?C7KL-\1RI N_J<3LT1SXI^\T-%; ![>H'8.6YEGD W"=YEZ[P\F@.:7!J
M92\E!HS5X@GKV=PTNXF/AXZ/(&86="7M1&X''T,\RH45D3W(\@RB]XH:U Y'
M5C,2<!20/)ID#@5$X,O=CF,G97O;]Z1#A:%DJ79]-6D<N[@(].+S-3?CD/M[
MAG$2M!5?6S7A69#.-$67E8]/3FW4FHKX/1O  XFJ:1^C6RVXRY.R)!V%OS6S
MI]X"'5(8*F("<GM%K88V[1 >(1^XN\?-$5D!8Q->*,S<>!+B2I;<&:ZK([;C
M.EL?:3>+;YZX:'F6*$Z%R"0IS+]E]%LFA.MN_/-P%D=AP4P&SUMMZ>B:"Q:@
M=1'MZV!WX%:N$&.TE0,ZL'*N>)H12P4PA9;F9^E"N B%Q-$<V>=9DQW!9BH0
M3P9G7]T$?PK1BVS4E"N"25V9X$"9SNK(5).@-*A*&_DY-+T34QC-*5H56=B\
MJW%<OO8PV&W&3R74T?FO5KN^Y@)33[AOY#/MQKFO3YF0OHN^/OS'DZS\ ><^
M&VACZ[$,U<C7=S!&WQ%>@*$ ,NU7^BQ#%OE4D,P:QW[;&$6;-W$/"1=<5,1B
MBJ":P1&3K#'32<2KA/&$DO&)KBQ,L/:I,<Z']1[<(0J1=%C<)2]EZM;L6QO4
MRWNVZJI3&4GB/W[=NCT":72!"IUC/^K(S;CT-O6VDERXU+VLWS4"2XR3**)8
MF"JV$].#>5B":.GL.#WJBCM \1+ W1NGLF,3]B>L"PT.X=+A6&7SX*B#3<^<
M2*/.G!:,-U=V'M5Y')'48Z:^%9UGM,8D[A5 3[1_UV%6&TAS'OH(37.U^N 3
M>G,709ZX(DXL.KZXE2/<KFK/(UL;LDLC=D88KFW=W"B/KMZ>LX\=G)@;S\I^
M]RJ7Y'E"64V-(>%^V_<J7N]CF(MH5M/0\,0DGH)CGVSTX-I1>[6P),FJ/+&S
MY7ZE/(5*J)L)7#F[?/<C/HY ZZ&0YDMCCJ682+_R\LW0W+D]NX]>J5(E_T2I
M@V!':!\GV(48GT5""&>L75234@K,)KT06Q-GL[#'I_Q6]_@Q>E=-"L(#\^3I
MN"V&^:(-@ULHJU >;4#.W^%^E?I@$0$,1\Z-0S^#(L<42,]MM=96=^=!_3CV
MP!VX[W]]S:T+@%',S;-DP>V96M:MKHRE.ZDD7EXS[^+A53XE_4D'9+KT<K,;
MM,#J0W'S3=_>>)["^]EC22%LFC['(24\($H;V]1)C*Z9"S\X2G.0ZH4C+Z%>
M/4W-,:4R?)(*OR 5GK@%TL'J$@6<K!PH&.FY<4]I25*R05U]VBCT(^1@.7.5
M!9IA@5^9X$C"H6G:I0M*UX=^9P+H$0_LD\CT".=EV>/+K^0>><[R.+JVW(TK
MMDH\82AE"NC11&;6F6Y*''],W<2*&FTM^3P?M"<4M?!\(-&8T<SV,9G!WE'M
M24[A]C%^*+T>]_[&MITD$E,5BXSMMIM9>BN_S$2J<?K8*%!(&S8SI1,6%;%B
M,U1$0*7=!J.=K#^K1-+^7A[+4Y'<%<D_>RJ2/XIG>2J28SW>&4U<Y"85]R[W
MU^[/4;K0_;4.A\&)\PX(0M5-.@TU383O$:O"" Y=?3:.JSW)[#3:C'PB(M_D
M'9B"3P5[<5*@.CZCR/B)0K'M==_+01(B)/PH>W'^>\K&G5;4//.%GB\^!IEC
M 2@EB 1A)!".-PC'/C!4IB]1NH*UV1GP+,DPIN?.%65*\N3BQ;RBDILM.M1I
MFYK6)+796.6#XD#&WC^C4;A3Z'T&E_"\".G)[3VNC1(\Y:5*/R3<YI^E IA'
M"W)'858F[I>75JFD/8J/6O:(SC/R?+D,O9I>*.5K'$.,H;B2>'Z766#"^;\C
M%RQ)LPH[6,P4Q"*PL:_=@4"X9Y8(I3:0^5G7:"3.B#?F_NQS%JE;?*A4,PDO
MXYUA9.Q[ T[R1LBV"%M(Q85U-%0NQEQ+;W.6YG8TA)%_VEH;C5SP^>IMDF%-
M*_W.<=0I/,GPC,K<V-8_%,J)<)3]\@7I[*UN=DXKPQK" +KW"=^]@@(E,N;A
MJ1#A?)<D^0L@;IT7Z3>6S'L>PU^>+LVP"(S$Y^QSG]@S-1:W5I+Z=VO^\6=@
M/H^S8^%5B3J_#>\^;L,_*5H*ABV$.+4D*S2&2FA1PXB(L6ZY'C^R]-Y^"*/?
M0VB.QZFVO*_/]W;)&9_F74"C,!WJ@5K<(UN.-!N3,;L0 *.W-0TP-T-?[<#U
M?&-JA!@'QS2Z+GW*%/@4YPD2)1XU'$R'%\>9J_\<P]II*\H1KB4:E(YE6#PE
MS[$[02H"5:CXP\40^JL(U0A/A>J!.W3=2G\ (DHH"DHD)J!SGE ];&*:5D9V
MQJ!BV\_/ZAV,_#=UDG5(E5C6CN@]*Z37K11O4&+J]Y:^2"0ST/8QIV])BFQA
MS?.QQ7R^)+^91]IP VQ0TMQON65YX<&G8$!:'^X3J_>QD4?M6/(KZX^6<S(%
MYG7AHV8O+HZEPM'A?;^QQ]:MATX&V9--%!JF4.Z[@[D)"1,!M#X@?7TQ*Y2@
M1X0V&C"1]0K@G+D^!"C0PA.8,[X1A(NGK*#;NY-7<5#\[>BX2U=0DB;3!,5"
M<@MU1GF72P9J\<5B7T0DE4@'99V#)W^2Q_]:V9:Z-$7,*;GQ6F^FV VZSL:O
MU$N,&SY];O&72TV[2.S>\1=E^B6R2IXX403=> 8H92!<1N> N3Z/DHP&2A9X
M&*R_@9F8Z5%&C74H0%',F5U"A7?OOR%\8/7X'0M'19@F5Q6I3M$4#S^7^?=G
M9XUG 3[#3A(@SE<>BP8BX&0C,?^L)-K_1OIZFWI@&MU/_[A>?1I>/VV 6KJ$
MLNV&9Q=;2F^A)7!CREU6:QCJ0ZZGJR8=W80P_6GN/SE0M3Y_3]FJNAWK6_.4
M@&M@@CLZ.W]H*#\;5M>+/RQ0"@<7N T&4_6U>#LQMZ6"J(A+GG8_'1$X & @
M\A]BL)CSAM$&6-/!8Y#]+YR(=E7Z?L(+4C*/B>I'>:^F9LWEIL% (\M".3/-
M^Z3KF5ST\]5+8_\CY^_.DDJ\?ASO\%3KA,5&UADB""VA07.3ACZXC=V.8\!*
MJ(JD]"&@8_6'\MK,XC@ +C5>@!U"%N!>+H'8-^[*HRU=::2W&69E^QDG.XKL
M@A2]FBJ PZ,Q,$-8ZAH9Z].IC9)TM\Q^@G"9%UWASE[9:*$912ZK>1E)-'0"
M<//Y*!:"*A]@=7<5CB(N_<<04"5C$H"M-3!$9><$_P#R3_8-.-UBQ&4#!$Z'
M!K#*Y+@D;QYFP.DK+"H7!A.B<F! 2LR)\Q]7"N#G0J;AF-F!<O(D! XN9?!A
M<6M9BHS\B^E?S(1D6:M_"13I"%$9&YGLRH<V9BVT8!4*@L7*'R=C190!ED!:
MY=;XHSPJ>[YRBFT+J?ZXL0F VP_5T##4)CQ2,,+<<1WNC7*S[LE<E,R1CI;@
MELK9AK@D<<7!V*\ ).Q7=976ADN,#QY6- /I"C<9>[.G7;]J^V 1(]SE(=&?
M<"0:"1^,T9AP=#$H/ZQ#\20BWCY7S&,4M"0G_:Z-LRRTQRJ99Q8@'@^XXE,9
MUY5Q?_-4QGT4S_)4QN4RKIT!SGW8U3?]J<Y9D1/"U">Y[!^!!IX=YNP9L:4=
M0>CH#6VTIZQ6-3+]!HXJDYE79Z(AA&DX]O"S$(F&DXA<@.:CH!#^_U-OFM/-
M\Z917Z,K'X-*-LI<TH,%B$(TRE%%[MI'C2+RUEF+<=ZSS(L\H>S5P]%S"]N<
M<00 IY($B6T?Q 29SJ@Z_R@( ^N9':P/FNU?:E](WFTT.+3(C^T/>5![")>G
M/ER'2#)W#VT2B<04XQRV/J^KIB&>4>JX"BG%P#U8$EGQ)3BUM8ZG6BW+CN[3
MH?+PQ P*0U2Z:Q\4#[Q-FHTP5-LO/P*SY@2!)7 VJ$6!@LBYS[VU6*.TV2%B
MN#QQ_QH\X(Y%<:\$@;$Z:T8@OF-ZDN%JK.#NJ_7U$G$Q"8?L^[;I*;[9!G-*
M#T59FA!2'1N1")<R_Q*:-M),^+H2S*DK74]'?O>TMT!P0/3=5(Q;VN_5?E^.
MS/ZMN(@'9PE4H586!F] 9A]X%/OLQTEQEYC(+3A5K-?AV/;G6AJYZ;1OR?*)
M\LOMT$.HL:6F9J;/D#.)DO):HAN()2#8_:&.F'R[;J*M:9>WJE<X VO[]J#)
MWP8]JMQU^(Z56?CI355&M>X9\Z2'3U0,3@E\PK[O+]7RPE'!^"9?HH->%B$=
M2+H%.^EBV;]W?NGC6#676;I=ZL<FR_MG*2)KS;D3,B1$;T'>(O^(2IG!JR1?
M<+0S+6WGZ0O"OA']DM_3&V\:4ZVC^@^BN9=4CZWB^@<B6*A3M0U%K1$2T_E4
M-,GT)Z^1Y'@#"TX@@QQD#.2NS.OQLB57^^J:<ECS!#4H38P&44HR%Q4#C(S"
MO]W:;]<[I8+ZP0J6X2@B$WCB^R?)S_F^SO9S"0;HG5<[^/*]_'SE ILR[P'O
MW0A!LHU^?V$O3:9FJF$:"F49U;#9Z2OY?K>I^+'[??72*"W>UV?70F^QBQFV
MVWYX'_.@<EZ%!3AC.?.T8RYGF8D2.!(IA;EFTCQ9SG>I[I9",,"30[<S=1B-
MX2(R^E[S4PT>4)'.5&GFU_,\P;*0]:B0C2J&DSS1T7(]#EO\P!-<JN9<U%,8
M49>+R\<.]B+0;1D6(NQ#QF3D1$#">SV.$;MX>FG7OWAZ*LG6-ON:'D<EW69=
MJGMPM8$_L";WO&;<#3!*X?G(.%?-CE'\'?GH8:$!S!;+4HXN*Z9./OV$(0GG
ML.W5L28<G.(* -"@L^;H!)\=V.#YZG]$^.@89S[,S_<A7#DHA@2,_DQSFPN5
MKL/V9! G#8%_SBC=[4AV0G!=4<2PHS$9=?CBSE8,QUV0!8@E2CM$L"N=!,'F
MK.]K:.@P''#G#[Q@2[OH>3M]PF0EQWJPN0@8<X+ULE<A\-)@E?XL4*5\-4=G
M;R_(@D1;ZE2/ICPYU%=36PDK&!I?B?^+^U]GUE+'R"F?"=C2AH>[\P4,*7 >
M0F1=AU@-M <4)^8_4OHSL_%A7EYZG:'(9I>(A2F5DH:+3@8^++D=$JWBQ)@5
MB2V@:%#9U0HM*18+#0>JF%[*ZR"?!2X9Y,LO)"9^B?6NWS[5NQ[%L_QRZET/
M=#1>PWJK 51BW92XQI\<K+REM+K'ML$A"KNBTGW(Q^SHZ%R'R'L[(><9/+=#
M,X[,Q%?3$7'.Y((\#Z/( 2()'D5;G:2VB+JNG9A!F4@.P3YE9W<,L&]8]HX/
M PW^_%MH5CH^S,?@#H6?];MF._-LJ,88#C!R-FH>KFZB\(*]GC!V.FD\!\E8
MXSM1S5+E$!,$H2+@=I,RS)/_I+V+3'GG;W-I,@V&*J6)%!Y*WG_D[KQ27FEU
M>7#2)VR&Q0<&9H6ST>?Q5!]8 9H2?0Q3.32LD2%Y(5X,.G1 8'-XFZ3*6._2
M'G_?,"2=[HT02OQP_9Q84<>ZG=]#1S$=.EJD<!^SX>(.P/D0V_<OCK7B7/+E
M7U%_TH89_DL;N2+-]?(&5J_ J3%8U:HNX$]7(C6%.9%A'>KCQ*7)MKK%2&;L
MQ,&_9^\9<Z2D<:RANQ;Y/U&.KK@\XY,?X:K'V,B[G8090M\%;C-A6O&&Y& *
MUG9UJ"O&+5?(P"?F0M^)GGJ86IJ9O_2W-<I-)P,S!]=EBO!G#K4S^T./%6-=
M0?8KLP4_><K76>1Y7+OL.BUN2O9SH84AD*<Z9]],J7B*XLZQER@\([(-ZWFE
M1;FHK"NX4V"V] 1S)$(0[&8(RXE"^:W"I!X&PGL<-OF!9^VK:Z*EQT G&YJ
M[S\D>QSBZMH?6Q(1-Y!]IT&HK+6P8IDS7X]PEU#R"8,"I/I1#.EE@N\X@*)#
MXJ--&K,^EQW,=@R^5&P_P"]EM_N5K_-@5> "E2>2;)2-&J<!3(%F]%(JYJ6N
MSE,4M=?MCB29J#LEG5)+J0UK*Z462@*4RU@IG9![?P$8L8>5?0\&C',9>@P;
M;ZU6XAW@@]9:L:*V0*_H^M7N432,V'MT)M6K<S\)K&+:C.$$@_6:6I3^K*TE
M\@KJT]V#&O?K-$\LLXVJJ,WUV:F7"CK,O;%0*[B=>;I6G/Y:S%Y_V#CY;@:H
M(D,"42\H:\:;Y0R_)0,@21=AK7^^^J+6?@_XZELYAY6"F$Q,"&JN!F!Q\'SU
M#CY56.3:)IXQ>^FQ3C2'(X?J>;)D$WQ/(1+$_@'O^R!_BA0<TO0Y<]7Y26QI
MRH7QX.S#^+8B@8YAU=+E4T 3Q<UK/O.VX2)#.Q_&K Y5?!ICI;T-07D]6]PR
MU<@,Q77EZ/OA[F6I\:00ZC+D^G=CW4@(T3R3V*WR/<K]DR7V.,SW0X&"0N!&
M%2?R$60!H@#550?)AO&F-D2(,;!BW70+D(?-U$!["PG ;7_5\=X6G@IV2$85
MSQLH1ZNAI"$^-<F:\92&??8HQOKB4?DZ8J#(DW8CW _) &M%7<44=NO8;;L6
M1TVZ>GI':BYI6/Z;T)?/6P1P,+ #3??FCH$2/"4>%HG^&1VWRVNC'^;]L..I
M/T;:\E&^NHZ-R6"W0_"?+PT*!*S8;%Q$M%VG<-4#_6-Y]90[M\('%7KJ"G=+
MR' 67W()T:.(%0]+^MD8[1[3=B@;FF^;,8SMMTIBWZ_^;,%Q^*N>-X_B/1Z.
M]9%<0S_EM=<93Q,?'&NW<]"*)_P]F@J4EN1^,!Y/=]9S6QZOJ#4UPL;"1+S/
M?:B;']6J63:B"U4O!]B0LES8;TG&Q;LQ#KJ]IO(4648E%0'B5@$#5H]:IU6J
M2 ""SW02UC IP^Y]71_QP5!3_0?_&=9!W>*_"'=;7:$K>?N^NN(K("72C)KY
M)=AQSSN><+3X3@@03L]LOL-34YR/3R)"U;#Y"E$E0/4P$2+SV^:J'S@A7$?%
M 5=NRV0(-(\6Q[.T["1IA$GP,*Y-;?F-78K^6NPVUTR1KO(T[)-Z704WCUY)
MTT;\\N1MOX6\LH .#(SD4]JNGNBSVZ.UVN;*8!8 L.\=5UG87%1H:XZP8-Q!
M&PZ= @5L)U)1I\@BZU>OG">RO$S1LVJ%.I:;!W);LN;X2CQ/SA/-)L=K3NS!
M4W-O2CG,X!62O&TKI_?A(S 1FD[N>F8#\"W/#""C\8_UE0[[C^''V?)/L%$R
MT*5!]M5PVQ82X7WUQ4O."Z>5[WC!\ 6W0./$Y;)*C"<X'^D!PQYZ*NJZHN[O
MGHJZC^)9?CE%W8OK\52]1QS7G1,,DJFO<:M#<,BZK8E3S!2 =I8X0A< VJ[/
M1Q!*@3=!N35%#6_Q?&'K0YG]737L(HS5# _!HO3 %7U BK5&\'U @E$=)WJ6
M6*CZ?MI=16G,,,J< HH4KS0(S2FE\A.#QF=:S*PQ$-,E +ESG/N5&AR12C9.
M[DQUJA@0XQV9Q(%Q'3W$,>C O-3RI4A9]CF2[/3FG)CXZ73=<_-4BL;$<;]6
M L>(^"P<#XBQ%Z,!M.:'A< #3_)Q/QR9"% X.?HH(:Y);:E*DAL4'5SOWF;:
M>A@J.>0M:5BDIZ@DX:;])=N8WZ?E<NS#_)R3(B+JW%*;Q,)+O.220TD7FN&Z
MK$T0R8YZ&X/:75T1I] 0(\57K__GZR^>O?@C/,[@Z@[3$6M3_;3KNFI/U]M*
M .7NG^ZV6FV^:OM-!=;DMT+\@,O%,H,T5297L>ZAVXK5MB2 X] > L5M99"U
MC6A_ZH8#T'[01K19.&?59(<QT]T=+F%,K--QAQ$1(8[SZFIJN ZZY]8.]7/R
M29#R15@ WP 2_>(/Q&#UZ2<A0"%PO%PV?/S7$..0]_/I[_&%%Y;Z<"Y59(Z1
M1ZR[(2QRI[G3:/:]*'0&J=>S^LU31[1)80K[6Q!/B ,_GQ5ER)$N")#!D$^U
MW4X#VXZ:?F_K?%<_$VXH1U3IK<=XFG;2*Y&/%W[>0KZV $C,.J?&\BIR:T.T
ME3+<(T<7X2$NT'_H* &+(_&%,ZG7-;N0D5K%5PAT*RM I.ZJK0HIZT]IA<Z3
M#&Q1;'7-*GKQFGP/OB9:R*3<(PU]\@@VZ8\_F/AS9-M;#MY@A@SA?__X;:B/
ME&6@N8<M/T6.7#X\*J0?[G-4)VV=EN,$()6,T1Z]?$"BMPW#M(Z YF]YQ=/<
M4FJ"+3V'"EQVX_U76HJQ@U>?4.@DB78.+:/AUG\+?_8B+@"=09*3'PI$URX.
MU^]*SU@,L,4\2W=YG?(MVX9-M$<N["+?FNWXI")!J%)=$5%D)7AOLJIC;'*B
M35X#T1))[?0M0?!H&2$OYZ5TN@4_(2:61>EF5Q_"NX*,/]P0C)@SVW3'TM2.
M%9I)>I-H3VMFH.6=N+:J#HCUQFK/1Z?ELAG-3G\?3,S&/N3NVU@M$U!RUOF/
MA45AHO.)%8Y#!5<0WD5/QUKD=UBT4AJD,BDH=SM;=:6B["PWA?*"9(T$.4:_
M-:\X;%JZ@')E:DU9!Y5>_/0QV*N7G?H>9,:%Q=EGDF,&(F8:'EJ?N" #,#IU
M62OYSM=FNF60O171O>@T)XN';$DI]QAUB2J[R[R!SY$DZLJQ#3X5=[!<U&\L
M\N [J8MS'C=IE0_[<?NQ\+3_G<<<H8<;)JE!)$7L@@"CX5H*SFMBS TJ4,ZP
M<Q3,7 *E #C)L$NRSI+<')?]LTH2Y IGBUSO=7/83&$%<TLH!<*7"BAJ+0BX
M2=X]'CI")[0%F9-]8$0VT@Y4LW(%83NZ\QNP/OV&=N&F)^M:D;5N25A<+W7B
M!+[6;TY@@T^3VVV_S:H:8>J*J?/\M%[*1<;2 N6C&S"RRX:N3HO)R[AE_;N:
M+'3=<6^O2XR6(^P+K+> TQ*9"-FCBAW\F9V+CW6?:ADZ[@JFZ9=:K7U@E=.U
MG%[P::2O\4),L_:TK=X8=5<]GU=VT3YX!%=N #4&++2)>9TAUZSJ<'(N2F*6
MI1E/[]+S)LH!7E?%CAL]'WS=*1X0SI3!3.R&ZE:R1)802B\8'J]J.9>5: <Q
MR%H]H+(13@L@:<TJO$0P+X<Q1BCFNSV*)7FGJU.L>.5\&G<5NL1F[/M%8<J%
M:;GD5C3AQUL&$*8.QLQ/T>*E -;T5&R,P3_&!\(,S&4H-\=[S\J AG20<:!:
M',],7^@-%OFF#IL. 3TY45Q*EF.&G%WU_\-;;"\DEQ__.DF"O<;2:$A^WI6*
MD[-)5Q<.HHNVC*'UWF^1(Y\^C/5_5_;WI?KE G]Z_DBFV8 %!B>@Q-!P6M..
MQ_\[3,$Z @H$T^E@"M:(J^]4,,@1! "S-C?/28<6?"T:9@KMO-UUBS*.KR^@
M8AO9P"-DYGJ#F57-9!E@BR([6;6>!Z/J=O[W_LX7LGWTJN";"+[ 4Y'5%5E_
M_U1D?13/\E1DQ7J4#<_ADJL.G:)20>6#=V<)HM>5'VR6O6 [$<T8CO]K49DH
MFJ=J]>V7W[R%T)/P"+C$GCFCW$8;')%AWF+;9WZB^!0IF&NPE^NBMT%I+7[6
M]/ )_R4TG.00B3@T%6;#TXHO)&\>,X$P_44G5#I:I>[!M5-$,%(W]9GJ&=PJ
M-@A'4[]W4@>[6>/C]L_?O"D<*I$<5"CIR?I+!5:(L+2*-/=O?7+ 27@-LW2#
M'=L<8-HPI@%%:;IL0/WUW562P^X!*_%KB;6X?14O4GP/$PW7<@"-\-"WW)T[
MZR[-.B4Y.9LW?6R$%C^Y%4?A^KRI=^'!C$L+:BEB<:'=S,/@4K%N2MY,)"$(
M=#S3W283DCRP]G40]&+JK-\KIGL3ULB8QN:1YQ=<PLXF4BMA?HD"=T0?"X8Y
M/.TSVZVS_"%HOVB^FGD/OZN6<QVN2%'F>]4J[0_=/R *2I>KR%0-2+D(6XDR
M>V5QIUM 2Y/F<98+C7YEP*?U*MUR@MBE>U-Q$B>1/!N;<O)Q3SF;\,.*>YG:
M^G3"[B%Q&N92F.-QD&Z*\1C;Z_TT)F _C)PT:!5""FG,HO(8+P>3 TJ%VXB%
M)OQ!RV)]M/7^>\2>.QZ9@D@KC=&<%&M,NG2#_Q]B1=YM8]W\,TP[%492. @U
MDG2Q6J[#K6_-IP(5]*38VP\G23C@O_QO(DVOWZ-D"[^?.D&=;)N;L,!BM@.6
M8 !!1.L[-S^"J/-M;(=,#JP[3ZG*G<@15.HC/R0%TD0.>!C('P%N!_?=GM=)
M[7GQY..T_T+(FF97[Y%O6J<G9&GS_=<#9N]/1XK=NZMG;;T__==GOPM_@6/<
M=,1R]%_/7OSA9YMA.DT^_=V?]&7^_8^0CLV+WU <];_^;\DE2>BKT[E.O8[U
M_1T2NM1-B%Q!0"'7W?%ZR$S,GY[F^P/.=W:047P0#,.)=.GD4*._+1UK3W/S
M8??BS#OXB0[^J#P8.SH8*7(5(C1ME7R:W0\YNZGK%<[U?EMEOE+4.-;JQ-.4
M?,@I,;P..[3:"]V=;)(>ZKC^B9S0ISG[@',6 P 3&D5<W^A>XJB 4D46"FB$
M\!$$ IJK4.0E_&/ME.!4B16BRV!^#6D%L+MR0J[2=>#Z$!1X/J_$7\!#)N+'
M(>C^HMYZ@>-/7OR.*UN?OA@%O?<JW'4*5W]%8>/J)7F.X1KN7[=2]F$1#:J)
M2][&?:<4EQ.ZF1+5.T[F'OH=08C^J5(N.BC6U,ITTPUQV1 %K91\QB.8;+KP
MXCX7 J!9V]^REZ30FFI7';DUQ)$9:;HD3] B_;OKC_H0'1#@Z7<BR):@TG9G
M %KEGDKKZ&<J9GY2\G/*<3KDDT'?'*P6>3ZE_55>/,4$5]OKIKYAGEO16B':
MMN8D.#ZC8L"2RKDU'B')UYW8-LHU"DV1@N.!VR.AK.:Z[W=KII*NC<,9-K^X
M_7B<@0 8&E5KOU<O#:Z-C(5KK!%L^%(>K-H,?;5[OGJ5]MV$6=OO&P:C)?3K
ML?LB[PY1':Y@'PAQQF1:A!_W4JR<R8],H#-A]#4WBR3F2/#BO%#IN@=Q5_'&
MPK=S(0%8*;'WOAJO=>A8B7[U5C)GE#_E- :5+GAATJS&-T>KR8UR!'9*>!@+
MS>/U=-I1?D7B6.55<K/,]'E<TR&L/J8:+22#RK-FIO!3:H1Y\0>#8TN'C'SZ
M6WSZ1VW3*#:^46?+:<9H:@5W&TP"%QD3&2_1<!7>J4ATXA?28)%/OIOCL 2'
M+2U<FOL2M@'&$=*^<36OW<H%=)UM&1@/>0ZIFG.&="]8#;FJM66X>@,[.%^2
M_JFBVC5D2HA#"04E??TJ4]?2*1>5.2+'&NMUD1U(%<N,;NP2/= OL9#_AZ="
M_J-XEE].(?_'J67MB038C*CIH[E.3-_?-M1H#S[4%<&-/P97Y<OH9)I9+H0)
MCR5*B-R//Z-3]4 _ZLGO7_;[/X(=4B96U9ZQFYJ;QCP67(B'/&FV-Q*J:7C#
M-5A%TSJ3@@[[>4B,3FF+AS_A>/@--S>OWD2.>WJ6EQ!RP92_HDMRL$O])!S7
M2CKX+VF;^I=AP_&J_S8<%AUA1?B?&EV?^JN:.^3IUR]?O>0HV_IXV3=,E5*E
M(1>_H%YU]Z+-* T+_$1ALJ]3NBSN46ANJA,K'3&\A E(S<TV)XN]:*9,3OD\
MM3^=XW\\=RGR_U7S:QY?*=WS4UM#;(SQR9F>2= )!"EL\GIX1G/HI6CH$_"Y
M8B-)4I9LS7X(<P+YKSU ""V,1&<W<_7K7S7Z?%2(UNX=V(%#F)9^QW2Z&R7]
M&^H-&Z-;'M^TY@HG "/V#9E28NC_@@BMOL6O:$%=A4=CY9FJI2XZ54B(68^%
MT2'S@/GMKJM6R"-)4H[^(]BVEO]V()R:H,Z;[GMA[PPOJ6\9.S%1\PL;YS =
MXM/^-*\'GFW-]B#!@\^/\CEH?X-=:G83(7.968"I\>RZ+"M&!"0X>:ZJ3KK"
M,&<W\C9I2W1'W,:0'JS!D0#XM^HOG*H?ZCEV"(E(X9?8#!6>F+I1PT+@,^&N
M>0GVF^#:/0SU(5(;T#IFL(,JR0J(L5%6RQ#)\GS: [@SU6UH&35Z[^)K8ZWR
MN UDNP;)Y7W!HE(4CUU51X8K3$S 2]=;>\I@/R*'L*O#*-ZR0B-Z=M P]OM/
M_B-LT'#./>OWSTA V2Y)HTA'YU5_:J0!A3O0]QY&A.&]>YWWI!URA;G;U%U-
M DK<MA?924BTU+\:0QB%(]&:+ S\[E_/@M9^.@F'Q7T>"9QWI-.WDSU0&F^:
M(-UF]0]'7DS\,AP@AT6%MC,\F:UTG5_PB90L:*7\0B/[038C=@D;#;@_YE'Z
M389\ZGG%F7HV;U;83YZ1:HT]!GP/&Q(O(>KLZ!NMX&]N:C*L+S[[[#_R;,R1
MGHADVZE1/3+F^VX6Q_Q=A/-E-BF8=TMLAG&>#31SE,BFLR4$TVK+--JO-]R&
MSF=UW!)T8;VR,H7S!A.?X-DKA/CASZ^G$XT$<9V*!.779(=/TXGW#-*MY&1
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M=?5B[68KW/R9C-=.I_Q5M:-.SJW.<UC.?EU>-T0;0Q&1ZD _P^KN!WC280
M-J=X(*I-'&!,0:A#%KC^ 24$N3)YSO4/X6JG['L2'BZ]PXNUL-WI^_+*E<T@
M(2;=Q)'!\;2 2R28S=7GTRX$P<YB_,$LQN>?+P26&G:;_;K3)IC:B&2F?BM:
MLF'2ME*(^7W^)T)*%IU>V[T:*F7A<>I4D^5@YA1 >V.HD[GL4NB&0+CT##M'
MEWB4:<;MISCF,,7K^UB17=]-5*IJ$^L1VVA?4:/3%#V%/6 9V').JN.*AEA\
MT2LX2<&9(.9*=<\N+';P#I\0L ?O?GO-5/SL:7(J0G-_SI+ :3B0(;T:^NDH
M\1/$Y$;?A(7C$WZ@E+CW:"#[00\O C]S>D'6)@<8)^.^W#D/D>P!&K"Q@<8>
M5HZK@](S$Q_B^7)'Z:/Q,)*)YIU4HI&++LA1A8LX3]T?F92P8*:#L10]8AHT
ME[SB8C2)0GKS#%Z&\"1(YZ]>=ZN7T]6D"!2NQ+X0"\%FX95T.D7S\*)H$=1C
M-_L/OUA-],!) >E[4G$>$I3_*VWPX,>2/%+XX'!H3J<:I\P7B#])N4!^&YZK
M&M\K$0PU6Q/=*^,]PT?#5<T4G_PSNR5._E,8<&)B_-\OGG]*.-VV=5&J9Y0-
M+_B9+38A:*Q&E^(.[PEG7Q;M58].%@VRPJ6OKFISV5SB/99LI[ :JQ.Z_O01
M"5\CNH\N$:'1*3EY /&H;W9U10U6I]J/:WA+,TWB78TB.R*M1C1]_T&G9+ M
M8S"3\;6C<@BY9(0MBGPL+T/LU'IK_ADGQ>$0U >1Z*F5@%$'[K-/PIBUX+"/
M0;%.//]+6'<:<74%R]0/X<.;9IB"$TLBY=^&HZW>\RGX97!E^D,8N;?U=D)S
MAB5RZ:<OO_WRK4"E^'7F@"G+.[,O\53#=C7L/S[5L!_%L_QR:M@7UR.P*^#U
MXBT<;9ECA2)@/\&+N;M6.82S)#?R;Q)6D/D4@2L-.HW[&-FL8%ZT!5 ]W& U
MS;0"0C6>E,3KF\H<+#-^BF]:?6:NURPK'R]#ZJM=O6(S[.VGVL,05G R84=1
M8' ,AD;*TS!U=$9EUW8@^OV%%]";L3V4AWV1\YJ]/) $5IC^=]4/X5P)OV.+
M[#R"3\OMH-:/S\K4Q=-)3SVB81\%),['E<^)7/?CD9 .],<#:TML)44F1.E;
MNK'RBNJ'*I7KJR[D.U.:D(J8CFM(.+<U;>T.82881:,W_4_Y:)5&+LG9[\,)
MX7P*E,QG42O5"M,16J]\_^$&_A<Y\.-U6.%[=)8::Y(+GA4"QAXWJ]I&9@"/
MQY-66OK/OU5R)%OB%*,O.5DIXVKQ=R]@<G*C .0CC4U*+I,'=^#T+B7*M\H7
M8;C H?+=YP-JF@*J* J68\V/B5_ST%=&!I3!D(Y501N$DB3M1?&AE!O10',^
MYI'VY92^TR1GG!SP"!["V-F?Z]-\!$G2:!0T=1=+M(JM2?OG'02D!"\RSB0#
M;3@@0086B%5/"ME]KIE*H.O5UP?,+D\D$M>"<;=J/UNJ3SZ#L_C--R_7LS*^
M71][784IS\($ELEI&H_!N]3)7UE))+V<)B0Y9Q .J6NP',L!5+=T])]5.@$7
MM^)'PK>9UL65JZF2.U".9-0"(#_V>:34=?=,$W HGXAT51*5(J?GWT2,V\XQ
ML] E830UO(F $*[C<:)"B<NE: >5IW-2W]NV%131KYN68]<P(TR3C)HE;V*,
ME64)DHI)4IQ<&Z(B3!?(YX)?VBGR8#X/(K@@\XM1]2>!RY)PN9/PSNDD# S>
M0MU@[[AT-9IK\A]( IU9*ZWIEUXZY3ZIC.8@N9B=.:+/X=]V;CK^[?;AQ:>D
M/0@>ZO9L2")AG^8OU1U"98>$"5LX+ 5B?KLQ^70A^BA6QL.<^)7MB_G,NJBT
M%?@MW9Z'E1>@NAEI -IT%,0K*T*2<]$DBIYDK"2 4JC;(\XW+>=)-\@$@-H[
MG'Y=F)@!(&]V'H3D183HY+1BS(8@$*^;8QC&TRWGA"(A;\*#H[7T"%:0O _G
M,$=F-^ =FE;0UV*"41.:)QX6;8]6J-F<F3%\>4KJT+'^3%\.;F2Q@F5Y$79X
M9!J$YC1/5+"W*XF0'?DC__O%9[]=;22?@VJ]\B]J:. S;7KQT<BQ8Y9,7V8+
MXEG+5CLTU%IJI/V$E/2QW](!SZIY&&;87%'G2)U/FZ0*FGVQWHHJ@NK,2N.5
M&H%HIR/Q]QHB(E/8:)_^1N(.^M7;^GCBH./%9[ZX41IQ0NOT$T!JNB_RU@1/
M_C6O[>I*9)%R(9&)+2MZ40D^%J;;IN)Y) ,C9PZ'6I+^#OLWOA[>F,\F>H1$
MGR5B-%@7F5DYH8[ _:ARLB&K'(%?L*JOJB[$V1AL'EVD_LC7 (A ZE@B\P)J
M_F3$=+7IR>CO9YO/W0AXF4XJRFX1S@<;*VN-A*.0C5K![XN:UH4J,XCO3B_]
MERD8" ,'F&)!Q4QJ#%090)KMIU.]D6ZG4S=.I'#*OE/8=VP8J4\DZOM])9O]
M'=1\D< =1TEI3MHB$V;Q4+UW)./L*I-2?'B5J=M7I%1%P8]NMIO(8Y[QT*F#
MI$.K>R=I7324HOQ("+\>D!?Y.0Y2.-I.LRFO+?_E+V]Y7X3+[:!C9.#OH3Z$
M+4$X)=*9"-[J!O1MAJ&%9:+CTX=6[$Y<*IW1]J<E(]5-/3^H:K;ZPA#CNR9$
MR'3V]S&I()<]JP<GH$(*RB4OC/)>^D@4%%MFG:"GVN$*.\ ]B*@SC.(<^[<M
MOF(XVUI.]E2%@F)"$E_-KJ;EWGWS UP!PIX/%#6P-V8'\]*KSHYJ"1BHU,<A
MK9D3J/\TA\3LJ4&E:8V&"!;=K.@W='Q\5=V@\OPWC4$2TY3VHH93**U^KCYW
M_J5'JER('71;T1$VBE\6KM*PPC+61"VI>I9GVMTP*-J(_Y<+E2]0EK(<VJ=_
M6"\B*[YHF)=', K8,-@\7;"R;1/>IFLJ&V1JI0C#<TL)Q&!F.>> L/-[RV]<
M503HS5OFQ!K.YPC'17Q4/"9-KMUR:3I]4V7JR\D"UK-$@^C[H7]]SLSWL3"
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MQU68X-43/6DOQ/1N@#K>V0G;6W??:_ VT<Y7RJV7XQA6!]*0O.;_%5(NJN&
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M\H?S057[_]J[LN6VD2S[*PC'3(0]05%<+,E+=$?(LEVE:B\:RY[J5X@ 1;A
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M2,! !%^_1O1.QHKD0FR>/4KIS-P3&*VA\8*>0/GOL.34F!_66HT'(5A(=,7
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MNMZYP5-B_ACJ#7/+P"J#D>8PAU'( @N)_6LYKAWI%<W3.$0>ZBP4HJI &=O
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M]'+*#-,68#M D=+ZAH-]3#+P;>F*<.X=L2FM.W"![4 9?#(=EAB,7>\<"L3
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M,VX[DUQ[OCBYMG^1!G/U?Y-B&O_S_P%02P,$%     @ )85D4P3_&?VB"P
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M1"6NB S4ER/!@3@1(J79N^CKQ-RKH!N2,:[#F]YUM-V,35-T(SY2XH"AP!:
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MIG]XAFVHM8I\NBF37)QY7Y!="1HC8Q93""C]^(0EUBH@2=L<9-#:5&K/O"+
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MH]7",NY)!%>NFHZ&>(K!':,<F)&@K*ISX'9%6;_QFGXE'GWA&O -]=.;\SE
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M617J:YR=%!)PP>'LG-XS*$H+)T0"I[P!A9Q!#&12A.AT\LB-<0T/U5U(?]@
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MR!O@@,@YNRB.^6UN(P\\UUZKH(%+2=:?#!%<T!R$B3H;VB:S:I.NOT'*_MV
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M:!VWF$G7)4^<*R&RYV"B%;2!.P_.(P>G!6-61.8;Q=3[C]?[0NY]A^LFJFT
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M+<P\H;X'(&D1H9L'EJ?3<\S/SR<DJP5M<S:F\U]>T/[B"T[2D/@:*$R61Z7
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MV&5C>D'>U$AAHVYCB-VU!MEJJ[/;_NL2X'8[,H\P#DP56P0K5>_J^Z4B>+
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M DV$*5)Z@TA#"5($$=:_@0P[E:R]64^F1JW?IX?_I<_%CJF_BX]@Z$-\YTB
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MQSUT838K_W.U,)OXOVI9[U9%\;#<J8&=SPO]JUV/_/?&Z?0S_3H+49I@+$+
M)$Y-@K<,,"@3D$K&$QA1PKE3];FA%)T:"6W[$SS5'0H>=8^*X(>%[I0L_FPR
M1CY7ETV4+?KG5QILX.V(;@K#.?0M]JNW=\%KR<J=%$QWVBBF\X49.:!6.3#W
MA7?!SI@WO0Y,MX,?3,?_?!<PJ9^5P;WX_]9%69^V4:4_QD!WV&.%C(&'Q&_1
MC*&4';>.QL"0'Y76&%I>OT7(3)(=.>T,^665F_FQ5:[5:I8B"A,]ZT (,VV>
M4J$ E@B"+(ZA-E'C$*)XI@UFMK)=7EQ5<.&9745&73CJ%</3@N$\2'8+P9#
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M84X'O)W2ID9?&V4#8695L5'7-?ZH"V$[8O*&V\!<M(6L(J)=]O'N.FR%B><
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M7'C\VOH\FQN3^B;P?BEV[@%_E=1<H8B'Y4=S4YLWY0*+JI#)]HHOHDR%C(<
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MBXCXKLM[7N#8A7DO=OU$9=[+[_2CD3<T7^I6B@\RKYK>WL>3D'&)4@XP#!F
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MN9@OUN7\R\ZQ]9NO?+$64IB$-,;5:]WJ=!A6\$[3VUNM7#$C24(H3"A@4$8
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MPB+% O$@(WAIP:D9NP\OAL0&#@FX!*^?48L)VL#&JQ'5 58+NY^,K>6-.#;
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M@"/7^<>']K Y8( U>G):VN5LX/]^\:37U4G?0FV)XJKK[ZHZN))9 3.@"F0
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M:1)B(K.('F2F,$*AL>!$_<48="E9%KAH@J(M">TD0;TC+FX_#VVFI XP>->
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M6T>1"<A)1A>TQG0 *_<@B5W&)(=$XOZ*ZZ+M\2V;?GO>&!ET7UA]U%MH:[%
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MOC8H^HY\KO72)4P6HE*$<&GKPT_'P4D;1(P\>1[;W!WN1O"XD=]0J+IU37@
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M'^WM]#:@^]V]L9J@1U3!(91B%<6,A4-@64+626;OG)?NV&HD?]?=MWK<D7M
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M?0ZKW?72 :AV%]P#[7.<"H%IQT Z)4@&(4 0@D0BN=5:U$F3(Y5E'7E[K:W
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M^Y#B".++'LB]AJ-&GR*+B(KIG"-EBJ%V )+.D$S1YI%Q8%[_;#7TC\F.3HR
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M0/F1,-]&8Z,\O"&[.[M>[#=]]99_+J8K6M6'D^6??68?]JG+L$]LI2A&<B"
MP"?)1VFN,HN*_)8%)60,#H/9KX#&Z:S47?6O7>^LV_UOYK.TX^./]*\E#:0V
M6MAB5)<497*%UX(3Y*VC\0RR A8%QARC2K:TN>7<<%+G806[ '%WV?1A$3%2
MJ[DK/.J#8M_AZ2TCO:8$^ZY0#G9]SRV2I&H6ZD-FP#DY=,%-E,87D<1/;U,G
M/$4?? QU&=/JB4(Q0%K56GI%N9"E]=&&P]7_7,[#@G:!77L+VDG_ Q.J7]::
M/;@@=:R^W];'SS*CD]'7GK*"PO*(#" F!K6>K>*.O,!>>RY[L:8?&\%8.E ,
M@XAYC^H9ND@X?MU4@[IU6-M3VA"#'2\E!V5J??QZ@5!3LI8X?:M >E,<3_M5
M>]ROA/B^PQJ.6'V\YN>MU3 T]_XBQO^=WA# D[)6TBB9C:HP'3 R'U1D/ HA
MO'4HML^ =T0>]Y\Z8)'Q-AJ;]R&^H?7^;[*NI(AWGV'Q!1)>K:8)+I?_FJ6;
MHNPR\ !*L80^,9T2Y5,I2)H+>J\5F"R?#>[W>=$PK),3H:-/(0_LA-XMYODJ
MK=XN-HT?KWL *6-#L9[)5*LB@C ,I$5FN/)>*>.RW:N*W5[^YK$1C*7IR> Q
MSM'J&0>\JKPV,UAN%E_B''-RFM!@>&TI;^H:L<Q$3%YK;G/I[_;ASF$,Y\2.
MU^R/,#E2S$/[KC^^DHAN[QF\QV\XN[KQP5K7QF,"F?>N5K+VM( L"2I3+NMT
ML0&SV<MO/?&2P<%PK/[F#80Y!C[$];;>S6U&0.E2$<Q@(0/*O6>^UL[USA>G
M<[:I596:^\,8+K[I%RO'RW@$ .G!3;^^O1-'CMK:H&H*&9!<M:;@S;O$R/;6
M37\M-;8JB-??+,;2B&?0 &IP>(Q@:6P,_V^DHYMCYC^GJ\\OKY:K^1=<O/H[
M75[EZ>S3!24T]"=_A+\G11@KHZ1\5RK+=+:1 ?C*[-0VFPPV;A]4]+0"#ACL
MT%?)AD+6_+1J'@&2'YO7+<EN@C1R)WQA1AM/4T#-O$3'I),!-%#$X]I$!4\.
M:]@\=C3H[$]U(\5A75:K-[AZ>;6HBIFH5% &27.P DA84;%H#;)HC)!0/$50
MIT/CUN"&#0U&C<ECU'AF)(^7\^5J.9VE.M-,O["X=B +3/-/L]IJK0GY8^^W
MMB2%'#;U$Y-%.&&[A."8\YRB7$R619$E"[4O#4J!/MKG]'#^9)$B?/0Z*)*"
M+K7Y*RWP3/Y!U)J"WCF31!LV\:]*%ND"NQ.01;KH?XQD$5ZT4%EXIE1E">HL
MJB0]2XJ"[^!RXG&ORXW_D$4.0L1S9)$NZCD;LDCR6:* R)+)M1"#*RR$DEG=
MNHM"&>]*?Y@[5[)()\T?1!;IHH:A#UX>L!U06U[W>9DL.=865;497=1,"P-1
MDOWW>K_..^=&%NFDL9UDD2[B&UKOS_(8K/+>4M9CUI2J5 O)1\$9I3W>0Z"_
MMGO#_+QDD8/1T:>0QW&:__#,.NDL07A@+HA*=@FR-I:R3)BB3;&(*/XABYPD
MQCE:/>. UR,GFY6)94 YIGDF=VT5+3X#EM8B"ED$A&C@ER.+=-+L7F21+F(>
MP4[LPS-K,L0F*? L2QGK(08R0"3!V,PE%K*RO$W/KNZ\@!-S2#JI]4E>0!<9
M#QW<O,?IEWA%C_J1_^( + ?TS,90>Y$59"$;PQR2KW5%)"?X7G'-[G>,D1]R
M" [Z%.70B'B*$I6M#Y*C82G6VNO)".;K<L\"LBR$>G#[7<X[EE_6^\E+(TST
M)<P1^)%>SZ1<R<@C3RRJ2'F"K&6Q+*6#A?*&K(!D:D]; .,?^M"!(?7@\!C!
MTCB$5V)HC1O,%"0H35/4QI&L*5-.0NM0M)46VQ1+^+7I0YV0U0-]J(N:1X#D
M]:DOR773%'LYL<)&Y&0(N)*U-RQ*%J(DD^ SUR%DR<5>.>4!AOKA2'XBDM Q
M&#Q*0:-D7[S!U>OY<GG=C_TK+CY\)HT<0JAX_$''<R3V&&!/?1U>P6)&]F/Y
M;O.2VP-G83TJ81/++E$>*:UG,=8Z!9$; 9*R351-5N&N$1UK9[:?>U<R1O'L
MT&3-;*@L2VXB"QXD<T88*< ;F]M48MXYI&&]7R^8V+8B_8C_?,S)X27.GGI<
M(]/2L ?X3C IX<%IY(P"$G))F",#A<!,)%]"JH\.3[/J^J=9;;_A!2RGZ<7W
MVM]D/GMY"<OE'?I-04]>TS-1'*VDS)&<J4.&V7 -Y%RY;E,J]J#ACM0P=<'2
M;G94*[6-(,B^F^3%;#7-T\NK&C9^P%3;E$]Q>9U(8+Y.-+Y\O;I6ZH\RN5=H
M#90JMI9<\$;4ZSZ! 8K$@DS!E!A":M20NO^Y#!OH-T;U( H_'S^]7N0S7$W7
M/[VDS^F39?WD"*+U@6]JY-T[3K&UXW?1)UL(/5F*6K5%6Q8@9A84%B,M+Z6T
MV8AM[_B/76OK+5'MA,Y  7 I2E)L35\"1F04<]M@39#<M^G"U>\\1AHJ=$%?
M.Z/:6=$CB"$N_H)%KEV1UR2'(+21D0(@#[XZ)Q>J"#.SVKD2<@$;7!.4/AC&
M6&C4I\?#=M/7@Y4S F3=>"G,54HX6VXT>+?G^>+[W>]L3C;7,[Z;]BR_NX39
M/5Z@RD#+.7&&,E*XHHRK535X/6,RDD(H5+Q1/=,&LQD6YT> :]N"#JWI$:#]
M%460\^^('U8455_?AKOA;.3D@*=ZF3&'VO&.DV^BI%)E3U*ET-MOTWK[BHQV
M#6E@^SHX6K8W,7M1W=!TF_=(L1#E#6NQ?IG/UK,A0=W]?/V3/V;3U7(SO>*T
M0:,4\Z;4UO7.,LC9LI1*5 I]B3(_EQ0=^.Z!6<1C@> I-#<"XWAD('5WXBFX
MRZ Y+4C.*<XWGA:D*)KE'&(IR828V[!.^YK!6-CSPX>V0T!B!$OA#:ZN]W'J
MCLY$8@8+%&N5>CM."\59%,8R!3D6*$"+N<VNP(-A#!R'#H*$>5]J.1A3WW 1
MYSVAZD^<?OI,CN*"'@J?\,U5]1)ORUI R[=7J^4*9I51M-XTG&3P.@&G=6LK
M;\36W1*?,C-%RR2=<=:U80%T&N:PIG(4J&RGUE&@]M&CN8DB@:FL'),I5O)H
M*2PZDYF20&EIMH72T9/L).^/PF;<W%&@\'@UC<#O[EA*_U.%2P'V]HJ:Y. T
MP20QQW6]<4-?0I:./$+1+F$],VMSGM%QH,.VR1X%/ENJ=@3(W1;:9EX3+L&#
M5125%$U!2I&612STK2L80^9:IS:QXXX!#=L.>Q1([$-5YW/(?KU;L:Q[$_B?
MJ^DWN*P[)^OEUO<I^QZO:G3,WG62K<_9:U6$ H'<+OK:TUIZ!C$GEKE,FC[+
M!+-?^9Q=8/ *4V#2*C+NA5/JIK)DM/Z<3]%DD<9.8!KQ.7L7]#4^9^^BZ!%X
M\2/G_.+[XP]8G]U%PU6R7K 8*X-;9$K\G'.D&NV\,SX8:(/YAI/ZJ3@ G;#:
M[T9I;\ 9[1JZ=P3#DP\0A&&BUJ75Q9=:HT,R*[0J%'4YT:B Y7,C.^L=UOX@
MM!>T#]3G"/"Y=6!WT_[%1N,$CTP$()_I"R44F#BST7.E-%D KYN \M'AC!&)
MAVK\AVNUQXI_?!A:'_J^__#'3:F'H!*WUM7DE!))9PT+A9-X4I19!BY#:+-S
M_^2PQKA3WP931ZAC!-C:373A B/D(%@NW#&M*4I9=W,U!@QX1X_2;6YG'\=1
M.O&^>T^8ZD<-0_.-'LSBW::L8Z7$W+1Q]2E%80R3VI+=-5(Q"%B84]+G8)('
MO@6I'>2B9UXTQ@WP(X'2NWQ'8'MZVY_E=4O69<.X5III\N$L:N&855)IC[PX
M^(<"]"MDMH=!XOR7PL676C)WHGPB.XF!S$FN=U43,#(TF4&!@N0TG%5MKACW
M,OPQIB&MD=<O_ ^ 0?NCI<T']4LD=_7?__7_4$L#!!0    ( "6%9%.6?1?]
M70@  ($G   9    ;6]R9BTR,#(Q.3,P>#$P<65X,S$Q+FAT;>U:;6_;MA;^
MOE_!N5B; +9L^>4F<=( KNVN!MHD<UQT^S10$F43H42-I.SX_OI[#BG%=NRL
M[NVZN<$*U)%$'O*\/'S.(:6+'P?7_<EO-T,R,XD@-Q_?O!_U2:56KW]J]>OU
MP61 WDT^O"=MK^&3B:*IYH;+E(IZ?7A5(969,5FW7E\L%MZBY4DUK4_&=1RJ
M71=2:N9%)JI<7N 3^&4TNOSAXL=:C0QDF"<L-214C!H6D5SS=$H^14S?D5JM
MZ-67V5+QZ<R09J/IDT]2W?$Y=>V&&\$NRW$NZN[^HFXGN0ADM+R\B/B<\.AU
MA9^VFOXI/0OCV.^T3YOLK!6W@_",!8QV3N/3QN\^*%F'[DY&FZ5@KRL)3VLS
MAO-WVTWOI).9\P6/S*SK-QH_56S7RXM8I@;F4R#O+MTP6X,9=F]J5/!IVK4F
M59QHV1Q*(57W1</^.\>66DP3+I;=5Q.>,$VNV(*,94+35U4-8:AIIGCL.FK^
M7P8Z@7KV=N%4/H%Q!$]9:8+?1*6']S,><$-:ON=O:KQN.%53L-W(#*1@V#7=
M0W V4_^0\OWA>#)Z.^KW)J/K*P#K^/9C[VI")M=D_/']D/@M6O/;1_287(^)
MWXG*F[=/&GHHADW>#<GML/]Q/)J,AK=D^&O_7>_JYR'I]2>@/O'/6NWJP1O1
MNR6]P?7-9#C8" W89</5:C31%FMJ;_RF=S6\K5W_^G[X6VEEL]%H[@O);VYB
M>Z>)HRJY473.6$IN/#+A&5<I2WF5A$P9'B^)F5'S\D7G]'SOM971* +JJPD6
MPRRGY6KC:02Q[-;PR3]DK.^51OS]LS]R2\/KH!M&9 ;.)XK-.5M TC SKLDO
M.54 >K$D8Y9)98A,R5NI$N(W:K\0&9,/4F4S'I)W4N"053)*0P^"=/8<@M0\
MN""]H1I" T%(EN0NE0O!HBFKNE@I%Z%(@@JIA.P/,U">$IHN29X:E3.P .H!
M6QI Z"A)X$YQ*DA,0WBDB$P@>QGI^FUU2%G(M*9JB5T2>L=@WK4Q-3R+0!F8
M4MBZ N; #B%74$= MQ3$09.(*;( S,R(SO%G);]@BA6#H $)UP(*#JQ=%MS,
MP$"=L= JB.-FH)J,P,PYB$4D6*Z[X;E L/7]0)"1F*<09,3+*JA5P!]TAV:U
MUL[3&%B$8KD+UZ'((Q@3@+,6P2J CB/S9!!WA"Q"68@5)@LXZ$=3 ^PC6T=7
ML4<NH , 40):['3:ZA-2/2.QD M=HE2Q*=<&BG!#*#YT>H.6U36PZ5*9+6V?
M"][:!X>WR49P7KXX;?HGY[I 5%$:($7(..9P:\,V(E0Q"Q (. \$PT 2!J@,
M!-<S[([=$J!'I$B\C[@.A=0YR"%Q*BD<4C(E0Q;!8TV. !@1 Z2YZ _OPQE-
MIXST@)/&N8 >MDCN'+%C*VJK9+QSMQS+Q]0A%,<G2%QKP'5 0EWVGBC>F"B&
MB=#.QW"&'IC:OZ)T:OWG@"!*#P>BOM<X03\,F(8= D3+9K3/0ZF*R3:DN=Y?
M!+->P  6Q4PNC\I<P0! 3G.N+>5!+Y;:<;!:7I'E.N$J)JC%69%(5UBI%F2,
MC1R($W314O#(GB+H/- \XE1Q-("[=&]30(HCY1I3L%V6VN9K2Y!2,U#( "&C
M4 ;5) ]S09'7P2RKQ"J5@X0K#-;K&;@*&'8$Z@5Y%GT%U1X4CH/#P7%!M9LP
MWINOMM"\/]/M#6I8"',>(5:IEBE%2J<:<(Y%)0*8JJ@$$\";TX +;I:8W'=-
MBTO+XLY"RJV*C:YK1:G-'/>%05FN,H"TML5(&$H5605L>3IE*=08 I -+2S#
M)8-=H/1VZ(6EQ3,@;XM?\@P '!X.@$LB'LZIR"U;87A9'$.!R.<0&+VCT'NE
M]^%==[N[ZK-0!4'@3.UJRT#FYNFY]\D,]*$WP\(Y_OQ>AP1E26Y7'W,^ 'T<
MTF""9P"VZ'# 5K*E"^8V*'##751LMF5G_?H%'(F)7(9AKC#T:UESQZB)U :>
MXU$EC*5#&.@/=X1#CIX0B0'#P%Z/>A>*PSZ)V;,"/$9(\P>]CIU6,ZH?2@SD
M/8MY%MF$8/U1D/62"'['1'%P\*A_]:M=Y#V#C5?GX/#]_VV\["%B5"Z-ZHJ;
MD"K7X;FB*038%Q0;6U7K@VH4*E<CE7[([_8!#)DDW!C&ME/ @V@@H8+ ]HB#
M?G:0(P Q\*Y&7H>_6#^7*X_]D7-0WZZR/ WMN<+QO_NK;Y;6>P)*,B@1.2 -
MM[2X.0XY V@4"?IAG[-@] XSKBO1;,ZUQ:4]W2S/@+X0<&Y/XDX4=A :C4!2
MLP<^>Q*=14T*(@ Q*!VK+N]K2/HZ3P @X"9K39%'=AZ7/:><?G@[H!ZD[E@!
M;6#4F64Z (X]C"X05G69CZ=S*>8,TU]*I\69NBK(D269D$L&K8N9=(Q(-_ +
M>/M+:H/]$I]=0A?&;IJ*Y@#@QU0-7"UHIEFWO#@'YLX$779Y:AUFA<Z+P0)I
MC$RZ^*I^CO0/]4+Q:M0"RC47;_'/SKR3Q@F^R#<*_D?EQ,4[?L^^XZ^;:+NM
MT_3:_MF3S0W/?[+MSX9M=[S6Z=.BZ\/6K<I.;7",SFCZNM*JE (%<+K-[)[X
MFR_P$4N/?>/<\O>O,/L9Q0!0:_,2N0(,)0' J%VU'WP\(*?PQI\8VD SO] Y
M&S+?OQ]?OFC#PK2_.U]2;WCSKW-1L4QQ%5N"(O8TCI3V?D\>W/UJ_X,W\+Z1
M[P[,.7;$+C<P6[B7NZ!LP01=)?T99S$9WK,PQ_,$<KU6;P^*:A6_D3JZ<4=,
MD""V.A]O.[ENN7WOKT%V?(:U)O/H2ZY,ND_9NNZH><ZVONU:(=SFE,9*A 8
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M_IUC2R6DL9"+[HNQB+DAUWQ.1BJFR8NR@3!4#-<B]!V-^(.#3J">NYU[E4]
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ML[J8,5=$)W\ 4$L! A0#%     @ )85D4PT8D+%K$@  O*,  !P
M     ( !     &5X:&EB:70Q,#$M<F5N=&%M96YD;65N="YH=&U02P$"% ,4
M    "  EA613]Z^^C<'& @#(?AH $0              @ &E$@  ;6]R9BTR
M,#(Q,#DS,"YH=&U02P$"% ,4    "  EA613!/\9_:(+  #:;P  $0
M        @ &5V0( ;6]R9BTR,#(Q,#DS,"YX<V102P$"% ,4    "  EA613
M(^5/+505  #[Q0  %0              @ %FY0( ;6]R9BTR,#(Q,#DS,%]C
M86PN>&UL4$L! A0#%     @ )85D4W_6 @M,.   XZX" !4
M ( ![?H" &UO<F8M,C R,3 Y,S!?9&5F+GAM;%!+ 0(4 Q0    ( "6%9%.F
ME1G^N94  #I9!@ 5              "  6PS P!M;W)F+3(P,C$P.3,P7VQA
M8BYX;6Q02P$"% ,4    "  EA613Y)NMI0=A   TI@0 %0
M@ %8R0, ;6]R9BTR,#(Q,#DS,%]P<F4N>&UL4$L! A0#%     @ )85D4Y9]
M%_U="   @2<  !D              ( !DBH$ &UO<F8M,C R,3DS,'@Q,'%E
M>#,Q,2YH=&U02P$"% ,4    "  EA613+84U+DD(  !)*   &0
M    @ $F,P0 ;6]R9BTR,#(Q.3,P>#$P<65X,S$R+FAT;5!+ 0(4 Q0    (
M "6%9%.8/SW"P00  %\1   9              "  :8[! !M;W)F+3(P,C$Y
M,S!X,3!Q97@S,C$N:'1M4$L! A0#%     @ )85D4Y/ANX*]!   ?1(  !D
M             ( !GD $ &UO<F8M,C R,3DS,'@Q,'%E>#,R,BYH=&U02P4&
2      L "P#P @  DD4$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
